<SEC-DOCUMENT>0001493152-23-025388.txt : 20230724
<SEC-HEADER>0001493152-23-025388.hdr.sgml : 20230724
<ACCEPTANCE-DATETIME>20230724172354
ACCESSION NUMBER:		0001493152-23-025388
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		76
FILED AS OF DATE:		20230724
DATE AS OF CHANGE:		20230724

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMPACT BIOMEDICAL INC.
		CENTRAL INDEX KEY:			0001834105
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				853926944
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-253037
		FILM NUMBER:		231105898

	BUSINESS ADDRESS:	
		STREET 1:		200 CANAL VIEW BLVD
		STREET 2:		SUITE 104
		CITY:			ROCHESTER
		STATE:			NY
		ZIP:			14623
		BUSINESS PHONE:		585 232 1500

	MAIL ADDRESS:	
		STREET 1:		200 CANAL VIEW BLVD
		STREET 2:		SUITE 104
		CITY:			ROCHESTER
		STATE:			NY
		ZIP:			14623
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>forms-1a.htm
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:IMPB="http://impactbiomedinc.com/20230331">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_03E_IMPB_impactbiomedinc.com_20230331 -->
<!-- Field: Set; Name: xdx; ID: xdx_04A_20230101_20230331 -->
<!-- Field: Set; Name: xdx; ID: xdx_057_edei%2D%2DEntityCentralIndexKey_0001834105 -->
<!-- Field: Set; Name: xdx; ID: xdx_055_edei%2D%2DAmendmentFlag_true -->
<!-- Field: Set; Name: xdx; ID: xdx_071_XDX_forms%2D1a.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="dei:EntityCentralIndexKey">0001834105</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="dei:AmendmentFlag">true</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-01to2023-03-31" id="xdx2ixbrl0010" name="dei:AmendmentDescription"><b>Amendment No. 13</b></ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-01to2023-03-31" id="xdx2ixbrl0011" name="dei:DocumentType">S-1/A</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2021-12-31" id="xdx2ixbrl0053" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember" id="xdx2ixbrl0094" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2021-12-31" id="xdx2ixbrl0095" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0174" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" id="xdx2ixbrl0197" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0198" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_srt_ScenarioPreviouslyReportedMember" id="xdx2ixbrl0217" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember_srt_ScenarioPreviouslyReportedMember" id="xdx2ixbrl0218" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember_srt_ScenarioPreviouslyReportedMember" id="xdx2ixbrl0255" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember_srt_ScenarioPreviouslyReportedMember" id="xdx2ixbrl0256" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember_srt_ScenarioPreviouslyReportedMember" id="xdx2ixbrl0257" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-12-31_us-gaap_NoncontrollingInterestMember_srt_ScenarioPreviouslyReportedMember" id="xdx2ixbrl0258" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-12-31_srt_ScenarioPreviouslyReportedMember" id="xdx2ixbrl0259" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="IMPB:StockIssuedDuringPeriodValueShareholder" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember_srt_ScenarioPreviouslyReportedMember" id="xdx2ixbrl0261" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="IMPB:StockIssuedDuringPeriodValueShareholder" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember_srt_ScenarioPreviouslyReportedMember" id="xdx2ixbrl0262" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="IMPB:StockIssuedDuringPeriodValueShareholder" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember_srt_ScenarioPreviouslyReportedMember" id="xdx2ixbrl0263" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="IMPB:StockIssuedDuringPeriodValueShareholder" contextRef="From2021-01-012021-12-31_us-gaap_NoncontrollingInterestMember_srt_ScenarioPreviouslyReportedMember" id="xdx2ixbrl0264" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="IMPB:StockIssuedDuringPeriodValueShareholder" contextRef="From2021-01-012021-12-31_srt_ScenarioPreviouslyReportedMember" id="xdx2ixbrl0265" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember_srt_ScenarioPreviouslyReportedMember" id="xdx2ixbrl0267" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember_srt_ScenarioPreviouslyReportedMember" id="xdx2ixbrl0268" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="IMPB:ImpairmentOfOtherInvestments" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0305" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsForProceedsFromProductiveAssets" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0335" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0450" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0452" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31_us-gaap_MachineryAndEquipmentMember" id="xdx2ixbrl0572" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31_us-gaap_ConstructionInProgressMember" id="xdx2ixbrl0579" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31" id="xdx2ixbrl0582" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31" id="xdx2ixbrl0585" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2022-12-31" id="xdx2ixbrl0587" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2021-12-31" id="xdx2ixbrl0588" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2021-12-31" id="xdx2ixbrl0591" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Depreciation" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0593" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Depreciation" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0595" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0603" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0747" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0748" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0750" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0751" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0753" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2021-01-012021-12-31" id="xdx2ixbrl0754" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsInvestments" contextRef="AsOf2021-12-31" id="xdx2ixbrl0774" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2021-12-31" id="xdx2ixbrl0777" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2021-12-31_us-gaap_RelatedPartyMember" id="xdx2ixbrl0828" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2021-12-31_us-gaap_RelatedPartyMember" id="xdx2ixbrl0831" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NotesAndLoansReceivableNetNoncurrent" contextRef="AsOf2023-03-31" id="xdx2ixbrl0859" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2023-03-31" id="xdx2ixbrl0895" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2022-12-31" id="xdx2ixbrl0896" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2022-01-012022-03-31" id="xdx2ixbrl0969" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="From2023-01-01to2023-03-31" id="xdx2ixbrl0974" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="From2022-01-012022-03-31" id="xdx2ixbrl0975" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-01-01to2023-03-31" id="xdx2ixbrl0980" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-01-012022-03-31" id="xdx2ixbrl0981" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-01to2023-03-31" id="xdx2ixbrl0995" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-01-012022-03-31" id="xdx2ixbrl0996" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl1015" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl1016" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl1053" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl1054" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredLiabilities" contextRef="From2022-01-012022-03-31" id="xdx2ixbrl1094" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="IMPB:IncreaseDecreaseInImpairmentofOtherInvestments" contextRef="From2022-01-012022-03-31" id="xdx2ixbrl1097" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsForProceedsFromProductiveAssets" contextRef="From2022-01-012022-03-31" id="xdx2ixbrl1115" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsToAcquireInvestments" contextRef="From2023-01-01to2023-03-31" id="xdx2ixbrl1117" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="From2023-01-01to2023-03-31" id="xdx2ixbrl1230" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="From2022-01-012022-03-31" id="xdx2ixbrl1232" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2022-12-31" id="xdx2ixbrl1345" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="From2023-01-01to2023-03-31" id="xdx2ixbrl1360" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="impb-20230331.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2023-01-01to2023-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_dei_BusinessContactMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_CommonStockMember_srt_ScenarioPreviouslyReportedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember_srt_ScenarioPreviouslyReportedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember_srt_ScenarioPreviouslyReportedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember_srt_ScenarioPreviouslyReportedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_CommonStockMember_srt_ScenarioPreviouslyReportedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember_srt_ScenarioPreviouslyReportedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember_srt_ScenarioPreviouslyReportedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_NoncontrollingInterestMember_srt_ScenarioPreviouslyReportedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_srt_ScenarioPreviouslyReportedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_srt_ScenarioPreviouslyReportedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-11-08_custom_SweetSenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:SweetSenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-11-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-072019-11-08_custom_SweetSenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:SweetSenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-07</xbrli:startDate>
        <xbrli:endDate>2019-11-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-162018-10-16_custom_GlobalBioMedicalPteLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">IMPB:GlobalBioMedicalPteLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-16</xbrli:startDate>
        <xbrli:endDate>2018-10-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-03-302020-03-31_custom_GlobalBioMedicalPteLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">IMPB:GlobalBioMedicalPteLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-03-30</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_SweetSenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:SweetSenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_SweetSenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:SweetSenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_srt_SubsidiariesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_srt_SubsidiariesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_GlobalBioMedicalIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:GlobalBioMedicalIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_GlobalBioMedicalIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:GlobalBioMedicalIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_GlobalBioMedicalIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:GlobalBioMedicalIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_GlobalBioLifeIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:GlobalBioLifeIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_GlobalBioLifeIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:GlobalBioLifeIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_GlobalBioLifeIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:GlobalBioLifeIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_BioLifeSugarIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:BioLifeSugarIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_BioLifeSugarIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:BioLifeSugarIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_BioLifeSugarIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:BioLifeSugarIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_HappySugarIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:HappySugarIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_HappySugarIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:HappySugarIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_HappySugarIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:HappySugarIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_SweetSenseIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:SweetSenseIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_SweetSenseIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:SweetSenseIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_SweetSenseIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:SweetSenseIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_GlobalSugarSolutionsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:GlobalSugarSolutionsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_GlobalSugarSolutionsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:GlobalSugarSolutionsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_GlobalSugarSolutionsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:GlobalSugarSolutionsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_GlobalBioMedicalIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:GlobalBioMedicalIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_GlobalBioMedicalIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:GlobalBioMedicalIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_GlobalBioLifeIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:GlobalBioLifeIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_GlobalBioLifeIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:GlobalBioLifeIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_BioLifeSugarIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:BioLifeSugarIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_BioLifeSugarIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:BioLifeSugarIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_HappySugarIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:HappySugarIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_HappySugarIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:HappySugarIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_SweetSenseIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:SweetSenseIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_SweetSenseIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:SweetSenseIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_GlobalSugarSolutionsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:GlobalSugarSolutionsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_GlobalSugarSolutionsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:GlobalSugarSolutionsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_GRDGscienceLLCMember_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">IMPB:GRDGscienceLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_GRDGscienceLLCMember_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">IMPB:GRDGscienceLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_GRDGscienceLLCMember_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">IMPB:GRDGscienceLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_GRDGscienceLLCMember_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">IMPB:GRDGscienceLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_GRDGscienceLLCMember_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">IMPB:GRDGscienceLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_GRDGscienceLLCMember_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">IMPB:GRDGscienceLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-02-21_custom_PromissoryNoteOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">IMPB:PromissoryNoteOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-02-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-202021-02-21_custom_PromissoryNoteOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">IMPB:PromissoryNoteOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-20</xbrli:startDate>
        <xbrli:endDate>2021-02-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-08-222022-08-22_custom_PromissoryNoteOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">IMPB:PromissoryNoteOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-08-22</xbrli:startDate>
        <xbrli:endDate>2022-08-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_PromissoryNoteOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">IMPB:PromissoryNoteOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_PromissoryNoteOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">IMPB:PromissoryNoteOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_PromissoryNoteOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">IMPB:PromissoryNoteOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-05-14_custom_PromissoryNoteTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">IMPB:PromissoryNoteTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-05-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-05-132021-05-14_custom_PromissoryNoteTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">IMPB:PromissoryNoteTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-05-13</xbrli:startDate>
        <xbrli:endDate>2021-05-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-05-14_srt_MaximumMember_custom_PromissoryNoteTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">IMPB:PromissoryNoteTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-05-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-01_srt_MaximumMember_custom_PromissoryNoteTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">IMPB:PromissoryNoteTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_PromissoryNoteTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">IMPB:PromissoryNoteTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_PromissoryNoteTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">IMPB:PromissoryNoteTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-02-21">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-02-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-202021-02-21">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-20</xbrli:startDate>
        <xbrli:endDate>2021-02-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-08-222022-08-22">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-08-22</xbrli:startDate>
        <xbrli:endDate>2022-08-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-182020-12-19_custom_AsiaPacificHoldingsLimitedMember_us-gaap_SubscriptionArrangementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">IMPB:AsiaPacificHoldingsLimitedMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:SubscriptionArrangementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-18</xbrli:startDate>
        <xbrli:endDate>2020-12-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-01-01_custom_NanoNineLLCMember_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">IMPB:NanoNineLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">IMPB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-01-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-01-01_custom_NanoNineLLCMember_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">IMPB:NanoNineLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">IMPB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-01-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_NanoNineLLCMember_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">IMPB:NanoNineLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">IMPB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_NanoNineLLCMember_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">IMPB:NanoNineLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">IMPB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-03-142021-03-15_custom_StockPurchaseAgreementMember_custom_VivacitasOncologyIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">IMPB:StockPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">IMPB:VivacitasOncologyIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-03-14</xbrli:startDate>
        <xbrli:endDate>2021-03-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-15_custom_VivacitasOncologyIncMember_custom_StockPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">IMPB:VivacitasOncologyIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">IMPB:StockPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-03-172021-03-18_custom_ImpactOncologyPTELtdMember_custom_StockPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">IMPB:ImpactOncologyPTELtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">IMPB:StockPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-03-17</xbrli:startDate>
        <xbrli:endDate>2021-03-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-03-172021-03-18_custom_StockPurchaseAgreementMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">IMPB:StockPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-03-17</xbrli:startDate>
        <xbrli:endDate>2021-03-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-04-01_custom_StockPurchaseAgreementMember_custom_VivacitasOncologyIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">IMPB:StockPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">IMPB:VivacitasOncologyIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-04-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_StockPurchaseAgreementMember_custom_VivacitasOncologyIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">IMPB:StockPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">IMPB:VivacitasOncologyIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-212021-07-22_custom_VivacitasAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">IMPB:VivacitasAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-21</xbrli:startDate>
        <xbrli:endDate>2021-07-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_VivacitasAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">IMPB:VivacitasAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_VivacitasAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">IMPB:VivacitasAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_NanoNineLLCMember_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">IMPB:NanoNineLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">IMPB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_MachineryAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_MachineryAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_MachineryAndEquipmentMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_MachineryAndEquipmentMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_ConstructionInProgressMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_ConstructionInProgressMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_MachineryAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_MachineryAndEquipmentMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_MachineryAndEquipmentMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_ConstructionInProgressMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-302022-06-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-30</xbrli:startDate>
        <xbrli:endDate>2022-06-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_DevelopedTechnologyRightsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_DevelopedTechnologyRightsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_DevelopedTechnologyRightsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_RevolvingPromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">IMPB:RevolvingPromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_RevolvingPromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">IMPB:RevolvingPromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_RevolvingPromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">IMPB:RevolvingPromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_RevolvingPromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">IMPB:RevolvingPromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-23_srt_BoardOfDirectorsChairmanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-23">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-11_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_srt_BoardOfDirectorsChairmanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_srt_BoardOfDirectorsChairmanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_GRDGscienceLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">IMPB:GRDGscienceLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_GRDGscienceLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">IMPB:GRDGscienceLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-142018-08-15_custom_RoyaltyAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">IMPB:RoyaltyAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-14</xbrli:startDate>
        <xbrli:endDate>2018-08-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-142018-08-15_custom_RoyaltyAgreementMember_custom_ChemiaCorporationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">IMPB:RoyaltyAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">IMPB:ChemiaCorporationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-14</xbrli:startDate>
        <xbrli:endDate>2018-08-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-11-262018-11-27_custom_RoyaltyAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">IMPB:RoyaltyAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-11-26</xbrli:startDate>
        <xbrli:endDate>2018-11-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-142022-02-15_custom_RoyaltyAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">IMPB:RoyaltyAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-14</xbrli:startDate>
        <xbrli:endDate>2022-02-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-03-182022-03-19_custom_LicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">IMPB:LicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-03-18</xbrli:startDate>
        <xbrli:endDate>2022-03-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-03-182022-03-19_custom_RoyaltyAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">IMPB:RoyaltyAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-03-18</xbrli:startDate>
        <xbrli:endDate>2022-03-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_RoyaltyAgreementMember_custom_ChemiaCorporationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">IMPB:RoyaltyAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">IMPB:ChemiaCorporationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-142022-02-15_custom_GlobalAndBioLifeSciencesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">IMPB:GlobalAndBioLifeSciencesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-14</xbrli:startDate>
        <xbrli:endDate>2022-02-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-03-192022-03-19_custom_LicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">IMPB:LicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-03-19</xbrli:startDate>
        <xbrli:endDate>2022-03-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001834105</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As
filed with the Securities and Exchange Commission on July 24, 2023</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Registration
No. 333-253037</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_904_edei--AmendmentDescription_dxL_c20230101__20230331_zIpHylBKGC72" style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span style="-sec-ix-hidden: xdx2ixbrl0010">Amendment
No. </span>13</b></span><b> <span style="font-family: Times New Roman, Times, Serif; font-size: 18pt">to</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_90D_edei--DocumentType_dxL_c20230101__20230331_zIh7mLFWfSKj" title="::XDX::S-1%2FA"><span style="-sec-ix-hidden: xdx2ixbrl0011">S-1</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REGISTRATION
STATEMENT UNDER THE SECURITIES ACT OF 1933</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_902_edei--EntityRegistrantName_c20230101__20230331_zqNQhtQL3XAf"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="dei:EntityRegistrantName">IMPACT
BIOMEDICAL INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Exact
name of registrant as specified in its charter)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90F_edei--EntityIncorporationStateCountryCode_c20230101__20230331_z6ce7bgCeGok"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8731</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90A_edei--EntityTaxIdentificationNumber_c20230101__20230331_zIEJlsaYlwB2"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="dei:EntityTaxIdentificationNumber">85-3926944</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(State
    or other jurisdiction of</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>incorporation
    or organization)</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Primary
    Standard Industrial</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Classification
    Code Number)</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(I.R.S.
    Employer</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Identification
    Number)</b></span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_906_edei--EntityAddressAddressLine1_c20230101__20230331_zPC8dHL44rS8"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="dei:EntityAddressAddressLine1">275
Wiregrass Pkwy</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_902_edei--EntityAddressCityOrTown_c20230101__20230331_zSB7Kp2Ksiqa"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="dei:EntityAddressCityOrTown">West
Henrietta</ix:nonNumeric></span>, <span id="xdx_907_edei--EntityAddressStateOrProvince_c20230101__20230331_zBDQpdtOJ9Sb"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="dei:EntityAddressStateOrProvince">NY</ix:nonNumeric></span> <span id="xdx_90A_edei--EntityAddressPostalZipCode_c20230101__20230331_zr4FRdU0fl9f"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="dei:EntityAddressPostalZipCode">14586</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_904_edei--CityAreaCode_c20230101__20230331_zEkICYR0ARb2"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="dei:CityAreaCode">+1</ix:nonNumeric></span>-<span id="xdx_90C_edei--LocalPhoneNumber_c20230101__20230331_zbvDgFmUQJ15"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="dei:LocalPhoneNumber">585-325-3610</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Address,
including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_902_edei--ContactPersonnelName_c20230101__20230331__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zHRcKPba6uRk"><ix:nonNumeric contextRef="From2023-01-012023-03-31_dei_BusinessContactMember" name="dei:ContactPersonnelName">Frank D. Heuszel</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Chief
Executive Officer</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_901_edei--EntityAddressAddressLine1_c20230101__20230331__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zpyNu7YUvPrd"><ix:nonNumeric contextRef="From2023-01-012023-03-31_dei_BusinessContactMember" name="dei:EntityAddressAddressLine1">Impact
BioMedical Inc.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90C_edei--EntityAddressAddressLine2_c20230101__20230331__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zUPFaKwONiT1"><ix:nonNumeric contextRef="From2023-01-012023-03-31_dei_BusinessContactMember" name="dei:EntityAddressAddressLine2">275
Wiregrass Pkwy</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_900_edei--EntityAddressCityOrTown_c20230101__20230331__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zWr22OSkjZV8"><ix:nonNumeric contextRef="From2023-01-012023-03-31_dei_BusinessContactMember" name="dei:EntityAddressCityOrTown">West
Henrietta</ix:nonNumeric></span>, <span id="xdx_90E_edei--EntityAddressStateOrProvince_c20230101__20230331__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zqW3rDTtEg1a"><ix:nonNumeric contextRef="From2023-01-012023-03-31_dei_BusinessContactMember" name="dei:EntityAddressStateOrProvince">NY</ix:nonNumeric></span> <span id="xdx_900_edei--EntityAddressPostalZipCode_c20230101__20230331__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zt7AlL0AWlI6"><ix:nonNumeric contextRef="From2023-01-012023-03-31_dei_BusinessContactMember" name="dei:EntityAddressPostalZipCode">14586</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_905_edei--CityAreaCode_c20230101__20230331__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zt1hX17ENdC5"><ix:nonNumeric contextRef="From2023-01-012023-03-31_dei_BusinessContactMember" name="dei:CityAreaCode">+1</ix:nonNumeric></span>-<span id="xdx_90F_edei--LocalPhoneNumber_c20230101__20230331__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zlvgYo82z1Bb"><ix:nonNumeric contextRef="From2023-01-012023-03-31_dei_BusinessContactMember" name="dei:LocalPhoneNumber">585-325-3610</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Name,
address, including zip code, and telephone number, including area code, of agent for service)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>With
a copy to:</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Darrin
M. Ocasio, Esq.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Sichenzia
Ross Ference LLP</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1185
Avenue of the Americas</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>New
York, NY 10036</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Telephone:
+1-212-930-9700</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As
soon as practicable after the effective date of this registration statement.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Approximate
date of commencement of proposed sale to the public)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act of 1933, check the following box.&#160;&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following
box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#160;&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering.&#160;&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering.&#160;&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;
&#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    Accelerated filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 15%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 15%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--EntityFilerCategory_c20230101__20230331_zkwywLoMqaGi"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated
    filer</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--EntitySmallBusiness_c20230101__20230331_zuJjbrbpP30h"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" format="ixt:booleantrue" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--EntityEmergingGrowthCompany_c20230101__20230331_z4DFgECmQ2Sl"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" format="ixt:booleantrue" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.&#160;<span id="xdx_907_edei--EntityExTransitionPeriod_c20230101__20230331_zp8PN3YSFgO3"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" format="ixt:booleanfalse" name="dei:EntityExTransitionPeriod">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed
upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the
Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective
in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the Registration Statement shall become effective
on such date as the Securities and Exchange Commission, acting pursuant to Section 8(a), may determine.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; color: #FC0014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #FC0014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; border-bottom: Black 4pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; color: #FC0014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; color: #FC0014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #FC0014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
information in this prospectus is not complete and may be changed. We may not issue these securities until the registration statement
filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not
soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #FC0014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SUBJECT
TO COMPLETION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #FC0014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PRELIMINARY
PROSPECTUS DATED JULY 24, 2023</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IMPACT
BIOMEDICAL INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>485,161,488
</b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>shares of Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(par
value $0.001 per share)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus is being furnished to you as a stockholder of DSS, Inc. (&#8220;DSS&#8221;), in connection with the planned distribution
to its stockholders of shares of common stock, par value $0.001 per share (the &#8220;<span style="text-decoration: underline">Common Stock</span>&#8221;) of Impact BioMedical
Inc. (the &#8220;<span style="text-decoration: underline">Company</span>,&#8221; &#8220;<span style="text-decoration: underline">Impact</span>,&#8221; &#8220;<span style="text-decoration: underline">we</span>,&#8221; &#8220;<span style="text-decoration: underline">our</span>&#8221; or &#8220;<span style="text-decoration: underline">us</span>&#8221;
as applicable) beneficially held by DSS, through its wholly-owned subsidiary, DSS BioHealth Security, Inc. (the &#8220;<span style="text-decoration: underline">Distribution</span>&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DSS&#8217;s
long-term plans for the Company include taking the Company public through an initial public offering. In concert with this planned public
offering, DSS, through its wholly-owned subsidiary DSS BioHealth Security, Inc. plans to distribute an aggregate of approximately 485,161,488
shares of our Common Stock (the &#8220;<span style="text-decoration: underline">Impact Shares</span>&#8221;) beneficially held by DSS BioHealth Security, Inc. in a distribution
to holders of DSS common stock, par value $0.02 per share (&#8220;<span style="text-decoration: underline">DSS Common Stock</span>&#8221;) as of July 10, 2023 (the &#8220;<span style="text-decoration: underline">Record
Date</span>&#8221;), except DSS will not cause to be distributed by DSS BioHealth Security, Inc. any Impact Shares to the Chairman of the
Board of DSS, Mr. Chan Heng Fai Ambrose, personally, or certain of his affiliates, including Heng Fai Holdings Limited,
that hold shares of DSS Common Stock. As of the Record Date, Mr. Chan, individually and through certain affiliates, beneficially
held 18,973,878 shares of DSS Common Stock (the &#8220;<span style="text-decoration: underline">Affiliate Shares</span>&#8221;). Except for the Affiliate Shares, each
share of DSS Common Stock outstanding as of 5:00 p.m., New York City time, held on the Record Date, will entitle the holder thereof
to receive four (4) Impact Shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immediately
prior to the Distribution, DSS, through its wholly-owned subsidiary Impact BioMedical Inc., will beneficially hold 100%, or 3,877,282,251
of the issued and outstanding shares of our Common Stock. The Distribution will be effective as of 5:00 p.m., New York City time, on
[__], 2023 (&#8220;Distribution Date&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Distribution will not occur until this Registration Statement becomes effective under the Securities Act of 1933, as amended (the &#8220;<span style="text-decoration: underline">Securities
Act</span>&#8221;). The Distribution will be made in book-entry form by a distribution agent. Each Impact Share distributed as part of the Distribution will be not be eligible for resale until 180 days from
the date of the Company&#8217;s initial public offering becomes effective under the Securities Act, subject to the discretion of the Company
to lift the restriction sooner.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of our outstanding shares of Common Stock are currently beneficially owned by DSS, through its wholly-owned subsidiary DSS BioHealth
Security, Inc. Accordingly, there currently is no public trading market for our Common Stock. Our Common Stock is currently not listed
for trading on any stock exchange or market. The Impact Shares may be illiquid as we cannot predict whether any trading market will develop.
We currently plan to apply for listing of our Common Stock on the over-the-counter board upon the effectiveness of the registration statement,
of which this prospectus forms a part. However, we can provide no assurance that our shares will be traded on the bulletin board or,
if traded, that a public market will materialize. If no market is ever developed for our shares, it will be difficult for shareholders
to sell their stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DSS
stockholders are not required to vote on or take any other action in connection with the Distribution. We are not asking you for a proxy,
and we request that you do not send us a proxy</b>. DSS stockholders will not be required to pay any consideration for the Impact Shares
that they receive in the Distribution, and they will not be required to surrender or exchange their shares of DSS Common Stock or take
any other action in connection with the Distribution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
are an &#8220;emerging growth company,&#8221; as defined under the federal securities laws, and have elected to comply with certain reduced
public company reporting requirements for this prospectus and for future filings.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Investing
in our securities involve a high degree of risk. Before buying any securities, you should carefully consider the matters described in
the section titled &#8220;Risk Factors&#8221; beginning on page 11  of this Prospectus.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>You
should rely only on the information contained in this prospectus or any prospectus supplement or amendment hereto. We have not authorized
anyone to provide you with different information.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved these securities or determined
if this Prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>This
Prospectus is not an offer to sell, or a solicitation of an offer to buy, any securities.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
date of this Prospectus is ________ ___, 2023.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="toc_011"></span>TABLE
OF CONTENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#gfd_001">QUESTIONS AND ANSWERS ABOUT THE DISTRIBUTION</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#gfd_002">SUMMARY</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#gfd_003">RISK FACTORS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#gfd_004">CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#gfd_005">MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES OF THE SPIN-OFF</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#gfd_006">USE OF PROCEEDS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#gfd_007">DETERMINATION OF OFFERING PRICE</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#gfd_008">DIVIDEND POLICY</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#gfd_009">CAPITALIZATION</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#gfd_010">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ax_001">BUSINESS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ax_002">MANAGEMENT</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ax_003">EXECUTIVE COMPENSATION</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ax_004">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ax_005">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ax_006">DESCRIPTION OF OUR CAPITAL STOCK</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">4<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ax_007">LEGAL MATTERS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ax_008">EXPERTS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">4<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ax_009">WHERE YOU CAN FIND MORE INFORMATION</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><a href="#toc_002">INDEX TO FINANCIAL STATEMENTS</a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">F-1</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_011" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="gfd_001"></span>QUESTIONS
AND ANSWERS ABOUT THE DISTRIBUTION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
following questions and answers briefly address some commonly asked questions about the Distribution. They may not include all the information
that is important to you. We encourage you to read carefully this entire Prospectus and the other documents to which we have referred
you. We have included references in certain parts of this section to direct you to a more detailed discussion of each topic presented
in this section.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Q:
    </i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>What
    is the Distribution?</i></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A:
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Distribution is a method by which we will begin to separate from DSS. DSS currently beneficially owns through its wholly-owned subsidiary,
    DSS BioHealth Security, Inc., 3,877,282,251 shares of our Common Stock, representing 100% of our issued and outstanding capital stock.
    In connection with the Distribution, DSS, through its wholly-owned subsidiary DSS BioHealth Security, Inc., will distribute to holders
    of DSS Common Stock an aggregate of 485,161,488 Impact Shares. Following the Distribution DSS, through its wholly-owned subsidiary
    DSS BioHealth Security, Inc., will retain approximately an 87% ownership interest in the Company or otherwise possess control over
    us. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Q:
    </i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Will
    the number of shares of DSS Common Stock I own change as a result of a Distribution?</i></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A:
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No,
    the number of shares of DSS Common Stock you own will not change as a result of a Distribution. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Q:
    </i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>What
    are the reasons for the Distribution?</i></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A:
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Distribution is a method by which DSS will begin to carry out the intention of management and the board of directors of DSS (&#8220;DSS
    Board&#8221;) to take the Company public and to reward DSS stockholders via the issuance of the Impact Shares. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Q:
    </i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>What
    will I receive in a Distribution?</i></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A:
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    a holder of DSS Common Stock, you will receive a dividend of four Impact BioMedical Shares for every share of DSS Common Stock you
    hold on the Record Date. The distribution agent will distribute only whole Impact Shares in the Distribution. Your proportionate
    interest in DSS will not change as a result of the Distribution. For a more detailed description, see &#8220;The Distribution.&#8221;
    </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Q:
    </i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>What
    is being distributed to holders of DSS Common Stock in the Distribution?</i></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A:
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DSS
    will cause its wholly-owned subsidiary DSS BioHealth Security, Inc. to distribute 485,161,488 Impact BioMedical Shares in
    the Distribution. Subsequent to the Distribution DSS will maintain through its wholly-owned subsidiary DSS BioHealth Security, Inc.
    approximately 87% of our issued and outstanding shares of Common Stock. For more information on the shares being distributed in the
    Distribution, see &#8220;Description of Our Capital Stock&#8212;Common Stock.&#8221;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_011" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Q:
    </i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>What
    is the record date for the Distribution?</i></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A:
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    DSS Board has designated 5:00 p.m., New York City time, on July 10, 2023 as the record ownership date for the Distribution.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Q:
    </i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>When
    will the Distribution to holders of DSS Common Stock occur?</i></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A:
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Distribution will be effective as of 5:00 p.m., New York City time on [__], 2023 (the &#8220;Distribution Date&#8221;). On
    or shortly after the Distribution Date, the Impact Shares will be credited in book-entry accounts for stockholders entitled to receive
    those shares in the Distribution. We expect that it may take the distribution agent up to two weeks after each Distribution Date
    to fully distribute the Impact Shares to DSS stockholders. See &#8220;Questions and Answers About the Distribution&#8212;How will
    DSS distribute the Impact Shares?&#8221; for more information on how to access your book-entry account or your bank, brokerage or
    other account holding Impact Shares that you will receive in the Distribution. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Q:
    </i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>What
    do I have to do to participate in the Distribution?</i></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A:
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
    are not required to take any action, but we urge you to read this Prospectus carefully. Holders of DSS Common Stock on the Record
    Date will not need to pay any cash or deliver any other consideration, including any shares of DSS Common Stock, in order to receive
    Impact Shares in the Distribution. No stockholder approval of the Distribution is required. We are not asking you for a vote, and
    we request that you do not send us a proxy card. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Q:
    </i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
    I sell my shares of DSS Common Stock on or before the Distribution Date, will I still be entitled to receive shares of Common Stock
    in the Distribution? </i></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A:
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    you hold shares of DSS Common Stock as of the Record Date and decide to sell them on or before the relevant Distribution Date, you
    will not be entitled to receive Impact Shares. You should discuss these alternatives with your bank, broker or other nominee. Each Impact Share distributed as part of the Distribution will be not be eligible for resale until 180 days from
the date of the Company&#8217;s initial public offering becomes effective under the Securities Act, subject to the discretion of the Company
to lift the restriction sooner.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Q:
    </i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>How
    will DSS distribute the Impact Shares?</i></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A:
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Registered
    stockholders</span>: If you are a registered stockholder (meaning you own your shares of DSS Common Stock directly through DSS&#8217;s
    transfer agent, American Stock Transfer &amp; Trust Company, LLC), our transfer agent, American Stock Transfer &amp; Trust Company,
    LLC, which is serving as the distribution agent in connection with the Distribution, will credit the Impact Shares you receive
    in the Distribution to a new book-entry account on or shortly after the Distribution Date. Our distribution agent will mail you a
    book-entry account statement that reflects the number of Impact Shares you own. You will be able to access information regarding
    your book-entry account holding the Impact Shares at <span style="background-color: white">American Stock Transfer &amp; Trust
    Company, LLC.</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">&#8220;Street
    name&#8221; or beneficial stockholders</span>: If you own your shares of DSS Common Stock beneficially through a bank, broker or other
    nominee, your bank, broker or other nominee will credit your account with the Impact Shares you receive in the Distribution on or
    shortly after the Distribution Date. Please contact your bank, broker or other nominee for further information about your account.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    will not issue any physical stock certificates to any stockholders, even if requested. See &#8220;The Distribution&#8212;When and
    How You Will Receive Company Shares&#8221; for a more detailed explanation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_011" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Q:
    </i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>What
    is the U.S. federal income tax consequences to me of the Distribution?</i></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A:
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DSS
    shareholders will be subject to being taxed on the distribution of the Impact Shares.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
    &#8220;Material U.S. Federal Income Tax Consequences of the Distribution&#8221; for more information regarding the potential tax
    consequences to you from the Distribution.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>You
    should consult your own tax advisors regarding the particular tax consequences of the Distribution to you, including the applicability
    and effect of any U.S. federal, state, local and non-U.S. tax laws.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Q:
    </i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Does
    the Company intend to pay cash dividends?</i></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A:
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
    the Distribution, we do not anticipate paying any dividends on Impact Shares in the foreseeable future. See &#8220;Dividend Policy&#8221;
    for more information.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Q:
    </i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>How
    will our Common Stock trade?</i></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A:
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    shares of Common Stock are not listed on any securities exchange and the Impact Shares may be illiquid as we cannot predict whether
    any trading market will develop.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Q:
    </i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Will
    my shares of DSS Common Stock continue to trade on the NYSE American LLC exchange (&#8220;NYSE Amex&#8221;) following the Distribution?</i></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A:
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes.
    Following the Distribution, DSS Common Stock will continue to trade on the NYSE Amex under the symbol &#8220;DSS&#8221; through and
    after the Distribution Date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Q:
    </i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Will
    the Distribution affect the trading price of my DSS Common Stock?</i></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A:
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    do not expect the trading price of shares of DSS Common Stock immediately following the Distribution to be materially lower or higher
    than immediately prior to the Distribution. However, until the market has fully analyzed the value of DSS without its ownership of
    the Impact Shares, the trading price of shares of DSS Common Stock may fluctuate. We cannot assure you that, following the Distribution,
    the combined trading prices of the DSS Common Stock and Impact Shares will equal or exceed what the trading price of DSS Common Stock
    would have been in the absence of the Distribution. It is possible that after the Distribution, the combined equity value of DSS
    and the Impact Shares will be less than DSS&#8217;s equity value before the Distribution.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_011" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Q:
    </i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Do
    I have appraisal rights in connection with the Distribution?</i></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A:
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No.
    Holders of DSS Common Stock are not entitled to appraisal rights in connection with the Distribution.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Q:
    </i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>What
    will the relationship be between DSS and the Company after the Distribution?</i></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A:
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
    the Distribution, DSS, through its wholly-owned subsidiary DSS BioHealth Security, Inc., will still have a continuing stock ownership
    interest in and is expected to possess control over the Company, until and if the proposed public offering of the Company is completed.
    </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Q:
    </i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Who
    is the transfer agent and registrar for our Common Stock? Who is the distribution agent in connection with the Distribution? </i></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A:
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">American
    Stock Transfer &amp; Trust Company,</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">
    LLC</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">is the transfer agent and registrar for our Common
    Stock and is serving as the distribution agent in connection with the Distribution. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Q:
    </i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Are
    there risks associated with owning shares of our Common Stock?</i></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A:
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes.
    Our business faces both general and specific risks and uncertainties. Our business also faces risks relating to the Distribution.
    Accordingly, you should read carefully the information set forth in the section titled &#8220;Risk Factors&#8221; in this Prospectus.
    </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Q:
    </i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Are
    there any conditions to completing the Distribution?</i></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A:
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes.
    The Distribution is conditional upon a number of matters, including but not limited to the authorization and approval of the DSS
    Board (which has been obtained) and the declaration of effectiveness of our Registration Statement on Form S-1, of which this Prospectus
    is a part, by the Securities and Exchange Commission. See &#8220;Summary&#8212;Summary of the Distribution&#8212; Conditions to the
    Distribution&#8221; for a more detailed explanation of the conditions to completing the Distribution. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Q:
    </i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Can
    DSS decide to not proceed with the Distribution even if all the conditions to the Distribution have been met?</i></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A:
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes.
    Until the Distribution has occurred, the DSS Board has the right to not proceed with the Distribution, even if all the conditions
    are satisfied. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Q:
    </i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Could
    there be any other classes of capital stock of the Company outstanding after the Distribution?</i></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A:
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No.
    After giving effect to the Distribution, the only class of our capital stock then outstanding is expected to be our Common Stock.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Q:
    </i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Where
    can I get more information?</i></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A:
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    you have any questions relating to the mechanics of the Distribution, you should contact the distribution agent, <span style="background-color: white">American
    Stock Transfer &amp; Trust Company, LLC</span>, at:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 40pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 40pt; text-align: justify">6201
15<sup>th</sup> Avenue</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 40pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 40pt; text-align: justify">Brooklyn,
NY 11219</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 40pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 40pt; text-align: justify"><span style="background-color: white">800-468-9716</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 40pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 40pt; text-align: justify">helpast@equiniti.com</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 40pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 40pt; text-align: justify">https://equiniti.com/us/ast-access</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->v<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_011" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="gfd_002"></span>SUMMARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>This
summary highlights certain information contained elsewhere in this Prospectus and may not contain all the information that is important
to you. To understand fully and for a more complete description of the terms and conditions of the Distribution, you should read this
Prospectus in its entirety, including the information presented under the section titled &#8220;Risk Factors&#8221; and the consolidated
financial statements and related notes, and the documents to which you are referred. See &#8220;Where You Can Find More Information.&#8221;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Except
where the context otherwise requires, or where otherwise indicated, references to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221;
or &#8220;our&#8221; are to are to Impact BioMedical Inc. and its subsidiaries.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Introduction</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impact
BioMedical is the developer of unique and differentiated technologies to address unmet healthcare and wellness needs. Our activities
range from the discovery of technologies and leveraging those technologies to create and commercialize product candidates. Currently,
our operations are conducted, and our assets are owned primarily through our principal subsidiaries: (i) Global BioLife, Inc. (&#8220;Global
BioLife&#8221;), which was incorporated on April 14, 2017, (ii) Impact BioLife Science (&#8220;Impact BioLife&#8221;), which was incorporated
on August 28, 2020, Global BioMedical, Inc. (&#8220;Global BioMedical&#8221;), which was incorporated on April 18, 2017, and (iii)
Sweet Sense, Inc. (&#8220;Sweet Sense&#8221;), which was incorporated on April 30, 2018.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Associated with Our Business</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business is subject to numerous risks described in the section entitled &#8220;Risk Factors&#8221; and elsewhere in this prospectus.
You should carefully consider these risks. Some of these risks include, but are not limited to that:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    cannot guarantee that we will find third-parties or customers that are interested in purchasing, licensing, or co-developing our
    products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">even
    if we are able to establish licensing arrangements, we cannot guarantee that licensors will be successful in their development efforts
    of products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    cannot guarantee that our products will ever be approved for clinical testing or commercialization by the FDA;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    have not yet generated any revenue from our operations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    have a history of net losses, negative cash flows, and accumulated deficits over the last two years; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    occurrence of an uncontrolled event such as the Covid-19 pandemic, is likely to negatively affect our operations.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Implications
of Being an Emerging Growth Company and a Smaller Reporting Company</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a company with less than $1.235 billion in revenue during our last fiscal year, we qualify as an &#8220;emerging growth company,&#8221;
as defined in the Jumpstart Our Business Startups Act (the &#8220;JOBS Act&#8221;). Section 107 of the JOBS Act provides that an emerging
growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as
amended (or the &#8220;Securities Act&#8221;), for complying with new or revised accounting standards. Thus, an emerging growth company
can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
emerging growth company may also take advantage of reduced reporting requirements that are otherwise applicable to public companies.
These provisions include, but are not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may present only two years of audited financial statements and only two years of related Management&#8217;s Discussion and Analysis
    of Financial Condition and Results of Operations; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">not
    being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, as amended,
    or the Sarbanes-Oxley Act; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced
    disclosure obligations regarding executive compensation in our periodic reports, proxy statements and registration statements; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exemptions
    from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may take advantage of these provisions until the last day of our fiscal year following the fifth anniversary of the date of the first
sale of our common equity securities pursuant to an effective registration statement under the Securities Act, which such fifth anniversary
will occur in 2026. However, if certain events occur prior to the end of such five-year period, including if we become a &#8220;large
accelerated filer,&#8221; our annual gross revenues exceed $1.235 billion or we issue more than $1.0 billion of non-convertible debt
in any three-year period, we will cease to be an emerging growth company prior to the end of such five-year period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<!-- Field: Page; Sequence: 8; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_011" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have elected to take advantage of certain of the reduced disclosure obligations regarding executive compensation in this prospectus and,
as long as we continue to qualify as an emerging growth company, we may elect to take advantage of this and other reduced burdens in
future filings. As a result, the information that we provide to our stockholders may be different than you might receive from other public
reporting companies in which you hold equity interests.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also a &#8220;smaller reporting company,&#8221; as defined under SEC Regulation S-K. As such, we also are exempt from the auditor
attestation requirements of Section 404 of the Sarbanes-Oxley Act and also are subject to less extensive disclosure requirements regarding
executive compensation in our periodic reports and proxy statements. We will continue to be deemed a smaller reporting company until
our public float exceeds $75 million on the last day of our second fiscal quarter in the preceding fiscal year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Business
Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impact
BioMedical Inc. (&#8220;Impact&#8221;) targets urgent medical needs and expands the borders of medical and pharmaceutical science.
Impact drives mission-oriented research and development, and commercialization of solutions for medical advances in human wellness
and healthcare. By leveraging technology and new science with strategic partnerships, Impact BioMedical provides advances in drug
discovery for the prevention, inhibition, and treatment of neurological, oncology and immuno-related diseases. Other exciting
technologies include a breakthrough alternative sugar aimed to combat diabetes and functional fragrance formulations aimed at the
industrial and medical industry. The research and development efforts have been primarily conducted in collaboration with
GRDG Sciences, LLC (&#8220;GRDG&#8221;) and with the expertise of Mr. Daryl Thompson as its Director of Scientific
Initiatives. We have initiated research regarding universal therapeutics as part of an attempt to help address some of the
world&#8217;s deadliest diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
business model of Impact BioMedical revolves around two methodologies &#8211; Licensing and Sales Distribution. Impact BioMedical
develops valuable and unique patented technologies which will be licensed to pharmaceutical, large consumer package goods companies
and venture capitalists in exchange for usage licensing and royalties. Impact also utilizes the DSS ecosystem to leverage distribution
networks on a global scale. Impact will engage in branded and private labelling of certain products for sales generation through these
channels. This global distribution model will give direct access to end users of Impact&#8217;s nutraceutical and health related products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Below
is a list of our principal subsidiaries:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impact
    BioLife Science, Inc.;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Global
    BioMedical, Inc.;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Global
    BioLife, Inc.; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sweet
    Sense, Inc.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Impact
BioLife Science, Inc</span>.</i> We are the sole owner of the outstanding equity of Impact BioLife Science, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Global
Biomedical, Inc.</span></i> We own 90.91% of Global Biomedical, Inc. outstanding equity, and the balance minority equity owner is Peggy
Tang.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Global
BioLife, Inc</span></i>. Through our majority owned subsidiary Global Biomedical, Inc., we own 90% of the outstanding equity of Global
BioLife, Inc. The other equity owner is Holista CollTech Limited (&#8220;Holista&#8221;) (10%).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Sweet
Sense, Inc</span></i><span style="text-decoration: underline">.</span> We are the owner of 50% of the outstanding equity of Sweet Sense. The other equity owner is BioLife Sugar,
Inc. (&#8220;BioLife Sugar&#8221;).</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_011" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Below
is an organization chart showing our ownership structure and ownership interests.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><img src="forms-1a_001.jpg" alt="" style="height: 867px; width: 670px"/>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impact
BioMedical and our majority-owned subsidiaries own or have rights to a portfolio of biomedical intellectual property and leverages its
scientific know-how and intellectual property rights to develop various emerging technologies, including biopharmaceuticals, antivirals,
antimicrobials, sugar alternatives, insect repellents, fragrances, bioplastics and natural preservatives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_011" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impact
BioMedical has had several important and valuable products, technology, or compounds that are in continuing development and/or licensing
stages. The Company has not conducted and has no current plans to conduct any preclinical testing for these products, technology,
or compounds:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LineBacker:
    Multi-faceted therapeutic platform intended for metabolic, neurologic, cancer, and infectious diseases.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equivir:
    A compound intended for antiviral infection treatments. Equivir/Nemovir is a novel blend of FDA Generally Recognized as Safe
    (&#8220;GRAS&#8221;) eligible natural compounds. These compounds are generally sourced from fruits, vegetables, and other
    natural substances. Please note, the FDA has not approved this product, GRAS designation means that the FDA does not question the
    basis for a notifier&#8217;s GRAS determination, and GRAS determination does not increase the likelihood that product candidates
    will receive marketing approval.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Laetose:
    Laetose technology is derived from a unique combination of sugar and other naturally occurring compounds which demonstrate
    the ability to inhibit the inflammatory and metabolic response of sugar alone. This compound is a sugar alternative aimed to combat diabetes.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3F:
    A botanical compound intended to serve as an insect repellent and anti-microbial agent. 3F is a unique formulation of specialized
    ingredients from naturally occurring botanical sources.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3F Mosquito Repellent:
    3F repellent contains botanical ingredients that mosquitos avoid. These ingredients affect the mosquito&#8217;s
    receptors, essentially making the insect blind to a human&#8217;s presence. This can be utilized as a stand-alone repellent or as
    an additive in detergents, lotions, shampoo, and other substances to provide mosquito protection.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3F
    Antimicrobial: 3F antimicrobial contains botanical ingredients known to kill viruses. These ingredients are intended to inhibit
    viral replication. This can be utilized as a stand-alone antimicrobial or as an additive in detergents, lotions, shampoo, fabrics,
    and other substances.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span>&#160;</p>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_011" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commercialization
Business Strategies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business model revolves mainly around two approaches &#8211; Licensing and Sales Distribution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">1.
Licensing</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
licensing strategy includes developing unique patented technologies which would then be licensed to external partners for developing,
registration, and commercialization as appropriate. We believe that interest in licensing certain projects may rise over time as validating
data becomes available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June of 2022, Impact BioMedical signed a License Agreement with ProPhase Labs to produce and distribute compound Equivir, which
has shown potential as a treatment to limit the occurrence of or reduce the risk or severity of viral outbreaks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In July of 2022, Global BioLife, Inc., a subsidiary
of Impact, executed a license agreement with ProPhase BioPharma, Inc. (&#8220;PBIO&#8221;), a subsidiary of ProPhase Labs, Inc., a rapidly
growing and diversified diagnostics, genomics and biotech company, for Global BioLife&#8217;s Linebacker portfolio (LB-1 and LB-2), two
patented small molecule PIM kinase inhibitors with significant potential across multiple therapeutic indications.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">2.
Sales Distribution</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are intending to pursue 3<sup>rd</sup> party partnerships specifically with large manufactures in the pharmaceutical, food, health and
beauty, and nutraceutical industries to commercialize our products, ideas and intellectual property. We will leverage their product development,
commercialization and distribution capabilities to take products to market through a licensing and/or private label sales model.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
<span style="text-decoration: underline">Research and Development</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have secured arrangements with certain affiliates to undertake activities to improve existing product candidates and develop new ones.
We believe the timely development of new, and the enhancement of our existing products, is essential to our success. Although we intend
to invest a substantial amount of our resources in research and development, there is no guarantee that our investment will translate
into improvements of existing products or the development of new products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Stockholders
Agreement between Global BioLife and the Global BioLife Stockholders</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 26, 2017, Global BioLife entered into a stockholders&#8217; agreement with its stockholders Global BioMedical, GRDG and Holista
(the &#8220;Global BioLife Stockholders&#8217; Agreement&#8221;). Pursuant to the Global BioLife Stockholder&#8217;s Agreement, GRDG has agreed to contribute to Global BioLife any and
all right, title, interest and ownership held by GRDG in any patent related to the uses of the &#8220;Linebacker Patents&#8221; as defined
in the Global BioLife Stockholders&#8217; Agreement. Further, pursuant to the Global BioLife Stockholders Agreement, GRDG has agreed
to contribute to Global BioLife the advice and services of Daryl Thompson as a scientist during the term of the agreement in connection
with the development of the Linebacker Patents and all projects associated therewith, as well as such other projects as Global BioLife
may from time to time pursue. In addition, Global BioLife agreed to contract with GRDG for the needed research in order to develop
the Linebacker Patents as well as new intellectual property. Compensation paid by Global BioLife for this work, if any, shall be provided
for in Global BioLife&#8217; budget</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Global BioLife Stockholders&#8217; Agreement, Global Biomedical has agreed to contribute to Global BioLife the funds set forth
in the Global BioLife budget and such reasonable amounts as the Global BioLife board of directors shall in future annual periods authorize
as Global BioLife&#8217;s business plan and budget. Such budget shall include (i) a payment of $20,994 per month to GRDG and (ii) such
other amounts as shall be necessary to fund the scientific operations that the Global BioLife board shall agree to pursue. The monthly
payments were adjusted for the increase in rent of GRDG office and general inflation. Current monthly payments approximate to $43,000.
For the years ended December 31, 2022 and 2021, the Company incurred expenses of $546,000 and $509,176, respectively. On December 31,
2022 and 2021, the Company owed this related party $0, and had prepaid monthly fees approximating $43,000. For the three months ended
March 31, 2023, this funding approximates $43,000 per month, and incurred approximately $129,000 in expenses. On March 31, 2023 and March
31, 2022, the Company owed this related party $0 and had prepaid monthly fees approximating $43,000 and $43,000, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the Global BioLife Stockholders&#8217; Agreement,
Holista has agreed to (i) assist in the global commercialization of Global BioLife&#8217;s intellectual property, (ii) assist in the
initiation and development of joint venture opportunities for Global BioLife, and (iii) provide the expertise of Dr. Rajen M. Dato to
Global BioLife as strategic director.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_011" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Global BioLife Stockholders&#8217; Agreement shall terminate (a) upon the dissolution and winding up of Global BioLife or (b) on the
date the parties terminate the agreement by unanimous written consent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 22, 2018, the parties to the Global BioLife Stockholders&#8217; Agreement entered into Amendment No. 1 to the agreement (&#8220;Amendment
No. 1 to the Global BioLife Stockholders Agreement&#8221;), and in August of 2020 the parties entered into Amendment No. 2 to the agreement
(&#8220;Amendment No. 2 to the Global BioLife Stockholders Agreement&#8221;). Pursuant to Amendment No. 2, the parties to the Global
BioLife Stockholders Agreement agreed to waive the obligations of GRDG to contribute any further inventions, discoveries or other items
of intellectual property developed by GRDG during the term of the Stockholders&#8217; Agreement subsequent to the date of Amendment No.
2, except for any invention, discovery or other items of intellectual property which is directly related to, or necessary for the sale,
licensing or further development of intellectual property owned by Global BioLife.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Licensing
Proceeds Distribution Agreement</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2022, Impact entered into a new licensing proceeds distribution agreement whereas GRDG will continue to invent and develop
Improvements and Discoveries for and on behalf Impact and agree to assign any such Discoveries/Improvements/advances to Impact generated
by its efforts and through the resources funded by Impact, directly or indirectly. Any such Discoveries assigned to Impact would be considered
Intellectual Property under this Agreement such that GRDG would receive 20% of the gross licensing or sale proceeds received by Impact
from the licensing of such discoveries. Under the same agreement, GRDG transferred all of its right, title, and interest that GRDG has,
if any, in Global as set forth in the Global Agreement back to Global, and all right, title and interest that GRDG has, if any, in Impact
back to Impact, and hereinafter having no further ownership, control, or interest in either Global or Impact.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Stockholders
Agreement between Impact BioLife and the Impact BioLife Stockholders</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2020, Impact BioLife entered into a stockholder&#8217;s agreement with its stockholders Impact BioMedical and GRDG (the &#8220;Impact
BioLife Stockholders&#8217; Agreement&#8221;). Pursuant to the Impact BioLife Stockholders&#8217; Agreement, GRDG agreed to (i) transfer
certain intellectual property as identified in the Stockholders&#8217; Agreement to Impact BioLife, (ii) present all suitable technologies
developed by GRDG to Impact BioLife, so as to provide Impact BioLife with the opportunity to fund, own and develop any intellectual property
developed by GRDG and (iii) retain the advice and services of Mr. Daryl Thompson as a scientist during the term of the Impact BioLife
Stockholders&#8217; Agreement in connection with all projects as Impact BioLife may from time to time pursue. Further, pursuant to the
Impact BioLife Stockholders&#8217; Agreement, GRDG also agreed that Daryl Thompson will devote most of his professional time and efforts
to the business of Impact BioLife, including but not limited to, the development of new intellectual property for Impact BioLife.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, pursuant to the Impact BioLife Stockholder&#8217;s Agreement, the Company has agreed to contribute to Impact BioLife such reasonable
amounts as the board of directors of Impact BioLife shall in future annual periods authorize as Impact BioLife&#8217;s business plan
and budget (the &#8220;Impact BioLife Budget&#8221;). The Impact BioLife Budget shall include (i) a payment approximating $43,000 per
month to GRDG and (ii) such other amounts as shall be necessary to fund the research, development and other scientific operations that
the Impact BioLife board of directors shall agree to pursue. For the years ended December 31, 2022 and 2021, the Company incurred expenses
of $546,000 and $509,176, respectively. On December 31, 2022 and 2021, the Company owed this related party $0, and had prepaid monthly
fees approximating $43,000. For the three months ended March 31, 2023, this funding approximates $43,000 per month, and incurred approximately
$129,000 in expenses. On March 31, 2023 and March 31, 2022, the Company owed this related party $0 and had prepaid monthly fees approximating
$43,000 and $43,000, respectively.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Impact BioLife Stockholders&#8217; Agreement, the board of directors of Impact BioLife shall never be less than one nor more than
five directors. GRDG shall be entitled to nominate one director to the Impact BioLife board of directors so long as it shall remain
a stockholder of Impact BioLife. The Company shall be entitled to nominate the remaining directors of the Impact BioLife. In addition,
pursuant to the Impact BioLife Stockholders&#8217; Agreement, so long as it is a stockholder of Impact BioLife, the Company is entitled
to appoint Impact BioLife&#8217;s chief executive officer, who, at the discretion of the Company, may also serve as a director of the
Impact BioLife board of directors. The parties to the Impact BioLife Stockholders&#8217; Agreement have agreed that the initial directors
of the Impact BioLife board of directors shall be Heng Fai Ambrose Chan, Frank D. Heuszel and Daryl Thompson. The Company shall appoint
the chairman of the Impact BioLife board of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Impact BioLife Stockholders&#8217; Agreement will terminate (a) upon the dissolution and winding up of Impact BioLife, (b) on the date
the parties terminate the agreement by unanimous written, (c) on the fifth anniversary of the date of the Impact BioLife Stockholders&#8217;
Agreement, unless the parties mutually agree to an extension, or (d) upon three months&#8217; written notice by either party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Licensing Proceeds Distribution Agreement
between GRDG Sciences, LLC, Global BioLife, Inc., and Impact BioLife Sciences, Inc., to include Impact Biomedical Inc.</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 15, 2022, the Company and Impact BioLife Sciences, Inc. (together, &#8220;Impact&#8221;), entered into a Licensing Proceeds Distribution Agreement (the &#8220;LPDA&#8221;)
with the Company&#8217;s subsidiary, Global BioLife, Inc. (&#8220;Global,&#8221; and together with Impact BioLife Sciences, Inc. and
the Company, the &#8220;Impact Parties&#8221;), and GRDG Sciences, LLC (&#8220;GRDG&#8221;), pursuant to which the parties clarified
the consideration due to GRDG under pre-existing agreements by and between GRDG and the Impact Parties. Pursuant to the LPDA, GRDG will
receive 20% of the gross licensing or sale proceeds from any of its developed improvements for and on behalf of Global and the Impact
Parties. Further, Impact agreed to provide periodic payments to GRDG for the purpose of paying or reimbursing certain salaries, overhead,
office rent reimbursements, and other operating costs. As compensation, GRDG will receive 20% of the gross licensing or sale proceeds
received by the Impact Parties for any intellectual property generated. Pursuant to the GRDG, Impact retroactively acknowledged that
GDRG (1) is not a shareholder in any company or subsidiary of the Impact Parties, and (2) that GDRG&#8217;s full consideration for the
improvement developments which it has or will develop is/was (a) monthly operating cash flow payments, and (2) 20% of the gross proceeds
from any licensing or sale of such improvements and discoveries. In addition, GRDG agreed to transfer all of its right, title and interest
in Global to Global, and all right, title and interest in Impact to Impact. Global has agreed to provide GRDG a financial interest in
revenue received directed to the licensing of the Global intellectual property, and Impact has agreed to provide GRDG an interest in
revenue received directed to the licensing of the impact intellectual property.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_011" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share
Exchange Transaction</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 21, 2020, we closed on a Share Exchange Agreement by and among DSS, DSS BioHealth Security, Inc., Alset International Ltd. (formerly
Singapore eDevelopment Ltd.), and Global Biomedical Pte Ltd. (&#8220;GBM&#8221;), pursuant to which we became a wholly-owned subsidiary
of DSS BioHealth Security, Inc. Shortly after closing, Frank D. Heuszel, Jason Grady, and John Thatch were appointed directors,
and Mr. Heng Fai Ambrose Chan remained on the Board of Directors and appointed Chief Executive Officer, Mr. Heuszel was appointed President,
Mr. Grady was appointed Chief Operating Officer and Todd Macko was appointed Secretary and Treasurer, replacing the officers and directors
who resigned in connection with the share exchange.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Chan is the Chief Executive Officer and largest shareholder of Alset International Ltd., as well as the Chairman of the Board and largest
shareholder of the DSS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impact
BioMedical Inc. is a Nevada corporation and was incorporated in October 2018. Our principal executive offices are located at 275
Wiregrass Parkway, West Henrietta, NY 14586. Our telephone number is +1-585-325-3610. Our website address is https://www.impbio.com.
Our website and the information contained thereon, or connected thereto, does not and will not constitute part of this Prospectus or
the Registration Statement on Form S-1 of which this Prospectus is a part.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
of the Distribution</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Distributing
    Company</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DSS,
    Inc., a New York corporation, which beneficially owns through its wholly-owned subsidiary DSS BioHealth Security, Inc. 3,877,282,251
    shares of our Common Stock, representing 100% of our outstanding shares of our Common Stock prior to the Distribution. After
    the Distribution, DSS will own approximately 87% of our Common Stock.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Distributed
    Company</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impact
    BioMedical Inc., a Nevada corporation and a subsidiary of DSS. At the time of the Distribution, we operate primarily through our
    principal subsidiaries, Impact BioLife, Global Biomedical, Global BioLife and Sweet Sense. Through our principal subsidiaries, we
    are committed to both funding research, developing and commercializing new offerings in pharmaceuticals, consumer and wellness products,
    including, but not limited to, a focus on: (i) the development of a universal therapeutic drug platform; (ii) a new sugar substitute;
    and (iii) a multi-use fragrance developed for industrial and medical applications, including an insect repellant, and (iv) an
    OTC medication with broad antiviral activity. Impact. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_011" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Distributed
    Securities in the Distribution</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">485,161,488
    </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of our Common Stock indirectly owned
    by DSS, which represent approximately 12</span>% <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of our
    Common Stock issued and outstanding immediately prior to the Distribution. Based on 140,264,250 shares of DSS Common Stock outstanding
    as of the close of business on the Record Date, not including the Affiliate Shares, this reflects a distribution ratio of four (4)
    Impact Shares for every one (1) share of DSS Common Stock.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Record
    Date</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Record Date is 5:00 p.m., New York City time, on July 10, 2023.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Distribution
    Date</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Distribution Date is [__], 2023, and we expect that the Distribution will be effective as of 5:00 p.m., New York City time.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Distribution
Ratio</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
    holder of DSS Common Stock will receive four (4) shares of our Common Stock for every one (1) share of DSS Common Stock it holds
    on the Record Date. The distribution agent will distribute only whole shares of our Common Stock in the Distribution.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
    note that if you sell your shares of DSS Common Stock on or before the Distribution Date, the buyer of those shares will in most
    circumstances be entitled to receive the shares of our Common Stock to be distributed in respect of the DSS shares that you sold.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
Distribution</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    the Distribution Date, DSS will release the shares of our Common Stock to the distribution agent to distribute to DSS stockholders.
    DSS will distribute our shares in book-entry form, and thus we will not issue any physical stock certificates. We expect that it
    will take the distribution agent up to two weeks to electronically issue shares of our Common Stock to you or your bank or brokerage
    firm on your behalf by way of direct registration in book-entry form. If you own your shares of DSS Common Stock through a bank,
    broker or other nominee, your bank, broker or other nominee will credit your account with the whole shares of our Common Stock that
    you receive in the Distribution on or shortly after the Distribution Date. You will not be required to make any payment, surrender
    or exchange your shares of DSS Common Stock or take any other action to receive your shares of our Common Stock.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_011" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Conditions
to the Distribution</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Distribution is subject to the satisfaction, or the DSS Board&#8217;s waiver, of the following conditions:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 44%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    DSS Board shall have authorized and approved the Distribution by its wholly-owned subsidiary DSS BioHealth Security, Inc. and not
    withdrawn such authorization and approval, and shall have declared the dividend of our Common Stock to DSS stockholders;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    SEC shall have declared effective our Registration Statement on Form S-1, of which this Prospectus is a part, under the Securities
    Act of 1933, as amended (the &#8220;Securities Act&#8221;), and no stop order suspending the effectiveness of our Registration Statement
    shall be in effect and no proceedings for that purpose shall be pending before or threatened by the SEC;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
    order, injunction or decree issued by any governmental authority of competent jurisdiction or other legal restraint or prohibition
    preventing consummation of the Distribution shall be in effect, and no other event outside the control of DSS shall have occurred
    or failed to occur that prevents the consummation of the Distribution; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
    other events or developments shall have occurred prior to the Distribution Date that, in the sole judgment of the DSS Board, would
    result in the Distribution having a material adverse effect on DSS or its stockholders; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Each Impact Share distributed as part of the Distribution will be not be eligible for resale until 180 days from
the date of the Company&#8217;s initial public offering becomes effective under the Securities Act, subject to the discretion of the Company
to lift the restriction sooner.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 253pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    fulfillment of the foregoing conditions will not create any obligation on the part of DSS to effect the Distribution. We are not
    aware of any material federal, foreign or state regulatory requirements with which we must comply, other than SEC rules and regulations,
    or any material approvals that we must obtain, other than the SEC&#8217;s declaration of the effectiveness of the Registration Statement,
    in connection with the Distribution. DSS has the right not to complete the Distribution if, at any time, the DSS Board determines,
    in its sole and absolute discretion, that the Distribution is not in the best interests of DSS or its stockholders or is otherwise
    not advisable. For a more detailed description, see &#8220;The Distribution&#8212;Conditions to the Distribution.&#8221;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    Market</b></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    of our outstanding shares of Common Stock are currently beneficially owned by DSS through its wholly-owned subsidiary DSS BioHealth
    Security, Inc. Accordingly, there currently is no public trading market for the Common Stock. The Common Stock is currently not listed
    for trading on any stock exchange or market. The Common Stock may be illiquid as we cannot predict whether any trading market will
    develop.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_011" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Tax
    Consequences to DS Stockholders</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DSS
    shareholders will be subject to a taxable event on the distribution of the Impact Shares. See &#8220;Material U.S. Federal Income
    Tax Consequences of the Distribution&#8221; for more information regarding the potential tax consequences to you of the Distribution.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>You
    should consult your own tax advisors regarding the particular tax consequences of the Distribution to you, including the applicability
    and effect of any U.S. federal, state, local and non-U.S. tax laws.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dividend
    Policy</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
    the Distribution, we do not anticipate paying any cash dividends on our Common Stock in the foreseeable future. See &#8220;Dividend
    Policy&#8221; for more information.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Transfer
    Agent and Distribution Agent</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">American
    Stock Transfer &amp; Trust Company,</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> LLC, the
    transfer agent and registrar for our Common Stock, will serve as distribution agent in connection with the Distribution.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risk
Factors</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    business faces both general and specific risks and uncertainties. Our business also faces risks relating to the Distribution. Accordingly,
    you should read carefully the information set forth under the section titled &#8220;Risk Factors.&#8221;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_011" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="gfd_003"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RISK
FACTORS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>You
should carefully consider all the information in this Prospectus and each of the risks described below, which we believe are the principal
risks that we face. Some of the risks relate to our business, others to the </i>Distribution<i>. Some risks relate principally to the
securities markets and ownership of our Common Stock. The risks and uncertainties described below are not the only ones faced by us.
Additional risks and uncertainties not presently known or that are currently deemed immaterial also may impair our business operations.
If any of the following risks occur, our business, financial condition, operating results and cash flows and the trading price of our
Common Stock could be materially adversely affected.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Relating to the Distribution</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
Distribution may not be completed on the terms or timeline currently contemplated, if at all.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we are actively engaged in planning for the Distribution, unanticipated developments could delay or negatively affect the Distribution,
including, but not limited to, those related to the filing and effectiveness of appropriate filings with the SEC and receiving any required
regulatory approvals. In addition, until a Distribution has occurred, the DSS Board, in its sole discretion, has the right to not proceed
with the Distribution, even if all the conditions are satisfied. Therefore, the Distribution may not be completed on the terms or timeline
currently contemplated, if at all<b><i>.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>DSS
expects the Distribution to be treated as a taxable non-liquidating distribution to its stockholders. As a result, a U.S. stockholder
of DSS may have a U.S. Federal income tax liability in respect of the Distribution without the receipt of cash from DSS or Impact.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DSS
expects the Distribution to be treated as a taxable, non-liquidating distribution to its stockholders. As such, for U.S. federal income
tax purposes, each U.S. stockholder of DSS receiving shares of Impact Common Stock in the Distribution would be treated as if such stockholder
had received a distribution in an amount equal to the fair market value of Impact Common Stock received, which would result in (1) a
taxable dividend to the extent of such stockholder&#8217;s pro rata share of DSS&#8217;s current and accumulated earnings and profits,
(2) a reduction in such stockholder&#8217;s basis (but not below zero) in DSS common stock to the extent the amount received exceeds
such stockholder&#8217;s share of earnings and profits and (3) a taxable gain to the extent the amount received exceeds the sum of the
amount treated as a dividend and the stockholder&#8217;s basis in the DSS Common Stock. Accordingly, such stockholder may have a U.S.
federal income tax liability in respect of the Distribution without the receipt of cash from DSS or Impact.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
a more detailed discussion, see the section entitled &#8220;The Distribution &#8211; U.S. Federal Income Tax Consequences of the Distribution&#8221;
below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have a limited operating history, and our historical financial information may not be a reliable indicator of our future results.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no historical financial information about us upon which to base an evaluation of our performance. As of the date of this report, we
have not generated any revenues from operations. We cannot guarantee we will be successful in our business operations. Our business is
subject to risks inherent in the establishment of a new business enterprise, including limited capital resources, possible delays our
research, testing and marketing efforts or wider economic downturns. For additional information about our past financial performance
and the basis of presentation of our financial statements, see &#8220;Management&#8217;s Discussion and Analysis of Financial Condition
and Results of Operations&#8221; and our historical financial statements and the notes thereto included elsewhere in this Prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_011" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Relating to Our Business</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we do not adequately protect our intellectual property rights, our operations may be materially harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on and expect to continue to rely on agreements with parties with whom we have relationships, as well as patent, trademark and trade
secret protection laws, to protect our intellectual property and proprietary rights. We cannot assure you that we can adequately protect
our intellectual property or successfully prosecute potential infringement of its intellectual property rights. Also, we cannot assure
you that others will not assert rights in, or ownership of, trademarks and other proprietary rights of ours or that we will be able to
successfully resolve these types of conflicts to our satisfaction. Our failure to protect our intellectual property rights may result
in a loss in potential revenue and could materially harm our operations and financial condition</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>New
legislation, regulations or rules related to obtaining patents or enforcing patents could significantly increase our operating costs
and decrease any potential revenue we might otherwise make.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
spend a significant amount of resources on its patent assets. If new legislation, regulations or rules are implemented either by Congress,
the U.S. Patent and Trademark Office (the &#8220;USPTO&#8221;) or the courts that impact the patent application process, the patent enforcement
process or the rights of patent holders, these changes could negatively affect its expenses, potential revenue and could negatively impact
the value of its assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Safety
and effectiveness concerns can have significant negative impacts on sales and results of operations, lead to litigation and cause reputational
damage.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concerns
about product safety, whether raised internally or by litigants, regulators or consumer advocates, and whether or not based on scientific
evidence, can result in safety alerts, product recalls, governmental investigations, regulatory action on the part of the FDA (or its
counterpart in other countries), private claims and lawsuits, payment of fines and settlements, declining sales and reputational damage.
These circumstances can also result in damage to brand image, brand equity and consumer trust in products. Product recalls could in the
future prompt government investigations and inspections, the shutdown of manufacturing facilities, continued product shortages and related
sales declines, significant remediation costs, reputational damage, possible civil penalties and criminal prosecution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Significant
challenges or delays in our innovation and development of new products, technologies and indications could have an adverse impact on
our long-term success.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
continued growth and success depend on our ability to innovate and develop new and differentiated products and services that address
the evolving health care needs of patients, providers and consumers. Development of successful products and technologies may also be
necessary to offset revenue losses should our products lose market share due to various factors such as competition and loss of patent
exclusivity. We cannot be certain when or whether we will be able to develop, license or otherwise acquire companies, products and technologies,
whether particular product candidates will be granted regulatory approval, and, if approved, whether the products will be commercially
successful. We pursue product development through internal research and development as well as through collaborations, acquisitions,
joint ventures and licensing or other arrangements with third parties. In all of these contexts, developing new products, particularly
biotechnology products, requires a significant commitment of resources over many years. Only a very few biopharmaceutical research and
development programs result in commercially viable products. The process depends on many factors, including the ability to discern patients&#8217;
and healthcare providers&#8217; future needs; develop new compounds, strategies and technologies; achieve successful clinical trial results;
secure effective intellectual property protection; obtain regulatory approvals on a timely basis; and, if and when they reach the market,
successfully differentiate its products from competing products and approaches to treatment. New products or enhancements to existing
products may not be accepted quickly or significantly in the marketplace for healthcare providers, and there may be uncertainty over
third-party reimbursement. Even following initial regulatory approval, the success of a product can be adversely impacted by safety and
efficacy findings in larger patient populations, as well as market entry of competitive products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are subject to risks related to corporate social responsibility and reputational matters.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
reputation and the reputation of our brands, including the perception held by our customers, end-users, business partners, investors,
other key stakeholders and the communities in which we do business are influenced by various factors. There is an increased focus from
our stakeholders on ESG practices and disclosure - and if we fail, or are perceived to have failed, in any number of ESG matters, such
as environmental stewardship, inclusion and diversity, workplace conduct and support for local communities, or to effectively respond
to changes in, or new, legal or regulatory requirements concerning climate change or other sustainability concerns, our reputation or
the reputation of our brands may suffer. Such damage to our reputation and the reputation of our brands may negatively impact our business,
financial condition and results of operations. In addition, negative or inaccurate postings or comments on social media or networking
websites about the Company or our brands could generate adverse publicity that could damage our reputation or the reputation of our brands.
If we are unable to effectively manage real or perceived issues, including concerns about product quality, safety, corporate social responsibility
or other matters, sentiments toward the Company or our products could be negatively impacted, and our financial results could suffer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>We may not have adequate funds to implement
our business plan</i></b>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="background-color: white">Although
we have received capital from our parent companies to meet our working capital and financing needs in the past, additional financing
may be required in order to meet our current and projected cash requirements for operations.&#160;</span>We cannot assure that we will
secure all or any of the funding we anticipate. If our entire original capital is fully expended and additional costs cannot be funded
from borrowings or capital from other sources, then our financial condition, results of operations and business performance would be
materially adversely affected. We cannot assure that we will have adequate capital or financing to conduct our business or to grow.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Currently,
there is no public market for our securities, and there can be no assurances that any public market will ever develop.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
our Common Stock is not listed or quoted on any public market, exchange, or quotation system. Although we plan to take steps to have
our Common Stock publicly traded, a market for our Common Stock may never develop. Even if we are successful in developing a public market,
there may not be enough liquidity in such market to enable stockholders to sell their stock. If a public market for our Common Stock
does not develop, DSS stockholders may not be able to re-sell the shares of our Common Stock that they have received, rendering their
shares effectively worthless.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_011" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Future
sales of our Common Stock in the public market could lower our stock price, and any additional capital raised by us through the sale
of equity or convertible securities may dilute our stockholders&#8217; ownership in us.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may sell additional shares of our Common Stock in public or private offerings. We also may issue convertible debt or equity securities.
No prediction can be made as to the effect, if any, that future sales or distributions of our Common Stock will have on the market price
of our Common Stock from time to time. Sales or distributions of substantial amounts of our Common Stock, or the perception that such
sales or distributions are likely to occur, could adversely affect the prevailing fair market price for our Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
do not intend to pay any cash dividends in the foreseeable future and, therefore, any return on your investment in our Common Stock must
come from increases in the fair market value of our Common Stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not intend to pay cash dividends on our Common Stock in the foreseeable future. We expect to retain future earnings, if any, for reinvestment
in our business. Also, any credit agreements, which we may enter into, may restrict our ability to pay dividends. Whether we pay cash
dividends in the future will be at the discretion of our Board and will be dependent upon our financial condition, results of operations,
cash requirements, future prospects and any other factors our Board deems relevant. Therefore, any return on your investment in our Common
Stock must come from increases in the fair market value of our Common Stock. For more information, see &#8220;Dividend Policy.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Your
percentage ownership in the Company may be diluted in the future.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Your
percentage ownership in the Company may be diluted in the future because of equity awards that we may grant to our directors, officers
and other employees. In addition, we may issue equity as all or part of the consideration paid for acquisitions and strategic investments
that we may make in the future or as necessary to finance our ongoing operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="gfd_004"></span>CAUTIONARY
STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Prospectus contains &#8220;forward-looking statements&#8221; within the meaning of the federal securities laws. Forward-looking statements
give our current expectations or forecasts of future events. You can identify these statements because they do not relate strictly to
historical or current facts. In some cases, these forward-looking statements can be identified by words or phrases such as &#8220;may,&#8221;
&#8220;will,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;aim,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221;
&#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;is/are likely to&#8221; or other similar
expressions. They also appear in any discussion of future operating or financial performance. In particular, these include statements
relating to future actions, future performance of our products, level of expenses and anticipated expense reductions, the outcome of
any legal proceedings, and financial results. Although we believe that we are basing our expectations and beliefs on reasonable assumptions
within the bounds of what we currently know about our business and operations, there can be no assurance that our actual results will
not differ materially from what we expect or believe. The following factors could cause our actual results to differ from our expectations
or beliefs:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    potential adverse impact on our business resulting from the Distribution;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    adverse effect from a decline in the securities markets or from catastrophic, unpredictable events like a global health pandemic;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    decline in the performance of our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    general downturn in the economy;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in government policy or regulation;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in our ability to attract or retain key employees;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unforeseen
    costs and other effects related to legal proceedings or investigations of governmental and self-regulatory organizations; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
    factors (including the risks contained in the section titled &#8220;Risk Factors&#8221;) relating to our industry, our operations
    and results of operations.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preceding list is not intended to be an exhaustive list of all of our forward-looking statements. Forward-looking statements are not
historical facts, and are based on current expectations, estimates and projections about our industry, management&#8217;s beliefs and
certain assumptions made by management, many of which, by their nature, are inherently uncertain and beyond our control. Accordingly,
you are cautioned that any forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties
and assumptions that are difficult to predict. Although we believe that the expectations reflected in our forward-looking statements
are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by
such forward-looking statements. Unless otherwise required by law, we also disclaim any obligation to update our view of any such risks
or uncertainties or to announce publicly the result of any revisions to the forward-looking statements made in this Prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_011" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THE
DISTRIBUTION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Background</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DSS
currently beneficially owns through its wholly owned subsidiary, DSS BioHealth Security, Inc., 3,877,282,251 shares of our Common
Stock, which represents 100% of the shares outstanding. These shares were acquired on August 21, 2020, upon closing of the Share Exchange
Agreement. DSS is deemed to be a beneficial owner of the shares of our Common Stock covered by this Prospectus because it has voting
and dispositive power over such shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 27, 2020, the DSS Board approved the Distribution. DSS will distribute part of its equity interest that it holds in us, consisting
of 485,161,488 shares of our Common Stock, to DSS stockholders, except for the holders of the Affiliate Shares. Following the
Distribution, DSS will own an equity interest in us of approximately 87%, giving DSS effective control over us. No approval of DSS Common
Stockholders is required in connection with the Distribution, and DSS stockholders will not have any appraisal rights in connection with
the Distribution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Distribution is subject to the satisfaction, or the DSS Board&#8217;s waiver, of a number of conditions. In addition, DSS has the right
not to complete the Distribution if, at any time, the DSS Board determines, in its sole and absolute discretion, that the Distribution
is not in the best interests of DSS or its stockholders or is otherwise not advisable. For a more detailed description, see &#8220;The
Distribution&#8212;Conditions to the Distribution.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reasons
for the Distribution</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Distribution is the method by which DSS will begin to carry out the intention of management of DSS and the DSS Board to take the Company
public and to reward DSS stockholders via the issuance of our shares of Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>When
and How You Will Receive Company Shares</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DSS
will distribute to its stockholders, as a dividend, 4 shares of our Common Stock for every share of DSS Common Stock outstanding, except
for the Affiliate Shares, as of 5:00 p.m., New York City time, July 10, 2023, the Record Date of the Distribution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the Distribution, DSS will deliver the Common Stock to the distribution agent. American Stock Transfer &amp; Trust Company,
LLC, the transfer agent and registrar for our Common Stock, will serve as distribution agent in connection with the Distribution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each Impact Share distributed as part of the Distribution will be not be eligible for resale until 180 days from
the date of the Company&#8217;s initial public offering becomes effective under the Securities Act, subject to the discretion of the Company
to lift the restriction sooner.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you own DSS common stock on the Record Date, the shares of our Common Stock that you are entitled to receive in the Distribution will
be issued to your account as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Registered
    stockholders</i>. If you own your shares of DSS Common Stock directly through DSS&#8217;s transfer agent, American Stock Transfer
    &amp; Trust Company, LLC, you are a registered stockholder. In this case, our transfer agent, American Stock Transfer &amp;
    Trust Company, LLC, which is serving as the distribution agent in connection with the Distribution, will credit the whole shares
    of our Common Stock you receive in the Distribution to a new book-entry account established on or shortly after the Distribution
    Date. Registration in book-entry form refers to a method of recording share ownership where no physical stock certificates are issued
    to stockholders, as is the case in the Distribution. You will be able to access information regarding your book-entry account holding
    our shares of Common Stock at American Stock Transfer &amp; Trust Company, LLC. Commencing on or shortly after the Distribution
    Date, the distribution agent will mail to you an account statement that indicates the number of whole shares of our Common Stock
    that have been registered in book-entry form in your name. We expect it will take the distribution agent up to two weeks after the
    Distribution Date to complete the distribution of the shares of our Common Stock and mail statements of holding to all registered
    stockholders.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<i>Street
    name</i>&#8221; <i>or beneficial stockholders</i>. If you own your shares of DSS Common Stock beneficially through a bank, broker
    or other nominee, the bank, broker or other nominee holds the shares in &#8220;street name&#8221; and records your ownership on its
    books. If you own your shares of DSS Common Stock through a bank, broker or other nominee, your bank, broker or other nominee will
    credit your account with the whole Impact Shares that you receive in the Distribution on or shortly after the Distribution Date.
    We encourage you to contact your bank, broker or other nominee if you have any questions concerning the mechanics of having shares
    held in &#8220;street name.&#8221;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will not issue any physical stock certificates to any stockholders, even if requested.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you sell any of your shares of DSS Common Stock on or before a Distribution Date, the buyer of those shares will in most circumstances
be entitled to receive the Impact Shares to be distributed in respect of the shares of DSS Common Stock you sold.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are not asking DSS stockholders to take any action in connection with the Distribution. No approval of the holders of DSS Common Stock
is required for the Distribution. We are not asking you for a proxy and request that you not send us a proxy. We are also not asking
you to make any payment or surrender or exchange any of your shares of DSS Common Stock for Impact Shares. The number of outstanding
shares of DSS Common Stock will not change as a result of the Distribution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
of Shares You Will Receive</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
the Distribution Date, you will receive four Impact Shares for every share of DSS Common Stock you held on the Record Date, unless you
sell any of your shares of DSS Common Stock on or before a Distribution Date, in which case the buyer of those shares may be entitled
to receive the Impact Shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_011" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results
of the Distribution</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
the Distribution, we expect to have approximately 300 holders of shares of our Common Stock, based on the number of DSS stockholders
and shares of DSS Common Stock outstanding. The actual number of holders of shares of our Common Stock will depend on the actual number
of holders of shares of DSS Common Stock outstanding on the Record Date. The Distribution will not affect the number of outstanding shares
of DSS Common Stock or any rights of DSS stockholders, although it is possible that the trading price of shares of DSS Common Stock immediately
following the Distribution may be lower than immediately prior to the Distribution because the trading price of DSS Common Stock will
no longer reflect the value of DSS ownership stake immediately before the Distribution. Nevertheless, we do not expect the trading price
of shares of DSS Common Stock immediately following the Distribution to be materially lower. However, until the market has fully analyzed
the value of DSS without the value represented by the Impact Shares distributed to DSS stockholders, the trading price of shares of DSS
Common Stock may fluctuate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Listing
and Trading of our Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of our outstanding shares of Common Stock are currently beneficially owned by DSS. Accordingly, there currently is no public trading
market for the Impact Shares. Our Common Stock is currently not listed for trading on any stock exchange or market. The Impact Shares
may be illiquid as we cannot predict whether any trading market will develop.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Conditions
to the Distribution</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that each Distribution will be effective on the Distribution Date, provided that the following conditions shall have been satisfied
or waived by DSS:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    DSS Board shall have authorized and approved the Distribution and not withdrawn such authorization and approval, and shall have declared
    the dividend of our Common Stock to DSS stockholders;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    SEC shall have declared effective our Registration Statement on Form S-1, of which this Prospectus is a part, under the Securities
    Act, and no stop order suspending the effectiveness of our Registration Statement shall be in effect and no proceedings for that
    purpose shall be pending before or threatened by the SEC;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
    order, injunction or decree issued by any governmental authority of competent jurisdiction or other legal restraint or prohibition
    preventing consummation of the Distribution shall be in effect, and no other event outside the control of DSS shall have occurred
    or failed to occur that prevents the consummation of the Distribution; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
    other events or developments shall have occurred prior to the Distribution Date that, in the judgment of the DSS Board, would result
    in the Distribution having a material adverse effect on DSS or its stockholders.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DSS
shall, in its sole and absolute discretion, determine the Record Date, the Distribution Date and all terms of the Distribution, including
the form, structure and terms of any transactions and/or offerings to effect the Distribution and the timing of and conditions to the
consummation thereof. In addition and notwithstanding anything to the contrary set forth in this Prospectus, DSS may at any time and
from time to time until the Distribution decide to abandon the Distribution including by accelerating or delaying the timing of the consummation
of all or part of the Distribution or modifying or changing the terms of the Distribution if, at any time, the DSS Board determines,
in its sole and absolute discretion, that the Distribution is not in the best interests of DSS or its stockholders or is otherwise not
advisable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reasons
for Furnishing this Prospectus</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are furnishing this Prospectus solely to provide information to DSS&#8217;s stockholders who will receive Impact Shares in the Distribution.
You should not construe this Prospectus as an inducement or encouragement to buy, hold or sell any of our securities or any securities
of DSS. We believe that the information contained in this Prospectus is accurate as of the date set forth on the cover. Changes to the
information contained in this Prospectus may occur after that date, and neither we nor DSS undertakes any obligation to update the information
except in the normal course of our and DSS&#8217;s public disclosure obligations and practices and except as required by applicable law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_011" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="gfd_005"></span>MATERIAL
U.S. FEDERAL INCOME TAX CONSEQUENCES OF THE DISTRIBUTION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consequences
to U.S. Holders of DSS Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of the material U.S. federal income tax consequences to holders of DSS Common Stock in connection with the Distribution.
This summary is based on the Code, the Treasury Regulations promulgated under the Code and judicial and administrative interpretations
of those laws, in each case as in effect and available as of the date of this Prospectus and all of which are subject to change at any
time, possibly with retroactive effect. Any such change could affect the tax consequences described below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
summary is limited to holders of DSS Common Stock that are U.S. Holders, as defined immediately below, that hold their DSS Common Stock
as a capital asset. A &#8220;U.S. Holder&#8221; is a beneficial owner of DSS Common Stock that is, for U.S. federal income tax purposes:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    individual who is a citizen or a resident of the United States;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    corporation, or other entity taxable as a corporation for U.S. federal income tax purposes, created or organized under the laws of
    the United States or any state thereof or the District of Columbia;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    estate the income of which is subject to U.S. federal income taxation regardless of its source; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    trust if a court within the United States is able to exercise primary jurisdiction over its administration and one or more U.S. persons
    have the authority to control all of its substantial decisions or, in the case of a trust that was treated as a domestic trust under
    law in effect before 1997, a valid election is in place under applicable Treasury Regulations.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
summary does not discuss all tax considerations that may be relevant to stockholders in light of their particular circumstances, nor
does it address the consequences to stockholders subject to special treatment under the U.S. federal income tax laws, such as:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">dealers
    or traders in securities or currencies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">tax-exempt
    entities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">banks,
    financial institutions or insurance companies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">real
    estate investment trusts, regulated investment companies or grantor trusts;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons
    who acquired DSS Common Stock pursuant to the exercise of employee stock options or otherwise as compensation;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">stockholders
    who own, or are deemed to own, 10% or more, by voting power or value, of DSS equity;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">stockholders
    owning DSS Common Stock as part of a position in a straddle or as part of a hedging, conversion or other risk reduction transaction
    for U.S. federal income tax purposes;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">certain
    former citizens or long-term residents of the United States or green card holders;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">stockholders
    who are subject to the alternative minimum tax; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons
    who own DSS Common Stock through partnerships, certain trusts or other pass-through entities.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
summary does not address any U.S. state, local or non-U.S. tax consequences or any estate, gift or other non-income tax consequences.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a partnership, or any other entity treated as a partnership for U.S. federal income tax purposes, holds DSS Common Stock, the tax treatment
of a partner in that partnership will generally depend on the status of the partner and the activities of the partnership. Such a partner
or partnership should consult its own tax advisor as to its tax consequences.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>YOU
SHOULD CONSULT YOUR OWN TAX ADVISOR WITH RESPECT TO THE U.S. FEDERAL, STATE AND LOCAL AND NON-U.S. TAX CONSEQUENCES OF THE DISTRIBUTION.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_011" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>General</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Distribution will be treated as a taxable non-liquidating distribution to DSS stockholders, As such, each U.S. stockholder receiving
Impact Shares in the Distribution will be treated as if such stockholder had received a distribution in an amount equal to the fair market
value of our Common Stock received, which would result in (1) a taxable dividend to the extent of such stockholder&#8217;s pro rata share
of Impact&#8217;s current and accumulated earnings and profits, (2) a reduction in such stockholder&#8217;s basis (but not below zero)
in DSS Common Stock to the extent the amount received exceeds such stockholder&#8217;s share of earnings and profits and (3) a taxable
gain to the extent the amount received exceeds the sum of the amount treated as a dividend and the stockholder&#8217;s basis in the DSS
Common Stock. Any such gain would generally be a capital gain if the DSS Common Stock is held by such stockholder as a capital asset
on the Distribution Date and subject to long-term capital gain treatment if the DSS Common Stock has been held by such stockholder for
more than one year on the Distribution Date. Distributions treated as dividends will be subject to tax at favorable long-term capital
gains rates provided that the stockholder has held his DSS stock for the period required for preferential dividend tax treatment generally.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
U.S. stockholder also may be subject to information reporting with respect to the Distribution. In addition, such stockholder may be
subject to &#8220;backup withholding&#8221; on the Distribution, unless such stockholder provides proof of any applicable exemption or
a correct taxpayer identification number, and otherwise complies with the requirements of the backup withholding rules. Backup withholding
is not an additional tax, and it may be refunded or credited against a U.S. stockholder&#8217;s U.S. federal income tax liability if
the required information is timely supplied to the IRS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="gfd_006"></span>USE
OF PROCEEDS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will not receive any proceeds from the Distribution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="gfd_007"></span><b>DETERMINATION
OF OFFERING PRICE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
consideration will be paid for the Impact Shares in the Distribution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="gfd_008"></span><b>DIVIDEND
POLICY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not intend, following the Distribution, to pay cash dividends on our Common Stock in the foreseeable future. We expect to retain future
earnings, if any, for reinvestment in our business. Any credit agreements which we may enter into may restrict our ability to pay dividends.
The payment of dividends in the future will be subject to the discretion of our Board and will depend, among other things, on our financial
condition, results of operations, cash requirements, future prospects and any other factors our Board deems relevant. There can be no
assurance that a payment of a dividend will occur in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="gfd_009"></span><b>CAPITALIZATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth our cash and capitalization as of <span style="background-color: white">March</span> 31, 2023.
The following table should be read in conjunction with &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results
of Operations&#8221; and our historical consolidated financial statements and the notes thereto included elsewhere in this Prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As
    of</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March
    31, 2023</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Actual</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 78%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    and cash equivalents</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
    payable, related party</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,008,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders&#8217;
    equity:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    stock, $.001 par value; 4,000,000,000 shares authorized, 3,877,282,251 shares issued and outstanding (3,877,282,251 on December 31,
    2022) &#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">125,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
    paid-in capital</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38,058,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated
    deficit &#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9,282,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Impact BioMedical stockholders&#8217; equity </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28,901,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    capitalization</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39,909,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_011" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="gfd_010"></span>MANAGEMENT&#8217;S
DISCUSSION AND ANALYSIS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
following discussion and analysis of our financial condition and results of operations should be read in conjunction with our audited
and unaudited financial statements and related notes, respectively, beginning on page F-1 below of this Prospectus. Some of the information
contained in this discussion and analysis constitutes forward-looking statements that involve risks and uncertainties. Actual results
could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to these differences
include, but are not limited to, those discussed below and elsewhere in this Prospectus, particularly under the section titled &#8220;Cautionary
Statement Concerning Forward-Looking Statements.&#8221;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Impact BioMedical Inc. targets urgent medical
needs and expands the borders of medical and pharmaceutical science. Impact drives mission-oriented research and development, and
commercialization of solutions for medical advances in human wellness and healthcare. By leveraging technology and new science with
strategic partnerships, Impact Bio provides advances in drug discovery for the prevention, inhibition, and treatment of
neurological, oncology and immuno-related diseases. Other exciting technologies include a breakthrough alternative sugar aimed to
combat diabetes and functional fragrance formulations aimed at the industrial and medical industry. The research and development
efforts are primarily conducted in collaboration with GRDG Sciences, LLC (&#8220;GRDG&#8221;) and with the expertise of Mr.
Daryl Thompson as its Director of Scientific Initiatives. We have initiated research regarding universal therapeutics as part of an
attempt to help address some of the world&#8217;s deadliest diseases.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
business model of Impact BioMedical revolves around a Licensing methodology for commercialization, sales and distribution. Impact
develops valuable and unique patented technologies which will be licensed to pharmaceutical, food, large consumer package goods
companies and venture capitalists in exchange for usage licensing and royalties. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Below
is a list of our principal subsidiaries:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impact
    BioLife Science, Inc.;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Global
    Biomedical, Inc.;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Global
    BioLife, Inc.; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sweet
    Sense, Inc.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Impact BioLife Science, Inc</span>.</i> We
are the sole owner of the outstanding equity of Impact BioLife Science, Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Global Biomedical, Inc.</span></i> We own 90.91%
of Global Biomedical, Inc. outstanding equity, and the balance minority equity owner is Peggy Tang.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Global BioLife, Inc</span></i>. Through our
majority owned subsidiary Global Biomedical, Inc., we own 90% of the outstanding equity of Global BioLife, Inc. The other equity owner
is Holista CollTech Limited (&#8220;Holista&#8221;) (10%).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Sweet Sense, Inc</span></i><span style="text-decoration: underline">.</span> We are
the owner of 50% of the outstanding equity of Sweet Sense. The other equity owner is BioLife Sugar, Inc. (&#8220;BioLife Sugar&#8221;).</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_011" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Below
is an organization chart showing our ownership structure and ownership interests.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img src="forms-1a_001.jpg" alt="" style="height: 867px; width: 670px"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_011" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
our majority-owned subsidiary Global BioLife, we own or have rights to a portfolio of biomedical intellectual property, including intellectual
property assigned to Global BioLife by GRDG. Global BioLife leverages its scientific know-how and intellectual property rights to develop
various emerging technologies, including biopharmaceuticals, antivirals, antimicrobials, sugar alternatives, insect repellents, fragrances,
bioplastics and natural preservatives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Biotech
and Impact BioMedical have several important and valuable products, technology or compounds that are in continuing development and/or
licensing stages:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="text-decoration: underline">Linebacker</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Linebacker is a multi-faceted therapeutic platform
intended for metabolic, neurologic, cancer, and infectious diseases. Our process features a molecular tuning technique that is
believed to modify a natural compound to induce potency, efficacy, bioavailability, and trans-membrane permeability while maintaining
safety, toxicity, and tolerability. Natural compounds used in the Linebacker platform may have potential in treating and
preventing a range of diseases by inhibiting TNF-alpha and indication specific causes (e.g. neurology, anti-inflammatory diseases, oncology).
Linebacker&#8217;s intended use is subject to FDA regulation, and the FDA must approve any drug or biologic product before it can be
marketed in the United States. In addition, prior to being sold outside the United States, our Linebacker technology must be approved
by the regulatory agencies of foreign governments. Prior to filing a new drug application or biologics license application with the FDA,
we would have to perform extensive clinical trials, and prior to beginning any clinical trial, we would need to perform extensive preclinical
testing which could take several years and may require substantial expenditures. To date, we have not conducted no preclinical testing
or clinical trials (human or otherwise) on Linebacker, nor have we received any FDA approval to conduct such any such preclinical testing
or clinical trials. Further, because we have not conducted any testing or studies on Linebacker, we are not able to substantiate or demonstrate
that Linebacker will function as planned, nor can we seek FDA approval to market and sell Linebacker. To date, we have not performed
the extensive preclinical testing necessary to begin any clinical trials for Linebacker; and until we have conducted the necessary clinical
trials, we will not be able to seek FDA approval for Linebacker. Currently, we have no plans to conduct preclinical testing or clinical
trials (human or otherwise) involving Linebacker.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to identify third parties or customers that are interested in purchasing, licensing or co-developing products that leverage our
Linebacker technology. We have not entered into any such agreements to date, and there can be no guarantee that we will enter into any
such agreements or that such agreements will be on terms that are favorable to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Laetose</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Laetose
technology is derived from a unique combination of sugar and other compounds, which is intended to inhibit the inflammatory response
of sugar alone. Based on our intended use for Laetose, Laetose is intended to be an high-intensity sweetener, yet to
be determined by the FDA. High-intensity sweeteners are commonly used as sugar substitutes or sugar alternatives because they are
many times sweeter than sugar but contribute only a few to no calories when added to foods. High-intensity sweeteners, like all other
ingredients added to food in the United States, must be safe for consumption. Further, a high intensity sweetener is regulated as a food
additive, unless its use as a sweetener is generally recognized as safe (GRAS). The use of a food additive must undergo premarket review
and approval by FDA before it can be used in food. In contrast, use of a GRAS substance does not require premarket approval. Rather,
the basis for a GRAS determination based on scientific procedures is that experts qualified by scientific training and experience to
evaluate its safety conclude, based on publicly available information, that the substance is safe under the conditions of its intended
use. A company can make an independent GRAS determination for a substance with or without notifying FDA. Regardless of whether a substance
is approved for use as a food additive or its use is determined to be GRAS, scientists must determine that it meets the safety standard
of reasonable certainty of no harm under the intended conditions of its use. This standard of safety is defined in FDA&#8217;s regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of this date, we have not performed any scientific testing to determine the safety of Laetose for human consumption, and no qualified
experts have evaluated the safety of Laetose. Therefore, we have not been able to make any determination that Laetose is safe for human
consumption. Currently, we have no plans to conduct any scientific testing relating to the safety of Laetose, and any there can be no
guarantee that any such testing will conclude that Laetose is safe for human consumption.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_011" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to identify third parties or customers that are interested in purchasing, licensing or co-developing products that leverage Laetose.
We have not entered into any such agreements to date, and there can be no guarantee that we will enter into any such agreements or that
such agreements will be on terms that are favorable to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is presently seeking to license Laetose by way of a business development agreement between Sweet Sense, Inc., a joint venture
established by Global BioLife and Quality Ingredients, LLC (&#8220;Sweet Sense&#8221;), and BFS. Sweet Sense was established for the
development, manufacture, and global distribution of the new sugar substitute. On November 8, 2019, the Company purchased 50% of Sweet
Sense Inc. from Quality Ingredients, LLC for $91,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Functional
Fragrance Formulation (&#8220;3F&#8221;)</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">3F is a unique formulation of specialized ingredients
from naturally occurring botanical sources with intended application as an insect repellent and an antimicrobial. Currently,
approximately 20 combination insect repellent-sunscreen drug products are available for consumers. These products consist of one of three
insect repellents (N,N-diethyl-meta-toluamide (DEET), oil of citronella, or IR3535) and a sunscreen component (one or more sunscreen
ingredients). Internal repellent tests results demonstrated the prevention and limitation of insect bites up to eight (8) hours. To date,
we have not conducted studies to establish marketing claims.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to identify third parties or customers that are interested in purchasing, licensing or co-developing products that leverage 3F.
We have not entered into any such agreements to date, and there can be no guarantee that we will enter into any such agreements or that
such agreements will be on terms that are favorable to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Equivir</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Equivir/Nemoviris a novel blend of naturally occurring
compounds that are sourced from fruits, vegetables, and other natural substances. Equivir is designed to work by impeding virulence while
also blocking multiple methods used by viruses to infect and replicate in host cells, following deployment in a manner similar to a vitamin,
and this intended use is subject to FDA regulation. The FDA must approve any drug or biologic product before it can be marketed in
the United States. In addition, prior to being sold outside the United States, our Equivir technology must be approved by the regulatory
agencies of foreign governments. Prior to filing a new drug application or biologics license application with the FDA, we would have
to perform extensive clinical trials, and prior to beginning any clinical trial, we would need to perform extensive preclinical testing
which could take several years and may require substantial expenditures. To date, we have conducted no preclinical testing or clinical
trials (human or otherwise) on Equivir. Further, because we have not conducted any testing or studies on Equivir, we are not able to
substantiate or demonstrate its benefits as a health supplement or seek FDA approval at this time. Currently, we have no plans to conduct
any preclinical testing or clinical trials (human or otherwise) involving Equivir.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to identify third parties or customers that are interested in purchasing, licensing or co-developing products that leverage Equivir.
We have not entered into any such agreements to date, and there can be no guarantee that we will enter into any such agreements or that
such agreements will be on terms that are favorable to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, other Equivir analogues are under development and provisional patents have been filed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company was incorporated in the State of Nevada as a for-profit company on October 16, 2018, and established a fiscal year end
of December 31st. The Company issued 9,000 shares to Global BioMedical Pte. Ltd., which was wholly&#8211;owned by Alset International
Limited (formally Singapore eDevelopment Limited), a multinational public company, listed on the Singapore Exchange Securities Trading
Limited (&#8220;SGXST&#8221;). On March 31, 2020, the Company issued 125,064,621 shares of common stock to its sole shareholder Global
BioMedical Pte. Ltd. On July 24, 2020, the Board approved the Stock Split, pursuant to which each share of the Company&#8217;s common
stock issued and outstanding was split into nine shares of the Company&#8217;s common stock. The numbers of authorized common stock and
issued and outstanding common stock in the reporting periods were retrospectively adjusted for the stock split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_011" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 12, 2020 Alset International Limited (&#8220;Alset&#8221;),
a related party, Global BioMedical Pte Ltd., a related party, DSS, Inc (&#8220;DSS&#8221;), a related party, and DSS BioHealth Security
Inc. (&#8220;DSS BioHealth&#8221;), a related party, signed Term Sheets and subsequently on April 21, 2020, these four companies entered
into Share Exchange Agreement (&#8220;Share Exchange&#8221;), based on which Global BioMedical Pte Ltd., agreed to sell all of the issued
and outstanding shares of the Company to DSS BioHealth in exchange for the combination of common and preferred shares of DSS. Under the
terms of the Share Exchange, DSS issued 483,334 shares of the DSS Common Stock nominally valued at $6.48 per share, and 46,868 newly
issued shares of the DSS Series A Convertible Preferred Stock (&#8220;<span style="text-decoration: underline">Series A Preferred Stock</span>&#8221;), with a stated value of
$46,868,000, or $1,000 per share, for a total consideration valued at $50 million. Due to several factors, including a discount for illiquidity,
the value of the Series A Preferred Stock was discounted from $46,868,000 to $35,187,000, thus reducing the final consideration given
to approximately $38,319,000. The Company&#8217;s Chairman, Heng Fai Ambrose Chan, a related party, who is also the largest shareholder
of Alset, at the time of the signing of the Share Exchange Agreement was the beneficial owner of approximately 18.3% of the outstanding
shares of DSS and is the Chairman of the Board of Directors of DSS. On August 21, 2020, the transaction was concluded, and the Company
became a direct wholly owned subsidiary of DSS BioHealth. In connection with the acquisition, and the related accounting determination,
DSS BioHealth has elected to apply push-down accounting and reflect in its financial statements of Impact BioMedical, the fair value
of its assets and liabilities. Utilizing an income approach, the Company has completed its valuations of certain developed technology
and pending patents assets acquired in the transaction as well the fair value of the non-controlling interests. More specifically, a
Multi-Period Excess Earnings Method (&#8220;MPEEM&#8221;) estimates the value of an intangible asset by quantifying the amount of residual
(or excess) estimated cash flows generated by the asset and discounting those cash flows to the present. These have been valued at approximately
$22,260,000 and $3,910,000, respectively, and are included on the Consolidated Balance Sheet on December 31, 2020. Estimated useful life
of these assets is twenty years, based on the remaining terms of the related patents, with annual amortization approximating $1,113,000.
The Company has also completed its valuation of goodwill and deferred tax liabilities of Impact BioMedical, and has recorded goodwill
of approximately $25,093,000, driven by other intangible assets that do not qualify for separate recognition, and a deferred tax liability
of approximately $5,234,000. The goodwill is not deductible for tax purposes and has been allocated to Impact BioMedical in totality
as a single reporting unit. The Company is committed to both funding research and developing intellectual property portfolio.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this report, we have not generated any revenues from operations. We cannot guarantee we will be successful in our business
operations. Our business is subject to risks inherent in the establishment of a new business enterprise, including possible delays our
research, testing and marketing efforts or wider economic downturns.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Fiscal Year Ended December 31, 2022, compared
to Year Ended December 31, 2021</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Results
of operations for the year ended December 31, 2022, as compared to year ended December 31, 2021.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cost
and expenses:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">% Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Sales, general and administrative compensation</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">325,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">398,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">-18</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,113,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,112,941</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">722,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">551,796</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,226,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,080,051</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">68,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">42,553</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">62</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-style: italic; text-align: left">Total costs and expenses</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,454,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,185,341</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling,
general and administrative compensation costs decreased 18% for the year ended December 31, 2022, as compared to the year ended December
31, 2021 due to decreases in head count at the Company. Also, the Company is allocated certain administrative labor cost from DSS as
shared resources which approximates $12,000 per month during the year ended December 31, 2022, as compared to $17,000 per month during
the year ended December 31, 2021.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
and Amortization expense of $1,113,000 for the year ended December 31, 2022, and 2021 represents the amortization of the associated with
the developed technology and patents acquired as part of the acquisition of Impact BioMedical by DSS. Amortization of these assets began
on January 1, 2021, and will have a 20-year term.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Professional
fees increased 31% for the year ended December 31, 2022, as compared to the year ended December 31, 2021 mostly due to increases in consulting
and legal services associated with developing and implementing Impact BioMedical&#8217;s business plan.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs represent costs consisted primarily of independent, third-party testing of the various properties of each technology
the Company owns possesses as well as research on new technologies. Research and development increased 14% for the year ended December
31, 2022, as compared to the year ended December 31, 2021 primarily due to exploration and development of new technologies during 2022.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
operating expenses consist primarily of office supplies, IT support, travel and insurance costs. These costs remained increased 62% for
the year ended December 31, 2022, as compared to year ended December 31, 2021 due primarily to increased IT support and travel costs</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_011" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
income (expense):</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">% Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Interest Income</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">24,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">165,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">-85</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest Expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(462,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(300,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">54</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other Income (expense)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">116,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">77,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">51</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Impairment of investment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,100,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-style: italic; text-align: left">Total other loss</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(4,422,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(58,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7524</td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
other income and expense as of December 31, 2022, is driven by the impairment of the Company&#8217;s Vivacitas investment in the amount
of $4,100,000. As of December 31, 2021, total other income and expense represents interest income and origination fee income
associated with the Company&#8217;s notes receivable offset by interest expense on its note payable to DSS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net
loss:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
    Change</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 46%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7,255,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,848,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-293</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
increase in net loss of 293% for the year ended December 31, 2022 as compared to the year ended December 31, 2021 is driven by
the impairment of the Company&#8217;s Vivacitas investment in the amount of $4,100,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three
Months Ended March 31, 2023, compared to Three Months Ended March 31, 2022</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Results
of operations for the three months ended March 31, 2023, as compared to the three months ended March 31, 2022.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cost
and expenses:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">% Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Sales, general and administrative compensation</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">40,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">123,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">-67</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">280,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">278,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">280,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">126,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">122</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">179,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">168,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">40,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">186</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-style: italic; text-align: left">Total costs and expenses</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">819,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">709,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16</td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling,
general and administrative compensation costs decreased 67% for the three months ended March 31, 2023, as compared to the three months
ended March 31, 2022 due to decreases in head count at the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
and Amortization expense remained relatively for the three months ended March 31, 2023, as compared to the three months ended March 31,
2022 and represents the amortization of the associated with the developed technology and patents acquired as part of the acquisition
of Impact BioMedical by DSS. Amortization of these assets began on January 1, 2021, and will have a 20-year term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Professional
fees increased 122% for the three months ended March 31, 2023, as compared to the three months ended March 31, 2022 mostly due to increases
in consulting and legal services associated with developing and implementing Impact BioMedical&#8217;s business plan, and other related
fees for the development of new technologies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs represent costs consisted primarily of independent, third-party testing of the various properties of each technology
the Company owns possesses as well as research on new technologies. Research and development increased 7% for the three months ended
March 31, 2023, as compared to the three months ended March 31, 2022 primarily due to exploration and development of new and existing
technologies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
operating expenses consist primarily of office supplies, IT support, travel and insurance costs. These costs remained increased 186%
for the three months ended March 31, 2023, as compared to the three months ended March 31, 2022 due primarily to increased IT support
and travel costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
income (expense):</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">% Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Interest Income</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">3,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">96,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">-97</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest Expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(101,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(462,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-78</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Other Income (expense)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">68,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NA</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-style: italic; text-align: left">Total other loss</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(30,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(366,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-92</td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
other income and expense represents interest income and origination fee income associated with the Company&#8217;s notes receivable offset
by interest expense on its note payable to DSS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net
loss:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">% Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 46%">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(849,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(746,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">-14</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
increase in net loss of 14% for the three months ended March 31, 2023, as compared to the three months ended March 31, 2022 is driven
increases in professional fees and research and development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_011" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
expense:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIQUIDITY
AND CAPITAL RESOURCES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has historically met its liquidity and
capital requirements primarily through the sale of its equity securities and debt financings. As of December 31, 2022, the Company
had cash of approximately $2,000. As of March 31, 2023, the Company had cash of approximately $1,000. As of
March 31, 2023, the Company believes that it has sufficient availability to cash via its revolving promissory note with
DSS to meet its cash requirements for at least the next 12 months from the filing date of this Prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Critical Accounting Policies</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements and related
disclosures in conformity with generally accepted accounting principles in the U.S. (&#8220;U.S. GAAP&#8221;) requires management to
make judgments, assumptions and estimates that affect the amounts reported in our consolidated financial statements and accompanying
notes. The Company&#8217;s consolidated financial statements for the year ended December 31, 2022 and 2021, describe the significant
accounting policies and methods used in the preparation of the consolidated financial statements. The Company&#8217;s consolidated
financial statements for the three months ended March 31, 2023 and 2022, describe the significant accounting
policies and methods used in the preparation of the consolidated financial statements.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fair
Value of Financial Instruments</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants at the measurement date. The Fair Value Measurement Topic of the Financial Accounting Standards Board (&#8220;FASB&#8221;)
Accounting Standards Codification (&#8220;ASC&#8221;) establishes a three-tier fair value hierarchy which prioritizes the inputs used
in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets
or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted
prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active;
and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions,
such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts reported in the balance sheet of cash and cash equivalents, prepaids, accounts payable and accrued expenses approximate
fair value because of the immediate or short-term maturity of these financial instruments. The fair value of notes receivable approximates
their carrying value as the stated or discounted rates of the notes do reflect recent market conditions. The Company&#8217;s investments
are record at cost as the fair value of these investment in are not readily available. The fair value of notes payable approximates its
carrying value as the stated interest rate reflects recent market conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Investments</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Investments in equity securities with a readily
determinable fair value, not accounted for under the equity method, are recorded at fair value with unrealized gains and losses included
in earnings. For equity securities without a readily determinable fair value, the investment is recorded at cost, less any impairment,
plus or minus adjustments related to observable transactions for the same or similar securities, with unrealized gains and losses included
in earnings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For equity method investments, the Company regularly
reviews its investments to determine whether there is a decline in fair value below book value. If there is a decline that is other-than-temporary,
the investment is written down to fair value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Goodwill
</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill
is the excess of cost of an acquired entity over the fair value of amounts assigned to assets acquired and liabilities assumed in a business
combination. Goodwill is subject to impairment testing at least annually and will be tested for impairment between annual tests if an
event occurs or circumstances change that would indicate the carrying amount may be impaired. FASB ASC Topic 350 provides an entity with
the option to first assess qualitative factors to determine whether the existence of events or circumstances leads to a determination
that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. Some of the qualitative
factors considered in applying this test include consideration of macroeconomic conditions, industry and market conditions, cost factors
affecting the business, and overall financial performance of the business. If, after completing the assessment, it is determined that
it is more likely than not that the fair value of a reporting unit is less than its carrying value, the Company will proceed to
a quantitative test. If qualitative factors are not deemed sufficient to conclude that the fair value of the reporting unit more likely
than not exceeds its carrying value, then a one-step approach is applied in making an evaluation. The evaluation utilizes multiple valuation
methodologies, including a market approach (market price multiples of comparable companies) and an income approach (discounted cash flow
analysis). The computations require management to make significant estimates and assumptions, including, among other things, selection
of comparable publicly traded companies, the discount rate applied to future earnings reflecting a weighted average cost of capital,
and earnings growth assumptions. The Company believes the estimates and assumptions used in our impairment assessments are reasonable
and based on available market information, but variations in any of the assumptions could result in materially different calculations
of fair value and determinations of whether or not an impairment is indicated. A discounted cash flow analysis requires management to
make various assumptions about future sales, operating margins, capital expenditures, working capital, and growth rates. Cash flow projections
are derived from one-year budgeted amounts plus an estimate of later period cash flows, all of which are determined by management.
Subsequent period cash flows are developed for each reporting unit using growth rates that management believes are reasonably likely
to occur. Impairment of goodwill is measured as the excess of the carrying amount of goodwill over the fair values of recognized and
unrecognized assets and liabilities of the reporting unit.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_011" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 15, 2020, a third party engaged by
the Company had completed a valuation of the acquisition price of ImpactBio by DSS BioHealth Security, Inc. It was determined that
DSS BioHealth Security, Inc.&#8217;s parent company, DSS (NYSE: DSS) publicly traded stock price on the valuation date of August 21,
2020, reflected all relevant data regarding the transaction and was applied to both the common A shares and preferred A shares given
as consideration for the acquisition of ImpactBio. The preferred A shares contained certain sell restrictions and a liquidity
discount was applied. Further, a valuation of the assets acquired was also completed as of the valuation date on March 25, 2021. As
no factors changed between, the completion of the valuation of the consideration given and the completion valuation of the assets
received no impairment was recorded during the fiscal years ended December 31, 2022 and December 31, 2021. Subsequently, as no
events or circumstances occurred as of March 31, 2023 and no impairment of goodwill was recorded for the three months
ended March 31, 2023 or year ended December 31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Intangible Assets</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The estimated fair values of acquired intangibles
are generally determined based upon future economic benefits such as earnings and cash flows. Acquired identifiable intangible assets
are recorded at fair value and are amortized over their estimated useful lives. Acquired intangible assets with an indefinite life are
not amortized but are reviewed for impairment at least annually as of December 31<sup>st</sup>, or more frequently whenever events or
changes in circumstances indicate that the carrying amounts of those assets are below their estimated fair values. Impairment is tested
under ASC 350. No impairment was recognized as of March 31, 2023 or years ended December 31, 2022 and December 31, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Recoverability
of Long-Lived Assets</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
evaluate long-lived assets such as property, equipment and definite lived intangible assets, such as patents, for impairment whenever
events or circumstances indicate that the carrying value of the assets recognized in our financial statements may not be recoverable.
Factors that we consider include whether there has been a significant decrease in the market value of an asset, a significant change
in the way an asset is being utilized, or a significant change, delay or departure in our strategy for that asset, or a significant change
in the macroeconomic environment, such as the impact of the COVID-19 pandemic. Our assessment of the recoverability of long-lived assets
involves significant judgment and estimation. These assessments reflect our assumptions, which, we believe, are consistent with the assumptions
hypothetical marketplace participants use. Factors that we must estimate when performing recoverability and impairment tests include,
among others, forecasted revenue, margin costs and the economic life of the asset. If impairment is indicated, we determine if the total
estimated future cash flows on an undiscounted basis are less than the carrying amounts of the asset or assets. If so, an impairment
loss is measured and recognized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
impairment loss calculations require that we apply judgment in identifying asset groups, estimating future cash flows, determining asset
fair values, and estimating asset&#8217;s useful lives. The Company reviews identifiable amortizable intangible assets for impairment
whenever events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. Determination of recoverability
is based on the lowest level of identifiable estimated undiscounted cash flows resulting from use of the asset and its eventual disposition.
Measurement of any impairment loss is based on the excess of the carrying value of the asset over its fair value. Based on the uncertainty
of forecasts inherent with a new product, events such as the failure to generate forecasted revenue from new products could result in
a non-cash impairment in future periods. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Continuing Operations and Going Concern</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Due to incurred operating losses as well as negative
cash flows from operating and investing activities over the past two years, the accompanying consolidated financial statements have been
prepared assuming that the Company will continue as a going concern. This basis of accounting contemplates the recovery of our assets
and the satisfaction of liabilities in the normal course of business. These consolidated financial statements do not include any adjustments
to the specific amounts and classifications of assets and liabilities, which might be necessary should we be unable to continue as a
going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To continue as a going concern, the Company has
entered into an updated revolving promissory note which extended the maturity through March 31, 2024, and DSS intends to continue to
fund the operations of the Company through a year from the date these financial statements were available to be issued. The Company&#8217;s
management intends to take actions necessary to continue as a going concern. Management&#8217;s plans concerning these matters include,
among other things, monetization of its intellectual properties, and tightly controlling operating costs. Based on this, the Company
has concluded that substantial doubt of its ability to continue as a going concern has been alleviated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Related Party Transactions</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Research and Development Activities</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Based on Shareholders Agreement entered into on
April 26, 2017, the Company would fund the scientific operations of GRDG, a company involved in research and development of biomedical
products which is a minority stockholder of two of the Company&#8217;s subsidiaries and is owned by Daryl Thompson, a director of many
subsidiaries of the Company, to do the development and research works on the biomedical products for the Company. As of December 31, 2022, this funding approximates $43,000 per month, and
incurred approximately $546,000 in expenses. On December 31, 2022 and December 31, 2021, the Company owed this related party $0 and had
prepaid monthly fees approximating $43,000 and $43,000, respectively. As of March 31, 2023,
this funding approximates $43,000 per month, and incurred approximately $129,000 in expenses. On March 31, 2023 and March 31, 2022, the
Company owed this related party $0 and had prepaid monthly fees approximating $43,000 and $43,000, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">General and Administrative Costs</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There are certain general and administrative
costs incurred by DSS, a related party on behalf of the Company which are passed through to the Company on a monthly basis. These
costs consist of primarily payroll costs for certain DSS employees and are allocated based on estimated time spent on behalf of the
Company. These costs approximate $12,000 per month. &#160;As of December 31, 2022, the Company incurred $117,000 in related
expenses. &#160;As of December 31, 2021, the Company incurred approximately $155,000 in related expenses. As of March 31, 2023, the
Company incurred $35,000 in related expenses. As of March 31, 2022, the Company incurred approximately $52,000 in related
expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Research and Development Activities</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Based on Shareholders Agreement entered into on
April 26, 2017, the Company would fund the scientific operations of GRDG, a company involved in research and development of biomedical
products which is a minority stockholder of two of the Company&#8217;s subsidiaries and is owned by Daryl Thompson, a director of many
subsidiaries of the Company, to do the development and research works on the biomedical products for the Company. As of December 31, 2022, this funding approximates $43,000 per month, and
incurred approximately $546,000 in expenses. On December 31, 2022 and December 31, 2021, the Company owed this related party $0 and had
prepaid monthly fees approximating $43,000 and $43,000, respectively. As of March 31, 2023,
this funding approximates $43,000 per month, and incurred approximately $129,000 in expenses. On March 31, 2023 and March 31, 2022, the
Company owed this related party $0 and had prepaid monthly fees approximating $43,000 and $43,000, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>General and Administrative Costs</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There are certain general and administrative
costs incurred by DSS, a related party on behalf of the Company which are passed through to the Company on a monthly basis. These
costs consist of primarily payroll costs for certain DSS employees and are allocated based on estimated time spent on behalf of the
Company. These costs approximate $12,000 per month. As of December 31, 2022, the Company incurred $117,000 in related expenses. As
of December 31, 2021, the Company incurred approximately $155,000 in related expenses. As of March 31, 2023, the Company incurred
$35,000 in related expenses. As of March 31, 2022, the Company incurred approximately $52,000 in related expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Off-Balance Sheet Arrangements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We do not have any material off-balance sheet arrangements
that have, or are reasonably likely to have, an effect on our financial condition, financial statements, revenues or expenses.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_011" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ax_001"></span>BUSINESS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Introduction</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
we are a holding company operating mainly through our majority owned subsidiary, Global BioLife, Inc., which was incorporated on April
14, 2017. The Company is committed to both funding research and developing intellectual property portfolio. We currently focus on research
in three main areas: (i) development of a universal therapeutic drug platform; (ii) a new sugar substitute; and (iii) a multi-use fragrance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Company</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Impact BioMedical Inc. targets urgent medical
needs and expands the borders of medical and pharmaceutical science. Impact drives mission-oriented research and development, and
commercialization of solutions for medical advances in human wellness and healthcare. By leveraging technology and new science with
strategic partnerships, Impact Bio provides advances in drug discovery for the prevention, inhibition, and treatment of
neurological, oncology and immuno-related diseases. Other exciting technologies include a breakthrough alternative sugar aimed to
combat diabetes and functional fragrance formulations aimed at the industrial and medical industry. The research and development
efforts are primarily conducted in collaboration with GRDG Sciences, LLC (&#8220;GRDG&#8221;) and with the expertise of Mr.
Daryl Thompson as its Director of Scientific Initiatives. We have initiated research regarding universal therapeutics as part of an
attempt to help address some of the world&#8217;s deadliest diseases.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Below
is a list of our principal subsidiaries:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impact
                                            BioLife Science, Inc.;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Global
                                            Biomedical, Inc.;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Global
                                            BioLife, Inc.; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sweet
                                            Sense, Inc.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Impact BioLife Science, Inc</span>.</i> We
are the sole owner of the outstanding equity of Impact BioLife Science, Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Global Biomedical, Inc.</span></i> We own 90.91%
of Global Biomedical, Inc. outstanding equity, and the balance minority equity owner is Peggy Tang.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Global BioLife, Inc</span></i>. Through our
majority owned subsidiary Global Biomedical, Inc., we own 90% of the outstanding equity of Global BioLife, Inc. The other equity owner
is Holista CollTech Limited (&#8220;Holista&#8221;) (10%).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Sweet Sense, Inc</span></i><span style="text-decoration: underline">.</span> We are
the owner of 50% of the outstanding equity of Sweet Sense. The other equity owner is BioLife Sugar, Inc. (&#8220;BioLife Sugar&#8221;).</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_011" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Below
is an organization chart showing our ownership structure and ownership interests.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img src="forms-1a_001.jpg" alt="" style="height: 867px; width: 670px"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
our majority-owned subsidiaries, Global BioLife and Impact BioLife, we own or have rights to a portfolio of biomedical intellectual property,
including intellectual property assigned to Global BioLife by GRDG. Global BioLife leverages its scientific know-how and intellectual
property rights to develop various emerging technologies, including biopharmaceuticals, antivirals, antimicrobials, sugar alternatives,
insect repellents, fragrances, bioplastics and natural preservatives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Linebacker</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Linebacker is a multi-faceted therapeutic platform
intended for metabolic, neurologic, cancer, and infectious diseases. Our process features a molecular tuning technique that is intended
to modify a natural compound to induce potency, efficacy, bioavailability, and trans-membrane permeability while maintaining safety,
toxicity, and tolerability. Natural compounds used in the Linebacker platform is designed to treat and prevent a range
of diseases by inhibiting TNF-alpha and indication specific causes (e.g., neurology, anti-inflammatory diseases, oncology). Linebacker&#8217;s
intended use is subject to FDA regulation, and the FDA must approve any drug or biologic product before it can be marketed in the United
States. In addition, prior to being sold outside the United States, our Linebacker technology must be approved by the regulatory agencies
of foreign governments. Prior to filing a new drug application or biologics license application with the FDA, we would have to perform
extensive clinical trials, and prior to beginning any clinical trial, we would need to perform extensive preclinical testing which could
take several years and may require substantial expenditures. To date, we have not conducted preclinical testing or clinical trials (human
or otherwise) on Linebacker nor have we received any FDA approval to conduct such any such preclinical testing or clinical trials. Further,
because we have not conducted any testing or studies on Linebacker, we are not able to substantiate or demonstrate that Linebacker will
function as planned, nor can we seek FDA approval to market and sell Linebacker. To date, we have not performed the extensive preclinical
testing necessary to begin any clinical trials for Linebacker; and until we have conducted the necessary clinical trials, we will not
be able to seek FDA approval for Linebacker. Currently, we have no plans to conduct preclinical testing or clinical trials (human or
otherwise) involving Linebacker.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to identify third parties or customers that are interested in purchasing, licensing or co-developing products that leverage our
Linebacker technology. We have not entered into any such agreements to date, and there can be no guarantee that we will enter into any
such agreements or that such agreements will be on terms that are favorable to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_011" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Laetose</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Laetose technology is derived from a unique combination
of sugar and other compounds, which demonstrates the ability to inhibit the inflammatory response of sugar alone. Based on our
intended use for Laetose, Laetose may be classified as a high-intensity sweetener by the FDA. High-intensity sweeteners are commonly
used as sugar substitutes or sugar alternatives because they are many times sweeter than sugar but contribute only a few to no calories
when added to foods. High-intensity sweeteners, like all other ingredients added to food in the United States, must be safe for consumption.
Further, a high intensity sweetener is regulated as a food additive, unless its use as a sweetener is generally recognized as safe (GRAS).
The use of a food additive must undergo premarket review and approval by FDA before it can be used in food. In contrast, use of a GRAS
substance does not require premarket approval. Rather, the basis for a GRAS determination based on scientific procedures is that experts
qualified by scientific training and experience to evaluate its safety conclude, based on publicly available information, that the substance
is safe under the conditions of its intended use. A company can make an independent GRAS determination for a substance with or without
notifying FDA. Regardless of whether a substance is approved for use as a food additive or its use is determined to be GRAS, scientists
must determine that it meets the safety standard of reasonable certainty of no harm under the intended conditions of its use. This standard
of safety is defined in FDA&#8217;s regulations.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of this date, we have not performed any scientific testing to determine the safety of Laetose for human consumption, and no qualified
experts have evaluated the safety of Laetose. Therefore, we have not been able to make any determination that Laetose is safe for human
consumption. Currently, we have no plans to conduct any scientific testing relating to the safety of Laetose, and any there can be no
guarantee that any such testing will conclude that Laetose is safe for human consumption.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to identify third parties or customers that are interested in purchasing, licensing or co-developing products that leverage Laetose.
We have not entered into any such agreements to date, and there can be no guarantee that we will enter into any such agreements or that
such agreements will be on terms that are favorable to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is presently seeking to license Laetose by way of a business development agreement between Sweet Sense, Inc., a joint venture
established by Global BioLife and Quality Ingredients, LLC (&#8220;Sweet Sense&#8221;), and BFS. Sweet Sense was established for the
development, manufacture, and global distribution of the new sugar substitute. On November 8, 2019, the Company purchased 50% of Sweet
Sense Inc. from Quality Ingredients, LLC for $91,000. Sweet Sense is now an 81.8% owned subsidiary of the Impact BioMedical.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Functional
Fragrance Formulation (&#8220;3F&#8221;)</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3F
is a unique formulation of specialized ingredients (e.g., terpenes) from botanical sources with potential application as an insect
repellent and an antimicrobial. Currently, approximately 20 combination insect repellent-sunscreen drug products are available for consumers.
These products consist of one of three insect repellents (N,N-diethyl-meta-toluamide (DEET), oil of citronella, or IR3535) and a sunscreen
component (one or more sunscreen ingredients). Internal repellent test results demonstrated the prevention and limitation of insect bites
up to eight (8) hours. To date, we have not conducted studies to establish marketing claims.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also intend to identify third parties or customers that are interested in purchasing, licensing or co-developing products that leverage
3F. We have not entered into any such agreements to date, and there can be no guarantee that we will enter into any such agreements or
that such agreements will be on terms that are favorable to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_011" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Equivir</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equivir/Nemovir
is a novel blend of naturally occurring compounds that are sourced from fruits, vegetables, and other natural substances. Equivir is
designed to work by impeding virulence while also blocking multiple methods used by viruses to infect and replicate in host cells,
following deployment in a manner similar to a vitamin, and this intended use is
subject to FDA regulation. The FDA must approve any drug or biologic product before it can be marketed in the United States. In addition,
prior to being sold outside the United States, our Equivir technology must be approved by the regulatory agencies of foreign governments.
Prior to filing a new drug application or biologics license application with the FDA, we would have to perform extensive clinical trials,
and prior to beginning any clinical trial, we would need to perform extensive preclinical testing which could take several years and
may require substantial expenditures. To date, we have conducted no preclinical testing or clinical trials (human or otherwise) on Equivir.
Further, because we have not conducted any testing or studies on Equivir, we are not able to substantiate or demonstrate its benefits
as a health supplement or seek FDA approval at this time. Currently, we have no plans to conduct any preclinical testing or clinical
trials (human or otherwise) involving Equivir.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to identify third parties or customers that are interested in purchasing, licensing or co-developing products that leverage Equivir.
We have not entered into any such agreements to date, and there can be no guarantee that we will enter into any such agreements or that
such agreements will be on terms that are favorable to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, other Equivir analogues are under development and provisional patents have been filed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
Products</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Though
not of substantive material impact to our business currently, we have three additional products; VanXin, Quantum, and CRST1, which we
believe to have high potentiality of viability and commercialization. VanXin is a natural food preservative booster made up of natural
occurring compounds, that can extend the shelf life of various products. Quantum, our Patent Cliff solution, uses advanced methods
to modify natural compounds and existing drugs, while maintaining the safety attributes of the original molecules. CRST 1 is our advanced
adjuvant for next generation vaccine applications. We intend to commercialize these future portfolio products through partnerships with
large manufactures in the pharmaceutical, food, health and beauty, and nutraceutical industries. We will leverage their product development,
commercialization, and distribution capabilities to take products to market through a licensing and/or private label sales model.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Developments </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>BioMed
Technologies Asia Pacific Holdings Limited Investment</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 19, 2020, the Company, entered into a subscription agreement (the &#8220;Subscription Agreement&#8221;) with BioMed Technologies
Asia Pacific Holdings Limited (&#8220;BioMed&#8221;), a limited liability company incorporated in the British Virgin Islands, pursuant
to which the Company agreed to purchase 525 ordinary shares or 4.99% of BioMed at a purchase price of approximately $630,000. The Subscription
Agreement provides, among other things, the Company the right to appoint a new director to the board of BioMed. With respect to an issuance
of shares to a third party by BioMed, the Company will have the right of first refusal to purchase such shares, as well as customary
tag-along rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Subscription Agreement, on
December 9, 2020, the Company entered into an exclusive distribution agreement (the &#8220;Distribution Agreement&#8221;) with BioMed,
to directly market, advertise, promote, distribute, and sell certain BioMed products, which focus on manufacturing natural probiotics,
to resellers. The Distribution Agreement is for an initial term of ten years, and upon expiration, renews for additional successive one-year
terms unless either party elects not to renew. The Distribution Agreement may be terminated by either party for cause as specified therein.
Pursuant to the Distribution Agreement, BioMed provides its products to the Company at the prices set forth in the Distribution Agreement,
such prices being firm and not subject to increase except for as provided in the Distribution Agreement. Further, pursuant to the Distribution
Agreement, BioMed is solely responsible for all costs and expenses relating to the Company&#8217;s distribution of BioMed&#8217;s products.
This investment is valued at cost as it does not have a readily determined fair value. For the three months ended March
31, 2023, the Company has generated approximately $68,000 through the sale of BioMed&#8217;s products under the Distribution
Agreement.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioMed
focuses on manufacturing natural probiotics, pursuant to which the Company will directly market, advertise, promote, distribute and sell
certain BioMed products to resellers. The products to be distributed by the Company include BioMed&#8217;s PGut Premium Probiotics&#174;,
PGut Allergy Probiotics&#174;, PGut SupremeSlim Probiotics&#174;, PGut Kids Probiotics&#174;, and PGut Baby Probiotics&#174;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_011" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Vivacitas
Investment </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 15, 2021, the Company entered into a Stock Purchase Agreement (the &#8220;Vivacitas Agreement #1&#8221;) with Vivacitas Oncology
Inc. (&#8220;Vivacitas&#8221;), to purchase 500,000 shares of its common stock at the per share price of $1.00, with an option to purchase
1,500,000 additional shares at the per share price of $1.00. This option will terminate upon one of the following events: (i) Vivacitas&#8217;
board of directors cancels this option because it is no longer in the best interest of the Company; (ii) December 31, 2021; or (iii)
the date on which Vivacitas receives more than $1.00 per share of the Company&#8217;s common stock in a private placement with gross
proceeds of $500,000. Under the terms of the Vivacitas Agreement #1, the Company will be allocated two seats on the board of Vivacitas.
On March 18, 2021, the Company entered into an agreement with Alset EHome International, Inc. (&#8220;Seller&#8221;) to purchase from
the Seller&#8217;s its wholly owned subsidiary Impact Oncology PTE Ltd. (&#8220;IOPL&#8221;) for a purchase price $2,480,000. The acquisition
of IOPL has been treated as an asset acquisition as IOPL does not meet the definition of a business as defined in Topic 805. IOPL owns
2,480,000 shares of common stock of Vivacitas along with the option to purchase an additional 250,000 shares of common stock. The Sellers
largest shareholder is Mr. Chan Heng Fai Ambrose, the Chairman of the Company&#8217;s board of directors and its largest shareholder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 1, 2021, the Company entered into an additional stock purchase agreement with Vivacitas (&#8220;Vivacitas Agreement #2&#8221;),
whereas Vivacitas wished to employ the service of the Chief Business Officer of Impact Biomedical, and in return for the services
of this individual, Vivacitas shall issue to the Company, the aggregate purchase price for the Class A Common Shares of Vivacitas at
the value of $1.00 per share shall be $120,000 to be paid in twelve (12) equal monthly installments for the period between April 1, 2021
and March 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 22, 2021, the Company exercised 1,000,000 of the available options under the Vivacitas Agreement #1 for $1,000,000. This, along
with the shares received as part Vivacitas Agreement #2 increased the Company&#8217;s equity position in Vivacitas to approximately 120,000
shares or 16% as of September 30, 2022. As of September 30, 2022, and December 31, 2021, the fair value of the Company&#8217;s investment
in Vivacitas is not readily available, and therefore is recorded at cost in the amount of $4,100,000 and $4,035,000, respectively. As
of December 31, 2022, the Company determined to impair 100% of its investment in Vivacitas, in the amount of $4,100,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Promissory
Note 1</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 21, 2021, Impact BioMedical, Inc.
entered into a promissory note (&#8220;Promissory Note 1&#8221;) with an individual. The Company loaned the principal sum of $206,000,
with interest at a rate of 6.5%, and maturity date of August 19, 2022. Monthly payments are due on the twenty-first day of each month
and continuing each month thereafter until August 19, 2022, at which time all accrued interest and the entire remaining principal shall
be due and payable in full. In August 2022, this note was amended to extend the maturity date to August 19, 2023. This note is secured
by certain real property situated in Collier County, Florida. The outstanding principal and interest approximated $205,000 and $206,000
as of March 31, 2023 and December 31, 2022, respectively. Of the $205,000 outstanding at March 31, 2023, $205,000 is classified in current
notes receivable on the accompanying consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Promissory
Note 2</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 14, 2021, DSS PureAir, Inc. (&#8220;DSS PureAir&#8221;), a wholly owned subsidiary of the Company, entered into a convertible promissory
note (&#8220;Promissory Note 2&#8221;) with a limited liability company registered in the state of Texas (&#8220;Borrower&#8221;). The
Promissory Note 2 has an aggregate principal balance up to $5,000,000, to be funded at request of the borrower. The Promissory Note 2,
which incurs interest at a rate of 6.5% due quarterly, has a maturity date of May 14, 2023. The Promissory Note 2 contains an options
conversion clause that allows the Company to convert all, or a portion of all, into new issued member units of the borrower with the
maximum principal amount equal to 18% of the total equity position at conversion. The outstanding principal and interest as of March
31, 2022, approximated $5,164,000, which is classified as Notes receivable on the consolidated balance sheet. Subsequent to the execution
of the Promissory Note 2, DSS PureAir entered into distribution agreement with Borrower, who is in the business of manufacturing and
supplying proactive air and surface purification systems, to sell its products within specified territories. In June of 2022, the Company
transferred its 100% of its interest in DSS Pure Air, Inc. to DSS Biohealth Holdings, Inc., a related party and wholly owned subsidiary
of DSS BioHealth Security, Inc. Associated with this transfer is Promissory Note 2 and the related Note payable, related party. The
outstanding principal and interest on December 31, 2022, and December 31, 2021 is $0 and $5,081,000, respectively.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_011" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>DSS
Note </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 31, 2020, and later amended on March 31, 2023, the Company executed a Revolving Promissory Note (&#8220;Note&#8221;) with DSS,
a related party, which accrues interest at a rate of 4.25% and is due in full at the maturity date of March 31, 2024. The revolving nature
of this Note permits for principal amounts borrowed to be repaid and reborrowed. In the case of default, at DSS&#8217;s option, (i) eighteen
percent (18%) per annum, or (ii) such lesser rate of interest as Lender in its sole discretion may choose to charge; but never more than
the Maximum Lawful Rate. DSS has not established a maximum borrowing amount and intends to continue to fund the operations of the Company
through a year from the date these financial statements were available to be issued. As of March 31, 2023 and December 31, 2022, this
Note has an outstanding balance, including interest of $11,008,000 and 9,529,000 respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Although there is no formal written agreement
to fund the Company, DSS may continue to fund the operations of the Company on an as needed basis to be decided by its board of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>GRDG
Licensing Proceeds Distribution Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 15, 2022, the Company entered into a Licensing Proceeds Distribution Agreement (the &#8220;Licensing Agreement&#8221;) with
GRDG Sciences, LLC (&#8220;GRDG&#8221;), Global BioLife, Inc., and Impact BioLife Sciences, Inc., pursuant to which GRDG will receive
20% of the gross licensing or sale proceeds received by the Company from the licensing of improvements with patent and patent applications
(the &#8220;Improvements&#8221;), and all research and technology, developed, made, owned, conceived, by GRDG in exchange for funding
from the Company for research and technology development activities. Pursuant to the Licensing Agreement, Impact continues to receive
consulting payments (the &#8220;Consulting Payments&#8221;) approximating $43,000 per month for the purpose of paying or reimbursing
certain salaries, overhead, office rent reimbursement, and other operating costs. As of December 1, 2022, the Company not made
any payments under the Licensing Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
term of the Licensing Agreement is from February 15, 2022, through the later of (1) the date of the last to expire of a valid patent
of intellectual property, or (2) the date of the last license or fee income generated from the Improvements. The Licensing Agreement
provides for termination for cause, which includes failure to make payment when due, unauthorized disclosure of confidential information,
and unauthorized assignment of the agreement. The parties may terminate the Licensing Agreement with or without cause by providing the
other party with at least two months advance written of a notice of intention of termination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>ProPhase
License Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 17, 2022, the Company entered into a License Agreement (the &#8220;License Agreement&#8221;) with ProPhase Labs, Inc. (&#8220;ProPhase&#8221;)
and Global BioLife, Inc., pursuant to which ProPhase obtained a license to intellectual property rights of Global BioLife, Inc. in exchange
for a royalty fee of five- and one-half percent (5.5%) of net sales. Pursuant to the License Agreement, Global BioLife, Inc. shall reimburse
ProPhase for fifty percent (50%) of the development costs up to one million two hundred fifty dollars ($1,250,000). The term (the &#8220;Term&#8221;)
of the License Agreement is the later of (a) the expiration date of the last to expire a valid claim comprising the licensed patents,
or (b) twelve (12) years from the date of first commercial sale. ProPhase may terminate this Agreement for any or no reason upon thirty
(30) days prior written notice to Global BioLife, Inc. In addition, At any time prior to expiration of the Term, either party may terminate
the License Agreement for cause by providing written notice.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 18, 2022, the Company entered into a License Agreement (&#8220;July License Agreement&#8221;) by and between ProPhase, and Global
BioLife, Inc., pursuant to which Global BioLife, Inc. licensed compounds to ProPhase for research purposes for a one-time upfront license
fee of fifty thousand dollars ($50,000). The July License Agreement contains milestones that may result in payment to Global BioLife,
Inc. of (a) nine hundred thousand dollars ($900,000) upon successful completion of a first Phase 3 study, which may be required by the
FDA, and (b) one million dollars ($1,000,000) for regulatory approval of an NDA for the first licensed product. In addition, ProPhase
will pay to Global BioLife, Inc. 3% royalties on net revenue of each licensed product from the date of first commercial sale and for
the term of the agreement. The term of the July License Agreement is automatically upon the last to occur of the expiration of the last-to-expire
licensed patent. ProPhase has the right to terminate the July License Agreement for any reason or for convenience in its sole discretion.
Global BioLife, Inc. has the right to terminate the July License Agreement only for uncured material breaches by ProPhase.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office
space is provided to Impact by DSS at no cost.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commercialization
Business Strategies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business model revolves mainly around two approaches &#8211; Licensing and Sales Distribution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">1.
Licensing</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
licensing strategy includes developing unique patented technologies which would then be licensed to external partners for developing,
registration, and commercialization as appropriate. We believe that interest in licensing certain projects may rise over time as validating
data becomes available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">2.
Sales Distribution</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
affiliates of ours have relationships with developing global distribution networks. We currently intend to pursue private labelling opportunities
in these and other networks. In addition, we intend to utilize our affiliates newly launched retail e-commerce site to allow us to take
orders and deliver products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Distribution
Agreement by and between BioMed Technologies Asia Pacific Holdings Limited and the Company</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 9, 2020, the Company entered into a distribution agreement (the &#8220;BioMed Distribution Agreement&#8221;) with BioMed Technologies
Asia Pacific Holdings Limited (&#8220;BioMed Technologies&#8221;), whereby BioMed Technologies agreed to sell to the Company, and the
Company agreed to purchase and resell BioMed Technologies&#8217; BioMed Gut Health Products (the &#8220;BioMed Products&#8221;) as identified
in the BioMed Distribution Agreement. Pursuant to the BioMed Distribution Agreement, the Company will act as the exclusive distributor
of the BioMed Products in the U.S., Canada, Singapore, Malaysia, and South Korea. The BioMed Distribution Agreement does not preclude
the Company from selling competing products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
initial term of the BioMed Distribution Agreement is ten (10) years from the December 9, 2020, effective date, unless earlier
terminated. Upon its expiration, the BioMed Distribution Agreement shall automatically renew for additional successive one (1) year term
unless and until either party provides notice of nonrenewal at least sixty (60) days before the end of the then-current term. The Company
may terminate the BioMed Distribution Agreement if BioMed Technologies: (a) repudiates any of its obligations under the BioMed
Distribution Agreement; (b) materially breaches any its representations, warranties or covenants; (c) fails to or threatens to fail to,
timely deliver the BioMed Products; (d) becomes insolvent or is generally unable to pay, or fails to pay, its debts as they become due
and payable, (ii) files or has filed against it, a petition for voluntary or involuntary bankruptcy, (iii) seeks reorganization, arrangement,
adjustment, winding-up, liquidation or dissolution or other relief from its debts, (iv) makes or seeks to make a general assignment for
the benefit of its creditors, (v) or applies for or has a receiver, trustee, custodian, or similar agent appointed by order of any court
of competent jurisdiction or (e) is unable to perform its obligations for more than thirty (30) consecutive business days due to a force
majeure event. In addition, the Company may terminate the BioMed Distribution Agreement at its option, at any time, and for any reason.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 38; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_011" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">3.
Research and Development</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Stockholders
Agreement between Global BioLife and the Global BioLife Stockholders</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 26, 2017, Global BioLife entered into a stockholders&#8217; agreement with its stockholders Global BioMedical, GRDG and Holista
(the &#8220;Global BioLife Stockholders&#8217; Agreement&#8221;). Pursuant to the Global BioLife Stockholder&#8217;s Agreement, GRDG has agreed to contribute to Global BioLife any and
all right, title, interest and ownership held by GRDG in any patent related to the uses of the &#8220;Linebacker Patents&#8221; as defined
in the Global BioLife Stockholders&#8217; Agreement. Further, pursuant to the Global BioLife Stockholders Agreement, GRDG has agreed
to contribute to Global BioLife the advice and services of Daryl Thompson as a scientist during the term of the agreement in connection
with the development of the Linebacker Patents and all projects associated therewith, as well as such other projects as Global BioLife
may from time to time pursue. In addition, Global BioLife has agreed to contract with GRDG for the needed research in order to develop
the Linebacker Patents as well as new intellectual property. Compensation paid by Global BioLife for this work, if any, shall be provided
for in Global BioLife&#8217; budget</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Global BioLife Stockholders&#8217; Agreement, Global Biomedical has agreed to contribute to Global BioLife the funds set forth
in the Global BioLife budget and such reasonable amounts as the Global BioLife board of directors shall in future annual periods authorize
as Global BioLife&#8217;s business plan and budget. Such budget shall include (i) a payment of $20,994 per month to GRDG and (ii) such
other amounts as shall be necessary to fund the scientific operations that the Global BioLife board shall agree to pursue. The monthly
payments were adjusted for the increase in rent of GRDG office and general inflation. Current monthly payments approximate to $43,000.
</span>For the years ended December 31, 2022 and 2021, the Company incurred expenses of $546,000 and $509,176, respectively. On December
31, 2022 and 2021, the Company owed this related party $0, and had prepaid monthly fees approximating $43,000. For the three months
ended March 31, 2023, this funding approximates $43,000 per month, and incurred approximately $129,000 in expenses. On March 31, 2023
and March 31, 2022, the Company owed this related party $0 and had prepaid monthly fees approximating $43,000 and $43,000, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Global BioLife Stockholders&#8217; Agreement, Holista has agreed to (i) assist in the global commercialization of Global BioLife&#8217;s
intellectual property, (ii) assist in the initiation and development of joint venture opportunities for Global BioLife, and (iii) provide
the expertise of Dr. Rajen M. Dato to Global BioLife, who shall be available to provide management service and assist in the strategic
director of Global BioLife.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Global BioLife Stockholders&#8217; Agreement shall terminate (a) upon the dissolution and winding up of Global BioLife or (b) on the
date the parties terminate the agreement by unanimous written consent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 22, 2018, the parties to the Global BioLife Stockholders&#8217; Agreement entered into Amendment No. 1 to the agreement (&#8220;Amendment
No. 1 to the Global BioLife Stockholders Agreement&#8221;), and in August of 2020 the parties entered into Amendment No. 2 to the agreement
(&#8220;Amendment No. 2 to the Global BioLife Stockholders Agreement&#8221;). Pursuant to Amendment No. 2, the parties to the Global
BioLife Stockholders Agreement agreed to waive the obligations of GRDG to contribute any further inventions, discoveries or other items
of intellectual property developed by GRDG during the term of the Stockholders&#8217; Agreement subsequent to the date of Amendment No.
2, except for any invention, discovery or other items of intellectual property which is directly related to, or necessary for the sale,
licensing or further development of intellectual property owned by Global BioLife.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 39; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_011" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Stockholders
Agreement between Impact BioLife and the Impact BioLife Stockholders</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2020, Impact BioLife entered into a stockholders agreement with its stockholders Impact BioMedical and GRDG (the &#8220;Impact
BioLife Stockholders&#8217; Agreement&#8221;). Pursuant to the Impact BioLife Stockholders&#8217; Agreement, GRDG agreed to (i) transfer
certain intellectual property as identified in the Stockholders&#8217; Agreement to Impact BioLife, (ii) present all suitable technologies
developed by GRDG to Impact BioLife, so as to provide Impact BioLife with the opportunity to fund, own and develop any intellectual property
developed by GRDG and (iii) retain the advice and services of Mr. Daryl Thompson as a scientist during the term of the Impact BioLife
Stockholders&#8217; Agreement in connection with all projects as Impact BioLife may from time to time pursue. Further, pursuant to the
Impact BioLife Stockholders&#8217; Agreement, GRDG also agreed that Daryl Thompson will devote most of his professional time per week
to the business of Impact BioLife, including but not limited to, the development of new intellectual property for Impact BioLife.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, pursuant to the Impact BioLife Stockholder&#8217;s Agreement, the Company has agreed to contribute to Impact BioLife such reasonable
amounts as the board of directors of Impact BioLife shall in future annual periods authorize as Impact BioLife&#8217;s business plan
and budget (the &#8220;Impact BioLife Budget&#8221;). The Impact BioLife Budget shall include (i) a payment approximating $43,000 per
month to GRDG and (ii) such other amounts as shall be necessary to fund the research, development and other scientific operations that
the Impact BioLife board of directors shall agree to pursue. </span>For the years ended December 31, 2022 and 2021, the Company incurred
expenses of $546,000 and $509,176, respectively. On December 31, 2022 and 2021, the Company owed this related party $0, and had prepaid
monthly fees approximating $43,000. For the three months ended March 31, 2023, this funding approximates $43,000 per month, and incurred
approximately $129,000 in expenses. On March 31, 2023 and March 31, 2022, the Company owed this related party $0 and had prepaid monthly
fees approximating $43,000 and $43,000, respectively.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Impact BioLife Stockholders&#8217; Agreement, the board of directors of Impact BioLife shall never be less than one nor more than
five directors. GRDG shall be entitled to nominate one director to the Impact BioLife board of directors so long as it shall remain
a stockholder of Impact BioLife. The Company shall be entitled to nominate the remaining directors of the Impact BioLife. In addition,
pursuant to the Impact BioLife Stockholders&#8217; Agreement, so long as it is a stockholder of Impact BioLife, the Company is entitled
to appoint Impact BioLife&#8217;s chief executive officer, who, at the discretion of the Company, may also serve as a director of the
Impact BioLife board of directors. The parties to the Impact BioLife Stockholders&#8217; Agreement have agreed that the initial directors
of the Impact BioLife board of directors shall be Heng Fai Ambrose Chan, Frank D. Heuszel and Daryl Thompson. The Company shall appoint
the chairman of the Impact BioLife board of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Impact BioLife Stockholders&#8217; Agreement will terminate (a) upon the dissolution and winding up of Impact BioLife, (b) on the date
the parties terminate the agreement by unanimous written, (c) on the fifth anniversary of the date of the Impact BioLife Stockholders&#8217;
Agreement, unless the parties mutually agree to an extension, or (d) upon three months&#8217; written notice by either party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employees</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have two employees focused primarily on the development and marketing of existing technologies as well as identifying new opportunities.
Certain services are provided to us and our subsidiaries by DSS as well as by GRDG, a related party, pursuant to the Global BioLife Stockholders&#8217;
Agreement and the Impact BioLife Stockholders&#8217; Agreement. At the present time, Global BioLife pays GRDG approximately $43,000
per month for services provided by GRDG.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Legal
Proceedings</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may be involved in various other claims and legal proceedings relating to claims arising out of our operations. We are
not currently a party to any material legal proceedings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Competition</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
biohealth business is highly competitive. Existing and future competitors may introduce products and services in the same markets we
serve, and competing products or services may have better performance, lower prices, better functionality and broader acceptance than
our products. This competition could result in increased sales and marketing expenses, thereby materially reducing our operating margins,
and could harm our ability to increase, or cause us to lose, market share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Most,
if not all, of our current and potential competitors may have significantly greater resources or better competitive positions in certain
product segments, geographic regions or user demographics than we do. These factors may allow our competitors to respond more effectively
than us to new or emerging technologies and changes in market conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 40; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_011" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
competitors may develop products, features or services that are similar to its own or that achieve greater acceptance, may undertake
more far-reaching and successful product development efforts or marketing campaigns, or may adopt more aggressive pricing policies. Certain
competitors could use strong or dominant positions in one or more markets to gain competitive advantage us in its target market or markets.
As a result, our competitors may acquire and engage customers or generate revenue at the expense of our own efforts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Future
Research/Emerging Technologies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to our current technologies, we continue our exploration and discovery efforts. Current areas of interest include natural entities
for drug development/treatment, food preservatives, and other categories. These efforts may result in new intellectual property, drug
treatments, and consumer and wellness offerings subject to study/data results. They may also never reach development milestones, prove
effective, or result in material value to the company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intellectual
Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
strive to protect the intellectual property that we believe is important to our business, including seeking and maintaining patent protection
intended to cover the composition of matter of our product candidates, their methods of use, their methods of production, related technologies
and other inventions. In addition to patent protection, we also rely on trade secrets to protect aspects of our business that are not
amenable to, or that we do not consider appropriate for, patent protection, including certain aspects of technical know-how.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success depends in part upon our ability to obtain and maintain patent and other proprietary protection for commercially important
technologies, inventions and know-how related to our business, defend and enforce our intellectual property rights, particularly our
patent rights, preserve the confidentiality of our trade secrets and operate without infringing valid and enforceable intellectual property
rights of others.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patent positions for companies like us are generally uncertain and can involve complex legal, scientific and factual issues. In addition,
the coverage claimed in a patent application can be significantly reduced before a patent is issued, and its scope can be reinterpreted
and even challenged after issuance. As a result, we cannot guarantee that any of our product candidates will be protectable or remain
protected by enforceable patents. We cannot predict whether the patent applications we are currently pursuing will issue as patents in
any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from competitors.
Any patents that we hold may be challenged, circumvented or invalidated by third parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_011" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows our material patents and the expiration date of each patent as of March 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 6%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Product</i></b></span></td>
    <td style="vertical-align: top; width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Patent No.</i></b></span></td>
    <td style="vertical-align: top; width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 5%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Status</i></b></span></td>
    <td style="vertical-align: top; width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 5%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Expiration Date</i></b></span></td>
    <td style="vertical-align: top; width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 39%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary</b></span></td>
    <td style="vertical-align: top; width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 25%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Ex US Status</i></b></span></td></tr>
  <tr>
    <td rowspan="4">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>LineBacker</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. 8,034,838</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted </span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2029</span></td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Method/Composition for Treatment of Neurological Disorders
    with Modified Flavonoid Compound</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. 10,123,991</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted </span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2036</span></td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Composition of Electrophilically Enhanced Phenolic
    Compounds (any chlorinated myricetin) for Treating Inflammatory Diseases and Disorders</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCT/US17/32897 (Foreign Filed in AU, BR, CA, CN, EP, HK, IN, JP, KR, RU)</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. 10,966,954</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2036</span></td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Composition of Electrophilically Enhanced Phenolic
    Compounds (specific mono and di-chlorinated myricetin) for Treating Inflammatory Diseases and Disorders</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCT/US2017/032897 (Foreign
    AU, BR, CN, EP, JP, KR, RU) (30-month date: Nov. 16, 2018)</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCT/US21/22538</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A (1) (2)</span></td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Method and Compositions for Treating, Preventing or
    Limiting the Occurrence of Viral Infection</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCT/US21/22538 (30-month
    date: Sept. 16, 2022)</span></td></tr>
  <tr>
    <td rowspan="4">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Equivir Nemovir</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Equivir G</b></p></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. 10,383,842; US 15/043,472</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2036</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Method/Composition for
    Preventing and Treating Viral Infections (Influenza)</span></td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">PCT/US2017/032897* (Foreign AU, BR, CN, EP, JP,
    KR, RU) (30-month date: Nov. 16, 2018) (* disclosure of both Linebacker and Equivir)</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US 11,033,528</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2036</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Method/Composition for
    Preventing and Treating Viral Infections (Ebola, Rhinovirus)</span></td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">PCT/US17/048892** (Foreign AU, CA, CN, JP, KR,
    EPO, RU) (** Equivir w/gallic acid) (30-month date: Feb. 28, 2020)</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US 17/346,569</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A (1) (3)</span></td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Method/Composition for Preventing and Treating Viral
    Infections (potentially Covid, others).</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td></tr>
  <tr>
    <td/>
    <td style="text-align: justify"/>
    <td/>
    <td style="text-align: justify"/>
    <td/>
    <td style="text-align: justify"/>
    <td/>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></td>
    <td/>
    <td style="text-align: justify"/></tr>
  <tr>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Laetose</b></span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15/698,159</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A (1) (4)</span></td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A composition including a select sugar source and
    myo-inositol that impacts the signaling of TNF-a and pro-inflammatory cytokines when metabolized, with ability to control blood glucose
    levels, treat diabetes and inflammatory diseases.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">PCT/US18/49965</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Foreign Filed in AU, BR, CA, CN, EP, HK, IN,
    JP, KR and RU (30-month date: Mar. 7, 2020)</p></td></tr>
  <tr>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3F (Anti-Viral)</b></span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/212,966</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A (1) (5)</span></td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Composition of natural elements for use as an antibacterial
    and antiviral agent</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">PCT/US19/64254</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Foreign Filed in AU, BR, CA, CN, EP, IN, JP,
    KR and RU (30- month Jun. 7, 2021</p></td></tr>
  <tr>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3F (DB Repellent)</b></span></td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">U.S. 16/593,693; U.S. 10,966,424</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">PCT/US520/54042</p></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2039</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unique weight-based
    composition/method of natural elements with DEET for use as insect repellent</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCT Filed October 2, 2020,
    PCT/US20/54042) &#8211; 30 Month Date April 4, 2022 (currently no foreign national stage countries pending </span></td></tr>
  <tr>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3F (Anti-Insect)</b></span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/270,857</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A (1) (6)</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unique weight-based composition/method of natural elements without DEET for use as insect repellent</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCT/US20/17183 (Foreign Filed in CA, JP, CN, KR, EPO, RU) (30 month: Jun. 7, 2021)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">1. The expiration date of pending patents are currently unknown
but typically approximately 20 years from filing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Patent application filed on September 23, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
Patent application filed on June 14, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
Patent application filed on September 7, 2017.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
Patent application filed December 7, 2018.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
Patent application filed February 8, 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 42; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_011" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Regulation
of the Biohealth Business</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, the drug, device and cosmetic industries have long been subject to regulation by various federal and state agencies,
primarily as to product safety, efficacy, manufacturing, advertising, labeling and safety reporting. The U.S. Food and Drug Administration,
or FDA, has broad regulatory powers. Extensive testing and documentation is required for FDA approval of new drugs and devices, increasing
the expense of product introduction. Significant expenses are also evident in major markets outside of the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
costs of human health care have been and continue to be a subject of study, investigation and regulation by governmental agencies and
legislative bodies around the world. In the United States, attention has been focused on drug prices and profits and programs that encourage
doctors to write prescriptions for particular drugs, or to recommend, use or purchase particular medical devices. The regulatory agencies
under whose purview Impact BioMedical may operate in the future have administrative powers that may subject partners to whom Impact BioMedical
licenses products to actions such as product withdrawals, recalls, seizure of products and other civil and criminal sanctions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, business practices in the health care industry have come under increased scrutiny, particularly in the United States, by government
agencies and state attorneys general, and resulting investigations and prosecutions carry the risk of significant civil and criminal
penalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Partners
to whom we license products in the future may need to rely on global supply chains, and production and distribution processes, that are
complex, subject to increasing regulatory requirements, and may be faced with unexpected changes that may affect sourcing, supply and
pricing of materials used in products which we have or will develop. These processes also are subject to lengthy regulatory approvals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share
Exchange Transaction</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 21, 2020, we closed on a Share Exchange Agreement by and among DSS, DSS BioHealth Security, Inc., Alset International Ltd. (formerly
Singapore eDevelopment Ltd.), and Global Biomedical Pte Ltd. (&#8220;GBM&#8221;), pursuant to which we became a wholly-owned subsidiary
of DSS BioHealth Security, Inc. Shortly after closing, Frank D. Heuszel, Jason Grady and John Thatch were appointed directors, and Mr.
Heng Fai Ambrose Chan remained on the Board of Directors and appointed Chief Executive Officer, Mr. Heuszel was appointed President,
Mr. Grady was appointed Chief Operating Officer and Todd Macko was appointed Secretary and Treasurer, replacing the officers and directors
who resigned in connection with the share exchange.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Chan is the Chief Executive Officer and largest beneficial owner of outstanding shares of common stock of Alset International Ltd., as
well as the Chairman of the Board and largest beneficial owner of outstanding shares of common stock of DSS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Limited
Operating History</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no historical financial information about us upon which to base an evaluation of our performance. As of the date of this report, we
have not generated any revenues from operations. We cannot guarantee we will be successful in our business operations. Our business is
subject to risks inherent in the establishment of a new business enterprise, including limited capital resources, possible delays our
research, testing and marketing efforts or wider economic downturns.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impact
BioMedical Inc. is a Nevada corporation and was incorporated in October 2018. Our principal executive offices are located at 275 Wiregrass
Parkway, West Henrietta, New York 14568. Our telephone number is +1-585-325-3610. Our website address is https://www.impbio.com.
Our website and the information contained thereon, or connected thereto, does not and will not constitute part of this Prospectus or
the Registration Statement on Form S-1 of which this Prospectus is a part.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 43; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_011" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ax_002"></span>MANAGEMENT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Officers
and Board of Directors Following the Distribution</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Nevada law, the business and affairs of the Company is managed under the direction of our Board. Our Amended and Restated Articles of
Incorporation provide that the number of directors may be fixed by our Board from time to time. Members of the Board are elected and
serve for one-year terms or until their successors are elected qualify. The following sets forth information regarding individuals who
are currently officers and directors in office and are expected to continue to serve in their positions after the Distribution (ages
as of June 24, 2022):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 29%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 7%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 60%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position
    </b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Heng
    Fai Ambrose Chan </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">77</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
    of the Board</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Frank
    D. Heuszel</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President,
    Chief Executive Officer and Director </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TJ
    Leonardo</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Operating Officer and Secretary</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Todd
    D. Macko </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian
    DeFrees</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controller</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Elise Brownell </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Melissa
    Sims</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Biographical
and certain other information concerning the Company&#8217;s officers and directors is set forth below. There are no familial relationships
among any of our directors. Except as indicated below, none of our directors is a director in any other reporting companies. None of
our directors has been affiliated with any company that has filed for bankruptcy within the last ten years. We are not aware of any proceedings
to which any of our directors, or any associate of any such director is a party adverse to us or any of our subsidiaries or has a material
interest adverse to us or any of our subsidiaries. Each executive officer serves at the pleasure of the Board of Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 22%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director/Officer</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Since</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 48%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal
    Occupation or Directorships</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Heng
    Fai Ambrose Chan</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">77</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2017</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Chan Heng Fai has served as an Executive director of DSS, Inc. (NYSE: DSS) (formerly known as Document Security Systems, Inc.) since
    January 2017 and as Executive Chairman of the Board since March 2019. Mr. Chan founded Alset EHome International, Inc. and has served
    as Chairman of the Board and Chief Executive Officer since inception in March 2018. Mr. Chan is an expert in banking and finance,
    with 45 years of experience in these industries. He has restructured numerous companies in various industries and countries during
    the past 40 years. Mr. Chan has served as the Chief Executive Officer of Alset EHome International Inc.&#8217;s subsidiary Alset
    International Limited (&#8220;Alset&#8221;) (SGX: 40V) since April 2014. Mr. Chan joined the Board of Directors of Alset in May 2013.
    Mr. Chan has served as a Director of Sharing Services Global Corporation since April 2020. Mr. Chan has served as a director of Alset&#8217;s
    99.69%-owned subsidiary GigWorld Inc. since October 2014. He also served as a director of Alset&#8217;s indirect subsidiary LiquidValue
    Development Inc. since January 2017. Mr. Chan has also appointed as Chairman and Chief Executive Officer of Alset Capital Acquisition
    Corp, a New York Stock Exchange Listed company, since October 2021. In addition, Mr. Chan appointed as a board member of Value Exchange
    International, Inc. since December 2021.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 44; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_011" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 22%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Frank
    D. Heuszel </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Frank Heuszel has served as President and Director of the Company since August 2020. Since April 2023, Mr. Heuszel
has also served as Chief Executive Officer of the Company. Since April 11, 2019, Mr. Heuszel has served as the Chief Executive Officer
of DSS since April 11, 2019, DSS&#8217;s Interim Chief Financial Officer from April 2019 to October 2020, and a director of DSS since
July 30, 2018. Mr. Heuszel has extensive expertise in a wide array of strategic, business, turnaround, and regulatory matters across several
industries as a result of his executive management, educational, and operational experience. Prior to joining DSS, Mr. Heuszel had a very
successful career in commercial banking. For over 35 years, Mr. Heuszel served in many senior executive roles with major US and international
banking organizations. As a banker Mr. Heuszel has served as General Counsel, Director of Special Assets, Credit Officer, Chief Financial
Officer and Auditor. Mr. Heuszel also operated a successful law practice focused on the litigation, corporate restructures, and merger
and acquisitions, and collections. In addition to being an attorney and executive manager, Mr. Heuszel is also a Certified Public Accountant
(retired), and a Certified Internal Auditor. Mr. Heuszel graduated from The University of Texas at Austin and from The South Texas College
of Law, Houston.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>

<tr style="vertical-align: top">
    <td style="width: 22%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">TJ Leonardo</p></td>
    <td style="width: 2%">&#160;</td>
    <td style="text-align: center; width: 6%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">44</p></td>
    <td style="width: 2%">&#160;</td>
    <td style="text-align: center; width: 18%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">2023</p></td>
    <td style="width: 2%">&#160;</td>
    <td style="text-align: justify; width: 48%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ms.
Leonardo joined DSS, Inc. in 2021 as the company&#8217;s Director of Strategic Operations, and was named Impact BioMedical&#8217;s Chief
Operating Officer and Secretary in May 2023. Through her diverse areas of expertise and problem-solving agility, she has become a trusted
partner and advisor to the leadership team of DSS, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to joining DSS, Inc., Ms. Leonardo has held various operational positions at a number of NYC-based firms. Most recently, she led Operations,
Onboarding, and Training and Development at Odgers Berndtson, Executive Recruiting Firm, from 2016 to 2020. During her time in NYC from
2001-2016, Ms. Leonardo worked in operations and administrative roles within the investment banking and wealth advisory services industries
in fast-paced, demanding, and client-centric environments at Allen &amp; Co., Mount Kellett Capital Management, and Wilmington Trust
Company, while also working as a freelance Editor/Writer. Prior to that, TJ supported Managing Directors at DDB Worldwide Advertising
Agency and a fellowship program within Columbia Law School.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>
                                                <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
                                                <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Ms. Leonardo is President of the Board of IC3 in Ithaca, NY, holds a BFA Degree from the State University of New
York at Brockport, and obtained a Human Resource Management Certificate from NYU&#8217;s School for Continuing and Professional Studies.</p></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 22%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 6%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 48%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Todd
    D. Macko </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Todd D. Macko has been Secretary and Treasurer of
    the Company since January 2021 and in May 2023 became Chief Financial Officer of the Company. Mr. Macko was promoted
    to Interim Chief Financial Officer of DSS effective October 28, 2020, and was appointed Chief Financial Officer on August 16, 2021.
    Mr. Macko previously served as the Vice President of Finance of DSS. As the Vice President of Finance, Mr. Macko&#8217;s
    responsibilities included assisting DSS&#8217;s Interim Chief Financial Officer in all aspects of financial and regulatory
    reporting. In addition, his responsibilities included the day-to-day management of the Company&#8217;s Accounting and Finance team
    and the financial leadership in the directing and improving of the accounting, reporting, audit, and tax activities. Prior to his
    role as Vice President of Finance for the Company, Mr. Macko joined the wholly owned subsidiary of DSS, Premier Packaging
    Corporation in January 2019, as its Vice President of Finance. Mr. Macko is a Certified Public Accountant with over 25 years of
    public and corporate financial management, business leadership and corporate strategy. Mr. Macko brings a wealth of experience with
    strengths in financial planning and analysis, business process re-engineering, budgeting, merger and acquisitions, financial
    reporting systems, project evaluation and treasury and capital management. Prior to joining the Company, Mr. Macko served as the
    Corporate Controller for Baldwin Richardson Foods, a leading custom ingredients manufacturer for the food and beverage industry from
    November 2015 until January 2019. Prior to that, Mr. Macko served as the Controller for The Outdoor Group, LLC., Genesis Vision,
    Inc., Complemar Partners, Inc., and Level 3 Communications, Inc. Mr. Macko obtained is Bachelor of Science in Accounting from
    Rochester Institute of Technology.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 45; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_011" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 22%"><p style="margin: 0">Brian DeFrees</p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 6%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">38</p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 48%">Brian DeFrees has served as Controller of
    the Company since May 2023. Mr. DeFrees joined DSS, Inc in the capacity of Controller
in September 2022. In this role, he is responsible for the accounting operations of the company and its subsidiaries, production of periodic
financial reports, maintenance of accounting records, and oversight of the accounting department.

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="margin: 0">Mr. DeFrees brings a combination of Public and Corporate sector accounting experience that spans a wide range
of industries.&#160; Most recently, he was the Financial Controller for Goodwill of the Finger Lakes from May 2015 to May 2021 and a
Senior Manager of Accounting for Genesee &amp; Wyoming Railroad from May 2021 to September 2022.&#160;</p>
</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Elise Brownell </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Elise Brownell has served as a director of the Company since January 2021. Dr. Brownell has more than 20 years of biotechnology and
    pharmaceutical project management experience with a proven track record of advancing programs through clinical development. She serves
    as a Life Sciences entrepreneurial advisor for ASTIA, the nation&#8217;s premier entrepreneurial organization focused on women-led
    businesses. Dr. Brownell is also a member of the Editorial Advisory Board for Contract Pharma Magazine, and previous Chair of the
    Leaders Network program of Women in Consulting. She is the co-founder of ZephyrBiotech, LLC, a project management firm dedicated
    to advancing therapeutic candidates through development to key inflection points for clients. Earlier, Dr. Brownell was a founding
    member, head of project management and senior director of Aerovance, Inc., a venture-backed biotechnology company spun out from Bayer
    Healthcare, where she created and managed effective team processes to bring product candidates into full scale clinical Phase 1 and
    2 developments. Prior to Aerovance, Dr. Brownell acted as head of project management for Bayer&#8217;s Biotechnology Unit,
    where she integrated project strategies to meet therapeutic and market needs. Other roles included building and negotiating partnerships
    with third parties to support development programs, leading research teams through early bench-to-clinic development phases, as well
    as entrepreneurial investment experience with Angel&#8217;s Forum. Dr. Brownell received her M.S., M.Phil. and Ph.D. in biology from
    Yale University and her B.S. in biology from Allegheny College.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Melissa Sims</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">54</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">2023</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Since May 2023, Melissa Sims has served as a director
    of the Company<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. </span>Ms. Sims is an Illinois licensed attorney having
practiced law since 1995. Following graduation from Northern Illinois University College of Law, Ms. Sims started the general practice
of law representing clients in banking, health care, real estate, criminal, dissolution, municipal and probate matters in state and appellate
courts. In 2006, she represented the Village of DePue, Illinois regarding legacy pollution from a Superfund site and set national precedent
before the Seventh Circuit Court of Appeals. In 2021, the United States Supreme Court cited the Village of DePue v. ExxonMobil as precedent
in the Atlantic Richfield v. Christian case.

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the past six years, Ms. Sims has been employed
with the international law firm, Milberg Coleman Bryson Phillps Grossman, PLLC and recently represented clients in the National Opioid
multidistrict litigation in the Northern District of Ohio. She also represents municipalities across the country in tort actions in state,
federal and appellate courts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="margin: 0">Ms. Sims will be an asset to the Board in that her decades of plaintiff litigation with offer keen insight into
potential matters which may be of importance on behalf of the Company. The Board believes that her legal background, knowledge expertise,
and litigation experience will add great value to the board slate.</p>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate
Governance</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors of the Company plans to adopt corporate governance guidelines that serve as a flexible framework within which our
Board of Directors and its committees operate. These guidelines will cover a number of areas including the size and composition of the
board, board membership criteria and director qualifications, director responsibilities, board agenda, roles of the chairman of the board
and Chief Executive Officer, meetings of independent directors, committee responsibilities and assignments, board member access to management
and independent advisors, director communications with third parties, director compensation, director orientation and continuing education,
evaluation of senior management and management succession planning.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 46; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_011" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Committees
of Our Board</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
presently do not have any committee of our Board. Currently, our full Board serves as the audit committee and approves, when applicable,
the appointment of auditors and the inclusion of financial statements in our periodic reports.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
Leadership Structure and Role in Risk Oversight</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors is primarily responsible for overseeing our risk management processes on behalf of our Company. The Board of Directors
receives and reviews periodic reports from management, auditors, legal counsel, and others, as considered appropriate regarding our company&#8217;s
assessment of risks. The Board of Directors focuses on the most significant risks facing our company and our company&#8217;s general
risk management strategy, and also ensures that risks undertaken by our Company are consistent with the board&#8217;s appetite for risk.
While the board oversees our company&#8217;s risk management, management is responsible for day-to-day risk management processes. We
believe this division of responsibilities is the most effective approach for addressing the risks facing our company and that our board
leadership structure supports this approach.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Legal
Proceedings</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None
of directors and executive officers has been involved in legal proceedings that would be material to an evaluation of our management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation
of Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has not paid any compensation to any directors since inception.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock
Ownership of Directors and Executive Officers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
&#8220;Security Ownership of Certain Beneficial Owners and Management.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ax_003"></span>EXECUTIVE
COMPENSATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has not paid any compensation to any name executive officers or directors since inception.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 47; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_011" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ax_004"></span>SECURITY
OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DSS
currently beneficially owns 100% of all of our Common Stock. After the Distribution, DSS will own approximately 87% of the outstanding
shares of our Common Stock. The following table provides information with respect to the expected beneficial ownership of our Common
Stock after giving effect to the Distribution by:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    person or entity that we believe, based on the assumptions described below, will be a beneficial owner of more than 5% of our outstanding
    Common Stock following the Distribution;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    person who we expect will serve as a director following the Distribution and each named executive officer; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
    our expected directors and executive officers following the Distribution as a group.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise noted in the footnotes below, we based the share amounts on each person&#8217;s or entity&#8217;s existing beneficial ownership
of our Common Stock and the number to be distributed to holders of DSS Common Stock at the distribution ratio of 4-1 shares of our Common
Stock for each share of DSS Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent our directors and officers own DSS Common Stock at the time of the Distribution, they will participate in the Distribution
on the same terms as other holders of DSS Common Stock, except for holders of any Affiliate Shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise noted in the footnotes below, each person or entity identified below has sole voting and investment power with respect to
such securities. The address of all of the officers and directors listed in the table below are in the care of Impact BioMedical Inc.,
275 Wiregrass Parkway, West Henrietta, NY 14586, unless otherwise indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, there were 3,877,282,251 shares of our Common Stock issued and outstanding. The actual number of shares
of our Common Stock outstanding following the Distribution will depend on several factors including then number of issued and outstanding
shares of DSS at the record date and the number of shares eliminated as a result of the cash out of fractional shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Name
    of Beneficial Owner</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of Shares <br/> Beneficially Owned<br/> Before Distribution</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Percentage
    of Shares <br/> Beneficially Owned<br/> Before Distribution</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of Shares<br/> Beneficially Owned<br/> After Distribution</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Percentage
    of Shares<br/> Beneficially Owned<br/> After Distribution</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 40%; font-weight: bold; font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif">5%
    or More Stockholders</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"/><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">DSS,
    Inc.</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,877,282,251</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left">(1)<span style="font-family: Times New Roman, Times, Serif"></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">100</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Directors
    and Executive Officers</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"/><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Heng
    Fai Ambrose Chan</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><p style="margin: 0">TJ Leonardo</p></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Frank
    D. Heuszel</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Dr.
    Elise Brownell</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">Todd D. Macko</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><p style="margin: 0">-</p></td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><p style="margin: 0">-</p></td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Brian DeFrees</p></td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">Melissa Sims</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">-</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">All
    officers and directors as a group (7 persons)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DSS
    indirectly owns the shares through DSS BioHealth Security, Inc., its wholly-owned subsidiary.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 48; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_011" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ax_005"></span>CERTAIN
RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 21, 2020, DSS completed its acquisition of the Company, pursuant to a Share Exchange Agreement by and among DSS, DSS BioHealth
Security, Inc., Alset International Ltd. (formerly Singapore eDevelopment Ltd.), and Global Biomedical Pte Ltd. (&#8220;GBM&#8221;) (the
&#8220;<span style="text-decoration: underline">Share Exchange</span>&#8221;). Under the terms of the Share Exchange, DSS issued 483,334 shares of the DSS Common Stock nominally
valued at $6.48 per share, and 46,868 newly issued shares of the DSS Series A Convertible Preferred Stock (&#8220;<span style="text-decoration: underline">Series A Preferred
Stock</span>&#8221;), with a stated value of $46,868,000, or $1,000 per share, for a total consideration valued at $50 million. Due to several
factors, including a discount for illiquidity, the value of the Series A Preferred Stock was discounted from $46,868,000 to $35,187,000,
thus reducing the final consideration given to approximately $38,319,000. As a result of the Share Exchange, Impact BioMedical became
a wholly-owned subsidiary of DSS BioHealth Security, Inc., DSS&#8217;s wholly-owned subsidiary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Heng Fai Ambrose Chan, the Chief Executive Officer
and Chairman of the Board of the Company, is the Chief Executive Officer and largest shareholder of Alset International Ltd., as well
as the Chairman of the Board and largest shareholder of DSS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the execution of the Share Exchange Agreement, our ownership of a suite of antiviral and medical technologies was valued at $382 million. Because the valuation was higher than the previously agreed value, the purchase price was capped
at a value of $50 million, pursuant to the terms of the Share Exchange Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">research and development efforts are currently
headed by Mr. Daryl Thompson, Founder and Owner of GRDG. Pursuant to a stockholders&#8217; agreement between Impact
BioLife, a majority-owned subsidiary of the Company, and its stockholders (including GRDG) and a stockholders agreement between Global
BioLife, a majority-owned subsidiary of the Company, and its stockholder (including GRDG), Mr. Thompson has agreed, through GRDG, to
conduct the development and research work on the biomedical products for Impact BioLife and Global BioLife, respectively. Mr. Thompson
also serves as the Director of Scientific Initiatives at Impact BioLife. The above-referenced stockholders&#8217; agreements are described
more fully below. For services provided by GRDG, Global BioLife pays GRDG approximately $43,000 per month.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 15, 2021, the Company, entered into a Stock Purchase Agreement (the &#8220;Agreement&#8221;) with Vivacitas Oncology Inc. (&#8220;Vivacitas&#8221;),
to purchase 500,000 shares of its common stock at the per share price of $1.00, with an option to purchase 1,500,000 additional shares
at the per share price of $1.00. This option will terminate upon one of the following events: (i) The Seller&#8217;s board of directors
cancels this option because it is no longer in the best interest of the Company; (ii) December 31, 2021; or (iii) the date on which the
Seller receives more than $1.00 per share of the Company&#8217;s common stock in a private placement with gross proceeds of $500,000.
Under the terms of the Agreement, the Company will be allocated two seats on the board of Vivacitas. On July 22, 2021, the Company exercised
its right to purchase 1,000,000 additional shares of Vivacitas at the per share price of $1.00. On March 18, 2021, the Company entered
into an agreement with Alset EHome International, Inc. (&#8220;Seller&#8221;) to purchase from the Seller&#8217;s its wholly owned subsidiary
Impact Oncology PTE Ltd. (&#8220;IOPL&#8221;) for a purchase price $2,480,000. The acquisition of IOPL has been treated as an asset acquisition
as IOPL does not meet the definition of a business as defined in Topic 805. IOPL owns 2,480,000 shares of common stock of Vivacitas along
with the option to purchase an additional 250,000 shares of common stock. As a result of these two transactions, the Company will have
an approximate 15.7% (subsequent transactions increase the Company ownership to approximately 19%) equity position in Vivacitas. As of
September 30, 2022, and December 31, 2021, the fair value of the Company&#8217;s investment in Vivacitas is not readily available, and
therefore is recorded at cost in the amount of $4,100,000 and $4,035,000, respectively. As of December 31, 2022, the Company determined
to impair 100% of its investment in Vivacitas, in the amount of $4,100,000. The Sellers largest shareholder is Mr. Heng Fai Ambrose
Chan, the Chief Executive Officer and Chairman of DSS&#8217;s board of directors and the largest shareholder of DSS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Stockholders
Agreement between Global BioLife and the Global BioLife Stockholders</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 26, 2017, Global BioLife entered into a stockholders&#8217; agreement with its stockholders Global BioMedical, GRDG and Holista
(the &#8220;Global BioLife Stockholders&#8217; Agreement&#8221;). Pursuant to the Global BioLife Stockholder&#8217;s Agreement, GRDG has agreed to contribute to Global BioLife any and
all right, title, interest and ownership held by GRDG in any patent related to the uses of the &#8220;Linebacker Patents&#8221; as defined
in the Global BioLife Stockholders&#8217; Agreement. Further, pursuant to the Global BioLife Stockholders Agreement, GRDG has agreed
to contribute to Global BioLife the advice and services of Daryl Thompson as a scientist during the term of the agreement in connection
with the development of the Linebacker Patents and all projects associated therewith, as well as such other projects as Global BioLife
may from time to time pursue. In addition, Global BioLife has agreed to contract with GRDG for the needed research in order to develop
the Linebacker Patents as well as new intellectual property. Compensation paid by Global BioLife for this work, if any, shall be provided
for in Global BioLife&#8217; budget</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Global BioLife Stockholders&#8217; Agreement, Global Biomedical has agreed to contribute to Global BioLife the funds set forth
in the Global BioLife budget and such reasonable amounts as the Global BioLife board of directors shall in future annual periods authorize
as Global BioLife&#8217;s business plan and budget. Such budget shall include (i) a payment of $20,994 per month to GRDG and (ii) such
other amounts as shall be necessary to fund the scientific operations that the Global BioLife board shall agree to pursue. The monthly
payments were adjusted for the increase in rent of GRDG office and general inflation. The current agreement provides for monthly payments
of approximately $43,000. As of December 31, 2022, this funding approximates $43,000 per month, and incurred approximately $546,000
in expenses. On December 31, 2022 and December 31, 2021, the Company owed this related party $0 and had prepaid monthly fees approximating
$43,000 and $43,000, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Global BioLife Stockholders&#8217; Agreement, Holista has agreed to (i) assist in the global commercialization of Global BioLife&#8217;s
intellectual property, (ii) assist in the initiation and development of joint venture opportunities for Global BioLife, and (iii) provide
the expertise of Dr. Rajen M. Dato to Global BioLife, who shall be available to provide management service and assist in the strategic
director of Global BioLife.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 49; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_011" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Global BioLife Stockholders&#8217; Agreement shall terminate (a) upon the dissolution and winding up of Global BioLife or (b) on the
date the parties terminate the agreement by unanimous written consent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 22, 2018, the parties to the Global BioLife Stockholders&#8217; Agreement entered into Amendment No. 1 to the agreement (&#8220;Amendment
No. 1 to the Global BioLife Stockholders Agreement&#8221;), and in August of 2020 the parties entered into Amendment No. 2 to the agreement
(&#8220;Amendment No. 2 to the Global BioLife Stockholders Agreement&#8221;). Pursuant to Amendment No. 2, the parties to the Global
BioLife Stockholders Agreement agreed to waive the obligations of GRDG to contribute any further inventions, discoveries or other items
of intellectual property developed by GRDG during the term of the Stockholders&#8217; Agreement subsequent to the date of Amendment No.
2, except for any invention, discovery or other items of intellectual property which is directly related to, or necessary for the sale,
licensing or further development of intellectual property owned by Global BioLife.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Stockholders
Agreement between Impact BioLife and the Impact BioLife Stockholders</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2020, Impact BioLife entered into a stockholders agreement with its stockholders Impact BioMedical and GRDG (the &#8220;Impact
BioLife Stockholders&#8217; Agreement&#8221;). Pursuant to the Impact BioLife Stockholders&#8217; Agreement, GRDG agreed to (i) transfer
certain intellectual property as identified in the Stockholders&#8217; Agreement to Impact BioLife, (ii) present all suitable technologies
developed by GRDG to Impact BioLife, so as to provide Impact BioLife with the opportunity to fund, own and develop any intellectual property
developed by GRDG and (iii) retain the advice and services of Mr. Daryl Thompson as a scientist during the term of the Impact BioLife
Stockholders&#8217; Agreement in connection with all projects as Impact BioLife may from time to time pursue. Further, pursuant to the
Impact BioLife Stockholders&#8217; Agreement, GRDG also agreed that Daryl Thompson will devote most of his professional time and efforts
each week to the business of Impact BioLife, including but not limited to, the development of new intellectual property for Impact BioLife.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, pursuant to the Impact BioLife Stockholder&#8217;s Agreement, the Company has agreed to contribute to Impact BioLife such reasonable
amounts as the board of directors of Impact BioLife shall in future annual periods authorize as Impact BioLife&#8217;s business plan
and budget (the &#8220;Impact BioLife Budget&#8221;). The Impact BioLife Budget shall include (i) a payment approximating $43,000 per
month to GRDG and (ii) such other amounts as shall be necessary to fund the research, development and other scientific operations that
the Impact BioLife board of directors shall agree to pursue. </span>For the years ended December 31, 2022 and 2021, the Company incurred
expenses of $546,000 and $509,176, respectively. On December 31, 2022 and 2021, the Company owed this related party $0, and had prepaid
monthly fees approximating $43,000. For the three months ended March 31, 2023, this funding approximates $43,000 per month, and incurred
approximately $129,000 in expenses. On March 31, 2023 and March 31, 2022, the Company owed this related party $0 and had prepaid monthly
fees approximating $43,000 and $43,000, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Impact BioLife Stockholders&#8217; Agreement, the board of directors of Impact BioLife shall never be less than one nor more than
five directors. GRDG shall be entitled to nominate one director to the Impact BioLife board of directors so long as it shall remain a
stockholder of Impact BioLife. The Company shall be entitled to nominate the remaining directors of Impact BioLife. In addition,
pursuant to the Impact BioLife Stockholders&#8217; Agreement, so long as it is a stockholder of Impact BioLife, the Company is entitled
to appoint Impact BioLife&#8217;s chief executive officer, who, at the discretion of the Company, may also serve as a director of the
Impact BioLife board of directors. The parties to the Impact BioLife Stockholders&#8217; Agreement have agreed that the initial directors
of the Impact BioLife board of directors shall be Heng Fai Ambrose Chan, Frank D. Heuszel and Daryl Thompson. The Company shall appoint
the chairman of the Impact BioLife board of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Impact BioLife Stockholders&#8217; Agreement will terminate (a) upon the dissolution and winding up of Impact BioLife, (b) on the date
the parties terminate the agreement by unanimous written, (c) on the fifth anniversary of the date of the Impact BioLife Stockholders&#8217;
Agreement, unless the parties mutually agree to an extension, or (d) upon three months&#8217; written notice by either party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 50; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_011" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 15, 2021, the Company entered into a Stock Purchase Agreement (the &#8220;Vivacitas Agreement #1&#8221;) with Vivacitas Oncology
Inc. (&#8220;Vivacitas&#8221;), to purchase 500,000 shares of its common stock at the per share price of $1.00, with an option to purchase
1,500,000 additional shares at the per share price of $1.00. This option will terminate upon one of the following events: (i) Vivacitas&#8217;
board of directors cancels this option because it is no longer in the best interest of the Company; (ii) December 31, 2021; or (iii)
the date on which Vivacitas receives more than $1.00 per share of the Company&#8217;s common stock in a private placement with gross
proceeds of $500,000. Under the terms of the Vivacitas Agreement #1, the Company will be allocated two seats on the board of Vivacitas.
On March 18, 2021, the Company entered into an agreement with Alset EHome International, Inc. (&#8220;Seller&#8221;) to purchase from
the Seller&#8217;s its wholly owned subsidiary Impact Oncology PTE Ltd. (&#8220;IOPL&#8221;) for a purchase price $2,480,000. The acquisition
of IOPL has been treated as an asset acquisition as IOPL does not meet the definition of a business as defined in Topic 805. IOPL owns
2,480,000 shares of common stock of Vivacitas along with the option to purchase an additional 250,000 shares of common stock. The Sellers
largest shareholder is Mr. Chan Heng Fai Ambrose, the Chairman of the Company&#8217;s board of directors and its largest shareholder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 1, 2021, the Company entered into an additional stock purchase agreement with Vivacitas (&#8220;Vivacitas Agreement #2&#8221;),
whereas Vivacities wished to employ the service of the Chief Business Officer of Impact Biomedical, and in return for the services of
this individual, Vivacitas shall issue to the Company, the aggregate purchase price for the Class A Common Shares of Vivacitas at the
value of $1.00 per share shall be $120,000 to be paid in twelve (12) equal monthly installments for the period between April 1, 2021
and March 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 22, 2021, the Company exercised 1,000,000 of the available options under the Vivacitas Agreement #1 for $1,000,000. This, along
with the shares received as part Vivacitas Agreement #2 increased the Company&#8217;s equity position in Vivacitas to approximately 16%
as of December 31, 2022. As of December 31, 2021, the fair value of the Company&#8217;s investment in Vivacitas is not readily available,
and therefore is recorded at cost in the amount of $4,035,000. For the fiscal year December 31, 2022, the company was unable to obtain
viable documentation in regards to Vivacitas&#8217;s ability to continue as a business and therefore as of December 31, 2022, the Company
determined to impair 100% of its investment in Vivacitas, in the amount of $4,100,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 31, 2020, and later amended on December 31, 2021, March 31, 2022, September 30, 2022, and December 31, 2022, the Company executed
a Revolving Promissory Note (&#8220;Note&#8221;) with DSS which accrues interest at a rate of 4.25% and is due in full at the maturity
date of December 31, 2023. The revolving nature of this Note permits for principal amounts borrowed to be repaid and reborrowed. DSS
has not established a maximum borrowing amount and intends to continue to fund the operations of the Company through a year from the
date these financial statements were available to be issued. As of December 31, 2022 and 2021, this Note had an outstanding balance of
$9,991,000 and $12,524,000, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">GRDG Licensing Proceeds Distribution Agreement</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 15, 2022, the Company entered into
a Licensing Proceeds Distribution Agreement (the &#8220;Licensing Agreement&#8221;) with GRDG Sciences, LLC (&#8220;GRDG&#8221;), Global
BioLife, Inc., and Impact BioLife Sciences, Inc., pursuant to which GRDG will receive 20% of the gross licensing or sale proceeds received
by the Company from the licensing of improvements with patent and patent applications (the &#8220;Improvements&#8221;), and all research
and technology, developed, made, owned, conceived, by GRDG in exchange for funding from the Company for research and technology development
activities. The term of the Licensing Agreement is from February 15, 2022, through the later of (1) the date of the last to expire of
a valid patent of intellectual property, or (2) the date of the last license or fee income generated from the Improvements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">ProPhase License Agreement</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 17, 2022, the Company entered into a
License Agreement (the &#8220;License Agreement&#8221;) with ProPhase Labs, Inc. (&#8220;ProPhase&#8221;) and Global BioLife, Inc., pursuant
to which ProPhase obtained a license to intellectual property rights of Global BioLife, Inc. in exchange for a royalty fee of five- and one-half percent (5.5%) of net sales. Pursuant to the License Agreement, Global BioLife, Inc. shall reimburse ProPhase for fifty percent
(50%) of the development costs up to one million two hundred fifty dollars ($1,250,000). The term (the &#8220;Term&#8221;) of the License
Agreement is the later of (a) the expiration date of the last to expire a valid claim comprising the licensed patents, or (b) twelve
(12) years from the date of first commercial sale. ProPhase may terminate this Agreement for any or no reason upon thirty (30) days prior
written notice to Global BioLife, Inc. In addition, at any time prior to expiration of the Term, either party may terminate the License
Agreement for cause by providing written notice.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 18, 2022, the Company entered into a License
Agreement (&#8220;July License Agreement&#8221;) by and between ProPhase, and Global BioLife, Inc., pursuant to which Global BioLife,
Inc. licensed compounds to ProPhase for research purposes for a one-time upfront license fee of fifty thousand dollars ($50,000). The
July License Agreement contains milestones that may result in payment to Global BioLife, Inc. of (a) nine hundred thousand dollars ($900,000)
upon successful completion of a first Phase 3 study, which may be required by the FDA, and (b) one million dollars ($1,000,000) for regulatory
approval of an NDA for the first licensed product. In addition, ProPhase will pay to Global BioLife, Inc. 3% royalties on net revenue
of each licensed product from the date of first commercial sale and for the term of the agreement. The term of the July License Agreement
is automatically upon the last to occur of the expiration of the last-to-expire licensed patent. ProPhase has the right to terminate
the July License Agreement for any reason or for convenience in its sole discretion. Global BioLife, Inc. has the right to terminate
the July License Agreement only for uncured material breaches by ProPhase.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">DSS PureAir, Inc. Assignment Agreement </span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 1, 2022, Impact Biolife Science, Inc. assigned and transferred
its entire interest of 100 shares of common stock of DSS PureAir, Inc.&#160;to DSS BioHealth Holdings, Inc. for consideration of $100.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>


<!-- Field: Page; Sequence: 51; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_011" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ax_006"></span>DESCRIPTION
OF OUR CAPITAL STOCK</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>General</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Amended and Restated Articles of Incorporation authorizes us to issue up to 4,000,000,000 shares of Common Stock, $0.001 par
value per share, and 100,000,000 shares of preferred stock, par value $0.001 per share. As of December 31, 2022, there were
125,073,621 shares of our Common Stock and no shares of preferred stock issued and outstanding. On May 11, 2023, the Company
effected a forward split. As a result, there were 3,877,282,251 shares of our Common Stock and no shares of preferred stock issued
and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Voting
Rights</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the rights of holders of any then-outstanding preferred stock, each holder of our Common Stock is entitled to one vote for each share
on all matters submitted to a vote of the stockholders, including the election of directors. Under our Amended and Restated Articles
of Incorporation, our stockholders will not have cumulative voting rights. Because of this, the holders of a majority of the shares of
Common Stock entitled to vote in any election of directors can elect all of the directors standing for election.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Dividend
Rights</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the rights of holders of any then-outstanding preferred stock, the holders of our Common Stock are entitled to receive ratably those
dividends, if any, as may be declared from time to time by the board of directors out of legally available funds. We do not anticipate
paying any cash dividends in the foreseeable future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Liquidation
Rights</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of our liquidation, dissolution or winding up, holders of common stock will be entitled to share ratably in the net assets
legally available for distribution to stockholders after the payment of all of our debts and other liabilities and the satisfaction of
any liquidation preference granted to the holders of any then-outstanding shares of preferred stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Preemptive
or Similar Rights</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of Common Stock have no preemptive, conversion or subscription rights and there is no redemption or sinking fund provisions applicable
to the common stock. The rights, preferences and privileges of the holders of common stock are subject to, and may be adversely affected
by, the rights of the holders of shares of any series of preferred stock that we may designate in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
shares of preferred stock are currently outstanding. We have no present plans to issue any shares of preferred stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Limitations
of Liability and Indemnification Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Amended and Restated Articles of Incorporation contains provisions that limit the liability of our current and former directors for monetary
damages to the fullest extent permitted by Nevada law. Nevada law provides that directors of a corporation will not be personally liable
for monetary damages for any breach of fiduciary duties as directors, except liability for intentional misconduct, fraud or a knowing
violation of law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Transfer
Agent and Registrar</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transfer agent and registrar for our Common Stock is American Stock Transfer &amp; Trust Company, LLC. The transfer agent&#8217;s
address is 6201 15th Avenue, Brooklyn, New York 11219 and the telephone number is (800) 468-9716.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>No
Listing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Common Stock is not listed on any securities exchange.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 52; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_011" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="ax_007"></span><b>LEGAL
MATTERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
validity of our Common Stock to be distributed in the Distribution will be passed upon for the Company by Sichenzia Ross Ference LLP,
New York, New York.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="ax_008"></span><b>EXPERTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The consolidated financial statements of Impact BioMedical
Inc. and subsidiaries as of and for the year ended December 31, 2021, included in this prospectus and elsewhere in the registration
statement have been so included in reliance upon the report of <i>Turner, Stone &amp; Company. LLP.,</i> independent registered public
accountants upon the authority of said firm as experts in accounting and auditing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements of Impact BioMedical Inc. and subsidiaries as of and for the year ended December 31, 2022, have
been included in reliance on the report of by <i>Grassi &amp; Co. CPAs, P.C.</i>, an independent registered public accounting
firm, as stated in its report incorporated by reference herein, and have been so incorporated in reliance upon such report and upon the
authority of such firm as experts in accounting and auditing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="ax_009"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>WHERE
YOU CAN FIND MORE INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have filed with the SEC a registration statement on Form S-1 under the Securities Act to register the shares of our Common Stock to be
distributed in the Distribution. The term registration statement means the original registration statement and any and all amendments
thereto, including the exhibits and schedules to the original registration statement and any amendments. This Prospectus, which constitutes
a part of the registration statement, does not contain all of the information set forth in the registration statement or the exhibits
and schedules filed therewith. For further information with respect to us, reference is made to the registration statement and the exhibits
and schedules filed therewith. Statements contained in this Prospectus regarding the contents of any contract or any other document that
is filed as an exhibit to the registration statement are not necessarily complete, and each such statement is qualified in all respects
by reference to the full text of such contract or other document filed as an exhibit to the registration statement. A copy of the registration
statement, along with the exhibits and schedules filed therewith, may be inspected without charge at the SEC&#8217;s Internet website.
The SEC maintains an Internet website at <i>www.sec.gov</i> that contains reports, proxy and information statements and other information
regarding registrants that file electronically with the SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
information contained on or accessible through our website or the SEC&#8217;s website shall not be deemed to be a part of this Prospectus
or the Registration Statement on Form S-1, of which this Prospectus is a part.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not authorized anyone to give any information or make any representation about the Distribution or of the Company that is different
from, or in addition to, that contained in this Prospectus. Therefore, if anyone does give you information of this sort, you should not
rely on it. If you are in a jurisdiction where offers to sell, or solicitations of offers to purchase, the securities offered by this
Prospectus or the solicitation of proxies is unlawful, or if you are a person to whom it is unlawful to direct these types of activities,
then the offer presented in this Prospectus does not extend to you. The information contained in this Prospectus speaks only as of the
date of this Prospectus unless the information specifically indicates that another date applies</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_011" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="toc_002"></span>FINANCIAL
STATEMENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Impact
BioMedical Inc and Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
31, 2022 </span>and December 31, 2021</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Table
of Contents</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 48px; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PAGE</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#ap_001">Reports of Independent Registered Public Accounting Firm</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
    Financial Statements</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ap_002">Consolidated Balance Sheets</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">F-4</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ap_003">Consolidated Statements of Operations</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ap_004">Consolidated Statements of Stockholder&#8217;s Equity</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">F-6</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ap_005">Consolidated Statements of Cash Flows</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ap_006">Notes to Consolidated Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-8</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 54; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt"><a href="#toc_002" style="font-style: italic">Table of Contents</a></p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Report
of Independent Registered Public Accounting Firm</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Board of Directors and Stockholders of</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impact
BioMedical, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Opinion
on the Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheets of Impact BioMedical, Inc. and subsidiaries (collectively, the &#8220;Company&#8221;)
as of December 31, 2021, and the related consolidated statements of operations, stockholders&#8217; equity and cash flows for the period
ended December 31, 2021, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion,
the financial statements present fairly, in all material respects, the financial position for the Company as of December 31, 2021, and
the results of its operations and its cash flows for the period ended December 31, 2021, in conformity with accounting principles generally
accepted in the United States of America.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
for Opinion</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s
financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audit in accordance with the standards of the PCAOB and in accordance with auditing standards generally accepted in the
United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the
financial statements are free of material misstatements, whether due to error or fraud. The Company is not required to have, nor were
we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an
understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the
Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or
fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides
a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Turner, Stone &amp; Company, LLP</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&#8217;s auditor since 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dallas,
Texas</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
24, 2022</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt"><a href="#toc_002" style="font-style: italic">Table of Contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="ap_001"></span>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Board of Directors of</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impact Biomedical, Inc.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion
on the Financial Statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheet of Impact Biomedical, Inc., and its subsidiaries (the &#8220;Company&#8221;)
as of December 31, 2022, and the related consolidated statement of operations, stockholders&#8217; equity, and cash flows for the year
ended December 31, 2022, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion,
the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022, and
the results of its operations and its cash flows for the year then ended, in conformity with accounting principles generally accepted
in the United States of America.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basis
for Opinion</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s
financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities
laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits,
we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion
on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits
provide a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Emphasis
of Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
discussed in Note 3 to the consolidated financial statements, the December 31, 2022 consolidated financial statements have been restated
to correct certain errors. Our opinion is not modified with respect to this matter.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><img src="aud_001.jpg" alt=""/></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GRASSI
    &amp; CO., CPAs, P.C.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have served as the Company&#8217;s auditor since 2021.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jericho,
    New York</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
                                            15, 2023, except for Note 3, as to which the date is June 2, 2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 56; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt"><a href="#toc_002" style="font-style: italic">Table of Contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Impact
BioMedical Inc and Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ap_002"></span>Consolidated
Balance Sheets</b></span></p>

<p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As
of December 31,</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_306_111_zJTy8R7s7Z88" summary="xdx: Statement - Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20221231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zXhsfoOWfQkb" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(restated)</b></p>
</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20211231_zOof8bSQZ5Vg" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AssetsAbstract_iB" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif">ASSETS</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AssetsCurrentAbstract_i01B" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Current assets:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_pp0p0_maACzj7l_zIfOIpQCA0vc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 60%; text-align: left">Cash and cash equivalents</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">46,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NotesAndLoansReceivableNetCurrent_i02I_pp0p0_maACzj7l_zFwGC0eRP8uk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Current portion of notes receivable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:NotesAndLoansReceivableNetCurrent" contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">16,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:NotesAndLoansReceivableNetCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">197,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_pp0p0_maACzj7l_zjUOjk08uW94" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Prepaid expenses and other current assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">104,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">44,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AssetsCurrent_i02TI_pp0p0_mtACzj7l_maAzYwP_zwdiLUm1YTT9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Total current assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">122,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">287,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_i01I_pp0p0_maAzYwP_z4WAFHRynMUk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Property, plant and equipment, net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">276,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0053">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OtherLongTermInvestments_i01I_pp0p0_maAzYwP_zEWDkj21xPhc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Other investments</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherLongTermInvestments" contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">782,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherLongTermInvestments" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,817,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NotesAndLoansReceivableNetNoncurrent_i01I_pp0p0_maAzYwP_zaMGOKMAts65" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Notes receivable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:NotesAndLoansReceivableNetNoncurrent" contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">190,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:NotesAndLoansReceivableNetNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,081,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--Goodwill_i01I_pp0p0_maAzYwP_zGhI93ca3hAk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Goodwill</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">25,093,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">25,093,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OtherIntangibleAssetsNet_i01I_pp0p0_maAzYwP_zJp1rAqHlTGl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Other intangible assets, net</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherIntangibleAssetsNet" contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">20,034,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherIntangibleAssetsNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">21,147,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--Assets_i01TI_pp0p0_mtAzYwP_z54xkXNp6QRf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">46,497,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">56,425,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">LIABILITIES AND STOCKHOLDER&#8217;S EQUITY</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LiabilitiesCurrentAbstract_i01B" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Current liabilities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccountsPayableCurrent_i02I_pp0p0_maLCz5nq_zgEFjpYUkoq7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Accounts payable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">539,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">115,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AccruedLiabilitiesCurrent_i02I_pp0p0_maLCz5nq_znAFXjFmiWP8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Accrued expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">63,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NotesPayableCurrent_i02I_pp0p0_maLCz5nq_zP22XijrVLKb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Note payable, related party</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,991,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">12,524,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesCurrent_i02TI_pp0p0_mtLCz5nq_maLzVkc_zWrciwfRgS28" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Total current liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,593,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">12,645,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredIncomeTaxLiabilitiesNet_i01I_pp0p0_maLzVkc_zUt7THis0ho4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Deferred tax liability, net</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,235,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,856,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--Liabilities_i01TI_pp0p0_mtLzVkc_maLASEzjYT_z7nUcyuIuEE3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Total liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">13,828,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">16,501,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CommitmentsAndContingencies_i01I_pp0p0_maLASEzjYT_z4nEt5q5knCj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Commitments and contingencies (Note 12)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0094">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0095">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_i01B" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Stockholder&#8217;s equity</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CommonStockValue_i02I_pp0p0_maSEzXp7_z0FsGQnUtzMj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Common stock, $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20221231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zgXm28NkUNlg" title="Common stock, par value"><span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20211231_zs84m0VfX3rb" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31" decimals="INF" unitRef="USDPShares">.001</ix:nonFraction></ix:nonFraction></span></span> par value; <span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_c20221231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zSLdi8GoZRNk" title="Common stock, shares authorized"><span id="xdx_90C_eus-gaap--CommonStockSharesAuthorized_iI_c20211231_z9SGEfJ6Vx94" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,000,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized, <span id="xdx_90B_eus-gaap--CommonStockSharesIssued_iI_c20221231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_znzd3rTA91n" title="Common stock, shares issued"><span id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_iI_c20221231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zuJPg4iO4OI3" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,877,282,251</ix:nonFraction></ix:nonFraction></span></span> shares issued and
    outstanding (<span id="xdx_905_eus-gaap--CommonStockSharesIssued_iI_c20211231_zjuuStpvwNC6" title="Common stock, shares issued"><span id="xdx_903_eus-gaap--CommonStockSharesOutstanding_iI_c20211231_zUGOK2nXmdfa" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,877,282,251</ix:nonFraction></ix:nonFraction></span></span> on December 31, 2021)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">125,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">125,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AdditionalPaidInCapital_i02I_pp0p0_maSEzXp7_zZ4r1YZYtDvc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Additional paid-in capital</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">38,058,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">38,058,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_pp0p0_maSEzXp7_zDcUTyDAR655" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Accumulated deficit</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">8,625,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,574,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--StockholdersEquity_i02TI_pp0p0_mtSEzXp7_maSEIPAzDRw_zzUmcUSlHkE1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Total stockholder&#8217;s equity of the company</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">29,558,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">36,609,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--MinorityInterest_i02I_pp0p0_maSEIPAzDRw_zYychM3zrica" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Non-controlling interest in subsidiary</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:MinorityInterest" contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,111,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:MinorityInterest" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,315,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_i02TI_pp0p0_mtSEIPAzDRw_maLASEzjYT_zJu9Zt4cKoH1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Total stockholder&#8217;s equity</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">32,669,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">39,924,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_pp0p0_mtLASEzjYT_zioa0BF0Wi26" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total liabilities and stockholder&#8217;s equity</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">46,497,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">56,425,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to the consolidated financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 57; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt"><a href="#toc_002" style="font-style: italic">Table of Contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Impact
BioMedical Inc and Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ap_003"></span>Consolidated
Statements of Operations</b></span></p>

<!-- Field: Rule-Page --><div style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30C_113_zpiye97V1Oxa" summary="xdx: Statement - Consolidated Statements of Operations" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20220101__20221231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zeq5siXHtmM6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(restated)</b></p>
</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20210101__20211231_zUV1kqsPQ1Sf" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CostsAndExpensesAbstract_iB" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Costs and expenses:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--SellingGeneralAndAdministrativeExpense_i01_pp0p0_maCAEzFOo_zig8AE6k0XGj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 60%; text-align: left">Selling, general and administrative compensation</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">325,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">398,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ResearchAndDevelopmentExpense_i01_pp0p0_maCAEzFOo_zCpbxJ2yku5j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Research &amp; Development</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,226,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,080,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ProfessionalFees_i01_pp0p0_maCAEzFOo_zI2OrUzZIpAe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Professional Services</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">722,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">552,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DepreciationAndAmortization_i01_pp0p0_maCAEzFOo_zo3ASiuyEPJ8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Amortization</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,113,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,113,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--OtherGeneralExpense_i01_pp0p0_maCAEzFOo_zYQ2GZSiOoHf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Other General Expense</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherGeneralExpense" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">68,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherGeneralExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">42,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CostsAndExpenses_i01T_pp0p0_mtCAEzFOo_msOILzcIH_zAEtAJASLJOj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Total costs and expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CostsAndExpenses" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,454,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CostsAndExpenses" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,185,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingIncomeLoss_iT_pp0p0_mtOILzcIH_maILFCOz9FG_zehSPD3WotZ6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Operating loss</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">3,454,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">3,185,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NonoperatingIncomeExpenseAbstract_iB" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Other income (expense):</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--InvestmentIncomeInterest_i01_pp0p0_maILFCOz9FG_zazao2emjU3c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Interest income</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">24,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">165,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OtherNonoperatingIncomeExpense_i01_pp0p0_maILFCOz9FG_ziqjrQ0w0YI7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Other income (expense)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">116,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">77,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--InterestExpense_i01N_pp0p0_di_msILFCOz9FG_znEAQsv3leuf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Interest expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">462,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">300,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--AssetImpairmentCharges_i01N_pp0p0_di_msILFCOz9FG_zwmyKLAXnLPf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1.5pt">Impairment of investment</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,100,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0174">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_pp0p0_mtILFCOz9FG_maPLzIAr_zb6EEEd7VOXf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Loss from continuing operations before income taxes</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">7,876,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">3,243,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncomeTaxExpenseBenefit_iN_di_msPLzIAr_zYZzbSs251Fk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Income tax (loss)/benefit</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">621,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,395,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ProfitLoss_iT_mtPLzIAr_maNILzLq1_zQ0LeGSWc41a" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,255,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,848,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_iN_pp0p0_di_msNILzLq1_zdPOJ0m77x04" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Loss from continuing operations attributed to noncontrolling interest</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">204,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">545,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLoss_iT_pp0p0_mtNILzLq1_zEvTlaqXV0ng" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net loss attributable to common stockholders</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">7,051,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,303,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--EarningsPerShareBasicAbstract_iB" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Loss per common share:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--EarningsPerShareBasic_i01_pdd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 2.5pt">Basic</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.00</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.00</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--EarningsPerShareDiluted_i01_pdd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 2.5pt">Diluted</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0197">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0198">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--WeightedAverageNumberOfSharesOutstandingAbstract_iB" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Shares used in computing loss per common share:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i01_zroTH2DAFW09" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 10pt">Basic</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,877,282,251</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,877,282,251</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_i01_z01GskNP1oJh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 10pt">Diluted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,877,282,251</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,877,282,251</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to the consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 58; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt"><a href="#toc_002" style="font-style: italic">Table of Contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Impact
BioMedical Inc and Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="ap_004"></span>Consolidated Statements of Stockholder&#8217;s
Equity</b></p>

<!-- Field: Rule-Page --><div style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_307_114_zeqFal829H5a" summary="xdx: Statement - Consolidated Statements of Stockholder's Equity" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_4B9_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zuLy03g18SMk" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_4B1_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_ztBDrcywqFjg" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_4BC_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zbMgF4wWzz0f" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_4BC_us-gaap--StatementEquityComponentsAxis_us-gaap--NoncontrollingInterestMember_zamb2MPfAjP4" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_4BD_zRcJsOEWR5Db" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Common Stock</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">Additional Paid-in</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">Accumulated</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">Non- controlling Interest in</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Shares</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Amount</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Capital</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Deficit<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>(restated)</b></p>
</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Subsidiary</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>(restated)</b></p>
</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_436_c20220101__20221231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_zhHjFUZnakfa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 40%">Balance, December 31, 2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharesOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkrKLQvum10b" title="Balance, shares" style="font: bold 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,877,282,251</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,000</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,058,000</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 6%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,574,000</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,315,000</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,924,000</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ProfitLoss_hsrt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zYjyoGJhkfHl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0217">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0218">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,051,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">204,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,255,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_43D_c20220101__20221231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_zKWE63pb8gai" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance December 31, 2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharesOutstanding_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zexONS1RIDP2" title="Balance, shares" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,877,282,251</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,000</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,058,000</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,625,000</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,111,000</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,669,000</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_43A_c20220101__20221231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_z8ILPuJ179xh" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharesOutstanding_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zePjb9pcbCw4" title="Balance, shares" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,877,282,251</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,000</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,058,000</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,625,000</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,111,000</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,669,000</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_436_c20210101__20211231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_zD3qRjjvliVc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Balance, December 31, 2020</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharesOutstanding_iS_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwHOIuArvkM" title="Balance, shares" style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,877,282,251</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,000</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,058,000</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">271,000</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2020-12-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,860,000</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,772,000</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_430_c20210101__20211231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_zkIiDPvpNfki" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Balance</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharesOutstanding_iS_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zOYNRJbMZBwf" title="Balance, shares" style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,877,282,251</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,000</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,058,000</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">271,000</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2020-12-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,860,000</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,772,000</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--StockIssuedDuringPeriodValueNewIssues_hsrt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zj6k29gPuoH4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Issuance of common stock, net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0255">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0256">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0257">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0258">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0259">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--StockIssuedDuringPeriodValueShareholder_hsrt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z38x6kuvuSoa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Proceeds from shareholder</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0261">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0262">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0263">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0264">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0265">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ProfitLoss_hsrt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zlFWbn95q3V9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0267">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0268">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,303,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-01-012021-12-31_us-gaap_NoncontrollingInterestMember_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">545,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-01-012021-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,848,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_439_c20210101__20211231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_zl1etSpg3GDf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance, December 31, 2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharesOutstanding_iE_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zv76DmEyGxV" title="Balance, shares" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,877,282,251</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,000</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,058,000</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,574,000</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,315,000</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,924,000</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_437_c20210101__20211231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_z01DgoR6Yqj2" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharesOutstanding_iE_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zxEVP2TEwOD4" title="Balance, shares" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,877,282,251</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,000</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,058,000</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,574,000</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,315,000</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,924,000</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to the consolidated financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 59; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt"><a href="#toc_002" style="font-style: italic">Table of Contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Impact
BioMedical Inc and Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="ap_005"></span>Consolidated Statements of Cash Flows</b></p>

<!-- Field: Rule-Page --><div style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_300_112_zjfQxlcqkawj" summary="xdx: Statement - Consolidated Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20220101__20221231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zLdyLtYnspK2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(restated)</b></p>
</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20210101__20211231_zx0XIPnIRUf8" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zROInWRuzVxd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Cash flows from operating activities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ProfitLoss_i01_pp0p0_maNCPBUzHtK_zAnNGFIN9ue3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Net loss</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">7,255,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,848,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_z1Unbq4Lp3ja" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Adjustments to reconcile net loss to net cash used by operating activities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DepreciationAndAmortization_i02_maNCPBUzHtK_z7siyV6impi9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Depreciation and amortization</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,113,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,113,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredIncomeTaxesAndTaxCredits_i02_pp0p0_maNCPBUzHtK_z3aeTPHbpeYd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Deferred tax benefit</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxesAndTaxCredits" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">621,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxesAndTaxCredits" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,395,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_405_ecustom--ImpairmentOfOtherInvestments_i02_pp0p0_maNCPBUzHtK_zO8hYUto5qJb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Impairment of other investments</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="IMPB:ImpairmentOfOtherInvestments" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,100,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0305">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncreaseDecreaseInOperatingAssetsAbstract_i02B_zQhC4TQAwAqc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Decrease (increase) in assets:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i03N_pp0p0_di_msNCPBUzHtK_zHQ6zaFX9ON" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Prepaid expenses and other current assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">60,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--IncreaseDecreaseInDeferredLiabilities_i03_maNCPBUzHtK_zJMwWggiNVj3" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Deferred Tax benefit</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--IncreaseDecreaseInImpairmentofOtherInvestments_i03N_di_msNCPBUzHtK_zTHNH2Kj4EVh" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Impairment of other investment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncreaseDecreaseInOperatingLiabilitiesAbstract_i02B_z80pvFUoI398" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Increase (decrease) in liabilities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncreaseDecreaseInAccountsPayable_i03_pp0p0_maNCPBUzHtK_zLQWLswetdbc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Accounts payable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">424,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">106,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncreaseDecreaseInAccruedLiabilities_i03_pp0p0_maNCPBUzHtK_zI2Qks12DY33" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Accrued expenses</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">57,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_pp0p0_mtNCPBUzHtK_maCCERCzgH9_zayW1DuNv3Bh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net cash used by operating activities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">2,242,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">2,027,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zn7siNwPyjaa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Cash flows from investing activities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PaymentsForProceedsFromProductiveAssets_i01N_pp0p0_di_msNCPBUzUyt_zZfUUNk2hI24" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Purchase of property, plant and equipment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsForProceedsFromProductiveAssets" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">276,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0335">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PaymentsToAcquireInvestments_i01N_pp0p0_di_msNCPBUzUyt_znC3ZPGmcUH9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Purchase of investment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireInvestments" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">65,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireInvestments" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,185,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_40E_ecustom--PaymentsForProceedsFromNoteReceivableInvestments_i01N_pp0p0_di_msNCPBUzUyt_zwtYDMXYwCx4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Note receivable investment</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="IMPB:PaymentsForProceedsFromNoteReceivableInvestments" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="IMPB:PaymentsForProceedsFromNoteReceivableInvestments" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,278,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_pp0p0_mtNCPBUzUyt_maCCERCzgH9_zTFGGq4fYlrd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net cash used by investing activities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">349,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">9,463,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_ziodtjWOai8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Cash flows from financing activities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ProceedsFromRelatedPartyDebt_i01_pp0p0_maNCPBUz0ZM_zU8xzntuUz1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Borrowings from parent</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,547,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,464,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_pp0p0_mtNCPBUz0ZM_maCCERCzgH9_ztWNET2c0amb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net cash provided by financing activities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,547,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,464,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_pp0p0_mtCCERCzgH9_zfUTtbDH8KE8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Net decrease in cash</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">44,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">27,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_pp0p0_zOxzo8nJqeW" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Cash and cash equivalents at beginning of year</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2021-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">46,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">72,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_pp0p0_z9ODi45hZJRb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Cash and cash equivalents at end of year</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">46,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to the consolidated financial statements</span></p>
<!-- Field: Split-Segment; Name: 001 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 60; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt"><a href="#toc_002" style="font-style: italic">Table of Contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IMPACT
Biomedical, Inc. and Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ap_006"></span>Notes to Consolidated Financial Statements</b></span></p>

<!-- Field: Rule-Page --><div style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p id="xdx_047_c20220101__20221231_z901KYhz1qul" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="us-gaap:NatureOfOperations"><p id="xdx_803_eus-gaap--NatureOfOperations_zxG7oDgoxgcc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
1. <span id="xdx_82C_zFqIBiDUxJ64">Nature of Operations and Basis of Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Nature
of Operations</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impact
BioMedical, Inc. (the &#8220;Company&#8221;, &#8220;Impact BioMedical&#8221;, &#8220;We&#8221;) through the utilization of its intellectual
property rights, or through investment in, or through acquisition of companies in the biohealth and biomedical fields, focuses on the
advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune related diseases. The
Company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis
and influenza.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Global
BioLife, Inc. (&#8220;Global BioLife&#8221;), one of the Company&#8217;s subsidiaries and the main operating company of the group, focuses
on research in four main areas: (i) the &#8220;Linebacker&#8221; project, which aims to develop a universal therapeutic drug platform;
(ii) a new sugar substitute called &#8220;Laetose,&#8221;; (iii) a multi-use fragrance called &#8220;3F&#8221; (Functional Fragrance
Formulation); and (iv) Equivir/Nemovir, a blend of natural polyphenols designed as an antimicrobial medication.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Linebacker</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unlike
the traditional approach to treat individual diseases with specific drugs, the Linebacker platform seeks to offer a breakthrough therapeutic
option for multiple diseases. Linebacker is designed to work by inhibiting a cascade of inflammatory responses responsible for many diseases.
Its design is in direct contrast to the traditional approach of targeting individual diseases with specific drugs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Laetose</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have also developed a low-calorie, low glycemic level, natural modified sugar through Global BioLife. The product, &#8220;Laetose,&#8221;
is designed to possess low glycemic properties and mitigate inflammation. The Company is presently seeking to license Laetose. Global
BioLife established a joint venture, Sweet Sense, Inc. (&#8220;Sweet Sense&#8221;), with Quality Ingredients, LLC for the development,
manufacture, and global distribution of the new sugar substitute. On November 8, 2019, the Company purchased <span id="xdx_90F_eus-gaap--MinorityInterestOwnershipPercentageByNoncontrollingOwners_iI_pid_dp_uPure_c20191108__srt--OwnershipAxis__custom--SweetSenseMember_z12C9V8yl8Pb" title="Minority interest ownership percentage"><ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" contextRef="AsOf2019-11-08_custom_SweetSenseMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></span>% of Sweet Sense Inc.
from Quality Ingredients, LLC for $<span id="xdx_90E_eus-gaap--BusinessCombinationConsiderationTransferred1_c20191107__20191108__srt--OwnershipAxis__custom--SweetSenseMember_zPzCUcqTajMb" title="Consideration given for purchase"><ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="From2019-11-072019-11-08_custom_SweetSenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">91,000</ix:nonFraction></span>. Sweet Sense is now an <span id="xdx_900_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20191108__srt--OwnershipAxis__custom--SweetSenseMember_zW35Gxw4yjJf" title="Ownership percentage"><ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByParent" contextRef="AsOf2019-11-08_custom_SweetSenseMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">81.8</ix:nonFraction></span>% owned subsidiary of Impact BioMedical.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Functional
Fragrance Formulation (&#8220;3F&#8221;)</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Global
BioLife has established a collaboration with U.S.-based Chemia Corporation (&#8220;Chemia&#8221;) to develop specialized fragrances to
counter mosquito-borne diseases such as Zika and Dengue, among other medical applications. The 3F mosquito fragrance product is made
from specialized oils sourced from botanicals that mosquitos avoid. Global BioLife is seeking to commercialize this product. Together
with Chemia, we are attempting to license 3F. Any potential profits from the 3F project will be split between Global BioLife and Chemia
pursuant to the terms of the 20- year Royalty Agreement (Note 12).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Equivir</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equivir,
is a polyphenol compound that is believed to be successful in antiviral infection treatments. Equivir is a patented medication, that
has broad antiviral efficacy against multiple types of infectious disease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company was incorporated in the State of Nevada as a for-profit company on October 16, 2018 and established a fiscal year end of December
31st. The Company issued <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20181016__20181016__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--GlobalBioMedicalPteLtdMember_zUob4L8G3Atg" title="Stock issued during period shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2018-10-162018-10-16_custom_GlobalBioMedicalPteLtdMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,000</ix:nonFraction></span> shares to its sole shareholder Global BioMedical Pte. Ltd., which was wholly owned by Alset International
Limited (formally Singapore eDevelopment Limited), a multinational public company, listed on the Singapore Exchange Securities Trading
Limited (&#8220;SGXST&#8221;). On March 31, 2020, the Company issued <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200330__20200331__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--GlobalBioMedicalPteLtdMember_zfH9lDxhTqYb" title="Stock issued during period shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2020-03-302020-03-31_custom_GlobalBioMedicalPteLtdMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">125,064,621</ix:nonFraction></span> shares of common stock to its sole shareholder Global
BioMedical Pte. Ltd. On July 24, 2020, the Board approved the Stock Split, pursuant to which each share of the Company&#8217;s common
stock issued and outstanding was split into nine shares of the Company&#8217;s common stock. The numbers of authorized common stock and
issued and outstanding common stock in the reporting periods were retrospectively adjusted for the stock split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this report, we have not generated significant revenues from operations. We cannot guarantee we will be successful in
our business operations. Our business is subject to risks inherent in the establishment of a new business enterprise, including possible
delays in our research, testing and marketing efforts or wider economic downturns.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Basis
of Presentation and Principles of Consolidation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the
United States of America (&#8220;U.S. GAAP&#8221;). The consolidated financial statements include all accounts of the Company and its
majority owned and controlled subsidiaries. The Company consolidates entities in which it owns more than <span id="xdx_90C_eus-gaap--MinorityInterestOwnershipPercentageByNoncontrollingOwners_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--SweetSenseMember_zjFOCeMosyi2" title="Minority interest ownership percentage"><ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" contextRef="AsOf2022-12-31_custom_SweetSenseMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></span>% of the voting common stock
and controls operations. All intercompany transactions and balances among consolidated subsidiaries have been eliminated. Non&#8211;controlling
interest represents the minority equity investment in the Company&#8217;s subsidiaries, plus the minority investors&#8217; share of the
net operating results and other components of equity relating to the non&#8211;controlling interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 61; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt"><a href="#toc_002" style="font-style: italic">Table of Contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IMPACT
Biomedical, Inc. and Subsidiaries</b></span></p>

<p style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="srt:ScheduleOfCondensedFinancialStatementsTableTextBlock"><p id="xdx_89B_esrt--ScheduleOfCondensedFinancialStatementsTableTextBlock_zI2mYLbcMG71" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements include all accounts of the entities as of the reporting period ending dates and for the reporting
periods as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_zrTi228E0Hve" style="display: none">Schedule
of Condensed Financial Statements</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Name of consolidated subsidiary</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">State or other jurisdiction of incorporation or organization</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Date of incorporation or formation</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Attributable interest as of <br/> December 31, <br/> 2022</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Attributable <br/> interest as of <br/> December 31, <br/> 2021</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: left">Global BioMedical, Inc.</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 18%"><span id="xdx_90F_ecustom--StateOrOtherJurisdictionOfIncorporationOrOrganization_c20220101__20221231__srt--OwnershipAxis__custom--GlobalBioMedicalIncMember_zj6YxyNf8Jba" title="State or other jurisdiction of incorporation or organization"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_GlobalBioMedicalIncMember" name="IMPB:StateOrOtherJurisdictionOfIncorporationOrOrganization">Nevada</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 18%"><span id="xdx_901_edei--EntityIncorporationDateOfIncorporation_dd_c20220101__20221231__srt--OwnershipAxis__custom--GlobalBioMedicalIncMember_z1oSxHwxLdE" title="Date of incorporation or formation"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_GlobalBioMedicalIncMember" format="ixt:datemonthdayyearen" name="dei:EntityIncorporationDateOfIncorporation">April 18, 2017</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_90F_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--GlobalBioMedicalIncMember_zNLFbG07qcq6" title="Attributable interest percentage"><ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByParent" contextRef="AsOf2022-12-31_custom_GlobalBioMedicalIncMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">90.9</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_906_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20211231__srt--OwnershipAxis__custom--GlobalBioMedicalIncMember_zvuByqKsBpL9" title="Attributable interest percentage"><ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByParent" contextRef="AsOf2021-12-31_custom_GlobalBioMedicalIncMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">90.9</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Global BioLife, Inc.</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_902_ecustom--StateOrOtherJurisdictionOfIncorporationOrOrganization_c20220101__20221231__srt--OwnershipAxis__custom--GlobalBioLifeIncMember_zw2zPHa5DFQ2" title="State or other jurisdiction of incorporation or organization"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_GlobalBioLifeIncMember" name="IMPB:StateOrOtherJurisdictionOfIncorporationOrOrganization">Nevada</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90A_edei--EntityIncorporationDateOfIncorporation_dd_c20220101__20221231__srt--OwnershipAxis__custom--GlobalBioLifeIncMember_zONGg88g42x9" title="Date of incorporation or formation"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_GlobalBioLifeIncMember" format="ixt:datemonthdayyearen" name="dei:EntityIncorporationDateOfIncorporation">April 14, 2017</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--GlobalBioLifeIncMember_zjFy7BH16Qhj" title="Attributable interest percentage"><ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByParent" contextRef="AsOf2022-12-31_custom_GlobalBioLifeIncMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">81.8</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20211231__srt--OwnershipAxis__custom--GlobalBioLifeIncMember_zXOvifpjTBt" title="Attributable interest percentage"><ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByParent" contextRef="AsOf2021-12-31_custom_GlobalBioLifeIncMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">63.6</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">BioLife Sugar, Inc</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90E_ecustom--StateOrOtherJurisdictionOfIncorporationOrOrganization_c20220101__20221231__srt--OwnershipAxis__custom--BioLifeSugarIncMember_z2DKWvZTkrFi" title="State or other jurisdiction of incorporation or organization"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_BioLifeSugarIncMember" name="IMPB:StateOrOtherJurisdictionOfIncorporationOrOrganization">Nevada</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90A_edei--EntityIncorporationDateOfIncorporation_dd_c20220101__20221231__srt--OwnershipAxis__custom--BioLifeSugarIncMember_zteqNjNmbVMk" title="Date of incorporation or formation"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_BioLifeSugarIncMember" format="ixt:datemonthdayyearen" name="dei:EntityIncorporationDateOfIncorporation">April 23, 2018</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90C_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--BioLifeSugarIncMember_zoAYF3xbSg83" title="Attributable interest percentage"><ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByParent" contextRef="AsOf2022-12-31_custom_BioLifeSugarIncMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">90.9</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20211231__srt--OwnershipAxis__custom--BioLifeSugarIncMember_ztM7xQ8lX8oc" title="Attributable interest percentage"><ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByParent" contextRef="AsOf2021-12-31_custom_BioLifeSugarIncMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">63.6</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Happy Sugar Inc</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_903_ecustom--StateOrOtherJurisdictionOfIncorporationOrOrganization_c20220101__20221231__srt--OwnershipAxis__custom--HappySugarIncMember_zv9GlHKO2uD3" title="State or other jurisdiction of incorporation or organization"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_HappySugarIncMember" name="IMPB:StateOrOtherJurisdictionOfIncorporationOrOrganization">Nevada</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90B_edei--EntityIncorporationDateOfIncorporation_dd_c20220101__20221231__srt--OwnershipAxis__custom--HappySugarIncMember_zs9MtTdiw097" title="Date of incorporation or formation"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_HappySugarIncMember" format="ixt:datemonthdayyearen" name="dei:EntityIncorporationDateOfIncorporation">August 17, 2018</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--HappySugarIncMember_zxvnxg59cDPi" title="Attributable interest percentage"><ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByParent" contextRef="AsOf2022-12-31_custom_HappySugarIncMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">81.8</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20211231__srt--OwnershipAxis__custom--HappySugarIncMember_zUa6AMo7MUq9" title="Attributable interest percentage"><ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByParent" contextRef="AsOf2021-12-31_custom_HappySugarIncMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">63.6</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Sweet Sense Inc.</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_906_ecustom--StateOrOtherJurisdictionOfIncorporationOrOrganization_c20220101__20221231__srt--OwnershipAxis__custom--SweetSenseIncMember_zT31tTWcA7xf" title="State or other jurisdiction of incorporation or organization"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_SweetSenseIncMember" name="IMPB:StateOrOtherJurisdictionOfIncorporationOrOrganization">Nevada</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_909_edei--EntityIncorporationDateOfIncorporation_dd_c20220101__20221231__srt--OwnershipAxis__custom--SweetSenseIncMember_zi1ZFP0VWiC8" title="Date of incorporation or formation"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_SweetSenseIncMember" format="ixt:datemonthdayyearen" name="dei:EntityIncorporationDateOfIncorporation">April 30, 2018</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--SweetSenseIncMember_znUTdBy2RC6" title="Attributable interest percentage"><ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByParent" contextRef="AsOf2022-12-31_custom_SweetSenseIncMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">95.5</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20211231__srt--OwnershipAxis__custom--SweetSenseIncMember_zlvDJinYJA2f" title="Attributable interest percentage"><ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByParent" contextRef="AsOf2021-12-31_custom_SweetSenseIncMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">81.8</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Global Sugar Solutions Inc.</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90A_ecustom--StateOrOtherJurisdictionOfIncorporationOrOrganization_c20220101__20221231__srt--OwnershipAxis__custom--GlobalSugarSolutionsIncMember_zmGAIxue30i5" title="State or other jurisdiction of incorporation or organization"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_GlobalSugarSolutionsIncMember" name="IMPB:StateOrOtherJurisdictionOfIncorporationOrOrganization">Nevada</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_909_edei--EntityIncorporationDateOfIncorporation_dd_c20220101__20221231__srt--OwnershipAxis__custom--GlobalSugarSolutionsIncMember_zZrTE1q0Ixig" title="Date of incorporation or formation"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_GlobalSugarSolutionsIncMember" format="ixt:datemonthdayyearen" name="dei:EntityIncorporationDateOfIncorporation">November 7, 2019</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--GlobalSugarSolutionsIncMember_zOJhwTFWaw1h" title="Attributable interest percentage"><ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByParent" contextRef="AsOf2022-12-31_custom_GlobalSugarSolutionsIncMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90C_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20211231__srt--OwnershipAxis__custom--GlobalSugarSolutionsIncMember_zvMjPp9213e2" title="Attributable interest percentage"><ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByParent" contextRef="AsOf2021-12-31_custom_GlobalSugarSolutionsIncMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">80</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_zhlBCspnZd14" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, and 2021, the aggregate noncontrolling interest was equity of $<span id="xdx_906_eus-gaap--MinorityInterest_iI_c20221231_zlZ5qceBXwMl" title="Noncontrolling interest"><ix:nonFraction name="us-gaap:MinorityInterest" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,111,000</ix:nonFraction></span> and $<span id="xdx_90E_eus-gaap--MinorityInterest_iI_c20211231_zLxUqf3vjUJe" title="Noncontrolling interest"><ix:nonFraction name="us-gaap:MinorityInterest" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,315,000</ix:nonFraction></span>, respectively, which are
separately disclosed on the Consolidated Balance Sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_804_eus-gaap--SignificantAccountingPoliciesTextBlock_z3qtt0DarICl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2. <span id="xdx_82B_zXidA4utt5I4">Summary of Significant Accounting and Reporting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="us-gaap:UseOfEstimates"><p id="xdx_847_eus-gaap--UseOfEstimates_z5wz0mcNenma" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zaqEKogB9ez9">Use
of estimates</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the dates of the balance
sheets and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from these estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_zP3j63KgdsR4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zTsxI67TiqM">Earnings
(Loss) per Share</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
earnings (loss) per share is computed by dividing the net income (loss) attributable to the common stockholders by weighted average number
of shares of common stock outstanding during the period. Fully diluted earnings (loss) per share is computed like basic income (loss)
per share except that the denominator is increased to include the number of additional common shares that would have been outstanding
if the potential common shares had been issued and if the additional common shares were dilutive. There were no dilutive financial instruments
issued or outstanding for the years ended December 31, 2022 or 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_843_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zDq08xlPnko" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_zCbRunpHjsuj">Fair
Value of Financial Instruments</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants at the measurement date. The Fair Value Measurement Topic of the Financial Accounting Standards Board (&#8220;FASB&#8221;)
Accounting Standards Codification (&#8220;ASC&#8221;) establishes a three-tier fair value hierarchy which prioritizes the inputs used
in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets
or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted
prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active;
and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions,
such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts reported in the balance sheet of cash and cash equivalents, prepaids, accounts payable and accrued expenses approximate
fair value because of the immediate or short-term maturity of these financial instruments. The fair value of notes receivable approximates
their carrying value as the stated or discounted rates of the notes do reflect recent market conditions. The Company&#8217;s investments
are record at cost as the fair value of these investment in are not readily available. The fair value of notes payable approximates its
carrying value as the stated interest rate reflects recent market conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 62; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt"><a href="#toc_002" style="font-style: italic">Table of Contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IMPACT
Biomedical, Inc. and Subsidiaries</b></span></p>

<p style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_841_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zdsWDnFzokXe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_864_zXeLEdoOSZU7">Cash
and cash equivalents</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid investments with a maturity of three months or less at the date of acquisition to be cash equivalents.
There were <span id="xdx_90A_eus-gaap--Cash_iI_do_c20221231_zo4fwXEFQlQ3" title="Cash"><span id="xdx_90F_eus-gaap--Cash_iI_do_c20211231_zcamax26Ny18" title="Cash"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2022-12-31" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2021-12-31" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span> cash equivalents as of December 31, 2022, and 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="us-gaap:InvestmentPolicyTextBlock"><p id="xdx_84D_eus-gaap--InvestmentPolicyTextBlock_z58oA0m51di5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_zA1Hah58AIw">Investments</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investments
in equity securities with a readily determinable fair value, not accounted for under the equity method, are recorded at fair value with
unrealized gains and losses included in earnings. For equity securities without a readily determinable fair value, the investment is
recorded at cost, less any impairment, plus or minus adjustments related to observable transactions for the same or similar securities,
with unrealized gains and losses included in earnings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
equity method investments, the Company regularly reviews its investments to determine whether there is a decline in fair value below
book value. If there is a decline that is other-than-temporary, the investment is written down to fair value. See Note 7 for further
discussion on investments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy"><p id="xdx_841_eus-gaap--GoodwillAndIntangibleAssetsGoodwillPolicy_zMDnF0JgVyJh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_zxq5H1ahqL6a">Goodwill</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill
is the excess of cost of an acquired entity over the fair value of amounts assigned to assets acquired and liabilities assumed in a business
combination. Goodwill is subject to impairment testing at least annually and will be tested for impairment between annual tests, which
takes place during the fourth quarter, if an event occurs or circumstances change that would indicate the carrying amount may be impaired.
FASB ASC Topic 350 provides an entity with the option to first assess qualitative factors to determine whether the existence of events
or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying
amount. Some of the qualitative factors considered in applying this test include consideration of macroeconomic conditions, industry
and market conditions, cost factors affecting the business, and overall financial performance of the business. If, after completing the
assessment, it is determined that it is more likely than not that the fair value of a reporting unit is less than its carrying value,
the Company will proceed to a quantitative test. If qualitative factors are not deemed sufficient to conclude that the fair value of
the reporting unit more likely than not exceeds its carrying value, then a one-step approach is applied in making an evaluation. The
evaluation utilizes an income approach (discounted cash flow analysis). The computations require management to make significant estimates
and assumptions, including, among other things, selection of comparable publicly traded companies, the discount rate applied to future
earnings reflecting a weighted average cost of capital, and earnings growth assumptions. The Company believes the estimates and assumptions
used in our impairment assessments are reasonable and based on available market information, but variations in any of the assumptions
could result in materially different calculations of fair value and determinations of whether or not an impairment is indicated. A discounted
cash flow analysis requires management to make various assumptions about future sales, operating margins, capital expenditures, working
capital, and growth rates. Cash flow projections are derived from one year budgeted amounts plus an estimate of later period cash flows,
all of which are determined by management. Subsequent period cash flows are developed for each reporting unit using growth rates that
management believes are reasonably likely to occur. Impairment of goodwill is measured as the excess of the carrying amount of goodwill
over the fair values of recognized and unrecognized assets and liabilities of the reporting unit. <span id="xdx_90E_eus-gaap--GoodwillImpairmentLoss_dxL_c20220101__20221231_zdxHnSdr2Oqc" title="Impairment of goodwill::XDX::-"><span id="xdx_907_eus-gaap--GoodwillImpairmentLoss_dxL_c20210101__20211231_zfDF0blYLHAe" title="Impairment of goodwill::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0450"><span style="-sec-ix-hidden: xdx2ixbrl0452">No</span></span></span></span> impairment was recognized during
the years ended December 31, 2022 or 2021 (see Note 8).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="us-gaap:IntangibleAssetsFiniteLivedPolicy"><p id="xdx_841_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zDznBH10mbZd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_zxv2HJgVHvih">Intangible
Assets</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated fair values of acquired intangibles are generally determined based upon future economic benefits such as earnings and cash
flows. Acquired identifiable intangible assets are recorded at fair value and are amortized over their estimated useful lives.
Acquired intangible assets with an indefinite life are not amortized but are reviewed for impairment at least annually as of
December 31<sup>st</sup>, or more frequently whenever events or changes in circumstances indicate that the carrying amounts of those
assets are below their estimated fair values. Impairment is tested under ASC 350 which provides an entity with the option to
first assess qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is
more likely than not that the fair value of a reporting unit is less than its carrying amount.  If, after completing the
assessment, it is determined that it is more likely than not that the fair value of a reporting unit is less than its carrying
value, the Company will proceed to a quantitative test. For the years ended December 31, 2022 and 2021, the Company utilized a
qualitative, as events and circumstances do not indicate that it is more likely than not (that is, a likelihood of more than 50%)
that an indefinite-lived intangible asset is impaired. Key factors considered while performing qualitative testing include industry
and market considerations, macroeconomic conditions, continued patent development of the technologies, as well as marketplace&#8217;s interest in the technologies. <span id="xdx_905_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_do_c20210101__20211231_zUAxRNfrKXb3"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="From2021-01-012021-12-31" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">No </ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">impairment
was recognized during the years ended December 31, 2022 or 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><p id="xdx_845_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zowPvJgkr1v1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86A_zrUkcJMmMgP4">Recoverability of Long-Lived Assets</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
evaluate long-lived assets such as property, equipment and definite lived intangible assets, such as patents, for impairment whenever
events or circumstances indicate that the carrying value of the assets recognized in our financial statements may not be recoverable.
Factors that we consider include whether there has been a significant decrease in the market value of an asset, a significant change
in the way an asset is being utilized, or a significant change, delay or departure in our strategy for that asset, or a significant change
in the macroeconomic environment, such as the impact of the COVID-19 pandemic. Our assessment of the recoverability of long-lived assets
involves significant judgment and estimation. These assessments reflect our assumptions, which, we believe, are consistent with the assumptions
hypothetical marketplace participants use. Factors that we must estimate when performing recoverability and impairment tests include,
among others, forecasted revenue, margin costs and the economic life of the asset. If impairment is indicated, we determine if the total
estimated future cash flows on an undiscounted basis are less than the carrying amounts of the asset or assets. If so, an impairment
loss is measured and recognized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
impairment loss calculations require that we apply judgment in identifying asset groups, estimating future cash flows, determining asset
fair values, and estimating asset&#8217;s useful lives. The Company reviews identifiable amortizable intangible assets for impairment
whenever events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. Determination of recoverability
is based on the lowest level of identifiable estimated undiscounted cash flows resulting from use of the asset and its eventual disposition.
Measurement of any impairment loss is based on the excess of the carrying value of the asset over its fair value. Based on the uncertainty
of forecasts inherent with a new product, events such as the failure to generate forecasted revenue from new products could result in
a non-cash impairment in future periods. </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_84D_eus-gaap--ResearchAndDevelopmentExpensePolicy_zUmodztQVwYh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_862_z12WkzOcodcd">Research
and Development</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed as incurred. Total research and development costs were $<span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231_zXrSS0mVKZme" title="Research and development cost"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,226,000</ix:nonFraction></span> for the year ended December 31,
2022, and $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20211231_z2jj3EC2bXLh" title="Research and development cost"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,080,000</ix:nonFraction></span> for year ended 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 63; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt"><a href="#toc_002" style="font-style: italic">Table of Contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IMPACT
Biomedical, Inc. and Subsidiaries</b></span></p>

<p style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zUyTpbk6CX49" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zsvnCvULgxk3">Recent
Accounting Standards</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Financial Accounting Standards Board (FASB) issues various Accounting Standards Updates relating to the treatment and recording of certain
accounting transactions. There are several new accounting pronouncements issued by FASB which are not yet effective. Each of these pronouncements,
as applicable, has been or will be adopted by the Company. As of December 31, 2022, none of these pronouncements is expected to have
a material effect on the financial position, results of operations or cash flows of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="IMPB:ContinuingOperationsAndGoingConcernPolicyTextBlock"><p id="xdx_84F_ecustom--ContinuingOperationsAndGoingConcernPolicyTextBlock_zABPPJrNc1Q6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_861_zeJYlmlxbFEd">Continuing
Operations and Going Concern</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to incurred operating losses as well as negative cash flows from operating and investing activities over the past two years, the accompanying
consolidated financial statements have been prepared assuming that the Company will continue as a going concern. This basis of accounting
contemplates the recovery of our assets and the satisfaction of liabilities in the normal course of business. These consolidated financial
statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary
should we be unable to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
continue as a going concern, the Company has entered into an updated revolving promissory note which extended the maturity through December
31, 2022, and DSS intends to continue to fund the operations of the Company through a year from the date these financial statements were
available to be issued. The Company&#8217;s management intends to take actions necessary to continue as a going concern. Management&#8217;s
plans concerning these matters include, among other things, monetization of its intellectual properties, and tightly controlling operating
costs. Based on this, the Company has concluded that substantial doubt of its ability to continue as a going concern has been alleviated.</span></p>

</ix:nonNumeric><p id="xdx_859_zzprbOpHUVP1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock"><p id="xdx_800_eus-gaap--ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_zFhQQRCK94Lh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 3. <span id="xdx_821_zG7r9IK2XGIb">Restatement</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has determined that a restatement
of the December 31, 2022 consolidated financial statements is appropriate in order to correct certain errors in the reporting of interest
expense on the related party note. In previously issued consolidated financial statements, there was no interest expense recorded. Interest
expense has been corrected and restated from $<span id="xdx_902_eus-gaap--InterestExpense_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zmWGH6VcJAaa" title="Interest expense"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2022-01-012022-12-31_srt_MinimumMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> to $<span id="xdx_90D_eus-gaap--InterestExpense_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zjOFTwccJ734" title="Interest expense"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2022-01-012022-12-31_srt_MaximumMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">462,000</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="IMPB:PrepaidExpensesTextBlock"><p id="xdx_801_ecustom--PrepaidExpensesTextBlock_zdfXN0Hrprt3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
4. <span id="xdx_828_zOq53fRflC37">Prepaid Expenses</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
expenses for the year ended December 31, 2022, includes prepared inventory approximating $<span id="xdx_901_eus-gaap--OtherPrepaidExpenseCurrent_iI_c20221231__dei--LegalEntityAxis__custom--GRDGscienceLLCMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zp6baYG5efAg" title="Prepaid expenses includes prepaid inventory"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2022-12-31_custom_GRDGscienceLLCMember_us-gaap_RelatedPartyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60,000</ix:nonFraction></span> and research and development
fees paid to GRDG Sciences, LLC. (&#8220;GRDG&#8221;), a related party, approximating $<span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--GRDGscienceLLCMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zYt5tYHgV7gc" title="Research and development"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31_custom_GRDGscienceLLCMember_us-gaap_RelatedPartyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,000</ix:nonFraction></span>. Prepaid expenses at December 31, 2021 consists primarily of research and development costs to GRDG approximating
$<span id="xdx_902_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_c20211231__dei--LegalEntityAxis__custom--GRDGscienceLLCMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zL4Qa03M4wQ7" title="Prepaid expenses"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2021-12-31_custom_GRDGscienceLLCMember_us-gaap_RelatedPartyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"><p id="xdx_803_eus-gaap--LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_z25wQoIJP1Mg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
5. <span id="xdx_820_z4SLpLRbLPj">Notes Receivable</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 21, 2021, Impact BioMedical, Inc. entered into a promissory note (&#8220;Promissory Note 1&#8221;) with an individual. The Company
loaned the principal sum of $<span id="xdx_908_eus-gaap--NotesReceivableNet_iI_c20210221__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember_z0VOMzV7pb49" title="Note receivable principal"><ix:nonFraction name="us-gaap:NotesReceivableNet" contextRef="AsOf2021-02-21_custom_PromissoryNoteOneMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">206,000</ix:nonFraction></span>, with interest at a rate of <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210221__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember_zXLD8rT5Hz57" title="Debt stated percentage"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2021-02-21_custom_PromissoryNoteOneMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6.5</ix:nonFraction></span>%, and maturity date of <span id="xdx_905_eus-gaap--DebtInstrumentMaturityDate_dd_c20210220__20210221__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember_zw4TD56Of3ca" title="Debt maturity date"><ix:nonNumeric contextRef="From2021-02-202021-02-21_custom_PromissoryNoteOneMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">August 19, 2022</ix:nonNumeric></span>. Monthly payments are due
on the twenty-first day of each month and continuing each month thereafter until August 19, 2022, at which time all accrued interest
and the entire remaining principal shall be due and payable in full. In August 2022, this note was amended to extend the maturity date
to <span id="xdx_905_eus-gaap--DebtInstrumentMaturityDate_dd_c20220822__20220822__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember_zCnMpw3rHbd9" title="Maturity date"><ix:nonNumeric contextRef="From2022-08-222022-08-22_custom_PromissoryNoteOneMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">August 19, 2023</ix:nonNumeric></span>. This note is secured by certain real property situated in Collier County, Florida. The outstanding principal and
interest approximated $<span id="xdx_90E_eus-gaap--DebtInstrumentPeriodicPayment_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember_zYMGdLsmiYhe" title="Debt principal and interest"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPayment" contextRef="From2022-01-012022-12-31_custom_PromissoryNoteOneMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">206,000</ix:nonFraction></span> and $<span id="xdx_906_eus-gaap--DebtInstrumentPeriodicPayment_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember_z5jFmGYFD047" title="Debt principal and interest"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPayment" contextRef="From2021-01-012021-12-31_custom_PromissoryNoteOneMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">197,000</ix:nonFraction></span> as of December 31, 2022 and December 31, 2021, respectively. Of the $<span id="xdx_905_eus-gaap--NotesReceivableNet_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember_z63QUl8VaF3g" title="Note receivable principal"><ix:nonFraction name="us-gaap:NotesReceivableNet" contextRef="AsOf2022-12-31_custom_PromissoryNoteOneMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">206,000</ix:nonFraction></span> outstanding
at December 31, 2022, $<span id="xdx_90C_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember_zkwGmNf4ujg" title="Notes receivable current"><ix:nonFraction name="us-gaap:NotesAndLoansReceivableGrossCurrent" contextRef="AsOf2022-12-31_custom_PromissoryNoteOneMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,000</ix:nonFraction></span> is classified in current notes receivable on the accompanying consolidated balance sheets, and the remaining
$<span id="xdx_90E_eus-gaap--NotesAndLoansReceivableNetNoncurrent_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember_zZ7Rd1CYaiQ6" title="Notes receivable"><ix:nonFraction name="us-gaap:NotesAndLoansReceivableNetNoncurrent" contextRef="AsOf2022-12-31_custom_PromissoryNoteOneMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">190,000</ix:nonFraction></span> is classified as note receivable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 14, 2021, DSS PureAir, Inc. (&#8220;DSS PureAir&#8221;), a wholly owned subsidiary of the Company, entered into a convertible promissory
note (&#8220;Promissory Note 2&#8221;) with a limited liability company registered in the state of Texas (&#8220;Borrower&#8221;). The
Promissory Note 2 has an aggregate principal balance up to $<span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_c20210514__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteTwoMember_zsvvAMeGZufd" title="Debt face amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2021-05-14_custom_PromissoryNoteTwoMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000,000</ix:nonFraction></span>, to be funded at the request of the borrower. Promissory Note 2,
which incurs interest at a rate of <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210514__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteTwoMember_zVMduuVTOT7" title="Debt stated percentage"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2021-05-14_custom_PromissoryNoteTwoMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6.5</ix:nonFraction></span>% due quarterly, has a maturity date of <span id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_dd_c20210513__20210514__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteTwoMember_zRpy7hm2QIGa" title="Debt maturity date"><ix:nonNumeric contextRef="From2021-05-132021-05-14_custom_PromissoryNoteTwoMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">May 14, 2023</ix:nonNumeric></span>. Promissory Note 2 contains an options conversion
clause that allows the Company to convert all, or a portion of all, into newly issued member units of the borrower with the maximum principal
amount equal to <span id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210514__srt--RangeAxis__srt--MaximumMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteTwoMember_zEqPWrYfoSxi" title="Debt stated percentage"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2021-05-14_srt_MaximumMember_custom_PromissoryNoteTwoMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">18</ix:nonFraction></span>% of the total equity position at conversion. On June 1, 2022, <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220601__srt--RangeAxis__srt--MaximumMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteTwoMember_zWWu3a2l4Q9c" title="Debt stated percentage"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2022-06-01_srt_MaximumMember_custom_PromissoryNoteTwoMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>% of the Company&#8217;s interest in DSS PureAir
was assigned to DSS BioHealth Holdings, Inc., a related party, and wholly owned subsidiary of DSS BioHealth Security, Inc. Included in
this transaction was the outstanding principal and interest of Promissory Note 2 along with the related Note payable, related party.
The outstanding principal and interest on December 31, 2022, and December 31, 2021 is $<span id="xdx_90F_eus-gaap--NotesAndLoansReceivableNetNoncurrent_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteTwoMember_z8CtEbgc2Pi" title="Notes and loans receivable"><ix:nonFraction name="us-gaap:NotesAndLoansReceivableNetNoncurrent" contextRef="AsOf2022-12-31_custom_PromissoryNoteTwoMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_901_eus-gaap--NotesAndLoansReceivableNetNoncurrent_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteTwoMember_zsyOmEy1a6mf" title="Notes and loans receivable"><ix:nonFraction name="us-gaap:NotesAndLoansReceivableNetNoncurrent" contextRef="AsOf2021-12-31_custom_PromissoryNoteTwoMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,081,000</ix:nonFraction></span>, respectively.</span></p>
<!-- Field: Split-Segment; Name: 002 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="us-gaap:InvestmentTextBlock"><p id="xdx_807_eus-gaap--InvestmentTextBlock_z85LC97Ofige" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
6. <span id="xdx_82A_znZzfzwUnAOa">Investments</span></b>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 19, 2020, Impact BioMedical entered into a subscription agreement (the &#8220;Subscription Agreement&#8221;) with BioMed Technologies
Asia Pacific Holdings Limited (&#8220;BioMed&#8221;), a limited liability company incorporated in the British Virgin Islands, pursuant
to which the Company agreed to purchase <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_c20201218__20201219__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AsiaPacificHoldingsLimitedMember__us-gaap--TypeOfArrangementAxis__us-gaap--SubscriptionArrangementMember_zdU5AwSuZvV4" title="Ordinary shares to purchase"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" contextRef="From2020-12-182020-12-19_custom_AsiaPacificHoldingsLimitedMember_us-gaap_SubscriptionArrangementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">525</ix:nonFraction></span> ordinary shares or <span id="xdx_90A_ecustom--OrdinarySharesPercentage_dp_uPure_c20201218__20201219__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AsiaPacificHoldingsLimitedMember__us-gaap--TypeOfArrangementAxis__us-gaap--SubscriptionArrangementMember_zzLXG5NijGJ4" title="Ordinary shares percentage"><ix:nonFraction name="IMPB:OrdinarySharesPercentage" contextRef="From2020-12-182020-12-19_custom_AsiaPacificHoldingsLimitedMember_us-gaap_SubscriptionArrangementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.99</ix:nonFraction></span>% of BioMed at a purchase price of approximately $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValuePurchaseOfAssets_c20201218__20201219__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AsiaPacificHoldingsLimitedMember__us-gaap--TypeOfArrangementAxis__us-gaap--SubscriptionArrangementMember_zq6IuAmFILjj" title="Purchase price of shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" contextRef="From2020-12-182020-12-19_custom_AsiaPacificHoldingsLimitedMember_us-gaap_SubscriptionArrangementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">632,000</ix:nonFraction></span>. The Subscription
Agreement provides, among other things, the Company the right to appoint a new director to the board of BioMed. With respect to an issuance
of shares to a third party by BioMed, the Company will have the right of first refusal to purchase such shares, as well as customary
tag-along rights. In connection with the Subscription Agreement, the Company entered into an exclusive distribution agreement (the &#8220;Distribution
Agreement&#8221;) with BioMed, to directly market, advertise, promote, distribute, and sell certain BioMed products, which focus on manufacturing
natural probiotics, to resellers. This investment is valued at cost as it does not have a readily determined fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioMed
focuses on manufacturing natural probiotics, pursuant to which the Company will directly market, advertise, promote, distribute and sell
certain BioMed products to resellers. The products to be distributed by the Company include BioMed&#8217;s PGut Premium Probiotics<sup>&#174;</sup>,
PGut Allergy Probiotics<sup>&#174;</sup>, PGut SupremeSlim Probiotics<sup>&#174;</sup>, PGut Kids Probiotics<sup>&#174;</sup>, and PGut
Baby Probiotics<sup>&#174;</sup>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
January 1, 2021, the Company entered into a securities purchase agreement (&#8220;SPA&#8221;) with Nano9, LLC. (&#8220;Nano9&#8221;),
a Utah limited partnership. For the consideration of $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210101__20210101__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NanoNineLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zuAHjH07hmw" title="Number of shares issued, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-01-01_custom_NanoNineLLCMember_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,000</ix:nonFraction></span> the Company obtained <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20210101__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NanoNineLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zbhIqxSc7iai" title="Number of shares issued, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-01-012021-01-01_custom_NanoNineLLCMember_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000</ix:nonFraction></span> membership units, or approximately <span id="xdx_900_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20210101__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NanoNineLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z5EPAckCKBwa" title="Equitable ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2021-01-01_custom_NanoNineLLCMember_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>% equitable
ownership of Nano9. Nano9 is a scientifically driven company, specializing in the development and production of leading nano-sized health
&amp; wellness products utilizing their proprietary nano technology. As of December 31, 2022 and December 31, 2021, the fair value
of the Company&#8217;s investment in Nano9 is not readily available, and therefore is recorded at cost of $<span id="xdx_905_eus-gaap--InvestmentOwnedAtFairValue_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NanoNineLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z00oCQqXFQc2" title="Investment owned at fair value"><span id="xdx_90E_eus-gaap--InvestmentOwnedAtFairValue_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NanoNineLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zhtpvgEcyjya" title="Investment owned at fair value"><ix:nonFraction name="us-gaap:InvestmentOwnedAtFairValue" contextRef="AsOf2022-12-31_custom_NanoNineLLCMember_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:InvestmentOwnedAtFairValue" contextRef="AsOf2021-12-31_custom_NanoNineLLCMember_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,000</ix:nonFraction></ix:nonFraction></span></span>.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 64; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt"><a href="#toc_002" style="font-style: italic">Table of Contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IMPACT
Biomedical, Inc. and Subsidiaries</b></span></p>

<p style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 15, 2021, the Company, through one of its subsidiaries, entered into a Stock Purchase Agreement (the &#8220;Vivacitas Agreement
#1&#8221;) with Vivacitas Oncology Inc. (&#8220;Vivacitas&#8221;), to purchase <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210314__20210315__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VivacitasOncologyIncMember_zoYFtGNMYMy9" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-03-142021-03-15_custom_StockPurchaseAgreementMember_custom_VivacitasOncologyIncMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500,000</ix:nonFraction></span> shares of its common stock at the per share price
of $<span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20210315__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VivacitasOncologyIncMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zimS4EPEhqR3" title="Common stock par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-03-15_custom_VivacitasOncologyIncMember_custom_StockPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span>, with an option to purchase <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20210314__20210315__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VivacitasOncologyIncMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_z9fAxVc6Rhy9" title="Options to purchase additional shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" contextRef="From2021-03-142021-03-15_custom_StockPurchaseAgreementMember_custom_VivacitasOncologyIncMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,500,000</ix:nonFraction></span> additional shares at the per share price of $<span id="xdx_907_eus-gaap--SharePrice_iI_c20210315__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VivacitasOncologyIncMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zGGS0KsTwUqc" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2021-03-15_custom_VivacitasOncologyIncMember_custom_StockPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span>. <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20210314__20210315__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VivacitasOncologyIncMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_z74PP9EIELSb" title="Option termination, description"><ix:nonNumeric contextRef="From2021-03-142021-03-15_custom_StockPurchaseAgreementMember_custom_VivacitasOncologyIncMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">This option will terminate upon one
of the following events: (i) Vivacitas&#8217; board of directors cancels this option because it is no longer in the best interest of
the Company; (ii) December 31, 2022; or (iii) the date on which Vivacitas receives more than $1.00 per share of the Company&#8217;s common
stock in a private placement with gross proceeds of $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20210314__20210315__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VivacitasOncologyIncMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zIcLfiErOfZd" title="Proceeds from private placement"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2021-03-142021-03-15_custom_StockPurchaseAgreementMember_custom_VivacitasOncologyIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000</ix:nonFraction></span>. Under the terms of the Vivacitas Agreement #1, the Company will be allocated
two seats on the board of Vivacitas</ix:nonNumeric></span>. On March 18, 2021, the Company entered into an agreement with Alset EHome International, Inc. (&#8220;Seller&#8221;)
to purchase from the Seller&#8217;s its wholly owned subsidiary Impact Oncology PTE Ltd. (&#8220;IOPL&#8221;) for a purchase price $<span id="xdx_905_eus-gaap--BusinessCombinationConsiderationTransferred1_c20210317__20210318__us-gaap--BusinessAcquisitionAxis__custom--ImpactOncologyPTELtdMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zqJsRxIgFptd" title="Purchase price"><ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="From2021-03-172021-03-18_custom_ImpactOncologyPTELtdMember_custom_StockPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,480,000</ix:nonFraction></span>.
The acquisition of IOPL has been treated as an asset acquisition as IOPL does not meet the definition of a business as defined in Topic
805. IOPL owns <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20210317__20210318__us-gaap--BusinessAcquisitionAxis__custom--ImpactOncologyPTELtdMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_z8oRAn06Lj2h" title="Number of common stock owned"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2021-03-172021-03-18_custom_ImpactOncologyPTELtdMember_custom_StockPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,480,000</ix:nonFraction></span> shares of common stock of Vivacitas along with the option to purchase an additional <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20210317__20210318__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zS4qqj45lBVb" title="Options to purchase common stock"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" contextRef="From2021-03-172021-03-18_custom_StockPurchaseAgreementMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250,000</ix:nonFraction></span> shares of common
stock. The Sellers largest shareholder is Mr. Chan Heng Fai Ambrose, the Chairman of the Company&#8217;s board of directors and its largest
shareholder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 1, 2021, the Company entered into an additional stock purchase agreement with Vivacitas (&#8220;Vivacitas Agreement #2&#8221;),
whereas Vivacities wished to employ the service of the Chief Business Officer of Impact Biomedical, and in return for the services of
this individual, Vivacitas shall issue to the Company, the aggregate purchase price for the Class A Common Shares of Vivacitas at the
value of $<span id="xdx_901_eus-gaap--SharePrice_iI_c20210401__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VivacitasOncologyIncMember_zrAimDrTV1Rk" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2021-04-01_custom_StockPurchaseAgreementMember_custom_VivacitasOncologyIncMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span> per share shall be $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20210401__20220331__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VivacitasOncologyIncMember_zSn8PkdKwse5" title="Proceeds from issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2021-04-012022-03-31_custom_StockPurchaseAgreementMember_custom_VivacitasOncologyIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120,000</ix:nonFraction></span> to be paid in twelve (12) equal monthly installments for the period between April 1, 2021
and March 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 22, 2021, the Company exercised <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210721__20210722__us-gaap--TypeOfArrangementAxis__custom--VivacitasAgreementMember_z3YlT07998yd" title="Stock option exercised, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2021-07-212021-07-22_custom_VivacitasAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span> of the available options under the Vivacitas Agreement #1 for $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_c20210721__20210722__us-gaap--TypeOfArrangementAxis__custom--VivacitasAgreementMember_zNAMq5OevIp2" title="Stock option exercised, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-07-212021-07-22_custom_VivacitasAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000,000</ix:nonFraction></span>. This, along
with the shares received as part Vivacitas Agreement #2 increased the Company&#8217;s equity position in Vivacitas to approximately 16%
as of December 31, 2022. As of December 31, 2021, the fair value of the Company&#8217;s investment in Vivacitas is not readily available,
and therefore is recorded at cost in the amount of $<span id="xdx_909_eus-gaap--InvestmentOwnedAtFairValue_iI_c20211231__us-gaap--TypeOfArrangementAxis__custom--VivacitasAgreementMember_zCDh09GDWFBc" title="Investment owned at fair value"><ix:nonFraction name="us-gaap:InvestmentOwnedAtFairValue" contextRef="AsOf2021-12-31_custom_VivacitasAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,035,000</ix:nonFraction></span>. For the fiscal year December 31, 2022, the company was unable to obtain
viable documentation in regards to Vivacitas&#8217;s ability to continue as a business and therefore as of December 31, 2022, the Company
determined to impair <span id="xdx_90C_eus-gaap--InvestmentOwnedPercentOfNetAssets_iI_pid_dp_c20221231__us-gaap--TypeOfArrangementAxis__custom--VivacitasAgreementMember_zKeNZ1wPUwq1" title="Investment cost, percent"><ix:nonFraction name="us-gaap:InvestmentOwnedPercentOfNetAssets" contextRef="AsOf2022-12-31_custom_VivacitasAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>% of its investment in Vivacitas, in the amount of $<span id="xdx_905_eus-gaap--InvestmentOwnedAtCost_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--VivacitasAgreementMember_zNncJJBhMJHc" title="Investment cost"><ix:nonFraction name="us-gaap:InvestmentOwnedAtCost" contextRef="AsOf2022-12-31_custom_VivacitasAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,100,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock"><p id="xdx_806_eus-gaap--PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock_z6I2wZvDeftg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
7. <span id="xdx_82F_zCX9GcFJoXfj">PROPERTY PLANT AND EQUIPMENT and INVESTMENT IN REAL ESTATE, NET</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><p id="xdx_897_eus-gaap--PropertyPlantAndEquipmentTextBlock_zeK0nWv9lJPb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property,
plant and equipment consisted of the following as of December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;<span id="xdx_8BF_z2t3OCgEixh5" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of Property Plant and Equipment&#160;</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_49A_20221231_zrXoMxm3v5O5" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_49E_20211231_zk829oJPVnK5" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Estimated</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Useful Life</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zmWwyyscexYl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 42%; text-align: left">Machinery and equipment</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MinimumMember_zcjv5qkHdFGl" title="Estimated Useful Life"><ix:nonNumeric contextRef="AsOf2022-12-31_us-gaap_MachineryAndEquipmentMember_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span>-<span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MaximumMember_z1s4xoixrAK1" title="Estimated Useful Life"><ix:nonNumeric contextRef="AsOf2022-12-31_us-gaap_MachineryAndEquipmentMember_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">10</ix:nonNumeric></span> years</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31_us-gaap_MachineryAndEquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0572">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_zQ6OaJkGOZVg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Construction in progress</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31_us-gaap_ConstructionInProgressMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">251,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0579">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzm9U_zBEEe2hg8FS6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Total Cost</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">276,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0582">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzm9U_zjxoGnO8mgk3" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Property, plant and equipment, gross</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">276,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0585">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iI_msPPAENzm9U_zvzGcF4BUl5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Less accumulated depreciation</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0587">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0588">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzm9U_zAXgLfCmKW82" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Property, plant and equipment, net</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">276,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0591">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_znc96iB43Mwi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
expense for the years ended December 31, 2022 and 2021 was $<span id="xdx_907_eus-gaap--Depreciation_dxL_c20220101__20221231_zpBMtDd7Vjq8" title="Depreciation expense::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0593">-</span></span> and $<span id="xdx_907_eus-gaap--Depreciation_dxL_c20210101__20211231_zrFWLUFxm5pa" title="Depreciation expense::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0595">-</span></span> respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="us-gaap:GoodwillDisclosureTextBlock"><p id="xdx_802_eus-gaap--GoodwillDisclosureTextBlock_zrV4G5cfoMVi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
8. <span id="xdx_825_zoOzzVnlFws3">Goodwill</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="us-gaap:ScheduleOfGoodwillTextBlock"><p id="xdx_89D_eus-gaap--ScheduleOfGoodwillTextBlock_zpmRTT97BXn8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Goodwill
balances and activity for the year ended December 31, 2022 and year ended December 31, 2021 consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B0_zxYACxWrYIO8" style="display: none">Schedule of Goodwill</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 80%">Balance at December 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--Goodwill_iS_c20220101__20221231_zxPgTUEzpXmk" title="Balance at December 31, 2022" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,093,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Goodwill adjustment</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--GoodwillImpairmentLoss_c20220101__20221231_zNm1t3Tac80c" title="Goodwill adjustment" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0603">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance at December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_989_eus-gaap--Goodwill_iE_c20220101__20221231_zUhDwIwxxPml" title="Balance at March 31, 2023" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,093,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_zEXCQ6xJ0cJ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During 2022 and 2021, management performed annual
goodwill impairment testing. No goodwill impairment was identified as a result of these tests. As of June 1, 2022 a quantitative
analysis was prepared utilizing the Market Approach and Income Approach valuing the Company. <span id="xdx_90A_ecustom--NoncashOrPartNoncashAcquisitionValueOfAssetAcquiredDescription_c20230101__20230331_z1z7YmGJRRth" title="Acquisition value of asset acquired, description"><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" name="IMPB:NoncashOrPartNoncashAcquisitionValueOfAssetAcquiredDescription">The guideline public company Market
Approach produced a mean business enterprise value indication using estimated 2025 results of $69.24 million. The Income Approach was
based upon the use of a discounted pro forma cash flow model and produced a business enterprise value indication of $56.54 million. A
weighting of 20% to the weighted value indicated was applied under the Market Approach, a weighting of 10% to the prior transaction value
and a weighting of 70% to the value indicated under the Income Approach. A lower weighting was applied to the Market Approach due to
the fact of using forecasted earnings of the Company. Based upon the above weightings, an initial value of $57.26 million for Impact
was calculated. Adding cash and cash equivalents of $<span id="xdx_901_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20220601_ziJRXcD9RlH1" title="Cash"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-06-01" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,000</ix:nonFraction></span> to the initial business enterprise value produced a concluded business enterprise
value of $57.29 million (rounded) for Impact.</ix:nonNumeric></span> Subtracting interest-bearing debt of $<span id="xdx_901_eus-gaap--LongTermDebtFairValue_iI_pn4n6_c20220601_zDoY0a4OFtfe" title="Long term debt fair value"><ix:nonFraction name="us-gaap:LongTermDebtFairValue" contextRef="AsOf2022-06-01" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">13.15</ix:nonFraction></span> million, results in a Fair Value for the common
equity of Impact of $<span id="xdx_908_eus-gaap--EquityFairValueAdjustment_pn4n6_c20220530__20220601_zYU3NrHfGN23" title="Equity fair value"><ix:nonFraction name="us-gaap:EquityFairValueAdjustment" contextRef="From2022-05-302022-06-01" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">44.14</ix:nonFraction></span> million. As of June 1, 2022, the indicated equity value exceeded the carrying amount by approximately $<span id="xdx_90E_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20220601_zj30yQs3bAs" title="Debt carrying amount"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2022-06-01" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.9</ix:nonFraction></span>
million or <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220601_zxVAADQ0Wyjb" title="Debt interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2022-06-01" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12.5</ix:nonFraction></span>%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During 2021, we used qualitative factors to determine
whether it was more likely than not (likelihood of more than 50%) that the fair value of a reporting unit exceeded its carrying amount.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="us-gaap:IntangibleAssetsDisclosureTextBlock"><p id="xdx_80F_eus-gaap--IntangibleAssetsDisclosureTextBlock_z2H0L9dY8BO2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
9. <span id="xdx_824_z1tn2rovw4W">Intangible Assets</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
definite-lived intangible assets, to be amortized over 20 years, balances and activity for the years ended December 31, 2022, and 2021
consisted of the following:</span></p>

<ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"><p id="xdx_894_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zHQdA7txJ6z4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B0_zqZtUD871FG4" style="display: none">Schedule
of Intangible Assets</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">12/31/2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">12/31/2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Gross Carrying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amount</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accumulated</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amortization</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net Carrying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amount</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Gross Carrying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amount</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accumulated</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amortization</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net Carrying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amount</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Definitive-lived:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left; padding-bottom: 1.5pt">Developed technology</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zgBIkWG91zXk" title="Gross Carrying Amount" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2022-12-31_us-gaap_DevelopedTechnologyRightsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,258,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zpuWVPx1EXc2" title="Accumulated Amortization" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2022-12-31_us-gaap_DevelopedTechnologyRightsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,226,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zRgOQZTT6Yd" title="Net Carrying Amount" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2022-12-31_us-gaap_DevelopedTechnologyRightsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,033,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zI7Y34SBRsqh" title="Gross Carrying Amount" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2021-12-31_us-gaap_DevelopedTechnologyRightsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,260,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_z5FrKHNRmm5a" title="Accumulated Amortization" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2021-12-31_us-gaap_DevelopedTechnologyRightsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,113,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zGbghpcnCqzc" title="Net Carrying Amount" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2021-12-31_us-gaap_DevelopedTechnologyRightsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,147,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Total</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20221231_zk1bqzZQHIJd" title="Gross Carrying Amount" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,258,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231_zhrxucA4Ylq2" title="Accumulated Amortization" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,226,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20221231_zwlty5MPwip8" title="Net Carrying Amount" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,033,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20211231_zY55HIRHhZ77" title="Gross Carrying Amount" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,260,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20211231_zdXvV8N6tel6" title="Accumulated Amortization" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,113,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20211231_zORzHT040mca" title="Net Carrying Amount" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,147,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_zJTTpTcsc7ml" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amounts
amortized for the year ended December 31, 2022 and 2021 was approximately $<span id="xdx_903_eus-gaap--DepreciationAndAmortization_c20220101__20221231_z07Xi7V36SDb" title="Amortization"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,113,000</ix:nonFraction></span> and $<span id="xdx_90D_eus-gaap--DepreciationAndAmortization_c20210101__20211231_zKiA3suvZwf2" title="Amortization"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,113,000</ix:nonFraction></span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"><p id="xdx_89F_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_ztrJEWSXpzQ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table represents future amortization of developed technologies:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B2_z5r4lxyudiOb" style="display: none">Schedule
of Future Amortization of Developed Technologies</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_497_20221231_z6eq82unuXc3" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_zFHMZ3jeS3b1" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">835,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_zjqgq8ica1v2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: right">2022</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,113,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_zYolTxwz4QS8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2023</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,113,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_zEbL6CCv6cT9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2024</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,113,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_zUhYP2MIBOXh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2025</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,113,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_zm9aNzIaiv73" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2026</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,113,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_zXVHPYqafEyl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">Thereafter</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,468,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_zbjcQpyG6dU2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 65; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt"><a href="#toc_002" style="font-style: italic">Table of Contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IMPACT
Biomedical, Inc. and Subsidiaries</b></span></p>

<p style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2021, the fair value of the assets acquired by DSS on August 21, 2020, was concluded. An impairment analysis was conducted for
financial reporting purposes in connection with U.S. GAAP and ASC 360-10, Impairment and Disposal of Long-Lived Assets. Although the
Company has a history of negative cash flows from operations, its financing arrangement with DSS (see Note 9) provides the opportunity
to fund ongoing operations. This, as well as there being no other indicators present for impairment, has led management to conclude that
no impairment is necessary for the years ended December 31, 2022, and 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_803_eus-gaap--DebtDisclosureTextBlock_zXSDRNLok2He" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
10. <span id="xdx_824_zbDeTJMfFkH4">Debt</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 31, 2020, and later amended on December 31, 2022, the Company executed a Revolving Promissory Note (&#8220;Note&#8221;) with
DSS, a related party, which accrues interest at a rate of <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20221231__us-gaap--DebtInstrumentAxis__custom--RevolvingPromissoryNoteMember_z6nKohDNKl16" title="Debt instrument interest, rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2022-12-31_custom_RevolvingPromissoryNoteMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.25</ix:nonFraction></span>% and is due in full at the maturity date of <span id="xdx_901_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--RevolvingPromissoryNoteMember_zrQGqf3Rhc9d" title="Debt instrument, maturity date"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_RevolvingPromissoryNoteMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">December 31, 2023</ix:nonNumeric></span>. The revolving
nature of this Note permits for principal amounts borrowed to be repaid and reborrowed. <span id="xdx_909_eus-gaap--DebtDefaultLongtermDebtDescriptionOfNoticeOfDefault_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--RevolvingPromissoryNoteMember_z7H9UcWthbZi" title="Long term debt, description"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_RevolvingPromissoryNoteMember" name="us-gaap:DebtDefaultLongtermDebtDescriptionOfNoticeOfDefault">In the case of default, at DSS&#8217;s option,
(i) eighteen percent (18%) per annum, or (ii) such lesser rate of interest as Lender in its sole discretion may choose to charge; but
never more than the Maximum Lawful Rate.</ix:nonNumeric></span> DSS has not established a maximum borrowing amount and intends to continue to fund the operations
of the Company through a year from the date these financial statements were available to be issued. As of December 31, 2022 and 2021,
this Note had an outstanding balance of $<span id="xdx_90D_eus-gaap--NotesPayable_iI_c20221231_zdm2M8yum3u" title="Outstanding balance"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,991,000</ix:nonFraction></span> and $<span id="xdx_907_eus-gaap--NotesPayable_iI_c20211231_zeMhgfyxMETj" title="Outstanding balance"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,524,000</ix:nonFraction></span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_80E_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z9NBT3j11CY" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
11. <span id="xdx_829_zSCBLTTc6NYa">Stockholders&#8217; Equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 23, 2021, the Company, the Company&#8217;s Board of Directors approved the total number of shares of Common Stock to be <span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_iI_c20210923__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zU9fmLrpw2Sf" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-09-23_srt_BoardOfDirectorsChairmanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,000,000,000</ix:nonFraction></span>
shares with a par value of $<span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20210923__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zqODeemrq8h5" title="Common stock par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-09-23_srt_BoardOfDirectorsChairmanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span>. Each share of Common Stock when issued, shall have one (1) vote on all matters presented to the stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Amended and Restated Articles of Incorporation authorizes us to issue up to <span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_c20210923_zppbOWSK5Na9" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-09-23" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,000,000,000</ix:nonFraction></span> shares of Common Stock, $<span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20210923_zZLPtRf8Lz8h" title="Common stock par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-09-23" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span> par value per
share, and <span id="xdx_908_eus-gaap--PreferredStockSharesAuthorized_iI_c20210923_zvr5fKKcPhVa" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2021-09-23" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000,000</ix:nonFraction></span> shares of preferred stock, par value $<span id="xdx_90D_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20210923_zvfDDGcIYoWk" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2021-09-23" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span> per share. On May 11, 2023, the Company effected a forward split.
As a result, there were <span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_c20230511__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zebBP2Ii6xj9" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-05-11_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,877,282,251</ix:nonFraction></span> shares of our Common Stock and <span id="xdx_90B_eus-gaap--PreferredStockSharesIssued_iI_do_c20230511__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zLSFnHmbxzpc" title="Preferred stock, shares issued"><span id="xdx_902_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20230511__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zhIadLxK5rX1" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-05-11_us-gaap_SubsequentEventMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-05-11_us-gaap_SubsequentEventMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></span></span> shares of preferred stock issued and outstanding. As of December
31, 2022 and 2021, there were <span id="xdx_901_eus-gaap--CommonStockSharesIssued_iI_c20221231_zDxLHWYU3G44" title="Common stock, shares issued"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">125,073,621</ix:nonFraction></span> shares of our Common Stock and outstanding which was converted to <span id="xdx_906_eus-gaap--CommonStockSharesOutstanding_iI_c20211231_zie7uVylp7lf" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,877,282,251</ix:nonFraction></span> shares. As
of December 31, 2022 and 2021, there were <span id="xdx_90A_eus-gaap--PreferredStockSharesIssued_iI_do_c20221231__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zjqSAF0L3Wu4" title="Preferred stock, shares issued"><span id="xdx_90C_eus-gaap--PreferredStockSharesIssued_iI_do_c20211231__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zlB3JKSKMMI8" title="Preferred stock, shares issued"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-12-31_us-gaap_SubsequentEventMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2021-12-31_us-gaap_SubsequentEventMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></span></span> preferred shares issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_80F_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zztEBZT4mjQg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
12. <span id="xdx_822_zvy9I2R7FfRg">Related Party Transactions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and Development Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on Shareholders Agreement entered into on April 26, 2017, the Company would fund the scientific operations of GRDG, a company involved
in research and development of biomedical products which is a minority stockholder of two of the Company&#8217;s subsidiaries and is
owned by Daryl Thompson, a director of many subsidiaries of the Company, to do the development and research works on the biomedical products
for the Company. As of December 31, 2022, this funding approximates $<span id="xdx_90A_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GRDGscienceLLCMember_zVjUWSovINQi" title="Payment in funding of research and development"><ix:nonFraction name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" contextRef="From2022-01-012022-12-31_custom_GRDGscienceLLCMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,000</ix:nonFraction></span> per month, and incurred approximately $<span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GRDGscienceLLCMember_zryqsaKOM4hf" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31_custom_GRDGscienceLLCMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">546,000</ix:nonFraction></span> in expenses. On
December 31, 2022 and December 31, 2021, the Company owed this related party $<span id="xdx_907_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20220101__20221231_z5iAXlXhFpw8" title="Related party owed transaction"><span id="xdx_908_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20210101__20211231_zt3FU3pWMl4c" title="Related party owed transaction"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></ix:nonFraction></span></span> and had prepaid monthly fees approximating $<span id="xdx_90C_eus-gaap--PrepaidExpenseCurrentAndNoncurrent_iI_c20221231_zqtTTZcDzusj" title="Prepaid monthly fees"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrentAndNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,000</ix:nonFraction></span> and
$<span id="xdx_90A_eus-gaap--PrepaidExpenseCurrentAndNoncurrent_iI_c20211231_zLvoos388iwl" title="Prepaid monthly fees"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrentAndNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,000</ix:nonFraction></span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
and Administrative Costs</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are certain general and administrative costs incurred by DSS, a related party on behalf of the Company which are passed through to the
Company on a monthly basis. These costs consist of primarily payroll costs for certain DSS employees and are allocated based on estimated
time spent on behalf of the Company. These costs approximate $<span id="xdx_905_eus-gaap--LaborAndRelatedExpense_c20220101__20221231_zTLH81H2p9u2" title="Related costs for employees"><ix:nonFraction name="us-gaap:LaborAndRelatedExpense" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,000</ix:nonFraction></span> per month. As of December 31, 2022, the Company incurred
$<span id="xdx_901_eus-gaap--GeneralAndAdministrativeExpense_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z1za1w1WTIj8" title="General and administrative expense"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-01-012022-12-31_us-gaap_RelatedPartyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">117,000</ix:nonFraction></span> in related expenses. As of December 31, 2021, the Company incurred approximately $<span id="xdx_906_eus-gaap--GeneralAndAdministrativeExpense_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zMLNxepSFCIl" title="General and administrative expense"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2021-01-012021-12-31_us-gaap_RelatedPartyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">155,000</ix:nonFraction></span> in related expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 66; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt"><a href="#toc_002" style="font-style: italic">Table of Contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IMPACT
Biomedical, Inc. and Subsidiaries</b></span></p>

<p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_808_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z5Xcxi9CgOB5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
13. <span id="xdx_82D_z9726DukHO4f">Commitments and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 15, 2018, the Company entered into Royalty Agreement with Chemia Corporation (&#8220;Chemia&#8221;) pursuant to which Chemia transferred
to the Company all of its right to 3F (Functional Fragrance Formulation). This agreement has a 20-year term and auto renews for a period
of 1 year unless mutually agreed upon by both parties. 3F consists of 3F Mosquito Repellant and 3F Anti-Viral formulations. Based on
the Royalty Agreement, the Company should cover all the costs to prepare and finalize necessary patent application and other intellectual
property related to 3F. Chemia agreed to support the Company in efforts leading to development of 3F intellectual property and it&#8217;s
licensing. Based on Royalty Agreement any payments received from development, sales, licensing or transfer of 3F technology will be paid
<span id="xdx_906_ecustom--RoyaltyPercentage_pid_dp_uPure_c20180814__20180815__us-gaap--TypeOfArrangementAxis__custom--RoyaltyAgreementMember_zes4xogi5U8j" title="Royalty percentage"><ix:nonFraction name="IMPB:RoyaltyPercentage" contextRef="From2018-08-142018-08-15_custom_RoyaltyAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></span>% to the Company and <span id="xdx_907_ecustom--RoyaltyPercentage_pid_dp_uPure_c20180814__20180815__us-gaap--TypeOfArrangementAxis__custom--RoyaltyAgreementMember__dei--LegalEntityAxis__custom--ChemiaCorporationMember_zoxr8l8BHGD4" title="Royalty percentage"><ix:nonFraction name="IMPB:RoyaltyPercentage" contextRef="From2018-08-142018-08-15_custom_RoyaltyAgreementMember_custom_ChemiaCorporationMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></span>% to Chemia. On November 27, 2018, Company and Chemia signed an Addendum to Royalty Agreement (&#8220;Addendum&#8221;),
according to which the Company granted Chemia a royalty-based limited license for purposes of making and selling fragrances embodying
the 3F technology. Based on the Addendum, Chemia should pay the Company <span id="xdx_90E_ecustom--SaleOfRoyaltyPercentage_pid_dp_uPure_c20181126__20181127__us-gaap--TypeOfArrangementAxis__custom--RoyaltyAgreementMember_zAcTF2elKA66" title="Net sales  royalty"><ix:nonFraction name="IMPB:SaleOfRoyaltyPercentage" contextRef="From2018-11-262018-11-27_custom_RoyaltyAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>% of net sales in royalty. On November 8, 2019, both companies
entered into Amendment no.1 to Royalty Agreement, based on which certain expenses bore by the Company towards patent application and
licensing should be reimbursed to the Company before any royalty payments are made. For the nine months ended December 31, 2022 and 2021,
there were no reimbursements or royalties paid to the Company and the Company cannot be assured that Chemia&#8217;s efforts will end
up in any future sales of the technology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 15, 2022, the Company and its subsidiaries, Global BioLife, Inc. (&#8220;Global&#8221;), and Impact BioLife Sciences, Inc. (&#8220;BioLife
Sciences&#8221;), and GRDG entered into a Licensing Proceeds Distribution Agreement (&#8220;GRDG Agreement&#8221;), whereas GRDG would
transfer its <span id="xdx_900_ecustom--SaleOfRoyaltyPercentage_pid_dp_uPure_c20220214__20220215__us-gaap--TypeOfArrangementAxis__custom--RoyaltyAgreementMember_z2dmeqsggJD2" title="Net sales  royalty"><ix:nonFraction name="IMPB:SaleOfRoyaltyPercentage" contextRef="From2022-02-142022-02-15_custom_RoyaltyAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">20</ix:nonFraction></span>% equity position in both Global and BioLife Sciences to the Company in exchange for 20% interest in Global and/or BioLife
Science revenue received from the exclusive or non-exclusive licensing of and/or the sale of Global Intellectual Property to a Third
Party, net of specific costs. As of the date of this report, no contingent liability has been recognized under the GRDG Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 19, 2022, Impact BioMedical entered into a License Agreement (&#8220;Equivir License&#8221;) with ProPhase Labs, Inc. (&#8220;ProPhase&#8221;)
where the ProPhase is granted the right, amongst other things, to develop, commercialize, and sell the Company&#8217;s Equivir technology.
In exchange, the Licensee shall pay the Company a royalty of <span id="xdx_90E_ecustom--SaleOfRoyaltyPercentage_pid_dp_uPure_c20220318__20220319__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zqoIlPkCQrs6" title="Net sales  royalty"><ix:nonFraction name="IMPB:SaleOfRoyaltyPercentage" contextRef="From2022-03-182022-03-19_custom_LicenseAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.5</ix:nonFraction></span>% of net sales. Under the terms of the Equivir Agreement, the Company
shall reimburse ProPhase for <span id="xdx_90D_ecustom--DevelopmentCostPercent_pid_dp_uPure_c20220318__20220319__us-gaap--TypeOfArrangementAxis__custom--RoyaltyAgreementMember_zqrzp8mvcYy2" title="Development cost, percent"><ix:nonFraction name="IMPB:DevelopmentCostPercent" contextRef="From2022-03-182022-03-19_custom_RoyaltyAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></span>% of the development costs provided that the development costs shall not exceed $<span id="xdx_908_eus-gaap--CostsIncurredDevelopmentCosts_c20220318__20220319__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zWbD77tzVuyg" title="Development costs"><ix:nonFraction name="us-gaap:CostsIncurredDevelopmentCosts" contextRef="From2022-03-182022-03-19_custom_LicenseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,250,000</ix:nonFraction></span>. As of December
31, 2022, no liability has been recorded in relation to the Equivir License as development of the Equivir technology has not begun and
no reasonable amount can be estimated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_807_eus-gaap--IncomeTaxDisclosureTextBlock_ztBNUKWeW0M7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
14. <span id="xdx_82C_zj0MygXbr8sj">Income Taxes</span></b>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the
financial reporting and tax basis of assets and liabilities. Deferred tax assets are reduced, if deemed necessary, by a valuation allowance
for the amount of tax benefits which are not expected to be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 67; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt"><a href="#toc_002" style="font-style: italic">Table of Contents</a></p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IMPACT
Biomedical, Inc. and Subsidiaries</b></span></p>

<p style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"><p id="xdx_890_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zeVbteJrx8E7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
components of income tax benefit for the years ended December 31, 2022, and 2021 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8BA_zVgJq1uKpHb7" style="display: none">Schedule of Components of Income Tax Benefit</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt">Federal</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_49D_20220101__20221231_zPPdkxgx7tbl" style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_494_20210101__20211231_zsPtO3r9p7Ce" style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif">Income Tax Expense (Benefit)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended <br/> December 31, 2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2021</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Current tax payable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CurrentFederalTaxExpenseBenefit_maCITEBzAu9_zu08Pc89efh1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt">Federal</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0747">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0748">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_maCITEBzAu9_zyQka61FNENh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; padding-bottom: 1.5pt">State</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0750">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0751">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--CurrentIncomeTaxExpenseBenefit_iT_mtCITEBzAu9_zwn135doikKf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Total current tax payable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0753">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0754">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Deferred tax</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_iN_di_maDITEBzd7s_zJhzyGuwsa15" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; width: 60%">Federal</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,619,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">456,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_iN_di_maDITEBzd7s_ztNBdi4bQlP4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; padding-bottom: 1.5pt">State</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">165,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,068,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredIncomeTaxExpenseBenefit_iNT_di_mtDITEBzd7s_maNDTEAzrUM_maITEBzC69_z0pScFqoLUA7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Total deferred tax</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,784,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,524,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_msNDTEAzrUM_msITEBzC69_z9vMFTeuyQkb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Less increase in valuation allowance</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,163,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">129,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzC69_zFxkACmaqe9h" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"> income tax benefit</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">621,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,395,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_z2YFqL6L0e2g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><p id="xdx_89C_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zFmIGnYwjsfk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Individual
components of deferred tax assets and liabilities are approximately as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BB_zpsriDR3yffg" style="display: none">Schedule of Deferred Tax Assets and Liabilities</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20221231_zgFXxnXr25p4" style="font: 10pt Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"/><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20211231_zfc5y7h5hsOf" style="font: 10pt Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif">Deferred Tax Assets &amp; Liabilities:</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Deferred Tax assets:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsInvestments_iI_maDTAGzKh6_zP0JbeoXEuxh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 60%">Impairment of investment</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInvestments" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">929,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0774">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_maDTAGzKh6_zCfppEN0bG37" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Research &amp; development cost</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0777">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzKh6_zdin9WgapdM3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Net Operating loss</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,611,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,258,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzKh6_z5xwgF3383b1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Gross deferred tax assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,790,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,258,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Deferred tax liability:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_msDITLzt6S_zqIynwAgaUsf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Intangible assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,414,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,667,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredIncomeTaxLiabilities_iNI_di_mtDITLzt6S_maDTLzghA_z2dRYnKjhO3l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Gross deferred tax liability</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,414,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,667,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsNet_iNI_di_msDTLzghA_zlUqxnG1rHM6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Less valuation allowance</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,611,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">447,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxLiabilities_iNTI_di_mtDTLzghA_zJEWI0M8rDVe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Net deferred tax liability</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilities" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,235,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilities" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,856,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_zLJkEhV9f6T5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><p id="xdx_89A_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zFj0WbmBh0U1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_zgvUJyg0FcFk" style="display: none">Summary of Effective Income Tax Rate</span></span></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20220101__20221231_zEzSJYNTofdd" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20210101__20211231_ztWgj4YVqOM4" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_z7KMU8LZR5oe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Statutory United States federal rate</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.0</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.0</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_zGPP7r08lLyl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">State income taxes net of federal benefit</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.7</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">26.0</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_zqPyqCsGPMKb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">14.8</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)%</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">4.0</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_zF8qM7kf9aZd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Effective rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.9</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">43</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_z5NWFScgoez6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, and 2021, the Company has net operating loss carry forwards of approximately $<span id="xdx_902_eus-gaap--OperatingLossCarryforwards_iI_c20221231_z6sRG8TZInN1" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,109,000</ix:nonFraction></span> and $<span id="xdx_90E_eus-gaap--OperatingLossCarryforwards_iI_c20211231_zDcnkvHmmQDb" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,551,000</ix:nonFraction></span> respectively.
The Company does not have other temporary differences associated with the amortization of intangible assets. As of December 31, 2022,
and 2021, the total deferred tax assets carry-forward were $<span id="xdx_904_eus-gaap--DeferredTaxAssetsGross_iI_c20221231_z7rdL5q1fGec" title="Deferred tax asset"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,790,000</ix:nonFraction></span> and $<span id="xdx_904_eus-gaap--DeferredTaxAssetsGross_iI_c20211231_z9OC4eKNilg8" title="Deferred tax asset"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,258,000</ix:nonFraction></span>, respectively. The deferred tax assets
could be carried forward indefinitely. The full utilization of the deferred tax assets in the future is dependent upon the Company&#8217;s
ability to generate taxable income. Considering the development stage of the Company, management believed that it was probable that the
Company would not use tax assets in the near future. Accordingly, a valuation allowance of an equal amount has been established. During
the years ended December 31, 2022 and December 31, 2021, the valuation allowance increased by $<span id="xdx_901_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20220101__20221231_zIe7xenSHJed" title="Valuation allowance deferred tax"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,163,000</ix:nonFraction></span> and decreased by $<span id="xdx_900_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20210101__20211231_zBZGwwXzSCM9" title="Valuation allowance deferred tax"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">129,000</ix:nonFraction></span>,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognizes interest accrued and penalties
related to unrecognized tax benefits in tax expense. During the years ended December 31, 2022 and 2021 the Company recognized no interest
and penalties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="us-gaap:CashFlowSupplementalDisclosuresTextBlock"><p id="xdx_80B_eus-gaap--CashFlowSupplementalDisclosuresTextBlock_z5XkKFkzbXA8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
15. <span id="xdx_827_zohXxhDiE5w4">Supplemental Cash Flow Information</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"><p id="xdx_89F_eus-gaap--ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_zvs4mQmfs7Ad" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes supplemental cash flows for the year ended December 31, 2022, and 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_zKkR64o8ofP9" style="display: none">Schedule
of Cash Flow Supplemental</span> </span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20221231_z0j9i297N2Ri" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20211231_ztiK3wFcXLIj" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ConvertibleNotesPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z1dieTBoYwnj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 60%">Transfer of promissory note 2 to related party</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 16%"><ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,081,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 16%"><span style="-sec-ix-hidden: xdx2ixbrl0828">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NotesPayable_iNI_di_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zmqZdDNDQEne" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Transfer of note payable, related party</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,081,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0831">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zbu28JYcdSOd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_809_eus-gaap--SubsequentEventsTextBlock_z5izBHh7vPAb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
16. <span id="xdx_82C_zSv7FR2YhL33">Subsequent Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has evaluated all subsequent events and transactions through June 2, 2023, the date that the consolidated financial statements
were available to be issued, and noted no subsequent events requiring financial statement recognition or disclosure.</span></p>

</ix:nonNumeric><p id="xdx_818_zzImG6paRIN5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 68; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt"><a href="#toc_002" style="font-style: italic">Table of Contents</a></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="toc_003"></span>Impact
BioMedical Inc and Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
31, 2023</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Table
of Contents</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PAGE</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
    Financial Statements</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ak_002">Consolidated
    Balance Sheets</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-17</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ak_003">Consolidated
    Statements of Operations</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-18</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ak_004">Consolidated
    Statements of Stockholder&#8217;s Equity</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-19</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ak_005">Consolidated
    Statements of Cash Flows</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-20</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ak_006">Notes
    to Consolidated Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-21</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 69 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_003" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Impact
BioMedical Inc and Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ak_002"></span>Consolidated
Balance Sheets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<table cellpadding="0" cellspacing="0" id="xdx_309_111_z62oYS1SMGI6" summary="xdx: Statement - Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20230331_ziSQrcwYDrSi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20221231_zd539kTYEnnk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AssetsAbstract_iB_zcNUoy8gPpAk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AssetsCurrentAbstract_i01B_zTuI10SVYoMg" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Current assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_zRx8RlxpZc4a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-left: 10pt">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NotesAndLoansReceivableNetCurrent_i02I_zxS6a2yaWIr1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Current portion of notes receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NotesAndLoansReceivableNetCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">205,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NotesAndLoansReceivableNetCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_zcVUrJ6VzCnh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Prepaid expenses and other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">183,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">104,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AssetsCurrent_i02TI_z9cd6WzS11Td" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Total current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">389,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">122,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentNet_i01I_zRjkMuAhHaz9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Property, plant and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">279,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">276,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OtherLongTermInvestments_i01I_zt5YOCKnQCre" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherLongTermInvestments" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">782,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherLongTermInvestments" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">782,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NotesAndLoansReceivableNetNoncurrent_i01I_zv9rICv2ekSh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Notes receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0859">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NotesAndLoansReceivableNetNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">190,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--Goodwill_i01I_zibiNN0xAUk9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Goodwill</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,093,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,093,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OtherIntangibleAssetsNet_i01I_zJS709E7Uno2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Other intangible assets, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherIntangibleAssetsNet" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,756,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherIntangibleAssetsNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,034,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--Assets_i01TI_z2YdRaisSxwa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,299,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,497,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_z1CS2C5m42be" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">LIABILITIES AND STOCKHOLDER&#8217;S EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LiabilitiesCurrentAbstract_i01B_zA2qPoYhwJtj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AccountsPayableCurrent_i02I_zMGRaKgnrRVe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">186,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">539,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AccruedLiabilitiesCurrent_i02I_zeVnH8mNQfn1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">63,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NotesPayableCurrent_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zyad0eDfCiq5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Note payable, related party</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2023-03-31_us-gaap_RelatedPartyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,008,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,529,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LiabilitiesCurrent_i02TI_zzgDsLfEMMn9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Total current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,244,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,131,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredIncomeTaxLiabilitiesNet_i01I_znVY8HGQ0XVg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Deferred tax liability, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,235,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,235,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--Liabilities_i01TI_zhwEPzGc3Ifc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,479,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,366,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--CommitmentsAndContingencies_i01I_zsi9EkGsRJT9" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Commitments and contingencies (Note 12)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0895">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0896">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_i01B_zG1VXGQOr518" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Stockholder&#8217;s equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CommonStockValue_i02I_z7JErCY9rFx2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Common stock, $<span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20230331_zhnzEBazmtWl" title="Common stock, par value"><span id="xdx_903_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20221231_zFceRrfBb0Lc" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-03-31" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31" decimals="INF" unitRef="USDPShares">.001</ix:nonFraction></ix:nonFraction></span></span>
    par value; <span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20230331_zdF0zuh0rYic" title="Common stock, shares authorized"><span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20221231_zgx1O1P9oJ5d" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,000,000,000</ix:nonFraction></ix:nonFraction></span></span>
    shares authorized, <span id="xdx_904_eus-gaap--CommonStockSharesIssued_iI_pid_c20230331_zquION8quo0e" title="Common stock, shares issued"><span id="xdx_909_eus-gaap--CommonStockSharesIssued_iI_pid_c20221231_zAfXz7eD2Ld8" title="Common stock, shares issued"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">125,073,621</ix:nonFraction></ix:nonFraction></span></span>
    shares issued and outstanding (<span><span id="xdx_902_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20230331_zenSBMNHOqcl" title="Common stock, shares outstanding"><span id="xdx_903_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20221231_zRdXvEjh3tfl" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">125,073,621</ix:nonFraction></ix:nonFraction></span></span></span>
    on March 31, 2023 and December 31, 2022)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AdditionalPaidInCapital_i02I_zXugtFDfH032" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,058,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,058,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_zr5SeIoMTQPf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,282,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,625,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--StockholdersEquity_i02TI_zyZdKvwWGOe8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Total stockholder&#8217;s equity of the company</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,901,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,558,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--MinorityInterest_i02I_zfiXpKEn3GQk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Non-controlling interest in subsidiary</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:MinorityInterest" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,919,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:MinorityInterest" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,111,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_i02TI_zwEV9uAzqnUh" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total stockholder&#8217;s equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,820,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,669,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_znJpUq0SRCNe" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total liabilities and stockholder&#8217;s equity</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,299,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,497,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to the consolidated financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 70 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_003" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Impact
BioMedical Inc and Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ak_003"></span>Consolidated
Statements of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30F_113_zR1vRwTbI5hf" summary="xdx: Statement - Consolidated Statements of Operations" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20230101__20230331_zlG8jQDJxq5e" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20220101__20220331_zCWDZCVprjFd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--CostsAndExpensesAbstract_iB_z4duEta3cuUi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; width: 64%">Costs and expenses:</td><td style="width: 2%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 14%">&#160;</td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 14%">&#160;</td><td style="text-align: left; width: 1%">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--SellingGeneralAndAdministrativeExpense_i01_zG8TyhFKNwxh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Selling, general and administrative compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">123,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ResearchAndDevelopmentExpense_i01_zsEsg4c7g0Hc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Research &amp; development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">179,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">168,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ProfessionalFees_i01_zGd91XQPqLyi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Professional services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">280,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">126,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DepreciationAndAmortization_i01_zUNtY80h9HN5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">280,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">278,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OtherGeneralExpense_i01_z2D8M9jHK1m3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Other general expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherGeneralExpense" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherGeneralExpense" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--CostsAndExpenses_i01T_z6d0dQD75Hsc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Total costs and expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CostsAndExpenses" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">819,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CostsAndExpenses" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">709,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingIncomeLoss_iT_z8id0VJ98oD6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">819,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">709,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zV4udWktEW81" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Other income (expense):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--InvestmentIncomeInterest_i01_zpkWTWBQUjS3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">96,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OtherNonoperatingIncomeExpense_i01_zi4EvsCKs6id" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Other income (expense)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">68,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0969">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--InterestExpense_i01N_di_z1tLhHG5fuSf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">101,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">133,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--AssetImpairmentCharges_i01N_di_zwejKKaJEbT2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt">Impairment of investment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0974">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0975">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_zzXoL1f0cRCc" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Loss from continuing operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">849,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">746,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--IncomeTaxExpenseBenefit_zvgutNELd5pd" style="vertical-align: bottom; background-color: White">
    <td>Income tax benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0980">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0981">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_iN_di_zePuiQmK1xuk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Loss from continuing operations attributed to noncontrolling interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">192,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">77,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLoss_iT_zmzC0MO8Wcnb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss attributable to common stockholders</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">657,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">669,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--EarningsPerShareBasicAbstract_iB_zYxjD9mR34n9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Loss per common share:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--EarningsPerShareBasic_i01_pid_z2PFYTURq4V4" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 10pt">Basic</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.00</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.01</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--EarningsPerShareDiluted_i01_pid_zdz4Z4vnhtHd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 10pt">Diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0995">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0996">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--WeightedAverageNumberOfSharesOutstandingAbstract_iB_zEuFVb50ZZhh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Shares used in computing loss per common share:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_zYKTvqxV7FT2" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-left: 10pt">Basic</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,877,282,251</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,877,282,251</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pid_z3xauRkaGQOl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-left: 10pt">Diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,877,282,251</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,877,282,251</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to the consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 71 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_003" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Impact
BioMedical Inc and Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ak_004"></span>Consolidated
Statements of Stockholder&#8217;s Equity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_303_114_z7Nc7H0a48kl" summary="xdx: Statement - Consolidated Statements of Stockholder's Equity" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B5_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zlXMEOU97ydb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4BA_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zIOkxXfnJKk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zTuBYmNysdI8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_us-gaap--NoncontrollingInterestMember_zd3v5buGKnZ8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Subsidiary</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4BD_zvmLc5zWlT4d" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Additional Paid-in</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Accumulated</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Non- controlling Interest in</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Subsidiary</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_43B_c20230101__20230331_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_zGzyfTcjhIl3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-weight: bold">Balance, December 31, 2022</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNOLEQ92E4H6" title="Balance, shares" style="width: 6%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,877,282,251</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 6%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,000</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 6%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,058,000</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 6%; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,625,000</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 6%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,111,000</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 6%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,669,000</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ProfitLoss_zywkS5hPHiRg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1015">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1016">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">657,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-01-012023-03-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">192,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">849,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_43B_c20230101__20230331_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_z27MJQWOMbJa" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance March 31, 2023</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharesOutstanding_iE_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2ZrqNAASTEe" title="Balance, shares" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,877,282,251</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,058,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,282,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-03-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,919,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,820,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_439_c20230101__20230331_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_ztCa05hAinYa" style="display: none; vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iE_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zK7DYLri9akh" title="Balance, shares" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,877,282,251</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,058,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,282,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-03-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,919,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,820,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_433_c20220101__20220331_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_zFqZGlAW3wT9" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Balance, December 31, 2021</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharesOutstanding_iS_pid_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zTsI4t75qO52" title="Balance, shares" style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,877,282,251</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,000</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,058,000</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,574,000</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,315,000</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,924,000</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_43C_c20220101__20220331_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_zkDJogMQQNz9" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Balance</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharesOutstanding_iS_pid_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zDin3EdeAK1f" title="Balance, shares" style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,877,282,251</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,000</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,058,000</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,574,000</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,315,000</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,924,000</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--ProfitLoss_zoc0ckqjOsWl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1053">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1054">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">669,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-012022-03-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">77,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">746,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_431_c20220101__20220331_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_zKoY78epN62" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance, March 31, 2022</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharesOutstanding_iE_pid_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmzhBgkBIM62" title="Balance, shares" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,877,282,251</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,058,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,243,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-03-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,238,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"/><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,178,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_430_c20220101__20220331_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_z7iKcdv2Cbp5" style="display: none; vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharesOutstanding_iE_pid_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXPzta5qRWBk" title="Balance, shares" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,877,282,251</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,058,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,243,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-03-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,238,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"/><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,178,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to the consolidated financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 72 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_003" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Impact
BioMedical Inc and Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ak_005"></span>Consolidated
Statements of Cash Flows</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the Three Months Ended March 31,</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_112_zdLEVN4bwNl" summary="xdx: Statement - Consolidated Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20230101__20230331_z9M409GfQBz7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20220101__20220331_zsvV2dTLEsl3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_z3srFCB04MPh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash flows from operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ProfitLoss_i01_zmZcTKwt4uN6" style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">849,000</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">746,000</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zSGXrtY8S0r9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Adjustments to reconcile net loss to net cash used by operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DepreciationAndAmortization_i02_zmdKVQ91PIVl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">280,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">278,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncreaseDecreaseInOperatingAssetsAbstract_i02B_zo2pBL4nbrIl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Decrease (increase) in assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i03N_di_zDAqshFMfz0h" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Prepaid expenses and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">79,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--IncreaseDecreaseInDeferredLiabilities_i03_zDIf6wh1Rux6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Deferred Tax benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1094">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--IncreaseDecreaseInImpairmentofOtherInvestments_i03N_di_ze4r0DaufR8g" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Impairment of other investment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1097">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncreaseDecreaseInOperatingLiabilitiesAbstract_i02B_zOXthVzc5Gvc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Increase (decrease) in liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncreaseDecreaseInAccountsPayable_i03_z3VVp5wdNzS8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">353,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">60,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--IncreaseDecreaseInAccruedLiabilities_i03_zx7FFg938Z7l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Accrued expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_zJ3Q6DqFa7Bj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net cash used by operating activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,014,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">533,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zJIJAbsNXGE6" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Cash flows from investing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PaymentsForProceedsFromProductiveAssets_i01N_di_zYI2KwPi0gtc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Purchase of property, plant and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsForProceedsFromProductiveAssets" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1115">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PaymentsToAcquireInvestments_i01N_di_zgozkjLJViI5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Purchase of investment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1117">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireInvestments" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_ecustom--PaymentsForProceedsFromNoteReceivableInvestments_i01N_di_zboktNpeVsLi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Note receivable investment, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="IMPB:PaymentsForProceedsFromNoteReceivableInvestments" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="IMPB:PaymentsForProceedsFromNoteReceivableInvestments" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">93,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_zLhugvGGQG92" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net cash used by investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">105,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zGReMDmF9ib1" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Cash flows from financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ProceedsFromRelatedPartyDebt_i01_zB25XbsGQ6wi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Borrowings from note payable, related party</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,017,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">625,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_zkRGIJbB5Mu2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net cash provided by financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,017,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">625,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_zXWlDz8OHymj" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Net decrease in cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_zRdGhuNZf1b5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Cash and cash equivalents at beginning of period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_zapNfEroeUk2" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Cash and cash equivalents at end of period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to the consolidated financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 73 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_003" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p id="xdx_042_c20230101__20230331_zdBt0Yq8EoE4" style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IMPACT
Biomedical, Inc. and Subsidiaries</b></span></p>

<p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ak_006"></span>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:NatureOfOperations"><p id="xdx_800_eus-gaap--NatureOfOperations_zdoXDDu1KQS5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
1. <span id="xdx_82D_zff7jzvZMrc5">Nature of Operations and Basis of Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Nature
of Operations</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impact
BioMedical, Inc. (the &#8220;Company&#8221;, &#8220;Impact BioMedical&#8221;, &#8220;We&#8221;) through the utilization of its intellectual
property rights, or through investment in, or through acquisition of companies in the biohealth and biomedical fields, focuses on the
advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune related diseases. The
Company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis
and influenza.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Global
BioLife, Inc. (&#8220;Global BioLife&#8221;), one of the Company&#8217;s subsidiaries and the main operating company of the group, focuses
on research in four main areas: (i) the &#8220;Linebacker&#8221; project, which aims to develop a universal therapeutic drug platform;
(ii) a new sugar substitute called &#8220;Laetose,&#8221;; (iii) a multi-use fragrance called &#8220;3F&#8221; (Functional Fragrance
Formulation); and (iv) Equivir/Nemovir, a blend of natural polyphenols designed as an antimicrobial medication.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Linebacker</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unlike
the traditional approach to treat individual diseases with specific drugs, the Linebacker platform seeks to offer a breakthrough therapeutic
option for multiple diseases. Linebacker is designed to work by inhibiting a cascade of inflammatory responses responsible for many diseases.
Its design is in direct contrast to the traditional approach of targeting individual diseases with specific drugs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Laetose</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have also developed a low-calorie, low glycemic level, natural modified sugar through Global BioLife. The product, &#8220;Laetose,&#8221;
is designed to possess low glycemic properties and mitigate inflammation. The Company is presently seeking to license Laetose. Global
BioLife established a joint venture, Sweet Sense, Inc. (&#8220;Sweet Sense&#8221;), with Quality Ingredients, LLC for the development,
manufacture, and global distribution of the new sugar substitute. On November 8, 2019, the Company purchased <span id="xdx_90F_eus-gaap--MinorityInterestOwnershipPercentageByNoncontrollingOwners_iI_pid_dp_uPure_c20191108__srt--OwnershipAxis__custom--SweetSenseMember_z6uVINfTNaf" title="Minority interest ownership percentage"><ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" contextRef="AsOf2019-11-08_custom_SweetSenseMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></span>% of Sweet Sense Inc.
from Quality Ingredients, LLC for $<span id="xdx_90F_eus-gaap--BusinessCombinationConsiderationTransferred1_c20191107__20191108__srt--OwnershipAxis__custom--SweetSenseMember_zMfNPrQHBMhg" title="Consideration given for purchase"><ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="From2019-11-072019-11-08_custom_SweetSenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">91,000</ix:nonFraction></span>. Sweet Sense is now an <span id="xdx_906_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20191108__srt--OwnershipAxis__custom--SweetSenseMember_zkdCM55H3RBk" title="Ownership percentage"><ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByParent" contextRef="AsOf2019-11-08_custom_SweetSenseMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">81.8</ix:nonFraction></span>% owned subsidiary of Impact BioMedical.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Functional
Fragrance Formulation (&#8220;3F&#8221;)</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Global
BioLife has established a collaboration with U.S.-based Chemia Corporation (&#8220;Chemia&#8221;) to develop specialized fragrances to
counter mosquito-borne diseases such as Zika and Dengue, among other medical applications. The 3F mosquito fragrance product is made
from specialized oils sourced from botanicals that mosquitos avoid. Global BioLife is seeking to commercialize this product. Together
with Chemia, we are attempting to license 3F. Any potential profits from the 3F project will be split between Global BioLife and Chemia
pursuant to the terms of the 20- year Royalty Agreement (Note 11).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Equivir</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equivir,
is a polyphenol compound that is believed to be successful in antiviral infection treatments. Equivir is a patented medication, that
has broad antiviral efficacy against multiple types of infectious disease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company was incorporated in the State of Nevada as a for-profit company on October 16, 2018 and established a fiscal year end of December
31st. The Company issued <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20181016__20181016__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--GlobalBioMedicalPteLtdMember_zaE7L99m5X6h" title="Stock issued during period shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2018-10-162018-10-16_custom_GlobalBioMedicalPteLtdMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,000</ix:nonFraction></span> shares to its sole shareholder Global BioMedical Pte. Ltd., which was wholly owned by Alset International
Limited (formally Singapore eDevelopment Limited), a multinational public company, listed on the Singapore Exchange Securities Trading
Limited (&#8220;SGXST&#8221;). On March 31, 2020, the Company issued <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200330__20200331__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--GlobalBioMedicalPteLtdMember_zpAK0gt5VdXi" title="Stock issued during period shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2020-03-302020-03-31_custom_GlobalBioMedicalPteLtdMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">125,064,621</ix:nonFraction></span> shares of common stock to its sole shareholder Global
BioMedical Pte. Ltd. On July 24, 2020, the Board approved the Stock Split, pursuant to which each share of the Company&#8217;s common
stock issued and outstanding was split into nine shares of the Company&#8217;s common stock. The numbers of authorized common stock and
issued and outstanding common stock in the reporting periods were retrospectively adjusted for the stock split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this report, we have not generated significant revenues from operations. We cannot guarantee we will be successful in
our business operations. Our business is subject to risks inherent in the establishment of a new business enterprise, including possible
delays in our research, testing and marketing efforts or wider economic downturns.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Basis
of Presentation and Principles of Consolidation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the
United States of America (&#8220;U.S. GAAP&#8221;). The consolidated financial statements include all accounts of the Company and its
majority owned and controlled subsidiaries. The Company consolidates entities in which it owns more than <span id="xdx_909_eus-gaap--MinorityInterestOwnershipPercentageByNoncontrollingOwners_iI_pid_dp_uPure_c20230331__srt--OwnershipAxis__custom--SweetSenseMember_zTatvyBe7BPd" title="Minority interest ownership percentage"><ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" contextRef="AsOf2023-03-31_custom_SweetSenseMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></span>% of the voting common stock
and controls operations. All intercompany transactions and balances among consolidated subsidiaries have been eliminated. Non&#8211;controlling
interest represents the minority equity investment in the Company&#8217;s subsidiaries, plus the minority investors&#8217; share of the
net operating results and other components of equity relating to the non&#8211;controlling interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 74 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_003" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IMPACT
Biomedical, Inc. and Subsidiaries</b></span></p>

<p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="srt:ScheduleOfCondensedFinancialStatementsTableTextBlock"><p id="xdx_898_esrt--ScheduleOfCondensedFinancialStatementsTableTextBlock_zCwUXDY4Qu6e" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements include all accounts of the entities as of the reporting period ending dates and for the reporting
periods as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_z4z5BYYYPCG7" style="display: none">Schedule
of Condensed Financial Statements</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: center">Name of consolidated subsidiary</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">State or other jurisdiction of incorporation or organization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">Date of incorporation or formation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Attributable interest as of <br/>March 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Attributable <br/>interest as of <br/>December 31, <br/>2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Global BioMedical, Inc.</td><td style="width: 2%">&#160;</td>
    <td style="width: 12%"><span id="xdx_900_ecustom--StateOrOtherJurisdictionOfIncorporationOrOrganization_c20230101__20230331__srt--OwnershipAxis__custom--GlobalBioMedicalIncMember_zIHBDFNktZWf" title="State or other jurisdiction of incorporation or organization"><ix:nonNumeric contextRef="From2023-01-012023-03-31_custom_GlobalBioMedicalIncMember" name="IMPB:StateOrOtherJurisdictionOfIncorporationOrOrganization">Nevada</ix:nonNumeric></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 12%"><span id="xdx_905_edei--EntityIncorporationDateOfIncorporation_dd_c20230101__20230331__srt--OwnershipAxis__custom--GlobalBioMedicalIncMember_zPVifDMn8HAd" title="Date of incorporation or formation"><ix:nonNumeric contextRef="From2023-01-012023-03-31_custom_GlobalBioMedicalIncMember" format="ixt:datemonthdayyearen" name="dei:EntityIncorporationDateOfIncorporation">April 18, 2017</ix:nonNumeric></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90C_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20230331__srt--OwnershipAxis__custom--GlobalBioMedicalIncMember_zICnblZve9hf" title="Attributable interest percentage"><ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByParent" contextRef="AsOf2023-03-31_custom_GlobalBioMedicalIncMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">90.9</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90B_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--GlobalBioMedicalIncMember_zoV5HtpvowU1" title="Attributable interest percentage"><ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByParent" contextRef="AsOf2022-12-31_custom_GlobalBioMedicalIncMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">90.9</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Global BioLife, Inc.</td><td>&#160;</td>
    <td><span id="xdx_901_ecustom--StateOrOtherJurisdictionOfIncorporationOrOrganization_c20230101__20230331__srt--OwnershipAxis__custom--GlobalBioLifeIncMember_z3aGwZ7PsBR4" title="State or other jurisdiction of incorporation or organization"><ix:nonNumeric contextRef="From2023-01-012023-03-31_custom_GlobalBioLifeIncMember" name="IMPB:StateOrOtherJurisdictionOfIncorporationOrOrganization">Nevada</ix:nonNumeric></span></td><td>&#160;</td>
    <td><span id="xdx_906_edei--EntityIncorporationDateOfIncorporation_dd_c20230101__20230331__srt--OwnershipAxis__custom--GlobalBioLifeIncMember_zaO5qwKuCCRe" title="Date of incorporation or formation"><ix:nonNumeric contextRef="From2023-01-012023-03-31_custom_GlobalBioLifeIncMember" format="ixt:datemonthdayyearen" name="dei:EntityIncorporationDateOfIncorporation">April 14, 2017</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20230331__srt--OwnershipAxis__custom--GlobalBioLifeIncMember_zRS65KdYQx7c" title="Attributable interest percentage"><ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByParent" contextRef="AsOf2023-03-31_custom_GlobalBioLifeIncMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">81.8</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--GlobalBioLifeIncMember_zO0xobSyy5K2" title="Attributable interest percentage"><ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByParent" contextRef="AsOf2022-12-31_custom_GlobalBioLifeIncMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">81.8</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">BioLife Sugar, Inc</td><td>&#160;</td>
    <td><span id="xdx_90B_ecustom--StateOrOtherJurisdictionOfIncorporationOrOrganization_c20230101__20230331__srt--OwnershipAxis__custom--BioLifeSugarIncMember_z1DG4rXM1ksi" title="State or other jurisdiction of incorporation or organization"><ix:nonNumeric contextRef="From2023-01-012023-03-31_custom_BioLifeSugarIncMember" name="IMPB:StateOrOtherJurisdictionOfIncorporationOrOrganization">Nevada</ix:nonNumeric></span></td><td>&#160;</td>
    <td><span id="xdx_905_edei--EntityIncorporationDateOfIncorporation_dd_c20230101__20230331__srt--OwnershipAxis__custom--BioLifeSugarIncMember_z1qWDh45VM08" title="Date of incorporation or formation"><ix:nonNumeric contextRef="From2023-01-012023-03-31_custom_BioLifeSugarIncMember" format="ixt:datemonthdayyearen" name="dei:EntityIncorporationDateOfIncorporation">April 23, 2018</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20230331__srt--OwnershipAxis__custom--BioLifeSugarIncMember_z16iaO8UNdwb" title="Attributable interest percentage"><ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByParent" contextRef="AsOf2023-03-31_custom_BioLifeSugarIncMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">90.9</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--BioLifeSugarIncMember_ztP2KJ3wcpWg" title="Attributable interest percentage"><ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByParent" contextRef="AsOf2022-12-31_custom_BioLifeSugarIncMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">90.9</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Happy Sugar Inc</td><td>&#160;</td>
    <td><span id="xdx_90E_ecustom--StateOrOtherJurisdictionOfIncorporationOrOrganization_c20230101__20230331__srt--OwnershipAxis__custom--HappySugarIncMember_zrdRrUOgSo69" title="State or other jurisdiction of incorporation or organization"><ix:nonNumeric contextRef="From2023-01-012023-03-31_custom_HappySugarIncMember" name="IMPB:StateOrOtherJurisdictionOfIncorporationOrOrganization">Nevada</ix:nonNumeric></span></td><td>&#160;</td>
    <td><span id="xdx_90C_edei--EntityIncorporationDateOfIncorporation_dd_c20230101__20230331__srt--OwnershipAxis__custom--HappySugarIncMember_z5SFO8dbSLSa" title="Date of incorporation or formation"><ix:nonNumeric contextRef="From2023-01-012023-03-31_custom_HappySugarIncMember" format="ixt:datemonthdayyearen" name="dei:EntityIncorporationDateOfIncorporation">August 17, 2018</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20230331__srt--OwnershipAxis__custom--HappySugarIncMember_zvQRNrD7qZu4" title="Attributable interest percentage"><ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByParent" contextRef="AsOf2023-03-31_custom_HappySugarIncMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">81.8</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--HappySugarIncMember_zMpA41Q67aPl" title="Attributable interest percentage"><ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByParent" contextRef="AsOf2022-12-31_custom_HappySugarIncMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">81.8</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Sweet Sense Inc.</td><td>&#160;</td>
    <td><span id="xdx_90A_ecustom--StateOrOtherJurisdictionOfIncorporationOrOrganization_c20230101__20230331__srt--OwnershipAxis__custom--SweetSenseIncMember_z0AuJTir93ta" title="State or other jurisdiction of incorporation or organization"><ix:nonNumeric contextRef="From2023-01-012023-03-31_custom_SweetSenseIncMember" name="IMPB:StateOrOtherJurisdictionOfIncorporationOrOrganization">Nevada</ix:nonNumeric></span></td><td>&#160;</td>
    <td><span id="xdx_906_edei--EntityIncorporationDateOfIncorporation_dd_c20230101__20230331__srt--OwnershipAxis__custom--SweetSenseIncMember_zVGoQe5wh5F" title="Date of incorporation or formation"><ix:nonNumeric contextRef="From2023-01-012023-03-31_custom_SweetSenseIncMember" format="ixt:datemonthdayyearen" name="dei:EntityIncorporationDateOfIncorporation">April 30, 2018</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20230331__srt--OwnershipAxis__custom--SweetSenseIncMember_zzHfN0CZ8nF9" title="Attributable interest percentage"><ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByParent" contextRef="AsOf2023-03-31_custom_SweetSenseIncMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">95.5</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--SweetSenseIncMember_zKKdzQEyIaZd" title="Attributable interest percentage"><ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByParent" contextRef="AsOf2022-12-31_custom_SweetSenseIncMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">95.5</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Global Sugar Solutions Inc.</td><td>&#160;</td>
    <td><span id="xdx_909_ecustom--StateOrOtherJurisdictionOfIncorporationOrOrganization_c20230101__20230331__srt--OwnershipAxis__custom--GlobalSugarSolutionsIncMember_zwczc9QUp25k" title="State or other jurisdiction of incorporation or organization"><ix:nonNumeric contextRef="From2023-01-012023-03-31_custom_GlobalSugarSolutionsIncMember" name="IMPB:StateOrOtherJurisdictionOfIncorporationOrOrganization">Nevada</ix:nonNumeric></span></td><td>&#160;</td>
    <td><span id="xdx_901_edei--EntityIncorporationDateOfIncorporation_dd_c20230101__20230331__srt--OwnershipAxis__custom--GlobalSugarSolutionsIncMember_zAroUALjZgTi" title="Date of incorporation or formation"><ix:nonNumeric contextRef="From2023-01-012023-03-31_custom_GlobalSugarSolutionsIncMember" format="ixt:datemonthdayyearen" name="dei:EntityIncorporationDateOfIncorporation">November 7, 2019</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20230331__srt--OwnershipAxis__custom--GlobalSugarSolutionsIncMember_zBtF5Fvi0OL" title="Attributable interest percentage"><ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByParent" contextRef="AsOf2023-03-31_custom_GlobalSugarSolutionsIncMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--GlobalSugarSolutionsIncMember_zfdpbWiabovk" title="Attributable interest percentage"><ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByParent" contextRef="AsOf2022-12-31_custom_GlobalSugarSolutionsIncMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_znvcOjfTbCY6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2023, and December 31, 2022, the aggregate noncontrolling interest was equity of $<span id="xdx_906_eus-gaap--MinorityInterest_iI_c20230331__srt--ConsolidatedEntitiesAxis__srt--SubsidiariesMember_zeIentK9UWxd" title="Noncontrolling interest"><ix:nonFraction name="us-gaap:MinorityInterest" contextRef="AsOf2023-03-31_srt_SubsidiariesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,919,000</ix:nonFraction></span>
and $<span id="xdx_906_eus-gaap--MinorityInterest_iI_c20221231__srt--ConsolidatedEntitiesAxis__srt--SubsidiariesMember_z2ty5bX55Whb" title="Noncontrolling interest"><ix:nonFraction name="us-gaap:MinorityInterest" contextRef="AsOf2022-12-31_srt_SubsidiariesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,111,000</ix:nonFraction></span>,
respectively, which are separately disclosed on the Consolidated Balance Sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_800_eus-gaap--SignificantAccountingPoliciesTextBlock_z7YJQDa0zWt2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2.<span id="xdx_82C_zjLhBS0H2V93"> Summary of Significant Accounting and Reporting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:UseOfEstimates"><p id="xdx_847_eus-gaap--UseOfEstimates_zdQf9jYkURy7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_zt6VwiVmfLrk">Use
of estimates</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the dates of the balance
sheets and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from these estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_842_eus-gaap--EarningsPerSharePolicyTextBlock_zyxlcJyJMqci" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86F_zkJB4Ss69lIi">Earnings
(Loss) per Share</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
earnings (loss) per share is computed by dividing the net income (loss) attributable to the common stockholders by weighted average number
of shares of common stock outstanding during the period. Fully diluted earnings (loss) per share is computed like basic income (loss)
per share except that the denominator is increased to include the number of additional common shares that would have been outstanding
if the potential common shares had been issued and if the additional common shares were dilutive. There were no dilutive financial instruments
issued or outstanding for the three months ended March 31, 2023 or 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_849_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zgcgbooGbEg6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_z9Je588BzIm4">Fair
Value of Financial Instruments</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants at the measurement date. The Fair Value Measurement Topic of the Financial Accounting Standards Board (&#8220;FASB&#8221;)
Accounting Standards Codification (&#8220;ASC&#8221;) establishes a three-tier fair value hierarchy which prioritizes the inputs used
in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets
or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted
prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active;
and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions,
such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts reported in the balance sheet of cash and cash equivalents, prepaids, accounts payable and accrued expenses approximate
fair value because of the immediate or short-term maturity of these financial instruments. The fair value of notes receivable approximates
their carrying value as the stated or discounted rates of the notes do reflect recent market conditions. The Company&#8217;s investments
are record at cost as the fair value of these investment in are not readily available. The fair value of notes payable approximates its
carrying value as the stated interest rate reflects recent market conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 75 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_003" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IMPACT
Biomedical, Inc. and Subsidiaries</b></span></p>

<p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_847_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zeTGsT6NkwGk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86F_zrkvNCrj2yh4">Cash
and cash equivalents</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid investments with a maturity of three months or less at the date of acquisition to be cash
equivalents. There were <span id="xdx_907_eus-gaap--Cash_iI_do_c20230331_zIikbZYCaAYd" title="Cash"><span id="xdx_90C_eus-gaap--Cash_iI_do_c20221231_zknDqfNKSt4g" title="Cash"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2023-03-31" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2022-12-31" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span>
cash equivalents as of March 31, 2023 and December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:InvestmentPolicyTextBlock"><p id="xdx_84F_eus-gaap--InvestmentPolicyTextBlock_zQ6ZqyOzbsx3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_zu17eaWGCxj2">Investments</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investments
in equity securities with a readily determinable fair value, not accounted for under the equity method, are recorded at fair value with
unrealized gains and losses included in earnings. For equity securities without a readily determinable fair value, the investment is
recorded at cost, less any impairment, plus or minus adjustments related to observable transactions for the same or similar securities,
with unrealized gains and losses included in earnings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
equity method investments, the Company regularly reviews its investments to determine whether there is a decline in fair value below
book value. If there is a decline that is other-than-temporary, the investment is written down to fair value. See Note 6 for further
discussion on investments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy"><p id="xdx_84F_eus-gaap--GoodwillAndIntangibleAssetsGoodwillPolicy_z9IxlP36xKl1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zo4sSSkpKQEi">Goodwill</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill
is the excess of cost of an acquired entity over the fair value of amounts assigned to assets acquired and liabilities assumed in a business
combination. Goodwill is subject to impairment testing at least annually and will be tested for impairment between annual tests, which
takes place during the fourth quarter, if an event occurs or circumstances change that would indicate the carrying amount may be impaired.
FASB ASC Topic 350 provides an entity with the option to first assess qualitative factors to determine whether the existence of events
or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying
amount. Some of the qualitative factors considered in applying this test include consideration of macroeconomic conditions, industry
and market conditions, cost factors affecting the business, and overall financial performance of the business. If, after completing the
assessment, it is determined that it is more likely than not that the fair value of a reporting unit is less than its carrying value,
the Company will proceed to a quantitative test. If qualitative factors are not deemed sufficient to conclude that the fair value of
the reporting unit more likely than not exceeds its carrying value, then a one-step approach is applied in making an evaluation. The
evaluation utilizes an income approach (discounted cash flow analysis). The computations require management to make significant estimates
and assumptions, including, among other things, selection of comparable publicly traded companies, the discount rate applied to future
earnings reflecting a weighted average cost of capital, and earnings growth assumptions. The Company believes the estimates and assumptions
used in our impairment assessments are reasonable and based on available market information, but variations in any of the assumptions
could result in materially different calculations of fair value and determinations of whether or not an impairment is indicated. A discounted
cash flow analysis requires management to make various assumptions about future sales, operating margins, capital expenditures, working
capital, and growth rates. Cash flow projections are derived from one year budgeted amounts plus an estimate of later period cash flows,
all of which are determined by management. Subsequent period cash flows are developed for each reporting unit using growth rates that
management believes are reasonably likely to occur. Impairment of goodwill is measured as the excess of the carrying amount of goodwill
over the fair values of recognized and unrecognized assets and liabilities of the reporting unit. <span id="xdx_904_eus-gaap--GoodwillImpairmentLoss_dxL_c20230101__20230331_z4XiXqSxlbza" title="Impairment of goodwill::XDX::-"><span id="xdx_901_eus-gaap--GoodwillImpairmentLoss_dxL_c20220101__20220331_zcT7vmeuBw04" title="Impairment of goodwill::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1230"><span style="-sec-ix-hidden: xdx2ixbrl1232">No</span></span></span></span> impairment was recognized during
the three months ended March 31, 2023 or year ended December 31, 2022 (see Note 7).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:IntangibleAssetsFiniteLivedPolicy"><p id="xdx_841_eus-gaap--IntangibleAssetsFiniteLivedPolicy_z1a3nqz7Lulf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_zU8Fi7Jev1Yb">Intangible
Assets</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated fair values of acquired intangibles are generally determined based upon future economic benefits such as earnings and cash
flows. Acquired identifiable intangible assets are recorded at fair value and are amortized over their estimated useful lives.
Acquired intangible assets with an indefinite life are not amortized but are reviewed for impairment at least annually as of
December 31<sup>st</sup>, or more frequently whenever events or changes in circumstances indicate that the carrying amounts of those
assets are below their estimated fair values. Impairment is tested under ASC 350. <span id="xdx_901_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_do_c20230101__20230331_zywcseRVtwQl" title="Impairment of intangible assets"><span id="xdx_900_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_do_c20220101__20221231_zdUpfxX3Zrwc" title="Impairment of intangible assets"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="From2023-01-01to2023-03-31" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="From2022-01-012022-12-31" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">No</ix:nonFraction></ix:nonFraction></span></span>
impairment was recognized as of March 31,  2023 or year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><p id="xdx_84C_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zDbHGeIMInR8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; background-color: white"><i><span id="xdx_860_zkK2hzCpGQ93">Recoverability
of Long-Lived Assets</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; background-color: white"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; background-color: white">We evaluate
long-lived assets such as property, equipment and definite lived intangible assets, such as patents, for impairment whenever events or
circumstances indicate that the carrying value of the assets recognized in our financial statements may not be recoverable. Factors that
we consider include whether there has been a significant decrease in the market value of an asset, a significant change in the way an
asset is being utilized, or a significant change, delay or departure in our strategy for that asset, or a significant change in the macroeconomic
environment, such as the impact of the COVID-19 pandemic. Our assessment of the recoverability of long-lived assets involves significant
judgment and estimation. These assessments reflect our assumptions, which, we believe, are consistent with the assumptions hypothetical
marketplace participants use. Factors that we must estimate when performing recoverability and impairment tests include, among others,
forecasted revenue, margin costs and the economic life of the asset. If impairment is indicated, we determine if the total estimated
future cash flows on an undiscounted basis are less than the carrying amounts of the asset or assets. If so, an impairment loss is measured
and recognized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 27.15pt; background-color: white">Our
impairment loss calculations require that we apply judgment in identifying asset groups, estimating future cash flows, determining asset
fair values, and estimating asset&#8217;s useful lives. The Company reviews identifiable amortizable intangible assets for impairment
whenever events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. Determination of recoverability
is based on the lowest level of identifiable estimated undiscounted cash flows resulting from use of the asset and its eventual disposition.
Measurement of any impairment loss is based on the excess of the carrying value of the asset over its fair value. Based on the uncertainty
of forecasts inherent with a new product, events such as the failure to generate forecasted revenue from new products could result in
a non-cash impairment in future periods. </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_847_eus-gaap--ResearchAndDevelopmentExpensePolicy_zGjVfszuc6gk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_861_zxMhjB9oXyT5">Research
and Development</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed as incurred. Total research and development costs were $<span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230331_zCs1D9tKs0sj" title="Research and development cost"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">179,000</ix:nonFraction></span> for the three months ended March 31,
2023, and $<span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20220331_zGlbHIaIRhXj" title="Research and development cost"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">168,000</ix:nonFraction></span> for three months ended March 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 76 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_003" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IMPACT
Biomedical, Inc. and Subsidiaries</b></span></p>

<p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_849_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zxAblYvjT77c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zeeCcaIvXdw5">Recent
Accounting Standards</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Financial Accounting Standards Board (FASB) issues various Accounting Standards Updates relating to the treatment and recording of certain
accounting transactions. There are several new accounting pronouncements issued by FASB which are not yet effective. Each of these pronouncements,
as applicable, has been or will be adopted by the Company. As of March 31, 2023, none of these pronouncements is expected to have a material
effect on the financial position, results of operations or cash flows of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">On January
1, 2022, the Company adopted amended accounting guidance &#8220;<i>ASU No.2016-13 &#8211; Credit Losses&#8221;</i> which requires an
allowance for credit losses to be deducted from the amortized cost basis of financial assets to present the net carrying value at the
amount that is expected to be collected over the contractual term of the asset considering relevant information about past events, current
conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. In estimating expected losses
in the loan and lease portfolio, borrower-specific financial data and macro-economic assumptions are utilized to project losses over
a reasonable and supportable forecast period. Assumptions and judgment are applied to measure amounts and timing of expected future cash
flows, collateral values and other factors used to determine the borrowers&#8217; abilities to repay obligations. After the forecast
period, the Company utilizes longer-term historical loss experience to estimate losses over the remaining contractual life of the loans.
Prior to 2022, the allowance for credit losses represented the amount that in management&#8217;s judgment reflected incurred credit losses
inherent in the loan and lease portfolio as of the balance sheet date. As of March 31, 2023 the Company has deemed that no reserve or
credit losses were necessary.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="IMPB:ContinuingOperationsAndGoingConcernPolicyTextBlock"><p id="xdx_84D_ecustom--ContinuingOperationsAndGoingConcernPolicyTextBlock_zcNMEQrOWwg3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_zTEGg80OPLSg">Continuing
Operations and Going Concern</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to incurred operating losses as well as negative cash flows from operating and investing activities over the past two years, the accompanying
consolidated financial statements have been prepared assuming that the Company will continue as a going concern. This basis of accounting
contemplates the recovery of our assets and the satisfaction of liabilities in the normal course of business. These consolidated financial
statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary
should we be unable to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
continue as a going concern, the Company has entered into an updated revolving promissory note which extended the maturity through March
31, 2024, and DSS intends to continue to fund the operations of the Company through a year from the date these financial statements were
available to be issued. The Company&#8217;s management intends to take actions necessary to continue as a going concern. Management&#8217;s
plans concerning these matters include, among other things, monetization of its intellectual properties, and tightly controlling operating
costs. Based on this, the Company has concluded that substantial doubt of its ability to continue as a going concern has been alleviated.</span></p>
</ix:nonNumeric><p id="xdx_859_zzXvj7vNEiFa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="IMPB:PrepaidExpensesTextBlock"><p id="xdx_800_ecustom--PrepaidExpensesTextBlock_zznagE0BnHkk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
3. <span id="xdx_82F_z0kqXkIuctMl">Prepaid Expenses</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
expenses for the three months ended March 31, 2023, includes prepaid inventory approximating $<span id="xdx_908_eus-gaap--OtherPrepaidExpenseCurrent_iI_c20230331__dei--LegalEntityAxis__custom--GRDGscienceLLCMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zlbBXjPsmgC8"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2023-03-31_custom_GRDGscienceLLCMember_us-gaap_RelatedPartyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">140,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and research and development fees paid to GRDG
Sciences, LLC. (&#8220;GRDG&#8221;), a related party, approximating $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230331__dei--LegalEntityAxis__custom--GRDGscienceLLCMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zBORT0DWnBtc"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-03-31_custom_GRDGscienceLLCMember_us-gaap_RelatedPartyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
Prepaid expenses at December 31, 2022 of $<span id="xdx_907_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_c20221231__dei--LegalEntityAxis__custom--GRDGscienceLLCMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zlZO6VO6Oms"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2022-12-31_custom_GRDGscienceLLCMember_us-gaap_RelatedPartyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">104,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">including research and development costs to GRDG
approximating $<span id="xdx_900_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20220331__dei--LegalEntityAxis__custom--GRDGscienceLLCMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zSEFo6gVrIpk"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-03-31_custom_GRDGscienceLLCMember_us-gaap_RelatedPartyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"><p id="xdx_806_eus-gaap--LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_zgenoMqUC08d" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
4. <span id="xdx_82E_zkgRqnZcy6wk">Notes Receivable</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 21, 2021, Impact BioMedical, Inc. entered into a promissory note (&#8220;Promissory Note 1&#8221;) with an individual. The Company
loaned the principal sum of $<span id="xdx_901_eus-gaap--NotesReceivableNet_iI_c20210221_zi2s8gcmDHjk" title="Note receivable principal"><ix:nonFraction name="us-gaap:NotesReceivableNet" contextRef="AsOf2021-02-21" format="ixt:numdotdecimal" decimals="0" unitRef="USD">206,000</ix:nonFraction></span>, with interest at a rate of <span id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20210221_zybpWoXqiFRa" title="Debt stated percentage"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2021-02-21" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6.5</ix:nonFraction></span>%, and maturity date of <span id="xdx_903_eus-gaap--DebtInstrumentMaturityDate_dd_c20210220__20210221_zL7CLUdbngic" title="Debt maturity date"><ix:nonNumeric contextRef="From2021-02-202021-02-21" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">August 19, 2022</ix:nonNumeric></span>. Monthly payments are due
on the twenty-first day of each month and continuing each month thereafter until August 19, 2022, at which time all accrued interest
and the entire remaining principal shall be due and payable in full. In August 2022, this note was amended to extend the maturity date
to <span id="xdx_90A_eus-gaap--DebtInstrumentMaturityDate_c20220822__20220822_zhwVnrh63cK9" title="Maturity date"><ix:nonNumeric contextRef="From2022-08-222022-08-22" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">August 19, 2023</ix:nonNumeric></span>. This note is secured by certain real property situated in Collier County, Florida. The outstanding principal and
interest approximated $<span id="xdx_904_eus-gaap--DebtInstrumentPeriodicPayment_c20230101__20230331_zZKwpYbDLMbe" title="Debt principal and interest"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPayment" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">205,000</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--DebtInstrumentPeriodicPayment_c20220101__20221231_zzNbTxwviz6a" title="Debt principal and interest"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPayment" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">206,000</ix:nonFraction></span> as of March 31, 2023 and December 31, 2022, respectively. Of the $<span id="xdx_90A_eus-gaap--NotesReceivableNet_iI_c20230331_zZXRt6Kecld3" title="Note receivable principal"><ix:nonFraction name="us-gaap:NotesReceivableNet" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">205,000</ix:nonFraction></span> outstanding at
March 31, 2023, $<span id="xdx_909_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20221231_zEjWmG4cOnMl" title="Notes receivable current"><ix:nonFraction name="us-gaap:NotesAndLoansReceivableGrossCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">205,000</ix:nonFraction></span> is classified in current notes receivable on the accompanying consolidated balance sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:InvestmentTextBlock"><p id="xdx_80E_eus-gaap--InvestmentTextBlock_zJHqZsL3mxo2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
5. <span id="xdx_82E_zBdG7zwNrMSd">Investments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 19, 2020, Impact BioMedical entered into a subscription agreement (the &#8220;Subscription Agreement&#8221;) with BioMed Technologies
Asia Pacific Holdings Limited (&#8220;BioMed&#8221;), a limited liability company incorporated in the British Virgin Islands, pursuant
to which the Company agreed to purchase <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_c20201218__20201219__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AsiaPacificHoldingsLimitedMember__us-gaap--TypeOfArrangementAxis__us-gaap--SubscriptionArrangementMember_zgIszdthOTFe" title="Ordinary shares to purchase"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" contextRef="From2020-12-182020-12-19_custom_AsiaPacificHoldingsLimitedMember_us-gaap_SubscriptionArrangementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">525</ix:nonFraction></span> ordinary shares or <span id="xdx_90A_ecustom--OrdinarySharesPercentage_dp_uPure_c20201218__20201219__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AsiaPacificHoldingsLimitedMember__us-gaap--TypeOfArrangementAxis__us-gaap--SubscriptionArrangementMember_zWZOepEBYtl" title="Ordinary shares percentage"><ix:nonFraction name="IMPB:OrdinarySharesPercentage" contextRef="From2020-12-182020-12-19_custom_AsiaPacificHoldingsLimitedMember_us-gaap_SubscriptionArrangementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.99</ix:nonFraction></span>% of BioMed at a purchase price of approximately $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValuePurchaseOfAssets_c20201218__20201219__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AsiaPacificHoldingsLimitedMember__us-gaap--TypeOfArrangementAxis__us-gaap--SubscriptionArrangementMember_zj4eH54KnRy2" title="Purchase price of shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" contextRef="From2020-12-182020-12-19_custom_AsiaPacificHoldingsLimitedMember_us-gaap_SubscriptionArrangementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">632,000</ix:nonFraction></span>. The Subscription
Agreement provides, among other things, the Company the right to appoint a new director to the board of BioMed. With respect to an issuance
of shares to a third party by BioMed, the Company will have the right of first refusal to purchase such shares, as well as customary
tag-along rights. In connection with the Subscription Agreement, the Company entered into an exclusive distribution agreement (the &#8220;Distribution
Agreement&#8221;) with BioMed, to directly market, advertise, promote, distribute, and sell certain BioMed products, which focus on manufacturing
natural probiotics, to resellers. This investment is valued at cost as it does not have a readily determined fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioMed
focuses on manufacturing natural probiotics, pursuant to which the Company will directly market, advertise, promote, distribute and sell
certain BioMed products to resellers. The products to be distributed by the Company include BioMed&#8217;s PGut Premium Probiotics<sup>&#174;</sup>,
PGut Allergy Probiotics<sup>&#174;</sup>, PGut SupremeSlim Probiotics<sup>&#174;</sup>, PGut Kids Probiotics<sup>&#174;</sup>, and PGut
Baby Probiotics<sup>&#174;</sup>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
January 1, 2021, the Company entered into a securities purchase agreement (&#8220;SPA&#8221;) with Nano9, LLC. (&#8220;Nano9&#8221;),
a Utah limited partnership. For the consideration of $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210101__20210101__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NanoNineLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z7yHKudmDdw7" title="Number of shares issued, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-01-01_custom_NanoNineLLCMember_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,000</ix:nonFraction></span> the Company obtained <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20210101__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NanoNineLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zcioHhGmp7yl" title="Number of shares issued, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-01-012021-01-01_custom_NanoNineLLCMember_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000</ix:nonFraction></span> membership units, or approximately <span id="xdx_900_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20210101__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NanoNineLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zXVnerZSExBj" title="Equitable ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2021-01-01_custom_NanoNineLLCMember_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>% equitable
ownership of Nano9. Nano9 is a scientifically driven company, specializing in the development and production of leading nano-sized health
&amp; wellness products utilizing their proprietary nano technology. As of Mach 31, 2023 and March 31, 2022, the fair value of the Company&#8217;s
investment in Nano9 is not readily available, and therefore is recorded at cost of $<span id="xdx_90F_eus-gaap--InvestmentOwnedAtFairValue_iI_c20230331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NanoNineLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zzAPgEMNCnS6" title="Investment owned at fair value"><span id="xdx_90C_eus-gaap--InvestmentOwnedAtFairValue_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NanoNineLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zAXFQBz9QGvj" title="Investment owned at fair value"><ix:nonFraction name="us-gaap:InvestmentOwnedAtFairValue" contextRef="AsOf2023-03-31_custom_NanoNineLLCMember_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:InvestmentOwnedAtFairValue" contextRef="AsOf2022-12-31_custom_NanoNineLLCMember_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,000</ix:nonFraction></ix:nonFraction></span></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 77 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_003" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IMPACT
Biomedical, Inc. and Subsidiaries</b></span></p>

<p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 15, 2021, the Company, through one of its subsidiaries, entered into a Stock Purchase Agreement (the &#8220;Vivacitas Agreement
#1&#8221;) with Vivacitas Oncology Inc. (&#8220;Vivacitas&#8221;), to purchase <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210314__20210315__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VivacitasOncologyIncMember_zPIyUHAVvWy7" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-03-142021-03-15_custom_StockPurchaseAgreementMember_custom_VivacitasOncologyIncMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500,000</ix:nonFraction></span> shares of its common stock at the per share price
of $<span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20210315__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VivacitasOncologyIncMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zHtIZ4p96zMl" title="Common stock par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-03-15_custom_VivacitasOncologyIncMember_custom_StockPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span>, with an option to purchase <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20210314__20210315__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VivacitasOncologyIncMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zyihgpA9OXYf" title="Options to purchase additional shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" contextRef="From2021-03-142021-03-15_custom_StockPurchaseAgreementMember_custom_VivacitasOncologyIncMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,500,000</ix:nonFraction></span> additional shares at the per share price of $<span id="xdx_907_eus-gaap--SharePrice_iI_c20210315__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VivacitasOncologyIncMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zEhLwmJ8fIZ3" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2021-03-15_custom_VivacitasOncologyIncMember_custom_StockPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span>. <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20210314__20210315__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VivacitasOncologyIncMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zfpqTSJdIJ5d" title="Option termination, description"><ix:nonNumeric contextRef="From2021-03-142021-03-15_custom_StockPurchaseAgreementMember_custom_VivacitasOncologyIncMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">This option will terminate upon one
of the following events: (i) Vivacitas&#8217; board of directors cancels this option because it is no longer in the best interest of
the Company; (ii) December 31, 2022; or (iii) the date on which Vivacitas receives more than $1.00 per share of the Company&#8217;s common
stock in a private placement with gross proceeds of $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20210314__20210315__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VivacitasOncologyIncMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_za7D9cHsg4Se" title="Proceeds from private placement"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2021-03-142021-03-15_custom_StockPurchaseAgreementMember_custom_VivacitasOncologyIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000</ix:nonFraction></span>. Under the terms of the Vivacitas Agreement #1, the Company will be allocated
two seats on the board of Vivacitas</ix:nonNumeric></span>. On March 18, 2021, the Company entered into an agreement with Alset EHome International, Inc. (&#8220;Seller&#8221;)
to purchase from the Seller&#8217;s its wholly owned subsidiary Impact Oncology PTE Ltd. (&#8220;IOPL&#8221;) for a purchase price $<span id="xdx_905_eus-gaap--BusinessCombinationConsiderationTransferred1_c20210317__20210318__us-gaap--BusinessAcquisitionAxis__custom--ImpactOncologyPTELtdMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zJhtKUYE4jMi" title="Purchase price"><ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="From2021-03-172021-03-18_custom_ImpactOncologyPTELtdMember_custom_StockPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,480,000</ix:nonFraction></span>.
The acquisition of IOPL has been treated as an asset acquisition as IOPL does not meet the definition of a business as defined in Topic
805. IOPL owns <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20210317__20210318__us-gaap--BusinessAcquisitionAxis__custom--ImpactOncologyPTELtdMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zUpl6Ci9Hrgk" title="Number of common stock owned"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2021-03-172021-03-18_custom_ImpactOncologyPTELtdMember_custom_StockPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,480,000</ix:nonFraction></span> shares of common stock of Vivacitas along with the option to purchase an additional <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20210317__20210318__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zn6gyNKQhbC6" title="Options to purchase common stock"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" contextRef="From2021-03-172021-03-18_custom_StockPurchaseAgreementMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250,000</ix:nonFraction></span> shares of common
stock. The Sellers largest shareholder is Mr. Chan Heng Fai Ambrose, the Chairman of the Company&#8217;s board of directors and its largest
shareholder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 1, 2021, the Company entered into an additional stock purchase agreement with Vivacitas (&#8220;Vivacitas Agreement #2&#8221;),
whereas Vivacities wished to employ the service of the Chief Business Officer of Impact Biomedical, and in return for the services of
this individual, Vivacitas shall issue to the Company, the aggregate purchase price for the Class A Common Shares of Vivacitas at the
value of $<span id="xdx_901_eus-gaap--SharePrice_iI_c20210401__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VivacitasOncologyIncMember_zheuHmk0bhm4" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2021-04-01_custom_StockPurchaseAgreementMember_custom_VivacitasOncologyIncMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span> per share shall be $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20210401__20220331__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VivacitasOncologyIncMember_zXTsGXfHj669" title="Proceeds from issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2021-04-012022-03-31_custom_StockPurchaseAgreementMember_custom_VivacitasOncologyIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120,000</ix:nonFraction></span> to be paid in twelve (12) equal monthly installments for the period between April 1, 2021
and March 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 22, 2021, the Company exercised <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210721__20210722__us-gaap--TypeOfArrangementAxis__custom--VivacitasAgreementMember_zbZcBFEWsNve" title="Stock option exercised, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2021-07-212021-07-22_custom_VivacitasAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span> of the available options under the Vivacitas Agreement #1 for $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_c20210721__20210722__us-gaap--TypeOfArrangementAxis__custom--VivacitasAgreementMember_zAvqYOHaSMr6" title="Stock option exercised, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-07-212021-07-22_custom_VivacitasAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000,000</ix:nonFraction></span>. This, along
with the shares received as part Vivacitas Agreement #2 increased the Company&#8217;s equity position in Vivacitas to approximately 16%
as of December 31, 2022. As of December 31, 2021, the fair value of the Company&#8217;s investment in Vivacitas is not readily available,
and therefore is recorded at cost in the amount of $<span id="xdx_909_eus-gaap--InvestmentOwnedAtFairValue_iI_c20211231__us-gaap--TypeOfArrangementAxis__custom--VivacitasAgreementMember_zvYB0cscwmz8" title="Investment owned at fair value"><ix:nonFraction name="us-gaap:InvestmentOwnedAtFairValue" contextRef="AsOf2021-12-31_custom_VivacitasAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,035,000</ix:nonFraction></span>. As of December 31, 2022, the Company determined to impair <span id="xdx_90C_eus-gaap--InvestmentOwnedPercentOfNetAssets_iI_pid_dp_c20221231__us-gaap--TypeOfArrangementAxis__custom--VivacitasAgreementMember_zq9VHFbjTEVa" title="Investment cost, percent"><ix:nonFraction name="us-gaap:InvestmentOwnedPercentOfNetAssets" contextRef="AsOf2022-12-31_custom_VivacitasAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>% of its investment
in Vivacitas, in the amount of $<span id="xdx_905_eus-gaap--InvestmentOwnedAtCost_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--VivacitasAgreementMember_zkmt2C76xxRf" title="Investment cost"><ix:nonFraction name="us-gaap:InvestmentOwnedAtCost" contextRef="AsOf2022-12-31_custom_VivacitasAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,100,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock"><p id="xdx_80A_eus-gaap--PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock_zoATX1p4YtJb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
6. <span><span id="xdx_827_zb0LjbGchzfg">PROPERTY PLANT AND EQUIPMENT and INVESTMENT IN REAL ESTATE, NET</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><p id="xdx_894_eus-gaap--PropertyPlantAndEquipmentTextBlock_zKmGCKB8jhLi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property,
plant and equipment consisted of the following as of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_zlqErWIC7q1i" style="display: none">Schedule
of Property Plant and Equipment</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">Estimated</td><td>&#160;</td>
    <td colspan="2" id="xdx_49D_20230331_zqqKxvPswvVe" style="text-align: center"><b>March 31,</b></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49B_20221231_zkPG2FKFlzKc" style="text-align: center"><b>December 31,</b></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Useful Life</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zqxZN27jvhsd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 54%; text-align: left">Machinery and equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 12%; text-align: right"><span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MinimumMember_ziKBKyunP5Wl"><ix:nonNumeric contextRef="AsOf2023-03-31_us-gaap_MachineryAndEquipmentMember_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span>-<span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MaximumMember_zBPBwmp0uYL3"><ix:nonNumeric contextRef="AsOf2023-03-31_us-gaap_MachineryAndEquipmentMember_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">10</ix:nonNumeric></span> years</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-03-31_us-gaap_MachineryAndEquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31_us-gaap_MachineryAndEquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_zySoihHYZMac" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Construction in progress</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: right; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-03-31_us-gaap_ConstructionInProgressMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">251,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31_us-gaap_ConstructionInProgressMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">251,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzm9U_zrVVWlbBESsb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total Cost</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">281,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">276,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzm9U_zAT672QBpB97" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Property, plant and equipment, gross</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">281,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">276,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iI_msPPAENzm9U_zuHGi7xUSjyj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: right; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1345">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzm9U_zPzbbi0iICH2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Property, plant and equipment, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: right; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">279,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">276,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_zk2xPcbLPHYe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
expense for the three months ended March 31, 2023 and 2022 was $<span id="xdx_909_eus-gaap--Depreciation_c20230101__20230331_zZ3Zs3o0Yhw7" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000</ix:nonFraction></span> and $<span id="xdx_90C_eus-gaap--Depreciation_c20220101__20220331_zzaWsqDjnn25" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:GoodwillDisclosureTextBlock"><p id="xdx_80A_eus-gaap--GoodwillDisclosureTextBlock_z84PkQfzbblh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
7. <span id="xdx_829_zHOdb8nvWfZ9">Goodwill</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:ScheduleOfGoodwillTextBlock"><p id="xdx_89D_eus-gaap--ScheduleOfGoodwillTextBlock_z8SUaUaDgTli" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Goodwill
balances and activity for the three months ended March 31, 2023 and year ended December 31, 2022 consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span style="display: none"><span id="xdx_8B3_zYQvG6r2jJ9c">Schedule
of Goodwill</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%">Balance at December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--Goodwill_iS_c20230101__20230331_zVuouwoCAx3" title="Balance at December 31, 2022" style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,093,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Goodwill adjustment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--GoodwillImpairmentLoss_c20230101__20230331_zVMey9wbMgll" title="Goodwill adjustment" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1360">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance at March 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--Goodwill_iE_c20230101__20230331_zffStzrknGr5" title="Balance at March 31, 2023" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,093,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_zVOXtbklTx6b" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2022, management performed annual goodwill impairment testing. No goodwill impairment was identified as a result of these tests. As of
June 1, 2022 a quantitative analysis was prepared utilizing the Market Approach and Income Approach valuing the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:IntangibleAssetsDisclosureTextBlock"><p id="xdx_80C_eus-gaap--IntangibleAssetsDisclosureTextBlock_zMSHpM4pv9I" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
8. <span id="xdx_824_zGUS3VAU8E0l">Intangible Assets</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
definite-lived intangible assets, to be amortized over 20 years, balances, and activity for the <span style="background-color: white">three
months</span> ended March 31, 2023, year ended December 31, 2022 consisted of the following:</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"><p id="xdx_894_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zGi1WtUkN6Li" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zwb1AaV397ea" style="display: none">Schedule
of Intangible Assets</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">03/31/2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">12/31/2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Gross Carrying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amount</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accumulated</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amortization</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net Carrying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amount</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Gross Carrying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amount</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accumulated</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amortization</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net Carrying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amount</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Definitive-lived:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; text-align: left; padding-bottom: 1.5pt">Developed technology</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20230331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zvIVcgBkvYKl" title="Gross Carrying Amount" style="border-bottom: Black 1.5pt solid; width: 6%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2023-03-31_us-gaap_DevelopedTechnologyRightsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,258,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20230331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zssAAxGCti9h" title="Accumulated Amortization" style="border-bottom: Black 1.5pt solid; width: 6%; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2023-03-31_us-gaap_DevelopedTechnologyRightsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,502,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20230331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zHjJx9BowYW5" title="Net Carrying Amount" style="border-bottom: Black 1.5pt solid; width: 6%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2023-03-31_us-gaap_DevelopedTechnologyRightsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,756,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zWXgbalgJz37" title="Gross Carrying Amount" style="border-bottom: Black 1.5pt solid; width: 6%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2022-12-31_us-gaap_DevelopedTechnologyRightsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,258,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_z0ahlEuoAWA" title="Accumulated Amortization" style="border-bottom: Black 1.5pt solid; width: 6%; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2022-12-31_us-gaap_DevelopedTechnologyRightsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,226,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zpwIrJiajne4" title="Net Carrying Amount" style="border-bottom: Black 1.5pt solid; width: 6%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2022-12-31_us-gaap_DevelopedTechnologyRightsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,033,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20230331_zJJvBS6Ctedk" title="Gross Carrying Amount" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,258,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20230331_z8G18z2Gh0Wf" title="Accumulated Amortization" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,502,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20230331_zZGqbkVkLHKe" title="Net Carrying Amount" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,756,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20221231_zYxx5eW0ZsLl" title="Gross Carrying Amount" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,258,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231_zabLixtyvSB7" title="Accumulated Amortization" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,226,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20221231_zX4zinQ5kTUl" title="Net Carrying Amount" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,033,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_zuyVZX6z4QU5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Amounts
amortized for the three months ended March 31, 2023 and 2022 was approximately $<span id="xdx_908_eus-gaap--DepreciationAndAmortization_c20230101__20230331_zQWq82HMhrMe" title="Amortization"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">280,000</ix:nonFraction></span> and $<span id="xdx_907_eus-gaap--DepreciationAndAmortization_c20220101__20220331_zgdMmAcg0Lqj" title="Amortization"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">278,000</ix:nonFraction></span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"><p id="xdx_898_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zJt835MlvhDc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table represents future amortization of developed technologies for the years ending December 31:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 11pt"><span id="xdx_8B1_zgtrZ9zobbee">Schedule
of Future Amortization of Developed Technologies</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49F_20230331_zYwsWZqnCvx7" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_z9IouMh1PgZa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: right">2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">835,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_zOgSIplEnwp8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: right">2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,113,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_zEjc0J7QM5Eg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">2025</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,113,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_zAeK6OAHhN1e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: right">2026</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,113,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_z9fBJamofKN7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">2027</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,113,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_zYjHglv38zI3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: right">Thereafter</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,469,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_z3Sidvpo3ag2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 78 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_003" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IMPACT
Biomedical, Inc. and Subsidiaries</b></span></p>

<p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An impairment analysis was conducted for
financial reporting purposes in connection with U.S. GAAP and ASC 360-10, Impairment and Disposal of Long-Lived Assets. Although the
Company has a history of negative cash flows from operations, its financing arrangement with DSS (see Note 9) provides the opportunity
to fund ongoing operations. This, as well as there being no other indicators present for impairment, has led management to conclude that
no impairment is necessary for the three months ended March 31, 2023, and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_809_eus-gaap--DebtDisclosureTextBlock_z6WPYl6rmHK1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
9. <span id="xdx_825_zvOkPjNjVYbc">Debt</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 31, 2020, and later amended on March 31, 2023, the Company executed a Revolving Promissory Note (&#8220;Note&#8221;) with DSS,
a related party, which accrues interest at a rate of <span id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20230331__us-gaap--DebtInstrumentAxis__custom--RevolvingPromissoryNoteMember_zuUBJvMCB1D7"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2023-03-31_custom_RevolvingPromissoryNoteMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.25</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
and is due in full at the maturity date of <span id="xdx_907_eus-gaap--DebtInstrumentMaturityDate_dd_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--RevolvingPromissoryNoteMember_zv495TGu08Vi"><ix:nonNumeric contextRef="From2023-01-012023-03-31_custom_RevolvingPromissoryNoteMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">March
31, 2024</ix:nonNumeric></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The revolving nature of this Note permits
for principal amounts borrowed to be repaid and reborrowed. <span id="xdx_909_eus-gaap--DebtDefaultLongtermDebtDescriptionOfNoticeOfDefault_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--RevolvingPromissoryNoteMember_zs8MAykuk7tj"><ix:nonNumeric contextRef="From2023-01-012023-03-31_custom_RevolvingPromissoryNoteMember" name="us-gaap:DebtDefaultLongtermDebtDescriptionOfNoticeOfDefault">In
the case of default, at DSS&#8217;s option, (i) eighteen percent (18%) per annum, or (ii) such lesser rate of interest as Lender in its
sole discretion may choose to charge; but never more than the Maximum Lawful Rate.</ix:nonNumeric></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DSS
has not established a maximum borrowing amount and intends to continue to fund the operations of the Company through a year from the
date these financial statements were available to be issued. As of March 31, 2023 and December 31, 2022, this Note has an outstanding
balance, including interest of $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_c20230331_zj0LuSnTzf94" title="Outstanding balance, including interest"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,008,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and <span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_c20221231_zmvODnojziL6" title="Outstanding balance, including interest"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,529,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_803_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zbKNOhCfXE94" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
10. <span id="xdx_82F_zUXganmVlNu7">Stockholders&#8217; Equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 23, 2021, the Company, the Company&#8217;s Board of Directors approved the total number of shares of Common Stock to be <span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_iI_c20210923__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zZfQue2LNov3" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-09-23_srt_BoardOfDirectorsChairmanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,000,000,000</ix:nonFraction></span>
shares with a par value of $<span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20210923__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zoo7rhQF5ghe" title="Common stock par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-09-23_srt_BoardOfDirectorsChairmanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span>. Each
share of Common Stock when issued, shall have one (1) vote on all matters presented to the stockholders. Our Amended and Restated Articles of Incorporation authorize us to issue up to <span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_c20230331__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zhVHcoGs4tf" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-03-31_srt_BoardOfDirectorsChairmanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,000,000,000</ix:nonFraction></span> shares of Common Stock,
$<span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230331__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zRCbHfeSZXHf" title="Common stock par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-03-31_srt_BoardOfDirectorsChairmanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span> par value per share, and <span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_c20230331__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zirSEAKoq2Xl" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-03-31_srt_BoardOfDirectorsChairmanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000,000</ix:nonFraction></span> shares of preferred stock, par value $<span id="xdx_90D_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20230331__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zYj2CBBVokk2" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-03-31_srt_BoardOfDirectorsChairmanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span> per share. As of December 31, 2022, there were
<span id="xdx_90C_eus-gaap--CommonStockSharesIssued_iI_c20221231__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zmBLBfIrkdW5" title="Common stock, shares issued"><span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_iI_c20221231__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zzyv6QBLAtO2" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-12-31_srt_BoardOfDirectorsChairmanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-12-31_srt_BoardOfDirectorsChairmanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">125,073,621</ix:nonFraction></ix:nonFraction></span></span> shares of our Common Stock and <span id="xdx_90C_eus-gaap--PreferredStockSharesIssued_iI_do_c20221231__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zza7rDYzbmu5" title="Preferred stock, shares issued"><span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20221231__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zLeIUCP9QFQ2" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-12-31_srt_BoardOfDirectorsChairmanMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-12-31_srt_BoardOfDirectorsChairmanMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></span></span> shares of preferred stock issued and outstanding. On May 11, 2023, the Company effected
a forward split. As a result, there were <span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_c20230511__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zCx6sDv8e111" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-05-11_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,877,282,251</ix:nonFraction></span> shares of our Common Stock and <span id="xdx_90B_eus-gaap--PreferredStockSharesIssued_iI_do_c20230511__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_znj1qlMbWG6d" title="Preferred stock, shares issued"><span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20230511__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zTNwSEegatod" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-05-11_us-gaap_SubsequentEventMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-05-11_us-gaap_SubsequentEventMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></span></span> shares of preferred stock issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_80D_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zrbITywKloki" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
11. <span id="xdx_827_zf0EomlVQZC6">Related Party Transactions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and Development Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on Shareholders Agreement entered into on April 26, 2017, the Company would fund the scientific operations of GRDG, a company involved
in research and development of biomedical products which is a minority stockholder of two of the Company&#8217;s subsidiaries and is
owned by Daryl Thompson, a director of many subsidiaries of the Company, to do the development and research works on the biomedical products
for the Company. As of March 31, 2023, this funding approximates $<span id="xdx_903_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20230101__20230331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GRDGscienceLLCMember_zMgYBTYQWtP7" title="Payment in funding of research and development"><ix:nonFraction name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" contextRef="From2023-01-012023-03-31_custom_GRDGscienceLLCMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,000</ix:nonFraction> </span>per month, and incurred approximately $<span id="xdx_901_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GRDGscienceLLCMember_z7qVznlEjroe" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-03-31_custom_GRDGscienceLLCMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">129,000</ix:nonFraction></span> in expenses. On
March 31, 2023 and March 31, 2022, the Company owed this related party $<span id="xdx_902_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20230101__20230331_zxj1qUuxOQ4k" title="Related party owed transaction"><span id="xdx_908_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20220101__20220331_zr8Sak1UglYa" title="Related party owed transaction"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></ix:nonFraction></span></span> and had prepaid monthly fees approximating $<span id="xdx_90E_eus-gaap--PrepaidExpenseCurrentAndNoncurrent_iI_c20230331_zdjBbtRg6Lx6" title="Prepaid monthly fees"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrentAndNoncurrent" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,000</ix:nonFraction> </span>and $<span id="xdx_901_eus-gaap--PrepaidExpenseCurrentAndNoncurrent_iI_c20220331_zsupyVW5PqB2" title="Prepaid monthly fees"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrentAndNoncurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,000</ix:nonFraction></span>,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
and Administrative Costs</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are certain general and administrative costs incurred by DSS, a related party on behalf of the Company which are passed through to the
Company on a monthly basis. These costs consist of primarily payroll costs for certain DSS employees and are allocated based on estimated
time spent on behalf of the Company. These costs approximate $<span id="xdx_906_eus-gaap--LaborAndRelatedExpense_c20230101__20230331_zojFxxmWo0xg" title="Related costs for employees"><ix:nonFraction name="us-gaap:LaborAndRelatedExpense" contextRef="From2023-01-01to2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,000</ix:nonFraction></span> per month. As of March 31, 2023, the Company incurred $<span id="xdx_90E_eus-gaap--GeneralAndAdministrativeExpense_c20230101__20230331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zWhTU71wDqE" title="General and administrative expense"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-012023-03-31_us-gaap_RelatedPartyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,000</ix:nonFraction></span> in
related expenses. As of March 31, 2022, the Company incurred approximately $<span id="xdx_90D_eus-gaap--GeneralAndAdministrativeExpense_c20220101__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z5ttMp7WAQ06" title="General and administrative expense"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-01-012022-03-31_us-gaap_RelatedPartyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,000</ix:nonFraction></span> in related expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 79 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_003" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IMPACT
Biomedical, Inc. and Subsidiaries</b></span></p>

<p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_803_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zdZObhLJsKj9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
12. <span id="xdx_82E_zpi1260TjC8d">Commitments and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 15, 2018, the Company entered into Royalty Agreement with Chemia Corporation (&#8220;Chemia&#8221;) pursuant to which Chemia
transferred to the Company all of its right to 3F (Functional Fragrance Formulation). This agreement has a 20-year term and auto
renews for a period of 1 year unless mutually agreed upon by both parties. 3F consists of 3F Mosquito Repellant and 3F Anti-Viral
formulations. Based on the Royalty Agreement, the Company should cover all the costs to prepare and finalize necessary patent
application and other intellectual property related to 3F. Chemia agreed to support the Company in efforts leading to development of
3F intellectual property and it&#8217;s licensing. Based on Royalty Agreement any payments received from development, sales,
licensing or transfer of 3F technology will be paid <span id="xdx_907_ecustom--RoyaltyPercentage_dp_uPure_c20180814__20180815__us-gaap--TypeOfArrangementAxis__custom--RoyaltyAgreementMember_za9Fvb7DQAua" title="Royalty percentage"><ix:nonFraction name="IMPB:RoyaltyPercentage" contextRef="From2018-08-142018-08-15_custom_RoyaltyAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></span>%
to the Company and <span id="xdx_900_ecustom--RoyaltyPercentage_dp_uPure_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--RoyaltyAgreementMember__dei--LegalEntityAxis__custom--ChemiaCorporationMember_z5vydKOIQZI8" title="Royalty percentage"><ix:nonFraction name="IMPB:RoyaltyPercentage" contextRef="From2023-01-012023-03-31_custom_RoyaltyAgreementMember_custom_ChemiaCorporationMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></span>%
to Chemia. On November 27, 2018, Company and Chemia signed an Addendum to Royalty Agreement (&#8220;Addendum&#8221;), according to
which the Company granted Chemia a royalty-based limited license for purposes of making and selling fragrances embodying the 3F
technology. Based on the Addendum, Chemia should pay the Company <span id="xdx_904_ecustom--SaleOfRoyaltyPercentage_dp_uPure_c20181126__20181127__us-gaap--TypeOfArrangementAxis__custom--RoyaltyAgreementMember_zZIO8sFf8Up5" title="Net sales  royalty"><ix:nonFraction name="IMPB:SaleOfRoyaltyPercentage" contextRef="From2018-11-262018-11-27_custom_RoyaltyAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>%
of net sales in royalty. On November 8, 2019, both companies entered into Amendment no.1 to Royalty Agreement, based on which
certain expenses bore by the Company towards patent application and licensing should be reimbursed to the Company before any royalty
payments are made. For the three months ended March 31, 2023 and 2022, there were no reimbursements or royalties paid to the
Company and the Company cannot be assured that Chemia&#8217;s efforts will end up in any future sales of the technology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 15, 2022, the Company and its subsidiaries, Global BioLife, Inc. (&#8220;Global&#8221;), and Impact BioLife Sciences, Inc. (&#8220;BioLife
Sciences&#8221;), and GRDG entered into a Licensing Proceeds Distribution Agreement (&#8220;GRDG Agreement&#8221;), whereas GRDG would
transfer its <span id="xdx_908_ecustom--SaleOfRoyaltyPercentage_dp_uPure_c20220214__20220215__us-gaap--TypeOfArrangementAxis__custom--GlobalAndBioLifeSciencesMember_z26GQVGAYaZd" title="Sale of royalty percentage"><ix:nonFraction name="IMPB:SaleOfRoyaltyPercentage" contextRef="From2022-02-142022-02-15_custom_GlobalAndBioLifeSciencesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">20</ix:nonFraction></span>% equity position in both Global and BioLife Sciences to the Company in exchange for 20% interest in Global and/or BioLife
Science revenue received from the exclusive or non-exclusive licensing of and/or the sale of Global Intellectual Property to a Third
Party, net of specific costs. As of the date of this report, no contingent liability has been recognized under the GRDG Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 19, 2022, Impact BioMedical entered into a License Agreement (&#8220;Equivir License&#8221;) with ProPhase Labs, Inc. (&#8220;ProPhase&#8221;)
where the ProPhase is granted the right, amongst other things, to develop, commercialize, and sell the Company&#8217;s Equivir technology.
In exchange, the Licensee shall pay the Company a royalty of <span id="xdx_904_ecustom--SaleOfRoyaltyPercentage_dp_uPure_c20220318__20220319__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zcDIe4uEolQa" title="Sale of royalty percentage"><ix:nonFraction name="IMPB:SaleOfRoyaltyPercentage" contextRef="From2022-03-182022-03-19_custom_LicenseAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.5</ix:nonFraction></span>% of net sales. Under the terms of the Equivir Agreement, the Company
shall reimburse ProPhase for <span id="xdx_90C_ecustom--DevelopmentCostPercent_dp_c20220319__20220319__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zrr2mSM4isa7" title="Development cost, percent"><ix:nonFraction name="IMPB:DevelopmentCostPercent" contextRef="From2022-03-192022-03-19_custom_LicenseAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></span>% of the development costs provided that the development costs shall not exceed $<span id="xdx_906_eus-gaap--CostsIncurredDevelopmentCosts_c20220318__20220319__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zBsePHomEbN7" title="Development costs"><ix:nonFraction name="us-gaap:CostsIncurredDevelopmentCosts" contextRef="From2022-03-182022-03-19_custom_LicenseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,250,000</ix:nonFraction></span>. As of March
31, 2023, no liability has been recorded in relation to the Equivir License as development of the Equivir technology has not begun and
no reasonable amount can be estimated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-03-31" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_804_eus-gaap--SubsequentEventsTextBlock_z2Sz8xAAJSI" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
13. <span id="xdx_820_zURC4ecPyPBa">Subsequent Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has evaluated all subsequent events and transactions through June 20, 2023, the date that the consolidated financial statements
were available to be issued and noted no subsequent events requiring financial statement recognition or disclosure.</span></p>

</ix:nonNumeric><p id="xdx_81D_zWRYyIueYZd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>


<!-- Field: Page; Sequence: 80 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_003" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART
II</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INFORMATION
NOT REQUIRED IN PROSPECTUS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    11.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Change in Auditors</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">On
June 29, 2022, the Company&#8217;s board of directors approved replacing Turner Stone as our independent registered public accounting
firm, with Grassi &amp; Co. CPAs, P.C. (the &#8220;New Accountant&#8221;) as our independent registered public accounting firm, effective
July 1, 2022. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">For the year ended December
31, 2021, and through the interim period ended September 30, 2022, there were no &#8220;disagreements&#8221; (as such term is defined
in Item 304 of Regulation S-K) with Turner Stone on any matter of accounting principles or practices, financial statement disclosure,
or auditing scope or procedures, which disagreements, if not resolved to the satisfaction of the Turner Stone, would have caused them
to make reference thereto in their reports on the financial statements for such periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Turner Stone&#8217;s audit report on our financial statements for the
year ended December 31, 2021 contained no adverse opinion or disclaimer of opinion, nor was it qualified or modified as to uncertainty,
audit scope or accounting principles.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We authorized the former
accountants to respond fully and without limitation to all requests of the New Accountant concerning all matters related to the audited
periods by the former accountants, including with respect to the subject matter of each reportable event.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Prior to retaining the
New Accountant, the Company did not consult with the New Accountant regarding either: (i) the application of accounting principles to
a specified transaction, either contemplated or proposed, or the type of audit opinion that might be rendered on the Company&#8217;s
financial statements; or (ii) any matter that was the subject of a &#8220;disagreement&#8221; or a &#8220;reportable event&#8221; (as
those terms are defined in Item 304 of Regulation S-K).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-size: 10pt"><b>Item 13.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt"><b>Other Expenses of Issuance and Distribution.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth an itemization of all estimated expenses in connection with the issuance and distribution of the securities
to be registered. All of the fees set forth below are estimates except for the SEC registration fee and transfer and distribution agent
fees and expenses:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Item</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 82%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Registration
    Statement filing fee</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">10.05</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Accountants
    fees and expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">15,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Legal
    fees and expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">75,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Printing</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Transfer
    and distribution agent fees and expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Miscellaneous</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">100,010.05</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    14.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Indemnification
    of Directors and Officers.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the provisions of the Amended and Restated Articles of Incorporation of the Company, as amended, as of the date of this Registration
Statement, the liability of directors and officers of the Company shall be eliminated or limited to the fullest extent permitted by the
Nevada Revised Statutes (&#8220;NRS&#8221;). If the NRS is amended to further eliminate or limit or authorize corporate action to further
eliminate or limit the liability of directors or officers, the liability of directors and officers of the Corporation shall be eliminated
or limited to the fullest extent permitted by the NRS, as so amended from time to time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    15.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
    Sales of Unregistered Securities.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    16.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibits
    and Financial Statement Schedules.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
the Exhibit Index immediately preceding the signature page hereto, which is incorporated by reference as if fully set forth herein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    Statement Schedules</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
financial statement schedules are provided because the information called for is not required or is shown either in our consolidated
financial statements or notes thereto.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    17.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Undertakings.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
    The undersigned registrant hereby undertakes to file, during any period in which offers or sales are being made, a post-effective
    amendment to this registration statement: (i) To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;
    (ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most
    recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information
    set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered
    (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high
    end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule
    424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering
    price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration statement; and (iii) To
    include any material information with respect to the plan of distribution not previously disclosed in the registration statement
    or any material change to such information in the registration statement.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    undersigned registrant hereby undertakes that, for the purpose of determining any liability under the Securities Act of 1933, each
    such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and
    the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    undersigned registrant hereby undertakes to remove from registration by means of a post-effective amendment any of the securities
    being registered which remain unsold at the termination of the offering.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 81; Options: NewSection; Value: 48 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_011" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration
    statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold
    to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and
    will be considered to offer or sell such securities to such purchaser:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule
    424 (&#167; 230.424 of this chapter);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by
    the undersigned registrant;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant
    or its securities provided by or on behalf of the undersigned registrant; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    other communication that is an offer in the offering made by the undersigned registrant to the purchaser.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insofar
    as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling
    persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion
    of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act of 1933
    and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment
    by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense
    of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities
    being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent,
    submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed
    in the Securities Act of 1933 and will be governed by the final adjudication of such issue.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    undersigned registrant hereby undertakes that:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed
    as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant
    to Rule 424(b) (1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the
    time it was declared effective.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of
    prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such
    securities at that time shall be deemed to be the initial bona fide offering thereof.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 82; Value: 48 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_011" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXHIBIT
INDEX</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    <br/>
    Number</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    Description</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1834105/000149315221024112/ex3-1.htm" style="-sec-extract: exhibit">Amended and Restated Articles of Incorporation of Impact BioMedical Inc. dated July 29, 2020</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1834105/000149315221003571/ex3-2.htm" style="-sec-extract: exhibit">Certificate
    of Amendment to the Amended and Restated Articles of Incorporation of Impact BioMedical Inc.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1834105/000149315221024112/ex3-3.htm" style="-sec-extract: exhibit">Certificate of Amendment to the Amended and Restated Articles of Incorporation of Impact BioMedical Inc.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">3.4**</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1834105/000149315223021957/ex3-4.htm" style="-sec-extract: exhibit">Certificate of Amendment to the Amended and Restated Articles of Incorporation of Impact BioMedical Inc.</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex5-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of Sichenzia Ross Ference LLP</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1834105/000149315221024112/ex10-1.htm" style="-sec-extract: exhibit">Share Exchange Agreement dated as of April 27, 2020, among Document Security Systems, Inc., DSS BioHealth Security, Inc., Singapore eDevelopment Limited and Global BioMedical Pte Ltd.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1834105/000149315222021049/ex10-2.htm" style="-sec-extract: exhibit">Subscription Agreement dated December 19, 2020, between the Company and BioMed Technologies Asia Pacific Holdings Limited</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1834105/000149315222023938/ex10-3.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Promissory Note with Dustin Michael Crum dated February 21, 2021</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1834105/000149315222017756/ex10-4.htm" style="-sec-extract: exhibit">Stock Purchase Agreement dated March 15, 2021 between the Company and Vivacitas Oncology Inc.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1834105/000149315222017756/ex10-5.htm" style="-sec-extract: exhibit">Convertible Promissory Note dated May 14, 2021</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1834105/000149315222021049/ex10-6.htm" style="-sec-extract: exhibit">Revolving Promissory Note dated December 31, 2020</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1834105/000149315222021049/ex10-7.htm" style="-sec-extract: exhibit">Royalty Agreement by and between Global BioLife Inc. and Chemia Corporation, dated August 15, 2018</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1834105/000149315222021049/ex10-8.htm" style="-sec-extract: exhibit">Addendum to Royalty Agreement by and between Global BioLife Inc. and Chemia Corporation, dated November 27, 2018</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1834105/000149315222021049/ex10-9.htm" style="-sec-extract: exhibit">Distribution Agreement by and between BioMed Technologies Asia Pacific Holdings Limited and Impact BioMedical Inc., dated December 9, 2020</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1834105/000149315222021049/ex10-10.htm" style="-sec-extract: exhibit">Global BioLife, Inc. Stockholders&#8217; Agreement among Global BioLife, Inc., Global BioMedical, Inc., Holista Colltech Limited, and GRDG Sciences, LLC, dated April 26, 2017</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1834105/000149315222021049/ex10-11.htm" style="-sec-extract: exhibit">Amendment No. 1 to Global BioLife, Inc. Stockholders&#8217; Agreement among Global BioLife, Inc., Global BioMedical, Inc., Holista Colltech Limited, and GRDG Sciences, LLC, dated May 22, 2018</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1834105/000149315222017756/ex10-12.htm" style="-sec-extract: exhibit">Amendment No. 2 to Global BioLife, Inc. Stockholders&#8217; Agreement among Global BioLife, Inc., Global BioMedical, Inc., Holista Colltech Limited, and GRDG Sciences, LLC, dated August 2020</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1834105/000149315222021049/ex10-13.htm" style="-sec-extract: exhibit">Impact BioLife Science, Inc. Stockholders Agreement among Impact BioLife Science, Inc., Impact BioMedical Inc. and GRDG Sciences, LLC, dated December 11, 2020</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">10.14**</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1834105/000149315222023938/ex10-14.htm" style="-sec-extract: exhibit">Licensing Proceeds Distribution Agreement with GRDG Sciences, LLC dated May 16, 2022</a></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1834105/000149315222021049/ex10-16.htm" style="-sec-extract: exhibit">Amendment No. 1 to Revolving Promissory Note dated December 31, 2021.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1834105/000149315222021049/ex10-17.htm" style="-sec-extract: exhibit">Amendment No. 2 to Revolving Promissory Note dated March 31, 2022.</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1834105/000149315222021049/ex10-18.htm" style="-sec-extract: exhibit">License Agreement with ProPhase Labs, Inc. dated March 17, 2022.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1834105/000149315222021049/ex10-19.htm" style="-sec-extract: exhibit">License Agreement with ProPhase Labs, Inc. dated July 18, 2022.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1834105/000149315222021049/ex10-20.htm" style="-sec-extract: exhibit">Licensing Proceeds Distribution Agreement with GRDG Sciences, LLC dated February 15, 2022.</a></span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">16.1**</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1834105/000149315222023938/ex16-1.htm" style="-sec-extract: exhibit">Letter from Freed Maxick CPAs, P.C.</a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">16.2</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex16-2.htm">Letter from Turner Stone &amp; Company LLP</a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.1in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1834105/000149315222017756/ex21-1.htm" style="-sec-extract: exhibit">List of subsidiaries of Impact BioMedical Inc.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex23-1.htm">Consent of Turner, Stone &amp; Company L.L.P.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">23.2</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex23-2.htm">Consent of Grassi &amp; Co., CPAs, P.C.</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.3*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex5-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Sichenzia Ross Ference LLP (included as part of Exhibit 5.1).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">107**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1834105/000149315222017756/ex107.htm" style="-sec-extract: exhibit">Filing Fee Table</a></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in">*</td>
    <td style="font: 10pt Times New Roman, Times, Serif">To
                                            be filed by amendment</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Previously
    filed</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 83; Value: 48 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc_011" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">Pursuant to the requirements of
the Securities Act, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto
duly authorized, in the city of West Henrietta, on the <span style="background-color: white">24th</span> day of July, 2023.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IMPACT
    BIOMEDICAL INC.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Frank D. Heuszel</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Frank
    D. Heuszel </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    July 24, 2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed below by the following persons
in the capacities indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Signature</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 57%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 14%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Frank D. Heuszel</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Frank
    D. Heuszel</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer (Principal Executive Officer),</span></p>
                                                                             <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President and Director</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">July
                                            24, 2023</p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    *</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Heng
    Fai Ambrose Chan </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">July
                                            24, 2023</p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    *</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Todd
    D. Macko </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> (Principal Financial Officer and Principal
Accounting Officer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">July
                                            24, 2023</p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    *</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">TJ Leonardo</p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Operating Officer and Secretary</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">July
                                            24, 2023</p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    *</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Elise Brownell </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">July
                                            24, 2023</p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><i>/s/</i> *</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">Melissa Sims</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">Director</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">July 24, 2023</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
    By: </span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 43%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Frank D. Heuszel</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 52%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Frank
    D. Heuszel</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Attorney-in-fact</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 84; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></p>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>forms-1a_001.jpg
<TEXT>
begin 644 forms-1a_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 60!$P# 2(  A$! Q$!_\0
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M0!F?VEJ7_/6;_OV?\:/[2U+_ )ZS?]^S_C6G_9K_ //8?]\T?V:__/8?]\T
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M 'S0!F?VEJ7_ #UF_P"_9_QH_M+4O^>LW_?L_P"-:?\ 9K_\]A_WS1_9K_\
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M_/8?]\T?V:__ #V'_?- &9_:6I?\]9O^_9_QH_M+4O\ GK-_W[/^-:?]FO\
M\]A_WS1_9K_\]A_WS0!F?VEJ7_/6;_OV?\:/[2U+_GK-_P!^S_C6G_9K_P#/
M8?\ ?-']FO\ \]A_WS0!F?VEJ7_/6;_OV?\ &C^TM2_YZS?]^S_C6G_9K_\
M/8?]\T?V:_\ SV'_ 'S0!F?VEJ7_ #UF_P"_9_QH_M+4O^>LW_?L_P"-:?\
M9K_\]A_WS1_9K_\ /8?]\T 9G]I:E_SUF_[]G_&C^TM2_P">LW_?L_XUI_V:
M_P#SV'_?-']FO_SV'_?- &9_:6I?\]9O^_9_QH_M+4O^>LW_ '[/^-:?]FO_
M ,]A_P!\T?V:_P#SV'_?- &9_:6I?\]9O^_9_P :/[2U+_GK-_W[/^-:?]FO
M_P ]A_WS1_9K_P#/8?\ ?- &9_:6I?\ /6;_ +]G_&C^TM2_YZS?]^S_ (UI
M_P!FO_SV'_?-']FO_P ]A_WS0!F?VEJ7_/6;_OV?\:/[2U+_ )ZS?]^S_C6G
M_9K_ //8?]\T?V:__/8?]\T 9G]I:E_SUF_[]G_&C^TM2_YZS?\ ?L_XUI_V
M:_\ SV'_ 'S1_9K_ //8?]\T 9G]I:E_SUF_[]G_ !H_M+4O^>LW_?L_XUI_
MV:__ #V'_?-']FO_ ,]A_P!\T 9G]I:E_P ]9O\ OV?\:/[2U+_GK-_W[/\
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M?]^S_C6G_9K_ //8?]\T?V:__/8?]\T 9G]I:E_SUF_[]G_&C^TM2_YZS?\
M?L_XUI_V:_\ SV'_ 'S1_9K_ //8?]\T 9G]I:E_SUF_[]G_ !H_M+4O^>LW
M_?L_XUI_V:__ #V'_?-']FO_ ,]A_P!\T 9G]I:E_P ]9O\ OV?\:/[2U+_G
MK-_W[/\ C6G_ &:__/8?]\T?V:__ #V'_?- &9_:6I?\]9O^_9_QH_M+4O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1W7_>7_P!"
M%%'=?]Y?_0A0!GS=9O\ @7_H J+1_P#CU;_KO)_)*EFZS?\  O\ T 5%H_\
MQZM_UWD_DE ',:I_Q_W?^]_[+73:?_JX/^!?^@-7,ZI_Q_W?^]_[+73:?_JX
M/^!?^@-0!K4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4=U_WE_P#0A11W7_>7_P!"% &?-UF_X%_Z *BT?_CU;_KO)_)*EFZS?\"_
M] %1:/\ \>K?]=Y/Y)0!S&J?\?\ =_[W_LM=-I_^K@_X%_Z U<SJG_'_ '?^
M]_[+73:?_JX/^!?^@-0!K4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4=U_P!Y?_0A11W7_>7_ -"% &?-UF_X%_Z *BT?_CU;_KO)
M_)*EFZS?\"_] %1:/_QZM_UWD_DE ',:I_Q_W?\ O?\ LM=-I_\ JX/^!?\
MH#5S.J?\?]W_ +W_ ++73:?_ *N#_@7_ * U &M1110 4444 %%%% !1110
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MWHKPC_AI3]G3_HX/X(?^'9\!?_+FC_AI3]G3_HX/X(?^'9\!?_+FG_9N:?\
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M $*LR_\ "#'_ /SN#Z]@O^@[+_\ PXX'_P":3W>BO"/^&E/V=/\ HX/X(?\
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M_1P?P0_\.SX"_P#ES1_PTI^SI_T<'\$/_#L^ O\ Y<T?V;FG_0JS+_P@Q_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4=U_WE_]"%%'=?\ >7_T(4 9\W6;_@7_ * *BT?_ (]6
M_P"N\G\DJ6;K-_P+_P! %1:/_P >K?\ 7>3^24 <QJG_ !_W?^]_[+73:?\
MZN#_ (%_Z U<SJG_ !_W?^]_[+73:?\ ZN#_ (%_Z U &M1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P#"++O_ )VA]4PO\N(_\+L7_P#+CW7_ (:E_:._Z+[\;?\ PZGC7_Y<4?\
M#4O[1W_1??C;_P"'4\:__+BO"J*/[=S;_H*A_P"$67?_ #M#ZIA?Y<1_X78O
M_P"7'NO_  U+^T=_T7WXV_\ AU/&O_RXH_X:E_:._P"B^_&W_P .IXU_^7%>
M%44?V[FW_05#_P (LN_^=H?5,+_+B/\ PNQ?_P N/=?^&I?VCO\ HOOQM_\
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MH[_HOOQM_P##J>-?_EQ7A5%']NYM_P!!4/\ PBR[_P"=H?5,+_+B/_"[%_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(Y$D8(DL,CLVP1I- \ADV/)Y:QI(7,A6*4B,*9&V%54L,%^V5B@12PDD6%,
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M^1HU7_<T?_U'M(J?X?\ _(U:7_W$/_37>5!XR_Y&C5?]S1__ %'M(J?X?_\
M(U:7_P!Q#_TUWE?A\_\ DXU3_LLJ_P#ZL<2?ITO^2.J?]D['_P!0H'^I#_P2
M*_Y1N?L@_P#9-+C_ -2KQ17Z5U^:G_!(K_E&Y^R#_P!DTN/_ %*O%%?I77\B
M>)?_ "<SQ'_[+KBK_P!:#.C^H.#/^2/X4_[)KA__ -4V "BBBOBSZ0**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *.Z_[R_P#H0HH[K_O+_P"A"@#/FZS?\"_] %1:/_QZM_UW
MD_DE2S=9O^!?^@"HM'_X]6_Z[R?R2@#F-4_X_P"[_P![_P!EKIM/_P!7!_P+
M_P! :N9U3_C_ +O_ 'O_ &6NFT__ %<'_ O_ $!J -:BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I!]]?JO_ +-2T@^^OU7_
M -FK*M_#EZP_].4P[?/_ -)D?YOG_!3G_DZ3Q-_V!]!_]&:G7YXI]T?C_,U^
MAW_!3G_DZ3Q-_P!@?0?_ $9J=?GBGW1^/\S7^IU3_<>'_P#LC>"?_5!$_@/$
M?[[F_P#V/LZ_]3ICJ***YC,**** "BBB@ HHHH *^P?^">7_ "?U^Q9_V=#\
M#_\ U8>A5\?5]@_\$\O^3^OV+/\ LZ'X'_\ JP]"KQ^(O^2>X@_[$&??^J3.
M#U,B_P"1]D/_ &/,G_\ 5G@C^D#_ (.=?^21?LC_ /95_B7_ .H/95_']7]@
M/_!SJ,_"+]D?V^*_Q+_]0>S_ ,#^1K^/W(Z?T/\ GM^?'6OSCP.E&/AMD[E*
M*2QF?)MR22:S>+:;;232:;3::33M9H^X\6$Y<<9Q&*<I>RR-\L4Y2L\JG%/E
MBG*SDG%/ELY)Q3<DTJUVR1VMT[$!8[>:1R2=JHL;,Q(Z 8SD\#G'>O[S/V_$
M?PI_P0P\2:1XBB'AO4=+_96_9M\*7^GZFZ6-W:^(9]4^"VB)H5S;D9BU)M5N
MX])6SW.SW<\=NA8S87^/_P#8(_9*\5_ML?M/?#OX(Z!I=S>>%+C5K#Q!\9]<
MC6[;3_"GP;TG4K0^.K^_GM 88-1U:R)\->$8+QUCN?&=_I"+')]DNA!_4%_P
M<:_M#:!X"_9>\!?LP>'+VTA\3_'/QKH?BK7=#L;93;6?P=^$EU9:FEQ<+9S^
M9I\ES\3V^&MEX>9K!]*O+#2_$-O-/9?V7:SUX/B9B*><<>^%_#& _>8_!YU'
MB''4J:2^J8.G5P>(A4JS@_W#=#+<3B*OMHTG"$L-4E=5Z4Y^IP%1EEO!_'F?
MUI..&Q64RR?"-J4'7QLOK5"M3I1;3J^SJXRC&G*DJDJLX5H1Y94:G)_&1I.K
MZOX<UC2O$?AS5=3\/>)-!U33M<\/>(]#U"[TC7?#VOZ+=+J&B:_HNJZ?+;W^
MFZSHVH11WNDZI8W5IJ&DWJQZEI]W;WMM"]?U&_L7_P#!QOJFA6NF>"?VX? &
MH>+(;9([.V^./PQ32F\13 .!;W7C?X73KH6E7UVBO,-3\0_#Z[L7:.WM([3X
M?RWEY/))_+!YT?FI &!GE5GBA',TBJ'9FCB&7=0L<K952"L4Q&?)EV/W ^X]
M00RD$9!#*2&4CD,"5(Y!P17ZCQ3P9POQIAJ&'S_!1KRH*:P&.P=:&%S'#.26
ME#%*%53HQ<$_J\J=2C93M"#:G#X#A_BS.N&*\ZN4XQ4W6<98C"UXQQ&$Q$8M
MPO4P\I1DYZ2A[:,XS3BHJ5HRIO\ OD^*G[%__!-+_@KA\.KWXU?"R;P,?$FK
MR7-U_P -!?!"U\/^&_B1!XHFTR'R[#XNZ!=:7:W/B6]CMQ9Q:AX8^+>CV_BK
M3K",2>&M5\)W$Z:O+_%E^UO^R;\6?V+/C?XB^!7QATZTCUK2+*RU_P .^)M-
MDW^'?B#X(UB]U33_  _XV\,>;<7-]!8ZC<Z)J]E?Z-JYAUOP_J>EW6GZHD\P
M%Y<?9_\ P1&^*GQ4^'?_  46^!7ACX<ZIK"^'/C#K&M^!_BSX2LHI;O1O%_@
MNR\">-/$D5]KNGB.:-+CX?ZGI,/B_1?$,*VNIZ(]MJ%BNIQ>'=?\4Z3KGZ=_
M\'/MAX='BW]BK4K86S>,+[0/C]I^H1I=S/J+^%]-U+X-2:$C:4MR8HK1=:UC
M7EM;]K(SW5P]U:K<2);K';_C_#,L]X!\1,+X=_VOB,_X<SK 5LPRFGC*LZN*
MRRK'!XS$4U1<?:NBJKR^KA<52C6EA:M/ZM7P^&P=6%95OTGB#^R^,.!*_&,<
MKP^39QE.8T<%F$\)1IT</CW5Q6$PU2=2,51YJDHX^C7A4E24Z;H5:<Y5(U54
MC_.Q^S7^TY\:_P!D?XJ:5\8O@3XQN/"OB[3[6ZTK4;6X7^T?"WBOPWJ(C_M'
MPOXU\-2LEEXF\/WK6UG*+*>6UN]-O[6QUW0M2TG7]*TG4[3^L_\ 92_X."OV
M5_C/H:_#G]L'P8OP!\3^(XO^$;\1ZWJ5I<^-?V>?$<&I6MO87J:I?:I:R^(_
M!>EZK]MN4NK#QWX9O_!6DZ08?MWQ#U/1G6_'\6,$\%T)6M9HKH0NZ3-;21SK
M"\:H\B.86<(\:21/*C$-&LL;R!5D0F96 ==J[F#KA,-\S!N%PI5B">"%96()
M"D$YK]0XO\-^&.,HTZV:8:MALSH4G3I9[E55T,S<()3HJM5A&I1QD</4BI4)
MN@\3[*-.E3Q-U1E#X+AKC/B+AB3H9=B)5\'4J/VV4YA"-?!3511ISI2IRITY
M8>[E62DI4J<95IRQ%.JH57/^TC]N[_@AI^SS^T-\.M2^-?[#FF>"OA5\5KO2
M;37_  UX,\"ZAI-C^SS\6M/!:XCM-#L-'B?P[X'U[6["=(_#?B3PA+IW@2>Y
M2UM/$^@3RW;^-M$_C'U?1M9\.:SK'ASQ)I.H>'_$GAO5]4\.^)?#VK1)!JGA
M[Q)H5]<:7K^@:I#%+/%%J>BZQ:7FF7T232*EQ:2A6(%?UM_\&T?Q0^)WB7P+
M^TK\(O$6JZKJ/P>^&&H?"_6OAK:ZA;O-HGA'Q)XUNOB/_P )MX<\/W5Y%*+.
MTU.WT3P[KM]X=M;Z/3+'4+F\\1:;I6F:AXJU[4-7_##_ (*^67AG3_\ @IE^
MV#!X1DM7T8?$G1[R7[!>?;[1O$6L_"_X<ZUXWW2R27+0WUOX]O?%<.I6MO/#
M;VNH?:K"6T22PA6'X/PRS;B/)^+N)_#7/<T_M_#</8)8[+\RQ=2=?&86E4KX
M5RI5L1.<JMJ^'Q5*JJ>,K5IX6I1Q2A.4)3C1^NX[P>2YGP]D'&N5Y?+)ZV<U
MIX3'9?1C2IX:M7HTL2E6IPITHTU&A6PM6#EAJ=*&)A5HRG:5->U_.2BD# C*
ME7!9T'ENDFYXY)(9$01LQ=TFBFA:--SB6&:/;OAE5 '(5AG#HLB$@C<CJ&1U
MSU5E(((X/U! _>'I9/1MR23T;<;<R2>K<;KF25XW7,E=7_)&FG9IIVO9IIVN
MU?5+2Z:OM=-7NFDM'=?]Y?\ T(44=U_WE_\ 0A6E+^+2_P"OM+_T[2(J?PZG
M_7NI_P"FZA_>MXU_Y5XK;_M%#X _]9H\.5_ SKO_ "#M>_[!^M?^DM]7]\WC
M7_E7BMO^T4/@#_UFCPY7\#.N_P#(.U[_ +!^M?\ I+?5^ >!?P>('_968W_U
M*S0_7O%G^+PG_P!DOA__ %&P9_?[_P %K/CG\5O@!_P3OOO$_P '/%M_X#\6
M>+_$GPW^%U[XNT.1[/Q1HWA;QGIU^?$+>%=8A9+KP]KE_;Z5%ID6O:?)!JVE
M6=Y>7FB7NFZU%IVIV7\!T>%C6),K%&L:1Q@D(B0PO;0HJ@A0L5L[P1* !'!(
M\*8C9E/]RO\ P<'_ /*-/0?^RT_ W_TU^(J_AM7H/H/Y5O\ 1_PU"EP;CL33
MI0AB,9Q#G$,55C&*J5X866 6&C4FHJ<XT/:U'2A.<H4W4G*G"$ISE/'Q=JU:
MW$>%HU*DI4<'DN3U,/2DVX4I8NEC(5W"+DXPE5=*FYRA&,IJ$(SE-0AR?V3?
M\&S?C#Q'K?[._P"T3\/]1O1=>&_ WQNT'Q!X9MI&NQ-ILGCOP;8/X@L8IGNY
M;=--:^\)IJ]M8V=C9!M2UOQ')J-QJ U?_0_Y0?VG]%TKP=^TG^TSX;T>)K70
MO"/[0WQW\/:1!)<SS/:Z-X<^*OB[2M-ADO+AIKF5H+"Q@C>[G>:X<H9I7DE+
M,W]3/_!L+_R2S]K7_LIWPO\ _4/UZOY?/VQ%+?M9?M>*I4,W[4?[284LP50Q
M^,WCG&YCPJY^\QX49)X%=7!%.%'Q?\6*%&$*5-QR"KR0C&$/:U?J$IU'&"A#
MFE*I*4GR)ZRN_>DY1Q7)U/#3P\K56ZE3FS>ESR;E/V5-8]0AS/FE9*$5;F=V
MHZ>['E_M8AUNX_8!_P""'&EZYX63_A'/'W@#]C[PWK>DZI821ZH-#^._QNTO
M16N->TV\6SNXY;73OC#\4I=0TIY[22R72(+>VNGEL+6ZD'\%&YC*)0TOFK(L
MHEEN9;FY$R.)!/)=R_OYKDNJRM<NWG-,#*6,@W#^\W]JN&7]HW_@A)KVJ^"X
MF UG]BCX._%>"SAFLM8FM(/A?H_P[^*GBCP[=WEK>0Z4^K:7%X2U;0-2,-Z)
M;?4K6_$%E=W&G3V;_P &".CJKKM =48;',L9+*"3',8;<S1$G,4K00M)&5<Q
M)NVCS? E4WA>.<=7J0CFM7BW&X?,Y<\8584H5L;B:5.H^:$Z=.>-JU924G&G
M6G%0FJDTCK\5Y576X.P-"+EE]/AO#XC!4:=-SBY^QPE%U*$8QG%2IT:<:LW1
MAS*-5N4HPO*70:'XH\4^&+;Q#9>&/%'B;PS9>+]!N?"GBZR\.>(=8T&S\6>%
M;V[LM0O/"_BFTTF]L[?Q%X:O+_3=.OKO0-9CO=)N;W3["[GLY+BSMI(L/&/Q
MYII8!HE((:>0Q0 CF>4,JF.$=97W.B[8PS;W5,;R%I<_(TF"45D1BH+$-*)#
M&-JY8[Q#*1A<?(V<<9_>O9PC-S5.$:E;DDYJG"-2LXQY*<G-0C.LXT_<@Y3J
MN-/W(.,/</R)5>>+C&HYPH\T9151SA1U]I.+BIRA2]Y^TG%QI>\_:33D^=K1
M4:2QRAFC;S%1BC,GS*KKC*LRY"L-RD@D'#QGI+&7DZU2U2DM8MR2DM8MQ?+)
M*2O%N,O=DDVXRTDHO05TVXIKFC9RC=<T>9<T;J]US1:E&Z7,G=76H4444#"B
MBB@ HHHH **** "KFF_\?\/_ %SF_P#:=4ZN:;_Q_P /_7.;_P!IU[_"O_)3
M</\ _8YRW_U*@>;G'_(IS+_L"Q'_ *;/C#QE_P C1JO^YH__ *CVD5/\/_\
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MWE_]"%%'=?\ >7_T(4 9\W6;_@7_ * *BT?_ (]6_P"N\G\DJ6;K-_P+_P!
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MFLH=7C8*\<@VR1NJO'(NUUPZ,K*RX=U*L"I5B"""0>/,<)+,,OQ^ C.-)X_
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MCNO^\O\ Z$**.Z_[R_\ H0H SYNLW_ O_0!46C_\>K?]=Y/Y)4LW6;_@7_H
MJ+1_^/5O^N\G\DH YC5/^/\ N_\ >_\ 9:Z;3_\ 5P?\"_\ 0&KF=4_X_P"[
M_P![_P!EKIM/_P!7!_P+_P! :@#6HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *0??7ZK_P"S4M(/OK]5_P#9JRK?PY>L/_3E
M,.WS_P#29'^;Y_P4Y_Y.D\3?]@?0?_1FIU^>*?='X_S-?H=_P4Y_Y.D\3?\
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MF44459 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MBBOBSZ0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%G:?4=5NX;:\ELM!T#38KWQ#XEU&&SO9=*\.Z7JFIK9W7V3R)/T,_P""@?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(/OK]5_]FI:0??7Z
MK_[-65;^'+UA_P"G*8=OG_Z3(_S?/^"G/_)TGB;_ + ^@_\ HS4Z_/%/NC\?
MYFOT._X*<_\ )TGB;_L#Z#_Z,U.OSQ3[H_'^9K_4ZI_N/#__ &1O!/\ ZH(G
M\!XC_?<W_P"Q]G7_ *G3'4445S&84444 %%%% !1110 4444 %%%% !1110
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M4GRNR=*M7F[WM&,WRMI*7\[).0YYRQ9CDLQ!8EC\SLSGENK,S'N2<FO[>?\
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MJ; !1117Q9](%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MS-2L?SS'H?H:_N3_ ."/QQ_P15U@^FD?MAG_ ,NSXBU_#5G(;_@0_2O[E/\
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M</\ _8YRW_U*@>;G'_(IS+_L"Q'_ *;/C#QE_P C1JO^YH__ *CVD5/\/_\
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MWE_]"%%'=?\ >7_T(4 9\W6;_@7_ * *BT?_ (]6_P"N\G\DJ6;K-_P+_P!
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M[WPP92JL",;7,P1L@_*QMY8+@(P)#^3/#*5R(YHGPX_M)_82\7Z7_P %5?\
M@C]\1?V1/%>HQ3?&/X8^!(?@;J&KZQ=R22VFM^%+.Q\2?LS?$^^D^QZKJ?\
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M&1[_ )'_  HY)>7_ (%#_P"3#V<_Y7^'^8M%)D>_Y'_"C(]_R/\ A1R2\O\
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MXFKEV+]K1J+"X^@I14.:=/#XF$5*E:;E$].%]X=[ZE /^WB#_P".4?;?#O\
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MT?;?#O\ T$X/_ B#_P".U\&;!_=7\E_^(HV#^ZOY+_\ $4?\1:R7_HW.0_\
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M#O\ T$X/_ B#_P".T?;?#O\ T$X/_ B#_P".U\&;!_=7\E_^(HV#^ZOY+_\
M$4?\1:R7_HW.0_\ AZSS_P"9@_U"J_\ 138G_P (*7^1]Y_;?#O_ $$X/_ B
M#_X[1]M\._\ 03@_\"(/_CM?!FP?W5_)?_B*-@_NK^2__$4?\1:R7_HW.0_^
M'K//_F8/]0JO_138G_P@I?Y'WG]M\._]!.#_ ,"(/_CM'VWP[_T$X/\ P(@_
M^.U\&;!_=7\E_P#B*-@_NK^2_P#Q%'_$6LE_Z-SD/_AZSS_YF#_4*K_T4V)_
M\(*7^1]Y_;?#O_03@_\  B#_ ..T?;?#O_03@_\  B#_ ..U\&;!_=7\E_\
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M_)?_ (BC8/[J_DO_ ,11_P 1:R7_ *-SD/\ X>L\_P#F8/\ 4*K_ -%-B?\
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M5XN_^)H_X86_:&_Z)7\5/_#5>+O_ (FO];3G^\W_ 'TW^-'/]YO^^F_QI?\
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M_P 37^MIS_>;_OIO\:.?[S?]]-_C1_Q'K@W_ *,QEO\ XG'$?_S('_$(L_\
M^CBXG_Q$\D_^;C_)+_X86_:&_P"B5_%3_P -5XN_^)H_X86_:&_Z)7\5/_#5
M>+O_ (FO];3G^\W_ 'TW^-'/]YO^^F_QH_XCUP;_ -&8RW_Q..(__F0/^(19
M_P#]'%Q/_B)Y)_\ -Q_DE_\ #"W[0W_1*_BI_P"&J\7?_$T?\,+?M#?]$K^*
MG_AJO%W_ ,37^MIS_>;_ +Z;_&CG^\W_ 'TW^-'_ !'K@W_HS&6_^)QQ'_\
M,@?\0BS_ /Z.+B?_ !$\D_\ FX_R2_\ AA;]H;_HE?Q4_P##5>+O_B:/^&%O
MVAO^B5_%3_PU7B[_ .)K_6TY_O-_WTW^-'/]YO\ OIO\:/\ B/7!O_1F,M_\
M3CB/_P"9 _XA%G__ $<7$_\ B)Y)_P#-Q_DE_P##"W[0W_1*_BI_X:KQ=_\
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M.?[S?]]-_C1S_>;_ +Z;_&OG_P#B/7!O_1F,M_\ $XXC_P#F0]?_ (A%G_\
MT<7$_P#B)Y)_\W'^27_PPM^T-_T2OXJ?^&J\7?\ Q-'_  PM^T-_T2OXJ?\
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M?^R;XS_]2^$C]GJ***^ /L0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "CN
MO^\O_H0HH[K_ +R_^A"@#/FZS?\  O\ T 5%H_\ QZM_UWD_DE2S=9O^!?\
MH J+1_\ CU;_ *[R?R2@#F-4_P"/^[_WO_9:Z;3_ /5P?\"_] :N9U3_ (_[
MO_>_]EKIM/\ ]7!_P+_T!J -:BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[O\ WO\ V6NFT_\ U<'_  +_ - :N9U3_C_N_P#>_P#9:Z;3_P#5P?\  O\
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M_C_N_P#>_P#9:Z;3_P#5P?\  O\ T!J -:BBB@ HHHH **** "BBB@ HHHH
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MJ*_E^HI?\0B\./\ HE,%_P"%6;__ #V*_P"(E<;?]#W$?^$^6_\ SJ/Z@?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1W7_>7_T(44=U_P!Y?_0A0!GS=9O^!?\
MH J+1_\ CU;_ *[R?R2I9NLW_ O_ $ 5%H__ !ZM_P!=Y/Y)0!S&J?\ '_=_
M[W_LM=-I_P#JX/\ @7_H#5S.J?\ '_=_[W_LM=-I_P#JX/\ @7_H#4 :U%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8_X)6_":WU_4O@YX>_X*=?L?Z[^U1I%WJ&AWGP5U&R\5>&?!4OC/2GN+;4O
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M:7V?;55NNU+ION=#1117GG0%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4=U_WE_P#0A11W7_>7_P!"% &?-UF_X%_Z
M *BT?_CU;_KO)_)*EFZS?\"_] %1:/\ \>K?]=Y/Y)0!S&J?\?\ =_[W_LM=
M-I_^K@_X%_Z U<SJG_'_ '?^]_[+73:?_JX/^!?^@-0!K4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !6'K/W8O]X?S-;E8>L_=B_P!X?S- '\*7_!PM_P I
M#5_[-Z^$/_I;XVK\.*_<?_@X6_Y2&K_V;U\(?_2WQM7X<5_H7X<_\D+PI_V(
M,J_]1ZY_%'&__)8\4_\ 8]Q/_J/@@HHHK[4^6"BBB@ HHHH _5;_ ((@_P#*
M5/\ 9*_Z_?CB?R_9D^-1_P ^O0\5^?/[0$*2_'7X[1R .K_&/XMJ01DKO\=^
M(4#J.0)4SOC?!,<BK(@#JI'V7_P2,^)WP^^#?_!1S]F/XD_%/Q?H/@+P%X>U
M+XK0:[XN\3W\>EZ#I$OB3X"_%7PGH8U+49OW-G'J7B/7=(TB&:8K$MU?P"1T
M0LZ^_P#CO]AS]BS4/B-XZ^*'Q+_X*V?LOK\._%?C?QCXUO\ 0O@;H^K?&CXL
MRV'B/7]3\4KX=\.>'/#:RWR:G+9SRZ7!XD_LS68["]^S6ZZ#?W>HVT*?FV99
MU@LAX[Q^)S"CF#ACN$<DPN#E@LIS+,9XNOALZXDJXG T)X# 8E1Q$X8O")TY
MXG"J2K0C6J0HU)R?V^#P.,S+A'!4,!5PT*M#B?-*N)=;-L%EKP^'K95DT*=>
MHL3F.#K3I.5"M*,J5*M*^&G&G^\Y4?:'QZ_:]UKX,^$O^"&7_!2OQ;X;M_B%
M\6;3X4_&3P#\25GU.QAUCXF>$-)T'2O -QJG]ORZ6C?\)3=:;XQ\9^+-#:ZF
MN=%T_P 3>)[RV07.FZGJNJW'SM\9/^";GPA_;2N_B7^TE_P3 ^/'A?XVQZWJ
M?B7XD_$C]D7Q]-8^%/CWX O_ !%K-UK&M:3H5AKL5A!K.@_VK?7.A^'T\4V5
MMIEQ;06D>@?$CXFSR6UWJ_D/QV_:0_9?_;^_:8^$GPEUCQ_JO['W[&7P(^!V
MH? #]F#Q9XAT636I?#&I:#INC?\ ".ZY\5=.TB^EO+;1O&5[X9\/6>JP6.NV
MJ^'/#OASPA?^)M>\/ZO?>*E3Z-_8T_9S^ G_  3@^/.F?MF?'7]O_P#9%\?>
M%?@SH7Q,G^'WPT_9"^(][\7_ (J_&K4/%G@CQ!X?L_"U[X66T\/:?X2\_3M6
M;6TTJVO-7T-M?MM)DUCQ/X7\+:$^L6GPE*ABN%<IH8O!XC.LFXYCE^:NAP_+
M(\SQ^ SS+<=Q/C\XR'A*I#"X26#6)P?UFM0>(R_-\LK93C\>H8NK6RRFJV(^
MQJ5,-Q%F53 5L'E>;<+U,=@*<\YEFN!RW$Y/FN%RC Y9C\_H5<16IX^HL?.C
MA:5'"U\!BZ.:TZ*J8;%?677IKY;_ .">O[57[-5A\"_VA_V"?VTKGQUX2_9W
M_:?U7PQXO7XS^![*:X\7_#'XC>%+CPG<Z9<:KI*:%XTNY="U&Z\(^&=336?^
M$8UL:!K6B:G;^)O#U[X>\22ZCX7\Q_;'_P"":WQ._96\$Z%\>O"?Q+^%7[4'
M[+/C;67T3PO\?/A!J\%QI-SJ.HV?B"[L[/7O"UO?Z^?#MY.N@:M9176D>(_B
M!X;MM3$7AO6O$%AJ>HM;I+\*OV?O@[^VO8?%_P"(I_:[^ O[,?[3/B3XZ^._
M&L_PG_:(\0/\.OA!XC^'?C:2P\;V>I>"OBN=%UBUTWQ#8>+]:\0Z9JWA>;1O
M%]_)HL>C7K:?X=26QDO/JGXKZK\$OV'/^":_QD_8@T7]HSX:?M1?'O\ :B^+
MG@3QOXQMOV>]>O?&WP7^"FB_#G6/!'B.RD_X3N\EM[76?%FM7'@+1M.DDL]$
MTC4]3,UI9W?A+0-$\*2>(I_H,3F>)RWB6C4X?Q><QSC/^(<JI\8\(8W)<;/!
MU:U3"T<-C^),%F+PL<'EOU/ T\-AJ6.P>:XK!9G4P]:*P]#$>V@O!H9=0QN2
M8E9O@\N_L[+<DQ\N&^)*.+R^>-PU/ZU.KA<FQ&"I5I5,TGBL7+$5ITYY=AJ^
M6QK*G[:M3HPF?AF.@_S_ (T4@Z#'H*6OV0_-0HHHH **** "O<?V8/\ DYG]
MG+_LN_PE_P#4[T*O#J]Q_9@_Y.9_9R_[+O\ "7_U.]"KAS7_ )%6;?\ 8IS7
M_P!5>9'3@O\ ?<'_ -AF$_\ 4K#G^E=K'_(YW'TC_P#2_7:]1T?JG_7%O_0E
MKR[6/^1SN/I'_P"E^NUZCH_5/^N+?^A+7^;N)_A/UI?^FZ1_>D/BK?\ 7^K^
M=,Z"BBBO/+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *.Z_P"\O_H0HH[K_O+_ .A"@#/FZS?\"_\ 0!46C_\ 'JW_
M %WD_DE2S=9O^!?^@"HM'_X]6_Z[R?R2@#F-4_X_[O\ WO\ V6NFT_\ U<'_
M  +_ - :N9U3_C_N_P#>_P#9:Z;3_P#5P?\  O\ T!J -:BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI_Q_W?\ O?\ LM=-I_\ JX/^!?\ H#4 :U%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %'=?]Y?_ $(4
M4=U_WE_]"% &?-UF_P"!?^@"HM'_ ./5O^N\G\DJ6;K-_P "_P#0!46C_P#'
MJW_7>3^24 <QJG_'_=_[W_LM=-I_^K@_X%_Z U<SJG_'_=_[W_LM=-I_^K@_
MX%_Z U &M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^15FW_8IS7_U5YD=."_WW!_]AF$_]2L.?Z5VL?\ (YW'TC_]+]=KU'1^J?\
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M?0_$_BK]H?P5\'O"^K:5->GQ;X8_9KUCQIX!T[1/LT^DK!XE\-?VKX5^)?C
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MXH?LNV?A/QQ\'? 7Q9\6?!G1OV=/!WQ)^/OQ \=ZYX%U73_AI\3[K4_$,'Q
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %'=?]Y?_0A11W7_ 'E_]"% &?-UF_X%_P"@"HM'
M_P"/5O\ KO)_)*EFZS?\"_\ 0!46C_\ 'JW_ %WD_DE ',:I_P ?]W_O?^RU
MTVG_ .K@_P"!?^@-7,ZI_P ?]W_O?^RUTVG_ .K@_P"!?^@-0!K4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M] \*>7I]Y)I&@M=-J?\ 8/\ ;>HSG2+ RZIJ=])Y +U0_9@_Y.9_9R_[+O\
M"7_U.]"KPZO<?V8/^3F?V<O^R[_"7_U.]"KMQ&"PV7Y!CL'A*?LL-A<AQN$H
M4W4J5'3P^$R;,:&&I<]6I4J3]E1BJ:G4G.K42YJM2K4O,X*=>KB\VAC,1+VF
M)Q>98?$8BKRQA[2K/%X=RE[.G&%*"Z*-.G3C;HWJ?Z5VL?\ (YW'TC_]+]=K
MU'1^J?\ 7%O_ $):\NUC_D<[CZ1_^E^NUZCH_5/^N+?^A+7^<^)_A/UI?^FZ
M1_=T/BK?]?ZOYTSH****\\L**** "BBB@ HHHH **** "BBB@ HHHH ****
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M0P<'<GFJ%P7,(*9F$9_>&)?-CWS!3$F]2S*,FOVU\8_\$ZK,_P#!:?3/V/\
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MI_Q_W?\ O?\ LM=-I_\ JX/^!?\ H#4 :U%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<=$]  /T%-_X16Q_YYC_ +XK;^TI_P#/_$_^#*__ ,TF'U./_/NE_P" 4O\
MY0?.?_"%?"W_ *(I\-O_  WGPI_^4-'_  A7PM_Z(I\-O_#>?"G_ .4-?1G_
M  BMC_SS'_?%'_"*V/\ SS'_ 'Q1_:4_^?\ B?\ P97_ /FD/J<?^?=+_P
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M (,K_P#S2?5?4X_\^Z7_ (!2_P#E!\Y_\(5\+?\ HBGPV_\ #>?"G_Y0T?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %'=?]Y?_0A11W7_ 'E_]"%
M&?-UF_X%_P"@"HM'_P"/5O\ KO)_)*EFZS?\"_\ 0!46C_\ 'JW_ %WD_DE
M',:I_P ?]W_O?^RUTVG_ .K@_P"!?^@-7,ZI_P ?]W_O?^RUTVG_ .K@_P"!
M?^@-0!K4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MY%HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *.Z_[R_\ H0HH[K_O+_Z$* ,^;K-_P+_T 5%H_P#QZM_U
MWD_DE2S=9O\ @7_H J+1_P#CU;_KO)_)* .8U3_C_N_][_V6NFT__5P?\"_]
M :N9U3_C_N_][_V6NFT__5P?\"_] :@#6HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ J.7_5/_ +IJ2HY?]4_^Z: .=U'_ %MI_P!=H_\ T(U_GJ?\
M%G_^4F?[3W_8?\+_ /JO?!=?Z%>H_P"MM/\ KM'_ .A&O\]3_@L__P I,_VG
MO^P_X7_]5[X+K]V^CU_R6V8?]DYC?_4K!'X]XV?\DM@/^Q[A?_4;%GY@4445
M_91_, 5VWPR^'^O?%OXF_#3X2^%9=+@\5?%?XC>!/A=X7GURZN;+1(?$OQ$\
M6:1X-T";6KVRLM3O++1XM7UNSDU2[M--U*ZM;!;B>WT^^FC2UEXFOI[]A_\
MY/?_ &)_^SR/V5?_ %?GP]KCS*M4PV6YEB:32JX;+LQQ-)M*257#9=F.)I-Q
M>DDJN&I-Q>DDG%Z29TX*C#$8W!8>I?V>(QN"P]3E;C+V>(QN#P]3EDM8R]GB
M*G+):QERR6L4>%_$3P7J_P +_B%X\^&/B>?37\3?#?QQXQ^'WB%]*NI;O2I=
M>\!^)=4\*Z]+I-Y<VMA<W>EMJ>DW;6%W<6-E-<630336EK)(T$?)>;'M1O,3
M:Y 1MZ[7)Z!#G#$]@,D]J_<K5/$NF_#OX>_\%I/BG8?#_P"$OC#XB>%/V_\
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M_C_N_P#>_P#9:Z;3_P#5P?\  O\ T!J -:BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "HY?]4_^Z:DJ.7_ %3_ .Z: .=U'_6VG_7:/_T(U_GJ?\%G
M_P#E)G^T]_V'_"__ *KWP77^A7J/^MM/^NT?_H1K_/4_X+/_ /*3/]I[_L/^
M%_\ U7O@NOW;Z/7_ "6V8?\ 9.8W_P!2L$?CWC9_R2V _P"Q[A?_ %&Q9^8%
M)GD]>,_IUXZ_I2U[E^S+^S[XR_:J^/?PW_9Z^'FH^%M)\9_$[4M9T[0M1\;7
M>MV'A6UFT+PKK_B^];6;WPYHWB#6;:*;3?#E[;VKV6CWS'49K1)D2W>:1/[!
MQN+H8#"8C'8J<:6$P5&IBL96D[1HX6C%SK56[2:5./O-J$VE=\CZ?S1A<+6Q
MN(HX3#QY\1B*D*-"GIS5JU22A3HTTY04JE23M"/,KM/56N>&$CZ_EZ9[D<8S
MSTXKH?!_BWQ'X!\7^$/'_@[5)M"\8> O%?AKQQX0UVWBM+B?0_%?@_6['Q'X
M;UJ"WOH;NQN)])UK3+'4(8+VUNK.:2W6.ZMIX&DB?Z \??LI:YX3^#=W\??
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4=U_WE_]"%%'=?\ >7_T(4 9\W6;_@7_ * *BT?_ (]6_P"N\G\DJ6;K-_P+
M_P! %1:/_P >K?\ 7>3^24 <QJG_ !_W?^]_[+73:?\ ZN#_ (%_Z U<SJG_
M !_W?^]_[+73:?\ ZN#_ (%_Z U &M1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !4<O^J?_=-25'+_ *I_]TT <[J/^MM/^NT?_H1K_/4_X+/_ /*3
M/]I[_L/^%_\ U7O@NO\ 0KU'_6VG_7:/_P!"-?YZG_!9_P#Y29_M/?\ 8?\
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MA^,OC!\7OB#\1_$7A=;1?"]YXK\27>I6OA<VC6<GF^&-%8)H/AF:\N;"UO\
M56\.Z7I,>L:FCZGJD5WJ%Q=7,]K2_P!I#X^Z)\6_$_QZT?XM>,]+^,WC.'Q)
M;^*OB3I^IFQ\3Z[%XOL5T_Q&E_=V<5O&Z:I;QPB>..&..-[>VEM5M[BVMIX=
M'P/FE%_6<NQ.5X+'83$9IC\BA..+QN5Y+B*_$.69IA,#&G6C2Q&,RRIE^&S#
M!8FG['!TW]>E%X-05PEQ5E=6+H8K XW%8?%0RK"9O6_V;#8O,Z%#)LPPN-Q4
MXPKUL/\ 6_KU3+Y4JM1NK*G1J32O%<_ZK?M$?%CPO\1OV/?^"D9^%IMKOX+_
M  9^-'[!?P!_9YM+"59D/P8^!D/QH\&>#KB#R$M(GD\>7^GZY\5)+JW2S&I7
MWQ&N=2BA@@O()YOK7XQ?$[]F#]D[]I?PS^R)<WOQ(\7_ +,EMX,^'7AFS_93
M^'G["W[//Q2\)_M/^#/'/PX\+ZO)\0=#^/6L?M!Q?%[XB_$/QCXEOX_%$7Q;
M\/:#I^LZ-K6E1:)IFDW']CSZOK'\W&D?$#QOH'@#Q3\*M%\3ZIIGPY\;ZIX7
MUOQ=X.M9(%T7Q!J_@I=17PG?ZA#);RR//H(U;418^7+'%_I<OGQ2XC">W>%O
MVU_VPO WPTB^#O@S]ISXV^%/AK:V=YIVF^&?#_C_ %S23HFFWUPEW-I?AS7+
M&X@\0>&-):>-=^F>'-3TJRDMI;ZPDA:QU;5X+_GQOAM7JTZ5&CCX5\+0Q&85
MJ>&Q&+Q.!FJF*P/#N$PV8T\;A<NS+$QS7#XK*,?F-2LE0K5'FM98;-<'BE*=
M7JPG'-"E4Q&(K82?UNO0P='VWU?#XJ@J='$9YB:V%>%J8C".6'G2S3"8*5*=
M5X>;R]5?J\J52+A]P>*_'WC3]F/]E;]@[2OV5_AM\.O&&@?M>^!?BQXL^)DW
MB[X-^"/CGK?[5_Q"M/B7XE\ W7[._C&WU30O&NHZEHOP]\#6GAKP>WPX^&&K
M^%+NXU3Q;K^M6-Y'XREEU^W^Q/V]+*P/Q7_X.%]5GL+:YO\ 0])_X)\W.D7[
M6UE+J>F27'C7X&Q7;:1>W:,UA/=0HL$SI+#',(XDNR\<8*_AIX'_ &H?VD/A
MC\-_%/P>^&_QR^*'@'X5^,_MQ\0^ _!_C#5=!T"=]4L)M,U233X;&2.;1)-5
ML)_[/U>32)K276=*@L]&U:2^T>TAL13\3_M&_';QK?\ QAU3Q=\4/%'B#4/V
M@T\&Q_'&[OY[-YOBFOP]N]'O?!;>+ MDL%S)X<N= T:736M(+1(VTZW5XWC\
MR.32' V:_P!JO%U9Y14Y,14JU<U>,SS$9MG,:G&N1\4QJYK/%3<_K.'RS*WD
M-%PKSA&-*C4IRITG!TL*_%V7RP$*%/#YG5M1E"&!J4\KPV"P*7">;Y*Z&!]A
M.H_JV)S#%T\3.%9RE2^LUJKG.4:O/^F'[1?C[XJ?LVW?[+_[+W[-OPZ\#ZK\
M'?B=^QC\'/B)<>'1\!OA]\5H_P!K3Q7\2/ U]KWQ;^)WBS4KWPYXJ^(/B?4=
M*U^[U*VLK7P7XPM;'X6:?X8T.'0[CP'X9@CU"\^L?V"/!NL>%_B=^QC^RY\;
MOC3\&;K0?V@_A1X:\=7?[$?A3]B_P[\2[+XC_ WX@_#F\U#1O'/QK^/%IX0T
M.ZT7XM^(6L;WXA^,_$\>J^(YM$32=%:[U/3=$6/25_#SPW^UU^U5X.^%][\%
M/"O[1GQE\/\ PFU&":SNO >C^/=;TW18]-OI)IM:T32FLIH+WPUX>\137%Q+
MXA\.^%KK1-$UDW=_%?6$UK?36]:/AK]M#]KGP=X%\'_#'PO^T?\ %S0_A[\/
M]:\/^(?!?@^R\77O]B^'M3\):O!X@\)K9Q3^?<2:)X:\06>GZ_HWA&XN9/!E
MEKFF:9JT7AX7MA:2P\N8^'>:8O)WEN'GD%#%>TS)U\X=7-99KFF*KPS&IA<Y
MQ6)JX6NL%4IXBK@KY9AJ.)KS4)*GGV6X:C"C+JPO%^44,S6/K4\WJX:"P*P>
M51A@%@L!2PWL(5<+2NX.5"5*%2T91E3E4DZTXU:U237T3\0X([7_ ()2?!>T
MMT=8;7_@HE^TQ!!%)(\LL=O;_ _P1%"CR2/+)*R1B-&FDDD:1L.\CL^YOS='
M3\6_F:[2^^(WCO4O >F_"^^\3ZC<_#O2/&NJ?$C3O!TK1'1[;Q_K>FZ7HVK^
M,501+<'7M1TG1]/T^>Y,Y@%M"%CM48[ZXL# Q_GK7Z#P_E6(RC#8ZA7G1J3Q
M><YCF7-1G5J1]GC7AJD(N=:G2J.I"=.I&HW"*;:DKIW?Q6;X^CF-;"5J%&>'
MC2RO 8.=&;C)TZF%C5A**G#W)PM*+C.*2:=FDXN\%U_Q[W?_ %YW7_I+<5_I
MYZ)_R /AS_V)7A#_ -1#0J_S#+K_ (][O_KSNO\ TEN*_P!//1/^0!\.?^Q*
M\(?^HAH5?A_TB/X7"_\ V$9Y_P"H^3'Z]X)_[QQ#_P!><N_]/3/<= _U0_W:
MZ^'_ %:_5_\ T-JY#0/]4/\ =KKX?]6OU?\ ]#:OY,6R]%^2/Z-):***8!11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1W7_>7_P!"%%'=?]Y?_0A0!GS=9O\ @7_H J+1_P#CU;_KO)_)*EFZ
MS?\  O\ T 5%H_\ QZM_UWD_DE ',:I_Q_W?^]_[+73:?_JX/^!?^@-7,ZI_
MQ_W?^]_[+73:?_JX/^!?^@-0!K4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\_P>5XRA*>$K8BC/VLG6IR]G4OI.%7WM'^=]%%%?HQ\:5[K_ (][O_KSNO\
MTEN*_P!//1/^0!\.?^Q*\(?^HAH5?YAEU_Q[W?\ UYW7_I+<5_IYZ)_R /AS
M_P!B5X0_]1#0J_G'Z1'\+A?_ +",\_\ 4?)C]S\$_P#>.(?^O.7?^GIGN.@?
MZH?[M=?#_JU^K_\ H;5R&@?ZH?[M=?#_ *M?J_\ Z&U?R8MEZ+\D?T:2T444
MP"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4=U_WE_]"%%'=?\ >7_T(4 9\W6;_@7_ * *BT?_ (]6_P"N\G\DJ6;K
M-_P+_P! %1:/_P >K?\ 7>3^24 <QJG_ !_W?^]_[+73:?\ ZN#_ (%_Z U<
MSJG_ !_W?^]_[+73:?\ ZN#_ (%_Z U &M1110 4444 %%%% !1110 4444
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M *BT?_CU;_KO)_)* .8U3_C_ +O_ 'O_ &6NFT__ %<'_ O_ $!JYG5/^/\
MN_\ >_\ 9:Z;3_\ 5P?\"_\ 0&H UJ*** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%+-)QE&[2E&<,@E"2=GK"<XNWNU)JTG^T-%?B]_P^N^#O_1HO_!1W_Q%8_\
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MO^'UWP=_Z-%_X*._^(K'_P";BC_A]=\'?^C1?^"CO_B*Q_\ FXH_XA9XF?\
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M*3D/'^RT\J'(SMWGQW(K%""C;6^5U=#A@11_P^N^#O\ T:+_ ,%'?_$5C_\
M-Q63\*_$I/W>"<VG%[2CC.&6G9N+37^NC<)1E&<90E:47%W5FKT^/N#4].(,
M(TTG&2P^;VE%I--7X?V:9^T-%?B]_P /KO@[_P!&B_\ !1W_ ,16/_S<4?\
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M3]C2G_QCS?/55*;BELDV_B1^R_\ 847]R'_OS1_847]R'_OS7PM_P\@\#?\
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M;_KO)_)* .8U3_C_ +O_ 'O_ &6NFT__ %<'_ O_ $!JYG5/^/\ N_\ >_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'X??\D'P7_V2N0?^JO"A1117P!]>%%%% !1110 4444 %%%% !1110 4444
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M* "BBB@ HHHH **** &O]QO]UOY&OSN\)_\ *3[XA?\ 9FWAC_U:-K7Z(O\
M<;_=;^1K\[O"?_*3[XA?]F;>&/\ U:-K7VO!O\#CK_LW'$O_ *M. 3Y3B?\
MC\)?]EKDO_J!Q.?HG1117Q1]6%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %'=?]Y?_0A11W7_ 'E_]"% &?-UF_X%_P"@"HM'_P"/5O\ KO)_)*EFZS?\
M"_\ 0!46C_\ 'JW_ %WD_DE ',:I_P ?]W_O?^RUTVG_ .K@_P"!?^@-7,ZI
M_P ?]W_O?^RUTVG_ .K@_P"!?^@-0!K4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 5\S_MI?\ )GG[5W_9M?QW_P#55^+*^F*^9_VTO^3//VKO^S:_CO\
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M+_UL,@/E^-_^2,XL_P"R8XC_ /5-B#]=-+_U.F?]@ZU_](X*W:PM+_U.F?\
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M=73VOJ.S[/9/Y/9^CZ/9]&:&1[_@"?Y"C(]_R/\ A65]HO7)Q;7$??F)BON
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MY=:6L5+EK=P9ADF-V4,0)& /+8R257!&=H &!GGF[#=I*ZJ655=2PZAA\NX
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MGJU<2S/-(I1AFF90BM(PCCL2H0CTC%>U?+&.R5]+L^G/^&W/VR_^CK?VB/\
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M6?\ ANP'_P Q!_:F:_\ 0US/_P +\3_\M/IS_AMS]LO_ *.M_:(_\.[XY_\
MEM0?VW/VS,,!^U;^T3\ZO&P'Q?\ '(RDB,DB-C6%RKHS(ZDX=6*L"K$'YCHH
M6493%IK*\LNFFO\ A.P&Z::_Y@EU2ZB>9YHTU+-,RE%IIIX[$M----->UU33
M::ZIGTZW[;W[9S$LW[6'[14A)RS/\7_'3.S'JS,VLLSL>K,Q+$Y)))Y3_AMS
M]LO_ *.M_:(_\.[XY_\ EM7S'1262Y/%*,<IRR*7;+L"[MMMR;EA)-MMZZI6
M2222!9GFJ2BLUS-)*R2Q^)LET27M=$NB/IS_ (;<_;+_ .CK?VB/_#N^.?\
MY;4?\-N?ME_]'6_M$?\ AW?'/_RVKYCHI_V/E/\ T*\L_P##=@/_ )B'_:F:
M_P#0US/_ ,+\3_\ +3Z<_P"&W/VR_P#HZW]HC_P[OCG_ .6U'_#;G[9?_1UO
M[1'_ (=WQS_\MJ^8Z*/['RG_ *%>6?\ ANP'_P Q!_:F:_\ 0US/_P +\3_\
MM/K+1/V^?VX?#FIV>K:+^UQ^T)9W]G/'-!+/\4O%FH0 AU#>;8:E>WFGWR!"
M6-G?VES8W)40W4+Q.V/[;/\ @D[^VOXO_;?_ &1[3Q_\2(;*W^*/P[\::E\+
M_'^IZ<L=M8^*K[3M'T;7M&\6PV$>X:?<ZSH>N62:M9Q[;9==L-6FLPEE<6T%
MO_GO-U!],G\L5_8Y_P &YY"?L<_'E@ KR?M#SAI!\K_NOAMH4ZEG&&.%A,:@
MMA=V1@ J?QOQMX;R/_4^KF5/+,'A\?@\QRA4<5A</0PU94\1B<7AJM"<J%&D
MIT94[2Y)1=JD5/FNDC]1\)<ZS:7$JP5?,<7B,'B,)CW*AB:]3$4W5H86CB(5
M8JI.3A5A)M*:M[DI0MK<_I1TK41>(A<[GW!R4P1@$,0<8P<#@8 -=(CAQN7.
M,D<C!R*\T\+S_N7 0C<H (/3<NT'@<X/)[_C7HL;;+=&QN(5<@=220#GKSSD
MU_&]2*A4G%;1=E=W>T7K]Y_3\&Y13>[7ZLI7;OO5 QRTI11P0"4+8.1D#@CN
M>V.X_ S]N/\ ;6^+T/Q@\5_"SX;>*=3\!>%O .IMHEW>Z#=R6>M^(-8AL89[
MN[N=3MF,L%C#/<B*PL;98 QMTGO+AT=X3^\U[<XO;;Y#_?QNQT63/;[QSUQQ
MBOY1_P!KO _:?^.P50H_X6)KV   !MGD0=,=$55''"HBCY5 '].?13X9R'B+
MCK.:N>Y9@\TADW#JQV IXZA3Q5##XVOFV#P7UE8:M"KAZM6-"I4IT_K&'Q-.
M'M9R]DY\LH_S]](O/LTR7A;):65YAB<MEF6=U</B:^#JU,/B9T</EF(Q$:,*
M]*4:E.%2JX^U46G.*BE*#C&<:!_:E_:4 !_X7O\ %3J.OC'5<#ZYE(_''TYK
MJ/"WQM_;/\<R:A%X)\>?M$>,FTFW%YJO_"(R>,_%']FV9\T?:[]-!M-0EM(
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M4\'7LFBVFEZ;'//_ &<M[<VQ6\U#4Y+,6L^I7<TB0-=R30VMM';PIO\ +?\
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M9 .)%(R <%<LIY[JP#*>H(!&" :_KRUBY8:W:1@,%A A(WD*Y\B";=M P/\
M6;=ISR"<\XK^%OI9\'\-Y'G'!F99)D^ R:OF>#S["YC#*L+0R_#8NG@:F35<
M)*KA<+2I8;VU%X[$1]O"C3JS@Z<:DZBIQ9_5_P!''B'.\QP/%& S'-,?F-#
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M '!!QT(/-?S@U_1Y_P &WG_);/VL/^R#^'?_ %.8*_.O%O\ Y-OQ=_V+:?\
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M_':UNK3P#H7PXM]1A\&:EI?Q8TFR^'GBTZ9X2TZ;4_!7Q T"YUA8=2T;V_\
M7'+H8B.#Q&#S3"XV']I/'82M1P3KY?'*\'A,?7E45/-(TL?*IA,;A\1A\/DV
M(S/&5:#JU_JGLJ%6WD1X;Q53#/&T<9EU;"36%^IUZ=7$<N/>+Q.)PE/V4)X6
M%7!TZ6(PE>EB,5FU/+L'0J*G3J8I5:]&%3\JJ*^W/VT/AAX.^$6NZ5X0L/V3
M?B_^S)X@M;RXETG5_&WQOLOC9X(^-'P^;SK?1_'_ (3\2P^"_#>C:G>7LYTJ
M_?6OAMKFN^ =5T[67AL=-T2?0S<^(/L[]C7]B'P-\=?@3^S7KJ?L:_&W]H;6
M?CI\;_C3\*?BE\7OAI\9?$'PXL/V=O#/A34OA5I7A7QU<V-UX*\6_#FZGM]/
M\;>,O$T5MXSAM--U=? -SI0_MNZU"*P6<1QKE6$R/"Y_B:6(I8+&UO9X=+$Y
M+4<X+"XK&NL\52SIY933P^$K*EA:F81Q^)Q2CEV'PDL?.-%K#\-XW%9SB,CH
MU</+&86E[6M+V69NC%?7*& 4(\F5UL1.7UG$TXRG'"NA3H\V+J5X82+Q"_%6
MBOM2X_9\'B+X.6-G\)?A_HGC[Q9XU_X*#>(/V:?A!\4SXS\=:!\7/']EIO@C
M3%\._#B^^!WB"UTGX/\ A#PUXTOO%OA+QA:^/]>\6V?Q$\)>+IKKP-XMT^R\
M%Z;JVMUC?$[]B_QO\/?#MSXR\._%S]G;XZ^#]&^)ND_!OQYKW[/WQ"\0>/[3
MX4_$'Q-'*?"=AX^DUCP+X+O[;1?%,VC>*K7P[\1/!?A[XC_#[5M8\-ZKX5L=
M2O\ Q3=Z%I-UVT^*\BG4A1J8ZEAJU:K7I8:EB9QIO$JC'"252$X0Q-&DL1+%
M>RPU'%5\/B:]?#8NA2HU:E%*?/+(<U49U*>#K5Z5&BJF(J4*<IK#U&\0OJTZ
M<YX>O.LGAIN<\/1KX:C"=*I7KT:=12/D2BOTE\6_\$N?C'X,U+XJZ;K?QV_8
MY$GP"\6PZ#^T+/9_'75+:#X$Z)J,^KVWAWQKX[M=6^'$5WJ_AWQ3=:79:=H7
MASX97'Q#^+=WXF\4^&O &L?#OPGXTO-3T_0?'M7_ &)/'GA7Q/\ $33/'_Q:
M_9\^''PU^'.B_"_Q+>_M)^,/'WB*R^ GBC2?CGX8;Q3\&3\-_$&D^ ?$GQ!^
M)=[\1]'M->U+1M+\-?"6"_\ #EMX/\:ZKXR2QT[PM?VDF6$XSX6QU7V.%SO
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MK_VS_F*\R\8_\B[XQ_[%CQ7_ .FG4*^,P'^]X;_L+R__ -6F6GT6+_W+&_\
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MX*\5>*I?#UY-;RZF4LVNKJ/RJ''_  [.M##XK$3RW$5L9A,%A:&-4'+$3QF
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MU[_D8+?_ *[?^V5E7\-_3&_WCP^_P\4?^D\-G]7?1EVXS].&O_2N)#U71?\
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M-3UNQ\<6UO<WFD:N'M;[3;?H/V"_$]C\/?VD?']PWQ8^$O@C5[K]GO\ :[\
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MX(^'?ABUC\2_$'Q!JS?%W46O?"<5U%->V^D0&R66?ST;[#_9X\=>']8\+_\
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M]9/_ -A#4_\ TZ7M>E3_ /'JW_7/_P!D-?PGC?\ W-5_.H?UYAME_P!>:?\
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M>(I8ETJD[T,1AXXJA]L?&SXW_!M/V?\ P]^RM^SY%\>]8^&>C_&^Y^/$^O\
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MG>(/^"E%U>^+]!^,FE?"JWT[XI:7_P %&]>_;D7PC]O:[^'$_ANZ^$OP_P#
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MTOX([V.VGN;:*\6:*VN[N&..YG_KI_X-VO\ DS'X\_\ 9P]Y_P"JNT>OX[&
MYX_A;^E?V)_\&[7_ "9C\>?^SA[S_P!5=H]?.>,M+V/AWBJ*DY1HXSARC!M6
M:I4,;6HTHO5\THTJ5.,IO6<E*<O>FSZ/PMJRK<98>K.W/4I9U4FTK)SJ8"%2
M32V2O-Z+S?5G]$O@;_CVC_WA_(5ZI!_J_P#@3?\ H1KROP-_Q[1_[P_D*]4@
M_P!7_P ";_T(U_$=;^+4_P 7_ML3^K*7\./I^K.<U/\ Y"4'T/\ Z"]?RG?M
M=_\ )T'QU_[*)K__ *535_5CJ?\ R$H/H?\ T%Z_E._:[_Y.@^.O_91-?_\
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MY_B:V\!2^+K3QK=:7%%I6HWD[V7AVZN(K>QO%AANKBSFA'^V&;9YE&2U,/\
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M]<.O?\C!;_\ 7;_VRLJ_D>B_UL7^^/Y&OZX=>_Y&"W_Z[?\ ME95_#GTQO\
M>/#[_#Q1_P"D\-G]7?1EVXS_ .[:_P#2N)3U71?^/4?]=5_E'73GJ?\ @/\
MZ M<QHO_ !ZC_KJO\HZZ<]3_ ,!_] 6OX8K_ ,6I_B_2)_7%/X(^GZL****R
M+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ H[K_O+_Z$**.Z_P"\O_H0H SYNLW_  +_ - %1:/_ ,>K?]=Y
M/Y)4LW6;_@7_ * *BT?_ (]6_P"N\G\DH YC5/\ C_N_][_V6NFT_P#U<'_
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M']J?]N+Q3\!];?P9\'?#7PQU?4?%=O\ %C6_#WQ*\>?%[XC+9^.O#'A?2_\
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M/H?YK2TG<?0_S6OH:W\&K_UZJ?\ I+/->S]/U1_21^R3_P FH_ ?_L3M9_\
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MZXM>_P"1@M_^NW_ME95_-WTPW-U?#QS24W#BCF2V3Y>&]-W^;/WOZ,VW&?\
MW;7_ *5Q*>JZ+_QZC_KJO\HZZ<]3_P !_P#0%KF-%_X]1_UU7^4==.>I_P"
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M-TGP_J_B3P+J.FCQ+\8/'7[/]AH\M[I3>);7XW_#F;PY;^*?A;KGA^._;5-
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MN#A4QT\JK8O/<KP&<Y=GM5Y!BL!QAG\<LXIQV5X^CEN.PV:4\OJ83$XC'8G
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M\>'W^'BC_P!)X;/ZM^C+MQG_ -VU_P"E<2GJNB_\>H_ZZK_*.NG/4_\  ?\
MT!:YC1?^/4?]=5_E'73GJ?\ @/\ Z M?PQ7_ (M3_%^D3^N*?P1]/U84445D
M6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1W7_>7_T(44=U_P!Y?_0A0!GS=9O^!?\ H J+1_\ CU;_ *[R
M?R2I9NLW_ O_ $ 5%H__ !ZM_P!=Y/Y)0!S&J?\ '_=_[W_LM=-I_P#JX/\
M@7_H#5S.J?\ '_=_[W_LM=-I_P#JX/\ @7_H#4 :U%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5EZM_
MQ[C_ 'A_-:U*R]6_X]Q_O#^:U4?BC_BC_P"E1)E\,O\ #+_TF1_+?_P<R?\
M)(/V2/\ LJWQ)_\ 4'M:_D3K^NS_ (.9/^20?LD?]E6^)/\ Z@]K7\B=?W/X
M)?\ )M\D_P"PG.O_ %;8D_D3Q5_Y+K./^O.5?^JO"A1117ZN?GA]O?"1(/'W
M[!_[77PQLE#^)_A1\7?V;_VN;.TBU/?+?^"-/MOB+^S5\2-5FM%TF6UL[;P1
M/\9/ >IW-M>:YI][?Z?K>I:Q;6[P^')+76/:/#_[8'PMT[XR_ Y->A\0:Y^S
MSJ_[%'[-'[)?[4/AY-"6+5HM2^&OA30[A_&_@JTO1(MWXT^#7Q=\/^$OB3\-
M]7L1]MU74?#$FC0QVUKXLMIKC\N02#D%@=KIPQ&4D4K(AP1E)%)61#\K@D,"
M":3:, 8& <@8X!.T$@= 2%4$]2%7/W1CY7&\)X+,IYE_:%:K6P^-Q.:8JC1I
MWHRPE;.LKR3+LQJ1JJ4I2JJIP]E>-P-:"HU,#B*4I4YN3C->_2X@Q-"&7*A3
MA&K@<+@L+.51JK2Q,<OS#-<=AE4HN*C[&4<VKX;$T)^UAB*+G":Y*LH'[+:9
M^VO\'_$VL_M<^!;OQ]IOPF\._%?]O/X]_M=?"WXI^.OV+?A/^V+H6L>"?C;=
M-:-X0\2?"[XMC^W_ (;>)Y-#\(> _%?AGQ%X:L+FWU!F\;>%_&\$;:5X6O(L
MKX)_MU?#33_B/^T=XI_: UKQY\8+U/BUX6_:S_93\;Q_#[1O ]QJ?[4WP,\(
M^+OAQ\'X?%_PP\!7C^"/"OASQIX=\1^!M0\06'A_4+KPQHDWPK\-KKMYK]KK
M&D"'\?L<D\Y(P3DY( ( )SD@ D '( )'0F@#'()!!)!!.06^\0<Y!; W>N!G
M.!7G?\0ZX<=/%T52Q5*GC*.$C4J4*]"GBZ6(PO\ 9B=;#8F.6T:U"GB:>5PI
MXG#PKQHU(8S,$Z4I8RK*7='C7.HU,+44L/+ZF\;["E.FWAW'&SQE2:KTG.<*
M[I5,?B*E*<J:K0J0PDX8JG+#1YOV&_85_:H_99^#>@_ #7O'7B6S^'7Q$^'7
MQ^E^)G[0&L3?L?\ PF_:0^(O[3.GM\0-&\3>!]8\&_&?XCZA+KWP+@^'NFWM
M_IOB6V\!V2>+K,0^)/B%X ?6O'WBR&_M^5^#?QT_9)UFY_8I\7_'7XB_%SP)
MKW[%/QQ\4:]:^#/!?PCTKXH:1\5O GB']JC6?VD_"?B#3M<O?&OAB7X?WFBZ
MAXG\2:3\0[#6M'\3:CJ/A+1O">L>$K*?Q1IMSI6J_E%M7G@<J%/NJC"J?55!
M*A3P%)4  D4;5]!@# '8 YR .@!R<@=<G/4UM+@/)I8C'8N.)S?#XG,%6A6K
M87&852I8;%T<TH8S 826*RO%U</@:E+,(8>C3E6Q-;#X7#QHT*V'7L?83'C'
M,OJ^&PE;"9;B<+AY49+#5:.(A2G/#XC+Z^'K594<5"O6KTIX*<XSG6A3E6Q-
M2I7I8J+G3J?LA^S?^U7^RIX&U"?QGXD\1V/PM\<V?[7?C#XR>._%&H_L6_"W
M]IOQS\>_@SJ?BO1_%GPY\$>!/&OQ2UH0_LZ:EX %MXNM]8N-*TD2W4WBW3?'
MVAZO>ZQ9BQN_'/B1XCT&/]E/]K3XBV$CWFE_MK?\%!K63X7IJ?\ :EKJ6I?#
MC]G:/XT?$CQ1XQFTI4N+]/[/O/VBOA5X3OTEUBUOX+S6-79X-*3PE>Q/^:G<
MD9!("D@D$J %"Y'.T* H&<!0% P,4'+%2Q9BBLJ%F8E%<EG5"2=H=B6<+@.Q
M);))-73X+P5#&PQE#&8^\L1EE3%TL376*C6P^6UZ^*CA:51T:%:FJF)JPG"I
MB*F)>%H4_J6$ITL))0CDN)J[P<\+4P>"4EA,SP^&JX6C'"NC4S+#3PDJ]2$9
M3IUN2E4<I0I4L'[6M:K-SG>I)!T'T'^>,?R%+117V1\R%?T>?\&WG_);/VL/
M^R#^'?\ U.8*_G#K^CS_ (-O/^2V?M8?]D'\._\ J<P5^=>+?_)M^+O^Q;3_
M /5CE9]QX;?\EQP[_P!A=;_U S$_K@\,?ZR?_L(:G_Z=+VO2I_\ CU;_ *Y_
M^R&O-?#'^LG_ .PAJ?\ Z=+VO2I_^/5O^N?_ +(:_A/&_P#N:K^=0_KS#;+_
M *\T_P#TW3/XGO\ @X]_Y/4^$7_9KW@__P!3OQ_7\_5?T"_\''O_ ">I\(O^
MS7O!_P#ZG?C^OY^J_O7PN_Y-YPC_ -B>E_Z=KG\=<?\ _):\3_\ 8WQ/Y4PH
MHI,D%2':,A@5D0J'C8 X="P90RG#*64@,!D$<5]YV\Y17I=VO\M_U6Y\>W9-
M]DWZV5[?/;]&>_>&_@-)KWP:\-_%>\\4V.C7WQ!_:/T/]G3X;>&+BQNKF37I
MXO#VEZ_\3_'^H7-I>-=6?AOX<W'C;X/^'I%MM$U274M2^(DP2;3Y-#%MKWN7
MQ,_X)[_%?X6?M;R_LC:]XK\$WOB";P%\1OB3X>^)&D?V[=?#SQ=X8^&7PB^(
MGQ3UZ[\/WATQ+N[ECU#X4^/?AC>6ZQFYT3X@^&M5T_6+>UL88+V[ZW[=I-[^
MRE_P35\6VE[:Z=H_PQ_:\_:&\#_$[<=.T[P[X8\5>(O&/[//Q3T37-9UB^U2
M"Z47WPTCAT_3]1U>SB>WT/P+/9>?%I7AN!C]R> _VC/@QX^_:8_:\T/XB?%C
MX>>';#X$_''_ (*F?'']D_XIZ_XTT3_A#OB-X _::\%_M#_##Q+\ O"?B5]9
M&A7-EXT\>^// 7[0'PIDTE[^77I[GXH1:+:WW_"6:?<2?DV9\0\48:ICL;EZ
MJ5<+AZ?$7ML/3RNGB*V#KK/:&0Y)*,Z5*K6Q*PTJ:Q-?"SI2K5,)GO\ :$J/
ML,J567Z!@LCX?Q#PV&Q<X4:U9Y#*->>+5.G7I/+L7F6;Q?-B(1I/$<V&ITZW
MM%"C6RYX7F53'2IQ_"C0_ /C[Q+X4UKQWX?\ ^.];\$>&%C_ .$M\:Z)X,\1
M:YX0\)32-$L=OXG\4:'I^I:+X>FD$T.P:W=::KM*L>0[*&9#X!\>7.M>%O#-
MKX%\77GB?QW8:#JG@/P[:^&M?N-:\<:=XJ0MX6U#PAI46FOJ7B73O$C*ZZ'>
MZ)9ZA'J@2062SW,4UK'^[?P#_:7\ :!\ ?V3-1\ Z;^S_J__  HWX&>,? OQ
M0\$?&[_@H'XP_9KM8/%EYXE^)][\1[/Q#^RE'XFM_!WQVT+XP^$_$^EZM#XH
M\.^%OBGXA\:-JMMX*\76MMXD\'Z;I&A?-'[/WQF^%FB_LE^"/CGKWC;P9H7[
M5'["GPR_:#_9V^"WAC5M3TJS^+7Q-L?VB]?TBV_9Z^(^B:+'J5O9:II7[+%_
M\8_VF?%>MII,^O#PE'X<\%ZQIADU/7;"_/=_K;GE19HJ7#4XT<%G&)RS!4KX
MB>)<L35S'!934QS]A4^K4,9C\OP<<1B:-6OA\!@\VHXVI5ITJ-6M+EI\/Y1*
MG@ZE3/4I8K*\-F&(J5(PHTG0A0H8O,'A9U)T7B,3A<-B:SIX/$4:5;$8G"5,
M%"FY\D)_FA-\*/BG%X(D^)[_  O^)-O\,8;DV<_Q'OOAYXVLO 4%TNIP:-):
MS^-6T"7P?#=+JMQ#I4<4VOH+S5I$TJP>[OBUNGJ/P#_9O\9?&;Q#I,5]I/C/
MPI\.];\*_'O7M'^*R> M8U/P/JGB;X#_  +^*GQJG\&:9XGU4:#X8U/4M7/P
MPNM U*VTS5]5N]'%\VH7>E7T&F:G9)^LWP:\5_!?PE^R[J=L/C3X)UG3]=_X
M)M?&GPUJ&K?$;_@H_P"*;7QSIOQI\2_L\>-K&3]FOP-^P@+^W\.^'M*\ _%)
M#X?^$KZYX7O-%U&WTSP]\0/ /CC5/%.K^ _#%^>!OB;._B3P=\4=$_;8^#7@
MG]F"7_@F_K'P9_X9TOOV@]#\$^*H/B%HO[$OQ$^'E_\ "+4/V>]*\1'9XCN_
MVD-/UGXPZ5XS\;>'M,\/^([[QAX<A\*>-=2\<:SHGAC5O*QO&6?5,OSVC@\N
MIX+$8?$XS+<-FF)P/$Z=>5##PG]2P>!EE>/Q=+,<564WA:]>$<!'#T*E5XZG
M]:PU&7HX/A3*:.)RJ>(S&6*HUZ%#&5<OH8O*+1]N_;QJ8R5/&86C#!45&G#$
MU8U)8V.(E"A_9]2FJE1?B%8_"WXHWW@67XJ6GPP^)%W\+[(0+??$BT\ >,-0
M\ 64\ES9V;Q77C73]&O?",+17VHV%HT4^NK.L]W!)=VL5A-'<R]K\4OA OP_
M^'_[/OQ'TK77\2>$_CQX$\3>((+QM.M]/E\-^/\ X;^.];^&WQ)^&]U$TEQ>
M7+>&KO2]%\3Z;K!N+6?7/"?CCP?K6NZ!I.HZO:RWW[/_ +$WBCX"^!_AC\'Y
M-0^-G@J_TG4_V7?V@[+XEZ]\;O\ @H3>^!+[X>?$SQS\/OB[H[_L[^"OV#;C
M6]-\(7_A*77];M-=T?Q#XBB\1^$O%6J>+=1\0Z;XG@\8PZ!H%Y^9'Q*M3H?_
M  3Y_8JTW5]1BFUSQO\ &O\ ;(^*^@:,SI)<Z)\/ OP!^#J2I97.K3ZCH^DZ
M_P#$3X6>.+G2IK?3+?0M1OM+\36=ELN].O#)[6!XDQV99U4P=3#U,'0PW$,L
MK<5A\9A)YO@YX+BBO.M.EC(RQ%+$X;%9%AZ_M<,X8=X+$4%4I4X8G#RQ'BXK
M(,-@<MIU(8BABJN*R5XWZQ'$TL0\NKTL9P[AO9P=.M!/#XFAF^*I*GBJ,,1'
M%86I4A4G*,H4_BP @ 'W_GQ^E+2#&..G:EK]&M;2ZE;3F5K2MIS*S:M*W,K-
MJTE9M6;^22LDDFDDDD[MI)))-NS;223;2;:;:3;2:W?_ '6_I7]B?_!NU_R9
MC\>?^SA[S_U5VCU_'8W?_=;^E?V)_P#!NU_R9C\>?^SA[S_U5VCU^2^-G_)
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M^K@_X%_Z U &M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^FZ9_$]_P<>_\GJ?"+_LU[P?_P"IWX_K^?JOZ!?^#CW_ )/4^$7_ &:]X/\
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M^]2G*+W5JC.<8SA&4E"K%0JP3]VK",XU(QJ+[2A5A3JQ[5*<'LFFBYP,]?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K&U)W>V;*$;6&#AB#SU/
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M%?Z*W_#'O["G_1D_[./_ (9OP3_\IZ/^&/?V%/\ HR?]G'_PS?@G_P"4]/\
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MT/\ "O\ 16_X8]_84_Z,G_9Q_P##-^"?_E/1_P ,>_L*?]&3_LX_^&;\$_\
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M@G_Y3T?\,>_L*?\ 1D_[./\ X9OP3_\ *>C_ (F#RO\ Z)S-?_"G)_\ ,/\
MB"N:?]#S*/\ P1G/^1_G4^<G_/:/_OH?X4Y9 <D2*P! ^4CJ>@Z=3@G'7 )
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M]X#_ /!#JW_R]KS/^)N>"_\ HG.+_OR/_P">1Z7_ !+7Q/\ ]%!P[_X#G?\
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M_$UZO@>@_(48'H/R%?!\\_YY_P#@<O\ Y(^OY8_RQ^Y?Y'E'_"*0_P#/LO\
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M<(@"CZ9YQ]:]4>,.I484G&#@'&"#TX]/6H/L[?\ /7_QP?\ Q55[2?\ //\
M\"E_F3RQ_EC]R_R/,O\ A$[?_GE/_P!\K_C1_P (G;_\\I_^^5_QKTW[.W_/
M7_QP?_%4?9V_YZ_^.#_XJCVD_P">?_@4O\PY8_RQ^Y?Y'F7_  B=O_SRG_[Y
M7_&C_A$[?_GE/_WRO^->F_9V_P">O_C@_P#BJ/L[?\]?_'!_\51[2?\ //\
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M *[R?R2@#F-4_P"/^[_WO_9:Z;3_ /5P?\"_] :N9U3_ (_[O_>_]EKIM/\
M]7!_P+_T!J -:BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH3T?_OG_ .O7X#=]W][_ ,S]LLNR^Y?Y$]%0?:$]'_[Y_P#KT?:$]'_[Y_\
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M:?\ ZN#_ (%_Z U<SJG_ !_W?^]_[+73:?\ ZN#_ (%_Z U &M1110 4444
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M+_Y74?\ #_7_ ()L?]%&^*7_ (93XA?_ "NK^"G;_N_]\_\ UZ-O^[_WS_\
M7KS_ /B7_@K_ *",Z_\ #FO_ )UG9_Q&;C#_ )]Y/_X;'_\ /0_O6_X?Z_\
M!-C_ **-\4O_  RGQ"_^5U'_  _U_P"";'_11OBE_P"&4^(7_P KJ_@IV_[O
M_?/_ ->C;_N_]\__ %Z/^)?^"O\ H(SK_P .:_\ G6'_ !&;C#_GWD__ (;'
M_P#/0_O9B_X+X?\ !-6:6*-OB7\1[=9)H8GN+OX*_$-(($FD$9N9W32II!!
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MQDXM7O9Q?*]>NJ>O4_>82YJ<)7OS0C*[5K\T5)77322/%?VC/VG/@?\ LL^
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M **-\4O_  RGQ"_^5U?P4[?]W_OG_P"O1M_W?^^?_KU]C_Q+_P %?]!&=?\
MAS7_ ,ZSY;_B,W&'_/O)_P#PV/\ ^>A_>M_P_P!?^";'_11OBE_X93XA?_*Z
MC_A_K_P38_Z*-\4O_#*?$+_Y75_!3M_W?^^?_KT;?]W_ +Y_^O1_Q+_P5_T$
M9U_X<U_\ZP_XC-QA_P ^\G_\-C_^>A_>L?\ @OK_ ,$V",?\+&^*7_AD_B$?
MS']G=/6OC3]NW_@I-_P2B_;M_9V\7? /QC\8?BOX2FU>\T3Q!X.\=VG[//C?
MQ#J/P_\ &?A_4'N++Q-INC:A!:V.H/=:3>:UX7U>SEGM)+[P]X@U6TAOK.XD
MM[JV_CTV_P"[_P!\_P#UZ-O^[_WS_P#7KORCP3X9R+-\LSW*,QS[ YMD^-P^
M89=C:69Q]IAL9A*CJX>JHSRJ4*BIU'-^SJQG2FJE6-2G.%6I"7)C_%?B3-,%
MBLNQ^$R3%8+&4:E#$X>IEDN2K2J0E"496S1-.TFXRBU*$U&I!QG",H_W-_#+
M_@M=_P $K/A%\/? OPN\"^,OB7H_@SX<>$O#_@CPGID?P1^(3M8:!X8TNWT?
M2H9+A[!IKF[%G;H;V^F9KF_N7GNKEWFFD9N[_P"'^O\ P38_Z*-\4O\ PRGQ
M"_\ E=7\%.W_ '?^^?\ Z]&W_=_[Y_\ KUR5O 3@_$5JN(KXS/:U>O5J5J]:
MKFSJ5:U:K.=2K5JU)Y9*=2K4J5*DZE2<I3G.<Y2E*4FWTT_&/BVE3I4:5'):
M=*A2I4*-.&5*,*=*C"-.G",8YFDE&$8I:7=KN[;;_O6_X?Z_\$V/^BC?%+_P
MRGQ"_P#E=1_P_P!?^";'_11OBE_X93XA?_*ZOX*=O^[_ -\__7HV_P"[_P!\
M_P#UZS_XE_X*_P"@C.O_  YK_P"=97_$9N,/^?>3_P#AL?\ \]#^];_A_K_P
M38_Z*-\4O_#*?$+_ .5U'_#_ %_X)KGK\1?BD1Z'X)_$(C\CIU?P4[?]W_OG
M_P"O1M_W?^^?_KT?\2_\%?\ 01G7_AS7_P ZP_XC-QA_S[R?_P -C_\ GH?W
MTZ/_ ,%X_P#@F9JVH6]A/\9/%OA\7$HB:_\ $7P>^)%CIMH64LLE_=0:!=BT
MMV("FYE001!A)/)%&&8?J[X1\>>&/&WAK0?&?@O6]*\5^$?%>CV6N^&?$WA_
M5(=1T#7M'OH4GM]0TC48"5N[8I)&K/Y4>UVV8W!U7_*X.1WQ@$\#'3''4]<U
M_:9_P;M^-?$.K?L/?$GP]J^J3WVC^ /C[KVG^#K*[EGGCT73M=\)Z'XFU;3+
M/S)G\K3Y=<N-6UQ+:,(L%YJFH+"5M3:6MK^<>)WA!D_"G#\<]R/&YA*=#&X3
M"XS"8^O2Q%"=#&SJT:5;#U8X7#5X8BG7I<LZ<U*BZ4N:-Y7M]WX?^)6<<19T
M\JSC#X!TJV&Q-7#XC!4*N&K4J^$ITZ\J=:G+$XFC5H5:%1N,H.%6%2"C+W6F
M_P"C>VN"Q(VDY=1DONX/&1QT'\R>>*T*X?0-0+@%Y$;:K $ASP?^!<9../RZ
MUVD3,Z!F Y)Q@$ CL1DGK7\]2BX2<7NG9VU6R>^G<_;4U))K9[="2BBBI&%%
M%% !1110 4444 %%%12NT:;AC /S$@D!<')P"#UP/QH KRW:HK%U51AAEI J
MDJ&)R2,* %)))"JH9B0JDU\0>,O^"@7[*7@[7=0\/ZA\1SJFIZ3<R6%^GAKP
M_KNO6D-U;R217$:7]K8)97 AF22&62UGGC$J,@8LK =S^V)X@U30_P!F;XZZ
MGHE[-8:C9^ -1@M;RUDF@N8#JMQ;V5P89HI(Y(IFMI9DAFB9)82S,K@]?Y3M
MF"0"V26=F9WD=V=F8L[R.S._0%V)9\;Y"\K22/\ U!]'[P.X?\4LNS[.^),P
MS?#X/*LRI91A,%DU?"82K6Q$\'3Q];%XK$XO!XS]S"E5IT*&'P].%1UE4JUJ
MGL_9P/Y^\9O%K.> ,PR?)\AP. JXK'X&KF>+QF:4YXJA&A'$3PM+"X7#4,1A
M)1K>T@ZU>OB*LZ;I.%.A3553D?TF_P##RO\ 9)_Z&[Q/_P"$'XA_^1J7_AY9
M^R7_ -#CXJ'T\#>(P/R\CBOYLMI_OG]?\:-I_OG]?\:_HO\ XE%\+?\ H,XT
M_P##YEG_ ,XC\5_XF0\0_P#H&X8_\-.)_P#GN?TF_P##RW]DO_H<?%7_ (0W
MB3_XQ1_P\M_9+_Z''Q5_X0WB3_XQ7\V6T_WS^O\ C1M/]\_K_C1_Q*+X6_\
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M^$-XD_\ C%?S9;3_ 'S^O^-&T_WS^O\ C6O_ !*+X6_]!G&G_A\RS_YQ$_\
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MA\U%+$LK$8S@'C&00 ,<_P!/2O2X/]6!V!*CV . /T[Y/O7EO@LDJV22!(@
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M_P"]_P"RUTVG_P"K@_X%_P"@-0!K4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !67JW_ ![C_>'\UK4K
M+U;_ (]Q_O#^:U4?BC_BC_Z5$F7PR_PR_P#29'\M_P#P<R?\D@_9(_[*M\2?
M_4'M:_D3K^NS_@YD_P"20?LD?]E6^)/_ *@]K7\B=?W/X)?\FWR3_L)SK_U;
M8D_D3Q5_Y+K./^O.5?\ JKPH=P "S$X554LS$]%55!9F)X"J"22  20*3LS
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M'G@'XE:VGP_\,VWB3P9?_%#Q]XZT;QA>:/X4\)?VEX7CAUVPL;B^U&\TNXU
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M?\AJZ_Z[1?\ HT5[1I?^J@_#_P!$"O\ &?$_\NO\'_R!_J+1WJ?XOUD7K_\
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MRDVAE>0&-)$:0Q+) [A5N(G=3LE@,D;I^\5S%\]?7B?#_3_AOX?_ &BDT_Q
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MM?W-AXBUF.:Y73_#UE??V=9?!SN\CM)([R2,06DD=I'8@!06=RS,0H"C).%
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MXN\&:!;:O9O/\]+\2]"7]D;XC?L_FSU9O&'C3]HCX4?&'3]3$%M_PC-IX<\
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M /L8Y#_ZL<4?0^$__)783_L'S;_U643^B?P7]U_^NB?^BTKU*#_5_P# F_\
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MC&2S25>%5RRUNMA.;.LTE2P55SPM!XVNZ5.+F[_2\7[23B[\0:/<_##PY/\
M"?6OAUX7^%UO\+-/\5>,?#=OI/A?P7XGG\:^');?QCH%]:>*+K6!XMO-7UWQ
M/?:C<WD'C&77KNTU&RM;>PB-_B^+_C]>^*[3Q_I\/@3PYX:TWQU\-_A/\,(=
M+T/5=772_"6@_"#7M!UW0+C1X-274M1U&XO_ /A&["PNX=6UAVMK>::4WVH2
MP0[_ )\GE\B*27&X1QR2%<XR(U+$ G@9 /)X'4UZWXS^#?CCPK\0O%/P[TO2
M-7\=ZCX6UG1]#N+WP=X=UO5H;F_UW1[75--MEM;.VN[F"[OI#J=OIUG-_I6I
M1:9->6D;Q;E3SY\+^'F4YEAXUL-A\#C(X3Z[!XK-,QAA/9Y9CLEA+'8N6/S1
MY>\:\5')XU\QQ<UC\;3IPIXC&UX7I5K?$7%>88.M1>+Q>/PT,1.E*G3P-#$U
MJ-3,<)FE2=&C]3RUXRGA987%8]1P\)/!8=>QY*%*I2H558^&/Q/T7P)H/Q \
M*^)OAMI_Q&\.?$2'P9%JNGWOC+Q3X2^S2>"M:U+7]/NH)O##6]Y)+->WD$4J
M?;H(3;VJETE<[:N:G\:9KR'Q1HVG>!?#WA[P=JOP@U+X*>%_"FBZIJ\=MX/\
M*:O\4/#OQ9U"^;5=3.K:_P")_$-WXHTC5[K4=1U758O[2O?$MY?1QZ7;V-CI
M*>867A?Q7J7B,^#M.\+>)=1\8"^NM+;PEI_A_5KOQ0FIV$\EM?:=+X?@M)=7
MBO[*XB>WO+-[-;FTF5HKB*.3 K.U#3M2TB^N]+UC3]2T?5-/GDM=0TO5M/NM
M,U.PNXF*RVM[I]]!!>6EQ$5(D@N((Y4^7<OS#/H+AW@O&9KB,4Z-#$9EC:5#
M.G0J9MBZBJ4J4,KI4,VP>32S>5'#JI#*<KP\<SH91AWBZ="&&CCL30Q&(I8G
MC7$&?4,MCA54Q=++J-3$Y9[9Y7.$8SKRS7ZUE\\TJY?&I)T*F=YE[3+IY@Y8
M"K6C-Y?AI4*52'T)=?M%7%S:W.L/\-_"$GQ=U'P,OPYU7XS'4O%EOKEWX:F\
M))X"U2^M?"*:Y<>%-,\>:QX)CC\*ZAX]M(5OWT]9[FVTVSO;YWMN7O/C3J=]
M;:]:3^&[ 0^(/V=_AQ^SU.%U>^:2TTSX?3?"V4>*(YA;0F\U'5!\-5\O394M
M[33GU1BL]TBW277C(Y /J!2UO0X#X3PRC&CE$%&"IPIJIB\PQ"HT:$\+/#87
M#_6\=BWAL#@_J6'A@,OPTJ& P-&,Z.%PM.G6J\U5^*N(,0TZV:5Y/W'/EAAJ
M/MJT:6)I5,5B/J^%PZQ&-Q7US$5<;C*RGB,7B)QKUI^TIP2]T@^/.L1:YX>U
M6;PCH%]IMA\#O#WP!\4^&-0U379-)\:>#-#L+>QDGN;O3;C1M=T#4[JYL-)\
M0V=SHFJPW.C:_HNES65V8;?!;I7B;X-WWBG4_$%_\*M'\(>$=!^&_BF'0OAS
MIWB7Q_XG/BKQY=0R:7X:N-4\4:DU[JL0L=6\2V.N7<XN-"TNST3PA>2WD>J:
MYJL8O_#::0<YXQ[^W3'!QW.1@\_C2K\#Y%*%=X&&/RC$8G#1P6(Q.49KF6"J
MUL-];KXJ?M:,,?' 5\6XXO&X2CF6(P-;,L'@\75P^"Q="$*,:2CQ-FR5)8B=
M#,:>'KK$X>ECL+@L3["O&CAJ,70K8C#5*]##WP>%KU\%0Q%'!XRO15;%8>M6
MG.HV1 JN&<N?[S*JDY9CT0 #T_#'3%?2_P"QO_R=/\!/^RC:'_Z+O*^:U&,_
MXY]?IZ^E?2G[&_\ R=/\!/\ LHVA_P#HN\JN/?\ DAN,/CTX2XG7[R2E-\O#
M><13G*-HRDU%.4DM6V]VS+A>_P#K+PSS.\GQ'D+D^\I9]E,I6MHE>;LEHDDE
MHD?TF6G_ "&KK_KM%_Z-%>T:7_JH/P_]$"O%[3_D-77_ %VB_P#1HKVC2_\
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M44 %%%% !1110 4444 %%%% !1W7_>7_ -"%%'=?]Y?_ $(4 9\W6;_@7_H
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M_P"Q/2_].US^.N/].->)FM&LWQ'_ +C&!<#&1^7_ -?/_P!8D'/9=O;C\O\
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MY_S^8_.BNH KZ2_8W_Y.G^ G_91M#_\ 1=Y7S;7TE^QO_P G3_ 3_LHVA_\
MHN\KY'C[_DA^,?\ LD^*/_6<SH]OAC_DIN&O^RCR#_U>9.?TF6G_ "&KK_KM
M%_Z-%>T:7_JH/P_]$"O%[3_D-77_ %VB_P#1HKVC2_\ 50?A_P"B!7^,^)_Y
M=?X/_D#_ %&H[U/\7ZR+U_\ \>S_ .>QK\K?^"I/_)M6@?\ 93M)_P#3!XFK
M]4K_ /X]G_SV-?E;_P %2?\ DVK0/^RG:3_Z8/$U?H_@E_R=SP[_ .RJRW_W
M:/@?%O\ Y-GQO_V(,7_Z<PA_/VO;_=7^M.IJ]O\ =7^M.K_7NC_"I_X(_J?Y
MOU?XM3_KY4_].3"BBK5C8WNJ7(LM,L=2U.\,%_=BSTJPFU"Z-GI.E:CKFJWG
ME0D'[+INEZ5>7E_)R+>W19&!#@54IPIQE.I.-.G!.4ZDY*,(15N:4I2<8QC%
M.[;E%+2[5U>"K7LG[.>J:9H7[0OP,US6M1LM(T;1_BSX"O\ 5=5U*YCLM-TV
MP@\2Z=+<7M_?W!CL[*T@1"TL]U-"@!P&/S8\6#Q&66%98I)8&"RA'5BI!(!(
M'S /M;86 $BC>N0:56CD7<CJZ.K+N1E974Y5U#*3E3DJP!P>0V:X<VR^6;91
MFN5RG4PT,URS,<M^L1@IRA1S/+L=@5B*<9+E;4,:ZM-2^+V6CL^9=6 Q2P./
MP&/BHU)8#'X',(0;7+.>7X_ XZ,96;M&4L'R2>\?:7T:/I32OB9KG@S]F+2=
M%\'_ !!O_"6O7'[2OB3QQK6F^'O%/]@^('\-0?#;X81>#O$=Y%8W]IK$/AY-
M=.L36.HJ8=.37=%6\DF74?#=G<:?[[\0/$5CXLUCXLZ/\*?C;X"^&&M:?^V#
M\6/B!<ZOJGQ&TWX=Z%XK\$:UI&G6_@SQIHWBQ+RVL?%.E^ KG3/&%U>:!H3:
MQK,=OXCBUG2].>6Y@O(_SQSR#N;B4SCYV $^XL9@H(42[F9O, #@DG(-(I"
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M%Q<>#-.6/483J%Q9M^B7Q@M=*^/?PH_9/^#(M[2R^-O[)G[$O[%'[1'P2/\
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MJW&F?%7Q!\;? ^H_$+X%_"7XF:K\)/BCXOU&TU/QIXN^#FI^.O"6O7GPUO\
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MQ_J8O]Y?_1;U_">-_P#<U7\ZA_7F&V7_ %YI_P#INF?Q0_\ !Q]_R>K\(_\
MLU_PA_ZG?C^OY^:_H&_X./O^3U?A'_V:_P"$/_4[\?U_/S7]Z^%W_)O.$?\
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M)_V#YM_ZK*)_1/X+^Z__ %T3_P!%I7J4'^K_ .!-_P"A&O+?!?W7_P"NB?\
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MD?$#2K;1K'QMINC^./A;X=\8:1J]HNF)>W-M:6]]<6TNF02#YQN/VCOBO?\
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MM3O?#=K-%91#29WC^-\8(P"!GH2K$?+D@E25)!."5RI*\=!7O>K_ !MO=?\
M!7QJAUIK^]^(WQZ^('A77?&^JQ:=96'AV'PGX4EUCQ#'INE&UU8WJZIJWC;4
M;+4;V"328].M]*T73K2"ZE :%/!3EG+$+R2?E1(QD\G"(J(B\D*B*J*  JJ
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M* "BBB@ HHHH **** "BBB@ H[K_ +R_^A"BCNO^\O\ Z$* ,^;K-_P+_P!
M%1:/_P >K?\ 7>3^25+-UF_X%_Z *BT?_CU;_KO)_)* .8U3_C_N_P#>_P#9
M:Z;3_P#5P?\  O\ T!JYG5/^/^[_ -[_ -EKIM/_ -7!_P "_P#0&H UJ***
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %'=?]Y?\ T(44=U_WE_\
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M%O\ P4U_Z(5H/_AXOA5_\U5'^O\ P/\ ]%;PY_X>,'_\F'^J/%?_ $3>>_\
MAKQ?_P @?D?17ZX?\.+?^"FO_1"M!_\ #Q?"K_YJJ/\ AQ;_ ,%-?^B%:#_X
M>+X5?_-51_K_ ,#_ /16\.?^'C!__)A_JCQ7_P!$WGO_ (:\7_\ ('Y'T5^N
M'_#BW_@IK_T0K0?_  \7PJ_^:JC_ (<6_P#!37_HA6@_^'B^%7_S54?Z_P#
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M5_\ 1-Y[_P"&O%__ "!^1]%?KA_PXM_X*:_]$*T'_P /%\*O_FJH_P"'%O\
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MM=?]$^T3_P .-X"_^:"C_AW1^UU_T3[1/_#C> O_ )H*/^(N>%__ $<#@_\
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M7II^44)T;[SD^U]?S;,C1-/%LPA+;<IN"X!!)4YQGN,$D#I6W-#O22(Y^8%
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M6/\ GO%_WY7_ ..4?V1K'_/>+_ORO_QRO=/^$<']P?I1_P (X/[@_2CZPO\
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M.M'I/'_WZ7_XY7N?_".#^X/TIJZ#&"K +P0PR.X.11];?\B_\"?^0?5X]_\
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MD[AGZX%="Q3225.*2Z)M+Y)1277IU];Y.C?><GZZ_FWKYG@?]DZS_P _$?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 5KCJGT?\ FE><>+O^1?\
M&7_8K^(?_3+?5Z/<=4^C_P TKSCQ=_R+_C+_ +%?Q#_Z9;ZN[+?]_P '_P!A
M>"_]3\O./,/]QQG_ &!XS_U"QA_'1>2+;QW<Y4OY(NI]N0N[RP[E<X.,[>NT
M@=P>A^@_^%#H/VCX_P!G9O&]@MV^I6NG'Q:VC8B$EQX$@\<.W_"._P!N^<7A
MAN!IS0C6=Q8+>;D5OLU?.^HH\EMJ$<:EY'2]1%&"2[QS(@'NS$*,]SZ5^H#?
MM9ZJG[5264?Q3T@? (-;Z4+_ /X1WPH]A%I$OPNCM;D1>)7\,-XRC>'Q0]S
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M*TZS+?\ U5M_OO\ ^CDK3K^83]]6R]%^2"BBB@84444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4=U_WE_\ 0A11W7_>7_T(4 9\W6;_ (%_Z *BT?\ X]6_
MZ[R?R2I9NLW_  +_ - %1:/_ ,>K?]=Y/Y)0!S&J?\?]W_O?^RUTVG_ZN#_@
M7_H#5S.J?\?]W_O?^RUTVG_ZN#_@7_H#4 :U%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7\Q'[\MEZ+\D%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4=U_WE_\ 0A11W7_>7_T(4 9\W6;_ (%_
MZ *BT?\ X]6_Z[R?R2I9NLW_  +_ - %1:/_ ,>K?]=Y/Y)0!S&J?\?]W_O?
M^RUTVG_ZN#_@7_H#5S.J?\?]W_O?^RUTVG_ZN#_@7_H#4 :U%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-&\/>"/A_J4^D#3=,T[QA/KEB-=U.YO=9\;Q2ZM+<1QV?A^>S^1\#THP/2O
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M?S$?OBV7HOR04444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_"/>(/\ H!Z[_P"$YXA_^5='_"/>(/\ H!Z[_P"$YXA_^5=>C]<P?_09@_\
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M;_??_P!')6G5"UC+0PD$#8[DYSS^\!X_[Y[U?K^<#]P6R]%^2"BBB@84444
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M_APR[_YK/HF72X$V^7J&J29SG&IR_+C&,[0W7)QG'0U"=.C R;W5 !U)U28
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MB_Z"&K_^#&;_  K;HH^IX;_GTO\ P*?_ ,F'M*G\[_#_ .1,3^PXO^@AJ_\
MX,9O\*/[#B_Z"&K_ /@QF_PK;HH^IX;_ )]+_P "G_\ )A[2I_._P_\ D3$_
ML.+_ *"&K_\ @QF_PH_L.+_H(:O_ .#&;_"MNBCZGAO^?2_\"G_\F'M*G\[_
M  _^1,3^PXO^@AJ__@QF_P */[#B_P"@AJ__ (,9O\*VZ*/J>&_Y]+_P*?\
M\F'M*G\[_#_Y$Q/[#B_Z"&K_ /@QF_PH_L.+_H(:O_X,9O\ "MNBCZGAO^?2
M_P# I_\ R8>TJ?SO\/\ Y$Q/[#B_Z"&K_P#@QF_PH_L.+_H(:O\ ^#&;_"MN
MBCZGAO\ GTO_  *?_P F'M*G\[_#_P"1,3^PXO\ H(:O_P"#&;_"C^PXO^@A
MJ_\ X,9O\*VZ*/J>&_Y]+_P*?_R8>TJ?SO\ #_Y$Q/[#B_Z"&K_^#&;_  H_
ML.+_ *"&K_\ @QF_PK;HH^IX;_GTO_ I_P#R8>TJ?SO\/_D3$_L.+_H(:O\
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MV/\ OB7_ .-UZ5_PB\/]P_\ ?8_^*H_X1>'^X?\ OL?_ !5'M,)_SY_\I_\
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M$7)ZRN]2Q;ILAC7G)#,P(P5);.".V<G&1D@9J>@#  ]!BBN4W"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ H[K_O+_Z$**.Z_P"\O_H0H SYNLW_
M  +_ - %1:/_ ,>K?]=Y/Y)4LW6;_@7_ * *BT?_ (]6_P"N\G\DH YC5/\
MC_N_][_V6NFT_P#U<'_ O_0&KF=4_P"/^[_WO_9:Z;3_ /5P?\"_] :@#6HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ KR/XB?\A'0_P#K^B_]$7%>N5Y'\1/^0CH?_7]%_P"B+BFMU_BC_P"E1,ZO
M\.?I^L2EW/T'\VJ&Y_U+_5/_ $8M3=S]!_-JR[X9:3DC$2MW_A+-Z]\8SUQ7
MTZ^&'^"'_I*.,?;:BFCP:MK4L8F71M,U;51"V/WPTW3;F^$&20-LC6ZC!8=<
MY%?YE/Q8^+/CKX\_$OQC\9?B7K]]XE\<>/M:OM<U75=0FFN)[>&]D:2TT2P>
M6=XK+0='@?\ L_2-(L;6SL[*TBW;)9;J;9_I:7IW>&O&Q.1GP7XRXR?X?#6I
M#K^!/KSS7^8!8?\ 'C9_]>T'_HM:_H3Z/^&H.OQ5BY4XRQ-.&1485IQC*=.G
M4HYE5FJ,I1E*BJC455]E*'M>2+J<_+%1_!/&FH^3AV@G+V,WF\Y4Y2E)2J4J
MV&H.4DWRR4N;F@I1?LTN5/J6/+7T'_?*_P#Q-'EKZ#_OE?\ XFGT5_2MWW?W
MGX/[.'\D/_ 8_P"0SRU]!_WRO_Q-&W[I5VC:&3SX'3Y7AN8PKPSPLI1H)DE2
M,K<Q,L\&T2PMYL<=/I,#W_ D?R-14BZD'!OW9:237-&46FI1E%Z.,D[----:
M--:%1C&$HS@E&46I1E%<LHR6THRC:46NC3371H_O;_X)4_&SQO\ 'K_@G3\(
M?&7C_5KS7/%OA.?QI\,+KQ%J,TMQJVNZ;\/O$LFG>&]1U.XFGN9KO4H=#,6F
MWE]/.UQ?/;1W<X\V>7;^C>EW0>&0 .5$Q5 2/E&< #DC ./;ZU^/G_!$AMG_
M  2Z\*$#/_%V_C:/?_D:F'7KW_&OULT.X/DQQE0 TFXMN/' )X(Z#;US^7;^
M">+,+3PG%G%-&A%0HT^(\UHTZ48J,(<E6C6M2A%*%.F_KCC&E"$8PY-%9I+^
MS>$:DZW#605:TYU*TLDRV<ZDYRDYJI2J\O-SRG*4XK#>]4E*4I\^K7*^;T&U
M9F1MS%B'(!8Y.-J''YDU9JK:$>6Q[,Y*GL1L3D'OGG&.N#CI5D$'O_0_D:\!
MIK=-:VU36NUM4M;Z6WOI:^A]$IP=K3@[WM:47>SL[6D[V>CM>ST=GH+129'J
M*7(_S[''^?\ Z]3=7Y;KF6KC=<R5[7<;\R5]+N*5]+WT*_SM\[7MTUMK;>VM
MK:A112$@=^^/QH;25VTEIJVDM=M6TM>FNO2X"T4F1Z_Y_P#K=_3O2T)I[-.S
M:=FG9K=.S=FNJ=FNJ0?Y)_)JZ?HUJGLUJFUJ%%%)D<>_3_/XTVTDFVDF[)MI
M)MZ))MI-MZ))MMZ)-Z!_7_#]OG86BBBA--7333V:::?HTVG\FP"BBB@ HHHR
M/6C_ (;YO9>KZ+=]+A_PWS>R]7T6[Z)A129'K_D49'J/\^OI24HNR4HMMM)*
M47=K=*S=VNJ5VNJ0FTK7:5[I7:5VM&E=J[3T:5VGHTGH+13=RXSD8Z9_P]?Z
MT[/ZU336Z:]4UMONEMU[=;!S)WLT[*[U6B>S>NB=G9NR=G9NSL44F1Z_YZ?S
MX^O'6EJ4TU=--/9III]-&FT]=-&]=-]!^75;KJO5;K=;KJNZN44A('^?\_AZ
MG@4;AC.1Z_T_GQ]>*>V^GKIT;ZVZ)OT3>R;2NF[)IO5633=U:ZLFW=75]-+J
M]KJZT4F1Z_Y_SWI:.SZ-)I]&GLT]FGT:;3Z-@FG>S3L[.S3L^SLW9ZK1V>JT
MU5RBBB@84444 %%%% !1110 4444 <_JG_'UIG_7TG_HB:OH.#_40_\ 7*/_
M - 6OGS5/^/K3/\ KZ3_ -$35]!P?ZB'_KE'_P"@+7B9A_O3_P"O<37!?P7_
M -?JO_I3):***XCK"BBB@!NQ=Q;:-QZG')^OY"EVCT'Y4M% $?E1?W%_*CRH
MO[B_E4E% $?E1?W%_*CRHO[B_E4E% $?E1?W%_*CRHO[B_E4E% $?E1?W%_*
MCRHO[B_E4E% $?E1?W%_*G!$7HH&?:G44 & .@Q1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1W7_>7_T(44=U_P!Y?_0A0!GS=9O^
M!?\ H J+1_\ CU;_ *[R?R2I9NLW_ O_ $ 5%H__ !ZM_P!=Y/Y)0!S&J?\
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M+?\ X*)_%/XHQ^(?%G[(?[!?QX_:F^"'AC6O$/A^3XZZ5\2_@E\'?"?CN_\
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M^R.1C'E70I-$T+%2 ;@-;RRVT2R8BEDEMP%F#6N5N?D7^;K]K+X]?'?XA?\
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M5:[\7ZGI]_;:?))80C2K-[.6X%])Y/U@IWO%'&DDDD[;88XXI)'<XW'"(K,
MB9DD9@JQ1))-(4BBD=?Y\/@C^Q=^SI^US^T-_P %0;G]H#Q%\0]5A\"_MO\
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M_P )?V>?A=^VO\>_V_?C3^TM\1/B1H7Q(_9K_:S\4? KX.:KX.^-?CKX1/\
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M?_T2>$_\2#&__.D_/O\ B#F!_P"BFQ*_[H6%_P#GJS_-O_X5K\2/^A \;?\
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MA&$8PC%N+<8PA"$5>$8QT4%;EBDE9:N[91113*"BBB@ HHHH Y_5/^/K3/\
MKZ3_ -$35]!P?ZB'_KE'_P"@+7SYJG_'UIG_ %])_P"B)J^@X/\ 40_]<H__
M $!:\3,/]Z?_ %[B:X+^"_\ K]5_]*9+1117$=84444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %'=?]Y?_ $(44=U_WE_]"% &?-UF_P"!?^@"HM'_ ./5O^N\G\DJ
M6;K-_P "_P#0!46C_P#'JW_7>3^24 <QJG_'_=_[W_LM=-I_^K@_X%_Z U<S
MJG_'_=_[W_LM=-I_^K@_X%_Z U &M1110 4444 %%%% !1110 4444 %%%%
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M_P#5P?\  O\ T!J -:BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5&?LI.2C9?./[9.KM:?M]?\ !)S08]6%K=7_ ,9_VPKV^TBVU&XMWOM,T_\
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MNO"7Q*T;7?".I:3%(VOV7A_XDZMK6E3W,4&LZ7>_5G@/X8_#OX6Z5=Z!\,_
MO@_X>Z#?ZUK'B6_T3P/X:T;PII%]XD\0WLNI:]X@O--T*SL+*[UO6+^:2ZU'
M5KF&74+N0J+BYE6*!89KXZE"MA<7"=:M[3(,FP57 PJT(X25?+/K.%J4,?1G
M2G*KAE5P\,13A!+VTZM7%PG3Q$YU"Z675ZE/$8.4:5/V6<X_&K&-5'B'1QD:
M,J4\-4A."51.-6ZFVJ56,.=332,[X.:E\5-6^%WP]U7XX>&_!_@WXPZCX:TF
MY^(OA3P#K.I:_P"#=$\77$?^GZ5X>U?5D6^OK..5X\ S:E!!=O-9:9K?B#3K
M>TUS4?QW_:+_ &8OB_\ L._!?]J/]L3]FS]O#XE>#-$T;Q?\<?VV-0^#7CWP
M?\*O&7[/'CS6O'_B34/B;XD^&ZJGAW3?$R6_Q-GU2'P=X4\06GC&YU2WU#4]
M%N_#ZV^N3:?K6G?NDNY)(Y%)5HI%E0AC]]"67<.C*&PQ0Y5\%'W*S _F_P"%
M_P#@DE^P+X0\2>'M?TCX*7]QI?@_6M/\0^#_ (:^(?BG\6O%?P8\*ZSI<ZW=
MA>:'\(/$WC;5O ,$5K?"6_ATNZT2\T..\O+Z1-*"7<T39Y3F"P=;%SJU*=##
M8B6&E6RZCE. QV&QE.A7JUGAIRS*.(^K.7MJD88F%)U:,I0J4JT*M&%5[YME
MN(QM'#TJ<)5JE"%2%'%8K,J]&KA*U2E3I?6O982C26*LZ-*?L)XJ,9*#C.#4
MY0EY=\*O&$?B/_@JK;^*?%.A7GA;Q'\8_P#@DM\&?&?A#P[X@M[B_P!2T^.+
MX[:[XF^+G@[1[NUTZ<_VQX>OO%'@%/%>@J;;5O$<-A::R8-?;PS?75CY7X2_
M9T\(_M8?MF?\%3S8>,-=\'0^ _VC_P!@#Q#\-/B]\+I?#%YJO@/]J7]FKX*:
MI+KNI66D^*-&U_PKXCU'POK/BO0]&\8Z1XM\,:GH_B6VUJ_\-7 CU.V>]TC]
M)?VD_P!C7]GC]K:T\(P?'+P5J.OZE\/M1OM4^'_BWPYXU\:?#_Q[X'N=6BM;
M;6X_"_CGP+KN@>)=-L]?LK2&QUZQ.H3VFKVX5[R%[N"TNK;5^&?[*OP:^"/P
M0U+X ?!#1-0^$'@K4=+\7VIU;P5JCR>.K7Q%XZM-0MO$?Q(3Q=XL@\47NI?$
MVYDU W=OXN\0Q:W/9RV.EV<-J-&L(-*7L_M7"0P]6OA7C,-F>(RK*\B<%"C[
M#!8/ 8ZK6J8NCBH8FI5Q+K8.5.C]2GAJ36+ECL2ZK5?#PCS/*LP;^KUH82M@
MZ>-S',W5CB\3]8Q=?'8##X982<*]'FPU"%7#^TC4IXRHHN?NQ4>:WXBZNUYX
M-\:W?B[P?JVJ?M(>&O!/[=G@'P'X*^(/QNU3PSX=TG]K3_@J5\3=4\)_"B'X
MK?$>]^'?@'PIHVG_ +//[ /@72;'PA\./"GPN\$6>B7_ ,4_#5Q9>'K6]\;_
M  ^\.>(O#O[#?LI_'?XE_%35OVA?AA\;/"'@CPM\7?V;?BOI7P\\4WOPLUC6
MM=^&_C#1?%GPM\$?%?P9XS\-QZ_I.F^)_#1U31O&:6>I>&_$/]KRZ9<V<5VG
MBG4X]2%EIW3ZC^Q]^SUJ?[/'AS]E>;P']B^"7@_2/"&E>$O#N@Z_XA\+ZYX8
MN/ 6HVNN^$?%&@>.O#&IZ/XWTGQUH_B>U'B\^.+'7X/%&J>*KO5=:US5-4N-
M:U@7_8_ _P" 'PQ_9W\(:GX*^&&EZW;Z=K_C76OB1XIUOQGXQ\7?$[QYXR^(
M/B.WM+'7?&_C/XB?$?6O%/C;Q3XHU/2]/TW1[C5]8URZNET?3=/TV"2&UM8X
MZPS#,,'F%":G0J+%4ZO)A,2X485:.&>-6(G4YZ#A2C6Q%'VU+%T/8SH2=7!0
MPTJ&'RRE0C>!RO-,%B8M8JE+!U<.YXK#Q<_93Q?LK4X5*53F=2.&Q%65;#UJ
M4X*G"C4IJ+EC:LI?CM^W-\//C1^WO^UYXP^ /[.GCOP_^SU\6/\ @G_\+?#G
MQ1\*?% ZWXQT?XH?%7Q=^TMX5O[>X^'7AKQ'X"UO1-8^&OP2B\':0?#_ ,6/
M&=O:^*M?A\8>*_ :0:+!HMQ<3WNQ_P $_OVJ$\;?'/X5?LA_ ;X%#]E[PQ\
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M2S=9O^!?^@"HM'_X]6_Z[R?R2@#F-4_X_P"[_P![_P!EKIM/_P!7!_P+_P!
M:N9U3_C_ +O_ 'O_ &6NFT__ %<'_ O_ $!J -:BBB@ HHHH **** "BBB@
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MX%9CA:V#K8B6+J4JV'^M8:HJGM92?M(2ES)04HWI0:_E3^U6G_/PO_?F[_\
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M3_\  U_D')/^67W&]16#_;+?\^MU_P" \G_Q-']LM_SZW7_@/)_\31]9P_\
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M)H_MEO\ GUNO_ >3_P")H^LX?_G]3_\  U_D')/^67W&]16#_;+?\^MU_P"
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M_P"?U/\ \#7^0<D_Y9?<-U5E6[TS<0/]+C'/')AGP/T/Y5]"0?ZB'_KE'_Z
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M)4LW6;_@7_H J+1_^/5O^N\G\DH YC5/^/\ N_\ >_\ 9:Z;3_\ 5P?\"_\
M0&KF=4_X_P"[_P![_P!EKIM/_P!7!_P+_P! :@#6HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M][_V6NFT_P#U<'_ O_0&H UJ*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MT/\ &C>G]Y?^^A_C6/\ Z1_SR_\ (8_^*H_TC_GE_P"0Q_\ %4 ;&]/[R_\
M?0_QHWI_>7_OH?XUC_Z1_P \O_(8_P#BJ/\ 2/\ GE_Y#'_Q5 &QO3^\O_?0
M_P :-Z?WE_[Z'^-8_P#I'_/+_P AC_XJC_2/^>7_ )#'_P 50!L;T_O+_P!]
M#_&C>G]Y?^^A_C6/_I'_ #R_\AC_ .*H_P!(_P">7_D,?_%4 ;&]/[R_]]#_
M !HWI_>7_OH?XUC_ .D?\\O_ "&/_BJ/](_YY?\ D,?_ !5 &QO3^\O_ 'T/
M\:-Z?WE_[Z'^-8_^D?\ /+_R&/\ XJC_ $C_ )Y?^0Q_\50!L;T_O+_WT/\
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MD?\ /+_R&/\ XJC_ $C_ )Y?^0Q_\50!L;T_O+_WT/\ &C>G]Y?^^A_C6/\
MZ1_SR_\ (8_^*H_TC_GE_P"0Q_\ %4 ;&]/[R_\ ?0_QHWI_>7_OH?XUC_Z1
M_P \O_(8_P#BJ/\ 2/\ GE_Y#'_Q5 &QO3^\O_?0_P :-Z?WE_[Z'^-8_P#I
M'_/+_P AC_XJC_2/^>7_ )#'_P 50!L;T_O+_P!]#_&C>G]Y?^^A_C6/_I'_
M #R_\AC_ .*H_P!(_P">7_D,?_%4 ;&]/[R_]]#_ !HWI_>7_OH?XUC_ .D?
M\\O_ "&/_BJ/](_YY?\ D,?_ !5 &QO3^\O_ 'T/\:-Z?WE_[Z'^-8_^D?\
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M&/\ XJC_ $C_ )Y?^0Q_\50!L;T_O+_WT/\ &C>G]Y?^^A_C6/\ Z1_SR_\
M(8_^*H_TC_GE_P"0Q_\ %4 ;&]/[R_\ ?0_QHWI_>7_OH?XUC_Z1_P \O_(8
M_P#BJ/\ 2/\ GE_Y#'_Q5 &QO3^\O_?0_P :-Z?WE_[Z'^-8_P#I'_/+_P A
MC_XJC_2/^>7_ )#'_P 50!L;T_O+_P!]#_&C>G]Y?^^A_C6/_I'_ #R_\AC_
M .*H_P!(_P">7_D,?_%4 ;&]/[R_]]#_ !HWI_>7_OH?XUC_ .D?\\O_ "&/
M_BJ/](_YY?\ D,?_ !5 &QO3^\O_ 'T/\:-Z?WE_[Z'^-8_^D?\ /+_R&/\
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MC_GE_P"0Q_\ %4 ;&]/[R_\ ?0_QHWI_>7_OH?XUC_Z1_P \O_(8_P#BJ/\
M2/\ GE_Y#'_Q5 &QO3^\O_?0_P :-Z?WE_[Z'^-8_P#I'_/+_P AC_XJC_2/
M^>7_ )#'_P 50!L;T_O+_P!]#_&C>G]Y?^^A_C6/_I'_ #R_\AC_ .*H_P!(
M_P">7_D,?_%4 :5PR>3)@KDKV(SDD?SJEI (M7!&#Y\G!^B56E^U>6VV+)^7
G'R ?QJ>S]AD\\407T5E'Y4JNTKDRR;2,*SX!48##C:/XCUZT ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>aud_001.jpg
<TEXT>
begin 644 aud_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  B +0# 2(  A$! Q$!_\0
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M']O:Q_T%K[_P(?\ QHHH /[>UC_H+7W_ ($/_C0=>UC!_P")M??^!#_XT44
M*==UC/\ R%;[_P "'_QI/[>UC_H+7W_@0_\ C110 ?V]K'_06OO_  (?_&C^
MWM8_Z"U]_P"!#_XT44 ']O:Q_P!!:^_\"'_QI1K.J/F1M2O"Z?=8SME<]<'/
M%%% "?V]K'_06OO_  (?_&C^WM8_Z"U]_P"!#_XT44 ']O:Q_P!!:^_\"'_Q
LH_M[6/\ H+7W_@0_^-%% 'J7@VXFNO#%K-<3232L6R\C%B?F/<T444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>4
<FILENAME>ex5-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
5.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
30, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex5-1_001.jpg" ALT="" STYLE="height: 75px; width: 100px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impact
BioMedical Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">275
Wiregrass Pkwy</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">West
Henrietta, NY 14586</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Re:
Registration Statement on Form S-1 (File No. 333-253037)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have acted as counsel to Impact BioMedical Inc., a Nevada corporation (the &ldquo;<B>Company</B>&rdquo;), in connection with the Registration
Statement on Form S-1 (File No. 333-253037) (the &ldquo;<B>Registration Statement</B>&rdquo;) filed by the Company with the Securities
and Exchange Commission under the Securities Act of 1933, as amended (the &ldquo;<B>Act</B>&rdquo;), for the registration of a distribution
to its stockholders beneficially held by DSS, Inc., through its wholly-owned subsidiary, DSS BioHealth Security, Inc., (&ldquo;<B>DSS
BioHealth</B>&rdquo;) of 485,161,488 shares (the &ldquo;<B>Shares</B>&rdquo;) of the Company&rsquo;s common stock, par value $0.001 per
share (the &ldquo;<B>Common Stock&rdquo;)</B>. The Shares consist of 485,161,488 shares of Common Stock (the &ldquo;<B>Distribution Shares</B>&rdquo;)
which will be distributed to the shareholders of DSS, Inc., on or around the effective date of the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
opinion expressed herein is limited exclusively to (i) the Nevada Revised Statutes (the &ldquo;<B>NRS</B>&rdquo;) and (ii) the laws of
the State of New York, in each case as in effect on the date hereof, and we have not considered, and express no opinion on, any other
laws or the laws of any other jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
rendering the opinions expressed herein, we have examined and relied upon the originals, or copies certified to our satisfaction, of
(i) the Registration Statement and the prospectus included therein (the &ldquo;<B>Prospectus</B>&rdquo;), and all exhibits thereto; (ii)
the Company&rsquo;s Articles of Incorporation, as amended; (iii) the Company&rsquo;s Bylaws; (iv) the resolutions of the Company&rsquo;s
board of directors with respect to the authorization of the issuance of the Securities covered by the Registration Statement and related
matters thereto; and (v) such other records, documents and instruments as we have deemed necessary for the expression of the opinions
stated herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
making the foregoing examinations, we have assumed the genuineness of all signatures (other than those of the Company), the authenticity
of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as certified or
photostatic copies thereof and the authenticity of the originals of such latter documents. As to all questions of fact material to this
opinion, where such facts have not been independently established, we have relied, to the extent we have deemed reasonably appropriate,
upon representations or certificates of officers of the Company or governmental officials and representations of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the foregoing, we are of the opinion that (i) upon the issuance of the Distribution Shares to DSS BioHealth., the Distribution Shares
will have been duly authorized for issuance by the Company and will be validly issued, fully paid and nonassessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
opinions set forth above with respect to the validity or binding effect of any security or obligation may be limited by (i) bankruptcy,
insolvency, reorganization, fraudulent conveyance, marshaling, moratorium or other similar laws affecting the enforcement generally of
the rights and remedies of creditors and secured parties or the obligations of debtors, (ii) general principles of equity (whether considered
in a proceeding in equity or at law), including but not limited to principles limiting the availability of specific performance or injunctive
relief, and concepts of materiality, reasonableness, good faith and fair dealing, (iii) the possible unenforceability under certain circumstances
of provisions providing for indemnification, contribution, exculpation, release or waiver that may be contrary to public policy or violative
of federal or state securities laws, rules or regulations, and (iv) the effect of course of dealing, course of performance, oral agreements
or the like that would modify the terms of an agreement or the respective rights or obligations of the parties under an agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1185
Avenue of the Americas <B>|</B> 31st Floor <B>|</B> New York, NY <B>|</B> 10036</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">T
(212) 930 9700 <B>|</B> F (212) 930 9725 <B>|</B> WWW.SRF.LAW</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hereby consent to the filing of this opinion with the Commission as Exhibit 5.1 to the Registration Statement and any abbreviated registration
statements relating thereto that may be filed to register additional securities identical to those covered by the Registration Statement
(including a registration statement filed pursuant to Rule 462(b) under the Securities Act), and to the reference to our firm under the
caption &ldquo;Legal Matters&rdquo; in the prospectus constituting part of such Registration Statement. In giving such consent, we do
not hereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Sichenzia
    Ross Ference LLP</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sichenzia Ross Ference LLP</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1185
Avenue of the Americas <B>|</B> 31st Floor <B>|</B> New York, NY <B>|</B> 10036</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">T
(212) 930 9700 <B>|</B> F (212) 930 9725 <B>|</B> WWW.SRF.LAW</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>ex5-1_001.jpg
<TEXT>
begin 644 ex5-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !+ &0# 2(  A$! Q$!_\0
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;1Q6L$+;HH8D8\95 #4U%%P"EHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-16.2
<SEQUENCE>6
<FILENAME>ex16-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
16.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Your
Vision Our Focus</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex23-1_001.jpg" ALT="Text Box:  &#13;&#10;&#13;&#10;" STYLE="width: 112px; height: 112px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
24,</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
and Exchange Commission</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100
F Street, N.E.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Washington,
DC 20549</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have read Impact BioMedical Inc&rsquo;s statements included under Item 11 on Form S-1 (Registration No. 333-253037) and we agree with
such statements insofar as they relate to our firm. With respect to all other matters, we have no basis to agree or disagree with the
statements made by the registrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sincerely,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ <I>Turner Stone &amp; Company L.L.P.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certified Public Accountants</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dallas, Texas</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Turner,
    Stone &amp; Company, L.L.P.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accountants
    and Consultants</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12700
    Park Central Drive, Suite 1400</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dallas,
    Texas 75251</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.15pt">Telephone:
    </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">972-239-1660 &frasl; Facsimile: 972-239-1665</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Toll
    Free: 877-853-4195</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.25pt">Web
    </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">site: turnerstone.com</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex23-1_003.jpg" ALT="" STYLE="height: 27px; width: 72px"></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>INTERNATIONAL
    ASSOCIATION OF ACCOUNTANTS AND AUDITORS</B></FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>7
<FILENAME>ex23-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Your
Vision Our Focus</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex23-1_001.jpg" ALT="Text Box:  &#13;&#10;&#13;&#10;" STYLE="width: 112px; height: 112px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0; color: #998B7D"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consent to the use of our report dated June 24, 2022, in Amendment No. 13 to the Registration Statement (No. 333-253037) on Form
S-1 of Impact BioMedical, Inc., for the registration of its common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also consent to the reference to our firm under the heading &ldquo;Experts&rdquo; in the Prospectus included in such Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Turner, Stone &amp; Company, L.L.P.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dallas,
Texas</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
24,</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Turner,
    Stone &amp; Company, L.L.P.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accountants
    and Consultants</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12700
    Park Central Drive, Suite 1400</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dallas,
    Texas 75251</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.15pt">Telephone:
    </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">972-239-1660 &frasl; Facsimile: 972-239-1665</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Toll
    Free: 877-853-4195</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.25pt">Web
    </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">site: turnerstone.com</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex23-1_003.jpg" ALT="" STYLE="height: 27px; width: 72px"></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>INTERNATIONAL
    ASSOCIATION OF ACCOUNTANTS AND AUDITORS</B></FONT></P></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>8
<FILENAME>ex23-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 23.2</B></P>

<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex23-2_001.jpg" ALT="" STYLE="height: 864px; width: 670px"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>ex23-1_001.jpg
<TEXT>
begin 644 ex23-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !P ' # 2(  A$! Q$!_\0
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MAM8X[RR%_J3*'D1SA(<]%]S6W:VNB^+-,E:&S2UN4^4E  4..#QU%#2W#4]
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M,CH"""%(T:N9IV.$M=5LXUN+MV<SR6GV9(%3Y.5 W;O3C./>LC[3.#"1*P,
MQ&1QMYSQ^-5)[>YT2^ETW4H5@GA!?"#$;QC)\R/  VX!+* -N"P 4,L,PYQC
MG/3%8NZ-E9E+6O#U[-:F?1)%TJ[N29'B*B..Y)ZE'Q\A/IT],5Y3J5C?Z=>O
M#J=O/!<Y^83@@M[Y/7ZBO?\ C2=!!F19;J_PRQRC<(XAT./4]O:LRYN(Y@T
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022?QJ:M$K&;=PHHHIB/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>ex23-1_003.jpg
<TEXT>
begin 644 ex23-1_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ; $@# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#@Z]>^!W_,
M>_[=_P#VI7D->O? [_F/?]N__M2OJ<?_ +O+Y?F?-8'^/'Y_D=W"F?&T\)9_
M*6T$@3>=H;<.<9JI+<W6B:O=7H:272_/$,T98MY7RJ0PSVRQ_P XJU#+&/'%
MQ)O'EM:",/\ PEMPXSTS5ZP>WNYM4A)61))^5/1E\M 3[C((KY,^G"5(9]8L
M)D=F22*1_ED.UL;<'&<'K4NL-,]D;2U;;<W.8T;^Z,$D_E^I%9&F:?=:5X@2
MT+&33UCD>W8\E,E<J35Z,#5=3GF2ZEB6W_<Q^60"W0LW(/!.!G_9I@3:!J#:
MCI$4LF1.F8I@>H=>#_C^-2:NTK6?V6V;;<7.8T;^[QDM^ !_'%8]E_Q)_%4]
MKYKR6UX@D+M@[9>>"0,#/]15Y NJZG/+'=2Q+;#RH_+(!;."S<@\?=&?]DT7
MT"VI+X?OVU#2(GES]HB)BF!ZAUX.?Y_C167:?\2;Q5-;^:\MM>H'9VP=DON0
M,#/]1130F?-E>O? [_F/?]N__M2O(:]>^!W_ #'O^W?_ -J5]5C_ /=Y?+\S
MYG _QX_/\CT2SG:^L;B^GFE11)($6-L>6JDCIW/&><TE]=,-)TZ9)I2))80S
MKD,ZG&>!SR/QJEJTKV%Y-#:MY<<Z[Y%'(+'@GGIGVJ;6_P#1=.TV.'Y526/:
M.N-O3K7RESZ<NZ/<27*7,XD>2S9_]'WG+X ^8'OUSUYJ"WN+BZ\.OJ7G,EPR
M-,O/RIC.%QTQ@8/XT^U @\1W447RQRQ+*ZCH7Z9]C52;Y-1;3%XLI)!NB'0A
MN2/4 DGB@"W<74DPT:96>/[3(N]58C(,;-@_B!5],G4IAN;:(D(7<< DMGC\
M!5?6$5=-,H4!X&62(C^%@<9_(D4NE2O/:-<2G=*WREL=AT_F:?470S;*XNYB
IGD/</*MZZ2%@2GE!R.IXR!CISFBI_#4C/9W&XY_TAS^).3^IHH0,_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>ex23-2_001.jpg
<TEXT>
begin 644 ex23-2_001.jpg
M_]C_X  02D9)1@ ! 0$!+0$L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 6+!$P# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3XMI8^=>?]GRS+!8-5^?GIX..%R^O3I*4US2IPJXBM[/5\L7R1?+%)?RQ?\
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M*G[2N@OJC<I/HGPSA^#VD:#''F0(D#:QJ?C?:"O-Q;W9=GQ"J?Z5_P#P3?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ J*?\ U3_3^HJ6H;C_ %+^ORXXSSN7'^>/0'-%
M^75[+5^BUZV7WM(#_-N_X)F?\IR?A;_V<W\;/_3=\3:_TD+K_CUN,#_EA-@#
M_KFW%?YD7@SXB+_P3W_X+!:E\1OBMHFLS:;\#_VKOB++XKLK.Q_XFEUX2UCQ
M!XFTB?7M'LYIXHKMKGPKX@7Q/HD)NTCU&%K-4N!'<+)7]B/Q(_X.'O\ @F%X
M<^'OB3Q!X,^..M?$;Q=9:!J%UH7P\T7X1?&/1=:\0:S]DE:PT6/6O%O@#0/"
M6G&6Z\J"YOK_ %^*UMXB]Q&UR56*3^X?I.<$\8<9<3>'V;\*<,YYQ'E>*X"R
M3 T\PR;+<7F&$ABI8_,,5&GB:^%I5(82,\-F&$K0JXJ5&C.G5<H5'[*M[/\
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M5%5>;[*/U"_X.S@?^$D_84.,$Z-^T5G'K]M^"6>?S_"OWF_X(@?\HK?V/_\
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M4WA.OL.OCS_@GE_R8/\ L3_]FG?L\_\ JIO"=?8=?P?Q5_R4_$?_ &/LX_\
M5AB#^D,F_P"1/E7_ &+<#_ZBT@HHHKP3T@HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ(_94_9*\$_L@?LW>#/V8OACX@\6:EX)\!VOBNUT+7/%E[I=[XL*^+O%&O\
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MXJ\.RZ/X@\,ZG\-++2IU%XXL=3;5]ZZG:RV$K<QK?[2WQ^\._#WX+>,O$?\
MPKO1]$^*'@J\\?Z]\3=/^$/Q=\9>"/ (N- \&:QX4\$^(_#WA+QGJOB#39M8
M;7/$-U/\1=4U?3_#-M9>'UMVT+[9>!D^.R7BWB7A[.I\1Y-G>88'/JCQ+JYM
M3K.6.JRQK<L7*K7J*<JD\3)N5:<W*=23<I2<FV>]C\DRC,\NCE./R_"XG+(^
MPC' SII8>*P[C[",*<.51C2Y8J"C91226A]O?!;X7:)\#_@_\+?@QX:N]3U#
MPY\)OA[X.^&^@7VM36USK%WHG@GP_I_AO2KC5;BRL].M)]1EL=-@>\FM;"RM
MY;@R/%:P(RQ+Z97(^ =?;Q3X'\(>)6U#PWJS:_X:T76'U3P=J4NL>$M0?4=.
MM[M[WPSJTR13:EH%RTIFTB]FBBFN;!X)98XY'9!UU>%7KUL57K8G$5)5<1B*
MM2O7JS^*K6K3=2K4E9)<TYRE)V25V[(]*E3A1ITZ-*"ITJ4(4Z<(JT84X148
M0BNBC%))=$@HHHK(L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<6R&<MX=TB[;P[I'B'1I-&\7VOAZ"STH^(I+>T@"?7E% 6ZVU[V/FK6/V6/
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MXN9);BX>.WA0//<2R3S/NEED>1F8]9110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1136.%8^BD\#/0>F1GZ9'U% #J*^#_@S^V3?_$O
M]MK]LC]C#Q-\.AX&UK]F+PS^SY\0O!7B_P#X2=M;@^-'PV^.OAKQ%=S^)K/1
M7T+29_"LO@;QIX4USP1K%FU_KT%W<1V6H6FHIYUW86?QQ_P37_X+%V'_  4#
M_:8_:+^ MS\%$^$^A^!=%\5?$G]F/X@#XCQ^.;?]J7X"^!?VBOBI^S5XP^+F
MC:=:>#= TKPWIVA^/? &@6ES;:1XG\>V$EUXQCM(M<\O3HKG5 #]MZ*_+?X(
M?\%2_@IXU\._M:_$_P"/&O\ PM_9:^!O[.O[:/Q,_8U\%?%3XP?&/POX7T?X
MM>(OA+9:#9^*?%$,WBJT\*Z'X<@O?&5]XA\-^&] A\0^(]6U*+PGJNIW8TP_
MZ!%^AOPS^*/PV^-'@?0/B9\(?'W@WXH?#KQ7:O?>&/'?P^\3Z)XR\'^(K*.>
M6UDNM%\2>'+[4M'U."*Z@GM9I+.\F$-U!/;R[)H9$4 [NBOR]UW_ (*G_L^_
M"W]K[]J;]FG]I'QU\&_V;?"'[._@7]F?Q5H/Q@^+_P ;/"7@?3?B7J_[0MC\
M4K^?PQ8Z-XP@\.6NF7G@Z'X;!]]EXE\0W&MPZR9WL-&CL%^V_;7CC]H[X _#
M+X6V_P </B-\:OA3X"^#%W8Z1J=E\6O&'Q"\(>'/AK?:=K\$=SH5_8^.-7UB
MT\,WEGK<$J3:1<VVIR0ZE"PFLGGA97(![117AW@W]IK]G7XB?"Z'XW^ OCM\
M(/&?P9N+R#3H/BQX8^)'@[7/AQ+J%UJUGH%KIZ>-=-UFY\.&_N=<U"PT:"R.
MI"ZEU6^L].2(WES! _ G]N_]BA?AYXR^+A_:W_9L_P"%5_#OQ:_@+Q[\2/\
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MX1U#6XO!VLZ[>7#V]OXFT_4;"\.GW$*02^]_!']L/]D_]I?5O$F@_L[?M+?
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MOAIXFC\8^-]-T^74;3X8^'M?M/$5WH3>.-7@B::UT)IY]6-BDU_!IEU%%M8
M_1^BOEK5OVT_V6_!WP+\#_M'?$_X_P#P3^%OP=\?66A2Z#\1O'/Q9\!^'_ %
M_JFNVDEQ#H6E^.-7UO3_  YK&IQS6VHVGV>QO'N))M,OP+=#:S)'WEG^T?\
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M+E\7Z=X9U.\N=/TWQ'?^&H[MM:L]!U&^L[NRL=8N;&+3KN\M;FT@N7N;>:)
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M>'2=6TNRAAUI+BTMD5/GS]FCX._!3X@_\%;_ /@X,U;7?AM\-O&5I8?L^?\
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M  3_ /#?B1_#D<^J6URT.C3Z_;6>L7NGQ!+6_P!2T[2KR]CN)])TU[7]A_\
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MO-_P6A^)MIX&\)P?$34/^"AO[5'B6[\;KH.FMXND\1>"?VY?#VB^$-9B\1M
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MACX(\1:=\-SH\5I;Z2? 5GJ^A7EOX0_LNVT^PMM-&@)IXT^WL;.&S$"6T*H
M?QC_ +//PY\8_$;_ ((C_M'?M!?!34/!?C#XO?\ !/3_ (*P?M)?MV_LX7?P
MW\':OX%^%^L+\ /B8GCGQ;X:^%_PTEU&\UCP)\*_B#\-->^(Q\/?"I9K^6R@
MUS3M"O;74]2BED?]P?\ @B1XIMOVM+[]NK_@J1_9&JZ3I?[;O[2S>$/@D-10
MQPWG[+'[)&@'X+?"'5[.&>*&_L[OQ%XM;XM>(O$=E=)']BU_4[S3X1/#9#4+
M_P#0/]J']F+XF^-/@9\2/A3^QE\0_A-^Q_XN^-GB'Q3J/Q4^*</P)7QMK-VG
MQ T"_P!&\<>.?#6D^%?B!\)+2'XY:C<-H>H6'Q,\877C&.-M(\O5/#VJSMI]
M[I?K_P"RI^S?\./V0/V=/@[^S+\([*^LOAU\%? VB^!?#/\ :MQ%=ZSJ$&E6
MX%]KVNW<%O:6UUX@\2:M)?\ B'7[JTL[.SN-9U.^FM+.TMI(K>, _-G_ (.%
MM-T]/^"-_P#P4&U>*PLTU>X^".C:?/J<=K"NHSV%E\2/"MS9V,UZL8N9;2TN
M+Z^N+:V>5H8)KR[EB1'N)F?9_P""N^F_L&^(OAS^R'X5_P""AGB;XF?#;X.Z
MC^U9\/M8\"?%SP=\1=:^$7@/X=_''PEX.\8Z]\/;GXO_ !0\.^(=!U7X?^&=
M;M;?Q%I6B>,$EM+;P[XF?3M3?Q1X*NK:R\16WZQ^-_ G@GXF>%=9\"?$?P?X
M7\?>"/$=LMEXA\'>-- TKQ3X6UZR6:*Y6SUKP_KEI?:3JEJMS!!<"WOK2>$3
MPPRA/,C1E7Q?X)\%_$7PMK'@CQYX5\->./!7B'3IM(\0^$?%NA:5XD\+Z]I5
MPH2?3-:T#6+2]TG5-.F"*)K*]M)[64*%DB91B@#^=?\ X)+3?LZ_"']MC]N7
MX4?\$]?B7X?\7_\ !+;X?? [X&^/]0OM'^,NI?&3X._"O]KC6]0\>)\1]%^%
MGQ5\5^+_ !9)=:+K7PD\.^%?&WQ0BM?%GBC1-"\0G3IY=0\/&\32Y_Z*?!'C
M?P;\2O"'AOX@?#SQ9X9\=^!?&.CV/B'PEXS\&:_I7BGPGXHT#5(%NM,UOP[X
MCT*ZOM&UO2-0M9([BRU+3+RZLKJ!UEMYY(V#'F?"_P &_A7\/? 5S\-/AQ\/
M/ OPX\ 2V6H62>#? G@OPGX7\)6T.IVQM+SR?"FF:-!X8(FMR(IH;C2)[2YC
M58KVWN808SE_L]?!CPS^SK\#/A+\"/!DUY<^%_A)X \,> =&O-1M]*L[_4+3
MPUI5OIO]I7MCH%AI7A_3KK4I8)+^?3?#VDZ/X?TV6X:QT/2-*TJWM-/M@#V.
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "D.<''!P<?7M2TU_N/P3\K=,@]#T(YS].?2@#\5OV
MY/V#?"'QI^+OQ@_:7_;D_;0^*W@?]C3X:_!+P['\,OA/\,OC%\2_V8/!GP2\
M1:%'XIU+XH_&[XF>+? WQ"L;?XF^,Y8[C3#X+UK4]/TK3- T&2]\)WGA'6&M
M(M:UO\@_A)X[_:P_:9^!G_!$_P#87_:/^-G[26C^$_VYOC!^VW\3?%WQ._X3
M'Q#\)_VF?C%^QA^RMX:\0>/O@3X+^+?C+0KQ/&.C7_QS\+^+OA]K?C2_T75X
M/$.L^"+2R@O/$<.LZI>7S?7'[?G[+?\ P5)_:*_;[MOB'=?LK_LY?M<?L(_!
M#3O#%W^SE^S;\5_VFO\ A6/P[USXM)H'F^(/CU\;O +?##QU'\1_&FBZEK^O
M^%_ 'AW7KC_A"_"6BZ7I6NV.BW/B2]U/5[SZ._:$_9]_X*(_M!^&/V*/VR])
M^#O[./PG_P""@_[$7QF^*GB'1O@7JOQA\2>,_@S\1O@=\7/!>H?#+XH?#F'X
MP:+X)TO5O#7BWQIX6C\,:]X=UFX\(WFB>'O$7ANVLM7BO;">>XMP#Q_]F#X4
M?M ?"KXW?\%>?^"7G[/W[4'Q'\/>&_#_ ,%_@!\7_P!C7XD_&C7_ !?\?O%7
M[+]W^TKX+^*'ACQGX?T[Q!XM\36WC'Q!HN@>-OA^_BOX>V=]XBNHO"<^HKJ-
MW'XGU637/[=\KLOV:+7]A[_@HO\ \$[/@A^QM^U=^U#\6?VC?B3KGBWQC_P4
M#\$_&+]H+XH_'+PAXZ_9<T3P'XKN/%?[07QN\,>*?$7B;2/ACXXU+XJZAI'A
M_P"!^JVMEX>M_$7C/Q)K.F6)N4L_$$MS[SX%_9B_X*K>%/ O_!3#]M)M*_9\
MT;_@I/\ MEZ%\(/AM^SW\(?#GC[4];^#_P"SI\,OA'IUYX*\*2:G\2?%/A>U
M'BCQOIZ^/OB!\7M4LI?#=UX1UGQ1I'A_3(7L[#Q%J6A:!QO_  3"^ '_  4P
M_8^UG0/"OQ _8*_9KBN/B]XSL/$/[97[:6I?MH7GQ0_:5^,&O7=QJ-UK/Q#\
M5QS_  7T2Y\52:3<:MJ,'@GX?IX@L?#GA'1KIM*T18Y9+^^U$ ^,/V_?A]XP
M_8Q^+/PD^)7C;]N+]IKQ5_P4J^+G[7?P\\?>'OCAJ'B[XD?!'_@G%\'OV5=1
M^.S^'[_X5?&GP]XG\87/[.?P\^"-K\((]3T.Y\%GQ+KOQF\8_%R[T>]TJZUJ
M/Q'=WNN?V.*=RAAR" 0<8SD9S7\W/[1G[+/_  6J^,GPS_:"_P""?.N^,_V7
M/BQ^S1^T=XF\<Z&W[=GQ#UC5]+^._P ._P!G7XI:_JFM>(O ^N_L[>$O!6B>
M"?%GQ6\":+=W_@KX>:SX:\1^&_!6H::GA.[O7\(R+J#>%OZ'/ GA'3OA]X'\
M&^ M'N-0N](\$>%/#OA#2KO5KA+O5;G3?#6D6>C6-QJ=W'#;QW.H36ME%)>7
M"6\"37+22+#$&"* ?E1^VK_P4H\6?!O]JSP9^Q3\ K']FM/C#J'P2O\ ]HCX
MD?$#]KGXXW_P,^"_PZ^';>+&\#^#-$M+[1/!_B[Q'XY^(?Q!\0V?B%].\/:-
M!9IH.@^&+[7-4EGMKJ%(?(/#G_!9[6];_8OUC]LNS_9HC\4>%/V=?VD/%7[/
M7_!0#0?AY\9M.^(-[^SG8_#K4M$M?B5\:_A)>>"?A]XFT_\ :1^&/A'0/$>@
M_$>[6SN?AUKA^&NI3>)([>X72[Y4G_;M_8!^*.N_MV^#OV]_@[^S1^S-^VS;
MZO\ LW2?LS?&/]F;]J'6_#G@VPMX/#OCVX^(7PO^+WPF\=^(_@]\8=/T?Q+H
MT^N>-?"WC/1=2TFSL=6\/:QI\]FM[J4"SZ5A>)OV,_V][S]D;0/V1_A_:_LS
M? ";]JSXU>.=7_;+^(?[-OAKPS\*_#G[,O[,_C&R2SUWX3_LYZ?H/@;0-1^*
M7QOU/P/9Z-\,=&^//C?P78WQ:/4==U2QTICX5O\ PR ;/B+_ (+@^#9/AW^U
MS^T7\)_@EJGQ=_9%_9W;P%\+_@_\?M'\</I4'[8W[5_Q%\4Z'X.T;X-_ +PX
MW@34].U7X;:+XG\3:%X6\8?'BY\8FRTWQ'-J-KX?\!^*M*TF^UY/7]._;I_:
M]_9X_P"%D:O_ ,%$_P!F+P-\.OA5X)_9D^(W[3K_ !\_9<\<>./C)\,_#*?"
MF+3KKQ=\"OB.OC/X;?#[4-!^*UUIFH+J_@/4=/FOO"_Q"CL];TO2FT_4=&G\
MSX0D_P""/?[1G@W]G7]J#_@FM\*?%OAZ']C*RUWX??M+_P#!.#XE^-O%^H:_
MXU_9W^.G@OXK:?\ &:]_9V^,&AS:=-J/B[X'WGQ/T:'6O#GBO18-8\2:!X2\
M1^)8M>F\8>);RPDTGZF\<_LX?\%&/V_K'Q[\+?VP9/A5^QO^SCK?[-7Q[^ '
MC?X;?L^_%4?M%W_[1GCKXS^&=*\,:5\5M1U?QO\ !CX<'X8^"/A%)ITWBOX=
M^&],FG\?:]K>K:AH_C75[/PH^I:3XB /)_@K_P %HOB;J7C?]CVX_:%^'7[*
M'ASX5?MV^._"'PS^&&F? 3]K;3OB]\>_@)\0OBCHUUX@^$WA/]HOX;:KX,\'
M6LX\6P6[^&];U_X=ZGJ5KX%\:1V^BZSIUTVL:?L]+'_!2C]N?XQ_%K]MWX??
MLD_L0_#;QCHG[ ?Q;UCX>>//$GQ?_: \3^#4_:(N=-\#Z%X[T_P'\!CX9^!_
MB6QT?XL:A8WFI6GB&Q\=7:^%/!0U;X8Z@=<\3)XTUBR\'>1?L@?L'?M<>$]=
M_92\#_%?]C'_ ()K? C2_P!EZ]\'7?Q2_:O^$_A?P!\4OBM^U5+\,_#EQH?A
ME_ '@C4OV<O 5[^S[J?C+Q'::'\1/&?CZ3QK=>+?#VIZ?#IO@BRMFU.[GTOQ
M+]DG7/\ @HWH_P"TM_P6BTG]D+X9?LU_$7P/X[_X*%^./"VG>)OC)\7O%/PR
MU?X#?%P_L]_!I=2^)VO^&-#^$OQ"C^,GP\N=(U;P-,O@O1M=\%^)HM7\(:O:
MK>FS\4)J.C@'H7[.G_!0K]H#]K__ (*Y_LG>(_@UI&G77[%GQR_X)8>)?CGH
MWA+5?V@/$>F?9]/U;XS?!;3/&7Q2\5_"G3_A->^%Y?CO\)?B2^J_ 33/!+^*
M]4LKWP?-XG\<Z?\ %;PS+>WGP\U/^EIPY&$.#GD^V#T/.#G!Z'Z&OY[OV;O^
M":?QM_8)_:D_X)X>*/@9X4\&?&3X(_!/_@GEKO[ _P ;-5U/XBW?PZ\7>&->
M\4_''X=?&OQ;\?\ P]X;UCP_XP@\9Z;KWB30/$URGPXMO$?AZ?3/[7:VL-8M
MK'3M+TZ^_H21BRAL8SG@'(ZD=<#.>O3'H2.2 ?QY?"W]K?X[?"K]I[_@I7^V
MA^U!^SZ?BS\4_@O^UKX8_8[_ &4_AWX,_;C^+6L6EE\:OBOX1^ O@GX3_LJ?
M#?X27_PE\$?!?_A!?&47Q5\1_$3QE^T1K?AV/QMX?U>YU^S7X:>*KF&/Q+=?
MMQ\"_P!M']IC1?VM/"_[%G[<OPC^"OPU^)GQA^#OB_XU_L^?$3]GWXG>,?B%
M\,/B':?#/5="TCXL?"W4[/XA_#SX?>*] ^(_@&W\2^'/&*W%O;ZQX<\3>$]<
ME:UNM,U+P[?0ZE\<^/\ _@EK^T3X_P##/_!1.;1O$7P^\!_%CXD_\%-/A'_P
M4)_8L\3>([_4M>\#KXM^ OA+X!S^!;/XQ:;H>G3ZSI?ASQ#XG^&GB7PWXDM=
M+L]9U72=&U.W\1Z?8ZM=VD&D7?T1\%O@!^V-^T'^W-\*?VW?VU?A1\)/V=-/
M_9>^"7Q2^$_P"^"GPK^-.J?'?7]?\=_'B[\)2?%GXK>//'/_  K3X9:)IOA:
MU\)^"O#?A#P'X$LM*UG4EUB?Q1X@UK5+-+;08]3 -[_@F%^WU^TW_P %%? ?
MP^_:;OOV9OAC\&?V3/BIX/\ '[>%-0?X\:QX\^-=A\0OAOX_'P^U6UU?PK;_
M  D\,>$[GP7XFUS3/&\7AC4K;Q)9Z[8:?X+75/$6D6L_BW2]'T_UK_@K_KNM
M^&/^"6?_  4'\2>&M8U3P]XAT+]D#X]ZIHFO:)J%WI&LZ/J=G\.]<FM-1TO5
M+":WO=.O[695EMKRTGAN+>11)%(C &N=_P"",_[*'Q8_8@_X)M?LX_LP?'*V
M\/VOQ3^&7_"X/^$IA\+:POB#0U'C/X]?%'XA:&;'6$M[07@?PYXLTB2YQ GV
M>[:XM?F,&]O:_P#@HY\$?'/[2_[!?[8'[/'PRBTJ;XB?&S]G/XN?#+P1'KNH
MKI&BOXH\8>#=4T714U75'BG73[![Z[B%S>&&;[/%NE,3*IP ?AM^P[^U-\=O
MA]^Q1^TO_P $]/VK_%NK:G\?_@]_P3Z\6?M"_LL_'"XU&X@U;]I#]D7QE\%]
M3O/!GBZWU9[QM2F^*/P"\1W<?PM^(TL+07JOIOA3Q$DFHR7]WXBU#W+]E[]N
M[X[Z5^S#_P $BOV/?V:/ _@KXZ?M=_''_@F3\"_VE_B!XF^/7Q,\5^$?A]\*
MO@]X1^$GPI\/ZK\3OB7X@\.^$/B%X\\7Z_\ $OXD^)+;P9X4TS2=*>>YUZ36
MO$/B36K6RTN.RUKU/_@H+_P2[\??M6?L"_ KPQ\*O$MI\,/V[OV2?@_I&G?
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MPMI?C/\ :$^+OP(_:Z/B7X>^)?VD_&'_  K7XC)<_LF?"ZW\-_%_XV_$J[\
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M-9T^Y_M[2BG]#*Y*#/)*C)]<CKP!_P"@CZ#I7\ZG[(/["7[6_ACQ%^RMX/\
MBQ^QC_P36^ &E_LP7GA.[^*7[4_PD\+_  _^*?Q5_:MNOASX:O?#WAI_A]X,
MU#]G+P!>?L\W'B[Q';:'\2/&'CJ3QI=>,M!U+3K31_!=E;+JVHSZ1_16,A!Z
M[1SD'MZ]#]>E '\U/_!1[]B7PIX!\$?MR_MV_MJ_M]?M)Z+XGL9]2UK]B4?
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M7CN>^TGQ#>^/=%OM4\4SV/A'R->U2W_J5&=HYYQUP>N.N#S^!K^472?V=?\
M@LRO[</Q3_;6^,7[#_[)W[5WC;3_ !1KNA_L?Q_$K]L:YT'P7^R-\%C<0II^
MF?"+X>'X->)M.TOXM^,+:RL;[XF_&R2Z_P"$T\0NJ:%I \-: NIZ;JX!ZCXX
M\+_&O]N/]M_]A?\ X)Y_ME_$+XH^"+;X;_\ !*+2?VW?VO\ P7\ ?BKXF^"^
MD?&K]IOQ/X\\&? :Z\/Z_P"*?A'JV@>)9?!/PT\<Z3X]\8Z#H?AWQ%I.BWVL
MZAHE[+)?V.EQV$D?[*?P,_:B_:$_9[_;5_X)RZ1^V[\:O!&B?L??\%,F^#O_
M  OJXU[7]?\ VC_%G[#<OASX<_&./X%Z+\:EU[2O%'A/XE6V@^/7\(V_QAN[
M?Q,\&@:,OA&T\,VNBZA:WV@_4G[1G[/'[?,'[0G[*7_!27]F+X8?L_:U^U-H
M_P"R?JG[,7[7'[,_Q'^*OB+PYX1\0^$O&VK>%/BK8Z3\+_C?I'@[58WO/@O\
M:K7Q(UM?^(_!MO8>.?".J7LMM:Z+K2V=O+\<^-?V&?\ @L!\/_V&/C5X>^!?
MB;X3K^W+^W]^V?XH_:-_;&\9_#KXM:I\++;X-?";Q/I>C:(OP9_9O^)?B+PC
MK.I6OB/3_!/@?P9X"L?B5J?A?4M3\(6^I>+;G1K#7[V/PYXOMP#J/V4_A3XD
M^%W_  4=_;#_ &4_^"=_[4'Q?O/V<_"?[$-S;?$R\^,GCKQI^UC\,OV6/^"@
M7C/Q7]@^$(\%:A\3_&MYKVM^)T^'-GKGCSXM?"F+Q?#I/^C:!8ZYK6GWE_9Z
M-X:\)^!_A.R_8Q_X*R?L6?LX>!OVL/VM?&OQHO\ P]\0]$_X*1?$#]J'XO?$
M&/\ 9Z_:B\5>*/@5;^//AS9_!CP_\9M;B\,^-/C+9?$G7+'5? OAC]G2RU*?
MX?\ PYM_%N@^,;R6ZL]?>?\ 0W]@/X-?MS_"3X3^)/V1Y/V,_P!FC_@G%\%;
M+X*^-=+^%_QB_9U^/.G_ +0GC_P_\;-2L='T+P[X[\2>#/&OPF\/Z7X_\4RI
M+J7C7Q%XS\?:EXBOO%&O^&K*R\41:K%K-Q<0>*V_[*7_  5X_:J\4_L3?"#]
MN>']E3PM\&_V+/VB?@[^TKXU_:1^$7CGQMXP^*O[5OC?]G&ZEOOA9#I/PXUK
MPAX>TOX31>-]6,6J_&.ZU+4]0,\TU['X,M]-L9!HMT ?T<HVY%;&-RJ>?< U
MX!^UG\<S^R_^RO\ M+_M+#PQ_P )L?V>/V?_ (R_',>#/[:_X1O_ (2X_"7X
M=>(_'P\+_P#"1'2=?&@?V^= &D_VU_86M?V7]K^W?V1J7D?8YN-^#_QU^('C
MS]J#]KCX(^(/ GAS2? /P#MOV?YOA[\1= \72^(K[QM=?%;P-KOB7QGX;\;:
M(NDVEGX#\9^ ]0TK3+I/#*:KK-[?^ O&G@+QI=?V=:^+-.MFE_;Q^$'C']H3
M]AS]LSX!_#N/3IOB!\</V4OVB/@_X&BUB^&F:3+XP^)?PB\8>"_#,>J:D8IA
MI^G/K6M62WMZT,JVML99S&XC*D _+CQW_P %9_VC_A;\"/A+\7?B/^SI\ ?"
M.J?MM^*O@3H7[!OAS5OVG+RRL&T[XT^%/$_CO7]8_:V\3ZA\*K/1OA99_ OX
M<>']-^('C^_^']S\1-&\07/B>R^'GA75)]3LO^$HU' N?^"D_C'XU_!W_@I?
M^RU\6+3X(>'?VCO@E^P7\5/C]X.^(O[)?Q^B^-7P;^(_PP\5_#[XD>'K+Q=X
M/\2?V5X3\=?#_P :?#OQ[H$OA;Q9X4\6:+#J5O<R>&O%^BZG+HOBO1HH^X_:
ML_X)K_%?XO?L0_\ !.S0/">@?!OQK^TI_P $^_\ AG_QC9_"'XTK9ZO\!OC;
M+X)^#T'PD^-'P7\7W][X0\;6=C:>-/#E_KB>"_&[>$-3.A>*M/T#4,Z1:SW&
MMZ7/\/?V*_VA/$_PB_;BU+Q'^R_^Q=^QOK?QY_92\>_L]_!7]G/]F_2_ >O7
MVE:SK_ACQ[9:AXZ^,7[1VC?!?X1:KK4_CO7-8\*:=I_@+0]%NO _@[PYX2L?
M$-Y=:AXLUK5K30P#C_V:?VIOVTM*_8Q_X)._"C]G'X%^&?B5XF^)7_!-+]GG
MXV?%G]J/]J+QY\0/ _[/GA.;2O@U\)=+C\'ZS\0/"O@7XAZ[XO\ CA\1]:U^
MXUVT\/3R:;?IX?TC6/$\S:S:C4I]%^&_VB_^"JW[8G[1_P"SO_P2]^,'[/OP
MU\,?#7Q3XO\ ^"P_@O\ 9/\ C[X8\._M5:UHGA'Q]\2_A7KGQ/T6'X+Z=X]\
M'?"'Q*/%O[-'QR/AE_%WB3XCO;RS^'+;0]$\+-\,_BGI&N7>NV?7:A_P29_:
MLLO$'_!/+6OB/^S+^RE^WW\-?V?_ /@FA^SI^R!JO[-O[37QS\5>$?A3^SW^
MT;X"\/:-HGQ&^.OAWPP_PC^,GPT^)WACQ#I=A8Z)K5U<?#V_\?WD'A31+CP^
MMH-+TQ;N+PM_P2@_;@^%?[%OP&\!>&?!'[/GB?XU?LK?\%M+K_@HUH_PU\+^
M,;GX-_"#XJ?":SUSXCS:9X3^&FHCPY\0'^$<%Q:?$.U?2?#'B?2M3?P?HOAZ
M_P!'637);?19=; /H7]H3_@IKX._8B^+W_!;SXQ>'/V:/%?C[Q[^Q[9_\$MH
M_'4%Y^TSXIM?#GQS7]I6WC\"^#[7P=X*\0^"_$W@G]GVX^&5CXGNGURX\)Z;
MJZ_&"\BMKWQ/-H%[;VU]:_6_@+_@H3^T9X1_;4\-?LK?MD_L^?"OX+Z%\8/V
M:_B5^TQ\)/'?PQ^-VI?%.7PCI?P=O_#47Q&^'/QKL=8^''@2SMO%&B:-XFMM
M;E\4^!;W7O!@GA.C:3<^)(99]?TW\^?VU_\ @EC^U_\ M'C_ (+<ZOX.\/>
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M"[NM5UGP[K$ TK3;^^U&QCLFFU."QCN;(W'\1O\ P4)_X1KQ[^SC_P % _\
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M6M!\/6?@32+O27;X?Z;X=T=/"UQ9:G#+JDWRUX1^%?[4G[6?[/7[5_[=NI?
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M#+&.KKTSUXQG'7IUZ>H!(X!(_CF^'OP0\-? OP1_P;G?MU>!M?\ B9-^UO\
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M_9N_X+O?L,_#'X@^&/\ @F2FC?'WX">#OV<_ ?CC]H=/'WP\_9N\3?M!^"?
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MU\.O&_B^'_A'YO!/B+7;SQ'XXT7P]8>$-!U&'3M)2Q@_2;]@W]G3X)?LM?\
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MXT;6-0M]3T2Z(!_5!<?M7?#NQ_;'T3]B-]+\7-\7?$G[-OBK]J6RU=--TE_
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M-/&E]J&LR6NLZ3H6CZU$ ?M_^Q?_ ,%3?@E^V;\0_&WP9C^$_P"T]^RY\<O
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M D^,">,/V<7UC0_COXI\5^//B5X#;XQ_'^R^%.H?$3QQ;FS\4_$OPY\(M/\
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M)KGB'PW8^.O .M^(M$\>^&H_$_AO4;OPXVGZF]Q: 'K5[^PS^S%J'PX_9/\
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M)+K3[6Z\0RZI/!'(OZ31QI#%'#$BQQQ1K%&BHJHB(H1%5$"HJJH "J%4 84
M8%?FI\;/^"HGP7^%^I?LJ>&?A[X#^+O[3'CC]N+X6>-/B[^RAX2^!WAWPX\G
MQ;\+>!-)^&?BS6W&O_$OQA\.O#7@B1OA]\3+7X@65WX_U3PUHTVA>&/$NF3Z
MM:>,I/"_A;Q-YEXQ_P""NNB:9XF\;^%/AE^Q/^VO\>=9^"'PF^&7Q;_:DTCX
M8^"?A)'XB_9GC^*?@F#XCZ+\*_&_AOQM\:/"&K>./CQI'@F1M=\2_"?X+6_Q
M+US3$ETZRAFO=0U&WM: /8O!7_!)O]@?X??%_1/C;X7^!C6?BSPM\2M;^,G@
M[PU=_$WXQ:Q\%? OQ9\0O>S:I\2O '[.>M?$+4?V?O ?CI[O4]3U&R\4^#_A
MEHFL:1JNH7FJZ1=V.H7,]Q)]2> _V:?@M\,OC?\ 'O\ :-\$>#?[%^,?[3MK
M\)[+XW^+O^$A\5:B/&MK\#O#>L>$OA;$/#^JZ[?>%O#7_"+^']?U?3]WA+1-
M!?6OM?VKQ VJWMO:W$/Q1\2/^"M7P \*:G^R%X=^&?@;XV?M)^*?V\_A5XJ^
M+W[*^A_ WP1I5^WC[PWX6TOP5K<R:]J'C_Q9\/\ 3OAP;C1O'6F:Q=:S\0+C
MP[X7\,Z9INO3>,-=\/W.GV]I?YV@_P#!7_\ 9TNOV2OC;^UAXU\#_&WX8+^S
MQ\;=6_9C^*/P \5^"=-U+]H.R_:3L=:\)^']%^"?A;PCX,\2^)_#WCGQ=XZU
M+QYX)_X0>\\+^++_ ,,:MIOB6T\07NO:5X>LM8U33@#[T^)G[//PB^+_ (^^
M!OQ/^(7A0Z]XX_9N\9Z]\0?@QK?]N^)M+'@_Q?XF\&ZU\/\ 6]6.F:+K6FZ1
MXA%[X1\1:SI/V#Q38:WIUL;S[?9VEOJ5O;7D7EUC^PE^RUIWPN_:P^#-K\,C
M'\.?VX?''Q;^(_[4'A__ (33XAN?B9XR^.GA'1O GQ4U@:M+XNDUWP9_PE/A
M70-*TPZ?X U3PKI6BFV-]X?L=*U"XN;J;YF\"_\ !6+X2_:OCEH7[3OP=^.?
M[#_C3X!?LZM^UOXK\'_M%:1X"O;W7/V<K>>\T[5?B-X-U3X*_$+XMZ%KMQX?
MU^TB\+^(? IU*S^(6F^)M5T30AX6N-2U,6\%GX!_\%2/#GQ<^+'P-^$_Q,_9
M7_:I_93O?VJ/"FO>,?V7/$WQ^\+_  T3PQ\:;/PWX6?Q]JOAF&Y^%7Q5^)]_
M\,_B-%\/(;OQS'\/OB_I_@3Q)-H>E:[%':-JVDOIUP ?66H?LC? "]U3]EW7
M;OP&9M3_ &,?[07]FRZ_X2GQK%_PK9=3^%U[\&;PB&+Q(EMXM\[X<:C>^'2?
M'</B@HTXUB#R]>BAU*/\AO\ @F=_P1%^!GP;_9I^&MA^UK\$M%U_]H'1_BE\
M9/B+X_T&#XJ_$7Q+\$O&'B#4?VA_B5XU^$/C7QO\&M.\96WP%^)'CKPO\.+W
MX=6NC^+?&/PYU[Q-X8D\.:!IMGJL3^%=+^Q_L!^UO^U3\+/V+O@)XT_:&^,,
MOB"3PCX/?0M.MM \&Z#<>*_'GCCQ=XNU[3?"?@CX?^ /"MI+!<>(_&WC;Q7K
M.D^'?#VEBXM+0WU^EWJVHZ5HUKJ.JV7RC\./^"FMAXK\:_%;X,_$7]DK]JGX
M'?M(?#CX%3_M)>'/V=O&FC?"#Q5\0_CA\(K34FT"^UCX)ZM\*/C)X]^'/BC7
M]*\4R:;X6UOPAK/CGPSXAT/6/$'AT:C9P6FI/<V@!W_Q0_X)>_L/_&;XV>)O
MVAOB%\&7U7XG_$#2/#N@?%"[TKXE?%WPEX,^,V@^$[%],\-:-\</A5X0\?Z%
M\*OC=I>CZ4YTRSL/BOX+\96BZ6L6G/ ]C#% K[__ ()??L0:G^SI\&_V5;KX
M+E/@Q^SSJJ:]\#--L/B-\6M)\=?"778I]:G@UOX??&;3/'EI\9O"NL6Y\0ZK
M#:ZII'CZVO[6TN([&WN8K.SL8+7X-_X($_M0_M%_MR?LP7W[7W[2'C3]H#5O
M%/Q4U?6I+;P?XQ^'?P;\ _LP>&K+3_'OCO3K#_AD]_!7A]?BKXA\*Z7HVG:3
MX5\9ZK\9O'/BW6AXGT.[6S?YKS4=1^A/CQ_P5P\!?![QK^TCHW@[]F3]J/\
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MXM^*?C7XU^ \&H^,O'WB_P /^/OB3I%A\1/BYX>^%'Q7\9>%X;6'0_$?Q?\
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MZEJ6D7VL^%]1N;KPOK^N:/J/WEX>_9S^#_A?X]_$#]IW1O";6GQQ^*7P_P#
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M\4/$_P 2H=8TK2-3L?B5K?C*]\>6%[HVC3V?B*%M)T[[-\T:;_P62_9\UO\
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MFIXBMVN].'Q3\ ?^"UOQ%^#^A_\ !1OQ7^TO\"/VM/CS\'?V4/\ @I1^U?\
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MQOX@U_5O#VB>)M+UGXO^)AXGU;PEI?C74==MO#&J7?A>'1KRY^:]?_81T_\
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M^PU^U)X"B^!?Q,?QGXJ_X.*==_:-\-^&%\*:HVM:Y\")OVZO /CR'XLZ98+
M;B[\"S>#=-O_ !+'XAB1K!M'M9K[S?(C9Q_6WTX P*;M7).U<GJ<#)^OK^-
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MX_=IQD#Y5XR #CCC( !QU  [4 ?P=_M"?LS?\% ?VB?V0?$UG\>O@E_P5/\
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M_P 1/"/[,7_!+CP]\(OV/O%GP?N]-_X+J_ ']L3XO_"#1OB-\1OVC/%GPO\
MA?/XT^,-UJOQ3^-WQ)\<>/?BKJ,_C%/!EQX%UCXU:MIWC?6_!.A^.]8U6QT/
M5;ZQCCU74OZE]B9SL3)&"=HSCKCITSSBG!0.B@?0#_/:@#^:+_@H;^QR;#_@
MIUHO[8WQ6_9X_:Y_:6_9E^*7[(NC? #7+7]B+XE_'/P-\8/@_P#&/X;_ !+U
M[QKX3UKQAX=^ ?QW^"WC7QO\+O'/A'Q9XATDW<-OXTM_#7C+2]*.H:;H-E>Q
MZI>>3Z]^POXZ\+? O_@G#-\&OV*?'_P)AU'_ (+]?!O]M;XJ?"ZX^*/Q-_:,
M^*7@_P"$Z^&/BGX4E^.7[2OC7QU\1OC#+X=\?:CX3TOP!>_%/3?#WQ'\3^"/
M"^MZI96XUB;7K[6B/ZM< G) )' ..>>OYTWRX^1Y:8/7Y%YYSSQSSS]>>M '
M\JOB+]E?]H^Z_P""0_\ P7;^$,/P1^)4OQ4^/7[=7_!1OQY\%? 2^%]3/BCX
MF>#/B1\7]*UGP!XF\&Z/Y7VG7-'\7Z7!-?Z!?64<L>I6L;RV[.@8U_0_X0^+
M6HV/Q6\%_L[W/P?^,\*Q_L\Z=\4[SXW2^$=,7X!V.HZ=XATKP3)\'KOQH?$8
MUV'XT3"X?Q?;>$_^$1;2G\%6-_JTGB*.]BCTR3Z+\M/[B?\ ?(],>GIQ].*4
M(@QA%&,XPH&,G)QQQD\GU/- #J*** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7PQINGQ*S1#PX+8+)=&;Y\@F(+-$Q_2"@ HHHH **** "BBB@ HH!SR.AHH
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MO"WAC1](5)]5M(6E?4[ID9W_ '1C /D3_@J!^W^?B]^T?\:OV=M(_:)^(_P
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P"$TU+PKX8T@WVGZ;I?Q5TW16N-3^&WC'QQ::;I+1V\VF7":9INK"W6&6.
M!_S1^/W[>%Q_P4 E_;9\5_&+]BG]L/6?V]/&6D>%/ W[(/PX\(?#'7]?T/\
M97\.?#GQ1H_BO3;JWU=K.#68O%&I^/-)DU_Q9J\'AV!KM+.WT3#PAUD_TN1=
M6@&!<6P'H)H@.!@?Q=@ /H*C$NG+*\ZR62SR*$>8/ )71>55I =S*#T!) [4
M ?YU_P 8OVN_VM?C+XMU+Q]_P4M_8._;%T^?X<?L4>)_@]^R_P" -'^#WB76
MO#<WQ<^)_@EO#7C?XY>--6CL;6SBUS54-I#I6EBV:7P_;S"-WB>:7S_5?"?@
MC_@J9^WU^R)_P3Z\)Z/^PAJVI_ C_@FS9_"?Q-\0/A9^T!J-S\+O$/[7GCWP
M!#%;6^A^!M.U2WM7_P"$?\.^%K:S\NZU399Z[JEQ<1+<SF9=/D_T /M=K_S\
MV_\ W^C_ /BJ/M=K_P _-O\ ]_H__BJ /YB_VFOCW_P54_X*-_!/7?V+?@U_
MP3O^*/[#[_%W0[3PG\7_ -H3X[^.?#%MX7^'WPXO9K2U\76GP[MO"HDU#Q!X
MCU+2OMVE:;'9QAK:VG:XS;>4LT?W?\8_^".7PU^*>K?!3XF^%/V@_P!H/]GG
M]H7X1?!'PI\!=1^./P&\7P^%?$7Q*\!>%K"&"TT[Q[IU]:ZGIFNF"\6XO=.N
MKU)KJP^T"))G6WMFA_87[7:_\_-O_P!_H_\ XJC[7:_\_-O_ -_H_P#XJ@#^
M3[]F_P#X)5?#W_@FI_P5+\)?%7XG:E^T/^T5X-^./B"[U7]GGXUZOK/B#Q*G
MPQ_:.\9Z/J%C\5K'XQ^&O"]I!X<M(?B/I]O#K.C?$6[TVQM9+Z%M(U=S<P6D
MT_\ 6!=0)>6MQ;.65+F"6!RIPRK,C1/@J2-P5CC!X-+]KM?^?FW_ ._T?_Q5
M'VNU_P"?FW_[_1__ !5 '\LO[..L_P#!1O\ X) P?%_]D_P?_P $Z_'7[:GP
M7U;XR_$CXH_ 3XT_"'Q]X;TB>71_B;XBN=>'A_XK6&NQW-[9:WHM[</#>:KM
M NK4+<AYT*,/!_VW/V=/^"U_[3?P@\1?'C]I;PWI.I?"R+XO? 7Q)J'_  3+
M^!6H:5XPUJY^#7PU\;'Q1XON-:\9$P?\);XYUFW\B/4O#6F7MQI6I6L"6QBD
M:W6&O[$OM=K_ ,_-O_W^C_\ BJ/M=K_S\V__ '^C_P#BJ /YWOA#%^T-^W]^
MW'^S?^U$_P"R+\3/V3/V:/V,/AI\3(/AOI?Q_P!.L/!7Q%^)7Q1^(&@6OA?3
MM.TKP'837-WX:\&>%],LYXGU/4X0L\DQ%I%Y2X7)\#_\%%/V]K+]M3]D[]AW
M]L+X)?#+X<^*/VG/#G[25WXMT;X<>)5\82:!X/\ "-HD7P[\60:U;7%S%;P:
MDAO?[1MYXH+@EK;>ELP=!^[/Q\\5_%'PK\&?B/XB^ W@SP]\3_C)I'A;4KSX
M<^ /$/B:V\*Z)XI\41Q@:?I>I^()]T6F6DCEI)9G,8<1^2)8FE61?Q4_X)U_
ML(?M;>*_VL=>_P""H7_!3+7? UE^TMKGPYD^%OP@_9_^'TR7W@W]GGP!=:@M
MUJ=L=<34[N'5O%.N&'-]+:S7=O"MQ)(VH3R3-%; 'P_^R?\ MXZM_P $-_"W
MC3]A']MO]G_XY-X)\%?%#XC>)/V<OCQ\*OA_K7CWP)\5?AQXW\4:CXFTBSN;
MK1TNY-.\6:8VH#3K_3[C:T5QM\Y(D_>/]E?!W_@I=_P4 _;I_:-^#MI^RE^Q
M;X]^#G['.E^*TU#XX?'+]I[0Y/ ^L^*O!\VFW/EZ/\-?"UU<K>/=27,]I=Q:
MG$FHM*(A"8[9&F"_T(7MOHFH^5]O33KT0OYD277V>X2.3C$B1REHQ(-HVOL+
MK_"PJ\MU9J JW%LJJ JJLL0"@#   ;  '  X H _ 3_@C'^S?\>?"O[0?_!4
M;]K#]I;P'KO@SXA?M"?M9:QX>\#R>)K::UO=7^#GPQCN-%\(ZKI-O/EH_#NH
M6LED=,E@?[->"T:9=PCC8>M:/^P_\:_C%_P5^\8?MH_M,6>E7OP*_9T^&>@^
M!OV'O"<&N6^L65KXI\6V3R_$SXG:KH8VOI/BB!6ET*SDO(&D\FY\VVN)5M;-
MT_:+[7:_\_-O_P!_H_\ XJC[7:_\_-O_ -_H_P#XJ@#\-O\ @OU\"O''C+]B
MO3/VB_@CX?;5OCS^PW\6O O[57PRL]/MV:^U&+P#?^7XWT.-+<>=-%JO@R^U
M@26L<<QEEMK9EC+HM?/>L?M\_M.MKGA#XP_M4?L.WG[1/_!-_P#:-^"'PI\8
M_#.?X2?"1?BS\3?A#X]\0^%;*X\;>'_B[\-M<MY=<U*PO=8N;^UTC4],T:*R
M6R?3/WWFF\@/])$\MA<Q203S6DL$R/'-#(\$D4L;J4>.2-RR.C*Q#(P*L.&!
M4D%()-.M88[>WDLK>W@C6*&&%X(H88D4*D<<:$*B(HPJJ %& .!0!_-)\%M?
M\?\ [+O[ /\ P5E_:M\"_"SQS^Q3\%-3\.?$WXL?LD?!SQCIT&E^+OAO/X3^
M$,NGWWCN/P'K4E[IG@E?'WQ'LHM?TOP4\2VJL[7/D-->_O/UL_X)A_%7XH?&
M#_@G/^R%\7_C?J\OB'XH>./@+X-\6^-M=$$$=UK>H7VG-<KJDUOIT,5N+[4+
M 6MU=QVMO&C7<LRI$N[97XA_\%E/A!_P4!_X*9_ME?#7_@FI\);36_@_^P@O
MA7PK\4_VE?CT;6^L]*\:6,NO78O_  )8:H)1I_B"ZTV+3;+^S?#$6QY-7NQ?
MZK_Q+K)"W].WPP\"^"?A%\-_ OPK\"VMEHO@SX=>$]!\%^%M*@>)(K#0O#FF
MV^DZ9;!=PR8[6UC#L>9'W.W+&@#\%?\ @BA\)]4^,/[0'_!1?_@J!\4O#>JZ
M5\1_VD?VB_%'P4^%\/B#3=5TG4/#G[/GP*FL_"VE6MGI^JQP3VL?B;Q'IAN+
MK,(62W\.Z<4;YI0?UY_:P^%O[1?Q3TSX2:;^SS\=+3X$GP]\:/ /BWXJ:@WA
MFV\0ZAXW^%6@ZJM]XL^'^D-=;H]'O/$UK$+!]46(RPP2R>7(C"OJF.>QB79'
M-:1IDD*DD2@$G). V,DY)/?/XT_[7:_\_-O_ -_H_P#XJ@#^<KX+?$OPC^R)
M_P %W?VXO!_Q_P!8TWP#'^W-\-_@/XY_9T\9^*+N'3= \;77PU\.#P9XG^'>
MEZU>R6]B/$=C?YU2WT@M]HO(KMGC3S"JO^MO[5?_  4!_98_8S\(>%O&7QQ^
M)6F:79^-?''AOX>>%=(\/RVOB3Q)KGB7Q1J4.F6,6GZ%I]TU]/96DDPN-5O4
MC,6GV:23RYVJC])^U3^QQ^RU^VOX'C^'O[3/PM\'?%'P]:7*WVCOK44<>M>&
M]24874_#7B"TDM]8T+4 I*_:-/O(21C<K$9KX2_9Z_X(0_\ !,C]G'XB:3\5
MO#/P>G\;^.O#6IPZOX0UGXN^.O$GQ.7PA?6Y9H)O#NG^*]4U#3-/:"4QS6[1
MV>Z"6""2(JT2$ 'UM\%/B1^VCXH_:J_:%\,?%KX*>!?!?[)7AS3O#,G[.?Q3
MTCQI%K/C+XDWE[%9RZU+X@\-QRB70[6);BZ:%;RSLI(G@AM5-ZY>9/N.H4N;
M=V")/"['[JI*C,<#)PH8DX'/ X%34 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !112$X!)Z $G\* .=\6>$/#'CK0=1\+>,=#T[Q'X=U>#[-J>C:K;K
M=:??0;UD\JX@?Y9$WHCX/1D4C! KP7_ABW]D_P#Z-^^%Y]SX6L/_ (BOB/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?$SX)?L[?&S]MK]CRQ_:.\"']E_X"_M^^%?&GQ&_:D_:)_8;U#PUX.M_VK]
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M2C\*:/XU\=GP]H&G:!X9TC3++7/$TWA6\\0QZK<Z+IUQ:_LD44L&/48^G!W
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !112'D$>HQR,_IW^E 'S%^VV?^
M,,?VN?\ LV'X^?\ JJO%E?DM_P $X/VN?%?@?P-_P0T_8LL_"NA7OA/X_?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/X@9OX5</T<=@^)LJH.M0S7!U*U+!83!<58QWGA\=ET)3S'&YI0IXO$8OA_
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5+_P5X6^'&B6?BW5K'2KCQEXG\0Z1;:AX<U7[=_X*/?\$LOCK^V-_P %)O\
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M]JVRY2WN3%]FEX7P9^T)=?$SX@_"WP_HMK'X>M_$OPV^.NI>._#>KVZ3^+/
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M\&?'O@[P/X@T637-#\:>)-<^&ESIVHVYFC2SA_LCPYXYUSQ19SWT#2W<0O\
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M(DU&Y^VZA+8:/90V5O-?77E0K/>3)");F2.&"$S._D06\/EP1]M110 4444
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M!OB;P=X5U_PIX:NK35_".@I;6]OI>AW&D:;>Z#97?A^WTM[6.P33=)UB]TB
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MP9X3EUW78K+4M6L=(O-9NB7'EOL:/X8_: ^#]]X_\.?#+P1\/?'7A3QOX_\
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MG\52:;I.DPVLOVY-?:TLK8+J CC %O73;^O2_P#6I^;<LOPT^''QSCUZ"?\
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M\<_VD/"\L$?[/'QD-T=1;2K2]O%>*!G>R:*VD47WV?SBL?SK\_\ CWP9XG\
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MCEB<')5@&"L"H_#C6-*\4?"']D'QUK^AZ9JNN?"_XV:M\3=/\=:)9QW-]<>
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M_%9UV+P]J]CJS^%]>N_"OB&.RN(YWT?Q%I]O:7-]HNH(C,;;4+6WOK*::VD
M98KJ"0;DD5CTE9>F:+INCG4&TZS@M7U;49=6U*2&)(Y+[49H8+9[RZ=0#/<&
MUM;6U$LA9UMK6W@!$4,:* ?G!+X&\;:1\=/VJ?CW\)5O+SQWX0^+G@_2?%7@
M&.2VBT_XU_#6U_9X^!FHS^#7>\58[+QGX=N=0UW6OA7KJ7-I%9>)-2U7P_JU
MPOA[Q;K<D'->&!:ZQ_P3SL?C3X:^T:5XS^$-M\</VA?AEJ]YI5Y;ZG9:]X8\
M7?%+Q!#IFHZ3=/8ZBNE^,O#D^H^#?%>ARR6MS+X=U_4;*![*_ALKRS_5? ]/
MK[_7UZ]Z, #&!@=L4 >-? 7P!%\/?ASI5K-J,VO>)?$SOXW\>>*KN".WO_%O
MCGQ3'%J?B+7[N"+*6D<MQ(FGZ/I<;R6^@>'=.T;P]8N-.TFTCC]FHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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D4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>12
<FILENAME>impb-20230331.xsd
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.19b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWa6DybP9z5Z8CekhvWBybfm6zyssVzADviD5roMG8VQJ -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:IMPB="http://impactbiomedinc.com/20230331" elementFormDefault="qualified" targetNamespace="http://impactbiomedinc.com/20230331">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://impactbiomedinc.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://impactbiomedinc.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - Consolidated Balance Sheets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://impactbiomedinc.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://impactbiomedinc.com/role/StatementsOfOperations" id="StatementsOfOperations">
          <link:definition>00000004 - Statement - Consolidated Statements of Operations</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://impactbiomedinc.com/role/StatementsOfStockholdersEquity" id="StatementsOfStockholdersEquity">
          <link:definition>00000005 - Statement - Consolidated Statements of Stockholder's Equity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://impactbiomedinc.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000006 - Statement - Consolidated Statements of Cash Flows</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://impactbiomedinc.com/role/NatureOfOperationsAndBasisOfPresentation" id="NatureOfOperationsAndBasisOfPresentation">
          <link:definition>00000007 - Disclosure - Nature of Operations and Basis of Presentation</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://impactbiomedinc.com/role/SummaryOfSignificantAccountingAndReportingPolicies" id="SummaryOfSignificantAccountingAndReportingPolicies">
          <link:definition>00000008 - Disclosure - Summary of Significant Accounting and Reporting Policies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://impactbiomedinc.com/role/Restatement" id="Restatement">
          <link:definition>00000009 - Disclosure - Restatement</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://impactbiomedinc.com/role/PrepaidExpenses" id="PrepaidExpenses">
          <link:definition>00000010 - Disclosure - Prepaid Expenses</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://impactbiomedinc.com/role/NotesReceivable" id="NotesReceivable">
          <link:definition>00000011 - Disclosure - Notes Receivable</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://impactbiomedinc.com/role/Investments" id="Investments">
          <link:definition>00000012 - Disclosure - Investments</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://impactbiomedinc.com/role/PropertyPlantAndEquipmentAndInvestmentInRealEstateNet" id="PropertyPlantAndEquipmentAndInvestmentInRealEstateNet">
          <link:definition>00000013 - Disclosure - PROPERTY PLANT AND EQUIPMENT and INVESTMENT IN REAL ESTATE, NET</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://impactbiomedinc.com/role/Goodwill" id="Goodwill">
          <link:definition>00000014 - Disclosure - Goodwill</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://impactbiomedinc.com/role/IntangibleAssets" id="IntangibleAssets">
          <link:definition>00000015 - Disclosure - Intangible Assets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://impactbiomedinc.com/role/Debt" id="Debt">
          <link:definition>00000016 - Disclosure - Debt</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://impactbiomedinc.com/role/StockholdersEquity" id="StockholdersEquity">
          <link:definition>00000017 - Disclosure - Stockholders&#8217; Equity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://impactbiomedinc.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
          <link:definition>00000018 - Disclosure - Related Party Transactions</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://impactbiomedinc.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
          <link:definition>00000019 - Disclosure - Commitments and Contingencies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://impactbiomedinc.com/role/IncomeTaxes" id="IncomeTaxes">
          <link:definition>00000020 - Disclosure - Income Taxes</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://impactbiomedinc.com/role/SupplementalCashFlowInformation" id="SupplementalCashFlowInformation">
          <link:definition>00000021 - Disclosure - Supplemental Cash Flow Information</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://impactbiomedinc.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>00000022 - Disclosure - Subsequent Events</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://impactbiomedinc.com/role/SummaryOfSignificantAccountingAndReportingPoliciesPolicies" id="SummaryOfSignificantAccountingAndReportingPoliciesPolicies">
          <link:definition>00000023 - Disclosure - Summary of Significant Accounting and Reporting Policies (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://impactbiomedinc.com/role/NatureOfOperationsAndBasisOfPresentationTables" id="NatureOfOperationsAndBasisOfPresentationTables">
          <link:definition>00000024 - Disclosure - Nature of Operations and Basis of Presentation (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://impactbiomedinc.com/role/PropertyPlantAndEquipmentAndInvestmentInRealEstateNetTables" id="PropertyPlantAndEquipmentAndInvestmentInRealEstateNetTables">
          <link:definition>00000025 - Disclosure - PROPERTY PLANT AND EQUIPMENT and INVESTMENT IN REAL ESTATE, NET (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://impactbiomedinc.com/role/GoodwillTables" id="GoodwillTables">
          <link:definition>00000026 - Disclosure - Goodwill (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://impactbiomedinc.com/role/IntangibleAssetsTables" id="IntangibleAssetsTables">
          <link:definition>00000027 - Disclosure - Intangible Assets (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://impactbiomedinc.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
          <link:definition>00000028 - Disclosure - Income Taxes (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://impactbiomedinc.com/role/SupplementalCashFlowInformationTables" id="SupplementalCashFlowInformationTables">
          <link:definition>00000029 - Disclosure - Supplemental Cash Flow Information (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://impactbiomedinc.com/role/ScheduleOfCondensedFinancialStatementsDetails" id="ScheduleOfCondensedFinancialStatementsDetails">
          <link:definition>00000030 - Disclosure - Schedule of Condensed Financial Statements (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://impactbiomedinc.com/role/NatureOfOperationsAndBasisOfPresentationDetailsNarrative" id="NatureOfOperationsAndBasisOfPresentationDetailsNarrative">
          <link:definition>00000031 - Disclosure - Nature of Operations and Basis of Presentation (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://impactbiomedinc.com/role/SummaryOfSignificantAccountingAndReportingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingAndReportingPoliciesDetailsNarrative">
          <link:definition>00000032 - Disclosure - Summary of Significant Accounting and Reporting Policies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://impactbiomedinc.com/role/RestatementDetailsNarrative" id="RestatementDetailsNarrative">
          <link:definition>00000033 - Disclosure - Restatement (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://impactbiomedinc.com/role/PrepaidExpensesDetailsNarrative" id="PrepaidExpensesDetailsNarrative">
          <link:definition>00000034 - Disclosure - Prepaid Expenses (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://impactbiomedinc.com/role/NotesReceivableDetailsNarrative" id="NotesReceivableDetailsNarrative">
          <link:definition>00000035 - Disclosure - Notes Receivable (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://impactbiomedinc.com/role/InvestmentsDetailsNarrative" id="InvestmentsDetailsNarrative">
          <link:definition>00000036 - Disclosure - Investments (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://impactbiomedinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" id="ScheduleOfPropertyPlantAndEquipmentDetails">
          <link:definition>00000037 - Disclosure - Schedule of Property Plant and Equipment (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://impactbiomedinc.com/role/PropertyPlantAndEquipmentAndInvestmentInRealEstateNetDetailsNarrative" id="PropertyPlantAndEquipmentAndInvestmentInRealEstateNetDetailsNarrative">
          <link:definition>00000038 - Disclosure - PROPERTY PLANT AND EQUIPMENT and INVESTMENT IN REAL ESTATE, NET (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://impactbiomedinc.com/role/ScheduleOfGoodwillDetails" id="ScheduleOfGoodwillDetails">
          <link:definition>00000039 - Disclosure - Schedule of Goodwill (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://impactbiomedinc.com/role/ScheduleOfIntangibleAssetsDetails" id="ScheduleOfIntangibleAssetsDetails">
          <link:definition>00000040 - Disclosure - Schedule of Intangible Assets (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://impactbiomedinc.com/role/GoodwillDetailsNarrative" id="GoodwillDetailsNarrative">
          <link:definition>00000041 - Disclosure - Goodwill (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://impactbiomedinc.com/role/ScheduleOfFutureAmortizationOfDevelopedTechnologiesDetails" id="ScheduleOfFutureAmortizationOfDevelopedTechnologiesDetails">
          <link:definition>00000042 - Disclosure - Schedule of Future Amortization of Developed Technologies (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://impactbiomedinc.com/role/IntangibleAssetsDetailsNarrative" id="IntangibleAssetsDetailsNarrative">
          <link:definition>00000043 - Disclosure - Intangible Assets (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://impactbiomedinc.com/role/DebtDetailsNarrative" id="DebtDetailsNarrative">
          <link:definition>00000044 - Disclosure - Debt (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://impactbiomedinc.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
          <link:definition>00000045 - Disclosure - Stockholders&#8217; Equity (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://impactbiomedinc.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
          <link:definition>00000046 - Disclosure - Related Party Transactions (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://impactbiomedinc.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
          <link:definition>00000047 - Disclosure - Commitments and Contingencies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://impactbiomedinc.com/role/ScheduleOfComponentsOfIncomeTaxBenefitDetails" id="ScheduleOfComponentsOfIncomeTaxBenefitDetails">
          <link:definition>00000048 - Disclosure - Schedule of Components of Income Tax Benefit (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://impactbiomedinc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" id="ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
          <link:definition>00000049 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://impactbiomedinc.com/role/SummaryOfEffectiveIncomeTaxRateDetails" id="SummaryOfEffectiveIncomeTaxRateDetails">
          <link:definition>00000050 - Disclosure - Summary of Effective Income Tax Rate (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://impactbiomedinc.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
          <link:definition>00000051 - Disclosure - Income Taxes (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://impactbiomedinc.com/role/ScheduleOfCashFlowSupplementalDetails" id="ScheduleOfCashFlowSupplementalDetails">
          <link:definition>00000052 - Disclosure - Schedule of Cash Flow Supplemental (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="impb-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="impb-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="impb-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="impb-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
    <element id="IMPB_SweetSenseMember" name="SweetSenseMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMPB_GlobalBioMedicalPteLtdMember" name="GlobalBioMedicalPteLtdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMPB_GlobalBioMedicalIncMember" name="GlobalBioMedicalIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMPB_GlobalBioLifeIncMember" name="GlobalBioLifeIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMPB_BioLifeSugarIncMember" name="BioLifeSugarIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMPB_HappySugarIncMember" name="HappySugarIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMPB_SweetSenseIncMember" name="SweetSenseIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMPB_GlobalSugarSolutionsIncMember" name="GlobalSugarSolutionsIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMPB_GRDGscienceLLCMember" name="GRDGscienceLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMPB_PromissoryNoteOneMember" name="PromissoryNoteOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMPB_PromissoryNoteTwoMember" name="PromissoryNoteTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMPB_AsiaPacificHoldingsLimitedMember" name="AsiaPacificHoldingsLimitedMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMPB_NanoNineLLCMember" name="NanoNineLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMPB_SecuritiesPurchaseAgreementMember" name="SecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMPB_StockPurchaseAgreementMember" name="StockPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMPB_VivacitasOncologyIncMember" name="VivacitasOncologyIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMPB_ImpactOncologyPTELtdMember" name="ImpactOncologyPTELtdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMPB_VivacitasAgreementMember" name="VivacitasAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMPB_RevolvingPromissoryNoteMember" name="RevolvingPromissoryNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMPB_RoyaltyAgreementMember" name="RoyaltyAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMPB_ChemiaCorporationMember" name="ChemiaCorporationMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMPB_LicenseAgreementMember" name="LicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMPB_GlobalAndBioLifeSciencesMember" name="GlobalAndBioLifeSciencesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMPB_StockIssuedDuringPeriodValueShareholder" name="StockIssuedDuringPeriodValueShareholder" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="IMPB_ImpairmentOfOtherInvestments" name="ImpairmentOfOtherInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="IMPB_IncreaseDecreaseInImpairmentofOtherInvestments" name="IncreaseDecreaseInImpairmentofOtherInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="IMPB_PaymentsForProceedsFromNoteReceivableInvestments" name="PaymentsForProceedsFromNoteReceivableInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="IMPB_DisclosurePrepaidExpensesAbstract" name="DisclosurePrepaidExpensesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="IMPB_PrepaidExpensesTextBlock" name="PrepaidExpensesTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="IMPB_ContinuingOperationsAndGoingConcernPolicyTextBlock" name="ContinuingOperationsAndGoingConcernPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="IMPB_StateOrOtherJurisdictionOfIncorporationOrOrganization" name="StateOrOtherJurisdictionOfIncorporationOrOrganization" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="IMPB_OrdinarySharesPercentage" name="OrdinarySharesPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="IMPB_NoncashOrPartNoncashAcquisitionValueOfAssetAcquiredDescription" name="NoncashOrPartNoncashAcquisitionValueOfAssetAcquiredDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="IMPB_RoyaltyPercentage" name="RoyaltyPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="IMPB_SaleOfRoyaltyPercentage" name="SaleOfRoyaltyPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="IMPB_DevelopmentCostPercent" name="DevelopmentCostPercent" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>13
<FILENAME>impb-20230331_cal.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.19b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://impactbiomedinc.com/role/Cover" xlink:href="impb-20230331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/BalanceSheets" xlink:href="impb-20230331.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/BalanceSheetsParenthetical" xlink:href="impb-20230331.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/StatementsOfOperations" xlink:href="impb-20230331.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/StatementsOfStockholdersEquity" xlink:href="impb-20230331.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/StatementsOfCashFlows" xlink:href="impb-20230331.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/NatureOfOperationsAndBasisOfPresentation" xlink:href="impb-20230331.xsd#NatureOfOperationsAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/SummaryOfSignificantAccountingAndReportingPolicies" xlink:href="impb-20230331.xsd#SummaryOfSignificantAccountingAndReportingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/Restatement" xlink:href="impb-20230331.xsd#Restatement" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/PrepaidExpenses" xlink:href="impb-20230331.xsd#PrepaidExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/NotesReceivable" xlink:href="impb-20230331.xsd#NotesReceivable" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/Investments" xlink:href="impb-20230331.xsd#Investments" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/PropertyPlantAndEquipmentAndInvestmentInRealEstateNet" xlink:href="impb-20230331.xsd#PropertyPlantAndEquipmentAndInvestmentInRealEstateNet" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/Goodwill" xlink:href="impb-20230331.xsd#Goodwill" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/IntangibleAssets" xlink:href="impb-20230331.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/Debt" xlink:href="impb-20230331.xsd#Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/StockholdersEquity" xlink:href="impb-20230331.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/RelatedPartyTransactions" xlink:href="impb-20230331.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/CommitmentsAndContingencies" xlink:href="impb-20230331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/IncomeTaxes" xlink:href="impb-20230331.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/SupplementalCashFlowInformation" xlink:href="impb-20230331.xsd#SupplementalCashFlowInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/SubsequentEvents" xlink:href="impb-20230331.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/SummaryOfSignificantAccountingAndReportingPoliciesPolicies" xlink:href="impb-20230331.xsd#SummaryOfSignificantAccountingAndReportingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/NatureOfOperationsAndBasisOfPresentationTables" xlink:href="impb-20230331.xsd#NatureOfOperationsAndBasisOfPresentationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/PropertyPlantAndEquipmentAndInvestmentInRealEstateNetTables" xlink:href="impb-20230331.xsd#PropertyPlantAndEquipmentAndInvestmentInRealEstateNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/GoodwillTables" xlink:href="impb-20230331.xsd#GoodwillTables" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/IntangibleAssetsTables" xlink:href="impb-20230331.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/IncomeTaxesTables" xlink:href="impb-20230331.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/SupplementalCashFlowInformationTables" xlink:href="impb-20230331.xsd#SupplementalCashFlowInformationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/ScheduleOfCondensedFinancialStatementsDetails" xlink:href="impb-20230331.xsd#ScheduleOfCondensedFinancialStatementsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/NatureOfOperationsAndBasisOfPresentationDetailsNarrative" xlink:href="impb-20230331.xsd#NatureOfOperationsAndBasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/SummaryOfSignificantAccountingAndReportingPoliciesDetailsNarrative" xlink:href="impb-20230331.xsd#SummaryOfSignificantAccountingAndReportingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/RestatementDetailsNarrative" xlink:href="impb-20230331.xsd#RestatementDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/PrepaidExpensesDetailsNarrative" xlink:href="impb-20230331.xsd#PrepaidExpensesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/NotesReceivableDetailsNarrative" xlink:href="impb-20230331.xsd#NotesReceivableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/InvestmentsDetailsNarrative" xlink:href="impb-20230331.xsd#InvestmentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" xlink:href="impb-20230331.xsd#ScheduleOfPropertyPlantAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/PropertyPlantAndEquipmentAndInvestmentInRealEstateNetDetailsNarrative" xlink:href="impb-20230331.xsd#PropertyPlantAndEquipmentAndInvestmentInRealEstateNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/ScheduleOfGoodwillDetails" xlink:href="impb-20230331.xsd#ScheduleOfGoodwillDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/ScheduleOfIntangibleAssetsDetails" xlink:href="impb-20230331.xsd#ScheduleOfIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/GoodwillDetailsNarrative" xlink:href="impb-20230331.xsd#GoodwillDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/ScheduleOfFutureAmortizationOfDevelopedTechnologiesDetails" xlink:href="impb-20230331.xsd#ScheduleOfFutureAmortizationOfDevelopedTechnologiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/IntangibleAssetsDetailsNarrative" xlink:href="impb-20230331.xsd#IntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/DebtDetailsNarrative" xlink:href="impb-20230331.xsd#DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/StockholdersEquityDetailsNarrative" xlink:href="impb-20230331.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="impb-20230331.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="impb-20230331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/ScheduleOfComponentsOfIncomeTaxBenefitDetails" xlink:href="impb-20230331.xsd#ScheduleOfComponentsOfIncomeTaxBenefitDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="impb-20230331.xsd#ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/SummaryOfEffectiveIncomeTaxRateDetails" xlink:href="impb-20230331.xsd#SummaryOfEffectiveIncomeTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/IncomeTaxesDetailsNarrative" xlink:href="impb-20230331.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/ScheduleOfCashFlowSupplementalDetails" xlink:href="impb-20230331.xsd#ScheduleOfCashFlowSupplementalDetails" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesAndLoansReceivableNetCurrent" xlink:label="loc_us-gaapNotesAndLoansReceivableNetCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapNotesAndLoansReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLongTermInvestments" xlink:label="loc_us-gaapOtherLongTermInvestments" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherLongTermInvestments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:label="loc_us-gaapNotesAndLoansReceivableNetNoncurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapNotesAndLoansReceivableNetNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIntangibleAssetsNet" xlink:label="loc_us-gaapOtherIntangibleAssetsNet" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherIntangibleAssetsNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilitiesNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilitiesNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaapMinorityInterest" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapMinorityInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaapCostsAndExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCostsAndExpenses" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCostsAndExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCostsAndExpenses" xlink:to="loc_us-gaapProfessionalFees" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCostsAndExpenses" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherGeneralExpense" xlink:label="loc_us-gaapOtherGeneralExpense" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCostsAndExpenses" xlink:to="loc_us-gaapOtherGeneralExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapCostsAndExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapInvestmentIncomeInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaapAssetImpairmentCharges" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapAssetImpairmentCharges" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapProfitLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapProfitLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/StatementsOfStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Stockholder&apos;s Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:label="loc_us-gaapDeferredIncomeTaxesAndTaxCredits" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDeferredIncomeTaxesAndTaxCredits" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_ImpairmentOfOtherInvestments" xlink:label="loc_IMPBImpairmentOfOtherInvestments" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_IMPBImpairmentOfOtherInvestments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredLiabilities" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_IncreaseDecreaseInImpairmentofOtherInvestments" xlink:label="loc_IMPBIncreaseDecreaseInImpairmentofOtherInvestments" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_IMPBIncreaseDecreaseInImpairmentofOtherInvestments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromProductiveAssets" xlink:label="loc_us-gaapPaymentsForProceedsFromProductiveAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsForProceedsFromProductiveAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaapPaymentsToAcquireInvestments" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireInvestments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_PaymentsForProceedsFromNoteReceivableInvestments" xlink:label="loc_IMPBPaymentsForProceedsFromNoteReceivableInvestments" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_IMPBPaymentsForProceedsFromNoteReceivableInvestments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/NatureOfOperationsAndBasisOfPresentation" xlink:title="00000007 - Disclosure - Nature of Operations and Basis of Presentation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/SummaryOfSignificantAccountingAndReportingPolicies" xlink:title="00000008 - Disclosure - Summary of Significant Accounting and Reporting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/Restatement" xlink:title="00000009 - Disclosure - Restatement" />
    <link:calculationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/PrepaidExpenses" xlink:title="00000010 - Disclosure - Prepaid Expenses" />
    <link:calculationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/NotesReceivable" xlink:title="00000011 - Disclosure - Notes Receivable" />
    <link:calculationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/Investments" xlink:title="00000012 - Disclosure - Investments" />
    <link:calculationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/PropertyPlantAndEquipmentAndInvestmentInRealEstateNet" xlink:title="00000013 - Disclosure - PROPERTY PLANT AND EQUIPMENT and INVESTMENT IN REAL ESTATE, NET" />
    <link:calculationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/Goodwill" xlink:title="00000014 - Disclosure - Goodwill" />
    <link:calculationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/IntangibleAssets" xlink:title="00000015 - Disclosure - Intangible Assets" />
    <link:calculationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/Debt" xlink:title="00000016 - Disclosure - Debt" />
    <link:calculationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/StockholdersEquity" xlink:title="00000017 - Disclosure - Stockholders&#8217; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/RelatedPartyTransactions" xlink:title="00000018 - Disclosure - Related Party Transactions" />
    <link:calculationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/CommitmentsAndContingencies" xlink:title="00000019 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/IncomeTaxes" xlink:title="00000020 - Disclosure - Income Taxes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/SupplementalCashFlowInformation" xlink:title="00000021 - Disclosure - Supplemental Cash Flow Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/SubsequentEvents" xlink:title="00000022 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/SummaryOfSignificantAccountingAndReportingPoliciesPolicies" xlink:title="00000023 - Disclosure - Summary of Significant Accounting and Reporting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/NatureOfOperationsAndBasisOfPresentationTables" xlink:title="00000024 - Disclosure - Nature of Operations and Basis of Presentation (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/PropertyPlantAndEquipmentAndInvestmentInRealEstateNetTables" xlink:title="00000025 - Disclosure - PROPERTY PLANT AND EQUIPMENT and INVESTMENT IN REAL ESTATE, NET (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/GoodwillTables" xlink:title="00000026 - Disclosure - Goodwill (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/IntangibleAssetsTables" xlink:title="00000027 - Disclosure - Intangible Assets (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/IncomeTaxesTables" xlink:title="00000028 - Disclosure - Income Taxes (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/SupplementalCashFlowInformationTables" xlink:title="00000029 - Disclosure - Supplemental Cash Flow Information (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/ScheduleOfCondensedFinancialStatementsDetails" xlink:title="00000030 - Disclosure - Schedule of Condensed Financial Statements (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/NatureOfOperationsAndBasisOfPresentationDetailsNarrative" xlink:title="00000031 - Disclosure - Nature of Operations and Basis of Presentation (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/SummaryOfSignificantAccountingAndReportingPoliciesDetailsNarrative" xlink:title="00000032 - Disclosure - Summary of Significant Accounting and Reporting Policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/RestatementDetailsNarrative" xlink:title="00000033 - Disclosure - Restatement (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/PrepaidExpensesDetailsNarrative" xlink:title="00000034 - Disclosure - Prepaid Expenses (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/NotesReceivableDetailsNarrative" xlink:title="00000035 - Disclosure - Notes Receivable (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/InvestmentsDetailsNarrative" xlink:title="00000036 - Disclosure - Investments (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" xlink:title="00000037 - Disclosure - Schedule of Property Plant and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/PropertyPlantAndEquipmentAndInvestmentInRealEstateNetDetailsNarrative" xlink:title="00000038 - Disclosure - PROPERTY PLANT AND EQUIPMENT and INVESTMENT IN REAL ESTATE, NET (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/ScheduleOfGoodwillDetails" xlink:title="00000039 - Disclosure - Schedule of Goodwill (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/ScheduleOfIntangibleAssetsDetails" xlink:title="00000040 - Disclosure - Schedule of Intangible Assets (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/GoodwillDetailsNarrative" xlink:title="00000041 - Disclosure - Goodwill (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/ScheduleOfFutureAmortizationOfDevelopedTechnologiesDetails" xlink:title="00000042 - Disclosure - Schedule of Future Amortization of Developed Technologies (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/IntangibleAssetsDetailsNarrative" xlink:title="00000043 - Disclosure - Intangible Assets (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/DebtDetailsNarrative" xlink:title="00000044 - Disclosure - Debt (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000045 - Disclosure - Stockholders&#8217; Equity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000046 - Disclosure - Related Party Transactions (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000047 - Disclosure - Commitments and Contingencies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/ScheduleOfComponentsOfIncomeTaxBenefitDetails" xlink:title="00000048 - Disclosure - Schedule of Components of Income Tax Benefit (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentFederalTaxExpenseBenefit" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapCurrentFederalTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="00000049 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInvestments" xlink:label="loc_us-gaapDeferredTaxAssetsInvestments" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsInvestments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:to="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaapDeferredTaxLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxLiabilities" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxLiabilities" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/SummaryOfEffectiveIncomeTaxRateDetails" xlink:title="00000050 - Disclosure - Summary of Effective Income Tax Rate (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000051 - Disclosure - Income Taxes (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/ScheduleOfCashFlowSupplementalDetails" xlink:title="00000052 - Disclosure - Schedule of Cash Flow Supplemental (Details)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>14
<FILENAME>impb-20230331_def.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.19b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://impactbiomedinc.com/role/Cover" xlink:href="impb-20230331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/BalanceSheets" xlink:href="impb-20230331.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/BalanceSheetsParenthetical" xlink:href="impb-20230331.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/StatementsOfOperations" xlink:href="impb-20230331.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/StatementsOfStockholdersEquity" xlink:href="impb-20230331.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/StatementsOfCashFlows" xlink:href="impb-20230331.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/NatureOfOperationsAndBasisOfPresentation" xlink:href="impb-20230331.xsd#NatureOfOperationsAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/SummaryOfSignificantAccountingAndReportingPolicies" xlink:href="impb-20230331.xsd#SummaryOfSignificantAccountingAndReportingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/Restatement" xlink:href="impb-20230331.xsd#Restatement" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/PrepaidExpenses" xlink:href="impb-20230331.xsd#PrepaidExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/NotesReceivable" xlink:href="impb-20230331.xsd#NotesReceivable" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/Investments" xlink:href="impb-20230331.xsd#Investments" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/PropertyPlantAndEquipmentAndInvestmentInRealEstateNet" xlink:href="impb-20230331.xsd#PropertyPlantAndEquipmentAndInvestmentInRealEstateNet" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/Goodwill" xlink:href="impb-20230331.xsd#Goodwill" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/IntangibleAssets" xlink:href="impb-20230331.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/Debt" xlink:href="impb-20230331.xsd#Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/StockholdersEquity" xlink:href="impb-20230331.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/RelatedPartyTransactions" xlink:href="impb-20230331.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/CommitmentsAndContingencies" xlink:href="impb-20230331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/IncomeTaxes" xlink:href="impb-20230331.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/SupplementalCashFlowInformation" xlink:href="impb-20230331.xsd#SupplementalCashFlowInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/SubsequentEvents" xlink:href="impb-20230331.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/SummaryOfSignificantAccountingAndReportingPoliciesPolicies" xlink:href="impb-20230331.xsd#SummaryOfSignificantAccountingAndReportingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/NatureOfOperationsAndBasisOfPresentationTables" xlink:href="impb-20230331.xsd#NatureOfOperationsAndBasisOfPresentationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/PropertyPlantAndEquipmentAndInvestmentInRealEstateNetTables" xlink:href="impb-20230331.xsd#PropertyPlantAndEquipmentAndInvestmentInRealEstateNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/GoodwillTables" xlink:href="impb-20230331.xsd#GoodwillTables" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/IntangibleAssetsTables" xlink:href="impb-20230331.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/IncomeTaxesTables" xlink:href="impb-20230331.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/SupplementalCashFlowInformationTables" xlink:href="impb-20230331.xsd#SupplementalCashFlowInformationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/ScheduleOfCondensedFinancialStatementsDetails" xlink:href="impb-20230331.xsd#ScheduleOfCondensedFinancialStatementsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/NatureOfOperationsAndBasisOfPresentationDetailsNarrative" xlink:href="impb-20230331.xsd#NatureOfOperationsAndBasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/SummaryOfSignificantAccountingAndReportingPoliciesDetailsNarrative" xlink:href="impb-20230331.xsd#SummaryOfSignificantAccountingAndReportingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/RestatementDetailsNarrative" xlink:href="impb-20230331.xsd#RestatementDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/PrepaidExpensesDetailsNarrative" xlink:href="impb-20230331.xsd#PrepaidExpensesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/NotesReceivableDetailsNarrative" xlink:href="impb-20230331.xsd#NotesReceivableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/InvestmentsDetailsNarrative" xlink:href="impb-20230331.xsd#InvestmentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" xlink:href="impb-20230331.xsd#ScheduleOfPropertyPlantAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/PropertyPlantAndEquipmentAndInvestmentInRealEstateNetDetailsNarrative" xlink:href="impb-20230331.xsd#PropertyPlantAndEquipmentAndInvestmentInRealEstateNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/ScheduleOfGoodwillDetails" xlink:href="impb-20230331.xsd#ScheduleOfGoodwillDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/ScheduleOfIntangibleAssetsDetails" xlink:href="impb-20230331.xsd#ScheduleOfIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/GoodwillDetailsNarrative" xlink:href="impb-20230331.xsd#GoodwillDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/ScheduleOfFutureAmortizationOfDevelopedTechnologiesDetails" xlink:href="impb-20230331.xsd#ScheduleOfFutureAmortizationOfDevelopedTechnologiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/IntangibleAssetsDetailsNarrative" xlink:href="impb-20230331.xsd#IntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/DebtDetailsNarrative" xlink:href="impb-20230331.xsd#DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/StockholdersEquityDetailsNarrative" xlink:href="impb-20230331.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="impb-20230331.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="impb-20230331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/ScheduleOfComponentsOfIncomeTaxBenefitDetails" xlink:href="impb-20230331.xsd#ScheduleOfComponentsOfIncomeTaxBenefitDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="impb-20230331.xsd#ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/SummaryOfEffectiveIncomeTaxRateDetails" xlink:href="impb-20230331.xsd#SummaryOfEffectiveIncomeTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/IncomeTaxesDetailsNarrative" xlink:href="impb-20230331.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/ScheduleOfCashFlowSupplementalDetails" xlink:href="impb-20230331.xsd#ScheduleOfCashFlowSupplementalDetails" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesLineItems" xlink:label="loc_deiEntityAddressesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesTable" xlink:label="loc_deiEntityAddressesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_deiEntityAddressesAddressTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_deiEntityAddressesTable" xlink:to="loc_deiEntityAddressesAddressTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="loc_deiAddressTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiEntityAddressesAddressTypeAxis" xlink:to="loc_deiAddressTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="loc_deiAddressTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiEntityAddressesAddressTypeAxis" xlink:to="loc_deiAddressTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember" xlink:label="loc_deiBusinessContactMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiAddressTypeDomain" xlink:to="loc_deiBusinessContactMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentType_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentFlag_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentDescription_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentRegistrationStatement_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAnnualReport_30" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentQuarterlyReport_30" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentTransitionReport_30" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyReport_30" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate_30" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodStartDate_30" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodEndDate_30" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus_30" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalYearFocus_30" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate_30" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFileNumber_30" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityRegistrantName_30" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCentralIndexKey_30" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPrimarySicNumber_30" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber_30" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode_30" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine1_30" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine2_30" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine3_30" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCityOrTown_30" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressStateOrProvince_30" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCountry_30" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressPostalZipCode_30" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCountryRegion_30" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCityAreaCode_30" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiLocalPhoneNumber_30" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiExtension_30" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiWrittenCommunications_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSolicitingMaterial_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementTenderOffer_30" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer_30" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12bTitle_30" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiNoTradingSymbolFlag_30" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiTradingSymbol_30" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityExchangeName_30" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12gTitle_30" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityReportingObligation_30" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAnnualInformationForm_30" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements_30" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer_30" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityVoluntaryFilers_30" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCurrentReportingStatus_30" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent_30" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFilerCategory_30" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntitySmallBusiness_30" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany_30" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityExTransitionPeriod_30" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAccountingStandard_30" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber_30" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityShellCompany_30" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPublicFloat_30" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent_30" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding_30" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock_30" xlink:type="arc" order="57" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName" xlink:label="loc_deiContactPersonnelName_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiContactPersonnelName_30" xlink:type="arc" order="58" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis" xlink:label="loc_srtRestatementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRestatementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srtScenarioPreviouslyReportedMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRestatementDomain" xlink:to="loc_srtScenarioPreviouslyReportedMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapAssetsCurrentAbstract_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesAndLoansReceivableNetCurrent" xlink:label="loc_us-gaapNotesAndLoansReceivableNetCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapNotesAndLoansReceivableNetCurrent_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapAssetsCurrent_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLongTermInvestments" xlink:label="loc_us-gaapOtherLongTermInvestments_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapOtherLongTermInvestments_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:label="loc_us-gaapNotesAndLoansReceivableNetNoncurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapNotesAndLoansReceivableNetNoncurrent_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapGoodwill_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIntangibleAssetsNet" xlink:label="loc_us-gaapOtherIntangibleAssetsNet_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapOtherIntangibleAssetsNet_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapAssets_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapAccountsPayableCurrent_70" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent_70" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapNotesPayableCurrent_70" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapLiabilitiesCurrent_70" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilitiesNet_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilitiesNet_70" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapLiabilities_70" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapCommitmentsAndContingencies_70" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_70" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_70" xlink:to="loc_us-gaapCommonStockValue_70" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_70" xlink:to="loc_us-gaapAdditionalPaidInCapital_70" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_70" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_70" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_70" xlink:to="loc_us-gaapStockholdersEquity_70" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaapMinorityInterest_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_70" xlink:to="loc_us-gaapMinorityInterest_70" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_70" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_70" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_70" xlink:type="arc" order="28" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis" xlink:label="loc_srtRestatementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRestatementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srtScenarioPreviouslyReportedMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRestatementDomain" xlink:to="loc_srtScenarioPreviouslyReportedMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_50" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis" xlink:label="loc_srtRestatementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRestatementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srtScenarioPreviouslyReportedMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRestatementDomain" xlink:to="loc_srtScenarioPreviouslyReportedMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaapCostsAndExpensesAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCostsAndExpensesAbstract_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCostsAndExpensesAbstract_50" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCostsAndExpensesAbstract_50" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCostsAndExpensesAbstract_50" xlink:to="loc_us-gaapProfessionalFees_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCostsAndExpensesAbstract_50" xlink:to="loc_us-gaapDepreciationAndAmortization_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherGeneralExpense" xlink:label="loc_us-gaapOtherGeneralExpense_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCostsAndExpensesAbstract_50" xlink:to="loc_us-gaapOtherGeneralExpense_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaapCostsAndExpenses_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCostsAndExpensesAbstract_50" xlink:to="loc_us-gaapCostsAndExpenses_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_50" xlink:to="loc_us-gaapInvestmentIncomeInterest_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_50" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_50" xlink:to="loc_us-gaapInterestExpense_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaapAssetImpairmentCharges_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_50" xlink:to="loc_us-gaapAssetImpairmentCharges_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_50" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit_50" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss_50" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest_50" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_50" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="loc_us-gaapEarningsPerShareBasicAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareBasicAbstract_50" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEarningsPerShareBasicAbstract_50" xlink:to="loc_us-gaapEarningsPerShareBasic_50" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEarningsPerShareBasicAbstract_50" xlink:to="loc_us-gaapEarningsPerShareDiluted_50" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract_50" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract_50" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_50" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaapWeightedAverageNumberDilutedSharesOutstandingAdjustment_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract_50" xlink:to="loc_us-gaapWeightedAverageNumberDilutedSharesOutstandingAdjustment_50" xlink:type="arc" order="23" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/StatementsOfStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Stockholder&apos;s Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaapNoncontrollingInterestMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapNoncontrollingInterestMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis" xlink:label="loc_srtRestatementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRestatementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srtScenarioPreviouslyReportedMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRestatementDomain" xlink:to="loc_srtScenarioPreviouslyReportedMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_StockIssuedDuringPeriodValueShareholder" xlink:label="loc_IMPBStockIssuedDuringPeriodValueShareholder_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMPBStockIssuedDuringPeriodValueShareholder_110" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis" xlink:label="loc_srtRestatementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRestatementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srtScenarioPreviouslyReportedMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRestatementDomain" xlink:to="loc_srtScenarioPreviouslyReportedMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_50" xlink:to="loc_us-gaapProfitLoss_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_50" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_50" xlink:to="loc_us-gaapDepreciationAndAmortization_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:label="loc_us-gaapDeferredIncomeTaxesAndTaxCredits_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_50" xlink:to="loc_us-gaapDeferredIncomeTaxesAndTaxCredits_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_ImpairmentOfOtherInvestments" xlink:label="loc_IMPBImpairmentOfOtherInvestments_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_50" xlink:to="loc_IMPBImpairmentOfOtherInvestments_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_50" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract_50" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredLiabilities_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract_50" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredLiabilities_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_IncreaseDecreaseInImpairmentofOtherInvestments" xlink:label="loc_IMPBIncreaseDecreaseInImpairmentofOtherInvestments_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract_50" xlink:to="loc_IMPBIncreaseDecreaseInImpairmentofOtherInvestments_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_50" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_50" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_50" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_50" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_50" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_50" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromProductiveAssets" xlink:label="loc_us-gaapPaymentsForProceedsFromProductiveAssets_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_50" xlink:to="loc_us-gaapPaymentsForProceedsFromProductiveAssets_50" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaapPaymentsToAcquireInvestments_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_50" xlink:to="loc_us-gaapPaymentsToAcquireInvestments_50" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_PaymentsForProceedsFromNoteReceivableInvestments" xlink:label="loc_IMPBPaymentsForProceedsFromNoteReceivableInvestments_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_50" xlink:to="loc_IMPBPaymentsForProceedsFromNoteReceivableInvestments_50" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_50" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities_50" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_50" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_50" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt_50" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_50" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities_50" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_50" xlink:type="arc" order="23" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/NatureOfOperationsAndBasisOfPresentation" xlink:title="00000007 - Disclosure - Nature of Operations and Basis of Presentation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/SummaryOfSignificantAccountingAndReportingPolicies" xlink:title="00000008 - Disclosure - Summary of Significant Accounting and Reporting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/Restatement" xlink:title="00000009 - Disclosure - Restatement" />
    <link:definitionLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/PrepaidExpenses" xlink:title="00000010 - Disclosure - Prepaid Expenses" />
    <link:definitionLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/NotesReceivable" xlink:title="00000011 - Disclosure - Notes Receivable" />
    <link:definitionLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/Investments" xlink:title="00000012 - Disclosure - Investments" />
    <link:definitionLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/PropertyPlantAndEquipmentAndInvestmentInRealEstateNet" xlink:title="00000013 - Disclosure - PROPERTY PLANT AND EQUIPMENT and INVESTMENT IN REAL ESTATE, NET" />
    <link:definitionLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/Goodwill" xlink:title="00000014 - Disclosure - Goodwill" />
    <link:definitionLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/IntangibleAssets" xlink:title="00000015 - Disclosure - Intangible Assets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/Debt" xlink:title="00000016 - Disclosure - Debt" />
    <link:definitionLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/StockholdersEquity" xlink:title="00000017 - Disclosure - Stockholders&#8217; Equity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/RelatedPartyTransactions" xlink:title="00000018 - Disclosure - Related Party Transactions" />
    <link:definitionLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/CommitmentsAndContingencies" xlink:title="00000019 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/IncomeTaxes" xlink:title="00000020 - Disclosure - Income Taxes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/SupplementalCashFlowInformation" xlink:title="00000021 - Disclosure - Supplemental Cash Flow Information" />
    <link:definitionLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/SubsequentEvents" xlink:title="00000022 - Disclosure - Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/SummaryOfSignificantAccountingAndReportingPoliciesPolicies" xlink:title="00000023 - Disclosure - Summary of Significant Accounting and Reporting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/NatureOfOperationsAndBasisOfPresentationTables" xlink:title="00000024 - Disclosure - Nature of Operations and Basis of Presentation (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/PropertyPlantAndEquipmentAndInvestmentInRealEstateNetTables" xlink:title="00000025 - Disclosure - PROPERTY PLANT AND EQUIPMENT and INVESTMENT IN REAL ESTATE, NET (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/GoodwillTables" xlink:title="00000026 - Disclosure - Goodwill (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/IntangibleAssetsTables" xlink:title="00000027 - Disclosure - Intangible Assets (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/IncomeTaxesTables" xlink:title="00000028 - Disclosure - Income Taxes (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/SupplementalCashFlowInformationTables" xlink:title="00000029 - Disclosure - Supplemental Cash Flow Information (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/ScheduleOfCondensedFinancialStatementsDetails" xlink:title="00000030 - Disclosure - Schedule of Condensed Financial Statements (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:label="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:label="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis" xlink:label="loc_srtOwnershipAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:to="loc_srtOwnershipAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="loc_srtOwnershipDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtOwnershipAxis" xlink:to="loc_srtOwnershipDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="loc_srtOwnershipDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtOwnershipAxis" xlink:to="loc_srtOwnershipDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_GlobalBioMedicalIncMember" xlink:label="loc_IMPBGlobalBioMedicalIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtOwnershipDomain" xlink:to="loc_IMPBGlobalBioMedicalIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_GlobalBioLifeIncMember" xlink:label="loc_IMPBGlobalBioLifeIncMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtOwnershipDomain" xlink:to="loc_IMPBGlobalBioLifeIncMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_BioLifeSugarIncMember" xlink:label="loc_IMPBBioLifeSugarIncMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtOwnershipDomain" xlink:to="loc_IMPBBioLifeSugarIncMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_HappySugarIncMember" xlink:label="loc_IMPBHappySugarIncMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtOwnershipDomain" xlink:to="loc_IMPBHappySugarIncMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_SweetSenseIncMember" xlink:label="loc_IMPBSweetSenseIncMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtOwnershipDomain" xlink:to="loc_IMPBSweetSenseIncMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_GlobalSugarSolutionsIncMember" xlink:label="loc_IMPBGlobalSugarSolutionsIncMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtOwnershipDomain" xlink:to="loc_IMPBGlobalSugarSolutionsIncMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_StateOrOtherJurisdictionOfIncorporationOrOrganization" xlink:label="loc_IMPBStateOrOtherJurisdictionOfIncorporationOrOrganization_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="loc_IMPBStateOrOtherJurisdictionOfIncorporationOrOrganization_310" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="loc_deiEntityIncorporationDateOfIncorporation_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="loc_deiEntityIncorporationDateOfIncorporation_310" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="loc_us-gaapMinorityInterestOwnershipPercentageByParent_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="loc_us-gaapMinorityInterestOwnershipPercentageByParent_310" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/NatureOfOperationsAndBasisOfPresentationDetailsNarrative" xlink:title="00000031 - Disclosure - Nature of Operations and Basis of Presentation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:label="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:label="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis" xlink:label="loc_srtOwnershipAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:to="loc_srtOwnershipAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="loc_srtOwnershipDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtOwnershipAxis" xlink:to="loc_srtOwnershipDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="loc_srtOwnershipDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtOwnershipAxis" xlink:to="loc_srtOwnershipDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_SweetSenseMember" xlink:label="loc_IMPBSweetSenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtOwnershipDomain" xlink:to="loc_IMPBSweetSenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_GlobalBioMedicalPteLtdMember" xlink:label="loc_IMPBGlobalBioMedicalPteLtdMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_IMPBGlobalBioMedicalPteLtdMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SubsidiariesMember" xlink:label="loc_srtSubsidiariesMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_srtSubsidiariesMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="loc_us-gaapMinorityInterestOwnershipPercentageByNoncontrollingOwners_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="loc_us-gaapMinorityInterestOwnershipPercentageByNoncontrollingOwners_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferred1_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="loc_us-gaapMinorityInterestOwnershipPercentageByParent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="loc_us-gaapMinorityInterestOwnershipPercentageByParent_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaapMinorityInterest_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="loc_us-gaapMinorityInterest_110" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/SummaryOfSignificantAccountingAndReportingPoliciesDetailsNarrative" xlink:title="00000032 - Disclosure - Summary of Significant Accounting and Reporting Policies (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/RestatementDetailsNarrative" xlink:title="00000033 - Disclosure - Restatement (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInterestExpense_30" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/PrepaidExpensesDetailsNarrative" xlink:title="00000034 - Disclosure - Prepaid Expenses (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_GRDGscienceLLCMember" xlink:label="loc_IMPBGRDGscienceLLCMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_IMPBGRDGscienceLLCMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_70" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/NotesReceivableDetailsNarrative" xlink:title="00000035 - Disclosure - Notes Receivable (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivableModificationsLineItems" xlink:label="loc_us-gaapFinancingReceivableModificationsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFinancingReceivableTroubledDebtRestructuringsTable" xlink:label="loc_us-gaapScheduleOfFinancingReceivableTroubledDebtRestructuringsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancingReceivableModificationsLineItems" xlink:to="loc_us-gaapScheduleOfFinancingReceivableTroubledDebtRestructuringsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFinancingReceivableTroubledDebtRestructuringsTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_PromissoryNoteOneMember" xlink:label="loc_IMPBPromissoryNoteOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_IMPBPromissoryNoteOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_PromissoryNoteTwoMember" xlink:label="loc_IMPBPromissoryNoteTwoMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_IMPBPromissoryNoteTwoMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFinancingReceivableTroubledDebtRestructuringsTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesReceivableNet" xlink:label="loc_us-gaapNotesReceivableNet_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFinancingReceivableModificationsLineItems" xlink:to="loc_us-gaapNotesReceivableNet_200" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFinancingReceivableModificationsLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_200" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFinancingReceivableModificationsLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate_200" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaapDebtInstrumentPeriodicPayment_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFinancingReceivableModificationsLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPayment_200" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesAndLoansReceivableGrossCurrent" xlink:label="loc_us-gaapNotesAndLoansReceivableGrossCurrent_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFinancingReceivableModificationsLineItems" xlink:to="loc_us-gaapNotesAndLoansReceivableGrossCurrent_200" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:label="loc_us-gaapNotesAndLoansReceivableNetNoncurrent_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFinancingReceivableModificationsLineItems" xlink:to="loc_us-gaapNotesAndLoansReceivableNetNoncurrent_200" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFinancingReceivableModificationsLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_200" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/InvestmentsDetailsNarrative" xlink:title="00000036 - Disclosure - Investments (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_AsiaPacificHoldingsLimitedMember" xlink:label="loc_IMPBAsiaPacificHoldingsLimitedMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_IMPBAsiaPacificHoldingsLimitedMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_NanoNineLLCMember" xlink:label="loc_IMPBNanoNineLLCMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_IMPBNanoNineLLCMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_VivacitasOncologyIncMember" xlink:label="loc_IMPBVivacitasOncologyIncMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_IMPBVivacitasOncologyIncMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubscriptionArrangementMember" xlink:label="loc_us-gaapSubscriptionArrangementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_us-gaapSubscriptionArrangementMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_SecuritiesPurchaseAgreementMember" xlink:label="loc_IMPBSecuritiesPurchaseAgreementMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_IMPBSecuritiesPurchaseAgreementMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_StockPurchaseAgreementMember" xlink:label="loc_IMPBStockPurchaseAgreementMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_IMPBStockPurchaseAgreementMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_VivacitasAgreementMember" xlink:label="loc_IMPBVivacitasAgreementMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_IMPBVivacitasAgreementMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_NanoNineLLCMember" xlink:label="loc_IMPBNanoNineLLCMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_IMPBNanoNineLLCMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_ImpactOncologyPTELtdMember" xlink:label="loc_IMPBImpactOncologyPTELtdMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_IMPBImpactOncologyPTELtdMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesPurchaseOfAssets_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesPurchaseOfAssets_160" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_OrdinarySharesPercentage" xlink:label="loc_IMPBOrdinarySharesPercentage_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMPBOrdinarySharesPercentage_160" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="loc_us-gaapStockIssuedDuringPeriodValuePurchaseOfAssets_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValuePurchaseOfAssets_160" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_160" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_160" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_160" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedAtFairValue" xlink:label="loc_us-gaapInvestmentOwnedAtFairValue_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInvestmentOwnedAtFairValue_160" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_160" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_160" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharePrice_160" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_160" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement_160" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferred1_160" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_160" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_160" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_160" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_160" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedPercentOfNetAssets" xlink:label="loc_us-gaapInvestmentOwnedPercentOfNetAssets_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInvestmentOwnedPercentOfNetAssets_160" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedAtCost" xlink:label="loc_us-gaapInvestmentOwnedAtCost_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInvestmentOwnedAtCost_160" xlink:type="arc" order="18" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" xlink:title="00000037 - Disclosure - Schedule of Property Plant and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaapMachineryAndEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapMachineryAndEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaapConstructionInProgressMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapConstructionInProgressMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_140" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_140" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_140" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_140" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/PropertyPlantAndEquipmentAndInvestmentInRealEstateNetDetailsNarrative" xlink:title="00000038 - Disclosure - PROPERTY PLANT AND EQUIPMENT and INVESTMENT IN REAL ESTATE, NET (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/ScheduleOfGoodwillDetails" xlink:title="00000039 - Disclosure - Schedule of Goodwill (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/ScheduleOfIntangibleAssetsDetails" xlink:title="00000040 - Disclosure - Schedule of Intangible Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaapDevelopedTechnologyRightsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapDevelopedTechnologyRightsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet_70" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/GoodwillDetailsNarrative" xlink:title="00000041 - Disclosure - Goodwill (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/ScheduleOfFutureAmortizationOfDevelopedTechnologiesDetails" xlink:title="00000042 - Disclosure - Schedule of Future Amortization of Developed Technologies (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/IntangibleAssetsDetailsNarrative" xlink:title="00000043 - Disclosure - Intangible Assets (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/DebtDetailsNarrative" xlink:title="00000044 - Disclosure - Debt (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_RevolvingPromissoryNoteMember" xlink:label="loc_IMPBRevolvingPromissoryNoteMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_IMPBRevolvingPromissoryNoteMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDefaultLongtermDebtDescriptionOfNoticeOfDefault" xlink:label="loc_us-gaapDebtDefaultLongtermDebtDescriptionOfNoticeOfDefault_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtDefaultLongtermDebtDescriptionOfNoticeOfDefault_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapNotesPayable_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_80" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000045 - Disclosure - Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:label="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:label="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="loc_srtBoardOfDirectorsChairmanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtBoardOfDirectorsChairmanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_100" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_100" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_100" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000046 - Disclosure - Related Party Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_GRDGscienceLLCMember" xlink:label="loc_IMPBGRDGscienceLLCMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_IMPBGRDGscienceLLCMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="loc_us-gaapPaymentsToAcquireInProcessResearchAndDevelopment_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapPaymentsToAcquireInProcessResearchAndDevelopment_150" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_150" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction_150" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrentAndNoncurrent_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapPrepaidExpenseCurrentAndNoncurrent_150" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="loc_us-gaapLaborAndRelatedExpense_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapLaborAndRelatedExpense_150" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense_150" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000047 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_RoyaltyAgreementMember" xlink:label="loc_IMPBRoyaltyAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_IMPBRoyaltyAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_LicenseAgreementMember" xlink:label="loc_IMPBLicenseAgreementMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_IMPBLicenseAgreementMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_GlobalAndBioLifeSciencesMember" xlink:label="loc_IMPBGlobalAndBioLifeSciencesMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_IMPBGlobalAndBioLifeSciencesMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_ChemiaCorporationMember" xlink:label="loc_IMPBChemiaCorporationMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_IMPBChemiaCorporationMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_RoyaltyPercentage" xlink:label="loc_IMPBRoyaltyPercentage_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_IMPBRoyaltyPercentage_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_SaleOfRoyaltyPercentage" xlink:label="loc_IMPBSaleOfRoyaltyPercentage_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_IMPBSaleOfRoyaltyPercentage_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_DevelopmentCostPercent" xlink:label="loc_IMPBDevelopmentCostPercent_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_IMPBDevelopmentCostPercent_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsIncurredDevelopmentCosts" xlink:label="loc_us-gaapCostsIncurredDevelopmentCosts_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCostsIncurredDevelopmentCosts_100" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/ScheduleOfComponentsOfIncomeTaxBenefitDetails" xlink:title="00000048 - Disclosure - Schedule of Components of Income Tax Benefit (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="00000049 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/SummaryOfEffectiveIncomeTaxRateDetails" xlink:title="00000050 - Disclosure - Summary of Effective Income Tax Rate (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000051 - Disclosure - Income Taxes (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/ScheduleOfCashFlowSupplementalDetails" xlink:title="00000052 - Disclosure - Schedule of Cash Flow Supplemental (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapNotesPayable_30" xlink:type="arc" order="1" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>15
<FILENAME>impb-20230331_lab.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.19b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_EntityAddressesAddressTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesAddressTypeAxis_lbl" xml:lang="en-US">Entity Addresses, Address Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember" xlink:label="dei_BusinessContactMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_BusinessContactMember_lbl" xml:lang="en-US">Business Contact [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementAxis_lbl" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioPreviouslyReportedMember" xlink:to="srt_ScenarioPreviouslyReportedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioPreviouslyReportedMember_lbl" xml:lang="en-US">Previously Reported [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US">Related Party [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipAxis_lbl" xml:lang="en-US">Ownership [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_SweetSenseMember" xlink:label="IMPB_SweetSenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_SweetSenseMember" xlink:to="IMPB_SweetSenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMPB_SweetSenseMember_lbl" xml:lang="en-US">Sweet Sense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xml:lang="en-US">Investment, Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_GlobalBioMedicalPteLtdMember" xlink:label="IMPB_GlobalBioMedicalPteLtdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_GlobalBioMedicalPteLtdMember" xlink:to="IMPB_GlobalBioMedicalPteLtdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMPB_GlobalBioMedicalPteLtdMember_lbl" xml:lang="en-US">Global Bio Medical Pte Ltd [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SubsidiariesMember" xlink:label="srt_SubsidiariesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SubsidiariesMember" xlink:to="srt_SubsidiariesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SubsidiariesMember_lbl" xml:lang="en-US">Subsidiaries [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_GlobalBioMedicalIncMember" xlink:label="IMPB_GlobalBioMedicalIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_GlobalBioMedicalIncMember" xlink:to="IMPB_GlobalBioMedicalIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMPB_GlobalBioMedicalIncMember_lbl" xml:lang="en-US">Global Bio Medical Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_GlobalBioLifeIncMember" xlink:label="IMPB_GlobalBioLifeIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_GlobalBioLifeIncMember" xlink:to="IMPB_GlobalBioLifeIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMPB_GlobalBioLifeIncMember_lbl" xml:lang="en-US">Global Bio Life Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_BioLifeSugarIncMember" xlink:label="IMPB_BioLifeSugarIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_BioLifeSugarIncMember" xlink:to="IMPB_BioLifeSugarIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMPB_BioLifeSugarIncMember_lbl" xml:lang="en-US">Bio Life Sugar Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_HappySugarIncMember" xlink:label="IMPB_HappySugarIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_HappySugarIncMember" xlink:to="IMPB_HappySugarIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMPB_HappySugarIncMember_lbl" xml:lang="en-US">Happy Sugar Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_SweetSenseIncMember" xlink:label="IMPB_SweetSenseIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_SweetSenseIncMember" xlink:to="IMPB_SweetSenseIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMPB_SweetSenseIncMember_lbl" xml:lang="en-US">Sweet Sense Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_GlobalSugarSolutionsIncMember" xlink:label="IMPB_GlobalSugarSolutionsIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_GlobalSugarSolutionsIncMember" xlink:to="IMPB_GlobalSugarSolutionsIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMPB_GlobalSugarSolutionsIncMember_lbl" xml:lang="en-US">Global Sugar Solutions Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_GRDGscienceLLCMember" xlink:label="IMPB_GRDGscienceLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_GRDGscienceLLCMember" xlink:to="IMPB_GRDGscienceLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMPB_GRDGscienceLLCMember_lbl" xml:lang="en-US">GRDG Science LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_PromissoryNoteOneMember" xlink:label="IMPB_PromissoryNoteOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_PromissoryNoteOneMember" xlink:to="IMPB_PromissoryNoteOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMPB_PromissoryNoteOneMember_lbl" xml:lang="en-US">Promissory Note One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_PromissoryNoteTwoMember" xlink:label="IMPB_PromissoryNoteTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_PromissoryNoteTwoMember" xlink:to="IMPB_PromissoryNoteTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMPB_PromissoryNoteTwoMember_lbl" xml:lang="en-US">Promissory Note Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_AsiaPacificHoldingsLimitedMember" xlink:label="IMPB_AsiaPacificHoldingsLimitedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_AsiaPacificHoldingsLimitedMember" xlink:to="IMPB_AsiaPacificHoldingsLimitedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMPB_AsiaPacificHoldingsLimitedMember_lbl" xml:lang="en-US">Asia Pacific Holdings Limited [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubscriptionArrangementMember" xlink:label="us-gaap_SubscriptionArrangementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubscriptionArrangementMember" xlink:to="us-gaap_SubscriptionArrangementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubscriptionArrangementMember_lbl" xml:lang="en-US">Subscription Arrangement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_NanoNineLLCMember" xlink:label="IMPB_NanoNineLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_NanoNineLLCMember" xlink:to="IMPB_NanoNineLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMPB_NanoNineLLCMember_lbl" xml:lang="en-US">Nano9 LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_SecuritiesPurchaseAgreementMember" xlink:label="IMPB_SecuritiesPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_SecuritiesPurchaseAgreementMember" xlink:to="IMPB_SecuritiesPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMPB_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_StockPurchaseAgreementMember" xlink:label="IMPB_StockPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_StockPurchaseAgreementMember" xlink:to="IMPB_StockPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMPB_StockPurchaseAgreementMember_lbl" xml:lang="en-US">Stock Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_VivacitasOncologyIncMember" xlink:label="IMPB_VivacitasOncologyIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_VivacitasOncologyIncMember" xlink:to="IMPB_VivacitasOncologyIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMPB_VivacitasOncologyIncMember_lbl" xml:lang="en-US">Vivacitas Oncology Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US">Business Acquisition [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_ImpactOncologyPTELtdMember" xlink:label="IMPB_ImpactOncologyPTELtdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_ImpactOncologyPTELtdMember" xlink:to="IMPB_ImpactOncologyPTELtdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMPB_ImpactOncologyPTELtdMember_lbl" xml:lang="en-US">Impact Oncology PTE Ltd [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_VivacitasAgreementMember" xlink:label="IMPB_VivacitasAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_VivacitasAgreementMember" xlink:to="IMPB_VivacitasAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMPB_VivacitasAgreementMember_lbl" xml:lang="en-US">Vivacitas Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xml:lang="en-US">Construction in Progress [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="us-gaap_DevelopedTechnologyRightsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DevelopedTechnologyRightsMember" xlink:to="us-gaap_DevelopedTechnologyRightsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DevelopedTechnologyRightsMember_lbl" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_RevolvingPromissoryNoteMember" xlink:label="IMPB_RevolvingPromissoryNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_RevolvingPromissoryNoteMember" xlink:to="IMPB_RevolvingPromissoryNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMPB_RevolvingPromissoryNoteMember_lbl" xml:lang="en-US">Revolving Promissory Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="srt_BoardOfDirectorsChairmanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl" xml:lang="en-US">Board of Directors Chairman [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_RoyaltyAgreementMember" xlink:label="IMPB_RoyaltyAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_RoyaltyAgreementMember" xlink:to="IMPB_RoyaltyAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMPB_RoyaltyAgreementMember_lbl" xml:lang="en-US">Royalty Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_ChemiaCorporationMember" xlink:label="IMPB_ChemiaCorporationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_ChemiaCorporationMember" xlink:to="IMPB_ChemiaCorporationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMPB_ChemiaCorporationMember_lbl" xml:lang="en-US">Chemia Corporation [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_LicenseAgreementMember" xlink:label="IMPB_LicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_LicenseAgreementMember" xlink:to="IMPB_LicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMPB_LicenseAgreementMember_lbl" xml:lang="en-US">License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_GlobalAndBioLifeSciencesMember" xlink:label="IMPB_GlobalAndBioLifeSciencesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_GlobalAndBioLifeSciencesMember" xlink:to="IMPB_GlobalAndBioLifeSciencesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMPB_GlobalAndBioLifeSciencesMember_lbl" xml:lang="en-US">Global And Bio Life Sciences [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesTable" xlink:label="dei_EntityAddressesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesTable" xlink:to="dei_EntityAddressesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesTable_lbl" xml:lang="en-US">Entity Addresses [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesLineItems" xlink:label="dei_EntityAddressesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesLineItems" xlink:to="dei_EntityAddressesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesLineItems_lbl" xml:lang="en-US">Entity Addresses [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName" xlink:label="dei_ContactPersonnelName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelName" xlink:to="dei_ContactPersonnelName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_ContactPersonnelName_lbl" xml:lang="en-US">Contact Personnel Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesAndLoansReceivableNetCurrent" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesAndLoansReceivableNetCurrent" xlink:to="us-gaap_NotesAndLoansReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent_lbl" xml:lang="en-US">Current portion of notes receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, plant and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLongTermInvestments" xlink:label="us-gaap_OtherLongTermInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLongTermInvestments" xlink:to="us-gaap_OtherLongTermInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLongTermInvestments_lbl" xml:lang="en-US">Other investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:label="us-gaap_NotesAndLoansReceivableNetNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:to="us-gaap_NotesAndLoansReceivableNetNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesAndLoansReceivableNetNoncurrent_lbl" xml:lang="en-US">Notes receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US">Goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIntangibleAssetsNet" xlink:label="us-gaap_OtherIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIntangibleAssetsNet" xlink:to="us-gaap_OtherIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIntangibleAssetsNet_lbl" xml:lang="en-US">Other intangible assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDER&#8217;S EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Note payable, related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xml:lang="en-US">Deferred tax liability, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies (Note 12)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xml:lang="en-US">Stockholder&#8217;s equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $.001 par value; 3,000,000,000 shares authorized, 125,073,621 shares issued and outstanding (125,073,621 on March 31, 2023 and December 31, 2022)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholder&#8217;s equity of the company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterest_lbl" xml:lang="en-US">Non-controlling interest in subsidiary</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Total stockholder&#8217;s equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholder&#8217;s equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US">Costs and expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, general and administrative compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research &amp; development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalFees_lbl" xml:lang="en-US">Professional services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherGeneralExpense" xlink:label="us-gaap_OtherGeneralExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralExpense" xlink:to="us-gaap_OtherGeneralExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherGeneralExpense_lbl" xml:lang="en-US">Other general expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US">Total costs and expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expense):</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other income (expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US">Impairment of investment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss from continuing operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax (loss)/benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Loss from continuing operations attributed to noncontrolling interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasicAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAbstract_lbl" xml:lang="en-US">Loss per common share:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">Shares used in computing loss per common share:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" xml:lang="en-US">Diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Income tax benefit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of common stock, net</link:label>
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_StockIssuedDuringPeriodValueShareholder" xlink:label="IMPB_StockIssuedDuringPeriodValueShareholder" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_StockIssuedDuringPeriodValueShareholder" xlink:to="IMPB_StockIssuedDuringPeriodValueShareholder_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMPB_StockIssuedDuringPeriodValueShareholder_lbl" xml:lang="en-US">Proceeds from shareholder</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used by operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:label="us-gaap_DeferredIncomeTaxesAndTaxCredits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="us-gaap_DeferredIncomeTaxesAndTaxCredits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxesAndTaxCredits_lbl" xml:lang="en-US">Deferred tax benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_ImpairmentOfOtherInvestments" xlink:label="IMPB_ImpairmentOfOtherInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_ImpairmentOfOtherInvestments" xlink:to="IMPB_ImpairmentOfOtherInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMPB_ImpairmentOfOtherInvestments_lbl" xml:lang="en-US">Impairment of other investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl" xml:lang="en-US">Decrease (increase) in assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:to="us-gaap_IncreaseDecreaseInDeferredLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities_lbl" xml:lang="en-US">Deferred Tax benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_IncreaseDecreaseInImpairmentofOtherInvestments" xlink:label="IMPB_IncreaseDecreaseInImpairmentofOtherInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_IncreaseDecreaseInImpairmentofOtherInvestments" xlink:to="IMPB_IncreaseDecreaseInImpairmentofOtherInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="IMPB_IncreaseDecreaseInImpairmentofOtherInvestments_lbl" xml:lang="en-US">Impairment of other investment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl" xml:lang="en-US">Increase (decrease) in liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used by operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromProductiveAssets" xlink:label="us-gaap_PaymentsForProceedsFromProductiveAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromProductiveAssets" xlink:to="us-gaap_PaymentsForProceedsFromProductiveAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForProceedsFromProductiveAssets_lbl" xml:lang="en-US">Purchase of property, plant and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInvestments" xlink:to="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xml:lang="en-US">Purchase of investment</link:label>
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_PaymentsForProceedsFromNoteReceivableInvestments" xlink:label="IMPB_PaymentsForProceedsFromNoteReceivableInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_PaymentsForProceedsFromNoteReceivableInvestments" xlink:to="IMPB_PaymentsForProceedsFromNoteReceivableInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="IMPB_PaymentsForProceedsFromNoteReceivableInvestments_lbl" xml:lang="en-US">Note receivable investment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used by investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xml:lang="en-US">Borrowings from note payable, related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net decrease in cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">Nature of Operations and Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting and Reporting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl" xml:lang="en-US">Accounting Changes and Error Corrections [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:to="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_lbl" xml:lang="en-US">Restatement</link:label>
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_DisclosurePrepaidExpensesAbstract" xlink:label="IMPB_DisclosurePrepaidExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_DisclosurePrepaidExpensesAbstract" xlink:to="IMPB_DisclosurePrepaidExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMPB_DisclosurePrepaidExpensesAbstract_lbl" xml:lang="en-US">Prepaid Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_PrepaidExpensesTextBlock" xlink:label="IMPB_PrepaidExpensesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_PrepaidExpensesTextBlock" xlink:to="IMPB_PrepaidExpensesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="IMPB_PrepaidExpensesTextBlock_lbl" xml:lang="en-US">Prepaid Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_ReceivablesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesAbstract_lbl" xml:lang="en-US">Receivables [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" xml:lang="en-US">Notes Receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="us-gaap_InvestmentsAllOtherInvestmentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract_lbl" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTextBlock" xlink:label="us-gaap_InvestmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTextBlock" xlink:to="us-gaap_InvestmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTextBlock_lbl" xml:lang="en-US">Investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock_lbl" xml:lang="en-US">PROPERTY PLANT AND EQUIPMENT and INVESTMENT IN REAL ESTATE, NET</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillDisclosureTextBlock" xlink:label="us-gaap_GoodwillDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillDisclosureTextBlock" xlink:to="us-gaap_GoodwillDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GoodwillDisclosureTextBlock_lbl" xml:lang="en-US">Goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:label="us-gaap_CashFlowSupplementalDisclosuresTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:to="us-gaap_CashFlowSupplementalDisclosuresTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowSupplementalDisclosuresTextBlock_lbl" xml:lang="en-US">Supplemental Cash Flow Information</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings (Loss) per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xml:lang="en-US">Investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xml:lang="en-US">Goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Recoverability of Long-Lived Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Standards</link:label>
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_ContinuingOperationsAndGoingConcernPolicyTextBlock" xlink:label="IMPB_ContinuingOperationsAndGoingConcernPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_ContinuingOperationsAndGoingConcernPolicyTextBlock" xlink:to="IMPB_ContinuingOperationsAndGoingConcernPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMPB_ContinuingOperationsAndGoingConcernPolicyTextBlock_lbl" xml:lang="en-US">Continuing Operations and Going Concern</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock_lbl" xml:lang="en-US">Schedule of Condensed Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of Property Plant and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="us-gaap_ScheduleOfGoodwillTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock_lbl" xml:lang="en-US">Schedule of Goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xml:lang="en-US">Schedule of Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of Future Amortization of Developed Technologies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of Components of Income Tax Benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Summary of Effective Income Tax Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xml:lang="en-US">Schedule of Cash Flow Supplemental</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:label="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:to="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_lbl" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:label="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_lbl" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_StateOrOtherJurisdictionOfIncorporationOrOrganization" xlink:label="IMPB_StateOrOtherJurisdictionOfIncorporationOrOrganization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_StateOrOtherJurisdictionOfIncorporationOrOrganization" xlink:to="IMPB_StateOrOtherJurisdictionOfIncorporationOrOrganization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMPB_StateOrOtherJurisdictionOfIncorporationOrOrganization_lbl" xml:lang="en-US">State or other jurisdiction of incorporation or organization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="dei_EntityIncorporationDateOfIncorporation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationDateOfIncorporation" xlink:to="dei_EntityIncorporationDateOfIncorporation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xml:lang="en-US">Date of incorporation or formation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xml:lang="en-US">Attributable interest percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" xml:lang="en-US">Minority interest ownership percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xml:lang="en-US">Consideration given for purchase</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_2_lbl" xml:lang="en-US">Ownership percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock issued during period shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MinorityInterest_2_lbl" xml:lang="en-US">Noncontrolling interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xml:lang="en-US">Impairment of goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xml:lang="en-US">Impairment of intangible assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Research and development cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_2_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses includes prepaid inventory</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_3_lbl" xml:lang="en-US">Research and development</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFinancingReceivableTroubledDebtRestructuringsTable" xlink:label="us-gaap_ScheduleOfFinancingReceivableTroubledDebtRestructuringsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFinancingReceivableTroubledDebtRestructuringsTable" xlink:to="us-gaap_ScheduleOfFinancingReceivableTroubledDebtRestructuringsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFinancingReceivableTroubledDebtRestructuringsTable_lbl" xml:lang="en-US">Financing Receivable, Modified [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivableModificationsLineItems" xlink:label="us-gaap_FinancingReceivableModificationsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancingReceivableModificationsLineItems" xlink:to="us-gaap_FinancingReceivableModificationsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancingReceivableModificationsLineItems_lbl" xml:lang="en-US">Financing Receivable, Modified [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesReceivableNet" xlink:label="us-gaap_NotesReceivableNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesReceivableNet" xlink:to="us-gaap_NotesReceivableNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesReceivableNet_lbl" xml:lang="en-US">Note receivable principal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Debt stated percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Maturity date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPayment" xlink:to="us-gaap_DebtInstrumentPeriodicPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_lbl" xml:lang="en-US">Debt principal and interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesAndLoansReceivableGrossCurrent" xlink:label="us-gaap_NotesAndLoansReceivableGrossCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesAndLoansReceivableGrossCurrent" xlink:to="us-gaap_NotesAndLoansReceivableGrossCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesAndLoansReceivableGrossCurrent_lbl" xml:lang="en-US">Notes receivable current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:to="us-gaap_NotesAndLoansReceivableNetNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NotesAndLoansReceivableNetNoncurrent_2_lbl" xml:lang="en-US">Notes and loans receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Debt face amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl" xml:lang="en-US">Ordinary shares to purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_OrdinarySharesPercentage" xlink:label="IMPB_OrdinarySharesPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_OrdinarySharesPercentage" xlink:to="IMPB_OrdinarySharesPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMPB_OrdinarySharesPercentage_lbl" xml:lang="en-US">Ordinary shares percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_lbl" xml:lang="en-US">Purchase price of shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xml:lang="en-US">Number of shares issued, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Number of shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Equitable ownership percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedAtFairValue" xlink:label="us-gaap_InvestmentOwnedAtFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedAtFairValue" xlink:to="us-gaap_InvestmentOwnedAtFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentOwnedAtFairValue_lbl" xml:lang="en-US">Investment owned at fair value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_2_lbl" xml:lang="en-US">Common stock par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xml:lang="en-US">Options to purchase common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xml:lang="en-US">Option termination, description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Proceeds from private placement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_2_lbl" xml:lang="en-US">Purchase price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US">Number of common stock owned</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Stock option exercised, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Stock option exercised, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedPercentOfNetAssets" xlink:label="us-gaap_InvestmentOwnedPercentOfNetAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedPercentOfNetAssets" xlink:to="us-gaap_InvestmentOwnedPercentOfNetAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentOwnedPercentOfNetAssets_lbl" xml:lang="en-US">Investment cost, percent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedAtCost" xlink:label="us-gaap_InvestmentOwnedAtCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedAtCost" xlink:to="us-gaap_InvestmentOwnedAtCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentOwnedAtCost_lbl" xml:lang="en-US">Investment cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property, plant and equipment, gross</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Estimated Useful Life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less accumulated depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">Property, plant and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_Goodwill_2_lbl" xml:lang="en-US">Balance at December 31, 2022</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GoodwillImpairmentLoss_2_lbl" xml:lang="en-US">Goodwill adjustment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_Goodwill_3_lbl" xml:lang="en-US">Balance at March 31, 2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Gross Carrying Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Accumulated Amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Net Carrying Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_NoncashOrPartNoncashAcquisitionValueOfAssetAcquiredDescription" xlink:label="IMPB_NoncashOrPartNoncashAcquisitionValueOfAssetAcquiredDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_NoncashOrPartNoncashAcquisitionValueOfAssetAcquiredDescription" xlink:to="IMPB_NoncashOrPartNoncashAcquisitionValueOfAssetAcquiredDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMPB_NoncashOrPartNoncashAcquisitionValueOfAssetAcquiredDescription_lbl" xml:lang="en-US">Acquisition value of asset acquired, description</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtFairValue" xlink:label="us-gaap_LongTermDebtFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtFairValue" xlink:to="us-gaap_LongTermDebtFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtFairValue_lbl" xml:lang="en-US">Long term debt fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityFairValueAdjustment" xlink:label="us-gaap_EquityFairValueAdjustment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityFairValueAdjustment" xlink:to="us-gaap_EquityFairValueAdjustment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityFairValueAdjustment_lbl" xml:lang="en-US">Equity fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Debt carrying amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_2_lbl" xml:lang="en-US">Debt interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US">2027</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DepreciationAndAmortization_2_lbl" xml:lang="en-US">Amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xml:lang="en-US">Schedule of Short-Term Debt [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US">Short-Term Debt [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_3_lbl" xml:lang="en-US">Debt instrument interest, rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentMaturityDate_2_lbl" xml:lang="en-US">Debt instrument, maturity date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDefaultLongtermDebtDescriptionOfNoticeOfDefault" xlink:label="us-gaap_DebtDefaultLongtermDebtDescriptionOfNoticeOfDefault" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDefaultLongtermDebtDescriptionOfNoticeOfDefault" xlink:to="us-gaap_DebtDefaultLongtermDebtDescriptionOfNoticeOfDefault_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDefaultLongtermDebtDescriptionOfNoticeOfDefault_lbl" xml:lang="en-US">Long term debt, description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayable_lbl" xml:lang="en-US">Outstanding balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_2_lbl" xml:lang="en-US">Outstanding balance, including interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_lbl" xml:lang="en-US">Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_lbl" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:to="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Payment in funding of research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xml:lang="en-US">Related party owed transaction</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl" xml:lang="en-US">Prepaid monthly fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LaborAndRelatedExpense" xlink:to="us-gaap_LaborAndRelatedExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LaborAndRelatedExpense_lbl" xml:lang="en-US">Related costs for employees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_RoyaltyPercentage" xlink:label="IMPB_RoyaltyPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_RoyaltyPercentage" xlink:to="IMPB_RoyaltyPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMPB_RoyaltyPercentage_lbl" xml:lang="en-US">Royalty percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_SaleOfRoyaltyPercentage" xlink:label="IMPB_SaleOfRoyaltyPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_SaleOfRoyaltyPercentage" xlink:to="IMPB_SaleOfRoyaltyPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMPB_SaleOfRoyaltyPercentage_lbl" xml:lang="en-US">Sale of royalty percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_DevelopmentCostPercent" xlink:label="IMPB_DevelopmentCostPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_DevelopmentCostPercent" xlink:to="IMPB_DevelopmentCostPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMPB_DevelopmentCostPercent_lbl" xml:lang="en-US">Development cost, percent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsIncurredDevelopmentCosts" xlink:label="us-gaap_CostsIncurredDevelopmentCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsIncurredDevelopmentCosts" xlink:to="us-gaap_CostsIncurredDevelopmentCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsIncurredDevelopmentCosts_lbl" xml:lang="en-US">Development costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US">Federal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">State</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total current tax payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Federal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">State</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total deferred tax</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Less increase in valuation allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_3_lbl" xml:lang="en-US">income tax benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInvestments" xlink:label="us-gaap_DeferredTaxAssetsInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInvestments" xlink:to="us-gaap_DeferredTaxAssetsInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInvestments_lbl" xml:lang="en-US">Impairment of investment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Research &amp; development cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net Operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Gross deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xml:lang="en-US">Intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US">Gross deferred tax liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Less valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xml:lang="en-US">Net deferred tax liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Statutory United States federal rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State income taxes net of federal benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating loss carryforwards</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_2_lbl" xml:lang="en-US">Deferred tax asset</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_2_lbl" xml:lang="en-US">Valuation allowance deferred tax</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl" xml:lang="en-US">Transfer of promissory note 2 to related party</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NotesPayable_2_lbl" xml:lang="en-US">Transfer of note payable, related party</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_AsiaPacificHoldingsLimitedMember" xlink:to="IMPB_AsiaPacificHoldingsLimitedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMPB_AsiaPacificHoldingsLimitedMember_doc" xml:lang="en-US">Asia Pacific Holdings Limited [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_OrdinarySharesPercentage" xlink:to="IMPB_OrdinarySharesPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMPB_OrdinarySharesPercentage_doc" xml:lang="en-US">Ordinary shares percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_NanoNineLLCMember" xlink:to="IMPB_NanoNineLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMPB_NanoNineLLCMember_doc" xml:lang="en-US">Nano9 LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_SecuritiesPurchaseAgreementMember" xlink:to="IMPB_SecuritiesPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMPB_SecuritiesPurchaseAgreementMember_doc" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_StockPurchaseAgreementMember" xlink:to="IMPB_StockPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMPB_StockPurchaseAgreementMember_doc" xml:lang="en-US">Stock Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_VivacitasOncologyIncMember" xlink:to="IMPB_VivacitasOncologyIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMPB_VivacitasOncologyIncMember_doc" xml:lang="en-US">Vivacitas Oncology Inc [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_ImpactOncologyPTELtdMember" xlink:to="IMPB_ImpactOncologyPTELtdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMPB_ImpactOncologyPTELtdMember_doc" xml:lang="en-US">Impact Oncology PTE Ltd [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_VivacitasAgreementMember" xlink:to="IMPB_VivacitasAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMPB_VivacitasAgreementMember_doc" xml:lang="en-US">Vivacitas Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_SweetSenseMember" xlink:to="IMPB_SweetSenseMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMPB_SweetSenseMember_doc" xml:lang="en-US">Sweet Sense [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_GlobalBioMedicalPteLtdMember" xlink:to="IMPB_GlobalBioMedicalPteLtdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMPB_GlobalBioMedicalPteLtdMember_doc" xml:lang="en-US">Global Bio Medical Pte Ltd [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_StateOrOtherJurisdictionOfIncorporationOrOrganization" xlink:to="IMPB_StateOrOtherJurisdictionOfIncorporationOrOrganization_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMPB_StateOrOtherJurisdictionOfIncorporationOrOrganization_doc" xml:lang="en-US">State or other jurisdiction of incorporation or organization.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_GlobalBioMedicalIncMember" xlink:to="IMPB_GlobalBioMedicalIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMPB_GlobalBioMedicalIncMember_doc" xml:lang="en-US">Global Bio Medical Inc [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_GlobalBioLifeIncMember" xlink:to="IMPB_GlobalBioLifeIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMPB_GlobalBioLifeIncMember_doc" xml:lang="en-US">Global Bio Life Inc [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_BioLifeSugarIncMember" xlink:to="IMPB_BioLifeSugarIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMPB_BioLifeSugarIncMember_doc" xml:lang="en-US">Bio Life Sugar Inc [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_HappySugarIncMember" xlink:to="IMPB_HappySugarIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMPB_HappySugarIncMember_doc" xml:lang="en-US">Happy Sugar Inc [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_SweetSenseIncMember" xlink:to="IMPB_SweetSenseIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMPB_SweetSenseIncMember_doc" xml:lang="en-US">Sweet Sense Inc [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_GlobalSugarSolutionsIncMember" xlink:to="IMPB_GlobalSugarSolutionsIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMPB_GlobalSugarSolutionsIncMember_doc" xml:lang="en-US">Global Sugar Solutions Inc [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_ContinuingOperationsAndGoingConcernPolicyTextBlock" xlink:to="IMPB_ContinuingOperationsAndGoingConcernPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMPB_ContinuingOperationsAndGoingConcernPolicyTextBlock_doc" xml:lang="en-US">Continuing Operations And Going Concern [Policy Text Block].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_PrepaidExpensesTextBlock" xlink:to="IMPB_PrepaidExpensesTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMPB_PrepaidExpensesTextBlock_doc" xml:lang="en-US">Prepaid Expenses [Text Block].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_RevolvingPromissoryNoteMember" xlink:to="IMPB_RevolvingPromissoryNoteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMPB_RevolvingPromissoryNoteMember_doc" xml:lang="en-US">Revolving Promissory Note [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_IncreaseDecreaseInImpairmentofOtherInvestments" xlink:to="IMPB_IncreaseDecreaseInImpairmentofOtherInvestments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMPB_IncreaseDecreaseInImpairmentofOtherInvestments_doc" xml:lang="en-US">Increase decrease in impairment of other investments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_PromissoryNoteTwoMember" xlink:to="IMPB_PromissoryNoteTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMPB_PromissoryNoteTwoMember_doc" xml:lang="en-US">Promissory Note Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_PaymentsForProceedsFromNoteReceivableInvestments" xlink:to="IMPB_PaymentsForProceedsFromNoteReceivableInvestments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMPB_PaymentsForProceedsFromNoteReceivableInvestments_doc" xml:lang="en-US">Payments for proceeds from note receivable investments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_PromissoryNoteOneMember" xlink:to="IMPB_PromissoryNoteOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMPB_PromissoryNoteOneMember_doc" xml:lang="en-US">Promissory Note One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_RoyaltyPercentage" xlink:to="IMPB_RoyaltyPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMPB_RoyaltyPercentage_doc" xml:lang="en-US">Royalty percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_SaleOfRoyaltyPercentage" xlink:to="IMPB_SaleOfRoyaltyPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMPB_SaleOfRoyaltyPercentage_doc" xml:lang="en-US">Sale of royalty percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_DevelopmentCostPercent" xlink:to="IMPB_DevelopmentCostPercent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMPB_DevelopmentCostPercent_doc" xml:lang="en-US">Development cost percent.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_LicenseAgreementMember" xlink:to="IMPB_LicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMPB_LicenseAgreementMember_doc" xml:lang="en-US">License Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_ImpairmentOfOtherInvestments" xlink:to="IMPB_ImpairmentOfOtherInvestments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMPB_ImpairmentOfOtherInvestments_doc" xml:lang="en-US">Increase decrease in impairment of other investments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_GRDGscienceLLCMember" xlink:to="IMPB_GRDGscienceLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMPB_GRDGscienceLLCMember_doc" xml:lang="en-US">GRDG Science LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_RoyaltyAgreementMember" xlink:to="IMPB_RoyaltyAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMPB_RoyaltyAgreementMember_doc" xml:lang="en-US">Royalty Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_StockIssuedDuringPeriodValueShareholder" xlink:to="IMPB_StockIssuedDuringPeriodValueShareholder_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMPB_StockIssuedDuringPeriodValueShareholder_doc" xml:lang="en-US">Stock Issued During Period Value Shareholder.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_ChemiaCorporationMember" xlink:to="IMPB_ChemiaCorporationMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMPB_ChemiaCorporationMember_doc" xml:lang="en-US">Chemia Corporation [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4_lbl" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpenses_2_lbl" xml:lang="en-US">Costs and Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetImpairmentCharges_2_lbl" xml:lang="en-US">Asset Impairment Charges</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_2_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_2_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_IncreaseDecreaseInImpairmentofOtherInvestments" xlink:to="IMPB_IncreaseDecreaseInImpairmentofOtherInvestments_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMPB_IncreaseDecreaseInImpairmentofOtherInvestments_3_lbl" xml:lang="en-US">IncreaseDecreaseInImpairmentofOtherInvestments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromProductiveAssets" xlink:to="us-gaap_PaymentsForProceedsFromProductiveAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForProceedsFromProductiveAssets_2_lbl" xml:lang="en-US">Payments for (Proceeds from) Productive Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInvestments" xlink:to="us-gaap_PaymentsToAcquireInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireInvestments_2_lbl" xml:lang="en-US">Payments to Acquire Investments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_PaymentsForProceedsFromNoteReceivableInvestments" xlink:to="IMPB_PaymentsForProceedsFromNoteReceivableInvestments_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMPB_PaymentsForProceedsFromNoteReceivableInvestments_3_lbl" xml:lang="en-US">PaymentsForProceedsFromNoteReceivableInvestments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMPB_PrepaidExpensesTextBlock" xlink:to="IMPB_PrepaidExpensesTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMPB_PrepaidExpensesTextBlock_3_lbl" xml:lang="en-US">Prepaid Expenses [Text Block].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillDisclosureTextBlock" xlink:to="us-gaap_GoodwillDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillDisclosureTextBlock_2_lbl" xml:lang="en-US">Goodwill Disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentPolicyTextBlock_2_lbl" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_2_lbl" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_2_lbl" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_2_lbl" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilities_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>16
<FILENAME>impb-20230331_pre.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.19b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://impactbiomedinc.com/role/Cover" xlink:href="impb-20230331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/BalanceSheets" xlink:href="impb-20230331.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/BalanceSheetsParenthetical" xlink:href="impb-20230331.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/StatementsOfOperations" xlink:href="impb-20230331.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/StatementsOfStockholdersEquity" xlink:href="impb-20230331.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/StatementsOfCashFlows" xlink:href="impb-20230331.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/NatureOfOperationsAndBasisOfPresentation" xlink:href="impb-20230331.xsd#NatureOfOperationsAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/SummaryOfSignificantAccountingAndReportingPolicies" xlink:href="impb-20230331.xsd#SummaryOfSignificantAccountingAndReportingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/Restatement" xlink:href="impb-20230331.xsd#Restatement" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/PrepaidExpenses" xlink:href="impb-20230331.xsd#PrepaidExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/NotesReceivable" xlink:href="impb-20230331.xsd#NotesReceivable" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/Investments" xlink:href="impb-20230331.xsd#Investments" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/PropertyPlantAndEquipmentAndInvestmentInRealEstateNet" xlink:href="impb-20230331.xsd#PropertyPlantAndEquipmentAndInvestmentInRealEstateNet" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/Goodwill" xlink:href="impb-20230331.xsd#Goodwill" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/IntangibleAssets" xlink:href="impb-20230331.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/Debt" xlink:href="impb-20230331.xsd#Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/StockholdersEquity" xlink:href="impb-20230331.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/RelatedPartyTransactions" xlink:href="impb-20230331.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/CommitmentsAndContingencies" xlink:href="impb-20230331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/IncomeTaxes" xlink:href="impb-20230331.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/SupplementalCashFlowInformation" xlink:href="impb-20230331.xsd#SupplementalCashFlowInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/SubsequentEvents" xlink:href="impb-20230331.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/SummaryOfSignificantAccountingAndReportingPoliciesPolicies" xlink:href="impb-20230331.xsd#SummaryOfSignificantAccountingAndReportingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/NatureOfOperationsAndBasisOfPresentationTables" xlink:href="impb-20230331.xsd#NatureOfOperationsAndBasisOfPresentationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/PropertyPlantAndEquipmentAndInvestmentInRealEstateNetTables" xlink:href="impb-20230331.xsd#PropertyPlantAndEquipmentAndInvestmentInRealEstateNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/GoodwillTables" xlink:href="impb-20230331.xsd#GoodwillTables" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/IntangibleAssetsTables" xlink:href="impb-20230331.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/IncomeTaxesTables" xlink:href="impb-20230331.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/SupplementalCashFlowInformationTables" xlink:href="impb-20230331.xsd#SupplementalCashFlowInformationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/ScheduleOfCondensedFinancialStatementsDetails" xlink:href="impb-20230331.xsd#ScheduleOfCondensedFinancialStatementsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/NatureOfOperationsAndBasisOfPresentationDetailsNarrative" xlink:href="impb-20230331.xsd#NatureOfOperationsAndBasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/SummaryOfSignificantAccountingAndReportingPoliciesDetailsNarrative" xlink:href="impb-20230331.xsd#SummaryOfSignificantAccountingAndReportingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/RestatementDetailsNarrative" xlink:href="impb-20230331.xsd#RestatementDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/PrepaidExpensesDetailsNarrative" xlink:href="impb-20230331.xsd#PrepaidExpensesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/NotesReceivableDetailsNarrative" xlink:href="impb-20230331.xsd#NotesReceivableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/InvestmentsDetailsNarrative" xlink:href="impb-20230331.xsd#InvestmentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" xlink:href="impb-20230331.xsd#ScheduleOfPropertyPlantAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/PropertyPlantAndEquipmentAndInvestmentInRealEstateNetDetailsNarrative" xlink:href="impb-20230331.xsd#PropertyPlantAndEquipmentAndInvestmentInRealEstateNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/ScheduleOfGoodwillDetails" xlink:href="impb-20230331.xsd#ScheduleOfGoodwillDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/ScheduleOfIntangibleAssetsDetails" xlink:href="impb-20230331.xsd#ScheduleOfIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/GoodwillDetailsNarrative" xlink:href="impb-20230331.xsd#GoodwillDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/ScheduleOfFutureAmortizationOfDevelopedTechnologiesDetails" xlink:href="impb-20230331.xsd#ScheduleOfFutureAmortizationOfDevelopedTechnologiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/IntangibleAssetsDetailsNarrative" xlink:href="impb-20230331.xsd#IntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/DebtDetailsNarrative" xlink:href="impb-20230331.xsd#DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/StockholdersEquityDetailsNarrative" xlink:href="impb-20230331.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="impb-20230331.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="impb-20230331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/ScheduleOfComponentsOfIncomeTaxBenefitDetails" xlink:href="impb-20230331.xsd#ScheduleOfComponentsOfIncomeTaxBenefitDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="impb-20230331.xsd#ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/SummaryOfEffectiveIncomeTaxRateDetails" xlink:href="impb-20230331.xsd#SummaryOfEffectiveIncomeTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/IncomeTaxesDetailsNarrative" xlink:href="impb-20230331.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://impactbiomedinc.com/role/ScheduleOfCashFlowSupplementalDetails" xlink:href="impb-20230331.xsd#ScheduleOfCashFlowSupplementalDetails" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesTable" xlink:label="loc_deiEntityAddressesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesLineItems" xlink:label="loc_deiEntityAddressesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesTable" xlink:to="loc_deiEntityAddressesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_deiEntityAddressesAddressTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesTable" xlink:to="loc_deiEntityAddressesAddressTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="loc_deiAddressTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesAddressTypeAxis" xlink:to="loc_deiAddressTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember" xlink:label="loc_deiBusinessContactMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiAddressTypeDomain" xlink:to="loc_deiBusinessContactMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName" xlink:label="loc_deiContactPersonnelName" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiContactPersonnelName" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis" xlink:label="loc_srtRestatementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRestatementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srtScenarioPreviouslyReportedMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementDomain" xlink:to="loc_srtScenarioPreviouslyReportedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesAndLoansReceivableNetCurrent" xlink:label="loc_us-gaapNotesAndLoansReceivableNetCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapNotesAndLoansReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLongTermInvestments" xlink:label="loc_us-gaapOtherLongTermInvestments" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOtherLongTermInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:label="loc_us-gaapNotesAndLoansReceivableNetNoncurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapNotesAndLoansReceivableNetNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIntangibleAssetsNet" xlink:label="loc_us-gaapOtherIntangibleAssetsNet" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOtherIntangibleAssetsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilitiesNet" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilitiesNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaapMinorityInterest" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="loc_us-gaapMinorityInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis" xlink:label="loc_srtRestatementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRestatementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srtScenarioPreviouslyReportedMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementDomain" xlink:to="loc_srtScenarioPreviouslyReportedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis" xlink:label="loc_srtRestatementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRestatementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srtScenarioPreviouslyReportedMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementDomain" xlink:to="loc_srtScenarioPreviouslyReportedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaapCostsAndExpensesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCostsAndExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCostsAndExpensesAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCostsAndExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCostsAndExpensesAbstract" xlink:to="loc_us-gaapProfessionalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCostsAndExpensesAbstract" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherGeneralExpense" xlink:label="loc_us-gaapOtherGeneralExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCostsAndExpensesAbstract" xlink:to="loc_us-gaapOtherGeneralExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaapCostsAndExpenses" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCostsAndExpensesAbstract" xlink:to="loc_us-gaapCostsAndExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInvestmentIncomeInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaapAssetImpairmentCharges" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapAssetImpairmentCharges" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="loc_us-gaapEarningsPerShareBasicAbstract" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareBasicAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaapWeightedAverageNumberDilutedSharesOutstandingAdjustment" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="loc_us-gaapWeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit_2" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit_2" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/StatementsOfStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Stockholder&apos;s Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaapNoncontrollingInterestMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapNoncontrollingInterestMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis" xlink:label="loc_srtRestatementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRestatementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srtScenarioPreviouslyReportedMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtScenarioPreviouslyReportedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_StockIssuedDuringPeriodValueShareholder" xlink:label="loc_IMPBStockIssuedDuringPeriodValueShareholder" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMPBStockIssuedDuringPeriodValueShareholder" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis" xlink:label="loc_srtRestatementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRestatementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srtScenarioPreviouslyReportedMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementDomain" xlink:to="loc_srtScenarioPreviouslyReportedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:label="loc_us-gaapDeferredIncomeTaxesAndTaxCredits" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxesAndTaxCredits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_ImpairmentOfOtherInvestments" xlink:label="loc_IMPBImpairmentOfOtherInvestments" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_IMPBImpairmentOfOtherInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredLiabilities" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_IncreaseDecreaseInImpairmentofOtherInvestments" xlink:label="loc_IMPBIncreaseDecreaseInImpairmentofOtherInvestments" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_IMPBIncreaseDecreaseInImpairmentofOtherInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromProductiveAssets" xlink:label="loc_us-gaapPaymentsForProceedsFromProductiveAssets" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsForProceedsFromProductiveAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaapPaymentsToAcquireInvestments" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_PaymentsForProceedsFromNoteReceivableInvestments" xlink:label="loc_IMPBPaymentsForProceedsFromNoteReceivableInvestments" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_IMPBPaymentsForProceedsFromNoteReceivableInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/NatureOfOperationsAndBasisOfPresentation" xlink:title="00000007 - Disclosure - Nature of Operations and Basis of Presentation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaapNatureOfOperations" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNatureOfOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/SummaryOfSignificantAccountingAndReportingPolicies" xlink:title="00000008 - Disclosure - Summary of Significant Accounting and Reporting Policies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/Restatement" xlink:title="00000009 - Disclosure - Restatement">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:label="loc_us-gaapScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" xlink:to="loc_us-gaapScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/PrepaidExpenses" xlink:title="00000010 - Disclosure - Prepaid Expenses">
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_DisclosurePrepaidExpensesAbstract" xlink:label="loc_IMPBDisclosurePrepaidExpensesAbstract" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_PrepaidExpensesTextBlock" xlink:label="loc_IMPBPrepaidExpensesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IMPBDisclosurePrepaidExpensesAbstract" xlink:to="loc_IMPBPrepaidExpensesTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/NotesReceivable" xlink:title="00000011 - Disclosure - Notes Receivable">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesAbstract" xlink:label="loc_us-gaapReceivablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="loc_us-gaapLoansNotesTradeAndOtherReceivablesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivablesAbstract" xlink:to="loc_us-gaapLoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/Investments" xlink:title="00000012 - Disclosure - Investments">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTextBlock" xlink:label="loc_us-gaapInvestmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" xlink:to="loc_us-gaapInvestmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/PropertyPlantAndEquipmentAndInvestmentInRealEstateNet" xlink:title="00000013 - Disclosure - PROPERTY PLANT AND EQUIPMENT and INVESTMENT IN REAL ESTATE, NET">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAndIntangibleAssetsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentAndIntangibleAssetsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/Goodwill" xlink:title="00000014 - Disclosure - Goodwill">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillDisclosureTextBlock" xlink:label="loc_us-gaapGoodwillDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapGoodwillDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/IntangibleAssets" xlink:title="00000015 - Disclosure - Intangible Assets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapIntangibleAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapIntangibleAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/Debt" xlink:title="00000016 - Disclosure - Debt">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/StockholdersEquity" xlink:title="00000017 - Disclosure - Stockholders&#8217; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/RelatedPartyTransactions" xlink:title="00000018 - Disclosure - Related Party Transactions">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/CommitmentsAndContingencies" xlink:title="00000019 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/IncomeTaxes" xlink:title="00000020 - Disclosure - Income Taxes">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/SupplementalCashFlowInformation" xlink:title="00000021 - Disclosure - Supplemental Cash Flow Information">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaapSupplementalCashFlowElementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:label="loc_us-gaapCashFlowSupplementalDisclosuresTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowElementsAbstract" xlink:to="loc_us-gaapCashFlowSupplementalDisclosuresTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/SubsequentEvents" xlink:title="00000022 - Disclosure - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/SummaryOfSignificantAccountingAndReportingPoliciesPolicies" xlink:title="00000023 - Disclosure - Summary of Significant Accounting and Reporting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="loc_us-gaapInvestmentPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInvestmentPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsGoodwillPolicy" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_ContinuingOperationsAndGoingConcernPolicyTextBlock" xlink:label="loc_IMPBContinuingOperationsAndGoingConcernPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_IMPBContinuingOperationsAndGoingConcernPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/NatureOfOperationsAndBasisOfPresentationTables" xlink:title="00000024 - Disclosure - Nature of Operations and Basis of Presentation (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:label="loc_srtScheduleOfCondensedFinancialStatementsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_srtScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/PropertyPlantAndEquipmentAndInvestmentInRealEstateNetTables" xlink:title="00000025 - Disclosure - PROPERTY PLANT AND EQUIPMENT and INVESTMENT IN REAL ESTATE, NET (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/GoodwillTables" xlink:title="00000026 - Disclosure - Goodwill (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="loc_us-gaapScheduleOfGoodwillTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfGoodwillTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/IntangibleAssetsTables" xlink:title="00000027 - Disclosure - Intangible Assets (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="loc_us-gaapScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/IncomeTaxesTables" xlink:title="00000028 - Disclosure - Income Taxes (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/SupplementalCashFlowInformationTables" xlink:title="00000029 - Disclosure - Supplemental Cash Flow Information (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaapSupplementalCashFlowElementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="loc_us-gaapScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowElementsAbstract" xlink:to="loc_us-gaapScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/ScheduleOfCondensedFinancialStatementsDetails" xlink:title="00000030 - Disclosure - Schedule of Condensed Financial Statements (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:label="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:label="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:to="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis" xlink:label="loc_srtOwnershipAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:to="loc_srtOwnershipAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="loc_srtOwnershipDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtOwnershipAxis" xlink:to="loc_srtOwnershipDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_GlobalBioMedicalIncMember" xlink:label="loc_IMPBGlobalBioMedicalIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtOwnershipDomain" xlink:to="loc_IMPBGlobalBioMedicalIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_GlobalBioLifeIncMember" xlink:label="loc_IMPBGlobalBioLifeIncMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtOwnershipDomain" xlink:to="loc_IMPBGlobalBioLifeIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_BioLifeSugarIncMember" xlink:label="loc_IMPBBioLifeSugarIncMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtOwnershipDomain" xlink:to="loc_IMPBBioLifeSugarIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_HappySugarIncMember" xlink:label="loc_IMPBHappySugarIncMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtOwnershipDomain" xlink:to="loc_IMPBHappySugarIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_SweetSenseIncMember" xlink:label="loc_IMPBSweetSenseIncMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtOwnershipDomain" xlink:to="loc_IMPBSweetSenseIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_GlobalSugarSolutionsIncMember" xlink:label="loc_IMPBGlobalSugarSolutionsIncMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtOwnershipDomain" xlink:to="loc_IMPBGlobalSugarSolutionsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_StateOrOtherJurisdictionOfIncorporationOrOrganization" xlink:label="loc_IMPBStateOrOtherJurisdictionOfIncorporationOrOrganization" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="loc_IMPBStateOrOtherJurisdictionOfIncorporationOrOrganization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="loc_deiEntityIncorporationDateOfIncorporation" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="loc_deiEntityIncorporationDateOfIncorporation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="loc_us-gaapMinorityInterestOwnershipPercentageByParent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="loc_us-gaapMinorityInterestOwnershipPercentageByParent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/NatureOfOperationsAndBasisOfPresentationDetailsNarrative" xlink:title="00000031 - Disclosure - Nature of Operations and Basis of Presentation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:label="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:label="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:to="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis" xlink:label="loc_srtOwnershipAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:to="loc_srtOwnershipAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="loc_srtOwnershipDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtOwnershipAxis" xlink:to="loc_srtOwnershipDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_SweetSenseMember" xlink:label="loc_IMPBSweetSenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtOwnershipDomain" xlink:to="loc_IMPBSweetSenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_GlobalBioMedicalPteLtdMember" xlink:label="loc_IMPBGlobalBioMedicalPteLtdMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_IMPBGlobalBioMedicalPteLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SubsidiariesMember" xlink:label="loc_srtSubsidiariesMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_srtSubsidiariesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="loc_us-gaapMinorityInterestOwnershipPercentageByNoncontrollingOwners" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="loc_us-gaapMinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferred1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="loc_us-gaapMinorityInterestOwnershipPercentageByParent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="loc_us-gaapMinorityInterestOwnershipPercentageByParent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaapMinorityInterest" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="loc_us-gaapMinorityInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/SummaryOfSignificantAccountingAndReportingPoliciesDetailsNarrative" xlink:title="00000032 - Disclosure - Summary of Significant Accounting and Reporting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairmentLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapGoodwillImpairmentLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/RestatementDetailsNarrative" xlink:title="00000033 - Disclosure - Restatement (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/PrepaidExpensesDetailsNarrative" xlink:title="00000034 - Disclosure - Prepaid Expenses (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_DisclosurePrepaidExpensesAbstract" xlink:label="loc_IMPBDisclosurePrepaidExpensesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IMPBDisclosurePrepaidExpensesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_GRDGscienceLLCMember" xlink:label="loc_IMPBGRDGscienceLLCMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_IMPBGRDGscienceLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/NotesReceivableDetailsNarrative" xlink:title="00000035 - Disclosure - Notes Receivable (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesAbstract" xlink:label="loc_us-gaapReceivablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFinancingReceivableTroubledDebtRestructuringsTable" xlink:label="loc_us-gaapScheduleOfFinancingReceivableTroubledDebtRestructuringsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivablesAbstract" xlink:to="loc_us-gaapScheduleOfFinancingReceivableTroubledDebtRestructuringsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivableModificationsLineItems" xlink:label="loc_us-gaapFinancingReceivableModificationsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFinancingReceivableTroubledDebtRestructuringsTable" xlink:to="loc_us-gaapFinancingReceivableModificationsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFinancingReceivableTroubledDebtRestructuringsTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_PromissoryNoteOneMember" xlink:label="loc_IMPBPromissoryNoteOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_IMPBPromissoryNoteOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_PromissoryNoteTwoMember" xlink:label="loc_IMPBPromissoryNoteTwoMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_IMPBPromissoryNoteTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFinancingReceivableTroubledDebtRestructuringsTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesReceivableNet" xlink:label="loc_us-gaapNotesReceivableNet" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancingReceivableModificationsLineItems" xlink:to="loc_us-gaapNotesReceivableNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancingReceivableModificationsLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancingReceivableModificationsLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaapDebtInstrumentPeriodicPayment" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancingReceivableModificationsLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesAndLoansReceivableGrossCurrent" xlink:label="loc_us-gaapNotesAndLoansReceivableGrossCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancingReceivableModificationsLineItems" xlink:to="loc_us-gaapNotesAndLoansReceivableGrossCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:label="loc_us-gaapNotesAndLoansReceivableNetNoncurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancingReceivableModificationsLineItems" xlink:to="loc_us-gaapNotesAndLoansReceivableNetNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancingReceivableModificationsLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/InvestmentsDetailsNarrative" xlink:title="00000036 - Disclosure - Investments (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_AsiaPacificHoldingsLimitedMember" xlink:label="loc_IMPBAsiaPacificHoldingsLimitedMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_IMPBAsiaPacificHoldingsLimitedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_NanoNineLLCMember" xlink:label="loc_IMPBNanoNineLLCMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_IMPBNanoNineLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_VivacitasOncologyIncMember" xlink:label="loc_IMPBVivacitasOncologyIncMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_IMPBVivacitasOncologyIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubscriptionArrangementMember" xlink:label="loc_us-gaapSubscriptionArrangementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_us-gaapSubscriptionArrangementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_SecuritiesPurchaseAgreementMember" xlink:label="loc_IMPBSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_IMPBSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_StockPurchaseAgreementMember" xlink:label="loc_IMPBStockPurchaseAgreementMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_IMPBStockPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_VivacitasAgreementMember" xlink:label="loc_IMPBVivacitasAgreementMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_IMPBVivacitasAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_NanoNineLLCMember" xlink:label="loc_IMPBNanoNineLLCMember_2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_IMPBNanoNineLLCMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_ImpactOncologyPTELtdMember" xlink:label="loc_IMPBImpactOncologyPTELtdMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_IMPBImpactOncologyPTELtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesPurchaseOfAssets" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_OrdinarySharesPercentage" xlink:label="loc_IMPBOrdinarySharesPercentage" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMPBOrdinarySharesPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="loc_us-gaapStockIssuedDuringPeriodValuePurchaseOfAssets" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValuePurchaseOfAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedAtFairValue" xlink:label="loc_us-gaapInvestmentOwnedAtFairValue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInvestmentOwnedAtFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferred1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedPercentOfNetAssets" xlink:label="loc_us-gaapInvestmentOwnedPercentOfNetAssets" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInvestmentOwnedPercentOfNetAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedAtCost" xlink:label="loc_us-gaapInvestmentOwnedAtCost" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInvestmentOwnedAtCost" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" xlink:title="00000037 - Disclosure - Schedule of Property Plant and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaapMachineryAndEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapMachineryAndEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaapConstructionInProgressMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapConstructionInProgressMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/PropertyPlantAndEquipmentAndInvestmentInRealEstateNetDetailsNarrative" xlink:title="00000038 - Disclosure - PROPERTY PLANT AND EQUIPMENT and INVESTMENT IN REAL ESTATE, NET (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/ScheduleOfGoodwillDetails" xlink:title="00000039 - Disclosure - Schedule of Goodwill (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairmentLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapGoodwillImpairmentLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill_2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapGoodwill_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/ScheduleOfIntangibleAssetsDetails" xlink:title="00000040 - Disclosure - Schedule of Intangible Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaapDevelopedTechnologyRightsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapDevelopedTechnologyRightsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/GoodwillDetailsNarrative" xlink:title="00000041 - Disclosure - Goodwill (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_NoncashOrPartNoncashAcquisitionValueOfAssetAcquiredDescription" xlink:label="loc_IMPBNoncashOrPartNoncashAcquisitionValueOfAssetAcquiredDescription" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_IMPBNoncashOrPartNoncashAcquisitionValueOfAssetAcquiredDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtFairValue" xlink:label="loc_us-gaapLongTermDebtFairValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebtFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityFairValueAdjustment" xlink:label="loc_us-gaapEquityFairValueAdjustment" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapEquityFairValueAdjustment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/ScheduleOfFutureAmortizationOfDevelopedTechnologiesDetails" xlink:title="00000042 - Disclosure - Schedule of Future Amortization of Developed Technologies (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/IntangibleAssetsDetailsNarrative" xlink:title="00000043 - Disclosure - Intangible Assets (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/DebtDetailsNarrative" xlink:title="00000044 - Disclosure - Debt (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_RevolvingPromissoryNoteMember" xlink:label="loc_IMPBRevolvingPromissoryNoteMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_IMPBRevolvingPromissoryNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDefaultLongtermDebtDescriptionOfNoticeOfDefault" xlink:label="loc_us-gaapDebtDefaultLongtermDebtDescriptionOfNoticeOfDefault" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtDefaultLongtermDebtDescriptionOfNoticeOfDefault" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000045 - Disclosure - Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:label="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:label="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="loc_srtTitleOfIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="loc_srtBoardOfDirectorsChairmanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtBoardOfDirectorsChairmanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000046 - Disclosure - Related Party Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_GRDGscienceLLCMember" xlink:label="loc_IMPBGRDGscienceLLCMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_IMPBGRDGscienceLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="loc_us-gaapPaymentsToAcquireInProcessResearchAndDevelopment" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapPaymentsToAcquireInProcessResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrentAndNoncurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapPrepaidExpenseCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="loc_us-gaapLaborAndRelatedExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapLaborAndRelatedExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000047 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_RoyaltyAgreementMember" xlink:label="loc_IMPBRoyaltyAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_IMPBRoyaltyAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_LicenseAgreementMember" xlink:label="loc_IMPBLicenseAgreementMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_IMPBLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_GlobalAndBioLifeSciencesMember" xlink:label="loc_IMPBGlobalAndBioLifeSciencesMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_IMPBGlobalAndBioLifeSciencesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_ChemiaCorporationMember" xlink:label="loc_IMPBChemiaCorporationMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_IMPBChemiaCorporationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_RoyaltyPercentage" xlink:label="loc_IMPBRoyaltyPercentage" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_IMPBRoyaltyPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_SaleOfRoyaltyPercentage" xlink:label="loc_IMPBSaleOfRoyaltyPercentage" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_IMPBSaleOfRoyaltyPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="impb-20230331.xsd#IMPB_DevelopmentCostPercent" xlink:label="loc_IMPBDevelopmentCostPercent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_IMPBDevelopmentCostPercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsIncurredDevelopmentCosts" xlink:label="loc_us-gaapCostsIncurredDevelopmentCosts" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCostsIncurredDevelopmentCosts" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/ScheduleOfComponentsOfIncomeTaxBenefitDetails" xlink:title="00000048 - Disclosure - Schedule of Components of Income Tax Benefit (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentFederalTaxExpenseBenefit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentFederalTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefit" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="00000049 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInvestments" xlink:label="loc_us-gaapDeferredTaxAssetsInvestments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilities" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaapDeferredTaxLiabilities" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/SummaryOfEffectiveIncomeTaxRateDetails" xlink:title="00000050 - Disclosure - Summary of Effective Income Tax Rate (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000051 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://impactbiomedinc.com/role/ScheduleOfCashFlowSupplementalDetails" xlink:title="00000052 - Disclosure - Schedule of Cash Flow Supplemental (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaapSupplementalCashFlowElementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowElementsAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139839840926256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesLineItems', window );"><strong>Entity Addresses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-1/A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">Amendment No. 13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">IMPACT
BIOMEDICAL INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001834105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">85-3926944<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">275
Wiregrass Pkwy<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">West
Henrietta<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">14586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">+1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">585-325-3610<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesLineItems', window );"><strong>Entity Addresses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Impact
BioMedical Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">275
Wiregrass Pkwy<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">West
Henrietta<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">14586<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">+1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">585-325-3610<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Frank D. Heuszel<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139839839475024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 46,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetCurrent', window );">Current portion of notes receivable</a></td>
<td class="nump">205,000<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
<td class="nump">197,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">183,000<span></span>
</td>
<td class="nump">104,000<span></span>
</td>
<td class="nump">44,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">389,000<span></span>
</td>
<td class="nump">122,000<span></span>
</td>
<td class="nump">287,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">279,000<span></span>
</td>
<td class="nump">276,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermInvestments', window );">Other investments</a></td>
<td class="nump">782,000<span></span>
</td>
<td class="nump">782,000<span></span>
</td>
<td class="nump">4,817,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetNoncurrent', window );">Notes receivable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">190,000<span></span>
</td>
<td class="nump">5,081,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">25,093,000<span></span>
</td>
<td class="nump">25,093,000<span></span>
</td>
<td class="nump">25,093,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIntangibleAssetsNet', window );">Other intangible assets, net</a></td>
<td class="nump">19,756,000<span></span>
</td>
<td class="nump">20,034,000<span></span>
</td>
<td class="nump">21,147,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">46,299,000<span></span>
</td>
<td class="nump">46,497,000<span></span>
</td>
<td class="nump">56,425,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">186,000<span></span>
</td>
<td class="nump">539,000<span></span>
</td>
<td class="nump">115,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">63,000<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Note payable, related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,524,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">11,244,000<span></span>
</td>
<td class="nump">10,131,000<span></span>
</td>
<td class="nump">12,645,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability, net</a></td>
<td class="nump">3,235,000<span></span>
</td>
<td class="nump">3,235,000<span></span>
</td>
<td class="nump">3,856,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">14,479,000<span></span>
</td>
<td class="nump">13,366,000<span></span>
</td>
<td class="nump">16,501,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 12)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholder&#8217;s equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $.001 par value; 3,000,000,000 shares authorized, 125,073,621 shares issued and outstanding (125,073,621 on March 31, 2023 and December 31, 2022)</a></td>
<td class="nump">125,000<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">38,058,000<span></span>
</td>
<td class="nump">38,058,000<span></span>
</td>
<td class="nump">38,058,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(9,282,000)<span></span>
</td>
<td class="num">(8,625,000)<span></span>
</td>
<td class="num">(1,574,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholder&#8217;s equity of the company</a></td>
<td class="nump">28,901,000<span></span>
</td>
<td class="nump">29,558,000<span></span>
</td>
<td class="nump">36,609,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interest in subsidiary</a></td>
<td class="nump">2,919,000<span></span>
</td>
<td class="nump">3,111,000<span></span>
</td>
<td class="nump">3,315,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholder&#8217;s equity</a></td>
<td class="nump">31,820,000<span></span>
</td>
<td class="nump">32,669,000<span></span>
</td>
<td class="nump">39,924,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholder&#8217;s equity</a></td>
<td class="nump">46,299,000<span></span>
</td>
<td class="nump">46,497,000<span></span>
</td>
<td class="nump">56,425,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Note payable, related party</a></td>
<td class="nump">$ 11,008,000<span></span>
</td>
<td class="nump">9,529,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetCurrent', window );">Current portion of notes receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">276,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermInvestments', window );">Other investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">782,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetNoncurrent', window );">Notes receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">190,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,093,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIntangibleAssetsNet', window );">Other intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,034,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,497,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">539,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Note payable, related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,991,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,593,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,235,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,828,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 12)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholder&#8217;s equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $.001 par value; 3,000,000,000 shares authorized, 125,073,621 shares issued and outstanding (125,073,621 on March 31, 2023 and December 31, 2022)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,058,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,625,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholder&#8217;s equity of the company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,558,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interest in subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,111,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholder&#8217;s equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,669,000<span></span>
</td>
<td class="nump">$ 39,924,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholder&#8217;s equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,497,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of financing receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansReceivableNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139839840701984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">3,000,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">125,073,621<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">125,073,621<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">4,000,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">3,877,282,251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">3,877,282,251<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139839833310160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative compensation</a></td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="nump">$ 123,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 398,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research &amp; development</a></td>
<td class="nump">179,000<span></span>
</td>
<td class="nump">168,000<span></span>
</td>
<td class="nump">$ 1,226,000<span></span>
</td>
<td class="nump">1,080,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional services</a></td>
<td class="nump">280,000<span></span>
</td>
<td class="nump">126,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">552,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">280,000<span></span>
</td>
<td class="nump">278,000<span></span>
</td>
<td class="nump">1,113,000<span></span>
</td>
<td class="nump">1,113,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralExpense', window );">Other general expense</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="nump">14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">819,000<span></span>
</td>
<td class="nump">709,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,185,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(819,000)<span></span>
</td>
<td class="num">(709,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,185,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">96,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="nump">68,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(101,000)<span></span>
</td>
<td class="num">(133,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(300,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of investment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss from continuing operations</a></td>
<td class="num">(849,000)<span></span>
</td>
<td class="num">(746,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,243,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (loss)/benefit</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">621,000<span></span>
</td>
<td class="nump">1,395,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(849,000)<span></span>
</td>
<td class="num">(746,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,848,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Loss from continuing operations attributed to noncontrolling interest</a></td>
<td class="nump">192,000<span></span>
</td>
<td class="nump">77,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">545,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (657,000)<span></span>
</td>
<td class="num">$ (669,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,303,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Loss per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic</a></td>
<td class="nump">$ (0.00)<span></span>
</td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ (0.00)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Shares used in computing loss per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic</a></td>
<td class="nump">3,877,282,251<span></span>
</td>
<td class="nump">3,877,282,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,877,282,251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Diluted</a></td>
<td class="nump">3,877,282,251<span></span>
</td>
<td class="nump">3,877,282,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,877,282,251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(621,000)<span></span>
</td>
<td class="num">$ (1,395,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">325,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research &amp; development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,226,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">722,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,113,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralExpense', window );">Other general expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,454,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,454,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(462,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss from continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,876,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (loss)/benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">621,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,255,000)<span></span>
</td>
<td class="num">$ (1,848,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Loss from continuing operations attributed to noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">204,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (7,051,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Loss per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ (0.00)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Shares used in computing loss per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,877,282,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,877,282,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (621,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general expenses not normally included in Other Operating Costs and Expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139839844713792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholder's Equity - USD ($)<br></strong></div></th>
<th class="th">
<div>Common Stock [Member] </div>
<div>Previously Reported [Member]</div>
</th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th">
<div>Additional Paid-in Capital [Member] </div>
<div>Previously Reported [Member]</div>
</th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th">
<div>Retained Earnings [Member] </div>
<div>Previously Reported [Member]</div>
</th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th">
<div>Noncontrolling Interest [Member] </div>
<div>Previously Reported [Member]</div>
</th>
<th class="th"><div>Noncontrolling Interest [Member]</div></th>
<th class="th"><div>Previously Reported [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,058,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (271,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,860,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,772,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,877,282,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,303,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (545,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,848,000)<span></span>
</td>
<td class="num">(1,848,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_IMPB_StockIssuedDuringPeriodValueShareholder', window );">Proceeds from shareholder</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="nump">38,058,000<span></span>
</td>
<td class="nump">38,058,000<span></span>
</td>
<td class="num">(1,574,000)<span></span>
</td>
<td class="num">(1,574,000)<span></span>
</td>
<td class="num">(3,315,000)<span></span>
</td>
<td class="nump">3,315,000<span></span>
</td>
<td class="nump">39,924,000<span></span>
</td>
<td class="nump">39,924,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2021</a></td>
<td class="nump">3,877,282,251<span></span>
</td>
<td class="nump">3,877,282,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(669,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(77,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(746,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,058,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,243,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,238,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,178,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,877,282,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="nump">38,058,000<span></span>
</td>
<td class="nump">38,058,000<span></span>
</td>
<td class="num">(1,574,000)<span></span>
</td>
<td class="num">(1,574,000)<span></span>
</td>
<td class="num">(3,315,000)<span></span>
</td>
<td class="nump">3,315,000<span></span>
</td>
<td class="nump">39,924,000<span></span>
</td>
<td class="nump">39,924,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2021</a></td>
<td class="nump">3,877,282,251<span></span>
</td>
<td class="nump">3,877,282,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,051,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(204,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,255,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="nump">$ 38,058,000<span></span>
</td>
<td class="nump">38,058,000<span></span>
</td>
<td class="num">$ (8,625,000)<span></span>
</td>
<td class="num">(8,625,000)<span></span>
</td>
<td class="nump">$ 3,111,000<span></span>
</td>
<td class="nump">3,111,000<span></span>
</td>
<td class="nump">$ 32,669,000<span></span>
</td>
<td class="nump">32,669,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,877,282,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(657,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(192,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(849,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,058,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (9,282,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,919,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,820,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,877,282,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMPB_StockIssuedDuringPeriodValueShareholder">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Value Shareholder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">IMPB_StockIssuedDuringPeriodValueShareholder</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>IMPB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139839839189552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (849,000)<span></span>
</td>
<td class="num">$ (746,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,848,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">280,000<span></span>
</td>
<td class="nump">278,000<span></span>
</td>
<td class="nump">$ 1,113,000<span></span>
</td>
<td class="nump">1,113,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,395,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_IMPB_ImpairmentOfOtherInvestments', window );">Impairment of other investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>Decrease (increase) in assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(79,000)<span></span>
</td>
<td class="num">(37,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredLiabilities', window );">Deferred Tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_IMPB_IncreaseDecreaseInImpairmentofOtherInvestments', window );">Impairment of other investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract', window );"><strong>Increase (decrease) in liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(353,000)<span></span>
</td>
<td class="num">(60,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(13,000)<span></span>
</td>
<td class="nump">32,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used by operating activities</a></td>
<td class="num">(1,014,000)<span></span>
</td>
<td class="num">(533,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,027,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromProductiveAssets', window );">Purchase of property, plant and equipment</a></td>
<td class="num">(5,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchase of investment</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(12,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,185,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_IMPB_PaymentsForProceedsFromNoteReceivableInvestments', window );">Note receivable investment, net</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="num">(93,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,278,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used by investing activities</a></td>
<td class="num">(4,000)<span></span>
</td>
<td class="num">(105,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,463,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Borrowings from note payable, related party</a></td>
<td class="nump">1,017,000<span></span>
</td>
<td class="nump">625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,464,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">1,017,000<span></span>
</td>
<td class="nump">625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,464,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash</a></td>
<td class="num">(1,000)<span></span>
</td>
<td class="num">(13,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">46,000<span></span>
</td>
<td class="nump">46,000<span></span>
</td>
<td class="nump">72,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">33,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">46,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,255,000)<span></span>
</td>
<td class="num">(1,848,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,113,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(621,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_IMPB_ImpairmentOfOtherInvestments', window );">Impairment of other investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>Decrease (increase) in assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(60,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract', window );"><strong>Increase (decrease) in liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">424,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used by operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,242,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromProductiveAssets', window );">Purchase of property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(276,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchase of investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(65,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_IMPB_PaymentsForProceedsFromNoteReceivableInvestments', window );">Note receivable investment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used by investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(349,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Borrowings from note payable, related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,547,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,547,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 46,000<span></span>
</td>
<td class="nump">46,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 46,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMPB_ImpairmentOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in impairment of other investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">IMPB_ImpairmentOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>IMPB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMPB_IncreaseDecreaseInImpairmentofOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in impairment of other investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">IMPB_IncreaseDecreaseInImpairmentofOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>IMPB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMPB_PaymentsForProceedsFromNoteReceivableInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments for proceeds from note receivable investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">IMPB_PaymentsForProceedsFromNoteReceivableInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>IMPB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change during the period in carrying value for all deferred liabilities due within one year or operating cycle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash outflow or inflow from purchases, sales and disposals of property, plant and equipment and other productive assets, including intangibles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139839840923888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Operations and Basis of Presentation</a></td>
<td class="text"><p id="xdx_800_eus-gaap--NatureOfOperations_zdoXDDu1KQS5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
1. <span id="xdx_82D_zff7jzvZMrc5">Nature of Operations and Basis of Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Nature
of Operations</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impact
BioMedical, Inc. (the &#8220;Company&#8221;, &#8220;Impact BioMedical&#8221;, &#8220;We&#8221;) through the utilization of its intellectual
property rights, or through investment in, or through acquisition of companies in the biohealth and biomedical fields, focuses on the
advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune related diseases. The
Company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis
and influenza.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Global
BioLife, Inc. (&#8220;Global BioLife&#8221;), one of the Company&#8217;s subsidiaries and the main operating company of the group, focuses
on research in four main areas: (i) the &#8220;Linebacker&#8221; project, which aims to develop a universal therapeutic drug platform;
(ii) a new sugar substitute called &#8220;Laetose,&#8221;; (iii) a multi-use fragrance called &#8220;3F&#8221; (Functional Fragrance
Formulation); and (iv) Equivir/Nemovir, a blend of natural polyphenols designed as an antimicrobial medication.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Linebacker</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unlike
the traditional approach to treat individual diseases with specific drugs, the Linebacker platform seeks to offer a breakthrough therapeutic
option for multiple diseases. Linebacker is designed to work by inhibiting a cascade of inflammatory responses responsible for many diseases.
Its design is in direct contrast to the traditional approach of targeting individual diseases with specific drugs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Laetose</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have also developed a low-calorie, low glycemic level, natural modified sugar through Global BioLife. The product, &#8220;Laetose,&#8221;
is designed to possess low glycemic properties and mitigate inflammation. The Company is presently seeking to license Laetose. Global
BioLife established a joint venture, Sweet Sense, Inc. (&#8220;Sweet Sense&#8221;), with Quality Ingredients, LLC for the development,
manufacture, and global distribution of the new sugar substitute. On November 8, 2019, the Company purchased <span id="xdx_90F_eus-gaap--MinorityInterestOwnershipPercentageByNoncontrollingOwners_iI_pid_dp_uPure_c20191108__srt--OwnershipAxis__custom--SweetSenseMember_z6uVINfTNaf" title="Minority interest ownership percentage">50</span>% of Sweet Sense Inc.
from Quality Ingredients, LLC for $<span id="xdx_90F_eus-gaap--BusinessCombinationConsiderationTransferred1_c20191107__20191108__srt--OwnershipAxis__custom--SweetSenseMember_zMfNPrQHBMhg" title="Consideration given for purchase">91,000</span>. Sweet Sense is now an <span id="xdx_906_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20191108__srt--OwnershipAxis__custom--SweetSenseMember_zkdCM55H3RBk" title="Ownership percentage">81.8</span>% owned subsidiary of Impact BioMedical.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Functional
Fragrance Formulation (&#8220;3F&#8221;)</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Global
BioLife has established a collaboration with U.S.-based Chemia Corporation (&#8220;Chemia&#8221;) to develop specialized fragrances to
counter mosquito-borne diseases such as Zika and Dengue, among other medical applications. The 3F mosquito fragrance product is made
from specialized oils sourced from botanicals that mosquitos avoid. Global BioLife is seeking to commercialize this product. Together
with Chemia, we are attempting to license 3F. Any potential profits from the 3F project will be split between Global BioLife and Chemia
pursuant to the terms of the 20- year Royalty Agreement (Note 11).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Equivir</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equivir,
is a polyphenol compound that is believed to be successful in antiviral infection treatments. Equivir is a patented medication, that
has broad antiviral efficacy against multiple types of infectious disease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company was incorporated in the State of Nevada as a for-profit company on October 16, 2018 and established a fiscal year end of December
31st. The Company issued <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20181016__20181016__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--GlobalBioMedicalPteLtdMember_zaE7L99m5X6h" title="Stock issued during period shares">9,000</span> shares to its sole shareholder Global BioMedical Pte. Ltd., which was wholly owned by Alset International
Limited (formally Singapore eDevelopment Limited), a multinational public company, listed on the Singapore Exchange Securities Trading
Limited (&#8220;SGXST&#8221;). On March 31, 2020, the Company issued <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200330__20200331__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--GlobalBioMedicalPteLtdMember_zpAK0gt5VdXi" title="Stock issued during period shares">125,064,621</span> shares of common stock to its sole shareholder Global
BioMedical Pte. Ltd. On July 24, 2020, the Board approved the Stock Split, pursuant to which each share of the Company&#8217;s common
stock issued and outstanding was split into nine shares of the Company&#8217;s common stock. The numbers of authorized common stock and
issued and outstanding common stock in the reporting periods were retrospectively adjusted for the stock split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this report, we have not generated significant revenues from operations. We cannot guarantee we will be successful in
our business operations. Our business is subject to risks inherent in the establishment of a new business enterprise, including possible
delays in our research, testing and marketing efforts or wider economic downturns.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Basis
of Presentation and Principles of Consolidation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the
United States of America (&#8220;U.S. GAAP&#8221;). The consolidated financial statements include all accounts of the Company and its
majority owned and controlled subsidiaries. The Company consolidates entities in which it owns more than <span id="xdx_909_eus-gaap--MinorityInterestOwnershipPercentageByNoncontrollingOwners_iI_pid_dp_uPure_c20230331__srt--OwnershipAxis__custom--SweetSenseMember_zTatvyBe7BPd" title="Minority interest ownership percentage">50</span>% of the voting common stock
and controls operations. All intercompany transactions and balances among consolidated subsidiaries have been eliminated. Non&#8211;controlling
interest represents the minority equity investment in the Company&#8217;s subsidiaries, plus the minority investors&#8217; share of the
net operating results and other components of equity relating to the non&#8211;controlling interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IMPACT
Biomedical, Inc. and Subsidiaries</b></span></p>

<p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_898_esrt--ScheduleOfCondensedFinancialStatementsTableTextBlock_zCwUXDY4Qu6e" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements include all accounts of the entities as of the reporting period ending dates and for the reporting
periods as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_z4z5BYYYPCG7" style="display: none">Schedule
of Condensed Financial Statements</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: center">Name of consolidated subsidiary</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">State or other jurisdiction of incorporation or organization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">Date of incorporation or formation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Attributable interest as of <br/>March 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Attributable <br/>interest as of <br/>December 31, <br/>2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Global BioMedical, Inc.</td><td style="width: 2%">&#160;</td>
    <td style="width: 12%"><span id="xdx_900_ecustom--StateOrOtherJurisdictionOfIncorporationOrOrganization_c20230101__20230331__srt--OwnershipAxis__custom--GlobalBioMedicalIncMember_zIHBDFNktZWf" title="State or other jurisdiction of incorporation or organization">Nevada</span></td><td style="width: 2%">&#160;</td>
    <td style="width: 12%"><span id="xdx_905_edei--EntityIncorporationDateOfIncorporation_dd_c20230101__20230331__srt--OwnershipAxis__custom--GlobalBioMedicalIncMember_zPVifDMn8HAd" title="Date of incorporation or formation">April 18, 2017</span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90C_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20230331__srt--OwnershipAxis__custom--GlobalBioMedicalIncMember_zICnblZve9hf" title="Attributable interest percentage">90.9</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90B_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--GlobalBioMedicalIncMember_zoV5HtpvowU1" title="Attributable interest percentage">90.9</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Global BioLife, Inc.</td><td>&#160;</td>
    <td><span id="xdx_901_ecustom--StateOrOtherJurisdictionOfIncorporationOrOrganization_c20230101__20230331__srt--OwnershipAxis__custom--GlobalBioLifeIncMember_z3aGwZ7PsBR4" title="State or other jurisdiction of incorporation or organization">Nevada</span></td><td>&#160;</td>
    <td><span id="xdx_906_edei--EntityIncorporationDateOfIncorporation_dd_c20230101__20230331__srt--OwnershipAxis__custom--GlobalBioLifeIncMember_zaO5qwKuCCRe" title="Date of incorporation or formation">April 14, 2017</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20230331__srt--OwnershipAxis__custom--GlobalBioLifeIncMember_zRS65KdYQx7c" title="Attributable interest percentage">81.8</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--GlobalBioLifeIncMember_zO0xobSyy5K2" title="Attributable interest percentage">81.8</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">BioLife Sugar, Inc</td><td>&#160;</td>
    <td><span id="xdx_90B_ecustom--StateOrOtherJurisdictionOfIncorporationOrOrganization_c20230101__20230331__srt--OwnershipAxis__custom--BioLifeSugarIncMember_z1DG4rXM1ksi" title="State or other jurisdiction of incorporation or organization">Nevada</span></td><td>&#160;</td>
    <td><span id="xdx_905_edei--EntityIncorporationDateOfIncorporation_dd_c20230101__20230331__srt--OwnershipAxis__custom--BioLifeSugarIncMember_z1qWDh45VM08" title="Date of incorporation or formation">April 23, 2018</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20230331__srt--OwnershipAxis__custom--BioLifeSugarIncMember_z16iaO8UNdwb" title="Attributable interest percentage">90.9</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--BioLifeSugarIncMember_ztP2KJ3wcpWg" title="Attributable interest percentage">90.9</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Happy Sugar Inc</td><td>&#160;</td>
    <td><span id="xdx_90E_ecustom--StateOrOtherJurisdictionOfIncorporationOrOrganization_c20230101__20230331__srt--OwnershipAxis__custom--HappySugarIncMember_zrdRrUOgSo69" title="State or other jurisdiction of incorporation or organization">Nevada</span></td><td>&#160;</td>
    <td><span id="xdx_90C_edei--EntityIncorporationDateOfIncorporation_dd_c20230101__20230331__srt--OwnershipAxis__custom--HappySugarIncMember_z5SFO8dbSLSa" title="Date of incorporation or formation">August 17, 2018</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20230331__srt--OwnershipAxis__custom--HappySugarIncMember_zvQRNrD7qZu4" title="Attributable interest percentage">81.8</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--HappySugarIncMember_zMpA41Q67aPl" title="Attributable interest percentage">81.8</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Sweet Sense Inc.</td><td>&#160;</td>
    <td><span id="xdx_90A_ecustom--StateOrOtherJurisdictionOfIncorporationOrOrganization_c20230101__20230331__srt--OwnershipAxis__custom--SweetSenseIncMember_z0AuJTir93ta" title="State or other jurisdiction of incorporation or organization">Nevada</span></td><td>&#160;</td>
    <td><span id="xdx_906_edei--EntityIncorporationDateOfIncorporation_dd_c20230101__20230331__srt--OwnershipAxis__custom--SweetSenseIncMember_zVGoQe5wh5F" title="Date of incorporation or formation">April 30, 2018</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20230331__srt--OwnershipAxis__custom--SweetSenseIncMember_zzHfN0CZ8nF9" title="Attributable interest percentage">95.5</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--SweetSenseIncMember_zKKdzQEyIaZd" title="Attributable interest percentage">95.5</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Global Sugar Solutions Inc.</td><td>&#160;</td>
    <td><span id="xdx_909_ecustom--StateOrOtherJurisdictionOfIncorporationOrOrganization_c20230101__20230331__srt--OwnershipAxis__custom--GlobalSugarSolutionsIncMember_zwczc9QUp25k" title="State or other jurisdiction of incorporation or organization">Nevada</span></td><td>&#160;</td>
    <td><span id="xdx_901_edei--EntityIncorporationDateOfIncorporation_dd_c20230101__20230331__srt--OwnershipAxis__custom--GlobalSugarSolutionsIncMember_zAroUALjZgTi" title="Date of incorporation or formation">November 7, 2019</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20230331__srt--OwnershipAxis__custom--GlobalSugarSolutionsIncMember_zBtF5Fvi0OL" title="Attributable interest percentage">100</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--GlobalSugarSolutionsIncMember_zfdpbWiabovk" title="Attributable interest percentage">100</span></td><td style="text-align: left">%</td></tr>
  </table>

<p id="xdx_8A1_znvcOjfTbCY6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2023, and December 31, 2022, the aggregate noncontrolling interest was equity of $<span id="xdx_906_eus-gaap--MinorityInterest_iI_c20230331__srt--ConsolidatedEntitiesAxis__srt--SubsidiariesMember_zeIentK9UWxd" title="Noncontrolling interest">2,919,000</span>
and $<span id="xdx_906_eus-gaap--MinorityInterest_iI_c20221231__srt--ConsolidatedEntitiesAxis__srt--SubsidiariesMember_z2ty5bX55Whb" title="Noncontrolling interest">3,111,000</span>,
respectively, which are separately disclosed on the Consolidated Balance Sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_803_eus-gaap--NatureOfOperations_zxG7oDgoxgcc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
1. <span id="xdx_82C_zFqIBiDUxJ64">Nature of Operations and Basis of Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Nature
of Operations</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impact
BioMedical, Inc. (the &#8220;Company&#8221;, &#8220;Impact BioMedical&#8221;, &#8220;We&#8221;) through the utilization of its intellectual
property rights, or through investment in, or through acquisition of companies in the biohealth and biomedical fields, focuses on the
advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune related diseases. The
Company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis
and influenza.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Global
BioLife, Inc. (&#8220;Global BioLife&#8221;), one of the Company&#8217;s subsidiaries and the main operating company of the group, focuses
on research in four main areas: (i) the &#8220;Linebacker&#8221; project, which aims to develop a universal therapeutic drug platform;
(ii) a new sugar substitute called &#8220;Laetose,&#8221;; (iii) a multi-use fragrance called &#8220;3F&#8221; (Functional Fragrance
Formulation); and (iv) Equivir/Nemovir, a blend of natural polyphenols designed as an antimicrobial medication.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Linebacker</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unlike
the traditional approach to treat individual diseases with specific drugs, the Linebacker platform seeks to offer a breakthrough therapeutic
option for multiple diseases. Linebacker is designed to work by inhibiting a cascade of inflammatory responses responsible for many diseases.
Its design is in direct contrast to the traditional approach of targeting individual diseases with specific drugs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Laetose</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have also developed a low-calorie, low glycemic level, natural modified sugar through Global BioLife. The product, &#8220;Laetose,&#8221;
is designed to possess low glycemic properties and mitigate inflammation. The Company is presently seeking to license Laetose. Global
BioLife established a joint venture, Sweet Sense, Inc. (&#8220;Sweet Sense&#8221;), with Quality Ingredients, LLC for the development,
manufacture, and global distribution of the new sugar substitute. On November 8, 2019, the Company purchased <span id="xdx_90F_eus-gaap--MinorityInterestOwnershipPercentageByNoncontrollingOwners_iI_pid_dp_uPure_c20191108__srt--OwnershipAxis__custom--SweetSenseMember_z12C9V8yl8Pb" title="Minority interest ownership percentage">50</span>% of Sweet Sense Inc.
from Quality Ingredients, LLC for $<span id="xdx_90E_eus-gaap--BusinessCombinationConsiderationTransferred1_c20191107__20191108__srt--OwnershipAxis__custom--SweetSenseMember_zPzCUcqTajMb" title="Consideration given for purchase">91,000</span>. Sweet Sense is now an <span id="xdx_900_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20191108__srt--OwnershipAxis__custom--SweetSenseMember_zW35Gxw4yjJf" title="Ownership percentage">81.8</span>% owned subsidiary of Impact BioMedical.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Functional
Fragrance Formulation (&#8220;3F&#8221;)</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Global
BioLife has established a collaboration with U.S.-based Chemia Corporation (&#8220;Chemia&#8221;) to develop specialized fragrances to
counter mosquito-borne diseases such as Zika and Dengue, among other medical applications. The 3F mosquito fragrance product is made
from specialized oils sourced from botanicals that mosquitos avoid. Global BioLife is seeking to commercialize this product. Together
with Chemia, we are attempting to license 3F. Any potential profits from the 3F project will be split between Global BioLife and Chemia
pursuant to the terms of the 20- year Royalty Agreement (Note 12).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Equivir</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equivir,
is a polyphenol compound that is believed to be successful in antiviral infection treatments. Equivir is a patented medication, that
has broad antiviral efficacy against multiple types of infectious disease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company was incorporated in the State of Nevada as a for-profit company on October 16, 2018 and established a fiscal year end of December
31st. The Company issued <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20181016__20181016__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--GlobalBioMedicalPteLtdMember_zUob4L8G3Atg" title="Stock issued during period shares">9,000</span> shares to its sole shareholder Global BioMedical Pte. Ltd., which was wholly owned by Alset International
Limited (formally Singapore eDevelopment Limited), a multinational public company, listed on the Singapore Exchange Securities Trading
Limited (&#8220;SGXST&#8221;). On March 31, 2020, the Company issued <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200330__20200331__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--GlobalBioMedicalPteLtdMember_zfH9lDxhTqYb" title="Stock issued during period shares">125,064,621</span> shares of common stock to its sole shareholder Global
BioMedical Pte. Ltd. On July 24, 2020, the Board approved the Stock Split, pursuant to which each share of the Company&#8217;s common
stock issued and outstanding was split into nine shares of the Company&#8217;s common stock. The numbers of authorized common stock and
issued and outstanding common stock in the reporting periods were retrospectively adjusted for the stock split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this report, we have not generated significant revenues from operations. We cannot guarantee we will be successful in
our business operations. Our business is subject to risks inherent in the establishment of a new business enterprise, including possible
delays in our research, testing and marketing efforts or wider economic downturns.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Basis
of Presentation and Principles of Consolidation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the
United States of America (&#8220;U.S. GAAP&#8221;). The consolidated financial statements include all accounts of the Company and its
majority owned and controlled subsidiaries. The Company consolidates entities in which it owns more than <span id="xdx_90C_eus-gaap--MinorityInterestOwnershipPercentageByNoncontrollingOwners_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--SweetSenseMember_zjFOCeMosyi2" title="Minority interest ownership percentage">50</span>% of the voting common stock
and controls operations. All intercompany transactions and balances among consolidated subsidiaries have been eliminated. Non&#8211;controlling
interest represents the minority equity investment in the Company&#8217;s subsidiaries, plus the minority investors&#8217; share of the
net operating results and other components of equity relating to the non&#8211;controlling interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IMPACT
Biomedical, Inc. and Subsidiaries</b></span></p>

<p style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_esrt--ScheduleOfCondensedFinancialStatementsTableTextBlock_zI2mYLbcMG71" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements include all accounts of the entities as of the reporting period ending dates and for the reporting
periods as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_zrTi228E0Hve" style="display: none">Schedule
of Condensed Financial Statements</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Name of consolidated subsidiary</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">State or other jurisdiction of incorporation or organization</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Date of incorporation or formation</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Attributable interest as of <br/> December 31, <br/> 2022</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Attributable <br/> interest as of <br/> December 31, <br/> 2021</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: left">Global BioMedical, Inc.</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 18%"><span id="xdx_90F_ecustom--StateOrOtherJurisdictionOfIncorporationOrOrganization_c20220101__20221231__srt--OwnershipAxis__custom--GlobalBioMedicalIncMember_zj6YxyNf8Jba" title="State or other jurisdiction of incorporation or organization">Nevada</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 18%"><span id="xdx_901_edei--EntityIncorporationDateOfIncorporation_dd_c20220101__20221231__srt--OwnershipAxis__custom--GlobalBioMedicalIncMember_z1oSxHwxLdE" title="Date of incorporation or formation">April 18, 2017</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_90F_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--GlobalBioMedicalIncMember_zNLFbG07qcq6" title="Attributable interest percentage">90.9</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_906_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20211231__srt--OwnershipAxis__custom--GlobalBioMedicalIncMember_zvuByqKsBpL9" title="Attributable interest percentage">90.9</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Global BioLife, Inc.</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_902_ecustom--StateOrOtherJurisdictionOfIncorporationOrOrganization_c20220101__20221231__srt--OwnershipAxis__custom--GlobalBioLifeIncMember_zw2zPHa5DFQ2" title="State or other jurisdiction of incorporation or organization">Nevada</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90A_edei--EntityIncorporationDateOfIncorporation_dd_c20220101__20221231__srt--OwnershipAxis__custom--GlobalBioLifeIncMember_zONGg88g42x9" title="Date of incorporation or formation">April 14, 2017</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--GlobalBioLifeIncMember_zjFy7BH16Qhj" title="Attributable interest percentage">81.8</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20211231__srt--OwnershipAxis__custom--GlobalBioLifeIncMember_zXOvifpjTBt" title="Attributable interest percentage">63.6</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">BioLife Sugar, Inc</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90E_ecustom--StateOrOtherJurisdictionOfIncorporationOrOrganization_c20220101__20221231__srt--OwnershipAxis__custom--BioLifeSugarIncMember_z2DKWvZTkrFi" title="State or other jurisdiction of incorporation or organization">Nevada</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90A_edei--EntityIncorporationDateOfIncorporation_dd_c20220101__20221231__srt--OwnershipAxis__custom--BioLifeSugarIncMember_zteqNjNmbVMk" title="Date of incorporation or formation">April 23, 2018</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90C_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--BioLifeSugarIncMember_zoAYF3xbSg83" title="Attributable interest percentage">90.9</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20211231__srt--OwnershipAxis__custom--BioLifeSugarIncMember_ztM7xQ8lX8oc" title="Attributable interest percentage">63.6</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Happy Sugar Inc</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_903_ecustom--StateOrOtherJurisdictionOfIncorporationOrOrganization_c20220101__20221231__srt--OwnershipAxis__custom--HappySugarIncMember_zv9GlHKO2uD3" title="State or other jurisdiction of incorporation or organization">Nevada</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90B_edei--EntityIncorporationDateOfIncorporation_dd_c20220101__20221231__srt--OwnershipAxis__custom--HappySugarIncMember_zs9MtTdiw097" title="Date of incorporation or formation">August 17, 2018</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--HappySugarIncMember_zxvnxg59cDPi" title="Attributable interest percentage">81.8</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20211231__srt--OwnershipAxis__custom--HappySugarIncMember_zUa6AMo7MUq9" title="Attributable interest percentage">63.6</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Sweet Sense Inc.</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_906_ecustom--StateOrOtherJurisdictionOfIncorporationOrOrganization_c20220101__20221231__srt--OwnershipAxis__custom--SweetSenseIncMember_zT31tTWcA7xf" title="State or other jurisdiction of incorporation or organization">Nevada</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_909_edei--EntityIncorporationDateOfIncorporation_dd_c20220101__20221231__srt--OwnershipAxis__custom--SweetSenseIncMember_zi1ZFP0VWiC8" title="Date of incorporation or formation">April 30, 2018</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--SweetSenseIncMember_znUTdBy2RC6" title="Attributable interest percentage">95.5</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20211231__srt--OwnershipAxis__custom--SweetSenseIncMember_zlvDJinYJA2f" title="Attributable interest percentage">81.8</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Global Sugar Solutions Inc.</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90A_ecustom--StateOrOtherJurisdictionOfIncorporationOrOrganization_c20220101__20221231__srt--OwnershipAxis__custom--GlobalSugarSolutionsIncMember_zmGAIxue30i5" title="State or other jurisdiction of incorporation or organization">Nevada</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_909_edei--EntityIncorporationDateOfIncorporation_dd_c20220101__20221231__srt--OwnershipAxis__custom--GlobalSugarSolutionsIncMember_zZrTE1q0Ixig" title="Date of incorporation or formation">November 7, 2019</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--GlobalSugarSolutionsIncMember_zOJhwTFWaw1h" title="Attributable interest percentage">100</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90C_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20211231__srt--OwnershipAxis__custom--GlobalSugarSolutionsIncMember_zvMjPp9213e2" title="Attributable interest percentage">80</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  </table>

<p id="xdx_8A2_zhlBCspnZd14" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, and 2021, the aggregate noncontrolling interest was equity of $<span id="xdx_906_eus-gaap--MinorityInterest_iI_c20221231_zlZ5qceBXwMl" title="Noncontrolling interest">3,111,000</span> and $<span id="xdx_90E_eus-gaap--MinorityInterest_iI_c20211231_zLxUqf3vjUJe" title="Noncontrolling interest">3,315,000</span>, respectively, which are
separately disclosed on the Consolidated Balance Sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139839847777216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting and Reporting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting and Reporting Policies</a></td>
<td class="text"><p id="xdx_800_eus-gaap--SignificantAccountingPoliciesTextBlock_z7YJQDa0zWt2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2.<span id="xdx_82C_zjLhBS0H2V93"> Summary of Significant Accounting and Reporting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_847_eus-gaap--UseOfEstimates_zdQf9jYkURy7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_zt6VwiVmfLrk">Use
of estimates</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the dates of the balance
sheets and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from these estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_842_eus-gaap--EarningsPerSharePolicyTextBlock_zyxlcJyJMqci" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86F_zkJB4Ss69lIi">Earnings
(Loss) per Share</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
earnings (loss) per share is computed by dividing the net income (loss) attributable to the common stockholders by weighted average number
of shares of common stock outstanding during the period. Fully diluted earnings (loss) per share is computed like basic income (loss)
per share except that the denominator is increased to include the number of additional common shares that would have been outstanding
if the potential common shares had been issued and if the additional common shares were dilutive. There were no dilutive financial instruments
issued or outstanding for the three months ended March 31, 2023 or 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_849_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zgcgbooGbEg6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_z9Je588BzIm4">Fair
Value of Financial Instruments</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants at the measurement date. The Fair Value Measurement Topic of the Financial Accounting Standards Board (&#8220;FASB&#8221;)
Accounting Standards Codification (&#8220;ASC&#8221;) establishes a three-tier fair value hierarchy which prioritizes the inputs used
in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets
or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted
prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active;
and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions,
such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts reported in the balance sheet of cash and cash equivalents, prepaids, accounts payable and accrued expenses approximate
fair value because of the immediate or short-term maturity of these financial instruments. The fair value of notes receivable approximates
their carrying value as the stated or discounted rates of the notes do reflect recent market conditions. The Company&#8217;s investments
are record at cost as the fair value of these investment in are not readily available. The fair value of notes payable approximates its
carrying value as the stated interest rate reflects recent market conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IMPACT
Biomedical, Inc. and Subsidiaries</b></span></p>

<p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_847_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zeTGsT6NkwGk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86F_zrkvNCrj2yh4">Cash
and cash equivalents</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid investments with a maturity of three months or less at the date of acquisition to be cash
equivalents. There were <span id="xdx_907_eus-gaap--Cash_iI_do_c20230331_zIikbZYCaAYd" title="Cash"><span id="xdx_90C_eus-gaap--Cash_iI_do_c20221231_zknDqfNKSt4g" title="Cash">no</span></span>
cash equivalents as of March 31, 2023 and December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84F_eus-gaap--InvestmentPolicyTextBlock_zQ6ZqyOzbsx3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_zu17eaWGCxj2">Investments</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investments
in equity securities with a readily determinable fair value, not accounted for under the equity method, are recorded at fair value with
unrealized gains and losses included in earnings. For equity securities without a readily determinable fair value, the investment is
recorded at cost, less any impairment, plus or minus adjustments related to observable transactions for the same or similar securities,
with unrealized gains and losses included in earnings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
equity method investments, the Company regularly reviews its investments to determine whether there is a decline in fair value below
book value. If there is a decline that is other-than-temporary, the investment is written down to fair value. See Note 6 for further
discussion on investments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84F_eus-gaap--GoodwillAndIntangibleAssetsGoodwillPolicy_z9IxlP36xKl1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zo4sSSkpKQEi">Goodwill</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill
is the excess of cost of an acquired entity over the fair value of amounts assigned to assets acquired and liabilities assumed in a business
combination. Goodwill is subject to impairment testing at least annually and will be tested for impairment between annual tests, which
takes place during the fourth quarter, if an event occurs or circumstances change that would indicate the carrying amount may be impaired.
FASB ASC Topic 350 provides an entity with the option to first assess qualitative factors to determine whether the existence of events
or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying
amount. Some of the qualitative factors considered in applying this test include consideration of macroeconomic conditions, industry
and market conditions, cost factors affecting the business, and overall financial performance of the business. If, after completing the
assessment, it is determined that it is more likely than not that the fair value of a reporting unit is less than its carrying value,
the Company will proceed to a quantitative test. If qualitative factors are not deemed sufficient to conclude that the fair value of
the reporting unit more likely than not exceeds its carrying value, then a one-step approach is applied in making an evaluation. The
evaluation utilizes an income approach (discounted cash flow analysis). The computations require management to make significant estimates
and assumptions, including, among other things, selection of comparable publicly traded companies, the discount rate applied to future
earnings reflecting a weighted average cost of capital, and earnings growth assumptions. The Company believes the estimates and assumptions
used in our impairment assessments are reasonable and based on available market information, but variations in any of the assumptions
could result in materially different calculations of fair value and determinations of whether or not an impairment is indicated. A discounted
cash flow analysis requires management to make various assumptions about future sales, operating margins, capital expenditures, working
capital, and growth rates. Cash flow projections are derived from one year budgeted amounts plus an estimate of later period cash flows,
all of which are determined by management. Subsequent period cash flows are developed for each reporting unit using growth rates that
management believes are reasonably likely to occur. Impairment of goodwill is measured as the excess of the carrying amount of goodwill
over the fair values of recognized and unrecognized assets and liabilities of the reporting unit. <span id="xdx_904_eus-gaap--GoodwillImpairmentLoss_dxL_c20230101__20230331_z4XiXqSxlbza" title="Impairment of goodwill::XDX::-"><span id="xdx_901_eus-gaap--GoodwillImpairmentLoss_dxL_c20220101__20220331_zcT7vmeuBw04" title="Impairment of goodwill::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1230"><span style="-sec-ix-hidden: xdx2ixbrl1232">No</span></span></span></span> impairment was recognized during
the three months ended March 31, 2023 or year ended December 31, 2022 (see Note 7).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--IntangibleAssetsFiniteLivedPolicy_z1a3nqz7Lulf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_zU8Fi7Jev1Yb">Intangible
Assets</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated fair values of acquired intangibles are generally determined based upon future economic benefits such as earnings and cash
flows. Acquired identifiable intangible assets are recorded at fair value and are amortized over their estimated useful lives.
Acquired intangible assets with an indefinite life are not amortized but are reviewed for impairment at least annually as of
December 31<sup>st</sup>, or more frequently whenever events or changes in circumstances indicate that the carrying amounts of those
assets are below their estimated fair values. Impairment is tested under ASC 350. <span id="xdx_901_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_do_c20230101__20230331_zywcseRVtwQl" title="Impairment of intangible assets"><span id="xdx_900_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_do_c20220101__20221231_zdUpfxX3Zrwc" title="Impairment of intangible assets">No</span></span>
impairment was recognized as of March 31,  2023 or year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"></p>

<p id="xdx_84C_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zDbHGeIMInR8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; background-color: white"><i><span id="xdx_860_zkK2hzCpGQ93">Recoverability
of Long-Lived Assets</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; background-color: white"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; background-color: white">We evaluate
long-lived assets such as property, equipment and definite lived intangible assets, such as patents, for impairment whenever events or
circumstances indicate that the carrying value of the assets recognized in our financial statements may not be recoverable. Factors that
we consider include whether there has been a significant decrease in the market value of an asset, a significant change in the way an
asset is being utilized, or a significant change, delay or departure in our strategy for that asset, or a significant change in the macroeconomic
environment, such as the impact of the COVID-19 pandemic. Our assessment of the recoverability of long-lived assets involves significant
judgment and estimation. These assessments reflect our assumptions, which, we believe, are consistent with the assumptions hypothetical
marketplace participants use. Factors that we must estimate when performing recoverability and impairment tests include, among others,
forecasted revenue, margin costs and the economic life of the asset. If impairment is indicated, we determine if the total estimated
future cash flows on an undiscounted basis are less than the carrying amounts of the asset or assets. If so, an impairment loss is measured
and recognized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 27.15pt; background-color: white">Our
impairment loss calculations require that we apply judgment in identifying asset groups, estimating future cash flows, determining asset
fair values, and estimating asset&#8217;s useful lives. The Company reviews identifiable amortizable intangible assets for impairment
whenever events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. Determination of recoverability
is based on the lowest level of identifiable estimated undiscounted cash flows resulting from use of the asset and its eventual disposition.
Measurement of any impairment loss is based on the excess of the carrying value of the asset over its fair value. Based on the uncertainty
of forecasts inherent with a new product, events such as the failure to generate forecasted revenue from new products could result in
a non-cash impairment in future periods. </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p id="xdx_847_eus-gaap--ResearchAndDevelopmentExpensePolicy_zGjVfszuc6gk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_861_zxMhjB9oXyT5">Research
and Development</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed as incurred. Total research and development costs were $<span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230331_zCs1D9tKs0sj" title="Research and development cost">179,000</span> for the three months ended March 31,
2023, and $<span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20220331_zGlbHIaIRhXj" title="Research and development cost">168,000</span> for three months ended March 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IMPACT
Biomedical, Inc. and Subsidiaries</b></span></p>

<p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_849_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zxAblYvjT77c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zeeCcaIvXdw5">Recent
Accounting Standards</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Financial Accounting Standards Board (FASB) issues various Accounting Standards Updates relating to the treatment and recording of certain
accounting transactions. There are several new accounting pronouncements issued by FASB which are not yet effective. Each of these pronouncements,
as applicable, has been or will be adopted by the Company. As of March 31, 2023, none of these pronouncements is expected to have a material
effect on the financial position, results of operations or cash flows of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">On January
1, 2022, the Company adopted amended accounting guidance &#8220;<i>ASU No.2016-13 &#8211; Credit Losses&#8221;</i> which requires an
allowance for credit losses to be deducted from the amortized cost basis of financial assets to present the net carrying value at the
amount that is expected to be collected over the contractual term of the asset considering relevant information about past events, current
conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. In estimating expected losses
in the loan and lease portfolio, borrower-specific financial data and macro-economic assumptions are utilized to project losses over
a reasonable and supportable forecast period. Assumptions and judgment are applied to measure amounts and timing of expected future cash
flows, collateral values and other factors used to determine the borrowers&#8217; abilities to repay obligations. After the forecast
period, the Company utilizes longer-term historical loss experience to estimate losses over the remaining contractual life of the loans.
Prior to 2022, the allowance for credit losses represented the amount that in management&#8217;s judgment reflected incurred credit losses
inherent in the loan and lease portfolio as of the balance sheet date. As of March 31, 2023 the Company has deemed that no reserve or
credit losses were necessary.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_ecustom--ContinuingOperationsAndGoingConcernPolicyTextBlock_zcNMEQrOWwg3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_zTEGg80OPLSg">Continuing
Operations and Going Concern</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to incurred operating losses as well as negative cash flows from operating and investing activities over the past two years, the accompanying
consolidated financial statements have been prepared assuming that the Company will continue as a going concern. This basis of accounting
contemplates the recovery of our assets and the satisfaction of liabilities in the normal course of business. These consolidated financial
statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary
should we be unable to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
continue as a going concern, the Company has entered into an updated revolving promissory note which extended the maturity through March
31, 2024, and DSS intends to continue to fund the operations of the Company through a year from the date these financial statements were
available to be issued. The Company&#8217;s management intends to take actions necessary to continue as a going concern. Management&#8217;s
plans concerning these matters include, among other things, monetization of its intellectual properties, and tightly controlling operating
costs. Based on this, the Company has concluded that substantial doubt of its ability to continue as a going concern has been alleviated.</span></p>
<p id="xdx_859_zzXvj7vNEiFa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_804_eus-gaap--SignificantAccountingPoliciesTextBlock_z3qtt0DarICl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2. <span id="xdx_82B_zXidA4utt5I4">Summary of Significant Accounting and Reporting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_847_eus-gaap--UseOfEstimates_z5wz0mcNenma" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zaqEKogB9ez9">Use
of estimates</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the dates of the balance
sheets and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from these estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_zP3j63KgdsR4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zTsxI67TiqM">Earnings
(Loss) per Share</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
earnings (loss) per share is computed by dividing the net income (loss) attributable to the common stockholders by weighted average number
of shares of common stock outstanding during the period. Fully diluted earnings (loss) per share is computed like basic income (loss)
per share except that the denominator is increased to include the number of additional common shares that would have been outstanding
if the potential common shares had been issued and if the additional common shares were dilutive. There were no dilutive financial instruments
issued or outstanding for the years ended December 31, 2022 or 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_843_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zDq08xlPnko" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_zCbRunpHjsuj">Fair
Value of Financial Instruments</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants at the measurement date. The Fair Value Measurement Topic of the Financial Accounting Standards Board (&#8220;FASB&#8221;)
Accounting Standards Codification (&#8220;ASC&#8221;) establishes a three-tier fair value hierarchy which prioritizes the inputs used
in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets
or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted
prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active;
and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions,
such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts reported in the balance sheet of cash and cash equivalents, prepaids, accounts payable and accrued expenses approximate
fair value because of the immediate or short-term maturity of these financial instruments. The fair value of notes receivable approximates
their carrying value as the stated or discounted rates of the notes do reflect recent market conditions. The Company&#8217;s investments
are record at cost as the fair value of these investment in are not readily available. The fair value of notes payable approximates its
carrying value as the stated interest rate reflects recent market conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IMPACT
Biomedical, Inc. and Subsidiaries</b></span></p>

<p style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p id="xdx_841_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zdsWDnFzokXe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_864_zXeLEdoOSZU7">Cash
and cash equivalents</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid investments with a maturity of three months or less at the date of acquisition to be cash equivalents.
There were <span id="xdx_90A_eus-gaap--Cash_iI_do_c20221231_zo4fwXEFQlQ3" title="Cash"><span id="xdx_90F_eus-gaap--Cash_iI_do_c20211231_zcamax26Ny18" title="Cash">no</span></span> cash equivalents as of December 31, 2022, and 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_eus-gaap--InvestmentPolicyTextBlock_z58oA0m51di5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_zA1Hah58AIw">Investments</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investments
in equity securities with a readily determinable fair value, not accounted for under the equity method, are recorded at fair value with
unrealized gains and losses included in earnings. For equity securities without a readily determinable fair value, the investment is
recorded at cost, less any impairment, plus or minus adjustments related to observable transactions for the same or similar securities,
with unrealized gains and losses included in earnings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
equity method investments, the Company regularly reviews its investments to determine whether there is a decline in fair value below
book value. If there is a decline that is other-than-temporary, the investment is written down to fair value. See Note 7 for further
discussion on investments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--GoodwillAndIntangibleAssetsGoodwillPolicy_zMDnF0JgVyJh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_zxq5H1ahqL6a">Goodwill</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill
is the excess of cost of an acquired entity over the fair value of amounts assigned to assets acquired and liabilities assumed in a business
combination. Goodwill is subject to impairment testing at least annually and will be tested for impairment between annual tests, which
takes place during the fourth quarter, if an event occurs or circumstances change that would indicate the carrying amount may be impaired.
FASB ASC Topic 350 provides an entity with the option to first assess qualitative factors to determine whether the existence of events
or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying
amount. Some of the qualitative factors considered in applying this test include consideration of macroeconomic conditions, industry
and market conditions, cost factors affecting the business, and overall financial performance of the business. If, after completing the
assessment, it is determined that it is more likely than not that the fair value of a reporting unit is less than its carrying value,
the Company will proceed to a quantitative test. If qualitative factors are not deemed sufficient to conclude that the fair value of
the reporting unit more likely than not exceeds its carrying value, then a one-step approach is applied in making an evaluation. The
evaluation utilizes an income approach (discounted cash flow analysis). The computations require management to make significant estimates
and assumptions, including, among other things, selection of comparable publicly traded companies, the discount rate applied to future
earnings reflecting a weighted average cost of capital, and earnings growth assumptions. The Company believes the estimates and assumptions
used in our impairment assessments are reasonable and based on available market information, but variations in any of the assumptions
could result in materially different calculations of fair value and determinations of whether or not an impairment is indicated. A discounted
cash flow analysis requires management to make various assumptions about future sales, operating margins, capital expenditures, working
capital, and growth rates. Cash flow projections are derived from one year budgeted amounts plus an estimate of later period cash flows,
all of which are determined by management. Subsequent period cash flows are developed for each reporting unit using growth rates that
management believes are reasonably likely to occur. Impairment of goodwill is measured as the excess of the carrying amount of goodwill
over the fair values of recognized and unrecognized assets and liabilities of the reporting unit. <span id="xdx_90E_eus-gaap--GoodwillImpairmentLoss_dxL_c20220101__20221231_zdxHnSdr2Oqc" title="Impairment of goodwill::XDX::-"><span id="xdx_907_eus-gaap--GoodwillImpairmentLoss_dxL_c20210101__20211231_zfDF0blYLHAe" title="Impairment of goodwill::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0450"><span style="-sec-ix-hidden: xdx2ixbrl0452">No</span></span></span></span> impairment was recognized during
the years ended December 31, 2022 or 2021 (see Note 8).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zDznBH10mbZd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_zxv2HJgVHvih">Intangible
Assets</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated fair values of acquired intangibles are generally determined based upon future economic benefits such as earnings and cash
flows. Acquired identifiable intangible assets are recorded at fair value and are amortized over their estimated useful lives.
Acquired intangible assets with an indefinite life are not amortized but are reviewed for impairment at least annually as of
December 31<sup>st</sup>, or more frequently whenever events or changes in circumstances indicate that the carrying amounts of those
assets are below their estimated fair values. Impairment is tested under ASC 350 which provides an entity with the option to
first assess qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is
more likely than not that the fair value of a reporting unit is less than its carrying amount.  If, after completing the
assessment, it is determined that it is more likely than not that the fair value of a reporting unit is less than its carrying
value, the Company will proceed to a quantitative test. For the years ended December 31, 2022 and 2021, the Company utilized a
qualitative, as events and circumstances do not indicate that it is more likely than not (that is, a likelihood of more than 50%)
that an indefinite-lived intangible asset is impaired. Key factors considered while performing qualitative testing include industry
and market considerations, macroeconomic conditions, continued patent development of the technologies, as well as marketplace&#8217;s interest in the technologies. <span id="xdx_905_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_do_c20210101__20211231_zUAxRNfrKXb3">No </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">impairment
was recognized during the years ended December 31, 2022 or 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p id="xdx_845_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zowPvJgkr1v1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86A_zrUkcJMmMgP4">Recoverability of Long-Lived Assets</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
evaluate long-lived assets such as property, equipment and definite lived intangible assets, such as patents, for impairment whenever
events or circumstances indicate that the carrying value of the assets recognized in our financial statements may not be recoverable.
Factors that we consider include whether there has been a significant decrease in the market value of an asset, a significant change
in the way an asset is being utilized, or a significant change, delay or departure in our strategy for that asset, or a significant change
in the macroeconomic environment, such as the impact of the COVID-19 pandemic. Our assessment of the recoverability of long-lived assets
involves significant judgment and estimation. These assessments reflect our assumptions, which, we believe, are consistent with the assumptions
hypothetical marketplace participants use. Factors that we must estimate when performing recoverability and impairment tests include,
among others, forecasted revenue, margin costs and the economic life of the asset. If impairment is indicated, we determine if the total
estimated future cash flows on an undiscounted basis are less than the carrying amounts of the asset or assets. If so, an impairment
loss is measured and recognized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
impairment loss calculations require that we apply judgment in identifying asset groups, estimating future cash flows, determining asset
fair values, and estimating asset&#8217;s useful lives. The Company reviews identifiable amortizable intangible assets for impairment
whenever events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. Determination of recoverability
is based on the lowest level of identifiable estimated undiscounted cash flows resulting from use of the asset and its eventual disposition.
Measurement of any impairment loss is based on the excess of the carrying value of the asset over its fair value. Based on the uncertainty
of forecasts inherent with a new product, events such as the failure to generate forecasted revenue from new products could result in
a non-cash impairment in future periods. </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_eus-gaap--ResearchAndDevelopmentExpensePolicy_zUmodztQVwYh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_862_z12WkzOcodcd">Research
and Development</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed as incurred. Total research and development costs were $<span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231_zXrSS0mVKZme" title="Research and development cost">1,226,000</span> for the year ended December 31,
2022, and $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20211231_z2jj3EC2bXLh" title="Research and development cost">1,080,000</span> for year ended 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IMPACT
Biomedical, Inc. and Subsidiaries</b></span></p>

<p style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zUyTpbk6CX49" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zsvnCvULgxk3">Recent
Accounting Standards</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Financial Accounting Standards Board (FASB) issues various Accounting Standards Updates relating to the treatment and recording of certain
accounting transactions. There are several new accounting pronouncements issued by FASB which are not yet effective. Each of these pronouncements,
as applicable, has been or will be adopted by the Company. As of December 31, 2022, none of these pronouncements is expected to have
a material effect on the financial position, results of operations or cash flows of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84F_ecustom--ContinuingOperationsAndGoingConcernPolicyTextBlock_zABPPJrNc1Q6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_861_zeJYlmlxbFEd">Continuing
Operations and Going Concern</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to incurred operating losses as well as negative cash flows from operating and investing activities over the past two years, the accompanying
consolidated financial statements have been prepared assuming that the Company will continue as a going concern. This basis of accounting
contemplates the recovery of our assets and the satisfaction of liabilities in the normal course of business. These consolidated financial
statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary
should we be unable to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
continue as a going concern, the Company has entered into an updated revolving promissory note which extended the maturity through December
31, 2022, and DSS intends to continue to fund the operations of the Company through a year from the date these financial statements were
available to be issued. The Company&#8217;s management intends to take actions necessary to continue as a going concern. Management&#8217;s
plans concerning these matters include, among other things, monetization of its intellectual properties, and tightly controlling operating
costs. Based on this, the Company has concluded that substantial doubt of its ability to continue as a going concern has been alleviated.</span></p>

<p id="xdx_859_zzprbOpHUVP1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139839847775152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restatement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Accounting Changes and Error Corrections [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock', window );">Restatement</a></td>
<td class="text"><p id="xdx_800_eus-gaap--ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_zFhQQRCK94Lh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 3. <span id="xdx_821_zG7r9IK2XGIb">Restatement</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has determined that a restatement
of the December 31, 2022 consolidated financial statements is appropriate in order to correct certain errors in the reporting of interest
expense on the related party note. In previously issued consolidated financial statements, there was no interest expense recorded. Interest
expense has been corrected and restated from $<span id="xdx_902_eus-gaap--InterestExpense_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zmWGH6VcJAaa" title="Interest expense">0</span> to $<span id="xdx_90D_eus-gaap--InterestExpense_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zjOFTwccJ734" title="Interest expense">462,000</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139839845588256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_IMPB_DisclosurePrepaidExpensesAbstract', window );"><strong>Prepaid Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_IMPB_PrepaidExpensesTextBlock', window );">Prepaid Expenses</a></td>
<td class="text"><p id="xdx_800_ecustom--PrepaidExpensesTextBlock_zznagE0BnHkk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
3. <span id="xdx_82F_z0kqXkIuctMl">Prepaid Expenses</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
expenses for the three months ended March 31, 2023, includes prepaid inventory approximating $<span id="xdx_908_eus-gaap--OtherPrepaidExpenseCurrent_iI_c20230331__dei--LegalEntityAxis__custom--GRDGscienceLLCMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zlbBXjPsmgC8">140,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and research and development fees paid to GRDG
Sciences, LLC. (&#8220;GRDG&#8221;), a related party, approximating $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230331__dei--LegalEntityAxis__custom--GRDGscienceLLCMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zBORT0DWnBtc">43,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
Prepaid expenses at December 31, 2022 of $<span id="xdx_907_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_c20221231__dei--LegalEntityAxis__custom--GRDGscienceLLCMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zlZO6VO6Oms">104,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">including research and development costs to GRDG
approximating $<span id="xdx_900_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20220331__dei--LegalEntityAxis__custom--GRDGscienceLLCMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zSEFo6gVrIpk">43,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_801_ecustom--PrepaidExpensesTextBlock_zdfXN0Hrprt3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
4. <span id="xdx_828_zOq53fRflC37">Prepaid Expenses</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
expenses for the year ended December 31, 2022, includes prepared inventory approximating $<span id="xdx_901_eus-gaap--OtherPrepaidExpenseCurrent_iI_c20221231__dei--LegalEntityAxis__custom--GRDGscienceLLCMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zp6baYG5efAg" title="Prepaid expenses includes prepaid inventory">60,000</span> and research and development
fees paid to GRDG Sciences, LLC. (&#8220;GRDG&#8221;), a related party, approximating $<span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--GRDGscienceLLCMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zYt5tYHgV7gc" title="Research and development">43,000</span>. Prepaid expenses at December 31, 2021 consists primarily of research and development costs to GRDG approximating
$<span id="xdx_902_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_c20211231__dei--LegalEntityAxis__custom--GRDGscienceLLCMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zL4Qa03M4wQ7" title="Prepaid expenses">43,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMPB_DisclosurePrepaidExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">IMPB_DisclosurePrepaidExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>IMPB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMPB_PrepaidExpensesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Expenses [Text Block].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">IMPB_PrepaidExpensesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>IMPB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139839840871920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Receivable<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock', window );">Notes Receivable</a></td>
<td class="text"><p id="xdx_806_eus-gaap--LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_zgenoMqUC08d" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
4. <span id="xdx_82E_zkgRqnZcy6wk">Notes Receivable</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 21, 2021, Impact BioMedical, Inc. entered into a promissory note (&#8220;Promissory Note 1&#8221;) with an individual. The Company
loaned the principal sum of $<span id="xdx_901_eus-gaap--NotesReceivableNet_iI_c20210221_zi2s8gcmDHjk" title="Note receivable principal">206,000</span>, with interest at a rate of <span id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20210221_zybpWoXqiFRa" title="Debt stated percentage">6.5</span>%, and maturity date of <span id="xdx_903_eus-gaap--DebtInstrumentMaturityDate_dd_c20210220__20210221_zL7CLUdbngic" title="Debt maturity date">August 19, 2022</span>. Monthly payments are due
on the twenty-first day of each month and continuing each month thereafter until August 19, 2022, at which time all accrued interest
and the entire remaining principal shall be due and payable in full. In August 2022, this note was amended to extend the maturity date
to <span id="xdx_90A_eus-gaap--DebtInstrumentMaturityDate_c20220822__20220822_zhwVnrh63cK9" title="Maturity date">August 19, 2023</span>. This note is secured by certain real property situated in Collier County, Florida. The outstanding principal and
interest approximated $<span id="xdx_904_eus-gaap--DebtInstrumentPeriodicPayment_c20230101__20230331_zZKwpYbDLMbe" title="Debt principal and interest">205,000</span> and $<span id="xdx_903_eus-gaap--DebtInstrumentPeriodicPayment_c20220101__20221231_zzNbTxwviz6a" title="Debt principal and interest">206,000</span> as of March 31, 2023 and December 31, 2022, respectively. Of the $<span id="xdx_90A_eus-gaap--NotesReceivableNet_iI_c20230331_zZXRt6Kecld3" title="Note receivable principal">205,000</span> outstanding at
March 31, 2023, $<span id="xdx_909_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20221231_zEjWmG4cOnMl" title="Notes receivable current">205,000</span> is classified in current notes receivable on the accompanying consolidated balance sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_803_eus-gaap--LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_z25wQoIJP1Mg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
5. <span id="xdx_820_z4SLpLRbLPj">Notes Receivable</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 21, 2021, Impact BioMedical, Inc. entered into a promissory note (&#8220;Promissory Note 1&#8221;) with an individual. The Company
loaned the principal sum of $<span id="xdx_908_eus-gaap--NotesReceivableNet_iI_c20210221__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember_z0VOMzV7pb49" title="Note receivable principal">206,000</span>, with interest at a rate of <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210221__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember_zXLD8rT5Hz57" title="Debt stated percentage">6.5</span>%, and maturity date of <span id="xdx_905_eus-gaap--DebtInstrumentMaturityDate_dd_c20210220__20210221__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember_zw4TD56Of3ca" title="Debt maturity date">August 19, 2022</span>. Monthly payments are due
on the twenty-first day of each month and continuing each month thereafter until August 19, 2022, at which time all accrued interest
and the entire remaining principal shall be due and payable in full. In August 2022, this note was amended to extend the maturity date
to <span id="xdx_905_eus-gaap--DebtInstrumentMaturityDate_dd_c20220822__20220822__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember_zCnMpw3rHbd9" title="Maturity date">August 19, 2023</span>. This note is secured by certain real property situated in Collier County, Florida. The outstanding principal and
interest approximated $<span id="xdx_90E_eus-gaap--DebtInstrumentPeriodicPayment_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember_zYMGdLsmiYhe" title="Debt principal and interest">206,000</span> and $<span id="xdx_906_eus-gaap--DebtInstrumentPeriodicPayment_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember_z5jFmGYFD047" title="Debt principal and interest">197,000</span> as of December 31, 2022 and December 31, 2021, respectively. Of the $<span id="xdx_905_eus-gaap--NotesReceivableNet_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember_z63QUl8VaF3g" title="Note receivable principal">206,000</span> outstanding
at December 31, 2022, $<span id="xdx_90C_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember_zkwGmNf4ujg" title="Notes receivable current">16,000</span> is classified in current notes receivable on the accompanying consolidated balance sheets, and the remaining
$<span id="xdx_90E_eus-gaap--NotesAndLoansReceivableNetNoncurrent_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember_zZ7Rd1CYaiQ6" title="Notes receivable">190,000</span> is classified as note receivable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 14, 2021, DSS PureAir, Inc. (&#8220;DSS PureAir&#8221;), a wholly owned subsidiary of the Company, entered into a convertible promissory
note (&#8220;Promissory Note 2&#8221;) with a limited liability company registered in the state of Texas (&#8220;Borrower&#8221;). The
Promissory Note 2 has an aggregate principal balance up to $<span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_c20210514__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteTwoMember_zsvvAMeGZufd" title="Debt face amount">5,000,000</span>, to be funded at the request of the borrower. Promissory Note 2,
which incurs interest at a rate of <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210514__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteTwoMember_zVMduuVTOT7" title="Debt stated percentage">6.5</span>% due quarterly, has a maturity date of <span id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_dd_c20210513__20210514__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteTwoMember_zRpy7hm2QIGa" title="Debt maturity date">May 14, 2023</span>. Promissory Note 2 contains an options conversion
clause that allows the Company to convert all, or a portion of all, into newly issued member units of the borrower with the maximum principal
amount equal to <span id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210514__srt--RangeAxis__srt--MaximumMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteTwoMember_zEqPWrYfoSxi" title="Debt stated percentage">18</span>% of the total equity position at conversion. On June 1, 2022, <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220601__srt--RangeAxis__srt--MaximumMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteTwoMember_zWWu3a2l4Q9c" title="Debt stated percentage">100</span>% of the Company&#8217;s interest in DSS PureAir
was assigned to DSS BioHealth Holdings, Inc., a related party, and wholly owned subsidiary of DSS BioHealth Security, Inc. Included in
this transaction was the outstanding principal and interest of Promissory Note 2 along with the related Note payable, related party.
The outstanding principal and interest on December 31, 2022, and December 31, 2021 is $<span id="xdx_90F_eus-gaap--NotesAndLoansReceivableNetNoncurrent_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteTwoMember_z8CtEbgc2Pi" title="Notes and loans receivable">0</span> and $<span id="xdx_901_eus-gaap--NotesAndLoansReceivableNetNoncurrent_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteTwoMember_zsyOmEy1a6mf" title="Notes and loans receivable">5,081,000</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//310-10/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139839840746544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTextBlock', window );">Investments</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--InvestmentTextBlock_zJHqZsL3mxo2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
5. <span id="xdx_82E_zBdG7zwNrMSd">Investments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 19, 2020, Impact BioMedical entered into a subscription agreement (the &#8220;Subscription Agreement&#8221;) with BioMed Technologies
Asia Pacific Holdings Limited (&#8220;BioMed&#8221;), a limited liability company incorporated in the British Virgin Islands, pursuant
to which the Company agreed to purchase <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_c20201218__20201219__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AsiaPacificHoldingsLimitedMember__us-gaap--TypeOfArrangementAxis__us-gaap--SubscriptionArrangementMember_zgIszdthOTFe" title="Ordinary shares to purchase">525</span> ordinary shares or <span id="xdx_90A_ecustom--OrdinarySharesPercentage_dp_uPure_c20201218__20201219__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AsiaPacificHoldingsLimitedMember__us-gaap--TypeOfArrangementAxis__us-gaap--SubscriptionArrangementMember_zWZOepEBYtl" title="Ordinary shares percentage">4.99</span>% of BioMed at a purchase price of approximately $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValuePurchaseOfAssets_c20201218__20201219__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AsiaPacificHoldingsLimitedMember__us-gaap--TypeOfArrangementAxis__us-gaap--SubscriptionArrangementMember_zj4eH54KnRy2" title="Purchase price of shares">632,000</span>. The Subscription
Agreement provides, among other things, the Company the right to appoint a new director to the board of BioMed. With respect to an issuance
of shares to a third party by BioMed, the Company will have the right of first refusal to purchase such shares, as well as customary
tag-along rights. In connection with the Subscription Agreement, the Company entered into an exclusive distribution agreement (the &#8220;Distribution
Agreement&#8221;) with BioMed, to directly market, advertise, promote, distribute, and sell certain BioMed products, which focus on manufacturing
natural probiotics, to resellers. This investment is valued at cost as it does not have a readily determined fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioMed
focuses on manufacturing natural probiotics, pursuant to which the Company will directly market, advertise, promote, distribute and sell
certain BioMed products to resellers. The products to be distributed by the Company include BioMed&#8217;s PGut Premium Probiotics<sup>&#174;</sup>,
PGut Allergy Probiotics<sup>&#174;</sup>, PGut SupremeSlim Probiotics<sup>&#174;</sup>, PGut Kids Probiotics<sup>&#174;</sup>, and PGut
Baby Probiotics<sup>&#174;</sup>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
January 1, 2021, the Company entered into a securities purchase agreement (&#8220;SPA&#8221;) with Nano9, LLC. (&#8220;Nano9&#8221;),
a Utah limited partnership. For the consideration of $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210101__20210101__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NanoNineLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z7yHKudmDdw7" title="Number of shares issued, value">150,000</span> the Company obtained <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20210101__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NanoNineLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zcioHhGmp7yl" title="Number of shares issued, shares">1,000</span> membership units, or approximately <span id="xdx_900_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20210101__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NanoNineLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zXVnerZSExBj" title="Equitable ownership percentage">10</span>% equitable
ownership of Nano9. Nano9 is a scientifically driven company, specializing in the development and production of leading nano-sized health
&amp; wellness products utilizing their proprietary nano technology. As of Mach 31, 2023 and March 31, 2022, the fair value of the Company&#8217;s
investment in Nano9 is not readily available, and therefore is recorded at cost of $<span id="xdx_90F_eus-gaap--InvestmentOwnedAtFairValue_iI_c20230331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NanoNineLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zzAPgEMNCnS6" title="Investment owned at fair value"><span id="xdx_90C_eus-gaap--InvestmentOwnedAtFairValue_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NanoNineLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zAXFQBz9QGvj" title="Investment owned at fair value">150,000</span></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IMPACT
Biomedical, Inc. and Subsidiaries</b></span></p>

<p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 15, 2021, the Company, through one of its subsidiaries, entered into a Stock Purchase Agreement (the &#8220;Vivacitas Agreement
#1&#8221;) with Vivacitas Oncology Inc. (&#8220;Vivacitas&#8221;), to purchase <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210314__20210315__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VivacitasOncologyIncMember_zPIyUHAVvWy7" title="Number of shares issued">500,000</span> shares of its common stock at the per share price
of $<span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20210315__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VivacitasOncologyIncMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zHtIZ4p96zMl" title="Common stock par value">1.00</span>, with an option to purchase <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20210314__20210315__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VivacitasOncologyIncMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zyihgpA9OXYf" title="Options to purchase additional shares">1,500,000</span> additional shares at the per share price of $<span id="xdx_907_eus-gaap--SharePrice_iI_c20210315__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VivacitasOncologyIncMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zEhLwmJ8fIZ3" title="Share price">1.00</span>. <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20210314__20210315__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VivacitasOncologyIncMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zfpqTSJdIJ5d" title="Option termination, description">This option will terminate upon one
of the following events: (i) Vivacitas&#8217; board of directors cancels this option because it is no longer in the best interest of
the Company; (ii) December 31, 2022; or (iii) the date on which Vivacitas receives more than $1.00 per share of the Company&#8217;s common
stock in a private placement with gross proceeds of $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20210314__20210315__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VivacitasOncologyIncMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_za7D9cHsg4Se" title="Proceeds from private placement">500,000</span>. Under the terms of the Vivacitas Agreement #1, the Company will be allocated
two seats on the board of Vivacitas</span>. On March 18, 2021, the Company entered into an agreement with Alset EHome International, Inc. (&#8220;Seller&#8221;)
to purchase from the Seller&#8217;s its wholly owned subsidiary Impact Oncology PTE Ltd. (&#8220;IOPL&#8221;) for a purchase price $<span id="xdx_905_eus-gaap--BusinessCombinationConsiderationTransferred1_c20210317__20210318__us-gaap--BusinessAcquisitionAxis__custom--ImpactOncologyPTELtdMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zJhtKUYE4jMi" title="Purchase price">2,480,000</span>.
The acquisition of IOPL has been treated as an asset acquisition as IOPL does not meet the definition of a business as defined in Topic
805. IOPL owns <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20210317__20210318__us-gaap--BusinessAcquisitionAxis__custom--ImpactOncologyPTELtdMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zUpl6Ci9Hrgk" title="Number of common stock owned">2,480,000</span> shares of common stock of Vivacitas along with the option to purchase an additional <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20210317__20210318__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zn6gyNKQhbC6" title="Options to purchase common stock">250,000</span> shares of common
stock. The Sellers largest shareholder is Mr. Chan Heng Fai Ambrose, the Chairman of the Company&#8217;s board of directors and its largest
shareholder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 1, 2021, the Company entered into an additional stock purchase agreement with Vivacitas (&#8220;Vivacitas Agreement #2&#8221;),
whereas Vivacities wished to employ the service of the Chief Business Officer of Impact Biomedical, and in return for the services of
this individual, Vivacitas shall issue to the Company, the aggregate purchase price for the Class A Common Shares of Vivacitas at the
value of $<span id="xdx_901_eus-gaap--SharePrice_iI_c20210401__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VivacitasOncologyIncMember_zheuHmk0bhm4" title="Share price">1.00</span> per share shall be $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20210401__20220331__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VivacitasOncologyIncMember_zXTsGXfHj669" title="Proceeds from issuance of common stock">120,000</span> to be paid in twelve (12) equal monthly installments for the period between April 1, 2021
and March 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 22, 2021, the Company exercised <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210721__20210722__us-gaap--TypeOfArrangementAxis__custom--VivacitasAgreementMember_zbZcBFEWsNve" title="Stock option exercised, shares">1,000,000</span> of the available options under the Vivacitas Agreement #1 for $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_c20210721__20210722__us-gaap--TypeOfArrangementAxis__custom--VivacitasAgreementMember_zAvqYOHaSMr6" title="Stock option exercised, value">1,000,000</span>. This, along
with the shares received as part Vivacitas Agreement #2 increased the Company&#8217;s equity position in Vivacitas to approximately 16%
as of December 31, 2022. As of December 31, 2021, the fair value of the Company&#8217;s investment in Vivacitas is not readily available,
and therefore is recorded at cost in the amount of $<span id="xdx_909_eus-gaap--InvestmentOwnedAtFairValue_iI_c20211231__us-gaap--TypeOfArrangementAxis__custom--VivacitasAgreementMember_zvYB0cscwmz8" title="Investment owned at fair value">4,035,000</span>. As of December 31, 2022, the Company determined to impair <span id="xdx_90C_eus-gaap--InvestmentOwnedPercentOfNetAssets_iI_pid_dp_c20221231__us-gaap--TypeOfArrangementAxis__custom--VivacitasAgreementMember_zq9VHFbjTEVa" title="Investment cost, percent">100</span>% of its investment
in Vivacitas, in the amount of $<span id="xdx_905_eus-gaap--InvestmentOwnedAtCost_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--VivacitasAgreementMember_zkmt2C76xxRf" title="Investment cost">4,100,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_807_eus-gaap--InvestmentTextBlock_z85LC97Ofige" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
6. <span id="xdx_82A_znZzfzwUnAOa">Investments</span></b>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 19, 2020, Impact BioMedical entered into a subscription agreement (the &#8220;Subscription Agreement&#8221;) with BioMed Technologies
Asia Pacific Holdings Limited (&#8220;BioMed&#8221;), a limited liability company incorporated in the British Virgin Islands, pursuant
to which the Company agreed to purchase <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_c20201218__20201219__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AsiaPacificHoldingsLimitedMember__us-gaap--TypeOfArrangementAxis__us-gaap--SubscriptionArrangementMember_zdU5AwSuZvV4" title="Ordinary shares to purchase">525</span> ordinary shares or <span id="xdx_90A_ecustom--OrdinarySharesPercentage_dp_uPure_c20201218__20201219__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AsiaPacificHoldingsLimitedMember__us-gaap--TypeOfArrangementAxis__us-gaap--SubscriptionArrangementMember_zzLXG5NijGJ4" title="Ordinary shares percentage">4.99</span>% of BioMed at a purchase price of approximately $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValuePurchaseOfAssets_c20201218__20201219__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AsiaPacificHoldingsLimitedMember__us-gaap--TypeOfArrangementAxis__us-gaap--SubscriptionArrangementMember_zq6IuAmFILjj" title="Purchase price of shares">632,000</span>. The Subscription
Agreement provides, among other things, the Company the right to appoint a new director to the board of BioMed. With respect to an issuance
of shares to a third party by BioMed, the Company will have the right of first refusal to purchase such shares, as well as customary
tag-along rights. In connection with the Subscription Agreement, the Company entered into an exclusive distribution agreement (the &#8220;Distribution
Agreement&#8221;) with BioMed, to directly market, advertise, promote, distribute, and sell certain BioMed products, which focus on manufacturing
natural probiotics, to resellers. This investment is valued at cost as it does not have a readily determined fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioMed
focuses on manufacturing natural probiotics, pursuant to which the Company will directly market, advertise, promote, distribute and sell
certain BioMed products to resellers. The products to be distributed by the Company include BioMed&#8217;s PGut Premium Probiotics<sup>&#174;</sup>,
PGut Allergy Probiotics<sup>&#174;</sup>, PGut SupremeSlim Probiotics<sup>&#174;</sup>, PGut Kids Probiotics<sup>&#174;</sup>, and PGut
Baby Probiotics<sup>&#174;</sup>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
January 1, 2021, the Company entered into a securities purchase agreement (&#8220;SPA&#8221;) with Nano9, LLC. (&#8220;Nano9&#8221;),
a Utah limited partnership. For the consideration of $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210101__20210101__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NanoNineLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zuAHjH07hmw" title="Number of shares issued, value">150,000</span> the Company obtained <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20210101__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NanoNineLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zbhIqxSc7iai" title="Number of shares issued, shares">1,000</span> membership units, or approximately <span id="xdx_900_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20210101__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NanoNineLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z5EPAckCKBwa" title="Equitable ownership percentage">10</span>% equitable
ownership of Nano9. Nano9 is a scientifically driven company, specializing in the development and production of leading nano-sized health
&amp; wellness products utilizing their proprietary nano technology. As of December 31, 2022 and December 31, 2021, the fair value
of the Company&#8217;s investment in Nano9 is not readily available, and therefore is recorded at cost of $<span id="xdx_905_eus-gaap--InvestmentOwnedAtFairValue_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NanoNineLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z00oCQqXFQc2" title="Investment owned at fair value"><span id="xdx_90E_eus-gaap--InvestmentOwnedAtFairValue_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NanoNineLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zhtpvgEcyjya" title="Investment owned at fair value">150,000</span></span>.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IMPACT
Biomedical, Inc. and Subsidiaries</b></span></p>

<p style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 15, 2021, the Company, through one of its subsidiaries, entered into a Stock Purchase Agreement (the &#8220;Vivacitas Agreement
#1&#8221;) with Vivacitas Oncology Inc. (&#8220;Vivacitas&#8221;), to purchase <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210314__20210315__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VivacitasOncologyIncMember_zoYFtGNMYMy9" title="Number of shares issued">500,000</span> shares of its common stock at the per share price
of $<span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20210315__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VivacitasOncologyIncMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zimS4EPEhqR3" title="Common stock par value">1.00</span>, with an option to purchase <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20210314__20210315__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VivacitasOncologyIncMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_z9fAxVc6Rhy9" title="Options to purchase additional shares">1,500,000</span> additional shares at the per share price of $<span id="xdx_907_eus-gaap--SharePrice_iI_c20210315__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VivacitasOncologyIncMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zGGS0KsTwUqc" title="Share price">1.00</span>. <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20210314__20210315__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VivacitasOncologyIncMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_z74PP9EIELSb" title="Option termination, description">This option will terminate upon one
of the following events: (i) Vivacitas&#8217; board of directors cancels this option because it is no longer in the best interest of
the Company; (ii) December 31, 2022; or (iii) the date on which Vivacitas receives more than $1.00 per share of the Company&#8217;s common
stock in a private placement with gross proceeds of $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20210314__20210315__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VivacitasOncologyIncMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zIcLfiErOfZd" title="Proceeds from private placement">500,000</span>. Under the terms of the Vivacitas Agreement #1, the Company will be allocated
two seats on the board of Vivacitas</span>. On March 18, 2021, the Company entered into an agreement with Alset EHome International, Inc. (&#8220;Seller&#8221;)
to purchase from the Seller&#8217;s its wholly owned subsidiary Impact Oncology PTE Ltd. (&#8220;IOPL&#8221;) for a purchase price $<span id="xdx_905_eus-gaap--BusinessCombinationConsiderationTransferred1_c20210317__20210318__us-gaap--BusinessAcquisitionAxis__custom--ImpactOncologyPTELtdMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zqJsRxIgFptd" title="Purchase price">2,480,000</span>.
The acquisition of IOPL has been treated as an asset acquisition as IOPL does not meet the definition of a business as defined in Topic
805. IOPL owns <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20210317__20210318__us-gaap--BusinessAcquisitionAxis__custom--ImpactOncologyPTELtdMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_z8oRAn06Lj2h" title="Number of common stock owned">2,480,000</span> shares of common stock of Vivacitas along with the option to purchase an additional <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20210317__20210318__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zS4qqj45lBVb" title="Options to purchase common stock">250,000</span> shares of common
stock. The Sellers largest shareholder is Mr. Chan Heng Fai Ambrose, the Chairman of the Company&#8217;s board of directors and its largest
shareholder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 1, 2021, the Company entered into an additional stock purchase agreement with Vivacitas (&#8220;Vivacitas Agreement #2&#8221;),
whereas Vivacities wished to employ the service of the Chief Business Officer of Impact Biomedical, and in return for the services of
this individual, Vivacitas shall issue to the Company, the aggregate purchase price for the Class A Common Shares of Vivacitas at the
value of $<span id="xdx_901_eus-gaap--SharePrice_iI_c20210401__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VivacitasOncologyIncMember_zrAimDrTV1Rk" title="Share price">1.00</span> per share shall be $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20210401__20220331__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VivacitasOncologyIncMember_zSn8PkdKwse5" title="Proceeds from issuance of common stock">120,000</span> to be paid in twelve (12) equal monthly installments for the period between April 1, 2021
and March 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 22, 2021, the Company exercised <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210721__20210722__us-gaap--TypeOfArrangementAxis__custom--VivacitasAgreementMember_z3YlT07998yd" title="Stock option exercised, shares">1,000,000</span> of the available options under the Vivacitas Agreement #1 for $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_c20210721__20210722__us-gaap--TypeOfArrangementAxis__custom--VivacitasAgreementMember_zNAMq5OevIp2" title="Stock option exercised, value">1,000,000</span>. This, along
with the shares received as part Vivacitas Agreement #2 increased the Company&#8217;s equity position in Vivacitas to approximately 16%
as of December 31, 2022. As of December 31, 2021, the fair value of the Company&#8217;s investment in Vivacitas is not readily available,
and therefore is recorded at cost in the amount of $<span id="xdx_909_eus-gaap--InvestmentOwnedAtFairValue_iI_c20211231__us-gaap--TypeOfArrangementAxis__custom--VivacitasAgreementMember_zCDh09GDWFBc" title="Investment owned at fair value">4,035,000</span>. For the fiscal year December 31, 2022, the company was unable to obtain
viable documentation in regards to Vivacitas&#8217;s ability to continue as a business and therefore as of December 31, 2022, the Company
determined to impair <span id="xdx_90C_eus-gaap--InvestmentOwnedPercentOfNetAssets_iI_pid_dp_c20221231__us-gaap--TypeOfArrangementAxis__custom--VivacitasAgreementMember_zKeNZ1wPUwq1" title="Investment cost, percent">100</span>% of its investment in Vivacitas, in the amount of $<span id="xdx_905_eus-gaap--InvestmentOwnedAtCost_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--VivacitasAgreementMember_zNncJJBhMJHc" title="Investment cost">4,100,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 321<br> -Publisher FASB<br> -URI https://asc.fasb.org//321/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 325<br> -Publisher FASB<br> -URI https://asc.fasb.org//325/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139839847817248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY PLANT AND EQUIPMENT and INVESTMENT IN REAL ESTATE, NET<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock', window );">PROPERTY PLANT AND EQUIPMENT and INVESTMENT IN REAL ESTATE, NET</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock_zoATX1p4YtJb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
6. <span><span id="xdx_827_zb0LjbGchzfg">PROPERTY PLANT AND EQUIPMENT and INVESTMENT IN REAL ESTATE, NET</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_894_eus-gaap--PropertyPlantAndEquipmentTextBlock_zKmGCKB8jhLi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property,
plant and equipment consisted of the following as of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_zlqErWIC7q1i" style="display: none">Schedule
of Property Plant and Equipment</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">Estimated</td><td>&#160;</td>
    <td colspan="2" id="xdx_49D_20230331_zqqKxvPswvVe" style="text-align: center"><b>March 31,</b></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49B_20221231_zkPG2FKFlzKc" style="text-align: center"><b>December 31,</b></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Useful Life</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zqxZN27jvhsd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 54%; text-align: left">Machinery and equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 12%; text-align: right"><span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MinimumMember_ziKBKyunP5Wl">5</span>-<span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MaximumMember_zBPBwmp0uYL3">10</span> years</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">30,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">25,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_zySoihHYZMac" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Construction in progress</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: right; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">251,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">251,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzm9U_zrVVWlbBESsb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total Cost</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">281,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">276,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzm9U_zAT672QBpB97" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Property, plant and equipment, gross</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">281,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">276,000</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iI_msPPAENzm9U_zuHGi7xUSjyj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: right; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1345">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzm9U_zPzbbi0iICH2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Property, plant and equipment, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: right; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">279,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">276,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AC_zk2xPcbLPHYe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
expense for the three months ended March 31, 2023 and 2022 was $<span id="xdx_909_eus-gaap--Depreciation_c20230101__20230331_zZ3Zs3o0Yhw7" title="Depreciation expense">2,000</span> and $<span id="xdx_90C_eus-gaap--Depreciation_c20220101__20220331_zzaWsqDjnn25" title="Depreciation expense">0</span> respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_806_eus-gaap--PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock_z6I2wZvDeftg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
7. <span id="xdx_82F_zCX9GcFJoXfj">PROPERTY PLANT AND EQUIPMENT and INVESTMENT IN REAL ESTATE, NET</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--PropertyPlantAndEquipmentTextBlock_zeK0nWv9lJPb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property,
plant and equipment consisted of the following as of December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;<span id="xdx_8BF_z2t3OCgEixh5" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of Property Plant and Equipment&#160;</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_49A_20221231_zrXoMxm3v5O5" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_49E_20211231_zk829oJPVnK5" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Estimated</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Useful Life</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zmWwyyscexYl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 42%; text-align: left">Machinery and equipment</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MinimumMember_zcjv5qkHdFGl" title="Estimated Useful Life">5</span>-<span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MaximumMember_z1s4xoixrAK1" title="Estimated Useful Life">10</span> years</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">25,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0572">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_zQ6OaJkGOZVg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Construction in progress</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">251,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0579">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzm9U_zBEEe2hg8FS6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Total Cost</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">276,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0582">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzm9U_zjxoGnO8mgk3" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Property, plant and equipment, gross</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">276,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0585">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iI_msPPAENzm9U_zvzGcF4BUl5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Less accumulated depreciation</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0587">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0588">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzm9U_zAXgLfCmKW82" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Property, plant and equipment, net</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">276,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0591">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_znc96iB43Mwi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
expense for the years ended December 31, 2022 and 2021 was $<span id="xdx_907_eus-gaap--Depreciation_dxL_c20220101__20221231_zpBMtDd7Vjq8" title="Depreciation expense::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0593">-</span></span> and $<span id="xdx_907_eus-gaap--Depreciation_dxL_c20210101__20211231_zrFWLUFxm5pa" title="Depreciation expense::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0595">-</span></span> respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for intangible assets and long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139839840694384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillDisclosureTextBlock', window );">Goodwill</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--GoodwillDisclosureTextBlock_z84PkQfzbblh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
7. <span id="xdx_829_zHOdb8nvWfZ9">Goodwill</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_89D_eus-gaap--ScheduleOfGoodwillTextBlock_z8SUaUaDgTli" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Goodwill
balances and activity for the three months ended March 31, 2023 and year ended December 31, 2022 consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span style="display: none"><span id="xdx_8B3_zYQvG6r2jJ9c">Schedule
of Goodwill</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%">Balance at December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--Goodwill_iS_c20230101__20230331_zVuouwoCAx3" style="width: 18%; text-align: right" title="Balance at December 31, 2022">25,093,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Goodwill adjustment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--GoodwillImpairmentLoss_c20230101__20230331_zVMey9wbMgll" style="border-bottom: Black 1.5pt solid; text-align: right" title="Goodwill adjustment"><span style="-sec-ix-hidden: xdx2ixbrl1360">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance at March 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--Goodwill_iE_c20230101__20230331_zffStzrknGr5" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance at March 31, 2023">25,093,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AF_zVOXtbklTx6b" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2022, management performed annual goodwill impairment testing. No goodwill impairment was identified as a result of these tests. As of
June 1, 2022 a quantitative analysis was prepared utilizing the Market Approach and Income Approach valuing the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_802_eus-gaap--GoodwillDisclosureTextBlock_zrV4G5cfoMVi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
8. <span id="xdx_825_zoOzzVnlFws3">Goodwill</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_eus-gaap--ScheduleOfGoodwillTextBlock_zpmRTT97BXn8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Goodwill
balances and activity for the year ended December 31, 2022 and year ended December 31, 2021 consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B0_zxYACxWrYIO8" style="display: none">Schedule of Goodwill</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 80%">Balance at December 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--Goodwill_iS_c20220101__20221231_zxPgTUEzpXmk" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Balance at December 31, 2022">25,093,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Goodwill adjustment</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--GoodwillImpairmentLoss_c20220101__20221231_zNm1t3Tac80c" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Goodwill adjustment"><span style="-sec-ix-hidden: xdx2ixbrl0603">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance at December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_989_eus-gaap--Goodwill_iE_c20220101__20221231_zUhDwIwxxPml" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance at March 31, 2023">25,093,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_zEXCQ6xJ0cJ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During 2022 and 2021, management performed annual
goodwill impairment testing. No goodwill impairment was identified as a result of these tests. As of June 1, 2022 a quantitative
analysis was prepared utilizing the Market Approach and Income Approach valuing the Company. <span id="xdx_90A_ecustom--NoncashOrPartNoncashAcquisitionValueOfAssetAcquiredDescription_c20230101__20230331_z1z7YmGJRRth" title="Acquisition value of asset acquired, description">The guideline public company Market
Approach produced a mean business enterprise value indication using estimated 2025 results of $69.24 million. The Income Approach was
based upon the use of a discounted pro forma cash flow model and produced a business enterprise value indication of $56.54 million. A
weighting of 20% to the weighted value indicated was applied under the Market Approach, a weighting of 10% to the prior transaction value
and a weighting of 70% to the value indicated under the Income Approach. A lower weighting was applied to the Market Approach due to
the fact of using forecasted earnings of the Company. Based upon the above weightings, an initial value of $57.26 million for Impact
was calculated. Adding cash and cash equivalents of $<span id="xdx_901_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20220601_ziJRXcD9RlH1" title="Cash">33,000</span> to the initial business enterprise value produced a concluded business enterprise
value of $57.29 million (rounded) for Impact.</span> Subtracting interest-bearing debt of $<span id="xdx_901_eus-gaap--LongTermDebtFairValue_iI_pn4n6_c20220601_zDoY0a4OFtfe" title="Long term debt fair value">13.15</span> million, results in a Fair Value for the common
equity of Impact of $<span id="xdx_908_eus-gaap--EquityFairValueAdjustment_pn4n6_c20220530__20220601_zYU3NrHfGN23" title="Equity fair value">44.14</span> million. As of June 1, 2022, the indicated equity value exceeded the carrying amount by approximately $<span id="xdx_90E_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20220601_zj30yQs3bAs" title="Debt carrying amount">4.9</span>
million or <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220601_zxVAADQ0Wyjb" title="Debt interest rate">12.5</span>%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During 2021, we used qualitative factors to determine
whether it was more likely than not (likelihood of more than 50%) that the fair value of a reporting unit exceeded its carrying amount.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350-20/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139839949007600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--IntangibleAssetsDisclosureTextBlock_zMSHpM4pv9I" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
8. <span id="xdx_824_zGUS3VAU8E0l">Intangible Assets</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
definite-lived intangible assets, to be amortized over 20 years, balances, and activity for the <span style="background-color: white">three
months</span> ended March 31, 2023, year ended December 31, 2022 consisted of the following:</span></p>

<p id="xdx_894_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zGi1WtUkN6Li" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zwb1AaV397ea" style="display: none">Schedule
of Intangible Assets</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">03/31/2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">12/31/2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Gross Carrying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amount</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accumulated</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amortization</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net Carrying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amount</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Gross Carrying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amount</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accumulated</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amortization</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net Carrying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amount</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Definitive-lived:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; text-align: left; padding-bottom: 1.5pt">Developed technology</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20230331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zvIVcgBkvYKl" style="border-bottom: Black 1.5pt solid; width: 6%; text-align: right" title="Gross Carrying Amount">22,258,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20230331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zssAAxGCti9h" style="border-bottom: Black 1.5pt solid; width: 6%; text-align: right" title="Accumulated Amortization">(2,502,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20230331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zHjJx9BowYW5" style="border-bottom: Black 1.5pt solid; width: 6%; text-align: right" title="Net Carrying Amount">19,756,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zWXgbalgJz37" style="border-bottom: Black 1.5pt solid; width: 6%; text-align: right" title="Gross Carrying Amount">22,258,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_z0ahlEuoAWA" style="border-bottom: Black 1.5pt solid; width: 6%; text-align: right" title="Accumulated Amortization">(2,226,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zpwIrJiajne4" style="border-bottom: Black 1.5pt solid; width: 6%; text-align: right" title="Net Carrying Amount">20,033,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20230331_zJJvBS6Ctedk" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Carrying Amount">22,258,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20230331_z8G18z2Gh0Wf" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated Amortization">(2,502,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20230331_zZGqbkVkLHKe" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Carrying Amount">19,756,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20221231_zYxx5eW0ZsLl" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Carrying Amount">22,258,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231_zabLixtyvSB7" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated Amortization">(2,226,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20221231_zX4zinQ5kTUl" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Carrying Amount">20,033,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AC_zuyVZX6z4QU5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Amounts
amortized for the three months ended March 31, 2023 and 2022 was approximately $<span id="xdx_908_eus-gaap--DepreciationAndAmortization_c20230101__20230331_zQWq82HMhrMe" title="Amortization">280,000</span> and $<span id="xdx_907_eus-gaap--DepreciationAndAmortization_c20220101__20220331_zgdMmAcg0Lqj" title="Amortization">278,000</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_898_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zJt835MlvhDc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table represents future amortization of developed technologies for the years ending December 31:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 11pt"><span id="xdx_8B1_zgtrZ9zobbee">Schedule
of Future Amortization of Developed Technologies</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49F_20230331_zYwsWZqnCvx7" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_z9IouMh1PgZa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: right">2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">835,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_zOgSIplEnwp8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: right">2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,113,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_zEjc0J7QM5Eg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">2025</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,113,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_zAeK6OAHhN1e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: right">2026</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,113,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_z9fBJamofKN7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">2027</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,113,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_zYjHglv38zI3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: right">Thereafter</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">14,469,000</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_z3Sidvpo3ag2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IMPACT
Biomedical, Inc. and Subsidiaries</b></span></p>

<p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An impairment analysis was conducted for
financial reporting purposes in connection with U.S. GAAP and ASC 360-10, Impairment and Disposal of Long-Lived Assets. Although the
Company has a history of negative cash flows from operations, its financing arrangement with DSS (see Note 9) provides the opportunity
to fund ongoing operations. This, as well as there being no other indicators present for impairment, has led management to conclude that
no impairment is necessary for the three months ended March 31, 2023, and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_80F_eus-gaap--IntangibleAssetsDisclosureTextBlock_z2H0L9dY8BO2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
9. <span id="xdx_824_z1tn2rovw4W">Intangible Assets</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
definite-lived intangible assets, to be amortized over 20 years, balances and activity for the years ended December 31, 2022, and 2021
consisted of the following:</span></p>

<p id="xdx_894_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zHQdA7txJ6z4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B0_zqZtUD871FG4" style="display: none">Schedule
of Intangible Assets</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">12/31/2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">12/31/2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Gross Carrying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amount</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accumulated</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amortization</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net Carrying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amount</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Gross Carrying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amount</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accumulated</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amortization</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net Carrying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amount</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Definitive-lived:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left; padding-bottom: 1.5pt">Developed technology</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zgBIkWG91zXk" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right" title="Gross Carrying Amount">22,258,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zpuWVPx1EXc2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right" title="Accumulated Amortization">(2,226,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zRgOQZTT6Yd" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right" title="Net Carrying Amount">20,033,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zI7Y34SBRsqh" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right" title="Gross Carrying Amount">22,260,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_z5FrKHNRmm5a" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right" title="Accumulated Amortization">(1,113,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zGbghpcnCqzc" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right" title="Net Carrying Amount">21,147,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Total</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20221231_zk1bqzZQHIJd" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gross Carrying Amount">22,258,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231_zhrxucA4Ylq2" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accumulated Amortization">(2,226,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20221231_zwlty5MPwip8" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net Carrying Amount">20,033,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20211231_zY55HIRHhZ77" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gross Carrying Amount">22,260,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20211231_zdXvV8N6tel6" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accumulated Amortization">(1,113,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20211231_zORzHT040mca" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net Carrying Amount">21,147,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AD_zJTTpTcsc7ml" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amounts
amortized for the year ended December 31, 2022 and 2021 was approximately $<span id="xdx_903_eus-gaap--DepreciationAndAmortization_c20220101__20221231_z07Xi7V36SDb" title="Amortization">1,113,000</span> and $<span id="xdx_90D_eus-gaap--DepreciationAndAmortization_c20210101__20211231_zKiA3suvZwf2" title="Amortization">1,113,000</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89F_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_ztrJEWSXpzQ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table represents future amortization of developed technologies:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B2_z5r4lxyudiOb" style="display: none">Schedule
of Future Amortization of Developed Technologies</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_497_20221231_z6eq82unuXc3" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_zFHMZ3jeS3b1" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">835,000</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_zjqgq8ica1v2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: right">2022</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">1,113,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_zYolTxwz4QS8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2023</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,113,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_zEbL6CCv6cT9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2024</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,113,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_zUhYP2MIBOXh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2025</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,113,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_zm9aNzIaiv73" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2026</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,113,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_zXVHPYqafEyl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">Thereafter</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">14,468,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A6_zbjcQpyG6dU2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IMPACT
Biomedical, Inc. and Subsidiaries</b></span></p>

<p style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2021, the fair value of the assets acquired by DSS on August 21, 2020, was concluded. An impairment analysis was conducted for
financial reporting purposes in connection with U.S. GAAP and ASC 360-10, Impairment and Disposal of Long-Lived Assets. Although the
Company has a history of negative cash flows from operations, its financing arrangement with DSS (see Note 9) provides the opportunity
to fund ongoing operations. This, as well as there being no other indicators present for impairment, has led management to conclude that
no impairment is necessary for the years ended December 31, 2022, and 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350-30/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139839844637168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text"><p id="xdx_809_eus-gaap--DebtDisclosureTextBlock_z6WPYl6rmHK1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
9. <span id="xdx_825_zvOkPjNjVYbc">Debt</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 31, 2020, and later amended on March 31, 2023, the Company executed a Revolving Promissory Note (&#8220;Note&#8221;) with DSS,
a related party, which accrues interest at a rate of <span id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20230331__us-gaap--DebtInstrumentAxis__custom--RevolvingPromissoryNoteMember_zuUBJvMCB1D7">4.25</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
and is due in full at the maturity date of <span id="xdx_907_eus-gaap--DebtInstrumentMaturityDate_dd_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--RevolvingPromissoryNoteMember_zv495TGu08Vi">March
31, 2024</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The revolving nature of this Note permits
for principal amounts borrowed to be repaid and reborrowed. <span id="xdx_909_eus-gaap--DebtDefaultLongtermDebtDescriptionOfNoticeOfDefault_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--RevolvingPromissoryNoteMember_zs8MAykuk7tj">In
the case of default, at DSS&#8217;s option, (i) eighteen percent (18%) per annum, or (ii) such lesser rate of interest as Lender in its
sole discretion may choose to charge; but never more than the Maximum Lawful Rate.</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DSS
has not established a maximum borrowing amount and intends to continue to fund the operations of the Company through a year from the
date these financial statements were available to be issued. As of March 31, 2023 and December 31, 2022, this Note has an outstanding
balance, including interest of $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_c20230331_zj0LuSnTzf94" title="Outstanding balance, including interest">11,008,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and <span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_c20221231_zmvODnojziL6" title="Outstanding balance, including interest">9,529,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
<td class="text"><p id="xdx_803_eus-gaap--DebtDisclosureTextBlock_zXSDRNLok2He" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
10. <span id="xdx_824_zbDeTJMfFkH4">Debt</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 31, 2020, and later amended on December 31, 2022, the Company executed a Revolving Promissory Note (&#8220;Note&#8221;) with
DSS, a related party, which accrues interest at a rate of <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20221231__us-gaap--DebtInstrumentAxis__custom--RevolvingPromissoryNoteMember_z6nKohDNKl16" title="Debt instrument interest, rate">4.25</span>% and is due in full at the maturity date of <span id="xdx_901_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--RevolvingPromissoryNoteMember_zrQGqf3Rhc9d" title="Debt instrument, maturity date">December 31, 2023</span>. The revolving
nature of this Note permits for principal amounts borrowed to be repaid and reborrowed. <span id="xdx_909_eus-gaap--DebtDefaultLongtermDebtDescriptionOfNoticeOfDefault_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--RevolvingPromissoryNoteMember_z7H9UcWthbZi" title="Long term debt, description">In the case of default, at DSS&#8217;s option,
(i) eighteen percent (18%) per annum, or (ii) such lesser rate of interest as Lender in its sole discretion may choose to charge; but
never more than the Maximum Lawful Rate.</span> DSS has not established a maximum borrowing amount and intends to continue to fund the operations
of the Company through a year from the date these financial statements were available to be issued. As of December 31, 2022 and 2021,
this Note had an outstanding balance of $<span id="xdx_90D_eus-gaap--NotesPayable_iI_c20221231_zdm2M8yum3u" title="Outstanding balance">9,991,000</span> and $<span id="xdx_907_eus-gaap--NotesPayable_iI_c20211231_zeMhgfyxMETj" title="Outstanding balance">12,524,000</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139839941357376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; Equity</a></td>
<td class="text"><p id="xdx_803_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zbKNOhCfXE94" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
10. <span id="xdx_82F_zUXganmVlNu7">Stockholders&#8217; Equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 23, 2021, the Company, the Company&#8217;s Board of Directors approved the total number of shares of Common Stock to be <span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_iI_c20210923__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zZfQue2LNov3" title="Common stock, shares authorized">3,000,000,000</span>
shares with a par value of $<span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20210923__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zoo7rhQF5ghe" title="Common stock par value">0.001</span>. Each
share of Common Stock when issued, shall have one (1) vote on all matters presented to the stockholders. Our Amended and Restated Articles of Incorporation authorize us to issue up to <span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_c20230331__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zhVHcoGs4tf" title="Common stock, shares authorized">4,000,000,000</span> shares of Common Stock,
$<span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230331__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zRCbHfeSZXHf" title="Common stock par value">0.001</span> par value per share, and <span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_c20230331__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zirSEAKoq2Xl" title="Preferred stock, shares authorized">100,000,000</span> shares of preferred stock, par value $<span id="xdx_90D_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20230331__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zYj2CBBVokk2" title="Preferred stock, par value">0.001</span> per share. As of December 31, 2022, there were
<span id="xdx_90C_eus-gaap--CommonStockSharesIssued_iI_c20221231__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zmBLBfIrkdW5" title="Common stock, shares issued"><span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_iI_c20221231__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zzyv6QBLAtO2" title="Common stock, shares outstanding">125,073,621</span></span> shares of our Common Stock and <span id="xdx_90C_eus-gaap--PreferredStockSharesIssued_iI_do_c20221231__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zza7rDYzbmu5" title="Preferred stock, shares issued"><span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20221231__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zLeIUCP9QFQ2" title="Preferred stock, shares outstanding">no</span></span> shares of preferred stock issued and outstanding. On May 11, 2023, the Company effected
a forward split. As a result, there were <span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_c20230511__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zCx6sDv8e111" title="Common stock, shares authorized">3,877,282,251</span> shares of our Common Stock and <span id="xdx_90B_eus-gaap--PreferredStockSharesIssued_iI_do_c20230511__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_znj1qlMbWG6d" title="Preferred stock, shares issued"><span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20230511__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zTNwSEegatod" title="Preferred stock, shares outstanding">no</span></span> shares of preferred stock issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
<td class="text"><p id="xdx_80E_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z9NBT3j11CY" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
11. <span id="xdx_829_zSCBLTTc6NYa">Stockholders&#8217; Equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 23, 2021, the Company, the Company&#8217;s Board of Directors approved the total number of shares of Common Stock to be <span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_iI_c20210923__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zU9fmLrpw2Sf" title="Common stock, shares authorized">3,000,000,000</span>
shares with a par value of $<span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20210923__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zqODeemrq8h5" title="Common stock par value">0.001</span>. Each share of Common Stock when issued, shall have one (1) vote on all matters presented to the stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Amended and Restated Articles of Incorporation authorizes us to issue up to <span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_c20210923_zppbOWSK5Na9" title="Common stock, shares authorized">4,000,000,000</span> shares of Common Stock, $<span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20210923_zZLPtRf8Lz8h" title="Common stock par value">0.001</span> par value per
share, and <span id="xdx_908_eus-gaap--PreferredStockSharesAuthorized_iI_c20210923_zvr5fKKcPhVa" title="Preferred stock, shares authorized">100,000,000</span> shares of preferred stock, par value $<span id="xdx_90D_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20210923_zvfDDGcIYoWk" title="Preferred stock, par value">0.001</span> per share. On May 11, 2023, the Company effected a forward split.
As a result, there were <span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_c20230511__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zebBP2Ii6xj9" title="Common stock, shares authorized">3,877,282,251</span> shares of our Common Stock and <span id="xdx_90B_eus-gaap--PreferredStockSharesIssued_iI_do_c20230511__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zLSFnHmbxzpc" title="Preferred stock, shares issued"><span id="xdx_902_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20230511__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zhIadLxK5rX1" title="Preferred stock, shares outstanding">no</span></span> shares of preferred stock issued and outstanding. As of December
31, 2022 and 2021, there were <span id="xdx_901_eus-gaap--CommonStockSharesIssued_iI_c20221231_zDxLHWYU3G44" title="Common stock, shares issued">125,073,621</span> shares of our Common Stock and outstanding which was converted to <span id="xdx_906_eus-gaap--CommonStockSharesOutstanding_iI_c20211231_zie7uVylp7lf" title="Common stock, shares outstanding">3,877,282,251</span> shares. As
of December 31, 2022 and 2021, there were <span id="xdx_90A_eus-gaap--PreferredStockSharesIssued_iI_do_c20221231__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zjqSAF0L3Wu4" title="Preferred stock, shares issued"><span id="xdx_90C_eus-gaap--PreferredStockSharesIssued_iI_do_c20211231__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zlB3JKSKMMI8" title="Preferred stock, shares issued">no</span></span> preferred shares issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139839849229408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zrbITywKloki" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
11. <span id="xdx_827_zf0EomlVQZC6">Related Party Transactions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and Development Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on Shareholders Agreement entered into on April 26, 2017, the Company would fund the scientific operations of GRDG, a company involved
in research and development of biomedical products which is a minority stockholder of two of the Company&#8217;s subsidiaries and is
owned by Daryl Thompson, a director of many subsidiaries of the Company, to do the development and research works on the biomedical products
for the Company. As of March 31, 2023, this funding approximates $<span id="xdx_903_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20230101__20230331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GRDGscienceLLCMember_zMgYBTYQWtP7" title="Payment in funding of research and development">43,000 </span>per month, and incurred approximately $<span id="xdx_901_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GRDGscienceLLCMember_z7qVznlEjroe" title="Research and development expense">129,000</span> in expenses. On
March 31, 2023 and March 31, 2022, the Company owed this related party $<span id="xdx_902_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20230101__20230331_zxj1qUuxOQ4k" title="Related party owed transaction"><span id="xdx_908_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20220101__20220331_zr8Sak1UglYa" title="Related party owed transaction">0</span></span> and had prepaid monthly fees approximating $<span id="xdx_90E_eus-gaap--PrepaidExpenseCurrentAndNoncurrent_iI_c20230331_zdjBbtRg6Lx6" title="Prepaid monthly fees">43,000 </span>and $<span id="xdx_901_eus-gaap--PrepaidExpenseCurrentAndNoncurrent_iI_c20220331_zsupyVW5PqB2" title="Prepaid monthly fees">43,000</span>,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
and Administrative Costs</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are certain general and administrative costs incurred by DSS, a related party on behalf of the Company which are passed through to the
Company on a monthly basis. These costs consist of primarily payroll costs for certain DSS employees and are allocated based on estimated
time spent on behalf of the Company. These costs approximate $<span id="xdx_906_eus-gaap--LaborAndRelatedExpense_c20230101__20230331_zojFxxmWo0xg" title="Related costs for employees">12,000</span> per month. As of March 31, 2023, the Company incurred $<span id="xdx_90E_eus-gaap--GeneralAndAdministrativeExpense_c20230101__20230331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zWhTU71wDqE" title="General and administrative expense">35,000</span> in
related expenses. As of March 31, 2022, the Company incurred approximately $<span id="xdx_90D_eus-gaap--GeneralAndAdministrativeExpense_c20220101__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z5ttMp7WAQ06" title="General and administrative expense">52,000</span> in related expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IMPACT
Biomedical, Inc. and Subsidiaries</b></span></p>

<p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
<td class="text"><p id="xdx_80F_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zztEBZT4mjQg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
12. <span id="xdx_822_zvy9I2R7FfRg">Related Party Transactions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and Development Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on Shareholders Agreement entered into on April 26, 2017, the Company would fund the scientific operations of GRDG, a company involved
in research and development of biomedical products which is a minority stockholder of two of the Company&#8217;s subsidiaries and is
owned by Daryl Thompson, a director of many subsidiaries of the Company, to do the development and research works on the biomedical products
for the Company. As of December 31, 2022, this funding approximates $<span id="xdx_90A_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GRDGscienceLLCMember_zVjUWSovINQi" title="Payment in funding of research and development">43,000</span> per month, and incurred approximately $<span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GRDGscienceLLCMember_zryqsaKOM4hf" title="Research and development expense">546,000</span> in expenses. On
December 31, 2022 and December 31, 2021, the Company owed this related party $<span id="xdx_907_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20220101__20221231_z5iAXlXhFpw8" title="Related party owed transaction"><span id="xdx_908_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20210101__20211231_zt3FU3pWMl4c" title="Related party owed transaction">0</span></span> and had prepaid monthly fees approximating $<span id="xdx_90C_eus-gaap--PrepaidExpenseCurrentAndNoncurrent_iI_c20221231_zqtTTZcDzusj" title="Prepaid monthly fees">43,000</span> and
$<span id="xdx_90A_eus-gaap--PrepaidExpenseCurrentAndNoncurrent_iI_c20211231_zLvoos388iwl" title="Prepaid monthly fees">43,000</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
and Administrative Costs</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are certain general and administrative costs incurred by DSS, a related party on behalf of the Company which are passed through to the
Company on a monthly basis. These costs consist of primarily payroll costs for certain DSS employees and are allocated based on estimated
time spent on behalf of the Company. These costs approximate $<span id="xdx_905_eus-gaap--LaborAndRelatedExpense_c20220101__20221231_zTLH81H2p9u2" title="Related costs for employees">12,000</span> per month. As of December 31, 2022, the Company incurred
$<span id="xdx_901_eus-gaap--GeneralAndAdministrativeExpense_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z1za1w1WTIj8" title="General and administrative expense">117,000</span> in related expenses. As of December 31, 2021, the Company incurred approximately $<span id="xdx_906_eus-gaap--GeneralAndAdministrativeExpense_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zMLNxepSFCIl" title="General and administrative expense">155,000</span> in related expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IMPACT
Biomedical, Inc. and Subsidiaries</b></span></p>

<p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139839843536336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p id="xdx_803_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zdZObhLJsKj9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
12. <span id="xdx_82E_zpi1260TjC8d">Commitments and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 15, 2018, the Company entered into Royalty Agreement with Chemia Corporation (&#8220;Chemia&#8221;) pursuant to which Chemia
transferred to the Company all of its right to 3F (Functional Fragrance Formulation). This agreement has a 20-year term and auto
renews for a period of 1 year unless mutually agreed upon by both parties. 3F consists of 3F Mosquito Repellant and 3F Anti-Viral
formulations. Based on the Royalty Agreement, the Company should cover all the costs to prepare and finalize necessary patent
application and other intellectual property related to 3F. Chemia agreed to support the Company in efforts leading to development of
3F intellectual property and it&#8217;s licensing. Based on Royalty Agreement any payments received from development, sales,
licensing or transfer of 3F technology will be paid <span id="xdx_907_ecustom--RoyaltyPercentage_dp_uPure_c20180814__20180815__us-gaap--TypeOfArrangementAxis__custom--RoyaltyAgreementMember_za9Fvb7DQAua" title="Royalty percentage">50</span>%
to the Company and <span id="xdx_900_ecustom--RoyaltyPercentage_dp_uPure_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--RoyaltyAgreementMember__dei--LegalEntityAxis__custom--ChemiaCorporationMember_z5vydKOIQZI8" title="Royalty percentage">50</span>%
to Chemia. On November 27, 2018, Company and Chemia signed an Addendum to Royalty Agreement (&#8220;Addendum&#8221;), according to
which the Company granted Chemia a royalty-based limited license for purposes of making and selling fragrances embodying the 3F
technology. Based on the Addendum, Chemia should pay the Company <span id="xdx_904_ecustom--SaleOfRoyaltyPercentage_dp_uPure_c20181126__20181127__us-gaap--TypeOfArrangementAxis__custom--RoyaltyAgreementMember_zZIO8sFf8Up5" title="Net sales  royalty">5</span>%
of net sales in royalty. On November 8, 2019, both companies entered into Amendment no.1 to Royalty Agreement, based on which
certain expenses bore by the Company towards patent application and licensing should be reimbursed to the Company before any royalty
payments are made. For the three months ended March 31, 2023 and 2022, there were no reimbursements or royalties paid to the
Company and the Company cannot be assured that Chemia&#8217;s efforts will end up in any future sales of the technology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 15, 2022, the Company and its subsidiaries, Global BioLife, Inc. (&#8220;Global&#8221;), and Impact BioLife Sciences, Inc. (&#8220;BioLife
Sciences&#8221;), and GRDG entered into a Licensing Proceeds Distribution Agreement (&#8220;GRDG Agreement&#8221;), whereas GRDG would
transfer its <span id="xdx_908_ecustom--SaleOfRoyaltyPercentage_dp_uPure_c20220214__20220215__us-gaap--TypeOfArrangementAxis__custom--GlobalAndBioLifeSciencesMember_z26GQVGAYaZd" title="Sale of royalty percentage">20</span>% equity position in both Global and BioLife Sciences to the Company in exchange for 20% interest in Global and/or BioLife
Science revenue received from the exclusive or non-exclusive licensing of and/or the sale of Global Intellectual Property to a Third
Party, net of specific costs. As of the date of this report, no contingent liability has been recognized under the GRDG Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 19, 2022, Impact BioMedical entered into a License Agreement (&#8220;Equivir License&#8221;) with ProPhase Labs, Inc. (&#8220;ProPhase&#8221;)
where the ProPhase is granted the right, amongst other things, to develop, commercialize, and sell the Company&#8217;s Equivir technology.
In exchange, the Licensee shall pay the Company a royalty of <span id="xdx_904_ecustom--SaleOfRoyaltyPercentage_dp_uPure_c20220318__20220319__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zcDIe4uEolQa" title="Sale of royalty percentage">5.5</span>% of net sales. Under the terms of the Equivir Agreement, the Company
shall reimburse ProPhase for <span id="xdx_90C_ecustom--DevelopmentCostPercent_dp_c20220319__20220319__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zrr2mSM4isa7" title="Development cost, percent">50</span>% of the development costs provided that the development costs shall not exceed $<span id="xdx_906_eus-gaap--CostsIncurredDevelopmentCosts_c20220318__20220319__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zBsePHomEbN7" title="Development costs">1,250,000</span>. As of March
31, 2023, no liability has been recorded in relation to the Equivir License as development of the Equivir technology has not begun and
no reasonable amount can be estimated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_808_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z5Xcxi9CgOB5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
13. <span id="xdx_82D_z9726DukHO4f">Commitments and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 15, 2018, the Company entered into Royalty Agreement with Chemia Corporation (&#8220;Chemia&#8221;) pursuant to which Chemia transferred
to the Company all of its right to 3F (Functional Fragrance Formulation). This agreement has a 20-year term and auto renews for a period
of 1 year unless mutually agreed upon by both parties. 3F consists of 3F Mosquito Repellant and 3F Anti-Viral formulations. Based on
the Royalty Agreement, the Company should cover all the costs to prepare and finalize necessary patent application and other intellectual
property related to 3F. Chemia agreed to support the Company in efforts leading to development of 3F intellectual property and it&#8217;s
licensing. Based on Royalty Agreement any payments received from development, sales, licensing or transfer of 3F technology will be paid
<span id="xdx_906_ecustom--RoyaltyPercentage_pid_dp_uPure_c20180814__20180815__us-gaap--TypeOfArrangementAxis__custom--RoyaltyAgreementMember_zes4xogi5U8j" title="Royalty percentage">50</span>% to the Company and <span id="xdx_907_ecustom--RoyaltyPercentage_pid_dp_uPure_c20180814__20180815__us-gaap--TypeOfArrangementAxis__custom--RoyaltyAgreementMember__dei--LegalEntityAxis__custom--ChemiaCorporationMember_zoxr8l8BHGD4" title="Royalty percentage">50</span>% to Chemia. On November 27, 2018, Company and Chemia signed an Addendum to Royalty Agreement (&#8220;Addendum&#8221;),
according to which the Company granted Chemia a royalty-based limited license for purposes of making and selling fragrances embodying
the 3F technology. Based on the Addendum, Chemia should pay the Company <span id="xdx_90E_ecustom--SaleOfRoyaltyPercentage_pid_dp_uPure_c20181126__20181127__us-gaap--TypeOfArrangementAxis__custom--RoyaltyAgreementMember_zAcTF2elKA66" title="Net sales  royalty">5</span>% of net sales in royalty. On November 8, 2019, both companies
entered into Amendment no.1 to Royalty Agreement, based on which certain expenses bore by the Company towards patent application and
licensing should be reimbursed to the Company before any royalty payments are made. For the nine months ended December 31, 2022 and 2021,
there were no reimbursements or royalties paid to the Company and the Company cannot be assured that Chemia&#8217;s efforts will end
up in any future sales of the technology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 15, 2022, the Company and its subsidiaries, Global BioLife, Inc. (&#8220;Global&#8221;), and Impact BioLife Sciences, Inc. (&#8220;BioLife
Sciences&#8221;), and GRDG entered into a Licensing Proceeds Distribution Agreement (&#8220;GRDG Agreement&#8221;), whereas GRDG would
transfer its <span id="xdx_900_ecustom--SaleOfRoyaltyPercentage_pid_dp_uPure_c20220214__20220215__us-gaap--TypeOfArrangementAxis__custom--RoyaltyAgreementMember_z2dmeqsggJD2" title="Net sales  royalty">20</span>% equity position in both Global and BioLife Sciences to the Company in exchange for 20% interest in Global and/or BioLife
Science revenue received from the exclusive or non-exclusive licensing of and/or the sale of Global Intellectual Property to a Third
Party, net of specific costs. As of the date of this report, no contingent liability has been recognized under the GRDG Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 19, 2022, Impact BioMedical entered into a License Agreement (&#8220;Equivir License&#8221;) with ProPhase Labs, Inc. (&#8220;ProPhase&#8221;)
where the ProPhase is granted the right, amongst other things, to develop, commercialize, and sell the Company&#8217;s Equivir technology.
In exchange, the Licensee shall pay the Company a royalty of <span id="xdx_90E_ecustom--SaleOfRoyaltyPercentage_pid_dp_uPure_c20220318__20220319__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zqoIlPkCQrs6" title="Net sales  royalty">5.5</span>% of net sales. Under the terms of the Equivir Agreement, the Company
shall reimburse ProPhase for <span id="xdx_90D_ecustom--DevelopmentCostPercent_pid_dp_uPure_c20220318__20220319__us-gaap--TypeOfArrangementAxis__custom--RoyaltyAgreementMember_zqrzp8mvcYy2" title="Development cost, percent">50</span>% of the development costs provided that the development costs shall not exceed $<span id="xdx_908_eus-gaap--CostsIncurredDevelopmentCosts_c20220318__20220319__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zWbD77tzVuyg" title="Development costs">1,250,000</span>. As of December
31, 2022, no liability has been recorded in relation to the Equivir License as development of the Equivir technology has not begun and
no reasonable amount can be estimated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139839843437648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_807_eus-gaap--IncomeTaxDisclosureTextBlock_ztBNUKWeW0M7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
14. <span id="xdx_82C_zj0MygXbr8sj">Income Taxes</span></b>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the
financial reporting and tax basis of assets and liabilities. Deferred tax assets are reduced, if deemed necessary, by a valuation allowance
for the amount of tax benefits which are not expected to be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IMPACT
Biomedical, Inc. and Subsidiaries</b></span></p>

<p style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_890_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zeVbteJrx8E7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
components of income tax benefit for the years ended December 31, 2022, and 2021 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8BA_zVgJq1uKpHb7" style="display: none">Schedule of Components of Income Tax Benefit</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt">Federal</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_49D_20220101__20221231_zPPdkxgx7tbl" style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_494_20210101__20211231_zsPtO3r9p7Ce" style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif">Income Tax Expense (Benefit)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended <br/> December 31, 2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2021</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Current tax payable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CurrentFederalTaxExpenseBenefit_maCITEBzAu9_zu08Pc89efh1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt">Federal</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0747">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0748">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_maCITEBzAu9_zyQka61FNENh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; padding-bottom: 1.5pt">State</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0750">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0751">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--CurrentIncomeTaxExpenseBenefit_iT_mtCITEBzAu9_zwn135doikKf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Total current tax payable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0753">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0754">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Deferred tax</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_iN_di_maDITEBzd7s_zJhzyGuwsa15" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; width: 60%">Federal</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">(1,619,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">(456,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_iN_di_maDITEBzd7s_ztNBdi4bQlP4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; padding-bottom: 1.5pt">State</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(165,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,068,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredIncomeTaxExpenseBenefit_iNT_di_mtDITEBzd7s_maNDTEAzrUM_maITEBzC69_z0pScFqoLUA7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Total deferred tax</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,784,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,524,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_msNDTEAzrUM_msITEBzC69_z9vMFTeuyQkb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Less increase in valuation allowance</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,163,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">129,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzC69_zFxkACmaqe9h" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"> income tax benefit</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(621,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,395,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  </table>

<p id="xdx_8AB_z2YFqL6L0e2g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89C_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zFmIGnYwjsfk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Individual
components of deferred tax assets and liabilities are approximately as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BB_zpsriDR3yffg" style="display: none">Schedule of Deferred Tax Assets and Liabilities</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20221231_zgFXxnXr25p4" style="font: 10pt Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20211231_zfc5y7h5hsOf" style="font: 10pt Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif">Deferred Tax Assets &amp; Liabilities:</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Deferred Tax assets:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsInvestments_iI_maDTAGzKh6_zP0JbeoXEuxh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 60%">Impairment of investment</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">929,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0774">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_maDTAGzKh6_zCfppEN0bG37" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Research &amp; development cost</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">250,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0777">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzKh6_zdin9WgapdM3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Net Operating loss</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,611,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,258,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzKh6_z5xwgF3383b1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Gross deferred tax assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,790,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,258,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Deferred tax liability:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_msDITLzt6S_zqIynwAgaUsf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Intangible assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(4,414,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(4,667,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredIncomeTaxLiabilities_iNI_di_mtDITLzt6S_maDTLzghA_z2dRYnKjhO3l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Gross deferred tax liability</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(4,414,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(4,667,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsNet_iNI_di_msDTLzghA_zlUqxnG1rHM6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Less valuation allowance</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,611,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(447,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxLiabilities_iNTI_di_mtDTLzghA_zJEWI0M8rDVe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Net deferred tax liability</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,235,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,856,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  </table>

<p id="xdx_8AD_zLJkEhV9f6T5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_89A_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zFj0WbmBh0U1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_zgvUJyg0FcFk" style="display: none">Summary of Effective Income Tax Rate</span></span></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20220101__20221231_zEzSJYNTofdd" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20210101__20211231_ztWgj4YVqOM4" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_z7KMU8LZR5oe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Statutory United States federal rate</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">21.0</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">21.0</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_zGPP7r08lLyl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">State income taxes net of federal benefit</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1.7</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">26.0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_zqPyqCsGPMKb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(14.8</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)%</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(4.0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_zF8qM7kf9aZd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Effective rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">7.9</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">43</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  </table>

<p id="xdx_8A7_z5NWFScgoez6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, and 2021, the Company has net operating loss carry forwards of approximately $<span id="xdx_902_eus-gaap--OperatingLossCarryforwards_iI_c20221231_z6sRG8TZInN1" title="Operating loss carryforwards">7,109,000</span> and $<span id="xdx_90E_eus-gaap--OperatingLossCarryforwards_iI_c20211231_zDcnkvHmmQDb" title="Operating loss carryforwards">5,551,000</span> respectively.
The Company does not have other temporary differences associated with the amortization of intangible assets. As of December 31, 2022,
and 2021, the total deferred tax assets carry-forward were $<span id="xdx_904_eus-gaap--DeferredTaxAssetsGross_iI_c20221231_z7rdL5q1fGec" title="Deferred tax asset">2,790,000</span> and $<span id="xdx_904_eus-gaap--DeferredTaxAssetsGross_iI_c20211231_z9OC4eKNilg8" title="Deferred tax asset">1,258,000</span>, respectively. The deferred tax assets
could be carried forward indefinitely. The full utilization of the deferred tax assets in the future is dependent upon the Company&#8217;s
ability to generate taxable income. Considering the development stage of the Company, management believed that it was probable that the
Company would not use tax assets in the near future. Accordingly, a valuation allowance of an equal amount has been established. During
the years ended December 31, 2022 and December 31, 2021, the valuation allowance increased by $<span id="xdx_901_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20220101__20221231_zIe7xenSHJed" title="Valuation allowance deferred tax">1,163,000</span> and decreased by $<span id="xdx_900_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20210101__20211231_zBZGwwXzSCM9" title="Valuation allowance deferred tax">129,000</span>,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognizes interest accrued and penalties
related to unrecognized tax benefits in tax expense. During the years ended December 31, 2022 and 2021 the Company recognized no interest
and penalties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139839844746528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Cash Flow Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock', window );">Supplemental Cash Flow Information</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--CashFlowSupplementalDisclosuresTextBlock_z5XkKFkzbXA8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
15. <span id="xdx_827_zohXxhDiE5w4">Supplemental Cash Flow Information</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_89F_eus-gaap--ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_zvs4mQmfs7Ad" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes supplemental cash flows for the year ended December 31, 2022, and 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_zKkR64o8ofP9" style="display: none">Schedule
of Cash Flow Supplemental</span> </span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20221231_z0j9i297N2Ri" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20211231_ztiK3wFcXLIj" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ConvertibleNotesPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z1dieTBoYwnj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 60%">Transfer of promissory note 2 to related party</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 16%">5,081,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 16%"><span style="-sec-ix-hidden: xdx2ixbrl0828">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NotesPayable_iNI_di_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zmqZdDNDQEne" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Transfer of note payable, related party</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(5,081,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0831">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A0_zbu28JYcdSOd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//230/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowSupplementalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139839849041888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p id="xdx_804_eus-gaap--SubsequentEventsTextBlock_z2Sz8xAAJSI" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
13. <span id="xdx_820_zURC4ecPyPBa">Subsequent Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has evaluated all subsequent events and transactions through June 20, 2023, the date that the consolidated financial statements
were available to be issued and noted no subsequent events requiring financial statement recognition or disclosure.</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_809_eus-gaap--SubsequentEventsTextBlock_z5izBHh7vPAb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
16. <span id="xdx_82C_zSv7FR2YhL33">Subsequent Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has evaluated all subsequent events and transactions through June 2, 2023, the date that the consolidated financial statements
were available to be issued, and noted no subsequent events requiring financial statement recognition or disclosure.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139839845401888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting and Reporting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><p id="xdx_847_eus-gaap--UseOfEstimates_zdQf9jYkURy7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_zt6VwiVmfLrk">Use
of estimates</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the dates of the balance
sheets and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from these estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<span></span>
</td>
<td class="text"><p id="xdx_847_eus-gaap--UseOfEstimates_z5wz0mcNenma" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zaqEKogB9ez9">Use
of estimates</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the dates of the balance
sheets and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from these estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings (Loss) per Share</a></td>
<td class="text"><p id="xdx_842_eus-gaap--EarningsPerSharePolicyTextBlock_zyxlcJyJMqci" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86F_zkJB4Ss69lIi">Earnings
(Loss) per Share</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
earnings (loss) per share is computed by dividing the net income (loss) attributable to the common stockholders by weighted average number
of shares of common stock outstanding during the period. Fully diluted earnings (loss) per share is computed like basic income (loss)
per share except that the denominator is increased to include the number of additional common shares that would have been outstanding
if the potential common shares had been issued and if the additional common shares were dilutive. There were no dilutive financial instruments
issued or outstanding for the three months ended March 31, 2023 or 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_zP3j63KgdsR4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zTsxI67TiqM">Earnings
(Loss) per Share</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
earnings (loss) per share is computed by dividing the net income (loss) attributable to the common stockholders by weighted average number
of shares of common stock outstanding during the period. Fully diluted earnings (loss) per share is computed like basic income (loss)
per share except that the denominator is increased to include the number of additional common shares that would have been outstanding
if the potential common shares had been issued and if the additional common shares were dilutive. There were no dilutive financial instruments
issued or outstanding for the years ended December 31, 2022 or 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p id="xdx_849_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zgcgbooGbEg6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_z9Je588BzIm4">Fair
Value of Financial Instruments</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants at the measurement date. The Fair Value Measurement Topic of the Financial Accounting Standards Board (&#8220;FASB&#8221;)
Accounting Standards Codification (&#8220;ASC&#8221;) establishes a three-tier fair value hierarchy which prioritizes the inputs used
in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets
or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted
prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active;
and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions,
such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts reported in the balance sheet of cash and cash equivalents, prepaids, accounts payable and accrued expenses approximate
fair value because of the immediate or short-term maturity of these financial instruments. The fair value of notes receivable approximates
their carrying value as the stated or discounted rates of the notes do reflect recent market conditions. The Company&#8217;s investments
are record at cost as the fair value of these investment in are not readily available. The fair value of notes payable approximates its
carrying value as the stated interest rate reflects recent market conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IMPACT
Biomedical, Inc. and Subsidiaries</b></span></p>

<p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<span></span>
</td>
<td class="text"><p id="xdx_843_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zDq08xlPnko" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_zCbRunpHjsuj">Fair
Value of Financial Instruments</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants at the measurement date. The Fair Value Measurement Topic of the Financial Accounting Standards Board (&#8220;FASB&#8221;)
Accounting Standards Codification (&#8220;ASC&#8221;) establishes a three-tier fair value hierarchy which prioritizes the inputs used
in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets
or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted
prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active;
and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions,
such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts reported in the balance sheet of cash and cash equivalents, prepaids, accounts payable and accrued expenses approximate
fair value because of the immediate or short-term maturity of these financial instruments. The fair value of notes receivable approximates
their carrying value as the stated or discounted rates of the notes do reflect recent market conditions. The Company&#8217;s investments
are record at cost as the fair value of these investment in are not readily available. The fair value of notes payable approximates its
carrying value as the stated interest rate reflects recent market conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IMPACT
Biomedical, Inc. and Subsidiaries</b></span></p>

<p style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text"><p id="xdx_847_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zeTGsT6NkwGk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86F_zrkvNCrj2yh4">Cash
and cash equivalents</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid investments with a maturity of three months or less at the date of acquisition to be cash
equivalents. There were <span id="xdx_907_eus-gaap--Cash_iI_do_c20230331_zIikbZYCaAYd" title="Cash"><span id="xdx_90C_eus-gaap--Cash_iI_do_c20221231_zknDqfNKSt4g" title="Cash">no</span></span>
cash equivalents as of March 31, 2023 and December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_841_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zdsWDnFzokXe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_864_zXeLEdoOSZU7">Cash
and cash equivalents</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid investments with a maturity of three months or less at the date of acquisition to be cash equivalents.
There were <span id="xdx_90A_eus-gaap--Cash_iI_do_c20221231_zo4fwXEFQlQ3" title="Cash"><span id="xdx_90F_eus-gaap--Cash_iI_do_c20211231_zcamax26Ny18" title="Cash">no</span></span> cash equivalents as of December 31, 2022, and 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--InvestmentPolicyTextBlock_zQ6ZqyOzbsx3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_zu17eaWGCxj2">Investments</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investments
in equity securities with a readily determinable fair value, not accounted for under the equity method, are recorded at fair value with
unrealized gains and losses included in earnings. For equity securities without a readily determinable fair value, the investment is
recorded at cost, less any impairment, plus or minus adjustments related to observable transactions for the same or similar securities,
with unrealized gains and losses included in earnings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
equity method investments, the Company regularly reviews its investments to determine whether there is a decline in fair value below
book value. If there is a decline that is other-than-temporary, the investment is written down to fair value. See Note 6 for further
discussion on investments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_84D_eus-gaap--InvestmentPolicyTextBlock_z58oA0m51di5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_zA1Hah58AIw">Investments</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investments
in equity securities with a readily determinable fair value, not accounted for under the equity method, are recorded at fair value with
unrealized gains and losses included in earnings. For equity securities without a readily determinable fair value, the investment is
recorded at cost, less any impairment, plus or minus adjustments related to observable transactions for the same or similar securities,
with unrealized gains and losses included in earnings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
equity method investments, the Company regularly reviews its investments to determine whether there is a decline in fair value below
book value. If there is a decline that is other-than-temporary, the investment is written down to fair value. See Note 7 for further
discussion on investments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--GoodwillAndIntangibleAssetsGoodwillPolicy_z9IxlP36xKl1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zo4sSSkpKQEi">Goodwill</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill
is the excess of cost of an acquired entity over the fair value of amounts assigned to assets acquired and liabilities assumed in a business
combination. Goodwill is subject to impairment testing at least annually and will be tested for impairment between annual tests, which
takes place during the fourth quarter, if an event occurs or circumstances change that would indicate the carrying amount may be impaired.
FASB ASC Topic 350 provides an entity with the option to first assess qualitative factors to determine whether the existence of events
or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying
amount. Some of the qualitative factors considered in applying this test include consideration of macroeconomic conditions, industry
and market conditions, cost factors affecting the business, and overall financial performance of the business. If, after completing the
assessment, it is determined that it is more likely than not that the fair value of a reporting unit is less than its carrying value,
the Company will proceed to a quantitative test. If qualitative factors are not deemed sufficient to conclude that the fair value of
the reporting unit more likely than not exceeds its carrying value, then a one-step approach is applied in making an evaluation. The
evaluation utilizes an income approach (discounted cash flow analysis). The computations require management to make significant estimates
and assumptions, including, among other things, selection of comparable publicly traded companies, the discount rate applied to future
earnings reflecting a weighted average cost of capital, and earnings growth assumptions. The Company believes the estimates and assumptions
used in our impairment assessments are reasonable and based on available market information, but variations in any of the assumptions
could result in materially different calculations of fair value and determinations of whether or not an impairment is indicated. A discounted
cash flow analysis requires management to make various assumptions about future sales, operating margins, capital expenditures, working
capital, and growth rates. Cash flow projections are derived from one year budgeted amounts plus an estimate of later period cash flows,
all of which are determined by management. Subsequent period cash flows are developed for each reporting unit using growth rates that
management believes are reasonably likely to occur. Impairment of goodwill is measured as the excess of the carrying amount of goodwill
over the fair values of recognized and unrecognized assets and liabilities of the reporting unit. <span id="xdx_904_eus-gaap--GoodwillImpairmentLoss_dxL_c20230101__20230331_z4XiXqSxlbza" title="Impairment of goodwill::XDX::-"><span id="xdx_901_eus-gaap--GoodwillImpairmentLoss_dxL_c20220101__20220331_zcT7vmeuBw04" title="Impairment of goodwill::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1230"><span style="-sec-ix-hidden: xdx2ixbrl1232">No</span></span></span></span> impairment was recognized during
the three months ended March 31, 2023 or year ended December 31, 2022 (see Note 7).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_841_eus-gaap--GoodwillAndIntangibleAssetsGoodwillPolicy_zMDnF0JgVyJh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_zxq5H1ahqL6a">Goodwill</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill
is the excess of cost of an acquired entity over the fair value of amounts assigned to assets acquired and liabilities assumed in a business
combination. Goodwill is subject to impairment testing at least annually and will be tested for impairment between annual tests, which
takes place during the fourth quarter, if an event occurs or circumstances change that would indicate the carrying amount may be impaired.
FASB ASC Topic 350 provides an entity with the option to first assess qualitative factors to determine whether the existence of events
or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying
amount. Some of the qualitative factors considered in applying this test include consideration of macroeconomic conditions, industry
and market conditions, cost factors affecting the business, and overall financial performance of the business. If, after completing the
assessment, it is determined that it is more likely than not that the fair value of a reporting unit is less than its carrying value,
the Company will proceed to a quantitative test. If qualitative factors are not deemed sufficient to conclude that the fair value of
the reporting unit more likely than not exceeds its carrying value, then a one-step approach is applied in making an evaluation. The
evaluation utilizes an income approach (discounted cash flow analysis). The computations require management to make significant estimates
and assumptions, including, among other things, selection of comparable publicly traded companies, the discount rate applied to future
earnings reflecting a weighted average cost of capital, and earnings growth assumptions. The Company believes the estimates and assumptions
used in our impairment assessments are reasonable and based on available market information, but variations in any of the assumptions
could result in materially different calculations of fair value and determinations of whether or not an impairment is indicated. A discounted
cash flow analysis requires management to make various assumptions about future sales, operating margins, capital expenditures, working
capital, and growth rates. Cash flow projections are derived from one year budgeted amounts plus an estimate of later period cash flows,
all of which are determined by management. Subsequent period cash flows are developed for each reporting unit using growth rates that
management believes are reasonably likely to occur. Impairment of goodwill is measured as the excess of the carrying amount of goodwill
over the fair values of recognized and unrecognized assets and liabilities of the reporting unit. <span id="xdx_90E_eus-gaap--GoodwillImpairmentLoss_dxL_c20220101__20221231_zdxHnSdr2Oqc" title="Impairment of goodwill::XDX::-"><span id="xdx_907_eus-gaap--GoodwillImpairmentLoss_dxL_c20210101__20211231_zfDF0blYLHAe" title="Impairment of goodwill::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0450"><span style="-sec-ix-hidden: xdx2ixbrl0452">No</span></span></span></span> impairment was recognized during
the years ended December 31, 2022 or 2021 (see Note 8).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets</a></td>
<td class="text"><p id="xdx_841_eus-gaap--IntangibleAssetsFiniteLivedPolicy_z1a3nqz7Lulf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_zU8Fi7Jev1Yb">Intangible
Assets</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated fair values of acquired intangibles are generally determined based upon future economic benefits such as earnings and cash
flows. Acquired identifiable intangible assets are recorded at fair value and are amortized over their estimated useful lives.
Acquired intangible assets with an indefinite life are not amortized but are reviewed for impairment at least annually as of
December 31<sup>st</sup>, or more frequently whenever events or changes in circumstances indicate that the carrying amounts of those
assets are below their estimated fair values. Impairment is tested under ASC 350. <span id="xdx_901_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_do_c20230101__20230331_zywcseRVtwQl" title="Impairment of intangible assets"><span id="xdx_900_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_do_c20220101__20221231_zdUpfxX3Zrwc" title="Impairment of intangible assets">No</span></span>
impairment was recognized as of March 31,  2023 or year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"></p>

<span></span>
</td>
<td class="text"><p id="xdx_841_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zDznBH10mbZd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_zxv2HJgVHvih">Intangible
Assets</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated fair values of acquired intangibles are generally determined based upon future economic benefits such as earnings and cash
flows. Acquired identifiable intangible assets are recorded at fair value and are amortized over their estimated useful lives.
Acquired intangible assets with an indefinite life are not amortized but are reviewed for impairment at least annually as of
December 31<sup>st</sup>, or more frequently whenever events or changes in circumstances indicate that the carrying amounts of those
assets are below their estimated fair values. Impairment is tested under ASC 350 which provides an entity with the option to
first assess qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is
more likely than not that the fair value of a reporting unit is less than its carrying amount.  If, after completing the
assessment, it is determined that it is more likely than not that the fair value of a reporting unit is less than its carrying
value, the Company will proceed to a quantitative test. For the years ended December 31, 2022 and 2021, the Company utilized a
qualitative, as events and circumstances do not indicate that it is more likely than not (that is, a likelihood of more than 50%)
that an indefinite-lived intangible asset is impaired. Key factors considered while performing qualitative testing include industry
and market considerations, macroeconomic conditions, continued patent development of the technologies, as well as marketplace&#8217;s interest in the technologies. <span id="xdx_905_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_do_c20210101__20211231_zUAxRNfrKXb3">No </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">impairment
was recognized during the years ended December 31, 2022 or 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Recoverability of Long-Lived Assets</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zDbHGeIMInR8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; background-color: white"><i><span id="xdx_860_zkK2hzCpGQ93">Recoverability
of Long-Lived Assets</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; background-color: white"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; background-color: white">We evaluate
long-lived assets such as property, equipment and definite lived intangible assets, such as patents, for impairment whenever events or
circumstances indicate that the carrying value of the assets recognized in our financial statements may not be recoverable. Factors that
we consider include whether there has been a significant decrease in the market value of an asset, a significant change in the way an
asset is being utilized, or a significant change, delay or departure in our strategy for that asset, or a significant change in the macroeconomic
environment, such as the impact of the COVID-19 pandemic. Our assessment of the recoverability of long-lived assets involves significant
judgment and estimation. These assessments reflect our assumptions, which, we believe, are consistent with the assumptions hypothetical
marketplace participants use. Factors that we must estimate when performing recoverability and impairment tests include, among others,
forecasted revenue, margin costs and the economic life of the asset. If impairment is indicated, we determine if the total estimated
future cash flows on an undiscounted basis are less than the carrying amounts of the asset or assets. If so, an impairment loss is measured
and recognized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 27.15pt; background-color: white">Our
impairment loss calculations require that we apply judgment in identifying asset groups, estimating future cash flows, determining asset
fair values, and estimating asset&#8217;s useful lives. The Company reviews identifiable amortizable intangible assets for impairment
whenever events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. Determination of recoverability
is based on the lowest level of identifiable estimated undiscounted cash flows resulting from use of the asset and its eventual disposition.
Measurement of any impairment loss is based on the excess of the carrying value of the asset over its fair value. Based on the uncertainty
of forecasts inherent with a new product, events such as the failure to generate forecasted revenue from new products could result in
a non-cash impairment in future periods. </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<span></span>
</td>
<td class="text"><p id="xdx_845_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zowPvJgkr1v1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86A_zrUkcJMmMgP4">Recoverability of Long-Lived Assets</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
evaluate long-lived assets such as property, equipment and definite lived intangible assets, such as patents, for impairment whenever
events or circumstances indicate that the carrying value of the assets recognized in our financial statements may not be recoverable.
Factors that we consider include whether there has been a significant decrease in the market value of an asset, a significant change
in the way an asset is being utilized, or a significant change, delay or departure in our strategy for that asset, or a significant change
in the macroeconomic environment, such as the impact of the COVID-19 pandemic. Our assessment of the recoverability of long-lived assets
involves significant judgment and estimation. These assessments reflect our assumptions, which, we believe, are consistent with the assumptions
hypothetical marketplace participants use. Factors that we must estimate when performing recoverability and impairment tests include,
among others, forecasted revenue, margin costs and the economic life of the asset. If impairment is indicated, we determine if the total
estimated future cash flows on an undiscounted basis are less than the carrying amounts of the asset or assets. If so, an impairment
loss is measured and recognized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
impairment loss calculations require that we apply judgment in identifying asset groups, estimating future cash flows, determining asset
fair values, and estimating asset&#8217;s useful lives. The Company reviews identifiable amortizable intangible assets for impairment
whenever events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. Determination of recoverability
is based on the lowest level of identifiable estimated undiscounted cash flows resulting from use of the asset and its eventual disposition.
Measurement of any impairment loss is based on the excess of the carrying value of the asset over its fair value. Based on the uncertainty
of forecasts inherent with a new product, events such as the failure to generate forecasted revenue from new products could result in
a non-cash impairment in future periods. </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p id="xdx_847_eus-gaap--ResearchAndDevelopmentExpensePolicy_zGjVfszuc6gk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_861_zxMhjB9oXyT5">Research
and Development</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed as incurred. Total research and development costs were $<span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230331_zCs1D9tKs0sj" title="Research and development cost">179,000</span> for the three months ended March 31,
2023, and $<span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20220331_zGlbHIaIRhXj" title="Research and development cost">168,000</span> for three months ended March 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IMPACT
Biomedical, Inc. and Subsidiaries</b></span></p>

<p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<span></span>
</td>
<td class="text"><p id="xdx_84D_eus-gaap--ResearchAndDevelopmentExpensePolicy_zUmodztQVwYh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_862_z12WkzOcodcd">Research
and Development</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed as incurred. Total research and development costs were $<span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231_zXrSS0mVKZme" title="Research and development cost">1,226,000</span> for the year ended December 31,
2022, and $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20211231_z2jj3EC2bXLh" title="Research and development cost">1,080,000</span> for year ended 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IMPACT
Biomedical, Inc. and Subsidiaries</b></span></p>

<p style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Standards</a></td>
<td class="text"><p id="xdx_849_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zxAblYvjT77c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zeeCcaIvXdw5">Recent
Accounting Standards</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Financial Accounting Standards Board (FASB) issues various Accounting Standards Updates relating to the treatment and recording of certain
accounting transactions. There are several new accounting pronouncements issued by FASB which are not yet effective. Each of these pronouncements,
as applicable, has been or will be adopted by the Company. As of March 31, 2023, none of these pronouncements is expected to have a material
effect on the financial position, results of operations or cash flows of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">On January
1, 2022, the Company adopted amended accounting guidance &#8220;<i>ASU No.2016-13 &#8211; Credit Losses&#8221;</i> which requires an
allowance for credit losses to be deducted from the amortized cost basis of financial assets to present the net carrying value at the
amount that is expected to be collected over the contractual term of the asset considering relevant information about past events, current
conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. In estimating expected losses
in the loan and lease portfolio, borrower-specific financial data and macro-economic assumptions are utilized to project losses over
a reasonable and supportable forecast period. Assumptions and judgment are applied to measure amounts and timing of expected future cash
flows, collateral values and other factors used to determine the borrowers&#8217; abilities to repay obligations. After the forecast
period, the Company utilizes longer-term historical loss experience to estimate losses over the remaining contractual life of the loans.
Prior to 2022, the allowance for credit losses represented the amount that in management&#8217;s judgment reflected incurred credit losses
inherent in the loan and lease portfolio as of the balance sheet date. As of March 31, 2023 the Company has deemed that no reserve or
credit losses were necessary.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zUyTpbk6CX49" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zsvnCvULgxk3">Recent
Accounting Standards</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Financial Accounting Standards Board (FASB) issues various Accounting Standards Updates relating to the treatment and recording of certain
accounting transactions. There are several new accounting pronouncements issued by FASB which are not yet effective. Each of these pronouncements,
as applicable, has been or will be adopted by the Company. As of December 31, 2022, none of these pronouncements is expected to have
a material effect on the financial position, results of operations or cash flows of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_IMPB_ContinuingOperationsAndGoingConcernPolicyTextBlock', window );">Continuing Operations and Going Concern</a></td>
<td class="text"><p id="xdx_84D_ecustom--ContinuingOperationsAndGoingConcernPolicyTextBlock_zcNMEQrOWwg3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_zTEGg80OPLSg">Continuing
Operations and Going Concern</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to incurred operating losses as well as negative cash flows from operating and investing activities over the past two years, the accompanying
consolidated financial statements have been prepared assuming that the Company will continue as a going concern. This basis of accounting
contemplates the recovery of our assets and the satisfaction of liabilities in the normal course of business. These consolidated financial
statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary
should we be unable to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
continue as a going concern, the Company has entered into an updated revolving promissory note which extended the maturity through March
31, 2024, and DSS intends to continue to fund the operations of the Company through a year from the date these financial statements were
available to be issued. The Company&#8217;s management intends to take actions necessary to continue as a going concern. Management&#8217;s
plans concerning these matters include, among other things, monetization of its intellectual properties, and tightly controlling operating
costs. Based on this, the Company has concluded that substantial doubt of its ability to continue as a going concern has been alleviated.</span></p>
<span></span>
</td>
<td class="text"><p id="xdx_84F_ecustom--ContinuingOperationsAndGoingConcernPolicyTextBlock_zABPPJrNc1Q6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_861_zeJYlmlxbFEd">Continuing
Operations and Going Concern</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to incurred operating losses as well as negative cash flows from operating and investing activities over the past two years, the accompanying
consolidated financial statements have been prepared assuming that the Company will continue as a going concern. This basis of accounting
contemplates the recovery of our assets and the satisfaction of liabilities in the normal course of business. These consolidated financial
statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary
should we be unable to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
continue as a going concern, the Company has entered into an updated revolving promissory note which extended the maturity through December
31, 2022, and DSS intends to continue to fund the operations of the Company through a year from the date these financial statements were
available to be issued. The Company&#8217;s management intends to take actions necessary to continue as a going concern. Management&#8217;s
plans concerning these matters include, among other things, monetization of its intellectual properties, and tightly controlling operating
costs. Based on this, the Company has concluded that substantial doubt of its ability to continue as a going concern has been alleviated.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMPB_ContinuingOperationsAndGoingConcernPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Continuing Operations And Going Concern [Policy Text Block].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">IMPB_ContinuingOperationsAndGoingConcernPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>IMPB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 12<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139839849110848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations and Basis of Presentation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfCondensedFinancialStatementsTableTextBlock', window );">Schedule of Condensed Financial Statements</a></td>
<td class="text"><p id="xdx_898_esrt--ScheduleOfCondensedFinancialStatementsTableTextBlock_zCwUXDY4Qu6e" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements include all accounts of the entities as of the reporting period ending dates and for the reporting
periods as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_z4z5BYYYPCG7" style="display: none">Schedule
of Condensed Financial Statements</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: center">Name of consolidated subsidiary</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">State or other jurisdiction of incorporation or organization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">Date of incorporation or formation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Attributable interest as of <br/>March 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Attributable <br/>interest as of <br/>December 31, <br/>2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Global BioMedical, Inc.</td><td style="width: 2%">&#160;</td>
    <td style="width: 12%"><span id="xdx_900_ecustom--StateOrOtherJurisdictionOfIncorporationOrOrganization_c20230101__20230331__srt--OwnershipAxis__custom--GlobalBioMedicalIncMember_zIHBDFNktZWf" title="State or other jurisdiction of incorporation or organization">Nevada</span></td><td style="width: 2%">&#160;</td>
    <td style="width: 12%"><span id="xdx_905_edei--EntityIncorporationDateOfIncorporation_dd_c20230101__20230331__srt--OwnershipAxis__custom--GlobalBioMedicalIncMember_zPVifDMn8HAd" title="Date of incorporation or formation">April 18, 2017</span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90C_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20230331__srt--OwnershipAxis__custom--GlobalBioMedicalIncMember_zICnblZve9hf" title="Attributable interest percentage">90.9</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90B_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--GlobalBioMedicalIncMember_zoV5HtpvowU1" title="Attributable interest percentage">90.9</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Global BioLife, Inc.</td><td>&#160;</td>
    <td><span id="xdx_901_ecustom--StateOrOtherJurisdictionOfIncorporationOrOrganization_c20230101__20230331__srt--OwnershipAxis__custom--GlobalBioLifeIncMember_z3aGwZ7PsBR4" title="State or other jurisdiction of incorporation or organization">Nevada</span></td><td>&#160;</td>
    <td><span id="xdx_906_edei--EntityIncorporationDateOfIncorporation_dd_c20230101__20230331__srt--OwnershipAxis__custom--GlobalBioLifeIncMember_zaO5qwKuCCRe" title="Date of incorporation or formation">April 14, 2017</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20230331__srt--OwnershipAxis__custom--GlobalBioLifeIncMember_zRS65KdYQx7c" title="Attributable interest percentage">81.8</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--GlobalBioLifeIncMember_zO0xobSyy5K2" title="Attributable interest percentage">81.8</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">BioLife Sugar, Inc</td><td>&#160;</td>
    <td><span id="xdx_90B_ecustom--StateOrOtherJurisdictionOfIncorporationOrOrganization_c20230101__20230331__srt--OwnershipAxis__custom--BioLifeSugarIncMember_z1DG4rXM1ksi" title="State or other jurisdiction of incorporation or organization">Nevada</span></td><td>&#160;</td>
    <td><span id="xdx_905_edei--EntityIncorporationDateOfIncorporation_dd_c20230101__20230331__srt--OwnershipAxis__custom--BioLifeSugarIncMember_z1qWDh45VM08" title="Date of incorporation or formation">April 23, 2018</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20230331__srt--OwnershipAxis__custom--BioLifeSugarIncMember_z16iaO8UNdwb" title="Attributable interest percentage">90.9</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--BioLifeSugarIncMember_ztP2KJ3wcpWg" title="Attributable interest percentage">90.9</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Happy Sugar Inc</td><td>&#160;</td>
    <td><span id="xdx_90E_ecustom--StateOrOtherJurisdictionOfIncorporationOrOrganization_c20230101__20230331__srt--OwnershipAxis__custom--HappySugarIncMember_zrdRrUOgSo69" title="State or other jurisdiction of incorporation or organization">Nevada</span></td><td>&#160;</td>
    <td><span id="xdx_90C_edei--EntityIncorporationDateOfIncorporation_dd_c20230101__20230331__srt--OwnershipAxis__custom--HappySugarIncMember_z5SFO8dbSLSa" title="Date of incorporation or formation">August 17, 2018</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20230331__srt--OwnershipAxis__custom--HappySugarIncMember_zvQRNrD7qZu4" title="Attributable interest percentage">81.8</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--HappySugarIncMember_zMpA41Q67aPl" title="Attributable interest percentage">81.8</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Sweet Sense Inc.</td><td>&#160;</td>
    <td><span id="xdx_90A_ecustom--StateOrOtherJurisdictionOfIncorporationOrOrganization_c20230101__20230331__srt--OwnershipAxis__custom--SweetSenseIncMember_z0AuJTir93ta" title="State or other jurisdiction of incorporation or organization">Nevada</span></td><td>&#160;</td>
    <td><span id="xdx_906_edei--EntityIncorporationDateOfIncorporation_dd_c20230101__20230331__srt--OwnershipAxis__custom--SweetSenseIncMember_zVGoQe5wh5F" title="Date of incorporation or formation">April 30, 2018</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20230331__srt--OwnershipAxis__custom--SweetSenseIncMember_zzHfN0CZ8nF9" title="Attributable interest percentage">95.5</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--SweetSenseIncMember_zKKdzQEyIaZd" title="Attributable interest percentage">95.5</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Global Sugar Solutions Inc.</td><td>&#160;</td>
    <td><span id="xdx_909_ecustom--StateOrOtherJurisdictionOfIncorporationOrOrganization_c20230101__20230331__srt--OwnershipAxis__custom--GlobalSugarSolutionsIncMember_zwczc9QUp25k" title="State or other jurisdiction of incorporation or organization">Nevada</span></td><td>&#160;</td>
    <td><span id="xdx_901_edei--EntityIncorporationDateOfIncorporation_dd_c20230101__20230331__srt--OwnershipAxis__custom--GlobalSugarSolutionsIncMember_zAroUALjZgTi" title="Date of incorporation or formation">November 7, 2019</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20230331__srt--OwnershipAxis__custom--GlobalSugarSolutionsIncMember_zBtF5Fvi0OL" title="Attributable interest percentage">100</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--GlobalSugarSolutionsIncMember_zfdpbWiabovk" title="Attributable interest percentage">100</span></td><td style="text-align: left">%</td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_89B_esrt--ScheduleOfCondensedFinancialStatementsTableTextBlock_zI2mYLbcMG71" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements include all accounts of the entities as of the reporting period ending dates and for the reporting
periods as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_zrTi228E0Hve" style="display: none">Schedule
of Condensed Financial Statements</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Name of consolidated subsidiary</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">State or other jurisdiction of incorporation or organization</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Date of incorporation or formation</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Attributable interest as of <br/> December 31, <br/> 2022</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Attributable <br/> interest as of <br/> December 31, <br/> 2021</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: left">Global BioMedical, Inc.</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 18%"><span id="xdx_90F_ecustom--StateOrOtherJurisdictionOfIncorporationOrOrganization_c20220101__20221231__srt--OwnershipAxis__custom--GlobalBioMedicalIncMember_zj6YxyNf8Jba" title="State or other jurisdiction of incorporation or organization">Nevada</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 18%"><span id="xdx_901_edei--EntityIncorporationDateOfIncorporation_dd_c20220101__20221231__srt--OwnershipAxis__custom--GlobalBioMedicalIncMember_z1oSxHwxLdE" title="Date of incorporation or formation">April 18, 2017</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_90F_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--GlobalBioMedicalIncMember_zNLFbG07qcq6" title="Attributable interest percentage">90.9</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_906_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20211231__srt--OwnershipAxis__custom--GlobalBioMedicalIncMember_zvuByqKsBpL9" title="Attributable interest percentage">90.9</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Global BioLife, Inc.</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_902_ecustom--StateOrOtherJurisdictionOfIncorporationOrOrganization_c20220101__20221231__srt--OwnershipAxis__custom--GlobalBioLifeIncMember_zw2zPHa5DFQ2" title="State or other jurisdiction of incorporation or organization">Nevada</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90A_edei--EntityIncorporationDateOfIncorporation_dd_c20220101__20221231__srt--OwnershipAxis__custom--GlobalBioLifeIncMember_zONGg88g42x9" title="Date of incorporation or formation">April 14, 2017</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--GlobalBioLifeIncMember_zjFy7BH16Qhj" title="Attributable interest percentage">81.8</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20211231__srt--OwnershipAxis__custom--GlobalBioLifeIncMember_zXOvifpjTBt" title="Attributable interest percentage">63.6</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">BioLife Sugar, Inc</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90E_ecustom--StateOrOtherJurisdictionOfIncorporationOrOrganization_c20220101__20221231__srt--OwnershipAxis__custom--BioLifeSugarIncMember_z2DKWvZTkrFi" title="State or other jurisdiction of incorporation or organization">Nevada</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90A_edei--EntityIncorporationDateOfIncorporation_dd_c20220101__20221231__srt--OwnershipAxis__custom--BioLifeSugarIncMember_zteqNjNmbVMk" title="Date of incorporation or formation">April 23, 2018</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90C_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--BioLifeSugarIncMember_zoAYF3xbSg83" title="Attributable interest percentage">90.9</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20211231__srt--OwnershipAxis__custom--BioLifeSugarIncMember_ztM7xQ8lX8oc" title="Attributable interest percentage">63.6</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Happy Sugar Inc</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_903_ecustom--StateOrOtherJurisdictionOfIncorporationOrOrganization_c20220101__20221231__srt--OwnershipAxis__custom--HappySugarIncMember_zv9GlHKO2uD3" title="State or other jurisdiction of incorporation or organization">Nevada</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90B_edei--EntityIncorporationDateOfIncorporation_dd_c20220101__20221231__srt--OwnershipAxis__custom--HappySugarIncMember_zs9MtTdiw097" title="Date of incorporation or formation">August 17, 2018</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--HappySugarIncMember_zxvnxg59cDPi" title="Attributable interest percentage">81.8</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20211231__srt--OwnershipAxis__custom--HappySugarIncMember_zUa6AMo7MUq9" title="Attributable interest percentage">63.6</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Sweet Sense Inc.</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_906_ecustom--StateOrOtherJurisdictionOfIncorporationOrOrganization_c20220101__20221231__srt--OwnershipAxis__custom--SweetSenseIncMember_zT31tTWcA7xf" title="State or other jurisdiction of incorporation or organization">Nevada</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_909_edei--EntityIncorporationDateOfIncorporation_dd_c20220101__20221231__srt--OwnershipAxis__custom--SweetSenseIncMember_zi1ZFP0VWiC8" title="Date of incorporation or formation">April 30, 2018</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--SweetSenseIncMember_znUTdBy2RC6" title="Attributable interest percentage">95.5</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20211231__srt--OwnershipAxis__custom--SweetSenseIncMember_zlvDJinYJA2f" title="Attributable interest percentage">81.8</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Global Sugar Solutions Inc.</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90A_ecustom--StateOrOtherJurisdictionOfIncorporationOrOrganization_c20220101__20221231__srt--OwnershipAxis__custom--GlobalSugarSolutionsIncMember_zmGAIxue30i5" title="State or other jurisdiction of incorporation or organization">Nevada</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_909_edei--EntityIncorporationDateOfIncorporation_dd_c20220101__20221231__srt--OwnershipAxis__custom--GlobalSugarSolutionsIncMember_zZrTE1q0Ixig" title="Date of incorporation or formation">November 7, 2019</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--GlobalSugarSolutionsIncMember_zOJhwTFWaw1h" title="Attributable interest percentage">100</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90C_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20211231__srt--OwnershipAxis__custom--GlobalSugarSolutionsIncMember_zvMjPp9213e2" title="Attributable interest percentage">80</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfCondensedFinancialStatementsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed financial statements, including, but not limited to, the balance sheet, income statement, and statement of cash flows.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Paragraph (a)<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfCondensedFinancialStatementsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139839849100528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY PLANT AND EQUIPMENT and INVESTMENT IN REAL ESTATE, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property Plant and Equipment</a></td>
<td class="text"><p id="xdx_894_eus-gaap--PropertyPlantAndEquipmentTextBlock_zKmGCKB8jhLi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property,
plant and equipment consisted of the following as of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_zlqErWIC7q1i" style="display: none">Schedule
of Property Plant and Equipment</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">Estimated</td><td>&#160;</td>
    <td colspan="2" id="xdx_49D_20230331_zqqKxvPswvVe" style="text-align: center"><b>March 31,</b></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49B_20221231_zkPG2FKFlzKc" style="text-align: center"><b>December 31,</b></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Useful Life</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zqxZN27jvhsd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 54%; text-align: left">Machinery and equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 12%; text-align: right"><span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MinimumMember_ziKBKyunP5Wl">5</span>-<span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MaximumMember_zBPBwmp0uYL3">10</span> years</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">30,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">25,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_zySoihHYZMac" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Construction in progress</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: right; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">251,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">251,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzm9U_zrVVWlbBESsb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total Cost</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">281,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">276,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzm9U_zAT672QBpB97" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Property, plant and equipment, gross</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">281,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">276,000</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iI_msPPAENzm9U_zuHGi7xUSjyj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: right; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1345">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzm9U_zPzbbi0iICH2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Property, plant and equipment, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: right; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">279,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">276,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_897_eus-gaap--PropertyPlantAndEquipmentTextBlock_zeK0nWv9lJPb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property,
plant and equipment consisted of the following as of December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;<span id="xdx_8BF_z2t3OCgEixh5" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of Property Plant and Equipment&#160;</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_49A_20221231_zrXoMxm3v5O5" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_49E_20211231_zk829oJPVnK5" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Estimated</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Useful Life</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zmWwyyscexYl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 42%; text-align: left">Machinery and equipment</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MinimumMember_zcjv5qkHdFGl" title="Estimated Useful Life">5</span>-<span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MaximumMember_z1s4xoixrAK1" title="Estimated Useful Life">10</span> years</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">25,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0572">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_zQ6OaJkGOZVg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Construction in progress</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">251,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0579">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzm9U_zBEEe2hg8FS6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Total Cost</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">276,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0582">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzm9U_zjxoGnO8mgk3" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Property, plant and equipment, gross</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">276,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0585">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iI_msPPAENzm9U_zvzGcF4BUl5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Less accumulated depreciation</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0587">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0588">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzm9U_zAXgLfCmKW82" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Property, plant and equipment, net</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">276,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0591">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139839849040048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Goodwill</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--ScheduleOfGoodwillTextBlock_z8SUaUaDgTli" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Goodwill
balances and activity for the three months ended March 31, 2023 and year ended December 31, 2022 consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span style="display: none"><span id="xdx_8B3_zYQvG6r2jJ9c">Schedule
of Goodwill</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%">Balance at December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--Goodwill_iS_c20230101__20230331_zVuouwoCAx3" style="width: 18%; text-align: right" title="Balance at December 31, 2022">25,093,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Goodwill adjustment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--GoodwillImpairmentLoss_c20230101__20230331_zVMey9wbMgll" style="border-bottom: Black 1.5pt solid; text-align: right" title="Goodwill adjustment"><span style="-sec-ix-hidden: xdx2ixbrl1360">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance at March 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--Goodwill_iE_c20230101__20230331_zffStzrknGr5" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance at March 31, 2023">25,093,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_89D_eus-gaap--ScheduleOfGoodwillTextBlock_zpmRTT97BXn8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Goodwill
balances and activity for the year ended December 31, 2022 and year ended December 31, 2021 consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B0_zxYACxWrYIO8" style="display: none">Schedule of Goodwill</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 80%">Balance at December 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--Goodwill_iS_c20220101__20221231_zxPgTUEzpXmk" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Balance at December 31, 2022">25,093,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Goodwill adjustment</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--GoodwillImpairmentLoss_c20220101__20221231_zNm1t3Tac80c" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Goodwill adjustment"><span style="-sec-ix-hidden: xdx2ixbrl0603">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance at December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_989_eus-gaap--Goodwill_iE_c20220101__20221231_zUhDwIwxxPml" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance at March 31, 2023">25,093,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139839833164896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of Intangible Assets</a></td>
<td class="text"><p id="xdx_894_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zGi1WtUkN6Li" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zwb1AaV397ea" style="display: none">Schedule
of Intangible Assets</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">03/31/2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">12/31/2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Gross Carrying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amount</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accumulated</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amortization</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net Carrying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amount</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Gross Carrying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amount</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accumulated</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amortization</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net Carrying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amount</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Definitive-lived:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; text-align: left; padding-bottom: 1.5pt">Developed technology</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20230331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zvIVcgBkvYKl" style="border-bottom: Black 1.5pt solid; width: 6%; text-align: right" title="Gross Carrying Amount">22,258,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20230331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zssAAxGCti9h" style="border-bottom: Black 1.5pt solid; width: 6%; text-align: right" title="Accumulated Amortization">(2,502,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20230331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zHjJx9BowYW5" style="border-bottom: Black 1.5pt solid; width: 6%; text-align: right" title="Net Carrying Amount">19,756,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zWXgbalgJz37" style="border-bottom: Black 1.5pt solid; width: 6%; text-align: right" title="Gross Carrying Amount">22,258,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_z0ahlEuoAWA" style="border-bottom: Black 1.5pt solid; width: 6%; text-align: right" title="Accumulated Amortization">(2,226,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zpwIrJiajne4" style="border-bottom: Black 1.5pt solid; width: 6%; text-align: right" title="Net Carrying Amount">20,033,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20230331_zJJvBS6Ctedk" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Carrying Amount">22,258,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20230331_z8G18z2Gh0Wf" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated Amortization">(2,502,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20230331_zZGqbkVkLHKe" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Carrying Amount">19,756,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20221231_zYxx5eW0ZsLl" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Carrying Amount">22,258,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231_zabLixtyvSB7" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated Amortization">(2,226,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20221231_zX4zinQ5kTUl" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Carrying Amount">20,033,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_894_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zHQdA7txJ6z4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B0_zqZtUD871FG4" style="display: none">Schedule
of Intangible Assets</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">12/31/2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">12/31/2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Gross Carrying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amount</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accumulated</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amortization</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net Carrying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amount</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Gross Carrying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amount</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accumulated</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amortization</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net Carrying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amount</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Definitive-lived:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left; padding-bottom: 1.5pt">Developed technology</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zgBIkWG91zXk" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right" title="Gross Carrying Amount">22,258,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zpuWVPx1EXc2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right" title="Accumulated Amortization">(2,226,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zRgOQZTT6Yd" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right" title="Net Carrying Amount">20,033,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zI7Y34SBRsqh" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right" title="Gross Carrying Amount">22,260,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_z5FrKHNRmm5a" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right" title="Accumulated Amortization">(1,113,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zGbghpcnCqzc" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right" title="Net Carrying Amount">21,147,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Total</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20221231_zk1bqzZQHIJd" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gross Carrying Amount">22,258,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231_zhrxucA4Ylq2" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accumulated Amortization">(2,226,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20221231_zwlty5MPwip8" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net Carrying Amount">20,033,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20211231_zY55HIRHhZ77" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gross Carrying Amount">22,260,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20211231_zdXvV8N6tel6" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accumulated Amortization">(1,113,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20211231_zORzHT040mca" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net Carrying Amount">21,147,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Future Amortization of Developed Technologies</a></td>
<td class="text"><p id="xdx_898_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zJt835MlvhDc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table represents future amortization of developed technologies for the years ending December 31:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 11pt"><span id="xdx_8B1_zgtrZ9zobbee">Schedule
of Future Amortization of Developed Technologies</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49F_20230331_zYwsWZqnCvx7" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_z9IouMh1PgZa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: right">2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">835,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_zOgSIplEnwp8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: right">2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,113,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_zEjc0J7QM5Eg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">2025</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,113,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_zAeK6OAHhN1e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: right">2026</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,113,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_z9fBJamofKN7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">2027</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,113,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_zYjHglv38zI3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: right">Thereafter</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">14,469,000</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_89F_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_ztrJEWSXpzQ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table represents future amortization of developed technologies:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B2_z5r4lxyudiOb" style="display: none">Schedule
of Future Amortization of Developed Technologies</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_497_20221231_z6eq82unuXc3" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_zFHMZ3jeS3b1" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">835,000</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_zjqgq8ica1v2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: right">2022</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">1,113,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_zYolTxwz4QS8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2023</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,113,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_zEbL6CCv6cT9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2024</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,113,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_zUhYP2MIBOXh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2025</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,113,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_zm9aNzIaiv73" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2026</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,113,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_zXVHPYqafEyl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">Thereafter</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">14,468,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139839840787760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Benefit</a></td>
<td class="text"><p id="xdx_890_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zeVbteJrx8E7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
components of income tax benefit for the years ended December 31, 2022, and 2021 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8BA_zVgJq1uKpHb7" style="display: none">Schedule of Components of Income Tax Benefit</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt">Federal</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_49D_20220101__20221231_zPPdkxgx7tbl" style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_494_20210101__20211231_zsPtO3r9p7Ce" style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif">Income Tax Expense (Benefit)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended <br/> December 31, 2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2021</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Current tax payable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CurrentFederalTaxExpenseBenefit_maCITEBzAu9_zu08Pc89efh1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt">Federal</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0747">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0748">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_maCITEBzAu9_zyQka61FNENh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; padding-bottom: 1.5pt">State</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0750">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0751">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--CurrentIncomeTaxExpenseBenefit_iT_mtCITEBzAu9_zwn135doikKf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Total current tax payable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0753">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0754">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Deferred tax</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_iN_di_maDITEBzd7s_zJhzyGuwsa15" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; width: 60%">Federal</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">(1,619,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">(456,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_iN_di_maDITEBzd7s_ztNBdi4bQlP4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; padding-bottom: 1.5pt">State</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(165,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,068,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredIncomeTaxExpenseBenefit_iNT_di_mtDITEBzd7s_maNDTEAzrUM_maITEBzC69_z0pScFqoLUA7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Total deferred tax</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,784,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,524,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_msNDTEAzrUM_msITEBzC69_z9vMFTeuyQkb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Less increase in valuation allowance</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,163,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">129,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzC69_zFxkACmaqe9h" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"> income tax benefit</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(621,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,395,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zFmIGnYwjsfk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Individual
components of deferred tax assets and liabilities are approximately as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BB_zpsriDR3yffg" style="display: none">Schedule of Deferred Tax Assets and Liabilities</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20221231_zgFXxnXr25p4" style="font: 10pt Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20211231_zfc5y7h5hsOf" style="font: 10pt Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif">Deferred Tax Assets &amp; Liabilities:</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Deferred Tax assets:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsInvestments_iI_maDTAGzKh6_zP0JbeoXEuxh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 60%">Impairment of investment</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">929,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0774">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_maDTAGzKh6_zCfppEN0bG37" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Research &amp; development cost</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">250,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0777">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzKh6_zdin9WgapdM3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Net Operating loss</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,611,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,258,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzKh6_z5xwgF3383b1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Gross deferred tax assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,790,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,258,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Deferred tax liability:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_msDITLzt6S_zqIynwAgaUsf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Intangible assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(4,414,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(4,667,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredIncomeTaxLiabilities_iNI_di_mtDITLzt6S_maDTLzghA_z2dRYnKjhO3l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Gross deferred tax liability</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(4,414,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(4,667,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsNet_iNI_di_msDTLzghA_zlUqxnG1rHM6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Less valuation allowance</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,611,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(447,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxLiabilities_iNTI_di_mtDTLzghA_zJEWI0M8rDVe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Net deferred tax liability</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,235,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,856,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Summary of Effective Income Tax Rate</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zFj0WbmBh0U1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_zgvUJyg0FcFk" style="display: none">Summary of Effective Income Tax Rate</span></span></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20220101__20221231_zEzSJYNTofdd" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20210101__20211231_ztWgj4YVqOM4" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_z7KMU8LZR5oe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Statutory United States federal rate</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">21.0</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">21.0</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_zGPP7r08lLyl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">State income taxes net of federal benefit</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1.7</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">26.0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_zqPyqCsGPMKb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(14.8</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)%</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(4.0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_zF8qM7kf9aZd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Effective rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">7.9</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">43</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 9<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139839849260496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Cash Flow Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Schedule of Cash Flow Supplemental</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_zvs4mQmfs7Ad" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes supplemental cash flows for the year ended December 31, 2022, and 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_zKkR64o8ofP9" style="display: none">Schedule
of Cash Flow Supplemental</span> </span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20221231_z0j9i297N2Ri" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20211231_ztiK3wFcXLIj" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ConvertibleNotesPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z1dieTBoYwnj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 60%">Transfer of promissory note 2 to related party</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 16%">5,081,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 16%"><span style="-sec-ix-hidden: xdx2ixbrl0828">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NotesPayable_iNI_di_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zmqZdDNDQEne" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Transfer of note payable, related party</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(5,081,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0831">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139839839244160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Condensed Financial Statements (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=IMPB_GlobalBioMedicalIncMember', window );">Global Bio Medical Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems', window );"><strong>Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_IMPB_StateOrOtherJurisdictionOfIncorporationOrOrganization', window );">State or other jurisdiction of incorporation or organization</a></td>
<td class="text">Nevada<span></span>
</td>
<td class="text">Nevada<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Date of incorporation or formation</a></td>
<td class="text">Apr. 18,  2017<span></span>
</td>
<td class="text">Apr. 18,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Attributable interest percentage</a></td>
<td class="nump">90.90%<span></span>
</td>
<td class="nump">90.90%<span></span>
</td>
<td class="nump">90.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=IMPB_GlobalBioLifeIncMember', window );">Global Bio Life Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems', window );"><strong>Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_IMPB_StateOrOtherJurisdictionOfIncorporationOrOrganization', window );">State or other jurisdiction of incorporation or organization</a></td>
<td class="text">Nevada<span></span>
</td>
<td class="text">Nevada<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Date of incorporation or formation</a></td>
<td class="text">Apr. 14,  2017<span></span>
</td>
<td class="text">Apr. 14,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Attributable interest percentage</a></td>
<td class="nump">81.80%<span></span>
</td>
<td class="nump">81.80%<span></span>
</td>
<td class="nump">63.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=IMPB_BioLifeSugarIncMember', window );">Bio Life Sugar Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems', window );"><strong>Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_IMPB_StateOrOtherJurisdictionOfIncorporationOrOrganization', window );">State or other jurisdiction of incorporation or organization</a></td>
<td class="text">Nevada<span></span>
</td>
<td class="text">Nevada<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Date of incorporation or formation</a></td>
<td class="text">Apr. 23,  2018<span></span>
</td>
<td class="text">Apr. 23,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Attributable interest percentage</a></td>
<td class="nump">90.90%<span></span>
</td>
<td class="nump">90.90%<span></span>
</td>
<td class="nump">63.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=IMPB_HappySugarIncMember', window );">Happy Sugar Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems', window );"><strong>Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_IMPB_StateOrOtherJurisdictionOfIncorporationOrOrganization', window );">State or other jurisdiction of incorporation or organization</a></td>
<td class="text">Nevada<span></span>
</td>
<td class="text">Nevada<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Date of incorporation or formation</a></td>
<td class="text">Aug. 17,  2018<span></span>
</td>
<td class="text">Aug. 17,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Attributable interest percentage</a></td>
<td class="nump">81.80%<span></span>
</td>
<td class="nump">81.80%<span></span>
</td>
<td class="nump">63.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=IMPB_SweetSenseIncMember', window );">Sweet Sense Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems', window );"><strong>Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_IMPB_StateOrOtherJurisdictionOfIncorporationOrOrganization', window );">State or other jurisdiction of incorporation or organization</a></td>
<td class="text">Nevada<span></span>
</td>
<td class="text">Nevada<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Date of incorporation or formation</a></td>
<td class="text">Apr. 30,  2018<span></span>
</td>
<td class="text">Apr. 30,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Attributable interest percentage</a></td>
<td class="nump">95.50%<span></span>
</td>
<td class="nump">95.50%<span></span>
</td>
<td class="nump">81.80%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=IMPB_GlobalSugarSolutionsIncMember', window );">Global Sugar Solutions Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems', window );"><strong>Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_IMPB_StateOrOtherJurisdictionOfIncorporationOrOrganization', window );">State or other jurisdiction of incorporation or organization</a></td>
<td class="text">Nevada<span></span>
</td>
<td class="text">Nevada<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Date of incorporation or formation</a></td>
<td class="text">Nov.  07,  2019<span></span>
</td>
<td class="text">Nov.  07,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Attributable interest percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMPB_StateOrOtherJurisdictionOfIncorporationOrOrganization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>State or other jurisdiction of incorporation or organization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">IMPB_StateOrOtherJurisdictionOfIncorporationOrOrganization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>IMPB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationDateOfIncorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when an entity was incorporated</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationDateOfIncorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=IMPB_GlobalBioMedicalIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=IMPB_GlobalBioMedicalIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=IMPB_GlobalBioLifeIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=IMPB_GlobalBioLifeIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=IMPB_BioLifeSugarIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=IMPB_BioLifeSugarIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=IMPB_HappySugarIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=IMPB_HappySugarIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=IMPB_SweetSenseIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=IMPB_SweetSenseIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=IMPB_GlobalSugarSolutionsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=IMPB_GlobalSugarSolutionsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139839845108096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Nature of Operations and Basis of Presentation (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Nov. 08, 2019</div></th>
<th class="th"><div>Oct. 16, 2018</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems', window );"><strong>Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,919,000<span></span>
</td>
<td class="nump">$ 3,111,000<span></span>
</td>
<td class="nump">$ 3,315,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember', window );">Subsidiaries [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems', window );"><strong>Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,919,000<span></span>
</td>
<td class="nump">$ 3,111,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=IMPB_GlobalBioMedicalPteLtdMember', window );">Global Bio Medical Pte Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems', window );"><strong>Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period shares</a></td>
<td class="nump">125,064,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=IMPB_SweetSenseMember', window );">Sweet Sense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems', window );"><strong>Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Minority interest ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration given for purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=IMPB_GlobalBioMedicalPteLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=IMPB_GlobalBioMedicalPteLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=IMPB_SweetSenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=IMPB_SweetSenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139839833782688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting and Reporting Policies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development cost</a></td>
<td class="nump">$ 179,000<span></span>
</td>
<td class="nump">$ 168,000<span></span>
</td>
<td class="nump">$ 1,226,000<span></span>
</td>
<td class="nump">$ 1,080,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139839839308688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restatement (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">$ 101,000<span></span>
</td>
<td class="nump">$ 133,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 462,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139839834153024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 179,000<span></span>
</td>
<td class="nump">$ 168,000<span></span>
</td>
<td class="nump">$ 1,226,000<span></span>
</td>
<td class="nump">$ 1,080,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses</a></td>
<td class="nump">183,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,000<span></span>
</td>
<td class="nump">44,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=IMPB_GRDGscienceLLCMember', window );">GRDG Science LLC [Member] | Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Prepaid expenses includes prepaid inventory</a></td>
<td class="nump">140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 43,000<span></span>
</td>
<td class="nump">$ 43,000<span></span>
</td>
<td class="nump">43,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104,000<span></span>
</td>
<td class="nump">$ 43,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=IMPB_GRDGscienceLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=IMPB_GRDGscienceLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139839834072576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Receivable (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 22, 2022</div></th>
<th class="th"><div>May 14, 2021</div></th>
<th class="th"><div>Feb. 21, 2021</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableModificationsLineItems', window );"><strong>Financing Receivable, Modified [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesReceivableNet', window );">Note receivable principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 206,000<span></span>
</td>
<td class="nump">$ 205,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">Aug. 19,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 19,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Debt principal and interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">205,000<span></span>
</td>
<td class="nump">$ 206,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableGrossCurrent', window );">Notes receivable current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">205,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetNoncurrent', window );">Notes and loans receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">190,000<span></span>
</td>
<td class="nump">$ 5,081,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,008,000<span></span>
</td>
<td class="nump">9,529,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=IMPB_PromissoryNoteOneMember', window );">Promissory Note One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableModificationsLineItems', window );"><strong>Financing Receivable, Modified [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesReceivableNet', window );">Note receivable principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 206,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">Aug. 19,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 19,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Debt principal and interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206,000<span></span>
</td>
<td class="nump">197,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableGrossCurrent', window );">Notes receivable current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetNoncurrent', window );">Notes and loans receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">190,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=IMPB_PromissoryNoteTwoMember', window );">Promissory Note Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableModificationsLineItems', window );"><strong>Financing Receivable, Modified [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 14,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetNoncurrent', window );">Notes and loans receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,081,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=IMPB_PromissoryNoteTwoMember', window );">Promissory Note Two [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableModificationsLineItems', window );"><strong>Financing Receivable, Modified [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments including both interest and principal payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableModificationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-42<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-42<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481933/310-10-55-12A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 33<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-33<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-34<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableModificationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost, before allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansReceivableGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of financing receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansReceivableNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=IMPB_PromissoryNoteOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=IMPB_PromissoryNoteOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=IMPB_PromissoryNoteTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=IMPB_PromissoryNoteTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139839836307984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 22, 2021</div></th>
<th class="th"><div>Mar. 18, 2021</div></th>
<th class="th"><div>Mar. 15, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Dec. 19, 2020</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 23, 2021</div></th>
<th class="th"><div>Apr. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=IMPB_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Nano9 LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equitable ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=IMPB_StockPurchaseAgreementMember', window );">Stock Purchase Agreement [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=IMPB_StockPurchaseAgreementMember', window );">Stock Purchase Agreement [Member] | Impact Oncology PTE Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,480,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Number of common stock owned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,480,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=IMPB_VivacitasAgreementMember', window );">Vivacitas Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtFairValue', window );">Investment owned at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,035,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock option exercised, shares</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock option exercised, value</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedPercentOfNetAssets', window );">Investment cost, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtCost', window );">Investment cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMPB_AsiaPacificHoldingsLimitedMember', window );">Asia Pacific Holdings Limited [Member] | Subscription Arrangement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Ordinary shares to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_IMPB_OrdinarySharesPercentage', window );">Ordinary shares percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets', window );">Purchase price of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 632,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMPB_NanoNineLLCMember', window );">Nano9 LLC [Member] | Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Number of shares issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtFairValue', window );">Investment owned at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMPB_VivacitasOncologyIncMember', window );">Vivacitas Oncology Inc [Member] | Stock Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Option termination, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">This option will terminate upon one
of the following events: (i) Vivacitas&#8217; board of directors cancels this option because it is no longer in the best interest of
the Company; (ii) December 31, 2022; or (iii) the date on which Vivacitas receives more than $1.00 per share of the Company&#8217;s common
stock in a private placement with gross proceeds of $500,000. Under the terms of the Vivacitas Agreement #1, the Company will be allocated
two seats on the board of Vivacitas<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMPB_OrdinarySharesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ordinary shares percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">IMPB_OrdinarySharesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>IMPB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedAtCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of the investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480493/946-210-55-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 5)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedAtCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in security owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480493/946-210-55-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedPercentOfNetAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of investment owned to net assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480493/946-210-55-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedPercentOfNetAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares purchased for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=IMPB_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=IMPB_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=IMPB_NanoNineLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=IMPB_NanoNineLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=IMPB_StockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=IMPB_StockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=IMPB_ImpactOncologyPTELtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=IMPB_ImpactOncologyPTELtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=IMPB_VivacitasAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=IMPB_VivacitasAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMPB_AsiaPacificHoldingsLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMPB_AsiaPacificHoldingsLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_SubscriptionArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_SubscriptionArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMPB_NanoNineLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMPB_NanoNineLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMPB_VivacitasOncologyIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMPB_VivacitasOncologyIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139839833237952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Property Plant and Equipment (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 281,000<span></span>
</td>
<td class="nump">$ 276,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">279,000<span></span>
</td>
<td class="nump">276,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and Equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and Equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 251,000<span></span>
</td>
<td class="nump">$ 251,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139839949003072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY PLANT AND EQUIPMENT and INVESTMENT IN REAL ESTATE, NET (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139839844790912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Goodwill (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at December 31, 2022</a></td>
<td class="nump">$ 25,093,000<span></span>
</td>
<td class="nump">$ 25,093,000<span></span>
</td>
<td class="nump">$ 25,093,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at March 31, 2023</a></td>
<td class="nump">$ 25,093,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,093,000<span></span>
</td>
<td class="nump">$ 25,093,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139839833804912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Intangible Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 22,258,000<span></span>
</td>
<td class="nump">$ 22,258,000<span></span>
</td>
<td class="nump">$ 22,260,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(2,502,000)<span></span>
</td>
<td class="num">(2,226,000)<span></span>
</td>
<td class="num">(1,113,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">19,756,000<span></span>
</td>
<td class="nump">20,033,000<span></span>
</td>
<td class="nump">21,147,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed Technology Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">22,258,000<span></span>
</td>
<td class="nump">22,258,000<span></span>
</td>
<td class="nump">22,260,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(2,502,000)<span></span>
</td>
<td class="num">(2,226,000)<span></span>
</td>
<td class="num">(1,113,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 19,756,000<span></span>
</td>
<td class="nump">$ 20,033,000<span></span>
</td>
<td class="nump">$ 21,147,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139839833176048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 01, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 21, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_IMPB_NoncashOrPartNoncashAcquisitionValueOfAssetAcquiredDescription', window );">Acquisition value of asset acquired, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The guideline public company Market
Approach produced a mean business enterprise value indication using estimated 2025 results of $69.24 million. The Income Approach was
based upon the use of a discounted pro forma cash flow model and produced a business enterprise value indication of $56.54 million. A
weighting of 20% to the weighted value indicated was applied under the Market Approach, a weighting of 10% to the prior transaction value
and a weighting of 70% to the value indicated under the Income Approach. A lower weighting was applied to the Market Approach due to
the fact of using forecasted earnings of the Company. Based upon the above weightings, an initial value of $57.26 million for Impact
was calculated. Adding cash and cash equivalents of $33,000 to the initial business enterprise value produced a concluded business enterprise
value of $57.29 million (rounded) for Impact.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash</a></td>
<td class="nump">$ 33,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 46,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long term debt fair value</a></td>
<td class="nump">13,150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityFairValueAdjustment', window );">Equity fair value</a></td>
<td class="nump">44,140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Debt carrying amount</a></td>
<td class="nump">$ 4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMPB_NoncashOrPartNoncashAcquisitionValueOfAssetAcquiredDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">IMPB_NoncashOrPartNoncashAcquisitionValueOfAssetAcquiredDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>IMPB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which an instrument classified in shareholders' equity could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139839833254320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Future Amortization of Developed Technologies (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">2023</a></td>
<td class="nump">$ 835,000<span></span>
</td>
<td class="nump">$ 835,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2024</a></td>
<td class="nump">1,113,000<span></span>
</td>
<td class="nump">1,113,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2025</a></td>
<td class="nump">1,113,000<span></span>
</td>
<td class="nump">1,113,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2026</a></td>
<td class="nump">1,113,000<span></span>
</td>
<td class="nump">1,113,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2027</a></td>
<td class="nump">1,113,000<span></span>
</td>
<td class="nump">1,113,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,113,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">$ 14,469,000<span></span>
</td>
<td class="nump">$ 14,468,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139839845162320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Amortization</a></td>
<td class="nump">$ 280,000<span></span>
</td>
<td class="nump">$ 278,000<span></span>
</td>
<td class="nump">$ 1,113,000<span></span>
</td>
<td class="nump">$ 1,113,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139839833771872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 22, 2022</div></th>
<th class="th"><div>Feb. 21, 2021</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest, rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument, maturity date</a></td>
<td class="text">Aug. 19,  2023<span></span>
</td>
<td class="text">Aug. 19,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Outstanding balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,991,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,524,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Outstanding balance, including interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,008,000<span></span>
</td>
<td class="nump">$ 9,529,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=IMPB_RevolvingPromissoryNoteMember', window );">Revolving Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest, rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.25%<span></span>
</td>
<td class="nump">4.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument, maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 31,  2024<span></span>
</td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDefaultLongtermDebtDescriptionOfNoticeOfDefault', window );">Long term debt, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In
the case of default, at DSS&#8217;s option, (i) eighteen percent (18%) per annum, or (ii) such lesser rate of interest as Lender in its
sole discretion may choose to charge; but never more than the Maximum Lawful Rate.<span></span>
</td>
<td class="text">In the case of default, at DSS&#8217;s option,
(i) eighteen percent (18%) per annum, or (ii) such lesser rate of interest as Lender in its sole discretion may choose to charge; but
never more than the Maximum Lawful Rate.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDefaultLongtermDebtDescriptionOfNoticeOfDefault">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the facts pertaining to a notice received from a lender that an event of default has occurred with respect to the long-term debt instrument or borrowing, and a description of the expected financial consequences of receiving such notice, including the effects of a demand for immediate repayment of all amounts due, and the classification of the debt on the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDefaultLongtermDebtDescriptionOfNoticeOfDefault</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=IMPB_RevolvingPromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=IMPB_RevolvingPromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139839834119168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Details Narrative) - $ / shares<br></strong></div></th>
<th class="th"><div>May 11, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 23, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000,000<span></span>
</td>
<td class="nump">3,000,000,000<span></span>
</td>
<td class="nump">4,000,000,000<span></span>
</td>
<td class="nump">4,000,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,073,621<span></span>
</td>
<td class="nump">125,073,621<span></span>
</td>
<td class="nump">3,877,282,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,073,621<span></span>
</td>
<td class="nump">125,073,621<span></span>
</td>
<td class="nump">3,877,282,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">3,877,282,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember', window );">Board of Directors Chairman [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,073,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,073,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139839839191632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research &amp; development</a></td>
<td class="nump">$ 179,000<span></span>
</td>
<td class="nump">$ 168,000<span></span>
</td>
<td class="nump">$ 1,226,000<span></span>
</td>
<td class="nump">$ 1,080,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party owed transaction</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent', window );">Prepaid monthly fees</a></td>
<td class="nump">43,000<span></span>
</td>
<td class="nump">43,000<span></span>
</td>
<td class="nump">43,000<span></span>
</td>
<td class="nump">43,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Related costs for employees</a></td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMPB_GRDGscienceLLCMember', window );">GRDG Science LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Payment in funding of research and development</a></td>
<td class="nump">43,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research &amp; development</a></td>
<td class="nump">129,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">546,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="nump">$ 52,000<span></span>
</td>
<td class="nump">$ 117,000<span></span>
</td>
<td class="nump">$ 155,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(7)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMPB_GRDGscienceLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMPB_GRDGscienceLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139839844530368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 19, 2022</div></th>
<th class="th"><div>Mar. 19, 2022</div></th>
<th class="th"><div>Feb. 15, 2022</div></th>
<th class="th"><div>Nov. 27, 2018</div></th>
<th class="th"><div>Aug. 15, 2018</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=IMPB_RoyaltyAgreementMember', window );">Royalty Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_IMPB_RoyaltyPercentage', window );">Royalty percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_IMPB_SaleOfRoyaltyPercentage', window );">Sale of royalty percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_IMPB_DevelopmentCostPercent', window );">Development cost, percent</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=IMPB_RoyaltyAgreementMember', window );">Royalty Agreement [Member] | Chemia Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_IMPB_RoyaltyPercentage', window );">Royalty percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=IMPB_LicenseAgreementMember', window );">License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_IMPB_SaleOfRoyaltyPercentage', window );">Sale of royalty percentage</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_IMPB_DevelopmentCostPercent', window );">Development cost, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsIncurredDevelopmentCosts', window );">Development costs</a></td>
<td class="nump">$ 1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=IMPB_GlobalAndBioLifeSciencesMember', window );">Global And Bio Life Sciences [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_IMPB_SaleOfRoyaltyPercentage', window );">Sale of royalty percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMPB_DevelopmentCostPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development cost percent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">IMPB_DevelopmentCostPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>IMPB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMPB_RoyaltyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">IMPB_RoyaltyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>IMPB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMPB_SaleOfRoyaltyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of royalty percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">IMPB_SaleOfRoyaltyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>IMPB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsIncurredDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development costs incurred, including capitalized costs and costs charged to expense, in oil and gas activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 932<br> -SubTopic 235<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482274/932-235-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsIncurredDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=IMPB_RoyaltyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=IMPB_RoyaltyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=IMPB_ChemiaCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=IMPB_ChemiaCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=IMPB_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=IMPB_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=IMPB_GlobalAndBioLifeSciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=IMPB_GlobalAndBioLifeSciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139839848102160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Components of Income Tax Benefit (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current tax payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,619,000)<span></span>
</td>
<td class="num">(456,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(165,000)<span></span>
</td>
<td class="num">(1,068,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,784,000)<span></span>
</td>
<td class="num">(1,524,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Less increase in valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,163,000<span></span>
</td>
<td class="nump">129,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">income tax benefit</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (621,000)<span></span>
</td>
<td class="num">$ (1,395,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139839833820048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInvestments', window );">Impairment of investment</a></td>
<td class="nump">$ 929,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research &amp; development cost</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net Operating loss</a></td>
<td class="nump">1,611,000<span></span>
</td>
<td class="nump">1,258,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">2,790,000<span></span>
</td>
<td class="nump">1,258,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible assets</a></td>
<td class="num">(4,414,000)<span></span>
</td>
<td class="num">(4,667,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Gross deferred tax liability</a></td>
<td class="num">(4,414,000)<span></span>
</td>
<td class="num">(4,667,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Less valuation allowance</a></td>
<td class="num">(1,611,000)<span></span>
</td>
<td class="num">(447,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liability</a></td>
<td class="num">$ (3,235,000)<span></span>
</td>
<td class="num">$ (3,856,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from investments (excludes investments in subsidiaries and equity method investments).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139839839452480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Effective Income Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory United States federal rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes net of federal benefit</a></td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(14.80%)<span></span>
</td>
<td class="num">(4.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective rate</a></td>
<td class="nump">7.90%<span></span>
</td>
<td class="nump">43.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139839840886736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 7,109,000<span></span>
</td>
<td class="nump">$ 5,551,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax asset</a></td>
<td class="nump">2,790,000<span></span>
</td>
<td class="nump">1,258,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance deferred tax</a></td>
<td class="nump">$ 1,163,000<span></span>
</td>
<td class="nump">$ 129,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139839839325296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Cash Flow Supplemental (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Transfer of note payable, related party</a></td>
<td class="num">$ (9,991,000)<span></span>
</td>
<td class="num">$ (12,524,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Transfer of promissory note 2 to related party</a></td>
<td class="nump">5,081,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Transfer of note payable, related party</a></td>
<td class="num">$ (5,081,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>forms-1a_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:IMPB="http://impactbiomedinc.com/20230331"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="impb-20230331.xsd" xlink:type="simple"/>
    <context id="From2023-01-01to2023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_dei_BusinessContactMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_CommonStockMember_srt_ScenarioPreviouslyReportedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember_srt_ScenarioPreviouslyReportedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember_srt_ScenarioPreviouslyReportedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember_srt_ScenarioPreviouslyReportedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_CommonStockMember_srt_ScenarioPreviouslyReportedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember_srt_ScenarioPreviouslyReportedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember_srt_ScenarioPreviouslyReportedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_NoncontrollingInterestMember_srt_ScenarioPreviouslyReportedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_srt_ScenarioPreviouslyReportedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_srt_ScenarioPreviouslyReportedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-11-08_custom_SweetSenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:SweetSenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-08</instant>
        </period>
    </context>
    <context id="From2019-11-072019-11-08_custom_SweetSenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:SweetSenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-07</startDate>
            <endDate>2019-11-08</endDate>
        </period>
    </context>
    <context id="From2018-10-162018-10-16_custom_GlobalBioMedicalPteLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">IMPB:GlobalBioMedicalPteLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-16</startDate>
            <endDate>2018-10-16</endDate>
        </period>
    </context>
    <context id="From2020-03-302020-03-31_custom_GlobalBioMedicalPteLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">IMPB:GlobalBioMedicalPteLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_SweetSenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:SweetSenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_SweetSenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:SweetSenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_srt_SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_srt_SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_GlobalBioMedicalIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:GlobalBioMedicalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_GlobalBioMedicalIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:GlobalBioMedicalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_GlobalBioMedicalIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:GlobalBioMedicalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_GlobalBioLifeIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:GlobalBioLifeIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_GlobalBioLifeIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:GlobalBioLifeIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_GlobalBioLifeIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:GlobalBioLifeIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_BioLifeSugarIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:BioLifeSugarIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_BioLifeSugarIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:BioLifeSugarIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_BioLifeSugarIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:BioLifeSugarIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_HappySugarIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:HappySugarIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_HappySugarIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:HappySugarIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_HappySugarIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:HappySugarIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_SweetSenseIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:SweetSenseIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_SweetSenseIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:SweetSenseIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_SweetSenseIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:SweetSenseIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_GlobalSugarSolutionsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:GlobalSugarSolutionsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_GlobalSugarSolutionsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:GlobalSugarSolutionsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_GlobalSugarSolutionsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:GlobalSugarSolutionsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_GlobalBioMedicalIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:GlobalBioMedicalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_GlobalBioMedicalIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:GlobalBioMedicalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_GlobalBioLifeIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:GlobalBioLifeIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_GlobalBioLifeIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:GlobalBioLifeIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_BioLifeSugarIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:BioLifeSugarIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_BioLifeSugarIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:BioLifeSugarIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_HappySugarIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:HappySugarIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_HappySugarIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:HappySugarIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_SweetSenseIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:SweetSenseIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_SweetSenseIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:SweetSenseIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_GlobalSugarSolutionsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:GlobalSugarSolutionsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_GlobalSugarSolutionsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">IMPB:GlobalSugarSolutionsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_GRDGscienceLLCMember_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">IMPB:GRDGscienceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_GRDGscienceLLCMember_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">IMPB:GRDGscienceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_GRDGscienceLLCMember_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">IMPB:GRDGscienceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_GRDGscienceLLCMember_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">IMPB:GRDGscienceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_GRDGscienceLLCMember_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">IMPB:GRDGscienceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_GRDGscienceLLCMember_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">IMPB:GRDGscienceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-02-21_custom_PromissoryNoteOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">IMPB:PromissoryNoteOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-21</instant>
        </period>
    </context>
    <context id="From2021-02-202021-02-21_custom_PromissoryNoteOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">IMPB:PromissoryNoteOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-20</startDate>
            <endDate>2021-02-21</endDate>
        </period>
    </context>
    <context id="From2022-08-222022-08-22_custom_PromissoryNoteOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">IMPB:PromissoryNoteOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-22</startDate>
            <endDate>2022-08-22</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_PromissoryNoteOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">IMPB:PromissoryNoteOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_PromissoryNoteOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">IMPB:PromissoryNoteOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_PromissoryNoteOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">IMPB:PromissoryNoteOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-05-14_custom_PromissoryNoteTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">IMPB:PromissoryNoteTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-14</instant>
        </period>
    </context>
    <context id="From2021-05-132021-05-14_custom_PromissoryNoteTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">IMPB:PromissoryNoteTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-13</startDate>
            <endDate>2021-05-14</endDate>
        </period>
    </context>
    <context id="AsOf2021-05-14_srt_MaximumMember_custom_PromissoryNoteTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">IMPB:PromissoryNoteTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-14</instant>
        </period>
    </context>
    <context id="AsOf2022-06-01_srt_MaximumMember_custom_PromissoryNoteTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">IMPB:PromissoryNoteTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-01</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_PromissoryNoteTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">IMPB:PromissoryNoteTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_PromissoryNoteTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">IMPB:PromissoryNoteTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-02-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
        </entity>
        <period>
            <instant>2021-02-21</instant>
        </period>
    </context>
    <context id="From2021-02-202021-02-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
        </entity>
        <period>
            <startDate>2021-02-20</startDate>
            <endDate>2021-02-21</endDate>
        </period>
    </context>
    <context id="From2022-08-222022-08-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
        </entity>
        <period>
            <startDate>2022-08-22</startDate>
            <endDate>2022-08-22</endDate>
        </period>
    </context>
    <context id="From2020-12-182020-12-19_custom_AsiaPacificHoldingsLimitedMember_us-gaap_SubscriptionArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">IMPB:AsiaPacificHoldingsLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:SubscriptionArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-18</startDate>
            <endDate>2020-12-19</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-01-01_custom_NanoNineLLCMember_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">IMPB:NanoNineLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">IMPB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="AsOf2021-01-01_custom_NanoNineLLCMember_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">IMPB:NanoNineLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">IMPB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_NanoNineLLCMember_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">IMPB:NanoNineLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">IMPB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_NanoNineLLCMember_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">IMPB:NanoNineLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">IMPB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-03-142021-03-15_custom_StockPurchaseAgreementMember_custom_VivacitasOncologyIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">IMPB:VivacitasOncologyIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">IMPB:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-14</startDate>
            <endDate>2021-03-15</endDate>
        </period>
    </context>
    <context id="AsOf2021-03-15_custom_VivacitasOncologyIncMember_custom_StockPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">IMPB:VivacitasOncologyIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">IMPB:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-15</instant>
        </period>
    </context>
    <context id="From2021-03-172021-03-18_custom_ImpactOncologyPTELtdMember_custom_StockPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">IMPB:ImpactOncologyPTELtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">IMPB:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-17</startDate>
            <endDate>2021-03-18</endDate>
        </period>
    </context>
    <context id="From2021-03-172021-03-18_custom_StockPurchaseAgreementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">IMPB:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-17</startDate>
            <endDate>2021-03-18</endDate>
        </period>
    </context>
    <context id="AsOf2021-04-01_custom_StockPurchaseAgreementMember_custom_VivacitasOncologyIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">IMPB:VivacitasOncologyIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">IMPB:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-01</instant>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_StockPurchaseAgreementMember_custom_VivacitasOncologyIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">IMPB:VivacitasOncologyIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">IMPB:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-07-212021-07-22_custom_VivacitasAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">IMPB:VivacitasAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-21</startDate>
            <endDate>2021-07-22</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_VivacitasAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">IMPB:VivacitasAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_VivacitasAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">IMPB:VivacitasAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_NanoNineLLCMember_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">IMPB:NanoNineLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">IMPB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_MachineryAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_MachineryAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_MachineryAndEquipmentMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_MachineryAndEquipmentMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_MachineryAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_MachineryAndEquipmentMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_MachineryAndEquipmentMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-06-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
        </entity>
        <period>
            <instant>2022-06-01</instant>
        </period>
    </context>
    <context id="From2022-05-302022-06-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
        </entity>
        <period>
            <startDate>2022-05-30</startDate>
            <endDate>2022-06-01</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_RevolvingPromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">IMPB:RevolvingPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_RevolvingPromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">IMPB:RevolvingPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_RevolvingPromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">IMPB:RevolvingPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_RevolvingPromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">IMPB:RevolvingPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-23_srt_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-23</instant>
        </period>
    </context>
    <context id="AsOf2021-09-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
        </entity>
        <period>
            <instant>2021-09-23</instant>
        </period>
    </context>
    <context id="AsOf2023-05-11_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-11</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_srt_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_srt_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_GRDGscienceLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">IMPB:GRDGscienceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_GRDGscienceLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">IMPB:GRDGscienceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2018-08-142018-08-15_custom_RoyaltyAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">IMPB:RoyaltyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-14</startDate>
            <endDate>2018-08-15</endDate>
        </period>
    </context>
    <context id="From2018-08-142018-08-15_custom_RoyaltyAgreementMember_custom_ChemiaCorporationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">IMPB:RoyaltyAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">IMPB:ChemiaCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-14</startDate>
            <endDate>2018-08-15</endDate>
        </period>
    </context>
    <context id="From2018-11-262018-11-27_custom_RoyaltyAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">IMPB:RoyaltyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-26</startDate>
            <endDate>2018-11-27</endDate>
        </period>
    </context>
    <context id="From2022-02-142022-02-15_custom_RoyaltyAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">IMPB:RoyaltyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-14</startDate>
            <endDate>2022-02-15</endDate>
        </period>
    </context>
    <context id="From2022-03-182022-03-19_custom_LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">IMPB:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-18</startDate>
            <endDate>2022-03-19</endDate>
        </period>
    </context>
    <context id="From2022-03-182022-03-19_custom_RoyaltyAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">IMPB:RoyaltyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-18</startDate>
            <endDate>2022-03-19</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_RoyaltyAgreementMember_custom_ChemiaCorporationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">IMPB:RoyaltyAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">IMPB:ChemiaCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-02-142022-02-15_custom_GlobalAndBioLifeSciencesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">IMPB:GlobalAndBioLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-14</startDate>
            <endDate>2022-02-15</endDate>
        </period>
    </context>
    <context id="From2022-03-192022-03-19_custom_LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">IMPB:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-19</startDate>
            <endDate>2022-03-19</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001834105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2023-01-01to2023-03-31">0001834105</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2023-01-01to2023-03-31">true</dei:AmendmentFlag>
    <dei:AmendmentDescription contextRef="From2023-01-01to2023-03-31" id="xdx2ixbrl0010">Amendment No. 13</dei:AmendmentDescription>
    <dei:DocumentType contextRef="From2023-01-01to2023-03-31" id="xdx2ixbrl0011">S-1/A</dei:DocumentType>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0053"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember"
      id="xdx2ixbrl0094"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0095"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetImpairmentCharges
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0174"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      id="xdx2ixbrl0197"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0198"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_srt_ScenarioPreviouslyReportedMember"
      id="xdx2ixbrl0217"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember_srt_ScenarioPreviouslyReportedMember"
      id="xdx2ixbrl0218"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember_srt_ScenarioPreviouslyReportedMember"
      id="xdx2ixbrl0255"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember_srt_ScenarioPreviouslyReportedMember"
      id="xdx2ixbrl0256"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember_srt_ScenarioPreviouslyReportedMember"
      id="xdx2ixbrl0257"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-12-31_us-gaap_NoncontrollingInterestMember_srt_ScenarioPreviouslyReportedMember"
      id="xdx2ixbrl0258"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-12-31_srt_ScenarioPreviouslyReportedMember"
      id="xdx2ixbrl0259"
      unitRef="USD"
      xsi:nil="true"/>
    <IMPB:StockIssuedDuringPeriodValueShareholder
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember_srt_ScenarioPreviouslyReportedMember"
      id="xdx2ixbrl0261"
      unitRef="USD"
      xsi:nil="true"/>
    <IMPB:StockIssuedDuringPeriodValueShareholder
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember_srt_ScenarioPreviouslyReportedMember"
      id="xdx2ixbrl0262"
      unitRef="USD"
      xsi:nil="true"/>
    <IMPB:StockIssuedDuringPeriodValueShareholder
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember_srt_ScenarioPreviouslyReportedMember"
      id="xdx2ixbrl0263"
      unitRef="USD"
      xsi:nil="true"/>
    <IMPB:StockIssuedDuringPeriodValueShareholder
      contextRef="From2021-01-012021-12-31_us-gaap_NoncontrollingInterestMember_srt_ScenarioPreviouslyReportedMember"
      id="xdx2ixbrl0264"
      unitRef="USD"
      xsi:nil="true"/>
    <IMPB:StockIssuedDuringPeriodValueShareholder
      contextRef="From2021-01-012021-12-31_srt_ScenarioPreviouslyReportedMember"
      id="xdx2ixbrl0265"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember_srt_ScenarioPreviouslyReportedMember"
      id="xdx2ixbrl0267"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember_srt_ScenarioPreviouslyReportedMember"
      id="xdx2ixbrl0268"
      unitRef="USD"
      xsi:nil="true"/>
    <IMPB:ImpairmentOfOtherInvestments
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0305"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsForProceedsFromProductiveAssets
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0335"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0450"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0452"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_us-gaap_MachineryAndEquipmentMember"
      id="xdx2ixbrl0572"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_us-gaap_ConstructionInProgressMember"
      id="xdx2ixbrl0579"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0582"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0585"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0587"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0588"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0591"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Depreciation
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0593"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Depreciation
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0595"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0603"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0747"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0748"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0750"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0751"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0753"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2021-01-012021-12-31"
      id="xdx2ixbrl0754"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsInvestments
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0774"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0777"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2021-12-31_us-gaap_RelatedPartyMember"
      id="xdx2ixbrl0828"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NotesPayable
      contextRef="AsOf2021-12-31_us-gaap_RelatedPartyMember"
      id="xdx2ixbrl0831"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NotesAndLoansReceivableNetNoncurrent
      contextRef="AsOf2023-03-31"
      id="xdx2ixbrl0859"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2023-03-31"
      id="xdx2ixbrl0895"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0896"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2022-01-012022-03-31"
      id="xdx2ixbrl0969"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetImpairmentCharges
      contextRef="From2023-01-01to2023-03-31"
      id="xdx2ixbrl0974"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetImpairmentCharges
      contextRef="From2022-01-012022-03-31"
      id="xdx2ixbrl0975"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-01to2023-03-31"
      id="xdx2ixbrl0980"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-03-31"
      id="xdx2ixbrl0981"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-01to2023-03-31"
      id="xdx2ixbrl0995"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-01-012022-03-31"
      id="xdx2ixbrl0996"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1015"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl1016"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1053"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl1054"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInDeferredLiabilities
      contextRef="From2022-01-012022-03-31"
      id="xdx2ixbrl1094"
      unitRef="USD"
      xsi:nil="true"/>
    <IMPB:IncreaseDecreaseInImpairmentofOtherInvestments
      contextRef="From2022-01-012022-03-31"
      id="xdx2ixbrl1097"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsForProceedsFromProductiveAssets
      contextRef="From2022-01-012022-03-31"
      id="xdx2ixbrl1115"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="From2023-01-01to2023-03-31"
      id="xdx2ixbrl1117"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2023-01-01to2023-03-31"
      id="xdx2ixbrl1230"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2022-01-012022-03-31"
      id="xdx2ixbrl1232"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl1345"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2023-01-01to2023-03-31"
      id="xdx2ixbrl1360"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:EntityRegistrantName contextRef="From2023-01-01to2023-03-31">IMPACT BIOMEDICAL INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2023-01-01to2023-03-31">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2023-01-01to2023-03-31">85-3926944</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2023-01-01to2023-03-31">275 Wiregrass Pkwy</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2023-01-01to2023-03-31">West Henrietta</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2023-01-01to2023-03-31">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2023-01-01to2023-03-31">14586</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2023-01-01to2023-03-31">+1</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2023-01-01to2023-03-31">585-325-3610</dei:LocalPhoneNumber>
    <dei:ContactPersonnelName contextRef="From2023-01-012023-03-31_dei_BusinessContactMember">Frank D. Heuszel</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1 contextRef="From2023-01-012023-03-31_dei_BusinessContactMember">Impact BioMedical Inc.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2023-01-012023-03-31_dei_BusinessContactMember">275 Wiregrass Pkwy</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2023-01-012023-03-31_dei_BusinessContactMember">West Henrietta</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2023-01-012023-03-31_dei_BusinessContactMember">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2023-01-012023-03-31_dei_BusinessContactMember">14586</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2023-01-012023-03-31_dei_BusinessContactMember">+1</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2023-01-012023-03-31_dei_BusinessContactMember">585-325-3610</dei:LocalPhoneNumber>
    <dei:EntityFilerCategory contextRef="From2023-01-01to2023-03-31">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2023-01-01to2023-03-31">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2023-01-01to2023-03-31">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2023-01-01to2023-03-31">false</dei:EntityExTransitionPeriod>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">2000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">46000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">16000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:NotesAndLoansReceivableNetCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">197000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">104000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">44000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">122000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">287000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">276000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherLongTermInvestments
      contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">782000</us-gaap:OtherLongTermInvestments>
    <us-gaap:OtherLongTermInvestments contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">4817000</us-gaap:OtherLongTermInvestments>
    <us-gaap:NotesAndLoansReceivableNetNoncurrent
      contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">190000</us-gaap:NotesAndLoansReceivableNetNoncurrent>
    <us-gaap:NotesAndLoansReceivableNetNoncurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">5081000</us-gaap:NotesAndLoansReceivableNetNoncurrent>
    <us-gaap:Goodwill
      contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">25093000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">25093000</us-gaap:Goodwill>
    <us-gaap:OtherIntangibleAssetsNet
      contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">20034000</us-gaap:OtherIntangibleAssetsNet>
    <us-gaap:OtherIntangibleAssetsNet contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">21147000</us-gaap:OtherIntangibleAssetsNet>
    <us-gaap:Assets
      contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">46497000</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">56425000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">539000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">115000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">63000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">6000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">9991000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">12524000</us-gaap:NotesPayableCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">10593000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">12645000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">3235000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">3856000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:Liabilities
      contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">13828000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">16501000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="INF"
      unitRef="Shares">4000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">4000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="INF"
      unitRef="Shares">3877282251</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="INF"
      unitRef="Shares">3877282251</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">3877282251</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">3877282251</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">125000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">125000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">38058000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">38058000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">-8625000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">-1574000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">29558000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">36609000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">3111000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">3315000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">32669000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">39924000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">46497000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">56425000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">325000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">398000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">1226000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">1080000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ProfessionalFees
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">722000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">552000</us-gaap:ProfessionalFees>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">1113000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">1113000</us-gaap:DepreciationAndAmortization>
    <us-gaap:OtherGeneralExpense
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">68000</us-gaap:OtherGeneralExpense>
    <us-gaap:OtherGeneralExpense
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">42000</us-gaap:OtherGeneralExpense>
    <us-gaap:CostsAndExpenses
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">3454000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">3185000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">-3454000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-3185000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">24000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">165000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">116000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">77000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InterestExpense
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">462000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">300000</us-gaap:InterestExpense>
    <us-gaap:AssetImpairmentCharges
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">4100000</us-gaap:AssetImpairmentCharges>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">-7876000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-3243000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">-621000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-1395000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">-7255000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-1848000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">-204000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-545000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">-7051000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-1303000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="INF"
      unitRef="USDPShares">-0.00</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.00</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="INF"
      unitRef="Shares">3877282251</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Shares">3877282251</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="INF"
      unitRef="Shares">3877282251</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Shares">3877282251</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">3877282251</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">125000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">38058000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-1574000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      unitRef="USD">3315000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">39924000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">-7051000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">-204000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">-7255000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">3877282251</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">125000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">38058000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-8625000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      unitRef="USD">3111000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">32669000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">3877282251</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">125000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">38058000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-8625000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      unitRef="USD">3111000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">32669000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">3877282251</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">125000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">38058000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-271000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2020-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      unitRef="USD">3860000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">41772000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">3877282251</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">125000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">38058000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-271000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2020-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      unitRef="USD">3860000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">41772000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">-1303000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-12-31_us-gaap_NoncontrollingInterestMember_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">-545000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">-1848000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">3877282251</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">125000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">38058000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-1574000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      unitRef="USD">-3315000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">39924000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">3877282251</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">125000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">38058000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-1574000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_srt_ScenarioPreviouslyReportedMember_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      unitRef="USD">-3315000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">39924000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">-7255000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-1848000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">1113000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">1113000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">-621000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-1395000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <IMPB:ImpairmentOfOtherInvestments
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">4100000</IMPB:ImpairmentOfOtherInvestments>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">60000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">8000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">424000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">106000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">57000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">5000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">-2242000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-2027000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsForProceedsFromProductiveAssets
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">276000</us-gaap:PaymentsForProceedsFromProductiveAssets>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">65000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">4185000</us-gaap:PaymentsToAcquireInvestments>
    <IMPB:PaymentsForProceedsFromNoteReceivableInvestments
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">8000</IMPB:PaymentsForProceedsFromNoteReceivableInvestments>
    <IMPB:PaymentsForProceedsFromNoteReceivableInvestments
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">5278000</IMPB:PaymentsForProceedsFromNoteReceivableInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">-349000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-9463000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">2547000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">11464000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">2547000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">11464000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">-44000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-27000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2021-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">46000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">72000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      unitRef="USD">2000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">46000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:NatureOfOperations contextRef="From2022-01-012022-12-31">&lt;p id="xdx_803_eus-gaap--NatureOfOperations_zxG7oDgoxgcc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
1. &lt;span id="xdx_82C_zFqIBiDUxJ64"&gt;Nature of Operations and Basis of Presentation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Nature
of Operations&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Impact
BioMedical, Inc. (the &#x201c;Company&#x201d;, &#x201c;Impact BioMedical&#x201d;, &#x201c;We&#x201d;) through the utilization of its intellectual
property rights, or through investment in, or through acquisition of companies in the biohealth and biomedical fields, focuses on the
advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune related diseases. The
Company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis
and influenza.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Global
BioLife, Inc. (&#x201c;Global BioLife&#x201d;), one of the Company&#x2019;s subsidiaries and the main operating company of the group, focuses
on research in four main areas: (i) the &#x201c;Linebacker&#x201d; project, which aims to develop a universal therapeutic drug platform;
(ii) a new sugar substitute called &#x201c;Laetose,&#x201d;; (iii) a multi-use fragrance called &#x201c;3F&#x201d; (Functional Fragrance
Formulation); and (iv) Equivir/Nemovir, a blend of natural polyphenols designed as an antimicrobial medication.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Linebacker&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Unlike
the traditional approach to treat individual diseases with specific drugs, the Linebacker platform seeks to offer a breakthrough therapeutic
option for multiple diseases. Linebacker is designed to work by inhibiting a cascade of inflammatory responses responsible for many diseases.
Its design is in direct contrast to the traditional approach of targeting individual diseases with specific drugs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Laetose&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
have also developed a low-calorie, low glycemic level, natural modified sugar through Global BioLife. The product, &#x201c;Laetose,&#x201d;
is designed to possess low glycemic properties and mitigate inflammation. The Company is presently seeking to license Laetose. Global
BioLife established a joint venture, Sweet Sense, Inc. (&#x201c;Sweet Sense&#x201d;), with Quality Ingredients, LLC for the development,
manufacture, and global distribution of the new sugar substitute. On November 8, 2019, the Company purchased &lt;span id="xdx_90F_eus-gaap--MinorityInterestOwnershipPercentageByNoncontrollingOwners_iI_pid_dp_uPure_c20191108__srt--OwnershipAxis__custom--SweetSenseMember_z12C9V8yl8Pb" title="Minority interest ownership percentage"&gt;50&lt;/span&gt;% of Sweet Sense Inc.
from Quality Ingredients, LLC for $&lt;span id="xdx_90E_eus-gaap--BusinessCombinationConsiderationTransferred1_c20191107__20191108__srt--OwnershipAxis__custom--SweetSenseMember_zPzCUcqTajMb" title="Consideration given for purchase"&gt;91,000&lt;/span&gt;. Sweet Sense is now an &lt;span id="xdx_900_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20191108__srt--OwnershipAxis__custom--SweetSenseMember_zW35Gxw4yjJf" title="Ownership percentage"&gt;81.8&lt;/span&gt;% owned subsidiary of Impact BioMedical.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Functional
Fragrance Formulation (&#x201c;3F&#x201d;)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Global
BioLife has established a collaboration with U.S.-based Chemia Corporation (&#x201c;Chemia&#x201d;) to develop specialized fragrances to
counter mosquito-borne diseases such as Zika and Dengue, among other medical applications. The 3F mosquito fragrance product is made
from specialized oils sourced from botanicals that mosquitos avoid. Global BioLife is seeking to commercialize this product. Together
with Chemia, we are attempting to license 3F. Any potential profits from the 3F project will be split between Global BioLife and Chemia
pursuant to the terms of the 20- year Royalty Agreement (Note 12).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Equivir&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equivir,
is a polyphenol compound that is believed to be successful in antiviral infection treatments. Equivir is a patented medication, that
has broad antiviral efficacy against multiple types of infectious disease.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company was incorporated in the State of Nevada as a for-profit company on October 16, 2018 and established a fiscal year end of December
31st. The Company issued &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20181016__20181016__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--GlobalBioMedicalPteLtdMember_zUob4L8G3Atg" title="Stock issued during period shares"&gt;9,000&lt;/span&gt; shares to its sole shareholder Global BioMedical Pte. Ltd., which was wholly owned by Alset International
Limited (formally Singapore eDevelopment Limited), a multinational public company, listed on the Singapore Exchange Securities Trading
Limited (&#x201c;SGXST&#x201d;). On March 31, 2020, the Company issued &lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200330__20200331__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--GlobalBioMedicalPteLtdMember_zfH9lDxhTqYb" title="Stock issued during period shares"&gt;125,064,621&lt;/span&gt; shares of common stock to its sole shareholder Global
BioMedical Pte. Ltd. On July 24, 2020, the Board approved the Stock Split, pursuant to which each share of the Company&#x2019;s common
stock issued and outstanding was split into nine shares of the Company&#x2019;s common stock. The numbers of authorized common stock and
issued and outstanding common stock in the reporting periods were retrospectively adjusted for the stock split.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of the date of this report, we have not generated significant revenues from operations. We cannot guarantee we will be successful in
our business operations. Our business is subject to risks inherent in the establishment of a new business enterprise, including possible
delays in our research, testing and marketing efforts or wider economic downturns.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Basis
of Presentation and Principles of Consolidation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the
United States of America (&#x201c;U.S. GAAP&#x201d;). The consolidated financial statements include all accounts of the Company and its
majority owned and controlled subsidiaries. The Company consolidates entities in which it owns more than &lt;span id="xdx_90C_eus-gaap--MinorityInterestOwnershipPercentageByNoncontrollingOwners_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--SweetSenseMember_zjFOCeMosyi2" title="Minority interest ownership percentage"&gt;50&lt;/span&gt;% of the voting common stock
and controls operations. All intercompany transactions and balances among consolidated subsidiaries have been eliminated. Non&#x2013;controlling
interest represents the minority equity investment in the Company&#x2019;s subsidiaries, plus the minority investors&#x2019; share of the
net operating results and other components of equity relating to the non&#x2013;controlling interest.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;IMPACT
Biomedical, Inc. and Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Consolidated Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_esrt--ScheduleOfCondensedFinancialStatementsTableTextBlock_zI2mYLbcMG71" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements include all accounts of the entities as of the reporting period ending dates and for the reporting
periods as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BF_zrTi228E0Hve" style="display: none"&gt;Schedule
of Condensed Financial Statements&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Name of consolidated subsidiary&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;State or other jurisdiction of incorporation or organization&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Date of incorporation or formation&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Attributable interest as of &lt;br/&gt; December 31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Attributable &lt;br/&gt; interest as of &lt;br/&gt; December 31, &lt;br/&gt; 2021&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: left"&gt;Global BioMedical, Inc.&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18%"&gt;&lt;span id="xdx_90F_ecustom--StateOrOtherJurisdictionOfIncorporationOrOrganization_c20220101__20221231__srt--OwnershipAxis__custom--GlobalBioMedicalIncMember_zj6YxyNf8Jba" title="State or other jurisdiction of incorporation or organization"&gt;Nevada&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18%"&gt;&lt;span id="xdx_901_edei--EntityIncorporationDateOfIncorporation_dd_c20220101__20221231__srt--OwnershipAxis__custom--GlobalBioMedicalIncMember_z1oSxHwxLdE" title="Date of incorporation or formation"&gt;April 18, 2017&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--GlobalBioMedicalIncMember_zNLFbG07qcq6" title="Attributable interest percentage"&gt;90.9&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20211231__srt--OwnershipAxis__custom--GlobalBioMedicalIncMember_zvuByqKsBpL9" title="Attributable interest percentage"&gt;90.9&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Global BioLife, Inc.&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_ecustom--StateOrOtherJurisdictionOfIncorporationOrOrganization_c20220101__20221231__srt--OwnershipAxis__custom--GlobalBioLifeIncMember_zw2zPHa5DFQ2" title="State or other jurisdiction of incorporation or organization"&gt;Nevada&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_edei--EntityIncorporationDateOfIncorporation_dd_c20220101__20221231__srt--OwnershipAxis__custom--GlobalBioLifeIncMember_zONGg88g42x9" title="Date of incorporation or formation"&gt;April 14, 2017&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--GlobalBioLifeIncMember_zjFy7BH16Qhj" title="Attributable interest percentage"&gt;81.8&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20211231__srt--OwnershipAxis__custom--GlobalBioLifeIncMember_zXOvifpjTBt" title="Attributable interest percentage"&gt;63.6&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;BioLife Sugar, Inc&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_ecustom--StateOrOtherJurisdictionOfIncorporationOrOrganization_c20220101__20221231__srt--OwnershipAxis__custom--BioLifeSugarIncMember_z2DKWvZTkrFi" title="State or other jurisdiction of incorporation or organization"&gt;Nevada&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_edei--EntityIncorporationDateOfIncorporation_dd_c20220101__20221231__srt--OwnershipAxis__custom--BioLifeSugarIncMember_zteqNjNmbVMk" title="Date of incorporation or formation"&gt;April 23, 2018&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--BioLifeSugarIncMember_zoAYF3xbSg83" title="Attributable interest percentage"&gt;90.9&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20211231__srt--OwnershipAxis__custom--BioLifeSugarIncMember_ztM7xQ8lX8oc" title="Attributable interest percentage"&gt;63.6&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Happy Sugar Inc&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_ecustom--StateOrOtherJurisdictionOfIncorporationOrOrganization_c20220101__20221231__srt--OwnershipAxis__custom--HappySugarIncMember_zv9GlHKO2uD3" title="State or other jurisdiction of incorporation or organization"&gt;Nevada&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_edei--EntityIncorporationDateOfIncorporation_dd_c20220101__20221231__srt--OwnershipAxis__custom--HappySugarIncMember_zs9MtTdiw097" title="Date of incorporation or formation"&gt;August 17, 2018&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--HappySugarIncMember_zxvnxg59cDPi" title="Attributable interest percentage"&gt;81.8&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20211231__srt--OwnershipAxis__custom--HappySugarIncMember_zUa6AMo7MUq9" title="Attributable interest percentage"&gt;63.6&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Sweet Sense Inc.&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_906_ecustom--StateOrOtherJurisdictionOfIncorporationOrOrganization_c20220101__20221231__srt--OwnershipAxis__custom--SweetSenseIncMember_zT31tTWcA7xf" title="State or other jurisdiction of incorporation or organization"&gt;Nevada&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_edei--EntityIncorporationDateOfIncorporation_dd_c20220101__20221231__srt--OwnershipAxis__custom--SweetSenseIncMember_zi1ZFP0VWiC8" title="Date of incorporation or formation"&gt;April 30, 2018&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--SweetSenseIncMember_znUTdBy2RC6" title="Attributable interest percentage"&gt;95.5&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20211231__srt--OwnershipAxis__custom--SweetSenseIncMember_zlvDJinYJA2f" title="Attributable interest percentage"&gt;81.8&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Global Sugar Solutions Inc.&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_ecustom--StateOrOtherJurisdictionOfIncorporationOrOrganization_c20220101__20221231__srt--OwnershipAxis__custom--GlobalSugarSolutionsIncMember_zmGAIxue30i5" title="State or other jurisdiction of incorporation or organization"&gt;Nevada&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_edei--EntityIncorporationDateOfIncorporation_dd_c20220101__20221231__srt--OwnershipAxis__custom--GlobalSugarSolutionsIncMember_zZrTE1q0Ixig" title="Date of incorporation or formation"&gt;November 7, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--GlobalSugarSolutionsIncMember_zOJhwTFWaw1h" title="Attributable interest percentage"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20211231__srt--OwnershipAxis__custom--GlobalSugarSolutionsIncMember_zvMjPp9213e2" title="Attributable interest percentage"&gt;80&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zhlBCspnZd14" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2022, and 2021, the aggregate noncontrolling interest was equity of $&lt;span id="xdx_906_eus-gaap--MinorityInterest_iI_c20221231_zlZ5qceBXwMl" title="Noncontrolling interest"&gt;3,111,000&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--MinorityInterest_iI_c20211231_zLxUqf3vjUJe" title="Noncontrolling interest"&gt;3,315,000&lt;/span&gt;, respectively, which are
separately disclosed on the Consolidated Balance Sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NatureOfOperations>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="AsOf2019-11-08_custom_SweetSenseMember"
      decimals="INF"
      unitRef="Pure">0.50</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="From2019-11-072019-11-08_custom_SweetSenseMember"
      decimals="0"
      unitRef="USD">91000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="AsOf2019-11-08_custom_SweetSenseMember"
      decimals="INF"
      unitRef="Pure">0.818</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2018-10-162018-10-16_custom_GlobalBioMedicalPteLtdMember"
      decimals="INF"
      unitRef="Shares">9000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2020-03-302020-03-31_custom_GlobalBioMedicalPteLtdMember"
      decimals="INF"
      unitRef="Shares">125064621</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="AsOf2022-12-31_custom_SweetSenseMember"
      decimals="INF"
      unitRef="Pure">0.50</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <srt:ScheduleOfCondensedFinancialStatementsTableTextBlock contextRef="From2022-01-012022-12-31">&lt;p id="xdx_89B_esrt--ScheduleOfCondensedFinancialStatementsTableTextBlock_zI2mYLbcMG71" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements include all accounts of the entities as of the reporting period ending dates and for the reporting
periods as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BF_zrTi228E0Hve" style="display: none"&gt;Schedule
of Condensed Financial Statements&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Name of consolidated subsidiary&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;State or other jurisdiction of incorporation or organization&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Date of incorporation or formation&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Attributable interest as of &lt;br/&gt; December 31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Attributable &lt;br/&gt; interest as of &lt;br/&gt; December 31, &lt;br/&gt; 2021&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: left"&gt;Global BioMedical, Inc.&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18%"&gt;&lt;span id="xdx_90F_ecustom--StateOrOtherJurisdictionOfIncorporationOrOrganization_c20220101__20221231__srt--OwnershipAxis__custom--GlobalBioMedicalIncMember_zj6YxyNf8Jba" title="State or other jurisdiction of incorporation or organization"&gt;Nevada&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18%"&gt;&lt;span id="xdx_901_edei--EntityIncorporationDateOfIncorporation_dd_c20220101__20221231__srt--OwnershipAxis__custom--GlobalBioMedicalIncMember_z1oSxHwxLdE" title="Date of incorporation or formation"&gt;April 18, 2017&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--GlobalBioMedicalIncMember_zNLFbG07qcq6" title="Attributable interest percentage"&gt;90.9&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20211231__srt--OwnershipAxis__custom--GlobalBioMedicalIncMember_zvuByqKsBpL9" title="Attributable interest percentage"&gt;90.9&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Global BioLife, Inc.&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_ecustom--StateOrOtherJurisdictionOfIncorporationOrOrganization_c20220101__20221231__srt--OwnershipAxis__custom--GlobalBioLifeIncMember_zw2zPHa5DFQ2" title="State or other jurisdiction of incorporation or organization"&gt;Nevada&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_edei--EntityIncorporationDateOfIncorporation_dd_c20220101__20221231__srt--OwnershipAxis__custom--GlobalBioLifeIncMember_zONGg88g42x9" title="Date of incorporation or formation"&gt;April 14, 2017&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--GlobalBioLifeIncMember_zjFy7BH16Qhj" title="Attributable interest percentage"&gt;81.8&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20211231__srt--OwnershipAxis__custom--GlobalBioLifeIncMember_zXOvifpjTBt" title="Attributable interest percentage"&gt;63.6&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;BioLife Sugar, Inc&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_ecustom--StateOrOtherJurisdictionOfIncorporationOrOrganization_c20220101__20221231__srt--OwnershipAxis__custom--BioLifeSugarIncMember_z2DKWvZTkrFi" title="State or other jurisdiction of incorporation or organization"&gt;Nevada&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_edei--EntityIncorporationDateOfIncorporation_dd_c20220101__20221231__srt--OwnershipAxis__custom--BioLifeSugarIncMember_zteqNjNmbVMk" title="Date of incorporation or formation"&gt;April 23, 2018&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--BioLifeSugarIncMember_zoAYF3xbSg83" title="Attributable interest percentage"&gt;90.9&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20211231__srt--OwnershipAxis__custom--BioLifeSugarIncMember_ztM7xQ8lX8oc" title="Attributable interest percentage"&gt;63.6&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Happy Sugar Inc&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_ecustom--StateOrOtherJurisdictionOfIncorporationOrOrganization_c20220101__20221231__srt--OwnershipAxis__custom--HappySugarIncMember_zv9GlHKO2uD3" title="State or other jurisdiction of incorporation or organization"&gt;Nevada&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_edei--EntityIncorporationDateOfIncorporation_dd_c20220101__20221231__srt--OwnershipAxis__custom--HappySugarIncMember_zs9MtTdiw097" title="Date of incorporation or formation"&gt;August 17, 2018&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--HappySugarIncMember_zxvnxg59cDPi" title="Attributable interest percentage"&gt;81.8&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20211231__srt--OwnershipAxis__custom--HappySugarIncMember_zUa6AMo7MUq9" title="Attributable interest percentage"&gt;63.6&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Sweet Sense Inc.&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_906_ecustom--StateOrOtherJurisdictionOfIncorporationOrOrganization_c20220101__20221231__srt--OwnershipAxis__custom--SweetSenseIncMember_zT31tTWcA7xf" title="State or other jurisdiction of incorporation or organization"&gt;Nevada&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_edei--EntityIncorporationDateOfIncorporation_dd_c20220101__20221231__srt--OwnershipAxis__custom--SweetSenseIncMember_zi1ZFP0VWiC8" title="Date of incorporation or formation"&gt;April 30, 2018&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--SweetSenseIncMember_znUTdBy2RC6" title="Attributable interest percentage"&gt;95.5&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20211231__srt--OwnershipAxis__custom--SweetSenseIncMember_zlvDJinYJA2f" title="Attributable interest percentage"&gt;81.8&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Global Sugar Solutions Inc.&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_ecustom--StateOrOtherJurisdictionOfIncorporationOrOrganization_c20220101__20221231__srt--OwnershipAxis__custom--GlobalSugarSolutionsIncMember_zmGAIxue30i5" title="State or other jurisdiction of incorporation or organization"&gt;Nevada&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_edei--EntityIncorporationDateOfIncorporation_dd_c20220101__20221231__srt--OwnershipAxis__custom--GlobalSugarSolutionsIncMember_zZrTE1q0Ixig" title="Date of incorporation or formation"&gt;November 7, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--GlobalSugarSolutionsIncMember_zOJhwTFWaw1h" title="Attributable interest percentage"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20211231__srt--OwnershipAxis__custom--GlobalSugarSolutionsIncMember_zvMjPp9213e2" title="Attributable interest percentage"&gt;80&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</srt:ScheduleOfCondensedFinancialStatementsTableTextBlock>
    <IMPB:StateOrOtherJurisdictionOfIncorporationOrOrganization contextRef="From2022-01-012022-12-31_custom_GlobalBioMedicalIncMember">Nevada</IMPB:StateOrOtherJurisdictionOfIncorporationOrOrganization>
    <dei:EntityIncorporationDateOfIncorporation contextRef="From2022-01-012022-12-31_custom_GlobalBioMedicalIncMember">2017-04-18</dei:EntityIncorporationDateOfIncorporation>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="AsOf2022-12-31_custom_GlobalBioMedicalIncMember"
      decimals="INF"
      unitRef="Pure">0.909</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="AsOf2021-12-31_custom_GlobalBioMedicalIncMember"
      decimals="INF"
      unitRef="Pure">0.909</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <IMPB:StateOrOtherJurisdictionOfIncorporationOrOrganization contextRef="From2022-01-012022-12-31_custom_GlobalBioLifeIncMember">Nevada</IMPB:StateOrOtherJurisdictionOfIncorporationOrOrganization>
    <dei:EntityIncorporationDateOfIncorporation contextRef="From2022-01-012022-12-31_custom_GlobalBioLifeIncMember">2017-04-14</dei:EntityIncorporationDateOfIncorporation>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="AsOf2022-12-31_custom_GlobalBioLifeIncMember"
      decimals="INF"
      unitRef="Pure">0.818</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="AsOf2021-12-31_custom_GlobalBioLifeIncMember"
      decimals="INF"
      unitRef="Pure">0.636</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <IMPB:StateOrOtherJurisdictionOfIncorporationOrOrganization contextRef="From2022-01-012022-12-31_custom_BioLifeSugarIncMember">Nevada</IMPB:StateOrOtherJurisdictionOfIncorporationOrOrganization>
    <dei:EntityIncorporationDateOfIncorporation contextRef="From2022-01-012022-12-31_custom_BioLifeSugarIncMember">2018-04-23</dei:EntityIncorporationDateOfIncorporation>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="AsOf2022-12-31_custom_BioLifeSugarIncMember"
      decimals="INF"
      unitRef="Pure">0.909</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="AsOf2021-12-31_custom_BioLifeSugarIncMember"
      decimals="INF"
      unitRef="Pure">0.636</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <IMPB:StateOrOtherJurisdictionOfIncorporationOrOrganization contextRef="From2022-01-012022-12-31_custom_HappySugarIncMember">Nevada</IMPB:StateOrOtherJurisdictionOfIncorporationOrOrganization>
    <dei:EntityIncorporationDateOfIncorporation contextRef="From2022-01-012022-12-31_custom_HappySugarIncMember">2018-08-17</dei:EntityIncorporationDateOfIncorporation>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="AsOf2022-12-31_custom_HappySugarIncMember"
      decimals="INF"
      unitRef="Pure">0.818</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="AsOf2021-12-31_custom_HappySugarIncMember"
      decimals="INF"
      unitRef="Pure">0.636</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <IMPB:StateOrOtherJurisdictionOfIncorporationOrOrganization contextRef="From2022-01-012022-12-31_custom_SweetSenseIncMember">Nevada</IMPB:StateOrOtherJurisdictionOfIncorporationOrOrganization>
    <dei:EntityIncorporationDateOfIncorporation contextRef="From2022-01-012022-12-31_custom_SweetSenseIncMember">2018-04-30</dei:EntityIncorporationDateOfIncorporation>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="AsOf2022-12-31_custom_SweetSenseIncMember"
      decimals="INF"
      unitRef="Pure">0.955</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="AsOf2021-12-31_custom_SweetSenseIncMember"
      decimals="INF"
      unitRef="Pure">0.818</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <IMPB:StateOrOtherJurisdictionOfIncorporationOrOrganization contextRef="From2022-01-012022-12-31_custom_GlobalSugarSolutionsIncMember">Nevada</IMPB:StateOrOtherJurisdictionOfIncorporationOrOrganization>
    <dei:EntityIncorporationDateOfIncorporation contextRef="From2022-01-012022-12-31_custom_GlobalSugarSolutionsIncMember">2019-11-07</dei:EntityIncorporationDateOfIncorporation>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="AsOf2022-12-31_custom_GlobalSugarSolutionsIncMember"
      decimals="INF"
      unitRef="Pure">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="AsOf2021-12-31_custom_GlobalSugarSolutionsIncMember"
      decimals="INF"
      unitRef="Pure">0.80</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterest contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">3111000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">3315000</us-gaap:MinorityInterest>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2022-01-012022-12-31">&lt;p id="xdx_804_eus-gaap--SignificantAccountingPoliciesTextBlock_z3qtt0DarICl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
2. &lt;span id="xdx_82B_zXidA4utt5I4"&gt;Summary of Significant Accounting and Reporting Policies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--UseOfEstimates_z5wz0mcNenma" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_860_zaqEKogB9ez9"&gt;Use
of estimates&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the dates of the balance
sheets and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from these estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_zP3j63KgdsR4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_860_zTsxI67TiqM"&gt;Earnings
(Loss) per Share&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
earnings (loss) per share is computed by dividing the net income (loss) attributable to the common stockholders by weighted average number
of shares of common stock outstanding during the period. Fully diluted earnings (loss) per share is computed like basic income (loss)
per share except that the denominator is increased to include the number of additional common shares that would have been outstanding
if the potential common shares had been issued and if the additional common shares were dilutive. There were no dilutive financial instruments
issued or outstanding for the years ended December 31, 2022 or 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zDq08xlPnko" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86D_zCbRunpHjsuj"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants at the measurement date. The Fair Value Measurement Topic of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;)
Accounting Standards Codification (&#x201c;ASC&#x201d;) establishes a three-tier fair value hierarchy which prioritizes the inputs used
in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets
or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;
Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;
Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted
prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active;
and&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;
Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions,
such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amounts reported in the balance sheet of cash and cash equivalents, prepaids, accounts payable and accrued expenses approximate
fair value because of the immediate or short-term maturity of these financial instruments. The fair value of notes receivable approximates
their carrying value as the stated or discounted rates of the notes do reflect recent market conditions. The Company&#x2019;s investments
are record at cost as the fair value of these investment in are not readily available. The fair value of notes payable approximates its
carrying value as the stated interest rate reflects recent market conditions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;IMPACT
Biomedical, Inc. and Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Consolidated Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zdsWDnFzokXe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_864_zXeLEdoOSZU7"&gt;Cash
and cash equivalents&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers all highly liquid investments with a maturity of three months or less at the date of acquisition to be cash equivalents.
There were &lt;span id="xdx_90A_eus-gaap--Cash_iI_do_c20221231_zo4fwXEFQlQ3" title="Cash"&gt;&lt;span id="xdx_90F_eus-gaap--Cash_iI_do_c20211231_zcamax26Ny18" title="Cash"&gt;no&lt;/span&gt;&lt;/span&gt; cash equivalents as of December 31, 2022, and 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--InvestmentPolicyTextBlock_z58oA0m51di5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_869_zA1Hah58AIw"&gt;Investments&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Investments
in equity securities with a readily determinable fair value, not accounted for under the equity method, are recorded at fair value with
unrealized gains and losses included in earnings. For equity securities without a readily determinable fair value, the investment is
recorded at cost, less any impairment, plus or minus adjustments related to observable transactions for the same or similar securities,
with unrealized gains and losses included in earnings.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
equity method investments, the Company regularly reviews its investments to determine whether there is a decline in fair value below
book value. If there is a decline that is other-than-temporary, the investment is written down to fair value. See Note 7 for further
discussion on investments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--GoodwillAndIntangibleAssetsGoodwillPolicy_zMDnF0JgVyJh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_869_zxq5H1ahqL6a"&gt;Goodwill&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Goodwill
is the excess of cost of an acquired entity over the fair value of amounts assigned to assets acquired and liabilities assumed in a business
combination. Goodwill is subject to impairment testing at least annually and will be tested for impairment between annual tests, which
takes place during the fourth quarter, if an event occurs or circumstances change that would indicate the carrying amount may be impaired.
FASB ASC Topic 350 provides an entity with the option to first assess qualitative factors to determine whether the existence of events
or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying
amount. Some of the qualitative factors considered in applying this test include consideration of macroeconomic conditions, industry
and market conditions, cost factors affecting the business, and overall financial performance of the business. If, after completing the
assessment, it is determined that it is more likely than not that the fair value of a reporting unit is less than its carrying value,
the Company will proceed to a quantitative test. If qualitative factors are not deemed sufficient to conclude that the fair value of
the reporting unit more likely than not exceeds its carrying value, then a one-step approach is applied in making an evaluation. The
evaluation utilizes an income approach (discounted cash flow analysis). The computations require management to make significant estimates
and assumptions, including, among other things, selection of comparable publicly traded companies, the discount rate applied to future
earnings reflecting a weighted average cost of capital, and earnings growth assumptions. The Company believes the estimates and assumptions
used in our impairment assessments are reasonable and based on available market information, but variations in any of the assumptions
could result in materially different calculations of fair value and determinations of whether or not an impairment is indicated. A discounted
cash flow analysis requires management to make various assumptions about future sales, operating margins, capital expenditures, working
capital, and growth rates. Cash flow projections are derived from one year budgeted amounts plus an estimate of later period cash flows,
all of which are determined by management. Subsequent period cash flows are developed for each reporting unit using growth rates that
management believes are reasonably likely to occur. Impairment of goodwill is measured as the excess of the carrying amount of goodwill
over the fair values of recognized and unrecognized assets and liabilities of the reporting unit. &lt;span id="xdx_90E_eus-gaap--GoodwillImpairmentLoss_dxL_c20220101__20221231_zdxHnSdr2Oqc" title="Impairment of goodwill::XDX::-"&gt;&lt;span id="xdx_907_eus-gaap--GoodwillImpairmentLoss_dxL_c20210101__20211231_zfDF0blYLHAe" title="Impairment of goodwill::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0450"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0452"&gt;No&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; impairment was recognized during
the years ended December 31, 2022 or 2021 (see Note 8).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zDznBH10mbZd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_866_zxv2HJgVHvih"&gt;Intangible
Assets&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
estimated fair values of acquired intangibles are generally determined based upon future economic benefits such as earnings and cash
flows. Acquired identifiable intangible assets are recorded at fair value and are amortized over their estimated useful lives.
Acquired intangible assets with an indefinite life are not amortized but are reviewed for impairment at least annually as of
December 31&lt;sup&gt;st&lt;/sup&gt;, or more frequently whenever events or changes in circumstances indicate that the carrying amounts of those
assets are below their estimated fair values. Impairment is tested under ASC 350 which provides an entity with the option to
first assess qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is
more likely than not that the fair value of a reporting unit is less than its carrying amount.  If, after completing the
assessment, it is determined that it is more likely than not that the fair value of a reporting unit is less than its carrying
value, the Company will proceed to a quantitative test. For the years ended December 31, 2022 and 2021, the Company utilized a
qualitative, as events and circumstances do not indicate that it is more likely than not (that is, a likelihood of more than 50%)
that an indefinite-lived intangible asset is impaired. Key factors considered while performing qualitative testing include industry
and market considerations, macroeconomic conditions, continued patent development of the technologies, as well as marketplace&#x2019;s interest in the technologies. &lt;span id="xdx_905_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_do_c20210101__20211231_zUAxRNfrKXb3"&gt;No &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;impairment
was recognized during the years ended December 31, 2022 or 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zowPvJgkr1v1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_86A_zrUkcJMmMgP4"&gt;Recoverability of Long-Lived Assets&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
evaluate long-lived assets such as property, equipment and definite lived intangible assets, such as patents, for impairment whenever
events or circumstances indicate that the carrying value of the assets recognized in our financial statements may not be recoverable.
Factors that we consider include whether there has been a significant decrease in the market value of an asset, a significant change
in the way an asset is being utilized, or a significant change, delay or departure in our strategy for that asset, or a significant change
in the macroeconomic environment, such as the impact of the COVID-19 pandemic. Our assessment of the recoverability of long-lived assets
involves significant judgment and estimation. These assessments reflect our assumptions, which, we believe, are consistent with the assumptions
hypothetical marketplace participants use. Factors that we must estimate when performing recoverability and impairment tests include,
among others, forecasted revenue, margin costs and the economic life of the asset. If impairment is indicated, we determine if the total
estimated future cash flows on an undiscounted basis are less than the carrying amounts of the asset or assets. If so, an impairment
loss is measured and recognized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
impairment loss calculations require that we apply judgment in identifying asset groups, estimating future cash flows, determining asset
fair values, and estimating asset&#x2019;s useful lives. The Company reviews identifiable amortizable intangible assets for impairment
whenever events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. Determination of recoverability
is based on the lowest level of identifiable estimated undiscounted cash flows resulting from use of the asset and its eventual disposition.
Measurement of any impairment loss is based on the excess of the carrying value of the asset over its fair value. Based on the uncertainty
of forecasts inherent with a new product, events such as the failure to generate forecasted revenue from new products could result in
a non-cash impairment in future periods. &lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--ResearchAndDevelopmentExpensePolicy_zUmodztQVwYh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_862_z12WkzOcodcd"&gt;Research
and Development&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs are expensed as incurred. Total research and development costs were $&lt;span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231_zXrSS0mVKZme" title="Research and development cost"&gt;1,226,000&lt;/span&gt; for the year ended December 31,
2022, and $&lt;span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20211231_z2jj3EC2bXLh" title="Research and development cost"&gt;1,080,000&lt;/span&gt; for year ended 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;IMPACT
Biomedical, Inc. and Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Consolidated Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zUyTpbk6CX49" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86B_zsvnCvULgxk3"&gt;Recent
Accounting Standards&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Financial Accounting Standards Board (FASB) issues various Accounting Standards Updates relating to the treatment and recording of certain
accounting transactions. There are several new accounting pronouncements issued by FASB which are not yet effective. Each of these pronouncements,
as applicable, has been or will be adopted by the Company. As of December 31, 2022, none of these pronouncements is expected to have
a material effect on the financial position, results of operations or cash flows of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_ecustom--ContinuingOperationsAndGoingConcernPolicyTextBlock_zABPPJrNc1Q6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_861_zeJYlmlxbFEd"&gt;Continuing
Operations and Going Concern&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Due
to incurred operating losses as well as negative cash flows from operating and investing activities over the past two years, the accompanying
consolidated financial statements have been prepared assuming that the Company will continue as a going concern. This basis of accounting
contemplates the recovery of our assets and the satisfaction of liabilities in the normal course of business. These consolidated financial
statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary
should we be unable to continue as a going concern.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;To
continue as a going concern, the Company has entered into an updated revolving promissory note which extended the maturity through December
31, 2022, and DSS intends to continue to fund the operations of the Company through a year from the date these financial statements were
available to be issued. The Company&#x2019;s management intends to take actions necessary to continue as a going concern. Management&#x2019;s
plans concerning these matters include, among other things, monetization of its intellectual properties, and tightly controlling operating
costs. Based on this, the Company has concluded that substantial doubt of its ability to continue as a going concern has been alleviated.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_859_zzprbOpHUVP1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2022-01-012022-12-31">&lt;p id="xdx_847_eus-gaap--UseOfEstimates_z5wz0mcNenma" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_860_zaqEKogB9ez9"&gt;Use
of estimates&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the dates of the balance
sheets and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from these estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2022-01-012022-12-31">&lt;p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_zP3j63KgdsR4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_860_zTsxI67TiqM"&gt;Earnings
(Loss) per Share&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
earnings (loss) per share is computed by dividing the net income (loss) attributable to the common stockholders by weighted average number
of shares of common stock outstanding during the period. Fully diluted earnings (loss) per share is computed like basic income (loss)
per share except that the denominator is increased to include the number of additional common shares that would have been outstanding
if the potential common shares had been issued and if the additional common shares were dilutive. There were no dilutive financial instruments
issued or outstanding for the years ended December 31, 2022 or 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2022-01-012022-12-31">&lt;p id="xdx_843_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zDq08xlPnko" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86D_zCbRunpHjsuj"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants at the measurement date. The Fair Value Measurement Topic of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;)
Accounting Standards Codification (&#x201c;ASC&#x201d;) establishes a three-tier fair value hierarchy which prioritizes the inputs used
in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets
or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;
Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;
Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted
prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active;
and&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;
Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions,
such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amounts reported in the balance sheet of cash and cash equivalents, prepaids, accounts payable and accrued expenses approximate
fair value because of the immediate or short-term maturity of these financial instruments. The fair value of notes receivable approximates
their carrying value as the stated or discounted rates of the notes do reflect recent market conditions. The Company&#x2019;s investments
are record at cost as the fair value of these investment in are not readily available. The fair value of notes payable approximates its
carrying value as the stated interest rate reflects recent market conditions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;IMPACT
Biomedical, Inc. and Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Consolidated Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2022-01-012022-12-31">&lt;p id="xdx_841_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zdsWDnFzokXe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_864_zXeLEdoOSZU7"&gt;Cash
and cash equivalents&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers all highly liquid investments with a maturity of three months or less at the date of acquisition to be cash equivalents.
There were &lt;span id="xdx_90A_eus-gaap--Cash_iI_do_c20221231_zo4fwXEFQlQ3" title="Cash"&gt;&lt;span id="xdx_90F_eus-gaap--Cash_iI_do_c20211231_zcamax26Ny18" title="Cash"&gt;no&lt;/span&gt;&lt;/span&gt; cash equivalents as of December 31, 2022, and 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:Cash contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">0</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">0</us-gaap:Cash>
    <us-gaap:InvestmentPolicyTextBlock contextRef="From2022-01-012022-12-31">&lt;p id="xdx_84D_eus-gaap--InvestmentPolicyTextBlock_z58oA0m51di5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_869_zA1Hah58AIw"&gt;Investments&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Investments
in equity securities with a readily determinable fair value, not accounted for under the equity method, are recorded at fair value with
unrealized gains and losses included in earnings. For equity securities without a readily determinable fair value, the investment is
recorded at cost, less any impairment, plus or minus adjustments related to observable transactions for the same or similar securities,
with unrealized gains and losses included in earnings.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
equity method investments, the Company regularly reviews its investments to determine whether there is a decline in fair value below
book value. If there is a decline that is other-than-temporary, the investment is written down to fair value. See Note 7 for further
discussion on investments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy contextRef="From2022-01-012022-12-31">&lt;p id="xdx_841_eus-gaap--GoodwillAndIntangibleAssetsGoodwillPolicy_zMDnF0JgVyJh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_869_zxq5H1ahqL6a"&gt;Goodwill&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Goodwill
is the excess of cost of an acquired entity over the fair value of amounts assigned to assets acquired and liabilities assumed in a business
combination. Goodwill is subject to impairment testing at least annually and will be tested for impairment between annual tests, which
takes place during the fourth quarter, if an event occurs or circumstances change that would indicate the carrying amount may be impaired.
FASB ASC Topic 350 provides an entity with the option to first assess qualitative factors to determine whether the existence of events
or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying
amount. Some of the qualitative factors considered in applying this test include consideration of macroeconomic conditions, industry
and market conditions, cost factors affecting the business, and overall financial performance of the business. If, after completing the
assessment, it is determined that it is more likely than not that the fair value of a reporting unit is less than its carrying value,
the Company will proceed to a quantitative test. If qualitative factors are not deemed sufficient to conclude that the fair value of
the reporting unit more likely than not exceeds its carrying value, then a one-step approach is applied in making an evaluation. The
evaluation utilizes an income approach (discounted cash flow analysis). The computations require management to make significant estimates
and assumptions, including, among other things, selection of comparable publicly traded companies, the discount rate applied to future
earnings reflecting a weighted average cost of capital, and earnings growth assumptions. The Company believes the estimates and assumptions
used in our impairment assessments are reasonable and based on available market information, but variations in any of the assumptions
could result in materially different calculations of fair value and determinations of whether or not an impairment is indicated. A discounted
cash flow analysis requires management to make various assumptions about future sales, operating margins, capital expenditures, working
capital, and growth rates. Cash flow projections are derived from one year budgeted amounts plus an estimate of later period cash flows,
all of which are determined by management. Subsequent period cash flows are developed for each reporting unit using growth rates that
management believes are reasonably likely to occur. Impairment of goodwill is measured as the excess of the carrying amount of goodwill
over the fair values of recognized and unrecognized assets and liabilities of the reporting unit. &lt;span id="xdx_90E_eus-gaap--GoodwillImpairmentLoss_dxL_c20220101__20221231_zdxHnSdr2Oqc" title="Impairment of goodwill::XDX::-"&gt;&lt;span id="xdx_907_eus-gaap--GoodwillImpairmentLoss_dxL_c20210101__20211231_zfDF0blYLHAe" title="Impairment of goodwill::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0450"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0452"&gt;No&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; impairment was recognized during
the years ended December 31, 2022 or 2021 (see Note 8).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="From2022-01-012022-12-31">&lt;p id="xdx_841_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zDznBH10mbZd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_866_zxv2HJgVHvih"&gt;Intangible
Assets&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
estimated fair values of acquired intangibles are generally determined based upon future economic benefits such as earnings and cash
flows. Acquired identifiable intangible assets are recorded at fair value and are amortized over their estimated useful lives.
Acquired intangible assets with an indefinite life are not amortized but are reviewed for impairment at least annually as of
December 31&lt;sup&gt;st&lt;/sup&gt;, or more frequently whenever events or changes in circumstances indicate that the carrying amounts of those
assets are below their estimated fair values. Impairment is tested under ASC 350 which provides an entity with the option to
first assess qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is
more likely than not that the fair value of a reporting unit is less than its carrying amount.  If, after completing the
assessment, it is determined that it is more likely than not that the fair value of a reporting unit is less than its carrying
value, the Company will proceed to a quantitative test. For the years ended December 31, 2022 and 2021, the Company utilized a
qualitative, as events and circumstances do not indicate that it is more likely than not (that is, a likelihood of more than 50%)
that an indefinite-lived intangible asset is impaired. Key factors considered while performing qualitative testing include industry
and market considerations, macroeconomic conditions, continued patent development of the technologies, as well as marketplace&#x2019;s interest in the technologies. &lt;span id="xdx_905_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_do_c20210101__20211231_zUAxRNfrKXb3"&gt;No &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;impairment
was recognized during the years ended December 31, 2022 or 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2022-01-012022-12-31">&lt;p id="xdx_845_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zowPvJgkr1v1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_86A_zrUkcJMmMgP4"&gt;Recoverability of Long-Lived Assets&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
evaluate long-lived assets such as property, equipment and definite lived intangible assets, such as patents, for impairment whenever
events or circumstances indicate that the carrying value of the assets recognized in our financial statements may not be recoverable.
Factors that we consider include whether there has been a significant decrease in the market value of an asset, a significant change
in the way an asset is being utilized, or a significant change, delay or departure in our strategy for that asset, or a significant change
in the macroeconomic environment, such as the impact of the COVID-19 pandemic. Our assessment of the recoverability of long-lived assets
involves significant judgment and estimation. These assessments reflect our assumptions, which, we believe, are consistent with the assumptions
hypothetical marketplace participants use. Factors that we must estimate when performing recoverability and impairment tests include,
among others, forecasted revenue, margin costs and the economic life of the asset. If impairment is indicated, we determine if the total
estimated future cash flows on an undiscounted basis are less than the carrying amounts of the asset or assets. If so, an impairment
loss is measured and recognized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
impairment loss calculations require that we apply judgment in identifying asset groups, estimating future cash flows, determining asset
fair values, and estimating asset&#x2019;s useful lives. The Company reviews identifiable amortizable intangible assets for impairment
whenever events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. Determination of recoverability
is based on the lowest level of identifiable estimated undiscounted cash flows resulting from use of the asset and its eventual disposition.
Measurement of any impairment loss is based on the excess of the carrying value of the asset over its fair value. Based on the uncertainty
of forecasts inherent with a new product, events such as the failure to generate forecasted revenue from new products could result in
a non-cash impairment in future periods. &lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2022-01-012022-12-31">&lt;p id="xdx_84D_eus-gaap--ResearchAndDevelopmentExpensePolicy_zUmodztQVwYh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_862_z12WkzOcodcd"&gt;Research
and Development&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs are expensed as incurred. Total research and development costs were $&lt;span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231_zXrSS0mVKZme" title="Research and development cost"&gt;1,226,000&lt;/span&gt; for the year ended December 31,
2022, and $&lt;span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20211231_z2jj3EC2bXLh" title="Research and development cost"&gt;1,080,000&lt;/span&gt; for year ended 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;IMPACT
Biomedical, Inc. and Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Consolidated Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      unitRef="USD">1226000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">1080000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2022-01-012022-12-31">&lt;p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zUyTpbk6CX49" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86B_zsvnCvULgxk3"&gt;Recent
Accounting Standards&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Financial Accounting Standards Board (FASB) issues various Accounting Standards Updates relating to the treatment and recording of certain
accounting transactions. There are several new accounting pronouncements issued by FASB which are not yet effective. Each of these pronouncements,
as applicable, has been or will be adopted by the Company. As of December 31, 2022, none of these pronouncements is expected to have
a material effect on the financial position, results of operations or cash flows of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <IMPB:ContinuingOperationsAndGoingConcernPolicyTextBlock contextRef="From2022-01-012022-12-31">&lt;p id="xdx_84F_ecustom--ContinuingOperationsAndGoingConcernPolicyTextBlock_zABPPJrNc1Q6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_861_zeJYlmlxbFEd"&gt;Continuing
Operations and Going Concern&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Due
to incurred operating losses as well as negative cash flows from operating and investing activities over the past two years, the accompanying
consolidated financial statements have been prepared assuming that the Company will continue as a going concern. This basis of accounting
contemplates the recovery of our assets and the satisfaction of liabilities in the normal course of business. These consolidated financial
statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary
should we be unable to continue as a going concern.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;To
continue as a going concern, the Company has entered into an updated revolving promissory note which extended the maturity through December
31, 2022, and DSS intends to continue to fund the operations of the Company through a year from the date these financial statements were
available to be issued. The Company&#x2019;s management intends to take actions necessary to continue as a going concern. Management&#x2019;s
plans concerning these matters include, among other things, monetization of its intellectual properties, and tightly controlling operating
costs. Based on this, the Company has concluded that substantial doubt of its ability to continue as a going concern has been alleviated.&lt;/span&gt;&lt;/p&gt;

</IMPB:ContinuingOperationsAndGoingConcernPolicyTextBlock>
    <us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock contextRef="From2022-01-012022-12-31">&lt;p id="xdx_800_eus-gaap--ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_zFhQQRCK94Lh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 3. &lt;span id="xdx_821_zG7r9IK2XGIb"&gt;Restatement&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has determined that a restatement
of the December 31, 2022 consolidated financial statements is appropriate in order to correct certain errors in the reporting of interest
expense on the related party note. In previously issued consolidated financial statements, there was no interest expense recorded. Interest
expense has been corrected and restated from $&lt;span id="xdx_902_eus-gaap--InterestExpense_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zmWGH6VcJAaa" title="Interest expense"&gt;0&lt;/span&gt; to $&lt;span id="xdx_90D_eus-gaap--InterestExpense_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zjOFTwccJ734" title="Interest expense"&gt;462,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;
</us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock>
    <us-gaap:InterestExpense
      contextRef="From2022-01-012022-12-31_srt_MinimumMember"
      decimals="0"
      unitRef="USD">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2022-01-012022-12-31_srt_MaximumMember"
      decimals="0"
      unitRef="USD">462000</us-gaap:InterestExpense>
    <IMPB:PrepaidExpensesTextBlock contextRef="From2022-01-012022-12-31">&lt;p id="xdx_801_ecustom--PrepaidExpensesTextBlock_zdfXN0Hrprt3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
4. &lt;span id="xdx_828_zOq53fRflC37"&gt;Prepaid Expenses&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid
expenses for the year ended December 31, 2022, includes prepared inventory approximating $&lt;span id="xdx_901_eus-gaap--OtherPrepaidExpenseCurrent_iI_c20221231__dei--LegalEntityAxis__custom--GRDGscienceLLCMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zp6baYG5efAg" title="Prepaid expenses includes prepaid inventory"&gt;60,000&lt;/span&gt; and research and development
fees paid to GRDG Sciences, LLC. (&#x201c;GRDG&#x201d;), a related party, approximating $&lt;span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--GRDGscienceLLCMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zYt5tYHgV7gc" title="Research and development"&gt;43,000&lt;/span&gt;. Prepaid expenses at December 31, 2021 consists primarily of research and development costs to GRDG approximating
$&lt;span id="xdx_902_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_c20211231__dei--LegalEntityAxis__custom--GRDGscienceLLCMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zL4Qa03M4wQ7" title="Prepaid expenses"&gt;43,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</IMPB:PrepaidExpensesTextBlock>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="AsOf2022-12-31_custom_GRDGscienceLLCMember_us-gaap_RelatedPartyMember"
      decimals="0"
      unitRef="USD">60000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31_custom_GRDGscienceLLCMember_us-gaap_RelatedPartyMember"
      decimals="0"
      unitRef="USD">43000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2021-12-31_custom_GRDGscienceLLCMember_us-gaap_RelatedPartyMember"
      decimals="0"
      unitRef="USD">43000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock contextRef="From2022-01-012022-12-31">&lt;p id="xdx_803_eus-gaap--LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_z25wQoIJP1Mg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
5. &lt;span id="xdx_820_z4SLpLRbLPj"&gt;Notes Receivable&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 21, 2021, Impact BioMedical, Inc. entered into a promissory note (&#x201c;Promissory Note 1&#x201d;) with an individual. The Company
loaned the principal sum of $&lt;span id="xdx_908_eus-gaap--NotesReceivableNet_iI_c20210221__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember_z0VOMzV7pb49" title="Note receivable principal"&gt;206,000&lt;/span&gt;, with interest at a rate of &lt;span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210221__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember_zXLD8rT5Hz57" title="Debt stated percentage"&gt;6.5&lt;/span&gt;%, and maturity date of &lt;span id="xdx_905_eus-gaap--DebtInstrumentMaturityDate_dd_c20210220__20210221__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember_zw4TD56Of3ca" title="Debt maturity date"&gt;August 19, 2022&lt;/span&gt;. Monthly payments are due
on the twenty-first day of each month and continuing each month thereafter until August 19, 2022, at which time all accrued interest
and the entire remaining principal shall be due and payable in full. In August 2022, this note was amended to extend the maturity date
to &lt;span id="xdx_905_eus-gaap--DebtInstrumentMaturityDate_dd_c20220822__20220822__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember_zCnMpw3rHbd9" title="Maturity date"&gt;August 19, 2023&lt;/span&gt;. This note is secured by certain real property situated in Collier County, Florida. The outstanding principal and
interest approximated $&lt;span id="xdx_90E_eus-gaap--DebtInstrumentPeriodicPayment_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember_zYMGdLsmiYhe" title="Debt principal and interest"&gt;206,000&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--DebtInstrumentPeriodicPayment_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember_z5jFmGYFD047" title="Debt principal and interest"&gt;197,000&lt;/span&gt; as of December 31, 2022 and December 31, 2021, respectively. Of the $&lt;span id="xdx_905_eus-gaap--NotesReceivableNet_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember_z63QUl8VaF3g" title="Note receivable principal"&gt;206,000&lt;/span&gt; outstanding
at December 31, 2022, $&lt;span id="xdx_90C_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember_zkwGmNf4ujg" title="Notes receivable current"&gt;16,000&lt;/span&gt; is classified in current notes receivable on the accompanying consolidated balance sheets, and the remaining
$&lt;span id="xdx_90E_eus-gaap--NotesAndLoansReceivableNetNoncurrent_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember_zZ7Rd1CYaiQ6" title="Notes receivable"&gt;190,000&lt;/span&gt; is classified as note receivable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 14, 2021, DSS PureAir, Inc. (&#x201c;DSS PureAir&#x201d;), a wholly owned subsidiary of the Company, entered into a convertible promissory
note (&#x201c;Promissory Note 2&#x201d;) with a limited liability company registered in the state of Texas (&#x201c;Borrower&#x201d;). The
Promissory Note 2 has an aggregate principal balance up to $&lt;span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_c20210514__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteTwoMember_zsvvAMeGZufd" title="Debt face amount"&gt;5,000,000&lt;/span&gt;, to be funded at the request of the borrower. Promissory Note 2,
which incurs interest at a rate of &lt;span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210514__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteTwoMember_zVMduuVTOT7" title="Debt stated percentage"&gt;6.5&lt;/span&gt;% due quarterly, has a maturity date of &lt;span id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_dd_c20210513__20210514__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteTwoMember_zRpy7hm2QIGa" title="Debt maturity date"&gt;May 14, 2023&lt;/span&gt;. Promissory Note 2 contains an options conversion
clause that allows the Company to convert all, or a portion of all, into newly issued member units of the borrower with the maximum principal
amount equal to &lt;span id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210514__srt--RangeAxis__srt--MaximumMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteTwoMember_zEqPWrYfoSxi" title="Debt stated percentage"&gt;18&lt;/span&gt;% of the total equity position at conversion. On June 1, 2022, &lt;span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220601__srt--RangeAxis__srt--MaximumMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteTwoMember_zWWu3a2l4Q9c" title="Debt stated percentage"&gt;100&lt;/span&gt;% of the Company&#x2019;s interest in DSS PureAir
was assigned to DSS BioHealth Holdings, Inc., a related party, and wholly owned subsidiary of DSS BioHealth Security, Inc. Included in
this transaction was the outstanding principal and interest of Promissory Note 2 along with the related Note payable, related party.
The outstanding principal and interest on December 31, 2022, and December 31, 2021 is $&lt;span id="xdx_90F_eus-gaap--NotesAndLoansReceivableNetNoncurrent_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteTwoMember_z8CtEbgc2Pi" title="Notes and loans receivable"&gt;0&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--NotesAndLoansReceivableNetNoncurrent_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteTwoMember_zsyOmEy1a6mf" title="Notes and loans receivable"&gt;5,081,000&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
    <us-gaap:NotesReceivableNet
      contextRef="AsOf2021-02-21_custom_PromissoryNoteOneMember"
      decimals="0"
      unitRef="USD">206000</us-gaap:NotesReceivableNet>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2021-02-21_custom_PromissoryNoteOneMember"
      decimals="INF"
      unitRef="Pure">0.065</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2021-02-202021-02-21_custom_PromissoryNoteOneMember">2022-08-19</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2022-08-222022-08-22_custom_PromissoryNoteOneMember">2023-08-19</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="From2022-01-012022-12-31_custom_PromissoryNoteOneMember"
      decimals="0"
      unitRef="USD">206000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="From2021-01-012021-12-31_custom_PromissoryNoteOneMember"
      decimals="0"
      unitRef="USD">197000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:NotesReceivableNet
      contextRef="AsOf2022-12-31_custom_PromissoryNoteOneMember"
      decimals="0"
      unitRef="USD">206000</us-gaap:NotesReceivableNet>
    <us-gaap:NotesAndLoansReceivableGrossCurrent
      contextRef="AsOf2022-12-31_custom_PromissoryNoteOneMember"
      decimals="0"
      unitRef="USD">16000</us-gaap:NotesAndLoansReceivableGrossCurrent>
    <us-gaap:NotesAndLoansReceivableNetNoncurrent
      contextRef="AsOf2022-12-31_custom_PromissoryNoteOneMember"
      decimals="0"
      unitRef="USD">190000</us-gaap:NotesAndLoansReceivableNetNoncurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2021-05-14_custom_PromissoryNoteTwoMember"
      decimals="0"
      unitRef="USD">5000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2021-05-14_custom_PromissoryNoteTwoMember"
      decimals="INF"
      unitRef="Pure">0.065</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2021-05-132021-05-14_custom_PromissoryNoteTwoMember">2023-05-14</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2021-05-14_srt_MaximumMember_custom_PromissoryNoteTwoMember"
      decimals="INF"
      unitRef="Pure">0.18</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2022-06-01_srt_MaximumMember_custom_PromissoryNoteTwoMember"
      decimals="INF"
      unitRef="Pure">1</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:NotesAndLoansReceivableNetNoncurrent
      contextRef="AsOf2022-12-31_custom_PromissoryNoteTwoMember"
      decimals="0"
      unitRef="USD">0</us-gaap:NotesAndLoansReceivableNetNoncurrent>
    <us-gaap:NotesAndLoansReceivableNetNoncurrent
      contextRef="AsOf2021-12-31_custom_PromissoryNoteTwoMember"
      decimals="0"
      unitRef="USD">5081000</us-gaap:NotesAndLoansReceivableNetNoncurrent>
    <us-gaap:InvestmentTextBlock contextRef="From2022-01-012022-12-31">&lt;p id="xdx_807_eus-gaap--InvestmentTextBlock_z85LC97Ofige" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
6. &lt;span id="xdx_82A_znZzfzwUnAOa"&gt;Investments&lt;/span&gt;&lt;/b&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 19, 2020, Impact BioMedical entered into a subscription agreement (the &#x201c;Subscription Agreement&#x201d;) with BioMed Technologies
Asia Pacific Holdings Limited (&#x201c;BioMed&#x201d;), a limited liability company incorporated in the British Virgin Islands, pursuant
to which the Company agreed to purchase &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_c20201218__20201219__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AsiaPacificHoldingsLimitedMember__us-gaap--TypeOfArrangementAxis__us-gaap--SubscriptionArrangementMember_zdU5AwSuZvV4" title="Ordinary shares to purchase"&gt;525&lt;/span&gt; ordinary shares or &lt;span id="xdx_90A_ecustom--OrdinarySharesPercentage_dp_uPure_c20201218__20201219__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AsiaPacificHoldingsLimitedMember__us-gaap--TypeOfArrangementAxis__us-gaap--SubscriptionArrangementMember_zzLXG5NijGJ4" title="Ordinary shares percentage"&gt;4.99&lt;/span&gt;% of BioMed at a purchase price of approximately $&lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValuePurchaseOfAssets_c20201218__20201219__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AsiaPacificHoldingsLimitedMember__us-gaap--TypeOfArrangementAxis__us-gaap--SubscriptionArrangementMember_zq6IuAmFILjj" title="Purchase price of shares"&gt;632,000&lt;/span&gt;. The Subscription
Agreement provides, among other things, the Company the right to appoint a new director to the board of BioMed. With respect to an issuance
of shares to a third party by BioMed, the Company will have the right of first refusal to purchase such shares, as well as customary
tag-along rights. In connection with the Subscription Agreement, the Company entered into an exclusive distribution agreement (the &#x201c;Distribution
Agreement&#x201d;) with BioMed, to directly market, advertise, promote, distribute, and sell certain BioMed products, which focus on manufacturing
natural probiotics, to resellers. This investment is valued at cost as it does not have a readily determined fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioMed
focuses on manufacturing natural probiotics, pursuant to which the Company will directly market, advertise, promote, distribute and sell
certain BioMed products to resellers. The products to be distributed by the Company include BioMed&#x2019;s PGut Premium Probiotics&lt;sup&gt;&#xae;&lt;/sup&gt;,
PGut Allergy Probiotics&lt;sup&gt;&#xae;&lt;/sup&gt;, PGut SupremeSlim Probiotics&lt;sup&gt;&#xae;&lt;/sup&gt;, PGut Kids Probiotics&lt;sup&gt;&#xae;&lt;/sup&gt;, and PGut
Baby Probiotics&lt;sup&gt;&#xae;&lt;/sup&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
January 1, 2021, the Company entered into a securities purchase agreement (&#x201c;SPA&#x201d;) with Nano9, LLC. (&#x201c;Nano9&#x201d;),
a Utah limited partnership. For the consideration of $&lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210101__20210101__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NanoNineLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zuAHjH07hmw" title="Number of shares issued, value"&gt;150,000&lt;/span&gt; the Company obtained &lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20210101__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NanoNineLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zbhIqxSc7iai" title="Number of shares issued, shares"&gt;1,000&lt;/span&gt; membership units, or approximately &lt;span id="xdx_900_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20210101__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NanoNineLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z5EPAckCKBwa" title="Equitable ownership percentage"&gt;10&lt;/span&gt;% equitable
ownership of Nano9. Nano9 is a scientifically driven company, specializing in the development and production of leading nano-sized health
&amp;amp; wellness products utilizing their proprietary nano technology. As of December 31, 2022 and December 31, 2021, the fair value
of the Company&#x2019;s investment in Nano9 is not readily available, and therefore is recorded at cost of $&lt;span id="xdx_905_eus-gaap--InvestmentOwnedAtFairValue_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NanoNineLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z00oCQqXFQc2" title="Investment owned at fair value"&gt;&lt;span id="xdx_90E_eus-gaap--InvestmentOwnedAtFairValue_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NanoNineLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zhtpvgEcyjya" title="Investment owned at fair value"&gt;150,000&lt;/span&gt;&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;IMPACT
Biomedical, Inc. and Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Consolidated Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 15, 2021, the Company, through one of its subsidiaries, entered into a Stock Purchase Agreement (the &#x201c;Vivacitas Agreement
#1&#x201d;) with Vivacitas Oncology Inc. (&#x201c;Vivacitas&#x201d;), to purchase &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210314__20210315__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VivacitasOncologyIncMember_zoYFtGNMYMy9" title="Number of shares issued"&gt;500,000&lt;/span&gt; shares of its common stock at the per share price
of $&lt;span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20210315__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VivacitasOncologyIncMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zimS4EPEhqR3" title="Common stock par value"&gt;1.00&lt;/span&gt;, with an option to purchase &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20210314__20210315__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VivacitasOncologyIncMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_z9fAxVc6Rhy9" title="Options to purchase additional shares"&gt;1,500,000&lt;/span&gt; additional shares at the per share price of $&lt;span id="xdx_907_eus-gaap--SharePrice_iI_c20210315__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VivacitasOncologyIncMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zGGS0KsTwUqc" title="Share price"&gt;1.00&lt;/span&gt;. &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20210314__20210315__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VivacitasOncologyIncMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_z74PP9EIELSb" title="Option termination, description"&gt;This option will terminate upon one
of the following events: (i) Vivacitas&#x2019; board of directors cancels this option because it is no longer in the best interest of
the Company; (ii) December 31, 2022; or (iii) the date on which Vivacitas receives more than $1.00 per share of the Company&#x2019;s common
stock in a private placement with gross proceeds of $&lt;span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20210314__20210315__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VivacitasOncologyIncMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zIcLfiErOfZd" title="Proceeds from private placement"&gt;500,000&lt;/span&gt;. Under the terms of the Vivacitas Agreement #1, the Company will be allocated
two seats on the board of Vivacitas&lt;/span&gt;. On March 18, 2021, the Company entered into an agreement with Alset EHome International, Inc. (&#x201c;Seller&#x201d;)
to purchase from the Seller&#x2019;s its wholly owned subsidiary Impact Oncology PTE Ltd. (&#x201c;IOPL&#x201d;) for a purchase price $&lt;span id="xdx_905_eus-gaap--BusinessCombinationConsiderationTransferred1_c20210317__20210318__us-gaap--BusinessAcquisitionAxis__custom--ImpactOncologyPTELtdMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zqJsRxIgFptd" title="Purchase price"&gt;2,480,000&lt;/span&gt;.
The acquisition of IOPL has been treated as an asset acquisition as IOPL does not meet the definition of a business as defined in Topic
805. IOPL owns &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20210317__20210318__us-gaap--BusinessAcquisitionAxis__custom--ImpactOncologyPTELtdMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_z8oRAn06Lj2h" title="Number of common stock owned"&gt;2,480,000&lt;/span&gt; shares of common stock of Vivacitas along with the option to purchase an additional &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20210317__20210318__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zS4qqj45lBVb" title="Options to purchase common stock"&gt;250,000&lt;/span&gt; shares of common
stock. The Sellers largest shareholder is Mr. Chan Heng Fai Ambrose, the Chairman of the Company&#x2019;s board of directors and its largest
shareholder.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 1, 2021, the Company entered into an additional stock purchase agreement with Vivacitas (&#x201c;Vivacitas Agreement #2&#x201d;),
whereas Vivacities wished to employ the service of the Chief Business Officer of Impact Biomedical, and in return for the services of
this individual, Vivacitas shall issue to the Company, the aggregate purchase price for the Class A Common Shares of Vivacitas at the
value of $&lt;span id="xdx_901_eus-gaap--SharePrice_iI_c20210401__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VivacitasOncologyIncMember_zrAimDrTV1Rk" title="Share price"&gt;1.00&lt;/span&gt; per share shall be $&lt;span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20210401__20220331__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VivacitasOncologyIncMember_zSn8PkdKwse5" title="Proceeds from issuance of common stock"&gt;120,000&lt;/span&gt; to be paid in twelve (12) equal monthly installments for the period between April 1, 2021
and March 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 22, 2021, the Company exercised &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210721__20210722__us-gaap--TypeOfArrangementAxis__custom--VivacitasAgreementMember_z3YlT07998yd" title="Stock option exercised, shares"&gt;1,000,000&lt;/span&gt; of the available options under the Vivacitas Agreement #1 for $&lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_c20210721__20210722__us-gaap--TypeOfArrangementAxis__custom--VivacitasAgreementMember_zNAMq5OevIp2" title="Stock option exercised, value"&gt;1,000,000&lt;/span&gt;. This, along
with the shares received as part Vivacitas Agreement #2 increased the Company&#x2019;s equity position in Vivacitas to approximately 16%
as of December 31, 2022. As of December 31, 2021, the fair value of the Company&#x2019;s investment in Vivacitas is not readily available,
and therefore is recorded at cost in the amount of $&lt;span id="xdx_909_eus-gaap--InvestmentOwnedAtFairValue_iI_c20211231__us-gaap--TypeOfArrangementAxis__custom--VivacitasAgreementMember_zCDh09GDWFBc" title="Investment owned at fair value"&gt;4,035,000&lt;/span&gt;. For the fiscal year December 31, 2022, the company was unable to obtain
viable documentation in regards to Vivacitas&#x2019;s ability to continue as a business and therefore as of December 31, 2022, the Company
determined to impair &lt;span id="xdx_90C_eus-gaap--InvestmentOwnedPercentOfNetAssets_iI_pid_dp_c20221231__us-gaap--TypeOfArrangementAxis__custom--VivacitasAgreementMember_zKeNZ1wPUwq1" title="Investment cost, percent"&gt;100&lt;/span&gt;% of its investment in Vivacitas, in the amount of $&lt;span id="xdx_905_eus-gaap--InvestmentOwnedAtCost_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--VivacitasAgreementMember_zNncJJBhMJHc" title="Investment cost"&gt;4,100,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
</us-gaap:InvestmentTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="From2020-12-182020-12-19_custom_AsiaPacificHoldingsLimitedMember_us-gaap_SubscriptionArrangementMember"
      decimals="INF"
      unitRef="Shares">525</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <IMPB:OrdinarySharesPercentage
      contextRef="From2020-12-182020-12-19_custom_AsiaPacificHoldingsLimitedMember_us-gaap_SubscriptionArrangementMember"
      decimals="INF"
      unitRef="Pure">0.0499</IMPB:OrdinarySharesPercentage>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="From2020-12-182020-12-19_custom_AsiaPacificHoldingsLimitedMember_us-gaap_SubscriptionArrangementMember"
      decimals="0"
      unitRef="USD">632000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-01-01_custom_NanoNineLLCMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="0"
      unitRef="USD">150000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-01-012021-01-01_custom_NanoNineLLCMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      unitRef="Shares">1000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2021-01-01_custom_NanoNineLLCMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      unitRef="Pure">0.10</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:InvestmentOwnedAtFairValue
      contextRef="AsOf2022-12-31_custom_NanoNineLLCMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="0"
      unitRef="USD">150000</us-gaap:InvestmentOwnedAtFairValue>
    <us-gaap:InvestmentOwnedAtFairValue
      contextRef="AsOf2021-12-31_custom_NanoNineLLCMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="0"
      unitRef="USD">150000</us-gaap:InvestmentOwnedAtFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-03-142021-03-15_custom_StockPurchaseAgreementMember_custom_VivacitasOncologyIncMember"
      decimals="INF"
      unitRef="Shares">500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-03-15_custom_VivacitasOncologyIncMember_custom_StockPurchaseAgreementMember"
      decimals="INF"
      unitRef="USDPShares">1.00</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="From2021-03-142021-03-15_custom_StockPurchaseAgreementMember_custom_VivacitasOncologyIncMember"
      decimals="INF"
      unitRef="Shares">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:SharePrice
      contextRef="AsOf2021-03-15_custom_VivacitasOncologyIncMember_custom_StockPurchaseAgreementMember"
      decimals="INF"
      unitRef="USDPShares">1.00</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="From2021-03-142021-03-15_custom_StockPurchaseAgreementMember_custom_VivacitasOncologyIncMember">This option will terminate upon one
of the following events: (i) Vivacitas&#x2019; board of directors cancels this option because it is no longer in the best interest of
the Company; (ii) December 31, 2022; or (iii) the date on which Vivacitas receives more than $1.00 per share of the Company&#x2019;s common
stock in a private placement with gross proceeds of $500,000. Under the terms of the Vivacitas Agreement #1, the Company will be allocated
two seats on the board of Vivacitas</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2021-03-142021-03-15_custom_StockPurchaseAgreementMember_custom_VivacitasOncologyIncMember"
      decimals="0"
      unitRef="USD">500000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="From2021-03-172021-03-18_custom_ImpactOncologyPTELtdMember_custom_StockPurchaseAgreementMember"
      decimals="0"
      unitRef="USD">2480000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2021-03-172021-03-18_custom_ImpactOncologyPTELtdMember_custom_StockPurchaseAgreementMember"
      decimals="INF"
      unitRef="Shares">2480000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="From2021-03-172021-03-18_custom_StockPurchaseAgreementMember_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:SharePrice
      contextRef="AsOf2021-04-01_custom_StockPurchaseAgreementMember_custom_VivacitasOncologyIncMember"
      decimals="INF"
      unitRef="USDPShares">1.00</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2021-04-012022-03-31_custom_StockPurchaseAgreementMember_custom_VivacitasOncologyIncMember"
      decimals="0"
      unitRef="USD">120000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2021-07-212021-07-22_custom_VivacitasAgreementMember"
      decimals="INF"
      unitRef="Shares">1000000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-07-212021-07-22_custom_VivacitasAgreementMember"
      decimals="0"
      unitRef="USD">1000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:InvestmentOwnedAtFairValue
      contextRef="AsOf2021-12-31_custom_VivacitasAgreementMember"
      decimals="0"
      unitRef="USD">4035000</us-gaap:InvestmentOwnedAtFairValue>
    <us-gaap:InvestmentOwnedPercentOfNetAssets
      contextRef="AsOf2022-12-31_custom_VivacitasAgreementMember"
      decimals="INF"
      unitRef="Pure">1</us-gaap:InvestmentOwnedPercentOfNetAssets>
    <us-gaap:InvestmentOwnedAtCost
      contextRef="AsOf2022-12-31_custom_VivacitasAgreementMember"
      decimals="0"
      unitRef="USD">4100000</us-gaap:InvestmentOwnedAtCost>
    <us-gaap:PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock contextRef="From2022-01-012022-12-31">&lt;p id="xdx_806_eus-gaap--PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock_z6I2wZvDeftg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
7. &lt;span id="xdx_82F_zCX9GcFJoXfj"&gt;PROPERTY PLANT AND EQUIPMENT and INVESTMENT IN REAL ESTATE, NET&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--PropertyPlantAndEquipmentTextBlock_zeK0nWv9lJPb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property,
plant and equipment consisted of the following as of December 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;span id="xdx_8BF_z2t3OCgEixh5" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Schedule
of Property Plant and Equipment&#160;&lt;/span&gt;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49A_20221231_zrXoMxm3v5O5" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49E_20211231_zk829oJPVnK5" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Estimated&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Useful Life&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zmWwyyscexYl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 42%; text-align: left"&gt;Machinery and equipment&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MinimumMember_zcjv5qkHdFGl" title="Estimated Useful Life"&gt;5&lt;/span&gt;-&lt;span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MaximumMember_z1s4xoixrAK1" title="Estimated Useful Life"&gt;10&lt;/span&gt; years&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;25,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl0572"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_zQ6OaJkGOZVg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Construction in progress&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;251,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0579"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzm9U_zBEEe2hg8FS6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Total Cost&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;276,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0582"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzm9U_zjxoGnO8mgk3" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Property, plant and equipment, gross&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;276,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0585"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iI_msPPAENzm9U_zvzGcF4BUl5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Less accumulated depreciation&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0587"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0588"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzm9U_zAXgLfCmKW82" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;Property, plant and equipment, net&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;276,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0591"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_znc96iB43Mwi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation
expense for the years ended December 31, 2022 and 2021 was $&lt;span id="xdx_907_eus-gaap--Depreciation_dxL_c20220101__20221231_zpBMtDd7Vjq8" title="Depreciation expense::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0593"&gt;-&lt;/span&gt;&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--Depreciation_dxL_c20210101__20211231_zrFWLUFxm5pa" title="Depreciation expense::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0595"&gt;-&lt;/span&gt;&lt;/span&gt; respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2022-01-012022-12-31">&lt;p id="xdx_897_eus-gaap--PropertyPlantAndEquipmentTextBlock_zeK0nWv9lJPb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property,
plant and equipment consisted of the following as of December 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;span id="xdx_8BF_z2t3OCgEixh5" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Schedule
of Property Plant and Equipment&#160;&lt;/span&gt;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49A_20221231_zrXoMxm3v5O5" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49E_20211231_zk829oJPVnK5" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Estimated&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Useful Life&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zmWwyyscexYl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 42%; text-align: left"&gt;Machinery and equipment&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MinimumMember_zcjv5qkHdFGl" title="Estimated Useful Life"&gt;5&lt;/span&gt;-&lt;span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MaximumMember_z1s4xoixrAK1" title="Estimated Useful Life"&gt;10&lt;/span&gt; years&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;25,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl0572"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_zQ6OaJkGOZVg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Construction in progress&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;251,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0579"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzm9U_zBEEe2hg8FS6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Total Cost&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;276,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0582"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzm9U_zjxoGnO8mgk3" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Property, plant and equipment, gross&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;276,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0585"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iI_msPPAENzm9U_zvzGcF4BUl5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Less accumulated depreciation&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0587"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0588"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzm9U_zAXgLfCmKW82" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;Property, plant and equipment, net&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;276,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0591"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="AsOf2022-12-31_us-gaap_MachineryAndEquipmentMember_srt_MinimumMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="AsOf2022-12-31_us-gaap_MachineryAndEquipmentMember_srt_MaximumMember">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_us-gaap_MachineryAndEquipmentMember"
      decimals="0"
      unitRef="USD">25000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_us-gaap_ConstructionInProgressMember"
      decimals="0"
      unitRef="USD">251000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">276000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">276000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">276000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:GoodwillDisclosureTextBlock contextRef="From2022-01-012022-12-31">&lt;p id="xdx_802_eus-gaap--GoodwillDisclosureTextBlock_zrV4G5cfoMVi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
8. &lt;span id="xdx_825_zoOzzVnlFws3"&gt;Goodwill&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfGoodwillTextBlock_zpmRTT97BXn8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Goodwill
balances and activity for the year ended December 31, 2022 and year ended December 31, 2021 consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B0_zxYACxWrYIO8" style="display: none"&gt;Schedule of Goodwill&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 80%"&gt;Balance at December 31, 2021&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--Goodwill_iS_c20220101__20221231_zxPgTUEzpXmk" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Balance at December 31, 2022"&gt;25,093,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Goodwill adjustment&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--GoodwillImpairmentLoss_c20220101__20221231_zNm1t3Tac80c" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Goodwill adjustment"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0603"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--Goodwill_iE_c20220101__20221231_zUhDwIwxxPml" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance at March 31, 2023"&gt;25,093,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zEXCQ6xJ0cJ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During 2022 and 2021, management performed annual
goodwill impairment testing. No goodwill impairment was identified as a result of these tests. As of June 1, 2022 a quantitative
analysis was prepared utilizing the Market Approach and Income Approach valuing the Company. &lt;span id="xdx_90A_ecustom--NoncashOrPartNoncashAcquisitionValueOfAssetAcquiredDescription_c20230101__20230331_z1z7YmGJRRth" title="Acquisition value of asset acquired, description"&gt;The guideline public company Market
Approach produced a mean business enterprise value indication using estimated 2025 results of $69.24 million. The Income Approach was
based upon the use of a discounted pro forma cash flow model and produced a business enterprise value indication of $56.54 million. A
weighting of 20% to the weighted value indicated was applied under the Market Approach, a weighting of 10% to the prior transaction value
and a weighting of 70% to the value indicated under the Income Approach. A lower weighting was applied to the Market Approach due to
the fact of using forecasted earnings of the Company. Based upon the above weightings, an initial value of $57.26 million for Impact
was calculated. Adding cash and cash equivalents of $&lt;span id="xdx_901_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20220601_ziJRXcD9RlH1" title="Cash"&gt;33,000&lt;/span&gt; to the initial business enterprise value produced a concluded business enterprise
value of $57.29 million (rounded) for Impact.&lt;/span&gt; Subtracting interest-bearing debt of $&lt;span id="xdx_901_eus-gaap--LongTermDebtFairValue_iI_pn4n6_c20220601_zDoY0a4OFtfe" title="Long term debt fair value"&gt;13.15&lt;/span&gt; million, results in a Fair Value for the common
equity of Impact of $&lt;span id="xdx_908_eus-gaap--EquityFairValueAdjustment_pn4n6_c20220530__20220601_zYU3NrHfGN23" title="Equity fair value"&gt;44.14&lt;/span&gt; million. As of June 1, 2022, the indicated equity value exceeded the carrying amount by approximately $&lt;span id="xdx_90E_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20220601_zj30yQs3bAs" title="Debt carrying amount"&gt;4.9&lt;/span&gt;
million or &lt;span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220601_zxVAADQ0Wyjb" title="Debt interest rate"&gt;12.5&lt;/span&gt;%.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During 2021, we used qualitative factors to determine
whether it was more likely than not (likelihood of more than 50%) that the fair value of a reporting unit exceeded its carrying amount.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:GoodwillDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock contextRef="From2022-01-012022-12-31">&lt;p id="xdx_89D_eus-gaap--ScheduleOfGoodwillTextBlock_zpmRTT97BXn8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Goodwill
balances and activity for the year ended December 31, 2022 and year ended December 31, 2021 consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B0_zxYACxWrYIO8" style="display: none"&gt;Schedule of Goodwill&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 80%"&gt;Balance at December 31, 2021&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--Goodwill_iS_c20220101__20221231_zxPgTUEzpXmk" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Balance at December 31, 2022"&gt;25,093,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Goodwill adjustment&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--GoodwillImpairmentLoss_c20220101__20221231_zNm1t3Tac80c" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Goodwill adjustment"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0603"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--Goodwill_iE_c20220101__20221231_zUhDwIwxxPml" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance at March 31, 2023"&gt;25,093,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">25093000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">25093000</us-gaap:Goodwill>
    <IMPB:NoncashOrPartNoncashAcquisitionValueOfAssetAcquiredDescription contextRef="From2023-01-01to2023-03-31">The guideline public company Market
Approach produced a mean business enterprise value indication using estimated 2025 results of $69.24 million. The Income Approach was
based upon the use of a discounted pro forma cash flow model and produced a business enterprise value indication of $56.54 million. A
weighting of 20% to the weighted value indicated was applied under the Market Approach, a weighting of 10% to the prior transaction value
and a weighting of 70% to the value indicated under the Income Approach. A lower weighting was applied to the Market Approach due to
the fact of using forecasted earnings of the Company. Based upon the above weightings, an initial value of $57.26 million for Impact
was calculated. Adding cash and cash equivalents of $33,000 to the initial business enterprise value produced a concluded business enterprise
value of $57.29 million (rounded) for Impact.</IMPB:NoncashOrPartNoncashAcquisitionValueOfAssetAcquiredDescription>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2022-06-01" decimals="0" unitRef="USD">33000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:LongTermDebtFairValue contextRef="AsOf2022-06-01" decimals="-4" unitRef="USD">13150000</us-gaap:LongTermDebtFairValue>
    <us-gaap:EquityFairValueAdjustment
      contextRef="From2022-05-302022-06-01"
      decimals="-4"
      unitRef="USD">44140000</us-gaap:EquityFairValueAdjustment>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="AsOf2022-06-01" decimals="-5" unitRef="USD">4900000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="AsOf2022-06-01" decimals="INF" unitRef="Pure">0.125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2022-01-012022-12-31">&lt;p id="xdx_80F_eus-gaap--IntangibleAssetsDisclosureTextBlock_z2H0L9dY8BO2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
9. &lt;span id="xdx_824_z1tn2rovw4W"&gt;Intangible Assets&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
definite-lived intangible assets, to be amortized over 20 years, balances and activity for the years ended December 31, 2022, and 2021
consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zHQdA7txJ6z4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B0_zqZtUD871FG4" style="display: none"&gt;Schedule
of Intangible Assets&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;12/31/2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;12/31/2021&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Gross Carrying&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Accumulated&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Amortization&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Net Carrying&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Gross Carrying&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Accumulated&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Amortization&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Net Carrying&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;Definitive-lived:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left; padding-bottom: 1.5pt"&gt;Developed technology&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zgBIkWG91zXk" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right" title="Gross Carrying Amount"&gt;22,258,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zpuWVPx1EXc2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right" title="Accumulated Amortization"&gt;(2,226,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zRgOQZTT6Yd" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right" title="Net Carrying Amount"&gt;20,033,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zI7Y34SBRsqh" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right" title="Gross Carrying Amount"&gt;22,260,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_z5FrKHNRmm5a" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right" title="Accumulated Amortization"&gt;(1,113,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zGbghpcnCqzc" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right" title="Net Carrying Amount"&gt;21,147,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20221231_zk1bqzZQHIJd" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gross Carrying Amount"&gt;22,258,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231_zhrxucA4Ylq2" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accumulated Amortization"&gt;(2,226,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20221231_zwlty5MPwip8" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net Carrying Amount"&gt;20,033,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20211231_zY55HIRHhZ77" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gross Carrying Amount"&gt;22,260,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20211231_zdXvV8N6tel6" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accumulated Amortization"&gt;(1,113,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20211231_zORzHT040mca" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net Carrying Amount"&gt;21,147,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zJTTpTcsc7ml" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amounts
amortized for the year ended December 31, 2022 and 2021 was approximately $&lt;span id="xdx_903_eus-gaap--DepreciationAndAmortization_c20220101__20221231_z07Xi7V36SDb" title="Amortization"&gt;1,113,000&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--DepreciationAndAmortization_c20210101__20211231_zKiA3suvZwf2" title="Amortization"&gt;1,113,000&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_ztrJEWSXpzQ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table represents future amortization of developed technologies:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B2_z5r4lxyudiOb" style="display: none"&gt;Schedule
of Future Amortization of Developed Technologies&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_497_20221231_z6eq82unuXc3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_zFHMZ3jeS3b1" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: right"&gt;2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;835,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_zjqgq8ica1v2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: right"&gt;2022&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;1,113,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_zYolTxwz4QS8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,113,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_zEbL6CCv6cT9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,113,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_zUhYP2MIBOXh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2025&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,113,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_zm9aNzIaiv73" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2026&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,113,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_zXVHPYqafEyl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;Thereafter&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;14,468,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zbjcQpyG6dU2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;IMPACT
Biomedical, Inc. and Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Consolidated Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
March 2021, the fair value of the assets acquired by DSS on August 21, 2020, was concluded. An impairment analysis was conducted for
financial reporting purposes in connection with U.S. GAAP and ASC 360-10, Impairment and Disposal of Long-Lived Assets. Although the
Company has a history of negative cash flows from operations, its financing arrangement with DSS (see Note 9) provides the opportunity
to fund ongoing operations. This, as well as there being no other indicators present for impairment, has led management to conclude that
no impairment is necessary for the years ended December 31, 2022, and 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="From2022-01-012022-12-31">&lt;p id="xdx_894_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zHQdA7txJ6z4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B0_zqZtUD871FG4" style="display: none"&gt;Schedule
of Intangible Assets&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;12/31/2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;12/31/2021&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Gross Carrying&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Accumulated&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Amortization&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Net Carrying&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Gross Carrying&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Accumulated&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Amortization&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Net Carrying&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;Definitive-lived:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left; padding-bottom: 1.5pt"&gt;Developed technology&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zgBIkWG91zXk" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right" title="Gross Carrying Amount"&gt;22,258,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zpuWVPx1EXc2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right" title="Accumulated Amortization"&gt;(2,226,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zRgOQZTT6Yd" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right" title="Net Carrying Amount"&gt;20,033,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zI7Y34SBRsqh" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right" title="Gross Carrying Amount"&gt;22,260,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_z5FrKHNRmm5a" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right" title="Accumulated Amortization"&gt;(1,113,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zGbghpcnCqzc" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right" title="Net Carrying Amount"&gt;21,147,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20221231_zk1bqzZQHIJd" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gross Carrying Amount"&gt;22,258,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231_zhrxucA4Ylq2" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accumulated Amortization"&gt;(2,226,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20221231_zwlty5MPwip8" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net Carrying Amount"&gt;20,033,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20211231_zY55HIRHhZ77" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gross Carrying Amount"&gt;22,260,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20211231_zdXvV8N6tel6" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accumulated Amortization"&gt;(1,113,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20211231_zORzHT040mca" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net Carrying Amount"&gt;21,147,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2022-12-31_us-gaap_DevelopedTechnologyRightsMember"
      decimals="0"
      unitRef="USD">22258000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2022-12-31_us-gaap_DevelopedTechnologyRightsMember"
      decimals="0"
      unitRef="USD">-2226000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2022-12-31_us-gaap_DevelopedTechnologyRightsMember"
      decimals="0"
      unitRef="USD">20033000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2021-12-31_us-gaap_DevelopedTechnologyRightsMember"
      decimals="0"
      unitRef="USD">22260000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2021-12-31_us-gaap_DevelopedTechnologyRightsMember"
      decimals="0"
      unitRef="USD">-1113000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2021-12-31_us-gaap_DevelopedTechnologyRightsMember"
      decimals="0"
      unitRef="USD">21147000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">22258000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">-2226000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">20033000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">22260000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">-1113000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">21147000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      unitRef="USD">1113000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">1113000</us-gaap:DepreciationAndAmortization>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="From2022-01-012022-12-31">&lt;p id="xdx_89F_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_ztrJEWSXpzQ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table represents future amortization of developed technologies:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B2_z5r4lxyudiOb" style="display: none"&gt;Schedule
of Future Amortization of Developed Technologies&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_497_20221231_z6eq82unuXc3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_zFHMZ3jeS3b1" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: right"&gt;2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;835,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_zjqgq8ica1v2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: right"&gt;2022&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;1,113,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_zYolTxwz4QS8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,113,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_zEbL6CCv6cT9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,113,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_zUhYP2MIBOXh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2025&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,113,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_zm9aNzIaiv73" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2026&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,113,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_zXVHPYqafEyl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;Thereafter&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;14,468,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">835000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1113000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1113000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1113000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1113000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1113000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">14468000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2022-01-012022-12-31">&lt;p id="xdx_803_eus-gaap--DebtDisclosureTextBlock_zXSDRNLok2He" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
10. &lt;span id="xdx_824_zbDeTJMfFkH4"&gt;Debt&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 31, 2020, and later amended on December 31, 2022, the Company executed a Revolving Promissory Note (&#x201c;Note&#x201d;) with
DSS, a related party, which accrues interest at a rate of &lt;span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20221231__us-gaap--DebtInstrumentAxis__custom--RevolvingPromissoryNoteMember_z6nKohDNKl16" title="Debt instrument interest, rate"&gt;4.25&lt;/span&gt;% and is due in full at the maturity date of &lt;span id="xdx_901_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--RevolvingPromissoryNoteMember_zrQGqf3Rhc9d" title="Debt instrument, maturity date"&gt;December 31, 2023&lt;/span&gt;. The revolving
nature of this Note permits for principal amounts borrowed to be repaid and reborrowed. &lt;span id="xdx_909_eus-gaap--DebtDefaultLongtermDebtDescriptionOfNoticeOfDefault_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--RevolvingPromissoryNoteMember_z7H9UcWthbZi" title="Long term debt, description"&gt;In the case of default, at DSS&#x2019;s option,
(i) eighteen percent (18%) per annum, or (ii) such lesser rate of interest as Lender in its sole discretion may choose to charge; but
never more than the Maximum Lawful Rate.&lt;/span&gt; DSS has not established a maximum borrowing amount and intends to continue to fund the operations
of the Company through a year from the date these financial statements were available to be issued. As of December 31, 2022 and 2021,
this Note had an outstanding balance of $&lt;span id="xdx_90D_eus-gaap--NotesPayable_iI_c20221231_zdm2M8yum3u" title="Outstanding balance"&gt;9,991,000&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--NotesPayable_iI_c20211231_zeMhgfyxMETj" title="Outstanding balance"&gt;12,524,000&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2022-12-31_custom_RevolvingPromissoryNoteMember"
      decimals="INF"
      unitRef="Pure">0.0425</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2022-01-012022-12-31_custom_RevolvingPromissoryNoteMember">2023-12-31</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtDefaultLongtermDebtDescriptionOfNoticeOfDefault contextRef="From2022-01-012022-12-31_custom_RevolvingPromissoryNoteMember">In the case of default, at DSS&#x2019;s option,
(i) eighteen percent (18%) per annum, or (ii) such lesser rate of interest as Lender in its sole discretion may choose to charge; but
never more than the Maximum Lawful Rate.</us-gaap:DebtDefaultLongtermDebtDescriptionOfNoticeOfDefault>
    <us-gaap:NotesPayable contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">9991000</us-gaap:NotesPayable>
    <us-gaap:NotesPayable contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">12524000</us-gaap:NotesPayable>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2022-01-012022-12-31">&lt;p id="xdx_80E_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z9NBT3j11CY" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
11. &lt;span id="xdx_829_zSCBLTTc6NYa"&gt;Stockholders&#x2019; Equity&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 23, 2021, the Company, the Company&#x2019;s Board of Directors approved the total number of shares of Common Stock to be &lt;span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_iI_c20210923__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zU9fmLrpw2Sf" title="Common stock, shares authorized"&gt;3,000,000,000&lt;/span&gt;
shares with a par value of $&lt;span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20210923__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zqODeemrq8h5" title="Common stock par value"&gt;0.001&lt;/span&gt;. Each share of Common Stock when issued, shall have one (1) vote on all matters presented to the stockholders.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
Amended and Restated Articles of Incorporation authorizes us to issue up to &lt;span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_c20210923_zppbOWSK5Na9" title="Common stock, shares authorized"&gt;4,000,000,000&lt;/span&gt; shares of Common Stock, $&lt;span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20210923_zZLPtRf8Lz8h" title="Common stock par value"&gt;0.001&lt;/span&gt; par value per
share, and &lt;span id="xdx_908_eus-gaap--PreferredStockSharesAuthorized_iI_c20210923_zvr5fKKcPhVa" title="Preferred stock, shares authorized"&gt;100,000,000&lt;/span&gt; shares of preferred stock, par value $&lt;span id="xdx_90D_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20210923_zvfDDGcIYoWk" title="Preferred stock, par value"&gt;0.001&lt;/span&gt; per share. On May 11, 2023, the Company effected a forward split.
As a result, there were &lt;span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_c20230511__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zebBP2Ii6xj9" title="Common stock, shares authorized"&gt;3,877,282,251&lt;/span&gt; shares of our Common Stock and &lt;span id="xdx_90B_eus-gaap--PreferredStockSharesIssued_iI_do_c20230511__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zLSFnHmbxzpc" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_902_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20230511__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zhIadLxK5rX1" title="Preferred stock, shares outstanding"&gt;no&lt;/span&gt;&lt;/span&gt; shares of preferred stock issued and outstanding. As of December
31, 2022 and 2021, there were &lt;span id="xdx_901_eus-gaap--CommonStockSharesIssued_iI_c20221231_zDxLHWYU3G44" title="Common stock, shares issued"&gt;125,073,621&lt;/span&gt; shares of our Common Stock and outstanding which was converted to &lt;span id="xdx_906_eus-gaap--CommonStockSharesOutstanding_iI_c20211231_zie7uVylp7lf" title="Common stock, shares outstanding"&gt;3,877,282,251&lt;/span&gt; shares. As
of December 31, 2022 and 2021, there were &lt;span id="xdx_90A_eus-gaap--PreferredStockSharesIssued_iI_do_c20221231__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zjqSAF0L3Wu4" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_90C_eus-gaap--PreferredStockSharesIssued_iI_do_c20211231__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zlB3JKSKMMI8" title="Preferred stock, shares issued"&gt;no&lt;/span&gt;&lt;/span&gt; preferred shares issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2021-09-23_srt_BoardOfDirectorsChairmanMember"
      decimals="INF"
      unitRef="Shares">3000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-09-23_srt_BoardOfDirectorsChairmanMember"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-09-23" decimals="INF" unitRef="Shares">4000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-09-23"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2021-09-23" decimals="INF" unitRef="Shares">100000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2021-09-23"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-05-11_us-gaap_SubsequentEventMember"
      decimals="INF"
      unitRef="Shares">3877282251</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-05-11_us-gaap_SubsequentEventMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-05-11_us-gaap_SubsequentEventMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">125073621</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">3877282251</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-12-31_us-gaap_SubsequentEventMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2021-12-31_us-gaap_SubsequentEventMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2022-01-012022-12-31">&lt;p id="xdx_80F_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zztEBZT4mjQg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
12. &lt;span id="xdx_822_zvy9I2R7FfRg"&gt;Related Party Transactions&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Research
and Development Activities&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Based
on Shareholders Agreement entered into on April 26, 2017, the Company would fund the scientific operations of GRDG, a company involved
in research and development of biomedical products which is a minority stockholder of two of the Company&#x2019;s subsidiaries and is
owned by Daryl Thompson, a director of many subsidiaries of the Company, to do the development and research works on the biomedical products
for the Company. As of December 31, 2022, this funding approximates $&lt;span id="xdx_90A_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GRDGscienceLLCMember_zVjUWSovINQi" title="Payment in funding of research and development"&gt;43,000&lt;/span&gt; per month, and incurred approximately $&lt;span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GRDGscienceLLCMember_zryqsaKOM4hf" title="Research and development expense"&gt;546,000&lt;/span&gt; in expenses. On
December 31, 2022 and December 31, 2021, the Company owed this related party $&lt;span id="xdx_907_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20220101__20221231_z5iAXlXhFpw8" title="Related party owed transaction"&gt;&lt;span id="xdx_908_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20210101__20211231_zt3FU3pWMl4c" title="Related party owed transaction"&gt;0&lt;/span&gt;&lt;/span&gt; and had prepaid monthly fees approximating $&lt;span id="xdx_90C_eus-gaap--PrepaidExpenseCurrentAndNoncurrent_iI_c20221231_zqtTTZcDzusj" title="Prepaid monthly fees"&gt;43,000&lt;/span&gt; and
$&lt;span id="xdx_90A_eus-gaap--PrepaidExpenseCurrentAndNoncurrent_iI_c20211231_zLvoos388iwl" title="Prepaid monthly fees"&gt;43,000&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;General
and Administrative Costs&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
are certain general and administrative costs incurred by DSS, a related party on behalf of the Company which are passed through to the
Company on a monthly basis. These costs consist of primarily payroll costs for certain DSS employees and are allocated based on estimated
time spent on behalf of the Company. These costs approximate $&lt;span id="xdx_905_eus-gaap--LaborAndRelatedExpense_c20220101__20221231_zTLH81H2p9u2" title="Related costs for employees"&gt;12,000&lt;/span&gt; per month. As of December 31, 2022, the Company incurred
$&lt;span id="xdx_901_eus-gaap--GeneralAndAdministrativeExpense_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z1za1w1WTIj8" title="General and administrative expense"&gt;117,000&lt;/span&gt; in related expenses. As of December 31, 2021, the Company incurred approximately $&lt;span id="xdx_906_eus-gaap--GeneralAndAdministrativeExpense_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zMLNxepSFCIl" title="General and administrative expense"&gt;155,000&lt;/span&gt; in related expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;IMPACT
Biomedical, Inc. and Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Consolidated Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="From2022-01-012022-12-31_custom_GRDGscienceLLCMember"
      decimals="0"
      unitRef="USD">43000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31_custom_GRDGscienceLLCMember"
      decimals="0"
      unitRef="USD">546000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      unitRef="USD">0</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">0</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:PrepaidExpenseCurrentAndNoncurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">43000</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
    <us-gaap:PrepaidExpenseCurrentAndNoncurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">43000</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
    <us-gaap:LaborAndRelatedExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      unitRef="USD">12000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-01-012022-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      unitRef="USD">117000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-01-012021-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      unitRef="USD">155000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2022-01-012022-12-31">&lt;p id="xdx_808_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z5Xcxi9CgOB5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
13. &lt;span id="xdx_82D_z9726DukHO4f"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 15, 2018, the Company entered into Royalty Agreement with Chemia Corporation (&#x201c;Chemia&#x201d;) pursuant to which Chemia transferred
to the Company all of its right to 3F (Functional Fragrance Formulation). This agreement has a 20-year term and auto renews for a period
of 1 year unless mutually agreed upon by both parties. 3F consists of 3F Mosquito Repellant and 3F Anti-Viral formulations. Based on
the Royalty Agreement, the Company should cover all the costs to prepare and finalize necessary patent application and other intellectual
property related to 3F. Chemia agreed to support the Company in efforts leading to development of 3F intellectual property and it&#x2019;s
licensing. Based on Royalty Agreement any payments received from development, sales, licensing or transfer of 3F technology will be paid
&lt;span id="xdx_906_ecustom--RoyaltyPercentage_pid_dp_uPure_c20180814__20180815__us-gaap--TypeOfArrangementAxis__custom--RoyaltyAgreementMember_zes4xogi5U8j" title="Royalty percentage"&gt;50&lt;/span&gt;% to the Company and &lt;span id="xdx_907_ecustom--RoyaltyPercentage_pid_dp_uPure_c20180814__20180815__us-gaap--TypeOfArrangementAxis__custom--RoyaltyAgreementMember__dei--LegalEntityAxis__custom--ChemiaCorporationMember_zoxr8l8BHGD4" title="Royalty percentage"&gt;50&lt;/span&gt;% to Chemia. On November 27, 2018, Company and Chemia signed an Addendum to Royalty Agreement (&#x201c;Addendum&#x201d;),
according to which the Company granted Chemia a royalty-based limited license for purposes of making and selling fragrances embodying
the 3F technology. Based on the Addendum, Chemia should pay the Company &lt;span id="xdx_90E_ecustom--SaleOfRoyaltyPercentage_pid_dp_uPure_c20181126__20181127__us-gaap--TypeOfArrangementAxis__custom--RoyaltyAgreementMember_zAcTF2elKA66" title="Net sales  royalty"&gt;5&lt;/span&gt;% of net sales in royalty. On November 8, 2019, both companies
entered into Amendment no.1 to Royalty Agreement, based on which certain expenses bore by the Company towards patent application and
licensing should be reimbursed to the Company before any royalty payments are made. For the nine months ended December 31, 2022 and 2021,
there were no reimbursements or royalties paid to the Company and the Company cannot be assured that Chemia&#x2019;s efforts will end
up in any future sales of the technology.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 15, 2022, the Company and its subsidiaries, Global BioLife, Inc. (&#x201c;Global&#x201d;), and Impact BioLife Sciences, Inc. (&#x201c;BioLife
Sciences&#x201d;), and GRDG entered into a Licensing Proceeds Distribution Agreement (&#x201c;GRDG Agreement&#x201d;), whereas GRDG would
transfer its &lt;span id="xdx_900_ecustom--SaleOfRoyaltyPercentage_pid_dp_uPure_c20220214__20220215__us-gaap--TypeOfArrangementAxis__custom--RoyaltyAgreementMember_z2dmeqsggJD2" title="Net sales  royalty"&gt;20&lt;/span&gt;% equity position in both Global and BioLife Sciences to the Company in exchange for 20% interest in Global and/or BioLife
Science revenue received from the exclusive or non-exclusive licensing of and/or the sale of Global Intellectual Property to a Third
Party, net of specific costs. As of the date of this report, no contingent liability has been recognized under the GRDG Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 19, 2022, Impact BioMedical entered into a License Agreement (&#x201c;Equivir License&#x201d;) with ProPhase Labs, Inc. (&#x201c;ProPhase&#x201d;)
where the ProPhase is granted the right, amongst other things, to develop, commercialize, and sell the Company&#x2019;s Equivir technology.
In exchange, the Licensee shall pay the Company a royalty of &lt;span id="xdx_90E_ecustom--SaleOfRoyaltyPercentage_pid_dp_uPure_c20220318__20220319__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zqoIlPkCQrs6" title="Net sales  royalty"&gt;5.5&lt;/span&gt;% of net sales. Under the terms of the Equivir Agreement, the Company
shall reimburse ProPhase for &lt;span id="xdx_90D_ecustom--DevelopmentCostPercent_pid_dp_uPure_c20220318__20220319__us-gaap--TypeOfArrangementAxis__custom--RoyaltyAgreementMember_zqrzp8mvcYy2" title="Development cost, percent"&gt;50&lt;/span&gt;% of the development costs provided that the development costs shall not exceed $&lt;span id="xdx_908_eus-gaap--CostsIncurredDevelopmentCosts_c20220318__20220319__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zWbD77tzVuyg" title="Development costs"&gt;1,250,000&lt;/span&gt;. As of December
31, 2022, no liability has been recorded in relation to the Equivir License as development of the Equivir technology has not begun and
no reasonable amount can be estimated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <IMPB:RoyaltyPercentage
      contextRef="From2018-08-142018-08-15_custom_RoyaltyAgreementMember"
      decimals="INF"
      unitRef="Pure">0.50</IMPB:RoyaltyPercentage>
    <IMPB:RoyaltyPercentage
      contextRef="From2018-08-142018-08-15_custom_RoyaltyAgreementMember_custom_ChemiaCorporationMember"
      decimals="INF"
      unitRef="Pure">0.50</IMPB:RoyaltyPercentage>
    <IMPB:SaleOfRoyaltyPercentage
      contextRef="From2018-11-262018-11-27_custom_RoyaltyAgreementMember"
      decimals="INF"
      unitRef="Pure">0.05</IMPB:SaleOfRoyaltyPercentage>
    <IMPB:SaleOfRoyaltyPercentage
      contextRef="From2022-02-142022-02-15_custom_RoyaltyAgreementMember"
      decimals="INF"
      unitRef="Pure">0.20</IMPB:SaleOfRoyaltyPercentage>
    <IMPB:SaleOfRoyaltyPercentage
      contextRef="From2022-03-182022-03-19_custom_LicenseAgreementMember"
      decimals="INF"
      unitRef="Pure">0.055</IMPB:SaleOfRoyaltyPercentage>
    <IMPB:DevelopmentCostPercent
      contextRef="From2022-03-182022-03-19_custom_RoyaltyAgreementMember"
      decimals="INF"
      unitRef="Pure">0.50</IMPB:DevelopmentCostPercent>
    <us-gaap:CostsIncurredDevelopmentCosts
      contextRef="From2022-03-182022-03-19_custom_LicenseAgreementMember"
      decimals="0"
      unitRef="USD">1250000</us-gaap:CostsIncurredDevelopmentCosts>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2022-01-012022-12-31">&lt;p id="xdx_807_eus-gaap--IncomeTaxDisclosureTextBlock_ztBNUKWeW0M7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
14. &lt;span id="xdx_82C_zj0MygXbr8sj"&gt;Income Taxes&lt;/span&gt;&lt;/b&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the
financial reporting and tax basis of assets and liabilities. Deferred tax assets are reduced, if deemed necessary, by a valuation allowance
for the amount of tax benefits which are not expected to be realized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;IMPACT
Biomedical, Inc. and Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Consolidated Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zeVbteJrx8E7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
components of income tax benefit for the years ended December 31, 2022, and 2021 are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span id="xdx_8BA_zVgJq1uKpHb7" style="display: none"&gt;Schedule of Components of Income Tax Benefit&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt"&gt;Federal&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_49D_20220101__20221231_zPPdkxgx7tbl" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;-&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_494_20210101__20211231_zsPtO3r9p7Ce" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;-&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif"&gt;Income Tax Expense (Benefit)&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Year Ended &lt;br/&gt; December 31, 2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Year Ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December 31, 2021&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Current tax payable&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--CurrentFederalTaxExpenseBenefit_maCITEBzAu9_zu08Pc89efh1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt"&gt;Federal&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0747"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0748"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_maCITEBzAu9_zyQka61FNENh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; padding-bottom: 1.5pt"&gt;State&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0750"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0751"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--CurrentIncomeTaxExpenseBenefit_iT_mtCITEBzAu9_zwn135doikKf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Total current tax payable&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0753"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0754"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Deferred tax&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_iN_di_maDITEBzd7s_zJhzyGuwsa15" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; width: 60%"&gt;Federal&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;(1,619,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;(456,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_iN_di_maDITEBzd7s_ztNBdi4bQlP4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; padding-bottom: 1.5pt"&gt;State&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(165,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(1,068,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredIncomeTaxExpenseBenefit_iNT_di_mtDITEBzd7s_maNDTEAzrUM_maITEBzC69_z0pScFqoLUA7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Total deferred tax&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(1,784,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(1,524,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_msNDTEAzrUM_msITEBzC69_z9vMFTeuyQkb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Less increase in valuation allowance&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,163,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;129,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzC69_zFxkACmaqe9h" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt; income tax benefit&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(621,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(1,395,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_z2YFqL6L0e2g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zFmIGnYwjsfk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Individual
components of deferred tax assets and liabilities are approximately as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BB_zpsriDR3yffg" style="display: none"&gt;Schedule of Deferred Tax Assets and Liabilities&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20221231_zgFXxnXr25p4" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20211231_zfc5y7h5hsOf" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif"&gt;Deferred Tax Assets &amp;amp; Liabilities:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Deferred Tax assets:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxAssetsInvestments_iI_maDTAGzKh6_zP0JbeoXEuxh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 60%"&gt;Impairment of investment&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;929,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0774"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_maDTAGzKh6_zCfppEN0bG37" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Research &amp;amp; development cost&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;250,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0777"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzKh6_zdin9WgapdM3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Net Operating loss&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,611,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,258,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzKh6_z5xwgF3383b1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Gross deferred tax assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,790,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,258,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Deferred tax liability:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_msDITLzt6S_zqIynwAgaUsf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Intangible assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(4,414,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(4,667,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredIncomeTaxLiabilities_iNI_di_mtDITLzt6S_maDTLzghA_z2dRYnKjhO3l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Gross deferred tax liability&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(4,414,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(4,667,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsNet_iNI_di_msDTLzghA_zlUqxnG1rHM6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Less valuation allowance&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(1,611,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(447,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxLiabilities_iNTI_di_mtDTLzghA_zJEWI0M8rDVe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Net deferred tax liability&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(3,235,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(3,856,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zLJkEhV9f6T5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zFj0WbmBh0U1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BB_zgvUJyg0FcFk" style="display: none"&gt;Summary of Effective Income Tax Rate&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20220101__20221231_zEzSJYNTofdd" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20210101__20211231_ztWgj4YVqOM4" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_z7KMU8LZR5oe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;Statutory United States federal rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;21.0&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;21.0&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_zGPP7r08lLyl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;State income taxes net of federal benefit&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1.7&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;26.0&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_zqPyqCsGPMKb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(14.8&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(4.0&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_zF8qM7kf9aZd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Effective rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;7.9&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;43&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_z5NWFScgoez6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2022, and 2021, the Company has net operating loss carry forwards of approximately $&lt;span id="xdx_902_eus-gaap--OperatingLossCarryforwards_iI_c20221231_z6sRG8TZInN1" title="Operating loss carryforwards"&gt;7,109,000&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--OperatingLossCarryforwards_iI_c20211231_zDcnkvHmmQDb" title="Operating loss carryforwards"&gt;5,551,000&lt;/span&gt; respectively.
The Company does not have other temporary differences associated with the amortization of intangible assets. As of December 31, 2022,
and 2021, the total deferred tax assets carry-forward were $&lt;span id="xdx_904_eus-gaap--DeferredTaxAssetsGross_iI_c20221231_z7rdL5q1fGec" title="Deferred tax asset"&gt;2,790,000&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--DeferredTaxAssetsGross_iI_c20211231_z9OC4eKNilg8" title="Deferred tax asset"&gt;1,258,000&lt;/span&gt;, respectively. The deferred tax assets
could be carried forward indefinitely. The full utilization of the deferred tax assets in the future is dependent upon the Company&#x2019;s
ability to generate taxable income. Considering the development stage of the Company, management believed that it was probable that the
Company would not use tax assets in the near future. Accordingly, a valuation allowance of an equal amount has been established. During
the years ended December 31, 2022 and December 31, 2021, the valuation allowance increased by $&lt;span id="xdx_901_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20220101__20221231_zIe7xenSHJed" title="Valuation allowance deferred tax"&gt;1,163,000&lt;/span&gt; and decreased by $&lt;span id="xdx_900_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20210101__20211231_zBZGwwXzSCM9" title="Valuation allowance deferred tax"&gt;129,000&lt;/span&gt;,
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company recognizes interest accrued and penalties
related to unrecognized tax benefits in tax expense. During the years ended December 31, 2022 and 2021 the Company recognized no interest
and penalties.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="From2022-01-012022-12-31">&lt;p id="xdx_890_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zeVbteJrx8E7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
components of income tax benefit for the years ended December 31, 2022, and 2021 are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span id="xdx_8BA_zVgJq1uKpHb7" style="display: none"&gt;Schedule of Components of Income Tax Benefit&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt"&gt;Federal&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_49D_20220101__20221231_zPPdkxgx7tbl" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;-&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_494_20210101__20211231_zsPtO3r9p7Ce" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;-&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif"&gt;Income Tax Expense (Benefit)&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Year Ended &lt;br/&gt; December 31, 2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Year Ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December 31, 2021&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Current tax payable&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--CurrentFederalTaxExpenseBenefit_maCITEBzAu9_zu08Pc89efh1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt"&gt;Federal&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0747"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0748"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_maCITEBzAu9_zyQka61FNENh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; padding-bottom: 1.5pt"&gt;State&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0750"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0751"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--CurrentIncomeTaxExpenseBenefit_iT_mtCITEBzAu9_zwn135doikKf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Total current tax payable&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0753"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0754"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Deferred tax&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_iN_di_maDITEBzd7s_zJhzyGuwsa15" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; width: 60%"&gt;Federal&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;(1,619,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;(456,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_iN_di_maDITEBzd7s_ztNBdi4bQlP4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; padding-bottom: 1.5pt"&gt;State&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(165,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(1,068,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredIncomeTaxExpenseBenefit_iNT_di_mtDITEBzd7s_maNDTEAzrUM_maITEBzC69_z0pScFqoLUA7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Total deferred tax&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(1,784,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(1,524,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_msNDTEAzrUM_msITEBzC69_z9vMFTeuyQkb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Less increase in valuation allowance&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,163,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;129,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzC69_zFxkACmaqe9h" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt; income tax benefit&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(621,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(1,395,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      unitRef="USD">1619000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">456000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      unitRef="USD">165000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">1068000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      unitRef="USD">1784000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">1524000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      unitRef="USD">1163000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">129000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      unitRef="USD">-621000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">-1395000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2022-01-012022-12-31">&lt;p id="xdx_89C_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zFmIGnYwjsfk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Individual
components of deferred tax assets and liabilities are approximately as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BB_zpsriDR3yffg" style="display: none"&gt;Schedule of Deferred Tax Assets and Liabilities&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20221231_zgFXxnXr25p4" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20211231_zfc5y7h5hsOf" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif"&gt;Deferred Tax Assets &amp;amp; Liabilities:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Deferred Tax assets:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxAssetsInvestments_iI_maDTAGzKh6_zP0JbeoXEuxh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 60%"&gt;Impairment of investment&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;929,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0774"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_maDTAGzKh6_zCfppEN0bG37" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Research &amp;amp; development cost&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;250,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0777"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzKh6_zdin9WgapdM3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Net Operating loss&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,611,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,258,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzKh6_z5xwgF3383b1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Gross deferred tax assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,790,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,258,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Deferred tax liability:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_msDITLzt6S_zqIynwAgaUsf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Intangible assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(4,414,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(4,667,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredIncomeTaxLiabilities_iNI_di_mtDITLzt6S_maDTLzghA_z2dRYnKjhO3l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Gross deferred tax liability&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(4,414,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(4,667,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsNet_iNI_di_msDTLzghA_zlUqxnG1rHM6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Less valuation allowance&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(1,611,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(447,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxLiabilities_iNTI_di_mtDTLzghA_zJEWI0M8rDVe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Net deferred tax liability&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(3,235,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(3,856,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsInvestments contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">929000</us-gaap:DeferredTaxAssetsInvestments>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">250000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1611000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1258000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">2790000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1258000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">-4414000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">-4667000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">4414000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">4667000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1611000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">447000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilities contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">3235000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">3856000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2022-01-012022-12-31">&lt;p id="xdx_89A_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zFj0WbmBh0U1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BB_zgvUJyg0FcFk" style="display: none"&gt;Summary of Effective Income Tax Rate&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20220101__20221231_zEzSJYNTofdd" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20210101__20211231_ztWgj4YVqOM4" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_z7KMU8LZR5oe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;Statutory United States federal rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;21.0&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;21.0&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_zGPP7r08lLyl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;State income taxes net of federal benefit&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1.7&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;26.0&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_zqPyqCsGPMKb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(14.8&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(4.0&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_zF8qM7kf9aZd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Effective rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;7.9&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;43&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      unitRef="Pure">0.017</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">0.260</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      unitRef="Pure">-0.148</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">-0.040</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      unitRef="Pure">0.079</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">0.43</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">7109000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">5551000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">2790000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1258000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      unitRef="USD">1163000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">129000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:CashFlowSupplementalDisclosuresTextBlock contextRef="From2022-01-012022-12-31">&lt;p id="xdx_80B_eus-gaap--CashFlowSupplementalDisclosuresTextBlock_z5XkKFkzbXA8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
15. &lt;span id="xdx_827_zohXxhDiE5w4"&gt;Supplemental Cash Flow Information&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_zvs4mQmfs7Ad" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes supplemental cash flows for the year ended December 31, 2022, and 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B2_zKkR64o8ofP9" style="display: none"&gt;Schedule
of Cash Flow Supplemental&lt;/span&gt; &lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20221231_z0j9i297N2Ri" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20211231_ztiK3wFcXLIj" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--ConvertibleNotesPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z1dieTBoYwnj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 60%"&gt;Transfer of promissory note 2 to related party&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 16%"&gt;5,081,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 16%"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0828"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--NotesPayable_iNI_di_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zmqZdDNDQEne" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Transfer of note payable, related party&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(5,081,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0831"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zbu28JYcdSOd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashFlowSupplementalDisclosuresTextBlock>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock contextRef="From2022-01-012022-12-31">&lt;p id="xdx_89F_eus-gaap--ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_zvs4mQmfs7Ad" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes supplemental cash flows for the year ended December 31, 2022, and 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B2_zKkR64o8ofP9" style="display: none"&gt;Schedule
of Cash Flow Supplemental&lt;/span&gt; &lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20221231_z0j9i297N2Ri" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20211231_ztiK3wFcXLIj" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--ConvertibleNotesPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z1dieTBoYwnj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 60%"&gt;Transfer of promissory note 2 to related party&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 16%"&gt;5,081,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 16%"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0828"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--NotesPayable_iNI_di_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zmqZdDNDQEne" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Transfer of note payable, related party&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(5,081,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0831"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      unitRef="USD">5081000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:NotesPayable
      contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      unitRef="USD">5081000</us-gaap:NotesPayable>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2022-01-012022-12-31">&lt;p id="xdx_809_eus-gaap--SubsequentEventsTextBlock_z5izBHh7vPAb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
16. &lt;span id="xdx_82C_zSv7FR2YhL33"&gt;Subsequent Events&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has evaluated all subsequent events and transactions through June 2, 2023, the date that the consolidated financial statements
were available to be issued, and noted no subsequent events requiring financial statement recognition or disclosure.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">1000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">2000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:NotesAndLoansReceivableNetCurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">205000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:NotesAndLoansReceivableNetCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">16000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">183000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">104000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">389000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">122000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">279000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">276000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherLongTermInvestments contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">782000</us-gaap:OtherLongTermInvestments>
    <us-gaap:OtherLongTermInvestments contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">782000</us-gaap:OtherLongTermInvestments>
    <us-gaap:NotesAndLoansReceivableNetNoncurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">190000</us-gaap:NotesAndLoansReceivableNetNoncurrent>
    <us-gaap:Goodwill contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">25093000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">25093000</us-gaap:Goodwill>
    <us-gaap:OtherIntangibleAssetsNet contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">19756000</us-gaap:OtherIntangibleAssetsNet>
    <us-gaap:OtherIntangibleAssetsNet contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">20034000</us-gaap:OtherIntangibleAssetsNet>
    <us-gaap:Assets contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">46299000</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">46497000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">186000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">539000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">50000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">63000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2023-03-31_us-gaap_RelatedPartyMember"
      decimals="0"
      unitRef="USD">11008000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      unitRef="USD">9529000</us-gaap:NotesPayableCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">11244000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">10131000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">3235000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">3235000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:Liabilities contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">14479000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">13366000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-03-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2023-03-31" decimals="INF" unitRef="Shares">3000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">3000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2023-03-31" decimals="INF" unitRef="Shares">125073621</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">125073621</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2023-03-31" decimals="INF" unitRef="Shares">125073621</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">125073621</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">125000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">125000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">38058000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">38058000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">-9282000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">-8625000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">28901000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">29558000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">2919000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">3111000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">31820000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">32669000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">46299000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">46497000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">40000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">123000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">179000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">168000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ProfessionalFees
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">280000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">126000</us-gaap:ProfessionalFees>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">280000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">278000</us-gaap:DepreciationAndAmortization>
    <us-gaap:OtherGeneralExpense
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">40000</us-gaap:OtherGeneralExpense>
    <us-gaap:OtherGeneralExpense
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">14000</us-gaap:OtherGeneralExpense>
    <us-gaap:CostsAndExpenses
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">819000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">709000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">-819000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">-709000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">3000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">96000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">68000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InterestExpense
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">101000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">133000</us-gaap:InterestExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">-849000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">-746000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">-192000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">-77000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">-657000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">-669000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-01to2023-03-31"
      decimals="INF"
      unitRef="USDPShares">-0.00</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-012022-03-31"
      decimals="INF"
      unitRef="USDPShares">-0.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-01to2023-03-31"
      decimals="INF"
      unitRef="Shares">3877282251</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-01-012022-03-31"
      decimals="INF"
      unitRef="Shares">3877282251</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="From2023-01-01to2023-03-31"
      decimals="INF"
      unitRef="Shares">3877282251</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="From2022-01-012022-03-31"
      decimals="INF"
      unitRef="Shares">3877282251</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">3877282251</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">125000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">38058000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-8625000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      unitRef="USD">3111000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">32669000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-657000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2023-01-012023-03-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      unitRef="USD">-192000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">-849000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">3877282251</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">125000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">38058000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-9282000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-03-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      unitRef="USD">2919000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">31820000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">3877282251</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">125000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">38058000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-9282000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-03-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      unitRef="USD">2919000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">31820000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">3877282251</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">125000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">38058000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-1574000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      unitRef="USD">3315000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">39924000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">3877282251</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">125000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">38058000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-1574000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      unitRef="USD">3315000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">39924000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-669000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-012022-03-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      unitRef="USD">-77000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">-746000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">3877282251</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">125000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">38058000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-2243000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-03-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      unitRef="USD">3238000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">39178000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">3877282251</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">125000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">38058000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-2243000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-03-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      unitRef="USD">3238000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">39178000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">-849000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">-746000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">280000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">278000</us-gaap:DepreciationAndAmortization>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">79000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">37000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">-353000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">-60000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">-13000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">32000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">-1014000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">-533000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsForProceedsFromProductiveAssets
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">5000</us-gaap:PaymentsForProceedsFromProductiveAssets>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">12000</us-gaap:PaymentsToAcquireInvestments>
    <IMPB:PaymentsForProceedsFromNoteReceivableInvestments
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">-1000</IMPB:PaymentsForProceedsFromNoteReceivableInvestments>
    <IMPB:PaymentsForProceedsFromNoteReceivableInvestments
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">93000</IMPB:PaymentsForProceedsFromNoteReceivableInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">-4000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">-105000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">1017000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">625000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">1017000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">625000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">-1000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">-13000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">2000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">46000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">1000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">33000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:NatureOfOperations contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_800_eus-gaap--NatureOfOperations_zdoXDDu1KQS5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
1. &lt;span id="xdx_82D_zff7jzvZMrc5"&gt;Nature of Operations and Basis of Presentation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Nature
of Operations&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Impact
BioMedical, Inc. (the &#x201c;Company&#x201d;, &#x201c;Impact BioMedical&#x201d;, &#x201c;We&#x201d;) through the utilization of its intellectual
property rights, or through investment in, or through acquisition of companies in the biohealth and biomedical fields, focuses on the
advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune related diseases. The
Company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis
and influenza.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Global
BioLife, Inc. (&#x201c;Global BioLife&#x201d;), one of the Company&#x2019;s subsidiaries and the main operating company of the group, focuses
on research in four main areas: (i) the &#x201c;Linebacker&#x201d; project, which aims to develop a universal therapeutic drug platform;
(ii) a new sugar substitute called &#x201c;Laetose,&#x201d;; (iii) a multi-use fragrance called &#x201c;3F&#x201d; (Functional Fragrance
Formulation); and (iv) Equivir/Nemovir, a blend of natural polyphenols designed as an antimicrobial medication.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Linebacker&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Unlike
the traditional approach to treat individual diseases with specific drugs, the Linebacker platform seeks to offer a breakthrough therapeutic
option for multiple diseases. Linebacker is designed to work by inhibiting a cascade of inflammatory responses responsible for many diseases.
Its design is in direct contrast to the traditional approach of targeting individual diseases with specific drugs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Laetose&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
have also developed a low-calorie, low glycemic level, natural modified sugar through Global BioLife. The product, &#x201c;Laetose,&#x201d;
is designed to possess low glycemic properties and mitigate inflammation. The Company is presently seeking to license Laetose. Global
BioLife established a joint venture, Sweet Sense, Inc. (&#x201c;Sweet Sense&#x201d;), with Quality Ingredients, LLC for the development,
manufacture, and global distribution of the new sugar substitute. On November 8, 2019, the Company purchased &lt;span id="xdx_90F_eus-gaap--MinorityInterestOwnershipPercentageByNoncontrollingOwners_iI_pid_dp_uPure_c20191108__srt--OwnershipAxis__custom--SweetSenseMember_z6uVINfTNaf" title="Minority interest ownership percentage"&gt;50&lt;/span&gt;% of Sweet Sense Inc.
from Quality Ingredients, LLC for $&lt;span id="xdx_90F_eus-gaap--BusinessCombinationConsiderationTransferred1_c20191107__20191108__srt--OwnershipAxis__custom--SweetSenseMember_zMfNPrQHBMhg" title="Consideration given for purchase"&gt;91,000&lt;/span&gt;. Sweet Sense is now an &lt;span id="xdx_906_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20191108__srt--OwnershipAxis__custom--SweetSenseMember_zkdCM55H3RBk" title="Ownership percentage"&gt;81.8&lt;/span&gt;% owned subsidiary of Impact BioMedical.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Functional
Fragrance Formulation (&#x201c;3F&#x201d;)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Global
BioLife has established a collaboration with U.S.-based Chemia Corporation (&#x201c;Chemia&#x201d;) to develop specialized fragrances to
counter mosquito-borne diseases such as Zika and Dengue, among other medical applications. The 3F mosquito fragrance product is made
from specialized oils sourced from botanicals that mosquitos avoid. Global BioLife is seeking to commercialize this product. Together
with Chemia, we are attempting to license 3F. Any potential profits from the 3F project will be split between Global BioLife and Chemia
pursuant to the terms of the 20- year Royalty Agreement (Note 11).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Equivir&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equivir,
is a polyphenol compound that is believed to be successful in antiviral infection treatments. Equivir is a patented medication, that
has broad antiviral efficacy against multiple types of infectious disease.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company was incorporated in the State of Nevada as a for-profit company on October 16, 2018 and established a fiscal year end of December
31st. The Company issued &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20181016__20181016__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--GlobalBioMedicalPteLtdMember_zaE7L99m5X6h" title="Stock issued during period shares"&gt;9,000&lt;/span&gt; shares to its sole shareholder Global BioMedical Pte. Ltd., which was wholly owned by Alset International
Limited (formally Singapore eDevelopment Limited), a multinational public company, listed on the Singapore Exchange Securities Trading
Limited (&#x201c;SGXST&#x201d;). On March 31, 2020, the Company issued &lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200330__20200331__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--GlobalBioMedicalPteLtdMember_zpAK0gt5VdXi" title="Stock issued during period shares"&gt;125,064,621&lt;/span&gt; shares of common stock to its sole shareholder Global
BioMedical Pte. Ltd. On July 24, 2020, the Board approved the Stock Split, pursuant to which each share of the Company&#x2019;s common
stock issued and outstanding was split into nine shares of the Company&#x2019;s common stock. The numbers of authorized common stock and
issued and outstanding common stock in the reporting periods were retrospectively adjusted for the stock split.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of the date of this report, we have not generated significant revenues from operations. We cannot guarantee we will be successful in
our business operations. Our business is subject to risks inherent in the establishment of a new business enterprise, including possible
delays in our research, testing and marketing efforts or wider economic downturns.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Basis
of Presentation and Principles of Consolidation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the
United States of America (&#x201c;U.S. GAAP&#x201d;). The consolidated financial statements include all accounts of the Company and its
majority owned and controlled subsidiaries. The Company consolidates entities in which it owns more than &lt;span id="xdx_909_eus-gaap--MinorityInterestOwnershipPercentageByNoncontrollingOwners_iI_pid_dp_uPure_c20230331__srt--OwnershipAxis__custom--SweetSenseMember_zTatvyBe7BPd" title="Minority interest ownership percentage"&gt;50&lt;/span&gt;% of the voting common stock
and controls operations. All intercompany transactions and balances among consolidated subsidiaries have been eliminated. Non&#x2013;controlling
interest represents the minority equity investment in the Company&#x2019;s subsidiaries, plus the minority investors&#x2019; share of the
net operating results and other components of equity relating to the non&#x2013;controlling interest.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;IMPACT
Biomedical, Inc. and Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Consolidated Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_esrt--ScheduleOfCondensedFinancialStatementsTableTextBlock_zCwUXDY4Qu6e" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements include all accounts of the entities as of the reporting period ending dates and for the reporting
periods as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BF_z4z5BYYYPCG7" style="display: none"&gt;Schedule
of Condensed Financial Statements&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Name of consolidated subsidiary&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;State or other jurisdiction of incorporation or organization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Date of incorporation or formation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Attributable interest as of &lt;br/&gt;March 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Attributable &lt;br/&gt;interest as of &lt;br/&gt;December 31, &lt;br/&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Global BioMedical, Inc.&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%"&gt;&lt;span id="xdx_900_ecustom--StateOrOtherJurisdictionOfIncorporationOrOrganization_c20230101__20230331__srt--OwnershipAxis__custom--GlobalBioMedicalIncMember_zIHBDFNktZWf" title="State or other jurisdiction of incorporation or organization"&gt;Nevada&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%"&gt;&lt;span id="xdx_905_edei--EntityIncorporationDateOfIncorporation_dd_c20230101__20230331__srt--OwnershipAxis__custom--GlobalBioMedicalIncMember_zPVifDMn8HAd" title="Date of incorporation or formation"&gt;April 18, 2017&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20230331__srt--OwnershipAxis__custom--GlobalBioMedicalIncMember_zICnblZve9hf" title="Attributable interest percentage"&gt;90.9&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--GlobalBioMedicalIncMember_zoV5HtpvowU1" title="Attributable interest percentage"&gt;90.9&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Global BioLife, Inc.&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span id="xdx_901_ecustom--StateOrOtherJurisdictionOfIncorporationOrOrganization_c20230101__20230331__srt--OwnershipAxis__custom--GlobalBioLifeIncMember_z3aGwZ7PsBR4" title="State or other jurisdiction of incorporation or organization"&gt;Nevada&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span id="xdx_906_edei--EntityIncorporationDateOfIncorporation_dd_c20230101__20230331__srt--OwnershipAxis__custom--GlobalBioLifeIncMember_zaO5qwKuCCRe" title="Date of incorporation or formation"&gt;April 14, 2017&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20230331__srt--OwnershipAxis__custom--GlobalBioLifeIncMember_zRS65KdYQx7c" title="Attributable interest percentage"&gt;81.8&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--GlobalBioLifeIncMember_zO0xobSyy5K2" title="Attributable interest percentage"&gt;81.8&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;BioLife Sugar, Inc&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span id="xdx_90B_ecustom--StateOrOtherJurisdictionOfIncorporationOrOrganization_c20230101__20230331__srt--OwnershipAxis__custom--BioLifeSugarIncMember_z1DG4rXM1ksi" title="State or other jurisdiction of incorporation or organization"&gt;Nevada&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span id="xdx_905_edei--EntityIncorporationDateOfIncorporation_dd_c20230101__20230331__srt--OwnershipAxis__custom--BioLifeSugarIncMember_z1qWDh45VM08" title="Date of incorporation or formation"&gt;April 23, 2018&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20230331__srt--OwnershipAxis__custom--BioLifeSugarIncMember_z16iaO8UNdwb" title="Attributable interest percentage"&gt;90.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--BioLifeSugarIncMember_ztP2KJ3wcpWg" title="Attributable interest percentage"&gt;90.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Happy Sugar Inc&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span id="xdx_90E_ecustom--StateOrOtherJurisdictionOfIncorporationOrOrganization_c20230101__20230331__srt--OwnershipAxis__custom--HappySugarIncMember_zrdRrUOgSo69" title="State or other jurisdiction of incorporation or organization"&gt;Nevada&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span id="xdx_90C_edei--EntityIncorporationDateOfIncorporation_dd_c20230101__20230331__srt--OwnershipAxis__custom--HappySugarIncMember_z5SFO8dbSLSa" title="Date of incorporation or formation"&gt;August 17, 2018&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20230331__srt--OwnershipAxis__custom--HappySugarIncMember_zvQRNrD7qZu4" title="Attributable interest percentage"&gt;81.8&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--HappySugarIncMember_zMpA41Q67aPl" title="Attributable interest percentage"&gt;81.8&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Sweet Sense Inc.&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span id="xdx_90A_ecustom--StateOrOtherJurisdictionOfIncorporationOrOrganization_c20230101__20230331__srt--OwnershipAxis__custom--SweetSenseIncMember_z0AuJTir93ta" title="State or other jurisdiction of incorporation or organization"&gt;Nevada&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span id="xdx_906_edei--EntityIncorporationDateOfIncorporation_dd_c20230101__20230331__srt--OwnershipAxis__custom--SweetSenseIncMember_zVGoQe5wh5F" title="Date of incorporation or formation"&gt;April 30, 2018&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20230331__srt--OwnershipAxis__custom--SweetSenseIncMember_zzHfN0CZ8nF9" title="Attributable interest percentage"&gt;95.5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--SweetSenseIncMember_zKKdzQEyIaZd" title="Attributable interest percentage"&gt;95.5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Global Sugar Solutions Inc.&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span id="xdx_909_ecustom--StateOrOtherJurisdictionOfIncorporationOrOrganization_c20230101__20230331__srt--OwnershipAxis__custom--GlobalSugarSolutionsIncMember_zwczc9QUp25k" title="State or other jurisdiction of incorporation or organization"&gt;Nevada&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span id="xdx_901_edei--EntityIncorporationDateOfIncorporation_dd_c20230101__20230331__srt--OwnershipAxis__custom--GlobalSugarSolutionsIncMember_zAroUALjZgTi" title="Date of incorporation or formation"&gt;November 7, 2019&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20230331__srt--OwnershipAxis__custom--GlobalSugarSolutionsIncMember_zBtF5Fvi0OL" title="Attributable interest percentage"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--GlobalSugarSolutionsIncMember_zfdpbWiabovk" title="Attributable interest percentage"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_znvcOjfTbCY6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of March 31, 2023, and December 31, 2022, the aggregate noncontrolling interest was equity of $&lt;span id="xdx_906_eus-gaap--MinorityInterest_iI_c20230331__srt--ConsolidatedEntitiesAxis__srt--SubsidiariesMember_zeIentK9UWxd" title="Noncontrolling interest"&gt;2,919,000&lt;/span&gt;
and $&lt;span id="xdx_906_eus-gaap--MinorityInterest_iI_c20221231__srt--ConsolidatedEntitiesAxis__srt--SubsidiariesMember_z2ty5bX55Whb" title="Noncontrolling interest"&gt;3,111,000&lt;/span&gt;,
respectively, which are separately disclosed on the Consolidated Balance Sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NatureOfOperations>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="AsOf2019-11-08_custom_SweetSenseMember"
      decimals="INF"
      unitRef="Pure">0.50</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="From2019-11-072019-11-08_custom_SweetSenseMember"
      decimals="0"
      unitRef="USD">91000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="AsOf2019-11-08_custom_SweetSenseMember"
      decimals="INF"
      unitRef="Pure">0.818</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2018-10-162018-10-16_custom_GlobalBioMedicalPteLtdMember"
      decimals="INF"
      unitRef="Shares">9000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2020-03-302020-03-31_custom_GlobalBioMedicalPteLtdMember"
      decimals="INF"
      unitRef="Shares">125064621</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="AsOf2023-03-31_custom_SweetSenseMember"
      decimals="INF"
      unitRef="Pure">0.50</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <srt:ScheduleOfCondensedFinancialStatementsTableTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_898_esrt--ScheduleOfCondensedFinancialStatementsTableTextBlock_zCwUXDY4Qu6e" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements include all accounts of the entities as of the reporting period ending dates and for the reporting
periods as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BF_z4z5BYYYPCG7" style="display: none"&gt;Schedule
of Condensed Financial Statements&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Name of consolidated subsidiary&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;State or other jurisdiction of incorporation or organization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Date of incorporation or formation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Attributable interest as of &lt;br/&gt;March 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Attributable &lt;br/&gt;interest as of &lt;br/&gt;December 31, &lt;br/&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Global BioMedical, Inc.&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%"&gt;&lt;span id="xdx_900_ecustom--StateOrOtherJurisdictionOfIncorporationOrOrganization_c20230101__20230331__srt--OwnershipAxis__custom--GlobalBioMedicalIncMember_zIHBDFNktZWf" title="State or other jurisdiction of incorporation or organization"&gt;Nevada&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%"&gt;&lt;span id="xdx_905_edei--EntityIncorporationDateOfIncorporation_dd_c20230101__20230331__srt--OwnershipAxis__custom--GlobalBioMedicalIncMember_zPVifDMn8HAd" title="Date of incorporation or formation"&gt;April 18, 2017&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20230331__srt--OwnershipAxis__custom--GlobalBioMedicalIncMember_zICnblZve9hf" title="Attributable interest percentage"&gt;90.9&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--GlobalBioMedicalIncMember_zoV5HtpvowU1" title="Attributable interest percentage"&gt;90.9&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Global BioLife, Inc.&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span id="xdx_901_ecustom--StateOrOtherJurisdictionOfIncorporationOrOrganization_c20230101__20230331__srt--OwnershipAxis__custom--GlobalBioLifeIncMember_z3aGwZ7PsBR4" title="State or other jurisdiction of incorporation or organization"&gt;Nevada&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span id="xdx_906_edei--EntityIncorporationDateOfIncorporation_dd_c20230101__20230331__srt--OwnershipAxis__custom--GlobalBioLifeIncMember_zaO5qwKuCCRe" title="Date of incorporation or formation"&gt;April 14, 2017&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20230331__srt--OwnershipAxis__custom--GlobalBioLifeIncMember_zRS65KdYQx7c" title="Attributable interest percentage"&gt;81.8&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--GlobalBioLifeIncMember_zO0xobSyy5K2" title="Attributable interest percentage"&gt;81.8&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;BioLife Sugar, Inc&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span id="xdx_90B_ecustom--StateOrOtherJurisdictionOfIncorporationOrOrganization_c20230101__20230331__srt--OwnershipAxis__custom--BioLifeSugarIncMember_z1DG4rXM1ksi" title="State or other jurisdiction of incorporation or organization"&gt;Nevada&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span id="xdx_905_edei--EntityIncorporationDateOfIncorporation_dd_c20230101__20230331__srt--OwnershipAxis__custom--BioLifeSugarIncMember_z1qWDh45VM08" title="Date of incorporation or formation"&gt;April 23, 2018&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20230331__srt--OwnershipAxis__custom--BioLifeSugarIncMember_z16iaO8UNdwb" title="Attributable interest percentage"&gt;90.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--BioLifeSugarIncMember_ztP2KJ3wcpWg" title="Attributable interest percentage"&gt;90.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Happy Sugar Inc&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span id="xdx_90E_ecustom--StateOrOtherJurisdictionOfIncorporationOrOrganization_c20230101__20230331__srt--OwnershipAxis__custom--HappySugarIncMember_zrdRrUOgSo69" title="State or other jurisdiction of incorporation or organization"&gt;Nevada&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span id="xdx_90C_edei--EntityIncorporationDateOfIncorporation_dd_c20230101__20230331__srt--OwnershipAxis__custom--HappySugarIncMember_z5SFO8dbSLSa" title="Date of incorporation or formation"&gt;August 17, 2018&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20230331__srt--OwnershipAxis__custom--HappySugarIncMember_zvQRNrD7qZu4" title="Attributable interest percentage"&gt;81.8&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--HappySugarIncMember_zMpA41Q67aPl" title="Attributable interest percentage"&gt;81.8&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Sweet Sense Inc.&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span id="xdx_90A_ecustom--StateOrOtherJurisdictionOfIncorporationOrOrganization_c20230101__20230331__srt--OwnershipAxis__custom--SweetSenseIncMember_z0AuJTir93ta" title="State or other jurisdiction of incorporation or organization"&gt;Nevada&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span id="xdx_906_edei--EntityIncorporationDateOfIncorporation_dd_c20230101__20230331__srt--OwnershipAxis__custom--SweetSenseIncMember_zVGoQe5wh5F" title="Date of incorporation or formation"&gt;April 30, 2018&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20230331__srt--OwnershipAxis__custom--SweetSenseIncMember_zzHfN0CZ8nF9" title="Attributable interest percentage"&gt;95.5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--SweetSenseIncMember_zKKdzQEyIaZd" title="Attributable interest percentage"&gt;95.5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Global Sugar Solutions Inc.&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span id="xdx_909_ecustom--StateOrOtherJurisdictionOfIncorporationOrOrganization_c20230101__20230331__srt--OwnershipAxis__custom--GlobalSugarSolutionsIncMember_zwczc9QUp25k" title="State or other jurisdiction of incorporation or organization"&gt;Nevada&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span id="xdx_901_edei--EntityIncorporationDateOfIncorporation_dd_c20230101__20230331__srt--OwnershipAxis__custom--GlobalSugarSolutionsIncMember_zAroUALjZgTi" title="Date of incorporation or formation"&gt;November 7, 2019&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20230331__srt--OwnershipAxis__custom--GlobalSugarSolutionsIncMember_zBtF5Fvi0OL" title="Attributable interest percentage"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20221231__srt--OwnershipAxis__custom--GlobalSugarSolutionsIncMember_zfdpbWiabovk" title="Attributable interest percentage"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</srt:ScheduleOfCondensedFinancialStatementsTableTextBlock>
    <IMPB:StateOrOtherJurisdictionOfIncorporationOrOrganization contextRef="From2023-01-012023-03-31_custom_GlobalBioMedicalIncMember">Nevada</IMPB:StateOrOtherJurisdictionOfIncorporationOrOrganization>
    <dei:EntityIncorporationDateOfIncorporation contextRef="From2023-01-012023-03-31_custom_GlobalBioMedicalIncMember">2017-04-18</dei:EntityIncorporationDateOfIncorporation>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="AsOf2023-03-31_custom_GlobalBioMedicalIncMember"
      decimals="INF"
      unitRef="Pure">0.909</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="AsOf2022-12-31_custom_GlobalBioMedicalIncMember"
      decimals="INF"
      unitRef="Pure">0.909</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <IMPB:StateOrOtherJurisdictionOfIncorporationOrOrganization contextRef="From2023-01-012023-03-31_custom_GlobalBioLifeIncMember">Nevada</IMPB:StateOrOtherJurisdictionOfIncorporationOrOrganization>
    <dei:EntityIncorporationDateOfIncorporation contextRef="From2023-01-012023-03-31_custom_GlobalBioLifeIncMember">2017-04-14</dei:EntityIncorporationDateOfIncorporation>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="AsOf2023-03-31_custom_GlobalBioLifeIncMember"
      decimals="INF"
      unitRef="Pure">0.818</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="AsOf2022-12-31_custom_GlobalBioLifeIncMember"
      decimals="INF"
      unitRef="Pure">0.818</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <IMPB:StateOrOtherJurisdictionOfIncorporationOrOrganization contextRef="From2023-01-012023-03-31_custom_BioLifeSugarIncMember">Nevada</IMPB:StateOrOtherJurisdictionOfIncorporationOrOrganization>
    <dei:EntityIncorporationDateOfIncorporation contextRef="From2023-01-012023-03-31_custom_BioLifeSugarIncMember">2018-04-23</dei:EntityIncorporationDateOfIncorporation>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="AsOf2023-03-31_custom_BioLifeSugarIncMember"
      decimals="INF"
      unitRef="Pure">0.909</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="AsOf2022-12-31_custom_BioLifeSugarIncMember"
      decimals="INF"
      unitRef="Pure">0.909</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <IMPB:StateOrOtherJurisdictionOfIncorporationOrOrganization contextRef="From2023-01-012023-03-31_custom_HappySugarIncMember">Nevada</IMPB:StateOrOtherJurisdictionOfIncorporationOrOrganization>
    <dei:EntityIncorporationDateOfIncorporation contextRef="From2023-01-012023-03-31_custom_HappySugarIncMember">2018-08-17</dei:EntityIncorporationDateOfIncorporation>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="AsOf2023-03-31_custom_HappySugarIncMember"
      decimals="INF"
      unitRef="Pure">0.818</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="AsOf2022-12-31_custom_HappySugarIncMember"
      decimals="INF"
      unitRef="Pure">0.818</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <IMPB:StateOrOtherJurisdictionOfIncorporationOrOrganization contextRef="From2023-01-012023-03-31_custom_SweetSenseIncMember">Nevada</IMPB:StateOrOtherJurisdictionOfIncorporationOrOrganization>
    <dei:EntityIncorporationDateOfIncorporation contextRef="From2023-01-012023-03-31_custom_SweetSenseIncMember">2018-04-30</dei:EntityIncorporationDateOfIncorporation>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="AsOf2023-03-31_custom_SweetSenseIncMember"
      decimals="INF"
      unitRef="Pure">0.955</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="AsOf2022-12-31_custom_SweetSenseIncMember"
      decimals="INF"
      unitRef="Pure">0.955</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <IMPB:StateOrOtherJurisdictionOfIncorporationOrOrganization contextRef="From2023-01-012023-03-31_custom_GlobalSugarSolutionsIncMember">Nevada</IMPB:StateOrOtherJurisdictionOfIncorporationOrOrganization>
    <dei:EntityIncorporationDateOfIncorporation contextRef="From2023-01-012023-03-31_custom_GlobalSugarSolutionsIncMember">2019-11-07</dei:EntityIncorporationDateOfIncorporation>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="AsOf2023-03-31_custom_GlobalSugarSolutionsIncMember"
      decimals="INF"
      unitRef="Pure">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="AsOf2022-12-31_custom_GlobalSugarSolutionsIncMember"
      decimals="INF"
      unitRef="Pure">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterest
      contextRef="AsOf2023-03-31_srt_SubsidiariesMember"
      decimals="0"
      unitRef="USD">2919000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="AsOf2022-12-31_srt_SubsidiariesMember"
      decimals="0"
      unitRef="USD">3111000</us-gaap:MinorityInterest>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_800_eus-gaap--SignificantAccountingPoliciesTextBlock_z7YJQDa0zWt2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
2.&lt;span id="xdx_82C_zjLhBS0H2V93"&gt; Summary of Significant Accounting and Reporting Policies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--UseOfEstimates_zdQf9jYkURy7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_867_zt6VwiVmfLrk"&gt;Use
of estimates&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the dates of the balance
sheets and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from these estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--EarningsPerSharePolicyTextBlock_zyxlcJyJMqci" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86F_zkJB4Ss69lIi"&gt;Earnings
(Loss) per Share&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
earnings (loss) per share is computed by dividing the net income (loss) attributable to the common stockholders by weighted average number
of shares of common stock outstanding during the period. Fully diluted earnings (loss) per share is computed like basic income (loss)
per share except that the denominator is increased to include the number of additional common shares that would have been outstanding
if the potential common shares had been issued and if the additional common shares were dilutive. There were no dilutive financial instruments
issued or outstanding for the three months ended March 31, 2023 or 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zgcgbooGbEg6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_867_z9Je588BzIm4"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants at the measurement date. The Fair Value Measurement Topic of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;)
Accounting Standards Codification (&#x201c;ASC&#x201d;) establishes a three-tier fair value hierarchy which prioritizes the inputs used
in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets
or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;
Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;
Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted
prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active;
and&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;
Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions,
such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amounts reported in the balance sheet of cash and cash equivalents, prepaids, accounts payable and accrued expenses approximate
fair value because of the immediate or short-term maturity of these financial instruments. The fair value of notes receivable approximates
their carrying value as the stated or discounted rates of the notes do reflect recent market conditions. The Company&#x2019;s investments
are record at cost as the fair value of these investment in are not readily available. The fair value of notes payable approximates its
carrying value as the stated interest rate reflects recent market conditions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;IMPACT
Biomedical, Inc. and Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Consolidated Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zeTGsT6NkwGk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86F_zrkvNCrj2yh4"&gt;Cash
and cash equivalents&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers all highly liquid investments with a maturity of three months or less at the date of acquisition to be cash
equivalents. There were &lt;span id="xdx_907_eus-gaap--Cash_iI_do_c20230331_zIikbZYCaAYd" title="Cash"&gt;&lt;span id="xdx_90C_eus-gaap--Cash_iI_do_c20221231_zknDqfNKSt4g" title="Cash"&gt;no&lt;/span&gt;&lt;/span&gt;
cash equivalents as of March 31, 2023 and December 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--InvestmentPolicyTextBlock_zQ6ZqyOzbsx3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_866_zu17eaWGCxj2"&gt;Investments&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Investments
in equity securities with a readily determinable fair value, not accounted for under the equity method, are recorded at fair value with
unrealized gains and losses included in earnings. For equity securities without a readily determinable fair value, the investment is
recorded at cost, less any impairment, plus or minus adjustments related to observable transactions for the same or similar securities,
with unrealized gains and losses included in earnings.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
equity method investments, the Company regularly reviews its investments to determine whether there is a decline in fair value below
book value. If there is a decline that is other-than-temporary, the investment is written down to fair value. See Note 6 for further
discussion on investments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--GoodwillAndIntangibleAssetsGoodwillPolicy_z9IxlP36xKl1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86B_zo4sSSkpKQEi"&gt;Goodwill&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Goodwill
is the excess of cost of an acquired entity over the fair value of amounts assigned to assets acquired and liabilities assumed in a business
combination. Goodwill is subject to impairment testing at least annually and will be tested for impairment between annual tests, which
takes place during the fourth quarter, if an event occurs or circumstances change that would indicate the carrying amount may be impaired.
FASB ASC Topic 350 provides an entity with the option to first assess qualitative factors to determine whether the existence of events
or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying
amount. Some of the qualitative factors considered in applying this test include consideration of macroeconomic conditions, industry
and market conditions, cost factors affecting the business, and overall financial performance of the business. If, after completing the
assessment, it is determined that it is more likely than not that the fair value of a reporting unit is less than its carrying value,
the Company will proceed to a quantitative test. If qualitative factors are not deemed sufficient to conclude that the fair value of
the reporting unit more likely than not exceeds its carrying value, then a one-step approach is applied in making an evaluation. The
evaluation utilizes an income approach (discounted cash flow analysis). The computations require management to make significant estimates
and assumptions, including, among other things, selection of comparable publicly traded companies, the discount rate applied to future
earnings reflecting a weighted average cost of capital, and earnings growth assumptions. The Company believes the estimates and assumptions
used in our impairment assessments are reasonable and based on available market information, but variations in any of the assumptions
could result in materially different calculations of fair value and determinations of whether or not an impairment is indicated. A discounted
cash flow analysis requires management to make various assumptions about future sales, operating margins, capital expenditures, working
capital, and growth rates. Cash flow projections are derived from one year budgeted amounts plus an estimate of later period cash flows,
all of which are determined by management. Subsequent period cash flows are developed for each reporting unit using growth rates that
management believes are reasonably likely to occur. Impairment of goodwill is measured as the excess of the carrying amount of goodwill
over the fair values of recognized and unrecognized assets and liabilities of the reporting unit. &lt;span id="xdx_904_eus-gaap--GoodwillImpairmentLoss_dxL_c20230101__20230331_z4XiXqSxlbza" title="Impairment of goodwill::XDX::-"&gt;&lt;span id="xdx_901_eus-gaap--GoodwillImpairmentLoss_dxL_c20220101__20220331_zcT7vmeuBw04" title="Impairment of goodwill::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1230"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1232"&gt;No&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; impairment was recognized during
the three months ended March 31, 2023 or year ended December 31, 2022 (see Note 7).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--IntangibleAssetsFiniteLivedPolicy_z1a3nqz7Lulf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_865_zU8Fi7Jev1Yb"&gt;Intangible
Assets&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
estimated fair values of acquired intangibles are generally determined based upon future economic benefits such as earnings and cash
flows. Acquired identifiable intangible assets are recorded at fair value and are amortized over their estimated useful lives.
Acquired intangible assets with an indefinite life are not amortized but are reviewed for impairment at least annually as of
December 31&lt;sup&gt;st&lt;/sup&gt;, or more frequently whenever events or changes in circumstances indicate that the carrying amounts of those
assets are below their estimated fair values. Impairment is tested under ASC 350. &lt;span id="xdx_901_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_do_c20230101__20230331_zywcseRVtwQl" title="Impairment of intangible assets"&gt;&lt;span id="xdx_900_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_do_c20220101__20221231_zdUpfxX3Zrwc" title="Impairment of intangible assets"&gt;No&lt;/span&gt;&lt;/span&gt;
impairment was recognized as of March 31,  2023 or year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zDbHGeIMInR8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; background-color: white"&gt;&lt;i&gt;&lt;span id="xdx_860_zkK2hzCpGQ93"&gt;Recoverability
of Long-Lived Assets&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; background-color: white"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; background-color: white"&gt;We evaluate
long-lived assets such as property, equipment and definite lived intangible assets, such as patents, for impairment whenever events or
circumstances indicate that the carrying value of the assets recognized in our financial statements may not be recoverable. Factors that
we consider include whether there has been a significant decrease in the market value of an asset, a significant change in the way an
asset is being utilized, or a significant change, delay or departure in our strategy for that asset, or a significant change in the macroeconomic
environment, such as the impact of the COVID-19 pandemic. Our assessment of the recoverability of long-lived assets involves significant
judgment and estimation. These assessments reflect our assumptions, which, we believe, are consistent with the assumptions hypothetical
marketplace participants use. Factors that we must estimate when performing recoverability and impairment tests include, among others,
forecasted revenue, margin costs and the economic life of the asset. If impairment is indicated, we determine if the total estimated
future cash flows on an undiscounted basis are less than the carrying amounts of the asset or assets. If so, an impairment loss is measured
and recognized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 27.15pt; background-color: white"&gt;Our
impairment loss calculations require that we apply judgment in identifying asset groups, estimating future cash flows, determining asset
fair values, and estimating asset&#x2019;s useful lives. The Company reviews identifiable amortizable intangible assets for impairment
whenever events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. Determination of recoverability
is based on the lowest level of identifiable estimated undiscounted cash flows resulting from use of the asset and its eventual disposition.
Measurement of any impairment loss is based on the excess of the carrying value of the asset over its fair value. Based on the uncertainty
of forecasts inherent with a new product, events such as the failure to generate forecasted revenue from new products could result in
a non-cash impairment in future periods. &lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--ResearchAndDevelopmentExpensePolicy_zGjVfszuc6gk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_861_zxMhjB9oXyT5"&gt;Research
and Development&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs are expensed as incurred. Total research and development costs were $&lt;span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230331_zCs1D9tKs0sj" title="Research and development cost"&gt;179,000&lt;/span&gt; for the three months ended March 31,
2023, and $&lt;span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20220331_zGlbHIaIRhXj" title="Research and development cost"&gt;168,000&lt;/span&gt; for three months ended March 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;IMPACT
Biomedical, Inc. and Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Consolidated Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zxAblYvjT77c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_860_zeeCcaIvXdw5"&gt;Recent
Accounting Standards&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Financial Accounting Standards Board (FASB) issues various Accounting Standards Updates relating to the treatment and recording of certain
accounting transactions. There are several new accounting pronouncements issued by FASB which are not yet effective. Each of these pronouncements,
as applicable, has been or will be adopted by the Company. As of March 31, 2023, none of these pronouncements is expected to have a material
effect on the financial position, results of operations or cash flows of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;On January
1, 2022, the Company adopted amended accounting guidance &#x201c;&lt;i&gt;ASU No.2016-13 &#x2013; Credit Losses&#x201d;&lt;/i&gt; which requires an
allowance for credit losses to be deducted from the amortized cost basis of financial assets to present the net carrying value at the
amount that is expected to be collected over the contractual term of the asset considering relevant information about past events, current
conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. In estimating expected losses
in the loan and lease portfolio, borrower-specific financial data and macro-economic assumptions are utilized to project losses over
a reasonable and supportable forecast period. Assumptions and judgment are applied to measure amounts and timing of expected future cash
flows, collateral values and other factors used to determine the borrowers&#x2019; abilities to repay obligations. After the forecast
period, the Company utilizes longer-term historical loss experience to estimate losses over the remaining contractual life of the loans.
Prior to 2022, the allowance for credit losses represented the amount that in management&#x2019;s judgment reflected incurred credit losses
inherent in the loan and lease portfolio as of the balance sheet date. As of March 31, 2023 the Company has deemed that no reserve or
credit losses were necessary.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_ecustom--ContinuingOperationsAndGoingConcernPolicyTextBlock_zcNMEQrOWwg3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_866_zTEGg80OPLSg"&gt;Continuing
Operations and Going Concern&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Due
to incurred operating losses as well as negative cash flows from operating and investing activities over the past two years, the accompanying
consolidated financial statements have been prepared assuming that the Company will continue as a going concern. This basis of accounting
contemplates the recovery of our assets and the satisfaction of liabilities in the normal course of business. These consolidated financial
statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary
should we be unable to continue as a going concern.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;To
continue as a going concern, the Company has entered into an updated revolving promissory note which extended the maturity through March
31, 2024, and DSS intends to continue to fund the operations of the Company through a year from the date these financial statements were
available to be issued. The Company&#x2019;s management intends to take actions necessary to continue as a going concern. Management&#x2019;s
plans concerning these matters include, among other things, monetization of its intellectual properties, and tightly controlling operating
costs. Based on this, the Company has concluded that substantial doubt of its ability to continue as a going concern has been alleviated.&lt;/span&gt;&lt;/p&gt;
&lt;p id="xdx_859_zzXvj7vNEiFa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_847_eus-gaap--UseOfEstimates_zdQf9jYkURy7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_867_zt6VwiVmfLrk"&gt;Use
of estimates&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the dates of the balance
sheets and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from these estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_842_eus-gaap--EarningsPerSharePolicyTextBlock_zyxlcJyJMqci" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86F_zkJB4Ss69lIi"&gt;Earnings
(Loss) per Share&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
earnings (loss) per share is computed by dividing the net income (loss) attributable to the common stockholders by weighted average number
of shares of common stock outstanding during the period. Fully diluted earnings (loss) per share is computed like basic income (loss)
per share except that the denominator is increased to include the number of additional common shares that would have been outstanding
if the potential common shares had been issued and if the additional common shares were dilutive. There were no dilutive financial instruments
issued or outstanding for the three months ended March 31, 2023 or 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_849_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zgcgbooGbEg6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_867_z9Je588BzIm4"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants at the measurement date. The Fair Value Measurement Topic of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;)
Accounting Standards Codification (&#x201c;ASC&#x201d;) establishes a three-tier fair value hierarchy which prioritizes the inputs used
in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets
or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;
Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;
Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted
prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active;
and&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;
Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions,
such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amounts reported in the balance sheet of cash and cash equivalents, prepaids, accounts payable and accrued expenses approximate
fair value because of the immediate or short-term maturity of these financial instruments. The fair value of notes receivable approximates
their carrying value as the stated or discounted rates of the notes do reflect recent market conditions. The Company&#x2019;s investments
are record at cost as the fair value of these investment in are not readily available. The fair value of notes payable approximates its
carrying value as the stated interest rate reflects recent market conditions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;IMPACT
Biomedical, Inc. and Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Consolidated Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_847_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zeTGsT6NkwGk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86F_zrkvNCrj2yh4"&gt;Cash
and cash equivalents&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers all highly liquid investments with a maturity of three months or less at the date of acquisition to be cash
equivalents. There were &lt;span id="xdx_907_eus-gaap--Cash_iI_do_c20230331_zIikbZYCaAYd" title="Cash"&gt;&lt;span id="xdx_90C_eus-gaap--Cash_iI_do_c20221231_zknDqfNKSt4g" title="Cash"&gt;no&lt;/span&gt;&lt;/span&gt;
cash equivalents as of March 31, 2023 and December 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:Cash contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">0</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">0</us-gaap:Cash>
    <us-gaap:InvestmentPolicyTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_84F_eus-gaap--InvestmentPolicyTextBlock_zQ6ZqyOzbsx3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_866_zu17eaWGCxj2"&gt;Investments&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Investments
in equity securities with a readily determinable fair value, not accounted for under the equity method, are recorded at fair value with
unrealized gains and losses included in earnings. For equity securities without a readily determinable fair value, the investment is
recorded at cost, less any impairment, plus or minus adjustments related to observable transactions for the same or similar securities,
with unrealized gains and losses included in earnings.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
equity method investments, the Company regularly reviews its investments to determine whether there is a decline in fair value below
book value. If there is a decline that is other-than-temporary, the investment is written down to fair value. See Note 6 for further
discussion on investments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_84F_eus-gaap--GoodwillAndIntangibleAssetsGoodwillPolicy_z9IxlP36xKl1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86B_zo4sSSkpKQEi"&gt;Goodwill&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Goodwill
is the excess of cost of an acquired entity over the fair value of amounts assigned to assets acquired and liabilities assumed in a business
combination. Goodwill is subject to impairment testing at least annually and will be tested for impairment between annual tests, which
takes place during the fourth quarter, if an event occurs or circumstances change that would indicate the carrying amount may be impaired.
FASB ASC Topic 350 provides an entity with the option to first assess qualitative factors to determine whether the existence of events
or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying
amount. Some of the qualitative factors considered in applying this test include consideration of macroeconomic conditions, industry
and market conditions, cost factors affecting the business, and overall financial performance of the business. If, after completing the
assessment, it is determined that it is more likely than not that the fair value of a reporting unit is less than its carrying value,
the Company will proceed to a quantitative test. If qualitative factors are not deemed sufficient to conclude that the fair value of
the reporting unit more likely than not exceeds its carrying value, then a one-step approach is applied in making an evaluation. The
evaluation utilizes an income approach (discounted cash flow analysis). The computations require management to make significant estimates
and assumptions, including, among other things, selection of comparable publicly traded companies, the discount rate applied to future
earnings reflecting a weighted average cost of capital, and earnings growth assumptions. The Company believes the estimates and assumptions
used in our impairment assessments are reasonable and based on available market information, but variations in any of the assumptions
could result in materially different calculations of fair value and determinations of whether or not an impairment is indicated. A discounted
cash flow analysis requires management to make various assumptions about future sales, operating margins, capital expenditures, working
capital, and growth rates. Cash flow projections are derived from one year budgeted amounts plus an estimate of later period cash flows,
all of which are determined by management. Subsequent period cash flows are developed for each reporting unit using growth rates that
management believes are reasonably likely to occur. Impairment of goodwill is measured as the excess of the carrying amount of goodwill
over the fair values of recognized and unrecognized assets and liabilities of the reporting unit. &lt;span id="xdx_904_eus-gaap--GoodwillImpairmentLoss_dxL_c20230101__20230331_z4XiXqSxlbza" title="Impairment of goodwill::XDX::-"&gt;&lt;span id="xdx_901_eus-gaap--GoodwillImpairmentLoss_dxL_c20220101__20220331_zcT7vmeuBw04" title="Impairment of goodwill::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1230"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1232"&gt;No&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; impairment was recognized during
the three months ended March 31, 2023 or year ended December 31, 2022 (see Note 7).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_841_eus-gaap--IntangibleAssetsFiniteLivedPolicy_z1a3nqz7Lulf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_865_zU8Fi7Jev1Yb"&gt;Intangible
Assets&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
estimated fair values of acquired intangibles are generally determined based upon future economic benefits such as earnings and cash
flows. Acquired identifiable intangible assets are recorded at fair value and are amortized over their estimated useful lives.
Acquired intangible assets with an indefinite life are not amortized but are reviewed for impairment at least annually as of
December 31&lt;sup&gt;st&lt;/sup&gt;, or more frequently whenever events or changes in circumstances indicate that the carrying amounts of those
assets are below their estimated fair values. Impairment is tested under ASC 350. &lt;span id="xdx_901_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_do_c20230101__20230331_zywcseRVtwQl" title="Impairment of intangible assets"&gt;&lt;span id="xdx_900_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_do_c20220101__20221231_zdUpfxX3Zrwc" title="Impairment of intangible assets"&gt;No&lt;/span&gt;&lt;/span&gt;
impairment was recognized as of March 31,  2023 or year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"&gt;&lt;/p&gt;

</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      unitRef="USD">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_84C_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zDbHGeIMInR8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; background-color: white"&gt;&lt;i&gt;&lt;span id="xdx_860_zkK2hzCpGQ93"&gt;Recoverability
of Long-Lived Assets&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; background-color: white"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; background-color: white"&gt;We evaluate
long-lived assets such as property, equipment and definite lived intangible assets, such as patents, for impairment whenever events or
circumstances indicate that the carrying value of the assets recognized in our financial statements may not be recoverable. Factors that
we consider include whether there has been a significant decrease in the market value of an asset, a significant change in the way an
asset is being utilized, or a significant change, delay or departure in our strategy for that asset, or a significant change in the macroeconomic
environment, such as the impact of the COVID-19 pandemic. Our assessment of the recoverability of long-lived assets involves significant
judgment and estimation. These assessments reflect our assumptions, which, we believe, are consistent with the assumptions hypothetical
marketplace participants use. Factors that we must estimate when performing recoverability and impairment tests include, among others,
forecasted revenue, margin costs and the economic life of the asset. If impairment is indicated, we determine if the total estimated
future cash flows on an undiscounted basis are less than the carrying amounts of the asset or assets. If so, an impairment loss is measured
and recognized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 27.15pt; background-color: white"&gt;Our
impairment loss calculations require that we apply judgment in identifying asset groups, estimating future cash flows, determining asset
fair values, and estimating asset&#x2019;s useful lives. The Company reviews identifiable amortizable intangible assets for impairment
whenever events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. Determination of recoverability
is based on the lowest level of identifiable estimated undiscounted cash flows resulting from use of the asset and its eventual disposition.
Measurement of any impairment loss is based on the excess of the carrying value of the asset over its fair value. Based on the uncertainty
of forecasts inherent with a new product, events such as the failure to generate forecasted revenue from new products could result in
a non-cash impairment in future periods. &lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_847_eus-gaap--ResearchAndDevelopmentExpensePolicy_zGjVfszuc6gk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_861_zxMhjB9oXyT5"&gt;Research
and Development&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs are expensed as incurred. Total research and development costs were $&lt;span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230331_zCs1D9tKs0sj" title="Research and development cost"&gt;179,000&lt;/span&gt; for the three months ended March 31,
2023, and $&lt;span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20220331_zGlbHIaIRhXj" title="Research and development cost"&gt;168,000&lt;/span&gt; for three months ended March 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;IMPACT
Biomedical, Inc. and Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Consolidated Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">179000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">168000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_849_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zxAblYvjT77c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_860_zeeCcaIvXdw5"&gt;Recent
Accounting Standards&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Financial Accounting Standards Board (FASB) issues various Accounting Standards Updates relating to the treatment and recording of certain
accounting transactions. There are several new accounting pronouncements issued by FASB which are not yet effective. Each of these pronouncements,
as applicable, has been or will be adopted by the Company. As of March 31, 2023, none of these pronouncements is expected to have a material
effect on the financial position, results of operations or cash flows of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;On January
1, 2022, the Company adopted amended accounting guidance &#x201c;&lt;i&gt;ASU No.2016-13 &#x2013; Credit Losses&#x201d;&lt;/i&gt; which requires an
allowance for credit losses to be deducted from the amortized cost basis of financial assets to present the net carrying value at the
amount that is expected to be collected over the contractual term of the asset considering relevant information about past events, current
conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. In estimating expected losses
in the loan and lease portfolio, borrower-specific financial data and macro-economic assumptions are utilized to project losses over
a reasonable and supportable forecast period. Assumptions and judgment are applied to measure amounts and timing of expected future cash
flows, collateral values and other factors used to determine the borrowers&#x2019; abilities to repay obligations. After the forecast
period, the Company utilizes longer-term historical loss experience to estimate losses over the remaining contractual life of the loans.
Prior to 2022, the allowance for credit losses represented the amount that in management&#x2019;s judgment reflected incurred credit losses
inherent in the loan and lease portfolio as of the balance sheet date. As of March 31, 2023 the Company has deemed that no reserve or
credit losses were necessary.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <IMPB:ContinuingOperationsAndGoingConcernPolicyTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_84D_ecustom--ContinuingOperationsAndGoingConcernPolicyTextBlock_zcNMEQrOWwg3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_866_zTEGg80OPLSg"&gt;Continuing
Operations and Going Concern&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Due
to incurred operating losses as well as negative cash flows from operating and investing activities over the past two years, the accompanying
consolidated financial statements have been prepared assuming that the Company will continue as a going concern. This basis of accounting
contemplates the recovery of our assets and the satisfaction of liabilities in the normal course of business. These consolidated financial
statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary
should we be unable to continue as a going concern.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;To
continue as a going concern, the Company has entered into an updated revolving promissory note which extended the maturity through March
31, 2024, and DSS intends to continue to fund the operations of the Company through a year from the date these financial statements were
available to be issued. The Company&#x2019;s management intends to take actions necessary to continue as a going concern. Management&#x2019;s
plans concerning these matters include, among other things, monetization of its intellectual properties, and tightly controlling operating
costs. Based on this, the Company has concluded that substantial doubt of its ability to continue as a going concern has been alleviated.&lt;/span&gt;&lt;/p&gt;
</IMPB:ContinuingOperationsAndGoingConcernPolicyTextBlock>
    <IMPB:PrepaidExpensesTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_800_ecustom--PrepaidExpensesTextBlock_zznagE0BnHkk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
3. &lt;span id="xdx_82F_z0kqXkIuctMl"&gt;Prepaid Expenses&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid
expenses for the three months ended March 31, 2023, includes prepaid inventory approximating $&lt;span id="xdx_908_eus-gaap--OtherPrepaidExpenseCurrent_iI_c20230331__dei--LegalEntityAxis__custom--GRDGscienceLLCMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zlbBXjPsmgC8"&gt;140,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and research and development fees paid to GRDG
Sciences, LLC. (&#x201c;GRDG&#x201d;), a related party, approximating $&lt;span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230331__dei--LegalEntityAxis__custom--GRDGscienceLLCMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zBORT0DWnBtc"&gt;43,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.
Prepaid expenses at December 31, 2022 of $&lt;span id="xdx_907_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_c20221231__dei--LegalEntityAxis__custom--GRDGscienceLLCMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zlZO6VO6Oms"&gt;104,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;including research and development costs to GRDG
approximating $&lt;span id="xdx_900_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20220331__dei--LegalEntityAxis__custom--GRDGscienceLLCMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zSEFo6gVrIpk"&gt;43,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</IMPB:PrepaidExpensesTextBlock>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="AsOf2023-03-31_custom_GRDGscienceLLCMember_us-gaap_RelatedPartyMember"
      decimals="0"
      unitRef="USD">140000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-03-31_custom_GRDGscienceLLCMember_us-gaap_RelatedPartyMember"
      decimals="0"
      unitRef="USD">43000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2022-12-31_custom_GRDGscienceLLCMember_us-gaap_RelatedPartyMember"
      decimals="0"
      unitRef="USD">104000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-03-31_custom_GRDGscienceLLCMember_us-gaap_RelatedPartyMember"
      decimals="0"
      unitRef="USD">43000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_806_eus-gaap--LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_zgenoMqUC08d" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
4. &lt;span id="xdx_82E_zkgRqnZcy6wk"&gt;Notes Receivable&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 21, 2021, Impact BioMedical, Inc. entered into a promissory note (&#x201c;Promissory Note 1&#x201d;) with an individual. The Company
loaned the principal sum of $&lt;span id="xdx_901_eus-gaap--NotesReceivableNet_iI_c20210221_zi2s8gcmDHjk" title="Note receivable principal"&gt;206,000&lt;/span&gt;, with interest at a rate of &lt;span id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20210221_zybpWoXqiFRa" title="Debt stated percentage"&gt;6.5&lt;/span&gt;%, and maturity date of &lt;span id="xdx_903_eus-gaap--DebtInstrumentMaturityDate_dd_c20210220__20210221_zL7CLUdbngic" title="Debt maturity date"&gt;August 19, 2022&lt;/span&gt;. Monthly payments are due
on the twenty-first day of each month and continuing each month thereafter until August 19, 2022, at which time all accrued interest
and the entire remaining principal shall be due and payable in full. In August 2022, this note was amended to extend the maturity date
to &lt;span id="xdx_90A_eus-gaap--DebtInstrumentMaturityDate_c20220822__20220822_zhwVnrh63cK9" title="Maturity date"&gt;August 19, 2023&lt;/span&gt;. This note is secured by certain real property situated in Collier County, Florida. The outstanding principal and
interest approximated $&lt;span id="xdx_904_eus-gaap--DebtInstrumentPeriodicPayment_c20230101__20230331_zZKwpYbDLMbe" title="Debt principal and interest"&gt;205,000&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--DebtInstrumentPeriodicPayment_c20220101__20221231_zzNbTxwviz6a" title="Debt principal and interest"&gt;206,000&lt;/span&gt; as of March 31, 2023 and December 31, 2022, respectively. Of the $&lt;span id="xdx_90A_eus-gaap--NotesReceivableNet_iI_c20230331_zZXRt6Kecld3" title="Note receivable principal"&gt;205,000&lt;/span&gt; outstanding at
March 31, 2023, $&lt;span id="xdx_909_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20221231_zEjWmG4cOnMl" title="Notes receivable current"&gt;205,000&lt;/span&gt; is classified in current notes receivable on the accompanying consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
    <us-gaap:NotesReceivableNet contextRef="AsOf2021-02-21" decimals="0" unitRef="USD">206000</us-gaap:NotesReceivableNet>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="AsOf2021-02-21" decimals="INF" unitRef="Pure">0.065</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2021-02-202021-02-21">2022-08-19</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2022-08-222022-08-22">2023-08-19</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">205000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      unitRef="USD">206000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:NotesReceivableNet contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">205000</us-gaap:NotesReceivableNet>
    <us-gaap:NotesAndLoansReceivableGrossCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">205000</us-gaap:NotesAndLoansReceivableGrossCurrent>
    <us-gaap:InvestmentTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_80E_eus-gaap--InvestmentTextBlock_zJHqZsL3mxo2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
5. &lt;span id="xdx_82E_zBdG7zwNrMSd"&gt;Investments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 19, 2020, Impact BioMedical entered into a subscription agreement (the &#x201c;Subscription Agreement&#x201d;) with BioMed Technologies
Asia Pacific Holdings Limited (&#x201c;BioMed&#x201d;), a limited liability company incorporated in the British Virgin Islands, pursuant
to which the Company agreed to purchase &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_c20201218__20201219__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AsiaPacificHoldingsLimitedMember__us-gaap--TypeOfArrangementAxis__us-gaap--SubscriptionArrangementMember_zgIszdthOTFe" title="Ordinary shares to purchase"&gt;525&lt;/span&gt; ordinary shares or &lt;span id="xdx_90A_ecustom--OrdinarySharesPercentage_dp_uPure_c20201218__20201219__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AsiaPacificHoldingsLimitedMember__us-gaap--TypeOfArrangementAxis__us-gaap--SubscriptionArrangementMember_zWZOepEBYtl" title="Ordinary shares percentage"&gt;4.99&lt;/span&gt;% of BioMed at a purchase price of approximately $&lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValuePurchaseOfAssets_c20201218__20201219__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AsiaPacificHoldingsLimitedMember__us-gaap--TypeOfArrangementAxis__us-gaap--SubscriptionArrangementMember_zj4eH54KnRy2" title="Purchase price of shares"&gt;632,000&lt;/span&gt;. The Subscription
Agreement provides, among other things, the Company the right to appoint a new director to the board of BioMed. With respect to an issuance
of shares to a third party by BioMed, the Company will have the right of first refusal to purchase such shares, as well as customary
tag-along rights. In connection with the Subscription Agreement, the Company entered into an exclusive distribution agreement (the &#x201c;Distribution
Agreement&#x201d;) with BioMed, to directly market, advertise, promote, distribute, and sell certain BioMed products, which focus on manufacturing
natural probiotics, to resellers. This investment is valued at cost as it does not have a readily determined fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioMed
focuses on manufacturing natural probiotics, pursuant to which the Company will directly market, advertise, promote, distribute and sell
certain BioMed products to resellers. The products to be distributed by the Company include BioMed&#x2019;s PGut Premium Probiotics&lt;sup&gt;&#xae;&lt;/sup&gt;,
PGut Allergy Probiotics&lt;sup&gt;&#xae;&lt;/sup&gt;, PGut SupremeSlim Probiotics&lt;sup&gt;&#xae;&lt;/sup&gt;, PGut Kids Probiotics&lt;sup&gt;&#xae;&lt;/sup&gt;, and PGut
Baby Probiotics&lt;sup&gt;&#xae;&lt;/sup&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
January 1, 2021, the Company entered into a securities purchase agreement (&#x201c;SPA&#x201d;) with Nano9, LLC. (&#x201c;Nano9&#x201d;),
a Utah limited partnership. For the consideration of $&lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210101__20210101__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NanoNineLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z7yHKudmDdw7" title="Number of shares issued, value"&gt;150,000&lt;/span&gt; the Company obtained &lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20210101__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NanoNineLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zcioHhGmp7yl" title="Number of shares issued, shares"&gt;1,000&lt;/span&gt; membership units, or approximately &lt;span id="xdx_900_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20210101__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NanoNineLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zXVnerZSExBj" title="Equitable ownership percentage"&gt;10&lt;/span&gt;% equitable
ownership of Nano9. Nano9 is a scientifically driven company, specializing in the development and production of leading nano-sized health
&amp;amp; wellness products utilizing their proprietary nano technology. As of Mach 31, 2023 and March 31, 2022, the fair value of the Company&#x2019;s
investment in Nano9 is not readily available, and therefore is recorded at cost of $&lt;span id="xdx_90F_eus-gaap--InvestmentOwnedAtFairValue_iI_c20230331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NanoNineLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zzAPgEMNCnS6" title="Investment owned at fair value"&gt;&lt;span id="xdx_90C_eus-gaap--InvestmentOwnedAtFairValue_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NanoNineLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zAXFQBz9QGvj" title="Investment owned at fair value"&gt;150,000&lt;/span&gt;&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;IMPACT
Biomedical, Inc. and Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Consolidated Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 15, 2021, the Company, through one of its subsidiaries, entered into a Stock Purchase Agreement (the &#x201c;Vivacitas Agreement
#1&#x201d;) with Vivacitas Oncology Inc. (&#x201c;Vivacitas&#x201d;), to purchase &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210314__20210315__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VivacitasOncologyIncMember_zPIyUHAVvWy7" title="Number of shares issued"&gt;500,000&lt;/span&gt; shares of its common stock at the per share price
of $&lt;span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20210315__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VivacitasOncologyIncMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zHtIZ4p96zMl" title="Common stock par value"&gt;1.00&lt;/span&gt;, with an option to purchase &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20210314__20210315__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VivacitasOncologyIncMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zyihgpA9OXYf" title="Options to purchase additional shares"&gt;1,500,000&lt;/span&gt; additional shares at the per share price of $&lt;span id="xdx_907_eus-gaap--SharePrice_iI_c20210315__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VivacitasOncologyIncMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zEhLwmJ8fIZ3" title="Share price"&gt;1.00&lt;/span&gt;. &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20210314__20210315__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VivacitasOncologyIncMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zfpqTSJdIJ5d" title="Option termination, description"&gt;This option will terminate upon one
of the following events: (i) Vivacitas&#x2019; board of directors cancels this option because it is no longer in the best interest of
the Company; (ii) December 31, 2022; or (iii) the date on which Vivacitas receives more than $1.00 per share of the Company&#x2019;s common
stock in a private placement with gross proceeds of $&lt;span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20210314__20210315__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VivacitasOncologyIncMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_za7D9cHsg4Se" title="Proceeds from private placement"&gt;500,000&lt;/span&gt;. Under the terms of the Vivacitas Agreement #1, the Company will be allocated
two seats on the board of Vivacitas&lt;/span&gt;. On March 18, 2021, the Company entered into an agreement with Alset EHome International, Inc. (&#x201c;Seller&#x201d;)
to purchase from the Seller&#x2019;s its wholly owned subsidiary Impact Oncology PTE Ltd. (&#x201c;IOPL&#x201d;) for a purchase price $&lt;span id="xdx_905_eus-gaap--BusinessCombinationConsiderationTransferred1_c20210317__20210318__us-gaap--BusinessAcquisitionAxis__custom--ImpactOncologyPTELtdMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zJhtKUYE4jMi" title="Purchase price"&gt;2,480,000&lt;/span&gt;.
The acquisition of IOPL has been treated as an asset acquisition as IOPL does not meet the definition of a business as defined in Topic
805. IOPL owns &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20210317__20210318__us-gaap--BusinessAcquisitionAxis__custom--ImpactOncologyPTELtdMember__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zUpl6Ci9Hrgk" title="Number of common stock owned"&gt;2,480,000&lt;/span&gt; shares of common stock of Vivacitas along with the option to purchase an additional &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20210317__20210318__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zn6gyNKQhbC6" title="Options to purchase common stock"&gt;250,000&lt;/span&gt; shares of common
stock. The Sellers largest shareholder is Mr. Chan Heng Fai Ambrose, the Chairman of the Company&#x2019;s board of directors and its largest
shareholder.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 1, 2021, the Company entered into an additional stock purchase agreement with Vivacitas (&#x201c;Vivacitas Agreement #2&#x201d;),
whereas Vivacities wished to employ the service of the Chief Business Officer of Impact Biomedical, and in return for the services of
this individual, Vivacitas shall issue to the Company, the aggregate purchase price for the Class A Common Shares of Vivacitas at the
value of $&lt;span id="xdx_901_eus-gaap--SharePrice_iI_c20210401__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VivacitasOncologyIncMember_zheuHmk0bhm4" title="Share price"&gt;1.00&lt;/span&gt; per share shall be $&lt;span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20210401__20220331__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VivacitasOncologyIncMember_zXTsGXfHj669" title="Proceeds from issuance of common stock"&gt;120,000&lt;/span&gt; to be paid in twelve (12) equal monthly installments for the period between April 1, 2021
and March 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 22, 2021, the Company exercised &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210721__20210722__us-gaap--TypeOfArrangementAxis__custom--VivacitasAgreementMember_zbZcBFEWsNve" title="Stock option exercised, shares"&gt;1,000,000&lt;/span&gt; of the available options under the Vivacitas Agreement #1 for $&lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_c20210721__20210722__us-gaap--TypeOfArrangementAxis__custom--VivacitasAgreementMember_zAvqYOHaSMr6" title="Stock option exercised, value"&gt;1,000,000&lt;/span&gt;. This, along
with the shares received as part Vivacitas Agreement #2 increased the Company&#x2019;s equity position in Vivacitas to approximately 16%
as of December 31, 2022. As of December 31, 2021, the fair value of the Company&#x2019;s investment in Vivacitas is not readily available,
and therefore is recorded at cost in the amount of $&lt;span id="xdx_909_eus-gaap--InvestmentOwnedAtFairValue_iI_c20211231__us-gaap--TypeOfArrangementAxis__custom--VivacitasAgreementMember_zvYB0cscwmz8" title="Investment owned at fair value"&gt;4,035,000&lt;/span&gt;. As of December 31, 2022, the Company determined to impair &lt;span id="xdx_90C_eus-gaap--InvestmentOwnedPercentOfNetAssets_iI_pid_dp_c20221231__us-gaap--TypeOfArrangementAxis__custom--VivacitasAgreementMember_zq9VHFbjTEVa" title="Investment cost, percent"&gt;100&lt;/span&gt;% of its investment
in Vivacitas, in the amount of $&lt;span id="xdx_905_eus-gaap--InvestmentOwnedAtCost_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--VivacitasAgreementMember_zkmt2C76xxRf" title="Investment cost"&gt;4,100,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:InvestmentTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="From2020-12-182020-12-19_custom_AsiaPacificHoldingsLimitedMember_us-gaap_SubscriptionArrangementMember"
      decimals="INF"
      unitRef="Shares">525</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <IMPB:OrdinarySharesPercentage
      contextRef="From2020-12-182020-12-19_custom_AsiaPacificHoldingsLimitedMember_us-gaap_SubscriptionArrangementMember"
      decimals="INF"
      unitRef="Pure">0.0499</IMPB:OrdinarySharesPercentage>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="From2020-12-182020-12-19_custom_AsiaPacificHoldingsLimitedMember_us-gaap_SubscriptionArrangementMember"
      decimals="0"
      unitRef="USD">632000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-01-01_custom_NanoNineLLCMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="0"
      unitRef="USD">150000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-01-012021-01-01_custom_NanoNineLLCMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      unitRef="Shares">1000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2021-01-01_custom_NanoNineLLCMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      unitRef="Pure">0.10</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:InvestmentOwnedAtFairValue
      contextRef="AsOf2023-03-31_custom_NanoNineLLCMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="0"
      unitRef="USD">150000</us-gaap:InvestmentOwnedAtFairValue>
    <us-gaap:InvestmentOwnedAtFairValue
      contextRef="AsOf2022-12-31_custom_NanoNineLLCMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="0"
      unitRef="USD">150000</us-gaap:InvestmentOwnedAtFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-03-142021-03-15_custom_StockPurchaseAgreementMember_custom_VivacitasOncologyIncMember"
      decimals="INF"
      unitRef="Shares">500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-03-15_custom_VivacitasOncologyIncMember_custom_StockPurchaseAgreementMember"
      decimals="INF"
      unitRef="USDPShares">1.00</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="From2021-03-142021-03-15_custom_StockPurchaseAgreementMember_custom_VivacitasOncologyIncMember"
      decimals="INF"
      unitRef="Shares">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:SharePrice
      contextRef="AsOf2021-03-15_custom_VivacitasOncologyIncMember_custom_StockPurchaseAgreementMember"
      decimals="INF"
      unitRef="USDPShares">1.00</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="From2021-03-142021-03-15_custom_StockPurchaseAgreementMember_custom_VivacitasOncologyIncMember">This option will terminate upon one
of the following events: (i) Vivacitas&#x2019; board of directors cancels this option because it is no longer in the best interest of
the Company; (ii) December 31, 2022; or (iii) the date on which Vivacitas receives more than $1.00 per share of the Company&#x2019;s common
stock in a private placement with gross proceeds of $500,000. Under the terms of the Vivacitas Agreement #1, the Company will be allocated
two seats on the board of Vivacitas</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2021-03-142021-03-15_custom_StockPurchaseAgreementMember_custom_VivacitasOncologyIncMember"
      decimals="0"
      unitRef="USD">500000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="From2021-03-172021-03-18_custom_ImpactOncologyPTELtdMember_custom_StockPurchaseAgreementMember"
      decimals="0"
      unitRef="USD">2480000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2021-03-172021-03-18_custom_ImpactOncologyPTELtdMember_custom_StockPurchaseAgreementMember"
      decimals="INF"
      unitRef="Shares">2480000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="From2021-03-172021-03-18_custom_StockPurchaseAgreementMember_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:SharePrice
      contextRef="AsOf2021-04-01_custom_StockPurchaseAgreementMember_custom_VivacitasOncologyIncMember"
      decimals="INF"
      unitRef="USDPShares">1.00</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2021-04-012022-03-31_custom_StockPurchaseAgreementMember_custom_VivacitasOncologyIncMember"
      decimals="0"
      unitRef="USD">120000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2021-07-212021-07-22_custom_VivacitasAgreementMember"
      decimals="INF"
      unitRef="Shares">1000000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-07-212021-07-22_custom_VivacitasAgreementMember"
      decimals="0"
      unitRef="USD">1000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:InvestmentOwnedAtFairValue
      contextRef="AsOf2021-12-31_custom_VivacitasAgreementMember"
      decimals="0"
      unitRef="USD">4035000</us-gaap:InvestmentOwnedAtFairValue>
    <us-gaap:InvestmentOwnedPercentOfNetAssets
      contextRef="AsOf2022-12-31_custom_VivacitasAgreementMember"
      decimals="INF"
      unitRef="Pure">1</us-gaap:InvestmentOwnedPercentOfNetAssets>
    <us-gaap:InvestmentOwnedAtCost
      contextRef="AsOf2022-12-31_custom_VivacitasAgreementMember"
      decimals="0"
      unitRef="USD">4100000</us-gaap:InvestmentOwnedAtCost>
    <us-gaap:PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_80A_eus-gaap--PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock_zoATX1p4YtJb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
6. &lt;span&gt;&lt;span id="xdx_827_zb0LjbGchzfg"&gt;PROPERTY PLANT AND EQUIPMENT and INVESTMENT IN REAL ESTATE, NET&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--PropertyPlantAndEquipmentTextBlock_zKmGCKB8jhLi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property,
plant and equipment consisted of the following as of:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B9_zlqErWIC7q1i" style="display: none"&gt;Schedule
of Property Plant and Equipment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Estimated&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20230331_zqqKxvPswvVe" style="text-align: center"&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20221231_zkPG2FKFlzKc" style="text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Useful Life&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zqxZN27jvhsd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 54%; text-align: left"&gt;Machinery and equipment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MinimumMember_ziKBKyunP5Wl"&gt;5&lt;/span&gt;-&lt;span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MaximumMember_zBPBwmp0uYL3"&gt;10&lt;/span&gt; years&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;30,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;25,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_zySoihHYZMac" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Construction in progress&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;251,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;251,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzm9U_zrVVWlbBESsb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total Cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;281,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;276,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzm9U_zAT672QBpB97" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Property, plant and equipment, gross&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;281,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;276,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iI_msPPAENzm9U_zuHGi7xUSjyj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1345"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzm9U_zPzbbi0iICH2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Property, plant and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;279,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;276,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zk2xPcbLPHYe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation
expense for the three months ended March 31, 2023 and 2022 was $&lt;span id="xdx_909_eus-gaap--Depreciation_c20230101__20230331_zZ3Zs3o0Yhw7" title="Depreciation expense"&gt;2,000&lt;/span&gt; and $&lt;span id="xdx_90C_eus-gaap--Depreciation_c20220101__20220331_zzaWsqDjnn25" title="Depreciation expense"&gt;0&lt;/span&gt; respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_894_eus-gaap--PropertyPlantAndEquipmentTextBlock_zKmGCKB8jhLi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property,
plant and equipment consisted of the following as of:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B9_zlqErWIC7q1i" style="display: none"&gt;Schedule
of Property Plant and Equipment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Estimated&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20230331_zqqKxvPswvVe" style="text-align: center"&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20221231_zkPG2FKFlzKc" style="text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Useful Life&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zqxZN27jvhsd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 54%; text-align: left"&gt;Machinery and equipment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MinimumMember_ziKBKyunP5Wl"&gt;5&lt;/span&gt;-&lt;span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MaximumMember_zBPBwmp0uYL3"&gt;10&lt;/span&gt; years&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;30,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;25,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_zySoihHYZMac" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Construction in progress&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;251,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;251,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzm9U_zrVVWlbBESsb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total Cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;281,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;276,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzm9U_zAT672QBpB97" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Property, plant and equipment, gross&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;281,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;276,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iI_msPPAENzm9U_zuHGi7xUSjyj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1345"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzm9U_zPzbbi0iICH2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Property, plant and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;279,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;276,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="AsOf2023-03-31_us-gaap_MachineryAndEquipmentMember_srt_MinimumMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="AsOf2023-03-31_us-gaap_MachineryAndEquipmentMember_srt_MaximumMember">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-03-31_us-gaap_MachineryAndEquipmentMember"
      decimals="0"
      unitRef="USD">30000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_us-gaap_MachineryAndEquipmentMember"
      decimals="0"
      unitRef="USD">25000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-03-31_us-gaap_ConstructionInProgressMember"
      decimals="0"
      unitRef="USD">251000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_us-gaap_ConstructionInProgressMember"
      decimals="0"
      unitRef="USD">251000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">281000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">276000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">281000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">276000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">2000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">279000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">276000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">2000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">0</us-gaap:Depreciation>
    <us-gaap:GoodwillDisclosureTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_80A_eus-gaap--GoodwillDisclosureTextBlock_z84PkQfzbblh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
7. &lt;span id="xdx_829_zHOdb8nvWfZ9"&gt;Goodwill&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfGoodwillTextBlock_z8SUaUaDgTli" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Goodwill
balances and activity for the three months ended March 31, 2023 and year ended December 31, 2022 consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span style="display: none"&gt;&lt;span id="xdx_8B3_zYQvG6r2jJ9c"&gt;Schedule
of Goodwill&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%"&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--Goodwill_iS_c20230101__20230331_zVuouwoCAx3" style="width: 18%; text-align: right" title="Balance at December 31, 2022"&gt;25,093,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"&gt;Goodwill adjustment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--GoodwillImpairmentLoss_c20230101__20230331_zVMey9wbMgll" style="border-bottom: Black 1.5pt solid; text-align: right" title="Goodwill adjustment"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1360"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance at March 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--Goodwill_iE_c20230101__20230331_zffStzrknGr5" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance at March 31, 2023"&gt;25,093,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zVOXtbklTx6b" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
2022, management performed annual goodwill impairment testing. No goodwill impairment was identified as a result of these tests. As of
June 1, 2022 a quantitative analysis was prepared utilizing the Market Approach and Income Approach valuing the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:GoodwillDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_89D_eus-gaap--ScheduleOfGoodwillTextBlock_z8SUaUaDgTli" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Goodwill
balances and activity for the three months ended March 31, 2023 and year ended December 31, 2022 consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span style="display: none"&gt;&lt;span id="xdx_8B3_zYQvG6r2jJ9c"&gt;Schedule
of Goodwill&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%"&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--Goodwill_iS_c20230101__20230331_zVuouwoCAx3" style="width: 18%; text-align: right" title="Balance at December 31, 2022"&gt;25,093,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"&gt;Goodwill adjustment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--GoodwillImpairmentLoss_c20230101__20230331_zVMey9wbMgll" style="border-bottom: Black 1.5pt solid; text-align: right" title="Goodwill adjustment"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1360"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance at March 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--Goodwill_iE_c20230101__20230331_zffStzrknGr5" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance at March 31, 2023"&gt;25,093,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">25093000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">25093000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_80C_eus-gaap--IntangibleAssetsDisclosureTextBlock_zMSHpM4pv9I" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
8. &lt;span id="xdx_824_zGUS3VAU8E0l"&gt;Intangible Assets&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
definite-lived intangible assets, to be amortized over 20 years, balances, and activity for the &lt;span style="background-color: white"&gt;three
months&lt;/span&gt; ended March 31, 2023, year ended December 31, 2022 consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zGi1WtUkN6Li" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B7_zwb1AaV397ea" style="display: none"&gt;Schedule
of Intangible Assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;03/31/2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;12/31/2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Gross Carrying&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Accumulated&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Amortization&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Net Carrying&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Gross Carrying&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Accumulated&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Amortization&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Net Carrying&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Definitive-lived:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 40%; text-align: left; padding-bottom: 1.5pt"&gt;Developed technology&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20230331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zvIVcgBkvYKl" style="border-bottom: Black 1.5pt solid; width: 6%; text-align: right" title="Gross Carrying Amount"&gt;22,258,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20230331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zssAAxGCti9h" style="border-bottom: Black 1.5pt solid; width: 6%; text-align: right" title="Accumulated Amortization"&gt;(2,502,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20230331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zHjJx9BowYW5" style="border-bottom: Black 1.5pt solid; width: 6%; text-align: right" title="Net Carrying Amount"&gt;19,756,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zWXgbalgJz37" style="border-bottom: Black 1.5pt solid; width: 6%; text-align: right" title="Gross Carrying Amount"&gt;22,258,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_z0ahlEuoAWA" style="border-bottom: Black 1.5pt solid; width: 6%; text-align: right" title="Accumulated Amortization"&gt;(2,226,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zpwIrJiajne4" style="border-bottom: Black 1.5pt solid; width: 6%; text-align: right" title="Net Carrying Amount"&gt;20,033,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20230331_zJJvBS6Ctedk" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Carrying Amount"&gt;22,258,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20230331_z8G18z2Gh0Wf" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated Amortization"&gt;(2,502,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20230331_zZGqbkVkLHKe" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Carrying Amount"&gt;19,756,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20221231_zYxx5eW0ZsLl" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Carrying Amount"&gt;22,258,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231_zabLixtyvSB7" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated Amortization"&gt;(2,226,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20221231_zX4zinQ5kTUl" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Carrying Amount"&gt;20,033,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zuyVZX6z4QU5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;Amounts
amortized for the three months ended March 31, 2023 and 2022 was approximately $&lt;span id="xdx_908_eus-gaap--DepreciationAndAmortization_c20230101__20230331_zQWq82HMhrMe" title="Amortization"&gt;280,000&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--DepreciationAndAmortization_c20220101__20220331_zgdMmAcg0Lqj" title="Amortization"&gt;278,000&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zJt835MlvhDc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table represents future amortization of developed technologies for the years ending December 31:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 11pt"&gt;&lt;span id="xdx_8B1_zgtrZ9zobbee"&gt;Schedule
of Future Amortization of Developed Technologies&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49F_20230331_zYwsWZqnCvx7" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_z9IouMh1PgZa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: right"&gt;2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;835,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_zOgSIplEnwp8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: right"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,113,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_zEjc0J7QM5Eg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: right"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,113,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_zAeK6OAHhN1e" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: right"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,113,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_z9fBJamofKN7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: right"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,113,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_zYjHglv38zI3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: right"&gt;Thereafter&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;14,469,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_z3Sidvpo3ag2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;IMPACT
Biomedical, Inc. and Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Consolidated Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;An impairment analysis was conducted for
financial reporting purposes in connection with U.S. GAAP and ASC 360-10, Impairment and Disposal of Long-Lived Assets. Although the
Company has a history of negative cash flows from operations, its financing arrangement with DSS (see Note 9) provides the opportunity
to fund ongoing operations. This, as well as there being no other indicators present for impairment, has led management to conclude that
no impairment is necessary for the three months ended March 31, 2023, and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_894_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zGi1WtUkN6Li" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B7_zwb1AaV397ea" style="display: none"&gt;Schedule
of Intangible Assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;03/31/2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;12/31/2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Gross Carrying&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Accumulated&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Amortization&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Net Carrying&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Gross Carrying&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Accumulated&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Amortization&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Net Carrying&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Definitive-lived:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 40%; text-align: left; padding-bottom: 1.5pt"&gt;Developed technology&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20230331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zvIVcgBkvYKl" style="border-bottom: Black 1.5pt solid; width: 6%; text-align: right" title="Gross Carrying Amount"&gt;22,258,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20230331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zssAAxGCti9h" style="border-bottom: Black 1.5pt solid; width: 6%; text-align: right" title="Accumulated Amortization"&gt;(2,502,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20230331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zHjJx9BowYW5" style="border-bottom: Black 1.5pt solid; width: 6%; text-align: right" title="Net Carrying Amount"&gt;19,756,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zWXgbalgJz37" style="border-bottom: Black 1.5pt solid; width: 6%; text-align: right" title="Gross Carrying Amount"&gt;22,258,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_z0ahlEuoAWA" style="border-bottom: Black 1.5pt solid; width: 6%; text-align: right" title="Accumulated Amortization"&gt;(2,226,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zpwIrJiajne4" style="border-bottom: Black 1.5pt solid; width: 6%; text-align: right" title="Net Carrying Amount"&gt;20,033,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20230331_zJJvBS6Ctedk" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Carrying Amount"&gt;22,258,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20230331_z8G18z2Gh0Wf" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated Amortization"&gt;(2,502,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20230331_zZGqbkVkLHKe" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Carrying Amount"&gt;19,756,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20221231_zYxx5eW0ZsLl" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross Carrying Amount"&gt;22,258,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231_zabLixtyvSB7" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated Amortization"&gt;(2,226,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20221231_zX4zinQ5kTUl" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Carrying Amount"&gt;20,033,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2023-03-31_us-gaap_DevelopedTechnologyRightsMember"
      decimals="0"
      unitRef="USD">22258000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2023-03-31_us-gaap_DevelopedTechnologyRightsMember"
      decimals="0"
      unitRef="USD">-2502000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2023-03-31_us-gaap_DevelopedTechnologyRightsMember"
      decimals="0"
      unitRef="USD">19756000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2022-12-31_us-gaap_DevelopedTechnologyRightsMember"
      decimals="0"
      unitRef="USD">22258000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2022-12-31_us-gaap_DevelopedTechnologyRightsMember"
      decimals="0"
      unitRef="USD">-2226000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2022-12-31_us-gaap_DevelopedTechnologyRightsMember"
      decimals="0"
      unitRef="USD">20033000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">22258000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">-2502000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">19756000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">22258000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">-2226000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">20033000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">280000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">278000</us-gaap:DepreciationAndAmortization>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_898_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zJt835MlvhDc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table represents future amortization of developed technologies for the years ending December 31:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 11pt"&gt;&lt;span id="xdx_8B1_zgtrZ9zobbee"&gt;Schedule
of Future Amortization of Developed Technologies&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49F_20230331_zYwsWZqnCvx7" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_z9IouMh1PgZa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: right"&gt;2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;835,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_zOgSIplEnwp8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: right"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,113,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_zEjc0J7QM5Eg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: right"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,113,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_zAeK6OAHhN1e" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: right"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,113,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_z9fBJamofKN7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: right"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,113,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_zYjHglv38zI3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: right"&gt;Thereafter&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;14,469,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">835000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">1113000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">1113000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">1113000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">1113000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">14469000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_809_eus-gaap--DebtDisclosureTextBlock_z6WPYl6rmHK1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
9. &lt;span id="xdx_825_zvOkPjNjVYbc"&gt;Debt&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 31, 2020, and later amended on March 31, 2023, the Company executed a Revolving Promissory Note (&#x201c;Note&#x201d;) with DSS,
a related party, which accrues interest at a rate of &lt;span id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20230331__us-gaap--DebtInstrumentAxis__custom--RevolvingPromissoryNoteMember_zuUBJvMCB1D7"&gt;4.25&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
and is due in full at the maturity date of &lt;span id="xdx_907_eus-gaap--DebtInstrumentMaturityDate_dd_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--RevolvingPromissoryNoteMember_zv495TGu08Vi"&gt;March
31, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;. The revolving nature of this Note permits
for principal amounts borrowed to be repaid and reborrowed. &lt;span id="xdx_909_eus-gaap--DebtDefaultLongtermDebtDescriptionOfNoticeOfDefault_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--RevolvingPromissoryNoteMember_zs8MAykuk7tj"&gt;In
the case of default, at DSS&#x2019;s option, (i) eighteen percent (18%) per annum, or (ii) such lesser rate of interest as Lender in its
sole discretion may choose to charge; but never more than the Maximum Lawful Rate.&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;DSS
has not established a maximum borrowing amount and intends to continue to fund the operations of the Company through a year from the
date these financial statements were available to be issued. As of March 31, 2023 and December 31, 2022, this Note has an outstanding
balance, including interest of $&lt;span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_c20230331_zj0LuSnTzf94" title="Outstanding balance, including interest"&gt;11,008,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and &lt;span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_c20221231_zmvODnojziL6" title="Outstanding balance, including interest"&gt;9,529,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2023-03-31_custom_RevolvingPromissoryNoteMember"
      decimals="INF"
      unitRef="Pure">0.0425</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2023-01-012023-03-31_custom_RevolvingPromissoryNoteMember">2024-03-31</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtDefaultLongtermDebtDescriptionOfNoticeOfDefault contextRef="From2023-01-012023-03-31_custom_RevolvingPromissoryNoteMember">In
the case of default, at DSS&#x2019;s option, (i) eighteen percent (18%) per annum, or (ii) such lesser rate of interest as Lender in its
sole discretion may choose to charge; but never more than the Maximum Lawful Rate.</us-gaap:DebtDefaultLongtermDebtDescriptionOfNoticeOfDefault>
    <us-gaap:DebtInstrumentFaceAmount contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">11008000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">9529000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_803_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zbKNOhCfXE94" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
10. &lt;span id="xdx_82F_zUXganmVlNu7"&gt;Stockholders&#x2019; Equity&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 23, 2021, the Company, the Company&#x2019;s Board of Directors approved the total number of shares of Common Stock to be &lt;span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_iI_c20210923__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zZfQue2LNov3" title="Common stock, shares authorized"&gt;3,000,000,000&lt;/span&gt;
shares with a par value of $&lt;span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20210923__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zoo7rhQF5ghe" title="Common stock par value"&gt;0.001&lt;/span&gt;. Each
share of Common Stock when issued, shall have one (1) vote on all matters presented to the stockholders. Our Amended and Restated Articles of Incorporation authorize us to issue up to &lt;span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_c20230331__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zhVHcoGs4tf" title="Common stock, shares authorized"&gt;4,000,000,000&lt;/span&gt; shares of Common Stock,
$&lt;span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230331__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zRCbHfeSZXHf" title="Common stock par value"&gt;0.001&lt;/span&gt; par value per share, and &lt;span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_c20230331__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zirSEAKoq2Xl" title="Preferred stock, shares authorized"&gt;100,000,000&lt;/span&gt; shares of preferred stock, par value $&lt;span id="xdx_90D_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20230331__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zYj2CBBVokk2" title="Preferred stock, par value"&gt;0.001&lt;/span&gt; per share. As of December 31, 2022, there were
&lt;span id="xdx_90C_eus-gaap--CommonStockSharesIssued_iI_c20221231__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zmBLBfIrkdW5" title="Common stock, shares issued"&gt;&lt;span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_iI_c20221231__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zzyv6QBLAtO2" title="Common stock, shares outstanding"&gt;125,073,621&lt;/span&gt;&lt;/span&gt; shares of our Common Stock and &lt;span id="xdx_90C_eus-gaap--PreferredStockSharesIssued_iI_do_c20221231__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zza7rDYzbmu5" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20221231__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zLeIUCP9QFQ2" title="Preferred stock, shares outstanding"&gt;no&lt;/span&gt;&lt;/span&gt; shares of preferred stock issued and outstanding. On May 11, 2023, the Company effected
a forward split. As a result, there were &lt;span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_c20230511__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zCx6sDv8e111" title="Common stock, shares authorized"&gt;3,877,282,251&lt;/span&gt; shares of our Common Stock and &lt;span id="xdx_90B_eus-gaap--PreferredStockSharesIssued_iI_do_c20230511__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_znj1qlMbWG6d" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20230511__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zTNwSEegatod" title="Preferred stock, shares outstanding"&gt;no&lt;/span&gt;&lt;/span&gt; shares of preferred stock issued and outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2021-09-23_srt_BoardOfDirectorsChairmanMember"
      decimals="INF"
      unitRef="Shares">3000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-09-23_srt_BoardOfDirectorsChairmanMember"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-03-31_srt_BoardOfDirectorsChairmanMember"
      decimals="INF"
      unitRef="Shares">4000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-03-31_srt_BoardOfDirectorsChairmanMember"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-03-31_srt_BoardOfDirectorsChairmanMember"
      decimals="INF"
      unitRef="Shares">100000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-03-31_srt_BoardOfDirectorsChairmanMember"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2022-12-31_srt_BoardOfDirectorsChairmanMember"
      decimals="INF"
      unitRef="Shares">125073621</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2022-12-31_srt_BoardOfDirectorsChairmanMember"
      decimals="INF"
      unitRef="Shares">125073621</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-12-31_srt_BoardOfDirectorsChairmanMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-12-31_srt_BoardOfDirectorsChairmanMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-05-11_us-gaap_SubsequentEventMember"
      decimals="INF"
      unitRef="Shares">3877282251</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-05-11_us-gaap_SubsequentEventMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-05-11_us-gaap_SubsequentEventMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_80D_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zrbITywKloki" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
11. &lt;span id="xdx_827_zf0EomlVQZC6"&gt;Related Party Transactions&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Research
and Development Activities&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Based
on Shareholders Agreement entered into on April 26, 2017, the Company would fund the scientific operations of GRDG, a company involved
in research and development of biomedical products which is a minority stockholder of two of the Company&#x2019;s subsidiaries and is
owned by Daryl Thompson, a director of many subsidiaries of the Company, to do the development and research works on the biomedical products
for the Company. As of March 31, 2023, this funding approximates $&lt;span id="xdx_903_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20230101__20230331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GRDGscienceLLCMember_zMgYBTYQWtP7" title="Payment in funding of research and development"&gt;43,000 &lt;/span&gt;per month, and incurred approximately $&lt;span id="xdx_901_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GRDGscienceLLCMember_z7qVznlEjroe" title="Research and development expense"&gt;129,000&lt;/span&gt; in expenses. On
March 31, 2023 and March 31, 2022, the Company owed this related party $&lt;span id="xdx_902_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20230101__20230331_zxj1qUuxOQ4k" title="Related party owed transaction"&gt;&lt;span id="xdx_908_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20220101__20220331_zr8Sak1UglYa" title="Related party owed transaction"&gt;0&lt;/span&gt;&lt;/span&gt; and had prepaid monthly fees approximating $&lt;span id="xdx_90E_eus-gaap--PrepaidExpenseCurrentAndNoncurrent_iI_c20230331_zdjBbtRg6Lx6" title="Prepaid monthly fees"&gt;43,000 &lt;/span&gt;and $&lt;span id="xdx_901_eus-gaap--PrepaidExpenseCurrentAndNoncurrent_iI_c20220331_zsupyVW5PqB2" title="Prepaid monthly fees"&gt;43,000&lt;/span&gt;,
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;General
and Administrative Costs&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
are certain general and administrative costs incurred by DSS, a related party on behalf of the Company which are passed through to the
Company on a monthly basis. These costs consist of primarily payroll costs for certain DSS employees and are allocated based on estimated
time spent on behalf of the Company. These costs approximate $&lt;span id="xdx_906_eus-gaap--LaborAndRelatedExpense_c20230101__20230331_zojFxxmWo0xg" title="Related costs for employees"&gt;12,000&lt;/span&gt; per month. As of March 31, 2023, the Company incurred $&lt;span id="xdx_90E_eus-gaap--GeneralAndAdministrativeExpense_c20230101__20230331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zWhTU71wDqE" title="General and administrative expense"&gt;35,000&lt;/span&gt; in
related expenses. As of March 31, 2022, the Company incurred approximately $&lt;span id="xdx_90D_eus-gaap--GeneralAndAdministrativeExpense_c20220101__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z5ttMp7WAQ06" title="General and administrative expense"&gt;52,000&lt;/span&gt; in related expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;IMPACT
Biomedical, Inc. and Subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Consolidated Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="From2023-01-012023-03-31_custom_GRDGscienceLLCMember"
      decimals="0"
      unitRef="USD">43000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-03-31_custom_GRDGscienceLLCMember"
      decimals="0"
      unitRef="USD">129000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">0</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">0</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:PrepaidExpenseCurrentAndNoncurrent contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">43000</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
    <us-gaap:PrepaidExpenseCurrentAndNoncurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">43000</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
    <us-gaap:LaborAndRelatedExpense
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      unitRef="USD">12000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-03-31_us-gaap_RelatedPartyMember"
      decimals="0"
      unitRef="USD">35000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-01-012022-03-31_us-gaap_RelatedPartyMember"
      decimals="0"
      unitRef="USD">52000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_803_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zdZObhLJsKj9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
12. &lt;span id="xdx_82E_zpi1260TjC8d"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 15, 2018, the Company entered into Royalty Agreement with Chemia Corporation (&#x201c;Chemia&#x201d;) pursuant to which Chemia
transferred to the Company all of its right to 3F (Functional Fragrance Formulation). This agreement has a 20-year term and auto
renews for a period of 1 year unless mutually agreed upon by both parties. 3F consists of 3F Mosquito Repellant and 3F Anti-Viral
formulations. Based on the Royalty Agreement, the Company should cover all the costs to prepare and finalize necessary patent
application and other intellectual property related to 3F. Chemia agreed to support the Company in efforts leading to development of
3F intellectual property and it&#x2019;s licensing. Based on Royalty Agreement any payments received from development, sales,
licensing or transfer of 3F technology will be paid &lt;span id="xdx_907_ecustom--RoyaltyPercentage_dp_uPure_c20180814__20180815__us-gaap--TypeOfArrangementAxis__custom--RoyaltyAgreementMember_za9Fvb7DQAua" title="Royalty percentage"&gt;50&lt;/span&gt;%
to the Company and &lt;span id="xdx_900_ecustom--RoyaltyPercentage_dp_uPure_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--RoyaltyAgreementMember__dei--LegalEntityAxis__custom--ChemiaCorporationMember_z5vydKOIQZI8" title="Royalty percentage"&gt;50&lt;/span&gt;%
to Chemia. On November 27, 2018, Company and Chemia signed an Addendum to Royalty Agreement (&#x201c;Addendum&#x201d;), according to
which the Company granted Chemia a royalty-based limited license for purposes of making and selling fragrances embodying the 3F
technology. Based on the Addendum, Chemia should pay the Company &lt;span id="xdx_904_ecustom--SaleOfRoyaltyPercentage_dp_uPure_c20181126__20181127__us-gaap--TypeOfArrangementAxis__custom--RoyaltyAgreementMember_zZIO8sFf8Up5" title="Net sales  royalty"&gt;5&lt;/span&gt;%
of net sales in royalty. On November 8, 2019, both companies entered into Amendment no.1 to Royalty Agreement, based on which
certain expenses bore by the Company towards patent application and licensing should be reimbursed to the Company before any royalty
payments are made. For the three months ended March 31, 2023 and 2022, there were no reimbursements or royalties paid to the
Company and the Company cannot be assured that Chemia&#x2019;s efforts will end up in any future sales of the technology.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 15, 2022, the Company and its subsidiaries, Global BioLife, Inc. (&#x201c;Global&#x201d;), and Impact BioLife Sciences, Inc. (&#x201c;BioLife
Sciences&#x201d;), and GRDG entered into a Licensing Proceeds Distribution Agreement (&#x201c;GRDG Agreement&#x201d;), whereas GRDG would
transfer its &lt;span id="xdx_908_ecustom--SaleOfRoyaltyPercentage_dp_uPure_c20220214__20220215__us-gaap--TypeOfArrangementAxis__custom--GlobalAndBioLifeSciencesMember_z26GQVGAYaZd" title="Sale of royalty percentage"&gt;20&lt;/span&gt;% equity position in both Global and BioLife Sciences to the Company in exchange for 20% interest in Global and/or BioLife
Science revenue received from the exclusive or non-exclusive licensing of and/or the sale of Global Intellectual Property to a Third
Party, net of specific costs. As of the date of this report, no contingent liability has been recognized under the GRDG Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 19, 2022, Impact BioMedical entered into a License Agreement (&#x201c;Equivir License&#x201d;) with ProPhase Labs, Inc. (&#x201c;ProPhase&#x201d;)
where the ProPhase is granted the right, amongst other things, to develop, commercialize, and sell the Company&#x2019;s Equivir technology.
In exchange, the Licensee shall pay the Company a royalty of &lt;span id="xdx_904_ecustom--SaleOfRoyaltyPercentage_dp_uPure_c20220318__20220319__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zcDIe4uEolQa" title="Sale of royalty percentage"&gt;5.5&lt;/span&gt;% of net sales. Under the terms of the Equivir Agreement, the Company
shall reimburse ProPhase for &lt;span id="xdx_90C_ecustom--DevelopmentCostPercent_dp_c20220319__20220319__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zrr2mSM4isa7" title="Development cost, percent"&gt;50&lt;/span&gt;% of the development costs provided that the development costs shall not exceed $&lt;span id="xdx_906_eus-gaap--CostsIncurredDevelopmentCosts_c20220318__20220319__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zBsePHomEbN7" title="Development costs"&gt;1,250,000&lt;/span&gt;. As of March
31, 2023, no liability has been recorded in relation to the Equivir License as development of the Equivir technology has not begun and
no reasonable amount can be estimated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <IMPB:RoyaltyPercentage
      contextRef="From2018-08-142018-08-15_custom_RoyaltyAgreementMember"
      decimals="INF"
      unitRef="Pure">0.50</IMPB:RoyaltyPercentage>
    <IMPB:RoyaltyPercentage
      contextRef="From2023-01-012023-03-31_custom_RoyaltyAgreementMember_custom_ChemiaCorporationMember"
      decimals="INF"
      unitRef="Pure">0.50</IMPB:RoyaltyPercentage>
    <IMPB:SaleOfRoyaltyPercentage
      contextRef="From2018-11-262018-11-27_custom_RoyaltyAgreementMember"
      decimals="INF"
      unitRef="Pure">0.05</IMPB:SaleOfRoyaltyPercentage>
    <IMPB:SaleOfRoyaltyPercentage
      contextRef="From2022-02-142022-02-15_custom_GlobalAndBioLifeSciencesMember"
      decimals="INF"
      unitRef="Pure">0.20</IMPB:SaleOfRoyaltyPercentage>
    <IMPB:SaleOfRoyaltyPercentage
      contextRef="From2022-03-182022-03-19_custom_LicenseAgreementMember"
      decimals="INF"
      unitRef="Pure">0.055</IMPB:SaleOfRoyaltyPercentage>
    <IMPB:DevelopmentCostPercent
      contextRef="From2022-03-192022-03-19_custom_LicenseAgreementMember"
      decimals="INF"
      unitRef="Pure">0.50</IMPB:DevelopmentCostPercent>
    <us-gaap:CostsIncurredDevelopmentCosts
      contextRef="From2022-03-182022-03-19_custom_LicenseAgreementMember"
      decimals="0"
      unitRef="USD">1250000</us-gaap:CostsIncurredDevelopmentCosts>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2023-01-01to2023-03-31">&lt;p id="xdx_804_eus-gaap--SubsequentEventsTextBlock_z2Sz8xAAJSI" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
13. &lt;span id="xdx_820_zURC4ecPyPBa"&gt;Subsequent Events&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has evaluated all subsequent events and transactions through June 20, 2023, the date that the consolidated financial statements
were available to be issued and noted no subsequent events requiring financial statement recognition or disclosure.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>70
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MW B_0.P-4^@5+?6%9E*HU2C'DX&.N_ >S3C=4M$06.FYG>%+(@;$%?P"+R5
MJTB.J\C;6CSEU;XI7L@7T1Z**?>QVQ&'<YY+7L](?:&95)Z<DHY+52+GR]QK
MEM(K6NH+S61/JU)^YF#6Z9 9Q7+F$3K=M6]43WV:_&A]RW%]>^'!-8[JS!1P
M  QD87QU:E*EA3''A?%WG83CV,Z$ :E1Z,3<5Z\F8UID<Y<T*T+.!8?&"#E0
M;A6Z\SSU:I*CY3G'Y?EEA_4XJ#-5MA0'#_5]]6I2I64]QV7]J,-]',.9&3OC
M"Q8!^.K5K#K26CW$L\=CB@5P"%=B0OL(':P9\-6K28Q6X"&NP+'* KRI,R'
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M@<,;6>VZY^KO*RFK;?=R(S)%66N@OG^HE&3NW[2/ZA]_R^'F/U!+ P04
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MX[[ZG#_]0W8;\FN\3;XOF_^=IW9LX,Z<S;&L\K2;K%:0)EG[-?[:$7$R0>'
M$W@W@;^<($8F>-T$[^6$Q<@$T4T04RWXW81FZ_-V[PUQ85S%5Q=%_N04]6B%
M5G_3L-_,5GPE61THMU6A?INH>=75.L_*?)]LXTING=M*?5%14)5.?N_\>I!%
M7'NS=,Z<WVY#Y]W?WE_,*V6TGCK?= :N6P-\Q(#G?,JS:E<Z4;:56V!^B,]G
M' &8J]WV6^;/6[[F*.*GN/C@>.PGA[O< Q:TGCZ=0_O!IX=R@TZ/ID]G"!E>
M[W^OP?-&_5\J;\?9UI%?5?(I97D.^;@%$3!(G<S.RT.\D9<SE:U*63S*V=6/
M/["%^S/$+R582 D6$8$-/"%Z3P@,_>I6)<LD>_C)>9"9NO#VC5/BK;KFD[*J
M+\1'Z6SRM'92<U5";FHM^(V%^HAXO!*N^G<Q?SSEWQS%N&<,"]'EVC)KVO16
MRU.; \[\GC,?Y>RS,AP7FYWS8YP>?E8'Q*,Z^0YU!H/8:;$6I_L.5B8]P+#%
MTJ3'!UCD"V-<!,"Y2W=TZXM^ZPMTZS=%?B_+^KQ6H5+3GVQD">UZ8=CG2R H
MS&$,V$V(+LHV*$R;OL]'F0EZ9@*4F5 JVYLD;@N1^B)*\Z)*_C=ZU033& *&
M!4!<F,,88^;E%7U[W&#WRW[W2W3WOU8[6?0YI$OJT*Z7AGTH5YBCF##WC"[)
M-BJ A8T'Q:JG9872\N^\4G1LC-,.8F9E+&#)@#QA#@M<<UB(KLN6&].FQY;^
M*#O,U66@BX=-6^QE#\X^+T%6.H!3VV<@+]! D!E\2;;40&9Q<DYJ9(862>TU
ME63J^)7.NRYTWH.%4H=$5"F1HH6D:!$5VM G7/N$HP'[,:NDPJTZMX"^X.;5
M H2K.6H%''SX<JS),XVR!1*JNIQG:(TZ$JH@.YZQ!*#,6>/VX'T[8/215NK
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MBMH?JOS0O(7G+J^J/&V^W<E8R8-Z@/K]?9Y7SS_4!OI715W]'U!+ P04
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MWI=2O^@H* LO6WK3J%AY[W4D%=Z%]]N7P/OQ^Y^N^Z4V:KKVYXV!V]H /V)
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MMRL5+51N&NC_+S-]YVT^& /[QTA-_@=02P,$%     @ Z(KX5J,A"N_8"@
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M63B#>O" .E?K:BFH;IY(;:E&H(@I" $))!4AJ+->Z6R%?&WG$$96KM3.1=N
MYF1N;$44"RY>C>NV':)\@E ZX9NYLEE3&( I84&K1=&HZA<Y$M\69@Y7P??O
M]$*UF(E^#R]%?-EB@#1GL)(W>I!*GU\Z[#EW.M?2DL?8@%A$)9^T)*Q"WRR:
M(K)8PN]UY[:$2SA4L!FA!(\;&QA(N,*]$$_T4]'#]#L$VEQF]\I&^>!.\P7&
M:"TG=0D3= 874C05+&L=- ,?*VL%(&<!&#5<1_W+9?)$8Q\)EZ^ATU):ULQK
MWW@EX/$"#FXED,H;IX9Q_TM(&&A+U'M] J7$PLJE)13ND<YN6Z&?W#85=Q^0
MZK9=G5 [T10<84\OV9Q/],-3\0TBY$';\0=5&OP"?6)>*+PEC%)R )/:%)MZ
MI2H4<:CN]++"MI)\@C^O2YU9,Z=<'\*'MAB)K3'%9Z2P>Y60I0&[7$?99 WS
M2I@5%N78@(]R"),CX#OHH=% >+I:97H1+0LX$JO>!JVIA5/JGCUD%@L\AR[@
M>]]+-*V+$E-S5@!5L&U=J%Z4]7CKGLY@3.V>F&^ZX 8&)3SA,IDSD"D>)%I-
M;Y 1 +X:"15:Q"L-VX8]";3=?LE;W^Y"^P&@N;; '>!=P6+.LXE^S7R$?6F7
MBH7YC2:$B@%JXD>5K.2#VLDDY%Z!SOD$$#,(OR'=B&6Q0>X#AX)6#3MXE"8'
M8] $<+?6WHUXSEP43WE#\708[\F>L6OC(+_;W3V6@C8IE+#'$DER:WF&WP_;
MA$(FK4/1*S8,$3(4V!<ZXQP9I=C/8 )51<X+C;:5[/'%H"()RNZHF$-QMZ;3
MRQTQV$MUO3?;/,<^^!O<HE'$WE9+BU"AIF@HWKV[84B0?Z/]J4@,$V"D6:":
M\G:DZC)8%'[U5L^;MJP1X:'<,A(?4>!1FTKD;'%.O6!Z,>RG6E$W2(W 2"Y.
M)^(B'4XF$W&>CL[%-H4D70H1O132*=NEG:?[U@/?/0NBQA42129P8(M\'MV-
M3N8LP0U.?EI"-%NW2]I-PJMMX[#-P(QJ&/47,.@R(V6 )#,-&@A$FG%(<=[$
MZM8%15O1_J'O)5OWC:J6#5FZ-%1(*5F(MA] K!4QLX4:+&:W'>=>2H[X)L25
M2 C)PIIR1T:CD4,=ZE#& N/MW'CT)-@$4J^0 UNN0/>#T?EH+XZ(=0_"J'\E
M"G)@#P8,=98!8AKD!&B1L*6##0%$1=5/2(^NO/9[D3"['8EKP@6Z261VROW6
M+*@;8UE]4#Q617BP*,1<04&@&A<>P*_VY273AKT3H,TUJ!A=-E.V="V"IY,3
ML4&I%M^;#5JRC;A&C(16ZPDUMR)-GX[:<M7^#BECR%Z!XH8 GL^#,?%VK@H-
ML' ^(5F;# !QBZ:@-$OE"VQDT74]U;9-<]OMPBZ2C ).VS(WY&T2@OH<R3CO
M,50+)%N9H2U<HN- "N_*C-_4RL5:L==I[?9W:TFU((L!H?*V;>4C%3'XH!YD
M+KD44PHY"<[:-D65^)AY0]&?GG'XG[,[=J-R@086\K+M8^''Z9&31C)+G=_/
MI:X!V06GBG1Z.IR</1N>35-Q[9+HR3Q*QVBT"L)[AAV7F<IXL525"@I1JJ>B
M1*#@SKE1$6JF.XZ,4*)082NF;"0"S2M%_#KX]5V:4(\W;QP*. I'G\O'_@O-
M[26C&+BPVMV3J1$LX13!>G1F:GOVT,)U/ @,M@:MHEX_*YJ<HHEJ%I7Y)$?O
MON%B3B*U?2@0 [[<-E#QDO8^U&W !79R='I9ZQP>4ZC]ANI=;M94<D@%/L,E
M^V>X</Z&!(0N!M;N^;P'J:ZWSKH5E(>ZP[K;'M;96W,*:-3.&BF#X2<SP#'G
M7,=9A>Z19UGQK0C!P06J+=ZK>@O=Y#..([AC!+.HUTA?\'^7ZJD@B&^OKS^U
MV3[ [[_+&SQ ?4S12N7V3A;A9.4=*NL7M#7(,3 MQ0 ><Z=EN*'NGSMVP=^3
M@MVO?3Q,AN,!0@\,D?J-I5R,]AA5]>W[3]<W/U!5+'<.T[3I7?^$0TG.)4#C
M35_7@X,4\NC_9I%.>-D]"I'*GH1+3$[)@.Z"MB1NVZ5T*Y.PDKDL8#RSQJ'J
M+D->:0H>*D"5G K+83V2#[)4X6#>TZ4S_Z9-=#96XR\-@@TV[*8$76[D!UC6
MFU*)-S$-_<>J,%2FFVL?&BE);3G-&Q!6/IJD_R[9UK3=B4A,P-? ?B'2T&(]
M%Q>3T87X.OXDN_7P(.&S2,BMU]?QIVND[JBO8[I=LNDLYO3=_;Y#L[()1#LT
MS;*!<NGS2+2[5Z]G/2#@;-+N=#HZI9WXI]4L;'5GBB:.CWKT7?L9MKT0*<K&
MU_%_*!GO^7C>CCJ'L1<+!:@;88:V52[1$W"S7]'$)$1L./5$WU')5-0_\4C@
M+V(ZO$A#K9H-TS0TN(?FA<>)VW'B=IRX'2=NQXG;<>)VG+@=)V['B=MQXG:<
MN$V/$[?CQ.TX<3M.W(X3M^/$[?]YXG8V&YW]@8E;)/M]$[=(]/LF;G%,]\<G
M;N?;@=N!X1IA#5?I'QVS;8=KL^$L/3TP9@M?THU[GX B#2WYRUC*C8B4\#5H
M][3[^/::OSD=;Y>'+W??XP"&*H^CT0*DD]'STT$85;4WWM3\02G:/6]*OEPI
MM(B6%N#]PB#\XPUMT'V2?/5O4$L#!!0    ( .B*^%9,L09YEA,  !1B   8
M    >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL[5UMC]PVDO[.7R%,#H$#M'O>
M'-N)7X#Q.-[UP;X8'CO[X7 ?V!*[F[%:[(C4C'M__3U514K4C&;BVTO6P&X#
M0=S=$LEZKZ>*!?OIE6L_^;4QH?B\J1O_[& =PO;'PT-?KLU&^[G;F@9/EJ[=
MZ("O[>K0;UNC*UZTJ0]/CHX>'FZT;0Z>/^7?WK7/G[HNU+8Q[]K"=YN-;G<O
M3.VNGAT<'Z0?WMO5.M /A\^?;O7*7)CP<?NNQ;?#?I?*;DSCK6N*UBR?'9P=
M_WC^@-[G%WZQYLIGGPOB9.'<)_KRNGIV<$0$F=J4@7;0^./2G)NZIHU QF]Q
MSX/^2%J8?TZ[OV+>P<M">W/NZK_9*JR?'3P^*"JSU%T=WKNKOYK(S_>T7^EJ
MS_\OKN3=[Q\=%&7G@]O$Q:!@8QOY4W^.<L@6/#ZZ9<%)7'#RI0M.XX)39E0H
M8[9>ZJ"?/VW=5='2V]B-/K!L>#6XL0UI\2*T>&JQ+CR_$.T5;EE<V%5CE[;4
M32C.RM)U3;#-JM!-5;PW6]?RMW>NMJ4U_NEAP.FTQV$93WHA)YW<<M)I\=8U
M8>V+GYK*5!/KS^]>?WQRQP:'8+OG_23Q_N+DSAW?ZG9>G![/BI.CD],I@NY>
M_M*4_?*3.\@Y[55QRON=WK)?)O,DY>*_SQ8^M+#U_YD2N.SW8'H_\O\?_5:7
MYMD!'-R;]M(<//_VF^.'1T^FF/V#-ANQ_J!G_<%=N_^A5GCG2=-\_)<+1IW,
MBW^4C.*C-PJ+C \6D04_?%@;A?VWNM4<K?"P=(W'^Q6>5\72-KHIK:X+'_ #
MPF+PA6WH)8K,-NP0!\*Z^#B_F!=_.3M[AXCY6V=!,9R_07BE%45P^/;)9.<2
M?=HC)&_I6%^$M0Y*+Y<(FOALL O1#@+TAECR1!C>-T&6UE8O;&V#C5M5UI>U
M\UUK(@?$-IU\VQK>D ZJF)SX9:%K<&L4ARE9-45(:RY-T\6CS6<D*H\O5=>2
MK ?JZ=O6M-95?@[=A Y2A& 0MSU([&HB&QRWQ;)U&UKG,PG-BY]TVV +K^Z]
M<=Y_1UL5%VL-%E]H;TMEXO/B7MT_]_S<TOZ;;4=D+W8XY=)6B;0&"=<V>&S2
M.AU":Q==T(O:D*;H+3S?P!H0U<M/:U=7IO6TTQ4G&Q+&I6FAW*+I-@O3DDGQ
MR5ZD/ZPMD(]A. T?GPE(Q#(O7G5U30363.N7<53;3Z0IB&#,B!I>-Y]+LPUL
M5*)DTSCD)!U<2UMA&8"$QUY@%U_JKC(B'&:';:VJ+%DF5);X$09YSRO6WAI2
M*!;&-#F7RHHI;>&JL,(;Z]>ZDC46UD^2A G%);>>>67 $PL)2&)./HOO_&/C
M^M\S5[4-8G''OJKB,6 \5P5\EX\,Z]:88B/IRE"Z*I!LRG6?;6@AI0VH2MM6
M_:+KCEWL57_8Z^$P>>>2WX&8 5(0U,C/12*M+4TNOP4Y2FE .RL"D*F&.,1E
MZ=RMMOP >:7QY">Z]^$=Q2"\ZUJ8)BR(7]$"N!8F7$' "A'R$S9": L(?EM-
M!$9[V$#[B!4<FR@ L$R9^D(X?)N]\,%M86HQ0@Q\9\'V@L2JV\H7+QS^*.Y]
M^\WCDY.C)Z_.+E[PQ^,GWZG)]\]=Q<&;"4_+SB[.TRJ*!_!+BX $XD5=]Q'!
M$#.(6!'U&M]):?#/M87N(&C7PI+^;D3PMH'C^**#P2N(39AG*^CW$ $,&ZV@
M%%F\AL>#B+3ICA32-;KZ%9 />ONM<_0'ZY83@\#=0H3OV=!L19Y00F82C15^
MRX/QO3>(IW5QG*N%XA(\@R@ ?K])@%M02N20%=F+NYR.=V'&$%=)9C[Y^H_%
MM]_\\/#1#T]4/'F6V^K-K7T'J>+)F-DQ:YG/W13#_-J!)Z,#XRD.S))7PJQ_
M3ZKL1!SH+"^JD'#+ #\@DIKAV\#)F 65L>#MQM:ZO9L!VO@N[F_?YP;)C0MQ
M\R>*5#R6S.E(,E-ZQIYBYK">@)]Q=./B,>3,&M'?^N!G9#PHM5QK(B817%00
MS6)&%1WIMH4E!J^:')#,5)(8^8<6D()8P\&*\W7_>Q%,N6[L;YW)B',-4[:A
MTWT&T9*NV]&OXL<5[0XK)2GEG+,-JU*W[8Y9B$"D1R8X- ,OA135E(BU7[,7
M\0<2 <XAO<P*AGRVPB<M8<DC3NY8S(S,RK*EK-%C&[W=MNXS(Q.519Z%*37"
M2@J.=K,QE<4[S-\:U-T/IMU .:%CUY7W_"VY2H)0MCU>A[48'].$D#=0XA4V
MP\N]9&153#>,5SGQ$3@D'O&MS=&>[%TY*O*I6N=CH(UH2T"1DH\C8>< (+K9
M46@^?O2$=(T8&23+:C:R$NF(4DSI?$ADC-D1[H>5[&G1*:BW8>&U^E+#D9+>
M)^71ZRH3!EFQNE,4%B)H*922%!+3_@ZN7[]]=W;^0;VPCO0*/Y\AVZ.6)!.Y
MZ!8>J%*W%,&I+H$V'&24U0Y#KKP8:H=SV**:,DHV\BACKD$LHTX-4$ Y"(*I
MX6.VRN4NM8>^9F 9I*%,8WR?]RNV3:"[$CMY*][K"(@0-2JCYCK*>IT=FGVF
M?$JK<+0W)=% XHA4)856AKP PB"5#>J<Q5"8;),B:@<()L@L[KHQ8>VJ63$8
MF&$3RZR"3E-=@]-JI/RJ6&GXE%0\@,6FSWH<*!+$!I[#<=.D RA^"?4"+09+
M]BHGD'Q@%H4/A5KHU;;T(H)/W;%FL"D^")00R;:F9LN!3K+ GX$[WR-7KS<F
M3SL##S/%\O^')*)&8L]-3?A-]MF:58=3:_IT21T[SB&Y97)Z$<E!16L3D[N1
M8D;C84DE/U$P"JA .XJ:B0F7O5Y.K>)L:B-FN$^8 9%V@WR@V]V$9HHKB ;U
M"(+=%5M\COPNX"[DP,5#%NZR:VE315&S\]P$Q7\9:ZCSG:NN+!PS?4"5(4:+
MNLO'(M!S#B(\7W)#H$J)UUU&$Q]'MI36D(21&<4(4O6>=KA9QB-ABQIUL>@\
M1.,1!-UF0<4>2,]HM83C%K]R@\%E]HCT[:5E$F"NFB)WTZ!4ITB,XW@M @2]
M%9TT6QMKC;B$7X*E, 1007^B4%UKY.2L]%TZ$C#0%.H2T\ZH^"-0<DG;N1)&
MS+Y1VK;L-E2O$=@JH>#5J'8BE%=2-.-J?0P-$ YW1++0::JYHD*D0%D1:YG3
M[X^  -PE(JS/$!&[#>WGMBDR+FWKI8GB"3O"GQ#)N=B$/[KV=C,7$&8(CU"_
MZ9*#Y0V^:FKGLZ*',"-'LWVSZ3*$HIJ?RCP"QQ0U^\K^F@UEG9>ND?4<@G@A
MN6@2E1)1P?JI@1 !P12#*1-%*]MNZYUHDDR>DFGJ'Z07^S[:1I>M0T2DUD.9
MY=49*0\AK]UQ'KR1=V?B/(D :8HEZTE&/F/C)%>B!#G J:UI^<8D"CY?0K$$
MRY:0,S=3:I-V5:)@B<XBM5ZIU9^OBYA05!Y@V>U@HZ6)D8"40V8JVB')<VR<
M4ED"5)4Q%!Q\MUQ2]U/ZD)!SZO=,D:W&[3LF?))K"G6F\E.,T*X4D% #W(</
M; 6F:50%EI%T;<68-OI3*DGZ8D*P_O"]Z(*MN9(GH4F[J]_N7H9L&4XMD3WP
MHJYWWL;:-_;-8@43F[-3O=F\'NF[D.I:GW86S1UTSRC:@/Q4ME(.G17#O9=T
M JFQ3#E\VRUJ6TJGAA(O/VHH6PLPBXP(-$TRH@#4 =F9H=<942O+[68[,F6=
M4F]A%+4X2;]VU;HK F8#.R-@3\G7FM3WN+55K:B/0NI#',]3P>!#/J(U[5W3
MEU0+[C?2?6""]\GS;2-WG-A\!F>E:K"U45_<Y4IUTX@*:2!+.UF,"0YKM;13
MJ:M,- &RE\ ILA<VR4R=N^9YS.474@3GHCJPS0T<<N=4TDXU+\ZRNDK=M+X[
M[P&(0]?YT0V 7A#N%'T#W=5D&F[+\13*AJQ6EF.CJ%9*4T1,O$T9U[7D2VJD
M^*CO5MKIYSV)\)Y?3823I*E164^%^PXF TU4*Y,W_AFVDK-&RR!Y$5QM8S=[
M<$% 4(K*+$]J!L@A?4!=[#*9S+F2@JQ(/C<VBDNY31'1AR'/OQ:A*,*O1OS*
MA4HF^MZX1[:YZ^.:$_"!H#HH' RL,O@4&VM]0W= >U,@)%NL)B!?O$@I':+.
MWR.T(\@^_#!]<Q-/&PM@#@"+L@RH8F7A6>I,UG(HC=JJKI_=@TK;KQ/AK$S#
M674WTAF[;[>% T<3[3/[ N\O;=8F[ -.*G,5ZY+N@-*1W#A;VMC72N?W/-]>
M['$PPF,(N0TLIR1;O#+PBABU[&H(#AJ?J[.;K*:CI%2EU,)M-QLHTRW-T*GK
MSZ'()(11P7,3"D_ 9Y*S>FE*P[<JI\<%GD)1[\$:!6SIY-/ET1LDDOMOV FC
MZOYF4E(TJJ:G-3^-5"=)PY/A,@$E#P6;K=#!@:WGY7**[=FP@PY2W5WC!H&P
M,219@:X(B&H,73, 'G'$M=[+$+.--%F28<?4,7FS2LB=Q"Y7(R(E:@2]2G";
MO/IJ )L]^AQ7F&MPQI=,>I3643WRO5?J&,8$-$"V>/DRN[8NEA]QU96FRDC)
M-8VE@]@-!:=4,\H=4\NIL5MK;E%7=-_,3A1E0:,#P:QVL;K7(=%QRUX# QG$
M5J:YM*UK!,8F!4M?<@OY)8V<__S+ZY?WCW^ [F'T6#@O?@8-0_X>8DQNIQSN
M;U@BZF)74UC-B%2_(G7TMAB=,F$[;T9((;4>G5 PX"S.'/C#I,@M/2!6/!56
M82C7\BRZWFT)D'%7/MZ 204ZN@9#>!C;%)VS04TR)#=R@%1-D'ZO"8.O+<<U
M=-]6&2%#Y$)JP2,,<O]5;LYG,9\S8//]34\?4CD$Y0[$6/\6*,)"&HK0>)D:
M'*.$%!%5C-I9:G5\@]@U&8BF6V4)OT.E,I';_(@V-E*V!J;2N]DUW$1-ISQ_
M*IDK2 &!S4]=?W\$W1)L3ZKB,K3HS0R"C!E%B&2J@ :Z+0PIV1_=]UV7P:R7
M6[\N:^_'(C/;@-_H&^"C)#-"TGU3+,]S,97<DO/&\5?=C+_1]67ZY/\3BF^+
ML2]''8B(3K(\1:$N@?CL7K+F>RN\/F(V2\7-5)7F(W1GM1#NS*Y11'_L82"7
M!4#-)6RS==*TGJO\@IHC]V[*XD;TW@+7;HI(( 6=G;<)7^1[=1!\&S34R/D[
M>3CI8BVE1^R!-X;Q=M65B,E1EWEHQ@DUV23PI^"N8(J;\4)$E.V5!FCZ^D?A
M*-?<9_GF<:*':_T@SGN$8+KD9B]\*=":WQT]J+(',4CQ7 G?A\5;6\!EZJX5
M'SC4M'%Y,;V<+Q+^HSA^],/LZ.BH.'[XF/_\,ZY8WO.%SO3  4'B+YMAH)[A
M=S*EXON";7+!QZT,47'WGEM*,D04 #9"GP<%T-)C*M#%>I0>]LN[_.GVA63N
M#3>Y6/O9ZS"$QI$9QIMF&7-!:<6]SJ'N(D_?P::-M-%H?N8GJJ#ZR[CQ1JC<
M8H^F)#^>#5 *$2CU@G7EMG&V*NM9 =^S=XT':.B6IS&W'4=.2D95QEL/'BG2
M?3&OA.KD=5F;+P:"63]0A@-BM<RE?#O*=,LQG3\WQ7]J@/1VI^)4Z/AV(_&G
M-S(2E(E]U<'RJ+D89U6*LXN/L,WYR='QP_O'I_SS\?&3XAR>@<+T#=^WQ&D6
M,EULTE&A_O- *QG'7QQMCN<PC*9XV1DEDUGL85D;(-[?:/(GFA;R,(N5=/\R
M?J60[Q=Q).7["_Y&5A!KR526;JEN"5>.*__8DB*F61S<5_C=F<AA&$S&*4UL
M&DF+->:E47=3IA3EEE:C5J8W2Y$ V;^$;QMKU:0 HH1N>NI8Y/<YC/%I1)$F
MPU0>,O!+W??D\EHZHNB&VD]$3]=*$AHZQ@)8I[E7&?>58T=+U8@8T7"O%P."
MAZ$31A[N>JA KNG&)PU!W3'H&3%QL:&F'[EA8RBAD17[-6<#!LLTG10G&>^6
ML%-W/!\[! 4!P[?G7$PZ!HY;D0=2%"J &)(VB$.N97QA(KGF<Q ODH(E7E2'
M->#9:BW!0L5@\4  U\N+"[ZK;^1NI*>2VZ%1K;FOC[R[WUE+&RO-ELK=]_7I
MBTR%E*#4T)R4:W$)J]/S#UES*:.6;KV*=%G;:^AWM?&VWRSMKV#CC4]OQ)L*
MSR(,V2S7=!L:/QG"FLGJY78V(&88F<.-G0.;0&X@HZIY\""TKJXY3Z4(HCB%
MCR"0]3<M)%TMQ"L3C_0=M,R 5JY;A$1(JJ'NEDE6Q(/J2RM=UZF!^/T@^7Z0
M?#](OA\D_YJ#Y R<X@1YUO$5=!F'R(_W0^3[(?+]$/E^B'P_1+X?(M\/D>^'
MR/\5A\AS:N;JPWZ(?#]$_F\U1/YH/T2^'R(/^R'R_1#Y?HA\/T2^'R+?#Y'O
MA\CW0^3[(?+]$/D?.T2>SPKJT7QU!I._\%;B_8U!WZF!])10S<08\#]O(%UE
M Y%?;R!=71\>_AH#Z6HTD%Y\S8%T-3607GR%@70U-9!>?+V!=)4/I!=?:R!=
MC0;2)P9,_UD#Z7DF^6H#Z>KZ0'H_G[D?2-\/I.\'TO^]!M)G)R</921]=O3X
M:#^4_J\YE'X#_?[?Y]+5,)=>_#ESZ?OY\/U\^'X^?#0?GOQ6#7Z['Q'?CXA_
M^8BX_#7GA]E?O+\Q[8K_/0+&+$V0OX.__[7_)P_.^&_Z/QQ>EW\OX:TT40$S
MEUAZ-'_T_4'1RK]!(%^"V_)?X[]P(;@-?UP;79F67L#SI8/QQR]T0/\/03S_
M7U!+ P04    " #HBOA6IPQ($\H"   ^!@  &    'AL+W=O<FMS:&5E=',O
M<VAE970Y+GAM;(552V_:0!"^YU>,W*JG"!M#TB@%)""IFD.J*.GC4/6PV ->
MQ=YQ9Y<0_GUFU\:E%2$7O(_YOOGFL<-H0_QH"T0'SU5I[#@JG*LOX]AF!5;*
M]JA&(S=+XDHYV?(JMC6CR@.H*N,T2<[C2FD334;A[(XG(UJ[4AN\8[#KJE*\
MG6%)FW'4CW8']WI5.'\03T:U6N$#NN_U'<LN[EAR7:&QF@PP+L?1M'\Y&WK[
M8/!#X\;NK<%'LB!Z])N;?!PE7A"6F#G/H.3SA',L2T\D,OZTG%'GT@/WUSOV
MSR%VB66A+,ZI_*ES5XRCBPAR7*IUZ>YI\P7;>,X\7T:E#;^P:6S/T@BRM754
MM6!14&G3?-5SFX<]P$7R"B!M 6G0W3@**J^44Y,1TP;86PN;7X10 UK$:>.+
M\N!8;K7@W.0>K5,.)<UN%#LA],=QUH)G#3A]!=Q/X9:,*RQ<FQSS?PEB4=+)
M27=R9NE1QBO,>C#HGT*:I.D1OD$7WB#P#5[AFV89K8W39@7S0ID56E FAVMF
M8I@3<],<%GY-%]:Q],CO0VEHG P/._'OYM+6*L-Q) _#(C]A-/GPKG^>?#H2
MPK +87B,_:T*'04?EO:5',*@!WO,\*U R4=5*[.%0EEI;(<L_88YN$(Y4/("
M.^L36LHI@E0+JP5R5S'())=4ZEP,<UAJHTRF50D=TH*6"M0U4\U:SD ;(,Z%
MPI& 0ST@0W8R3@!]E:PW\<X8:^)02?&NC<@302?X+./)(M#.J RN:\5N"T8"
M[<&- 8G]2=/:EEOQ;]=B\*;04\_'"!M)AJ'.(>P<BE(O//?\_VGQ^5L@FEU
MXL$W79M <<=4P7M(8'B>GB9) H>Z)-Y[TQ7R*DPN"Z&=F^?=G7;#<=K,A+_F
MS62]5;S2TN,E+@6:]#Z>1<#-M&HVCNHP(1;D9-Z$92$#'MD;R/V2))'MQCOH
M_C(F+U!+ P04    " #HBOA6LW!F-=<"  #L!P  &0   'AL+W=O<FMS:&5E
M=',O<VAE970Q,"YX;6RM5=ENVS 0?/=7+)0B: '#.G,@L0TD3IH62 HC0=MG
M6EI;1"12)>GK[[ND9-5-;",]'FR>,YSAKI;]I53/.D<TL"H+H0=>;DQUX?LZ
MS;%DNB<K%+0RE:IDAH9JYNM*(<L<J"S\* A._9)QX0W[;FZLAGTY-P47.%:@
MYV7)U/H:"[D<>*&WF7CDL]S8"7_8K]@,G]!\K<:*1G[+DO$2A>92@,+IP+L*
M+T:)W>\V?..XU%M]L$XF4C[;P>=LX 56$!:8&LO J%G@"(O"$I&,'PVGUQYI
M@=O]#?M'YYV\3)C&D2R^\\SD ^_<@PRG;%Z81[G\A(V?$\N7RD*[?UC6>\,S
M#]*Y-K)LP*2@Y*)NV:JYARW >; '$#6 Z*V N '$SFBMS-FZ888-^THN0=G=
MQ&8[[FX<FMQP8:/X9!2M<L*9X5AAQ7@&MRO*"XVZ[QMBM6M^VC!<UPS1'H88
M'J0PN89;D6&V S\ZC ^C P0^V6D]11M/U]%!Q@>F>A"'78B"*-XEZ##\!M,6
M'AV0$[=7'#N^^!^NN&9(=C/8+_E"5RS%@4>?JD:U0&]X?!2>!I>[[/TGLM_,
M)JW9Y!#[F\P>9-BM[XLTV(E[\))^,]'!S005-C YTD\A0EEG%MK, LJ+-&\3
MHPM<I,4\(TS5L'*Q0&&D6@.K*B57G,H$%S-X!V$2=(,@Z#"1@17EF.P@PP55
MPHKJFH$I6BY+9"3</=[<=9Y2CB)%W87[^U$/WA\?G4=1<&G77#>\_- %1HP%
M,R2P8LJLNZ\.3V)[-O0Z&_>M66: LA7+":HV8T%.K> @<8)KCY9GK^Q4:J-;
MR?L.AUV9]K>13/XDDFN2W43PE=F7051X*(JG+H@;2TVS*^G]K8):HIJY=T;3
M3<V%J6MK.]L^95>N@ON_MM?O("7=C L-!4X)&O3.3CQ0]=M2#XRL7'F>2$/%
MWG5S>HY1V0VT/I5T8\W 'M ^\,.?4$L#!!0    ( .B*^%9E5/=E9 ,  (L)
M   9    >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;.5638_;-A"]^U<,E"!H
M@(7U96^<7=N [6V0'+8U=M/F4/1 2V.+"$6J)&6O_WV&E"4[6Z\1%+GU(I+#
M>8_S9DB1XYW27TV!:.&I%-),@L+:ZB8,359@R4Q?52AI9JUTR2P-]28TE4:6
M>U IPB2*KL.2<1E,Q]ZVU-.QJJW@$I<:3%V63._G*-1N$L1!:WC@F\(Z0S@=
M5VR#CVC_J)::1F''DO,2I>%*@L;U))C%-XN!\_<.?W+<F9,^."4KI;ZZP:=\
M$D0N(!286<? J-GB H5P1!3&/P?.H%O2 4_[+?L'KYVTK)C!A1)?>&Z+23 *
M(,<UJX5]4+N/>- S='R9$L9_8=?X)FD 66VL*@]@BJ#DLFG9TR$/)X!1] (@
M.0"2'P6D!T#JA3:1>5EWS++I6*L=:.=-;*[C<^/1I(9+5\5'JVF6$\Y.?U,6
M#3Q@AGS+5@+'H256-Q=F!X9YPY"\P)#"O9*V,/"KS#$_@U]<QL?)!8*0Y'2:
MDE;3/+G(>,]T']+X"I(H2<\%=!E^AUD'3RZ$DW8I3CU?^@+?,;D&_IJMC-6T
M=_\^E^B&9W">QYWG&U.Q#"<!'5B#>HO!],VK^#JZ/2?R)Y%])WG021Y<8O^A
M7761X7Q\CK8WZ,-S>OA=]C[@2M?T'X*DJ1Q]/Y5$8&'.U3WF/&."3))JB]*B
MQARXM H85%J5W!A%6$G$\,N;5Z,DB6Z71[M;$&)OCV_?TA&U!3!)!#G?\KQF
MH@^?"X2%HA7EOB<4D\1OR51I+C->,>'^DZ#6\)J"N[Z*H@BN^T.8U1LZXQ"_
M;W;;LW%*GZ'W;3''<=.>*_Q_3>SP_Y78QC=^_^Z[!,>M.?(MZ;]G>X@'K?2[
MQT=8UAIG7!]$MZI.9EH]5Y2$7:&$V(/:N<!-O3(\YRZ;%+$]*KMZGKM,R2UJ
MRUT1CGGL7<QC\BR/('C)+7$*SE9<<+LG6K\<W;\;;MH%?2#&,J*@J#[C$S/=
M&G.EZ>QC)\G7H_>OE:$@#!6.;39$[9B.]5DQP62&4%= TEZ#W[E=H4[2FT(\
M@ICLD?,9Q6=V>/,W"D_NNQ+UQC\##(FKI6VNOL[:O31F_H(-C^[-,X7NB@V7
M!@2N"1KUWPT#T,W5WPRLJOSMN5*6[F+?+>BUA-HYT/Q:40(. [= ]_Z:?@-0
M2P,$%     @ Z(KX5L(0]+7^!0  D18  !D   !X;"]W;W)K<VAE971S+W-H
M965T,3(N>&UL[5A-;]LX$+W[5Q!.4:2 X0_93M-\ 8Z[W:9H&J-)NX?%'FAI
M;!&A2"U)Q<V_WT=*EI74=8M%C[[8(CDSG'DS;TCP;*7-O4V)'/N6267/VZES
M^4FO9^.4,FZ[.B>%E84V&7<8FF7/YH9X$I0RV8OZ_:->QH5J7YR%N9FY.-.%
MDT+1S#!;9!DWCY<D]>J\/6BO)SZ+9>K\1._B+.=+NB7W)9\9C'JUE41DI*S0
MBAE:G+<G@Y/IR,L'@:^"5K;QS7PD<ZWO_> J.6_WO4,D*7;> L?? TU)2F\(
M;OQ;V6S76WK%YO?:^KL0.V*9<TM3+?\2B4O/V\=MEM""%])]UJOW5,4S]O9B
M+6WX9:M2=G349G%AG<XJ97B0"57^\V\5#@V%X_X/%*)*(?I5A6&E, R!EIZ%
ML-YRQR_.C%XQXZ5AS7\$;((VHA'*9_'6&:P*Z+F+*_5 UB$MSI[U' SZZ5Y<
M*5^6RM$/E(?L6BN76O:'2BC9HC_=K3^(=ACH(9(ZG&@=SF6TT^(U-UTV''18
MU(^&VQS:K?Z6XEH]VN'.L$9W&.P-?XYNATVD9#<N)<,:T^SOR=PZ@VK^9QO^
MI?G1=O.>X2<VYS&=MT%A2^:!VA<O#P9'_=-ML?\F8T^0&-5(C'99_UF=[53>
M[MHG[:@U[CX!\T:UD$+*Y@!Y\":DL=]A5QET';L4^IH2$7/)($R&$B:4TXRC
MA<UM;$1>-I:E(?+FV"&2Q5X>'$=1__2V*3)9BX3%P>DKD-:EU0;LCN)4::F7
M@FQK8@5G,QZ+A8C9>RT3H9:6?129<! ]K*R7FFMK';@D*PDI^%Q(X1Y9K!&&
M>H3/L3:Y-MR% )AW\M(()VS*O@JSQ-25E5PE*+F\,+;@RK40YBH5<1JDIY6E
M$&G"L :Y.$4S9.-HS$;=-V_8T3#J]/O]*J;60J,7D64(/N.J6 #/PB 4IC@^
M@&AN]%QH)^+&KFSKKBL!'B3"H(_+1U@S]^00<?) !C%0QYO*D-L.A, ,,2\<
M,83#T/ME*X84SJ8UUI!-BAB9QU:^,J0D8[OL#OLUE^;4,):P^>,3CX"H+!)B
MFRP,7I]:-ONS<&QF*!-%AO]U?*B(P>O1Z<Z_/Q8+"N=3ZP/0PNG(RIZ"W^;&
MS\N0XL(G$CC7"6E4X[H29Y.G9?>)*XU:__AQVJV%PEQ=3RW.OCB>UD65<^,4
M@$I%WF4X#8-3L<;1G!#JRI>X7K 7;##NAR(8E+_]>N+J>C:9WK4 6%8R"B13
M:)T^39XI(A'<^#@\2:VOOBFL:RF24+7OA.(J%BB;6X>)FKOHWBB6P7@+5GY@
M=+%,48+DO1-0L8VM.L_1O'4ZOF>S-9"3K;3^*A[ 3<?M9KUU,'B*[T;F!M0#
MKQ_+8 ^?V]CP]PFE^A6(W8#DD^%=*L"ILJD$7B "'/+ A!6YSX*B%F+U#B^T
MQ(W+4XX>/%XG[%"\8D_V1M6RN>8F\?B4#-/&LAA8DP0/&IO-*>8@-%!DF%2:
M2:V6:)I5/YFCHWH<@2<^]*+5R,0I-L;.=9]='Y>G#(6$):QY:9]IWR[*!K#!
M$%X1B&%9I@U!DBOV(F"1PY9-N0G9;>Q7\Q$-,-.J94->X2@'Q6$6V^029T/(
M;4C8TFAK/?]CM#=;EO(:]J@S.O[NJZIJ5. $)N6OD!7;)XGP6***2Y>V</99
M_7Q7,8VJ/(@V=%WADD!8K>0\D59H[V6OIBR7NFQ@_B04\0:P5-""7186QR<
MN%G@S &H6-V<@#5?/56%OXBC?RM4EVE:M&7.41I")>)!)(57V;B-/*%8A;4%
M>9>>\=0C@+B6(35K4 !L3/4^4\GAX<1K(:?LUN<]9&JS!W=>LO7 94%5.PH,
MBNID?2AP@$31UF1](Q/C-$G*WK7I8N%KU.D/QU5/\Z-!-;_MTO1_;R9'^YO)
M_F:ROYGL;R;[F\G^9K*_F>QO)K_Q9E*^P/0:KWX9F65X#/7%6"A7/@#6L_5[
MZR0\,_8VXN5C+=H;3F?+)"V@VN^^'K>9*1] RX'3>7A#G&OG=!8^4^+HR5X
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M5XD<+V(ZQ@[M$\:3+[_H'Z??[DO!OP3V(B'#+B'#0^@'O78P<C^O]\9C=))
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M[A^:"_HZ0\L3:'QFZ*W4/O "W??>Y&]02P,$%     @ Z(KX5A^"(!*'!0
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M\)'\5064(:R7:!ZSE$0@5 &5<'0F:*Y0'0'-!2J$O!PJ(0)7(ESINA%J!_B
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MT\4B/)9T]4/+!O1^92B6ML,3=)?)Z9]02P,$%     @ Z(KX5C08V>4S!0
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M:O/ZO_2/WKVX_^OPB:H5$YIP6*)JW)^.0Z+\<]Q/C"S=$W@A#3ZHW7"-_V!
M60'<7TJ\B>N)/:#Y3S3[#U!+ P04    " #HBOA6@8Z5NY<"   ,!@  &0
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MPSQ7E2KJQ$[-X22H.XQ[@MX&AA]3FKBJ3V176,_%-5@DB:ABT\XK4W 6'Z$
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MGU;T-$@L:ADLJK!Z^>V$]G W+ /"&$F.MT,BGW04E.=]S1U) B:I-6H51Y'
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MQ:A= GW/%?EI%^Z ;KHG?P%02P,$%     @ Z(KX5L$6!0MU!0  )RH  !D
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MZG#>0>QPC.8.HVS(%%M]?*KHX;QM]FBI3N,J7=.''MA5P"I_.*\10%I(,U.
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M81KH^VO.U=N)V7LN?R\Q_P]02P,$%     @ Z(KX5G64*UP< P  >PL  !D
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MTD#L+PCAVXET4'^+N'\!4$L#!!0    ( .B*^%91ZN[PD08  /A    9
M>&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;+6<6X^;1AB&_\K(K:I$VJX9?-YZ
M+27+*54W725->Q'U MMC&X6#"^-U5NJ/[W (&'L\0/7F9FWL^9X9X!$#KV'G
MQRC^DNP8X^1KX(?)?6_'^?ZNWT]6.Q:XR6VT9Z'X9A/%@<O%8KSM)_N8N>NL
M*/#[NJ:-^X'KA;W%//OL*5[,HP/WO9 ]Q20Y!($;O[QE?G2\[]'>MP\^>-L=
M3S_H+^9[=\L^,OYI_Q2+I7Y)67L!"Q,O"DG,-O>]-_3.T2=I0=;B3X\=DY/W
M)%V5911]21?>K>][6CHBYK,53Q&N>'EF#\SW4Y(8QS\%M%?VF1:>OO]&M[*5
M%RNS=!/V$/E_>6N^N^]->V3--N[!YQ^BH\.*%1JEO%7D)]E?<LS;#D7CU2'A
M45 4BQ$$7IB_NE^+#7%2(#CR KTHT,\+AE<*!D7!H&T/PZ)@V+9@5!2,S@O&
M5PK&1<&X[3I,BH))VX)I43#-]FZ^.[)]:;C<7<SCZ$CBM+6@I6\R(;)JL0N]
M,'7W(X_%MYZHXXOW$6<)^<!6S'MVESXCKPS&7<]/R'LWCMU4K-?D9_+IHT%>
M_?AZWN>BS[2RORKX9L[7K_ 'Y#$*^2XA9KAF:TF]I:ZGN@+0%RM;KK'^;8W?
MZDKBF\/VENCZ#=$U79<,Z$%=_NB^$#K,JJFDVE!76VPI.J=7R\VFSN-;,LC+
M![*-J2XWV*HLEZVZW;Y<-GA'7?[K(;PEFK3WVHX<E.H.,M[@VK;T0C=<>>'V
M1-\;8<O:VWAL33[_)MJ3=YP%R=^2P;[-X4,Y/)TR[I*]NV+W/3$G)"Q^9KW%
M3S_0L?:+S!DDS$#"3"3,0L)L),P!P6HB#DL1ARIZ=@P5\WAY"-W'GO!R[_HR
M[92HKMHA848.&V6P])3G>:%K8TW3YOWG4Z%DS487S2SDT&PDS '!:JJ,2E5&
M2E4,MN0DX2X7!Z@]BU<LY.(,4>:)DM/5$R3,R&&S$P&T6VT\.M,$V:6%A-E(
MF"/;&%2O-D;-DG%IR5AIR:/+#[''7\A:B"*30UV>G>'0V0VY=IKPH*SOZD.'
MP<A..DSD8"PDS$;"'!"L)M2D%&K2?-@IIR7BAFOBA9R)CKA,+R6LZ[$'"3.0
M,#.'C9MFLDFK>=%&#LT!P6JR3$M9IHVG,\GI^<SJ$,=BHI*9HB1U-04),Y P
M$PFSIJVTLY%].B!8S:=9Z=.LA4_I,<>/W/#4+)E12E97HY P PDS_P>,R&2:
M7<A$9]JE3+.+8]A(F]*+=@YH'6N>4*W*HK3F:6HC^,0-HH/\B*-&=!4$2C.@
M-+.@G>XT*G;9]'*&*EJ>6C ;Z;-+#: #=%"TNBTGR255VO(41X&7)%'\0K(K
M\-]#1CX_LF#)8FG@H\9U-@=),Z T$TJSH#0;2G-0M+J">J6@_CTCR(*.,A))
M,Z T$TJSH#0;2G-0M+J1529.E4EGMRQ2S>KL'S0$+VB-<22T5ZN@C1MZM:&]
M.BA:W9DJOJ;J_+I]**D&=18&&E\7M*9<$MJI!:794)J#HM6MJI)NJHZZ&T/,
MAOKF%%,-Z.Q/A^%(<TSH<"PHS8;2'!2M;E:5CE-UI-PQS533.A^TH-DYE&9"
M:59!:YX++]O1V>0R6T"-KFY-%8%3=0;>)=94HSHK XW H3032K/H9:1.9<9
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M+R,)K1J":@Y4<Z&:!]5\E-;^)8"F=$B3EPZUZ_9$"='IOZ7(J7,#"=5TJ&9
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MRP^H&R]G5&E(5N@FO& 26[I>KG&L U<!^'[)F-P;:H/ZCX+W&U!+ P04
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M((R!WE]QK@X3XZ!I2>,_4$L#!!0    ( .B*^%:T^6LX'@,  , ,   9
M>&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;+5776^;,!3]*Q:;IDY:RU?(1Y<@
MM4'=*K53U:S;P[0'A]PD5@%GMDG:_?I= V7)XK!,8B\)AG..?0[X<AENN'B4
M2P!%GM(DDR-KJ=3JW+9EO(24RC.^@@ROS+E(J<*A6-AR)8#."E*:V)[C=.V4
MLLP*A\6Y.Q$.>:X2EL&=(#)/4RJ>+R'AFY'E6B\G[MEBJ?0).QRNZ (FH!Y6
M=P)'=JTR8REDDO&,")B/K OW/'(=32@07QALY-8QT5:FG#_JP?5L9#EZ19!
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M7[-[A6]>R9*PE K-I !%%]?M<?=J-K#VSN O1M=Z[QGL3.92/MJ7N^2Z[=N
M**>QL0P$?Y[H+>7<$F$8WS:<[=*E!>X_;]EG;NXXESG1]%;ROUEB5M?MRS8D
M=$%R;K[(]:]T,Y_(\L62:_<7UH5M%+8ASK61Z0:,$:1,%+_D^R8/>X!N[Q5
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MB;KUQ:2J:;<7TUXX< 2K!C/;)-T^_6R@*%%(2*>] 3_<_^YW!^8(MXP_B0Q
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M ?G]BE+Q=J'.();'8.?_ U!+ P04    " #HBOA6.NIQEA$$   '%0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6RU6&UOVS80_BN$5A0ML$9OEIVD
MMH$F4K,"R6 DZ_:AV =&.MM")5(C:3O^]R,E6;8B1K8!]HLM4?<\Q^>..)(W
MWE#VDR\!!'K),\(GUE*(XMJV>;R$'/,+6@"17^:4Y5C(5[:P><$ )R4HSVS/
M<89VCE-B3<?EV(Q-QW0ELI3 C"&^RG/,MC>0T<W$<JW=P&.Z6 HU8$_'!5[
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MER/W5]V.7*/7(Z-LH5&VR!1;.T7[*Y+;?T>Z P(,9V49QTF>DI2+JFV!X*4
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M5T#GP+,&ZOL%8W)_DG50;0@<_PM02P,$%     @ Z(KX5HQ7HVBC P  B1$
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MI0+D]16EXK&B.NB^OL2_ 5!+ P04    " #HBOA6B^X4#" #   0"@  &0
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M-7(0Q6W)[LYQ;>Y*GZE<LEP1#@N$>J=]Y)#5]:.::%&4)_A,:+P/E,,57ME
MF@#\OA!"/T_,I:"Y!"9_ %!+ P04    " #HBOA61QQQK\H"  #8!P  &0
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M;INE+KT@S (]7W"N=AVS05O,TS]02P,$%     @ Z(KX5HR3^PFH @  _P8
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MBQ)MW+83Q2N;6$NN=/[98:'_4"!,@7Z^XEQM)V:#_I^7_@902P,$%     @
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MW&,EC'%BM/XU@LD/['X 4$L#!!0    ( .B*^%9[,UWLA 0  '(B   /
M>&PO=V]R:V)O;VLN>&ULQ9I=<]HX%$#_BL9/V9<%?Y"VF=(9-I N,UWB!;8S
M^]01M@B:R!*59$CRZRN)99$3]G9?;O($EHU\+-GWW"OS<:_T_4JI>_+0"&F&
MR<;:[56O9ZH-:ZCY56V9='O62C?4NDU]US-;S6AM-HS91O2R?O^RUU NDT\?
MCWV5NA=O*,LJRY5TC;[A*V=[<]KO-\F.&[[B@MO'81*^"Y:0ADO>\"=6#Y-^
M0LQ&[7]7FC\I::E85%H),4S2PXZO3%M>O6A>>,@E79G08NEJ3AW(,+GLNP[7
M7!L;C@C]4\>X8^[@PU9KU0T7ENDQM>RS5NV6RSO?C;N*7G0981R.GX=!O-+_
M9QC5>LTK-E95VS!I#^.HF?" TFSXUB1$TH8-DVNU8]I?CSO!M#Y<FW50T4CI
M*^YVZ&D=\#!1I%&"U^[L-?F-"BHK1L(0F@@P P"S-P,D%R6-(', ,G]%R(6'
M\#\P1*W)[;8SU04 6;P9Y,*J*H(< )"#-X.\IF8305X"D)>XD#-J6\V.LWO8
M3ZCT]Z?AAD20[P#(=[B0B[9IJ'X,T\OO)'<_H]*2456I5EH>0;X'(-_C0LZ9
M.<YQ!/0! /J "U1JMJ6\)I,'UXEA<1!,^U"8[B/?<DZYALQ9Q?B.AE.?N$!]
M(/MC*G=N"L,S&B-!PDB1C5'.;\O)?/DW*;^,9DLRFHW)Y,^_IN4?$[=%98P)
M*2-%=L9GI>H]%R+F@>R0(NMAZI(P>>=/2D;&=/V?0D9(D94P9JLX.*10X$^1
M([\7Y?U&B9II\XU,OK<NOXW9H'B?(@?\N6]TUBRIMH]DJ:DT-&3IG9F$@GV*
M'.VO5=/P0[ (NG2RMRX'9[+BW4@+"2!%-L!45JIA9$D?.DP9%/TSY.B_:+=;
M$2Q)1<B#R(U0>S*5A]YB3$@&&;(,%NW*L.^M.XA,=L^4D($U!+(2P%SH6Q9C
M0DK(D)4 YI5=3,@4&;(I0,%V,2%O9,C>. J67"Q]QF1^B<$@B63($GEAVK.$
MD$HR9)7$,? L'&21#-DB8##LWGZ01S)DCRQ<'W4KPN/L1%?[<J(F-UQ2ISL:
MIWTYI)8<N[  8TX>8T)JR='5 D7P#B8DFAQ9-%$]2R[&S%(N#)E1[0=VQ^)'
M* >7JY!%\[S*?<8:8T*BR9%%\[SH!3 AT>3(HHEJX)]-.J2='+MVB0)2J5U/
MODPHA7^,_/,>8T+NR9'= V<7G2<=LE".;:%H-$^9QC^SWYES2$+Y*TKH3-H1
M+TQ#$BJ0)?1B ,\_/@5DH +;0-%0WK1!FJ-&:<N?PK$Q)F2@ ME 9V8Y'M,8
M$S)0@6P@OZCSL]D&WY4@J^?<0D_$&V-"ZBF0U?/?:SX!-L:$U%,@JP=<^.F&
M(4@]!?8KDT[*WFR5/+Y["@51C FIIWA%]8S9FFGM[@!7J[U<MRT@]Q38[CFE
M[)/UFH67\>146<;O&R'W#)#=TZUU7T2D&!/2S^ 5]7,J>O^MA6-,2#^#H)_>
M\3\.-5MSR>J9.X5Q[1455:F)_SB\QBD&?BUVW0IQ[=INY1=%Z^-?)HY_]_CT
M U!+ P04    " #HBOA6BC%V7\\!   S'P  &@   'AL+U]R96QS+W=O<FMB
M;V]K+GAM;"YR96QSS=G+:L) &(;A6Y%<@.-_B#V@7773;?$&@AT/>$C(3*G>
M?447]@M==%/F6X5)R)\7 @]A,GN/^R9OVV/:;+LT.AWVQS2O-CEWSR&DY28>
MFC1NNWB\7%FU_:')EV6_#EVSW#7K&'0RF8;^YXSJ9?9SYFAQ[N)?)K:KU789
M7]OEYR$>\R^#PU?;[](FQER-%DV_CGE>A=/^?CJ%ZT'&E\G5Z.UC7O5O'U*%
MTD$*05H^R"#(R@<Y!'GYH!J"ZO)!4PB:E@]Z@*"'\D&/$/18/N@)@I[*!\D$
M99P0) VP)M!:D&LA\%H0;"$06Y!L(3!;$&TA4%N0;2%P6Q!N(9!;D&XAL%L0
M;R'06U%O)=!;46\ET%L'']L$>BOJK01Z*^JM!'HKZJT$>BOJK01Z*^JM!'HK
MZJT$>BOJK01Z&^IM!'H;ZFT$>AOJ;01ZVV"SA$!O0[V-0&]#O8U ;T.]C4!O
M0[V-0&]#O8U ;T.]C4!O1[V=0&]'O9U ;T>]G4!O1[V=0&\?;'83Z.VHMQ/H
M[:BW$^CMJ+<3Z.VHMQ/H[:BW$^A=H]XU@=XUZET3Z%VCWO5_ZIWR>1_3O>>V
MQN?_)]7Y<F^\/_ZZO)T<O)<KS@'^D;]\ U!+ P04    " #HBOA6,N&!X<<!
M   2'P  $P   %M#;VYT96YT7U1Y<&5S72YX;6S-V<ENPC 4!=!?0=E6Q'B
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M<' N>&UL4$L! A0#%     @ Z(KX5C^OU_7N    *P(  !$
M ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ Z(KX5IE<G",0
M!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q0
M2P$"% ,4    " #HBOA6\#_8Q,8$  "%%   &               @($-"
M>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ Z(KX5@6/N0<Y
M"0  UT$  !@              ("!"0T  'AL+W=O<FMS:&5E=',O<VAE970R
M+GAM;%!+ 0(4 Q0    ( .B*^%8U<+:JD@(   H(   8              "
M@7@6  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " #HBOA6
M;R]FMB,)   V2@  &               @(% &0  >&PO=V]R:W-H965T<R]S
M:&5E=#0N>&UL4$L! A0#%     @ Z(KX5AJU-3RU!@  )3L  !@
M     ("!F2(  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    (
M .B*^%:&GYMT_0@  %)*   8              " @80I  !X;"]W;W)K<VAE
M971S+W-H965T-BYX;6Q02P$"% ,4    " #HBOA6HR$*[]@*  ">+   &
M            @(&W,@  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#
M%     @ Z(KX5DRQ!GF6$P  %&(  !@              ("!Q3T  'AL+W=O
M<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( .B*^%:G#$@3R@(  #X&
M   8              " @9%1  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q0
M2P$"% ,4    " #HBOA6LW!F-=<"  #L!P  &0              @(&15
M>&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( .B*^%9E5/=E
M9 ,  (L)   9              " @9]7  !X;"]W;W)K<VAE971S+W-H965T
M,3$N>&UL4$L! A0#%     @ Z(KX5L(0]+7^!0  D18  !D
M ("!.EL  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " #H
MBOA6%$C#^XP#  "F"@  &0              @(%O80  >&PO=V]R:W-H965T
M<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( .B*^%95Y[X;!P4  /L-   9
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M970Q."YX;6Q02P$"% ,4    " #HBOA6-!C9Y3,%   M$@  &0
M    @(%>?   >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    (
M .B*^%:P]*Y@:P4  !\-   9              " @<B!  !X;"]W;W)K<VAE
M971S+W-H965T,C N>&UL4$L! A0#%     @ Z(KX5H&.E;N7 @  # 8  !D
M             ("!:H<  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"
M% ,4    " #HBOA6NGJB2:\"  #P!P  &0              @($XB@  >&PO
M=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( .B*^%:#@Y(OQQ0
M 'YJ   9              " @1Z-  !X;"]W;W)K<VAE971S+W-H965T,C,N
M>&UL4$L! A0#%     @ Z(KX5BL[3-JB P  N0L  !D              ("!
M'*(  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " #HBOA6
MP";"<E$#  !D"0  &0              @('UI0  >&PO=V]R:W-H965T<R]S
M:&5E=#(U+GAM;%!+ 0(4 Q0    ( .B*^%81YV>)P@(   ,(   9
M      " @7VI  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%
M  @ Z(KX5I$AO^V' P  1 P  !D              ("!=JP  'AL+W=O<FMS
M:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " #HBOA6_]\@E%L$  !-"P
M&0              @($TL   >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+
M 0(4 Q0    ( .B*^%8Y2-0_F (  .D%   9              " @<:T  !X
M;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ Z(KX5L$6!0MU
M!0  )RH  !D              ("!E;<  'AL+W=O<FMS:&5E=',O<VAE970S
M,"YX;6Q02P$"% ,4    " #HBOA6*K_C$ZD$   [(0  &0
M@(%!O0  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( .B*
M^%9UE"M<' ,  'L+   9              " @2'"  !X;"]W;W)K<VAE971S
M+W-H965T,S(N>&UL4$L! A0#%     @ Z(KX5E!.@AG9 @  $PP  !D
M         ("!=,4  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4
M    " #HBOA6X6&5J3P#  "7#   &0              @(&$R   >&PO=V]R
M:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( .B*^%91ZN[PD08  /A
M   9              " @??+  !X;"]W;W)K<VAE971S+W-H965T,S4N>&UL
M4$L! A0#%     @ Z(KX5DRRJHA7"@  GW4  !D              ("!O](
M 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " #HBOA6YB2H
M;=0#   J%P  &0              @(%-W0  >&PO=V]R:W-H965T<R]S:&5E
M=#,W+GAM;%!+ 0(4 Q0    ( .B*^%;<9'K7P (  #0(   9
M  " @5CA  !X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @
MZ(KX5FE)>03= @  G@H  !D              ("!3^0  'AL+W=O<FMS:&5E
M=',O<VAE970S.2YX;6Q02P$"% ,4    " #HBOA6M/EK.!X#  # #   &0
M            @(%CYP  >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4
M Q0    ( .B*^%:=^.-Q$ 4  $X4   9              " @;CJ  !X;"]W
M;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ Z(KX5J6';'*X @
MUP@  !D              ("!_^\  'AL+W=O<FMS:&5E=',O<VAE970T,BYX
M;6Q02P$"% ,4    " #HBOA6Z?*<&9<"  #1!P  &0              @('N
M\@  >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( .B*^%;.
M&IH VP0  .H;   9              " @;SU  !X;"]W;W)K<VAE971S+W-H
M965T-#0N>&UL4$L! A0#%     @ Z(KX5A#EMDQ5!0  $BL  !D
M     ("!SOH  'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .B*^%9'''&OR@(  -@'   9              "
M@> 0 0!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ Z(KX
M5HR3^PFH @  _P8  !D              ("!X1,! 'AL+W=O<FMS:&5E=',O
M<VAE970U,2YX;6Q02P$"% ,4    " #HBOA6"BG)6J\"  #A"   &0
M        @(' %@$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0
M   ( .B*^%;"6&<N)P,  $H2   -              "  :89 0!X;"]S='EL
M97,N>&UL4$L! A0#%     @ Z(KX5I>*NQS     $P(   L
M ( !^!P! %]R96QS+RYR96QS4$L! A0#%     @ Z(KX5GLS7>R$!   <B(
M  \              ( !X1T! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (
M .B*^%:*,79?SP$  #,?   :              "  9(B 0!X;"]?<F5L<R]W
M;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( .B*^%8RX8'AQP$  !(?   3
M              "  9DD 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     \
- #P 6Q   )$F 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>178</ContextCount>
  <ElementCount>207</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>41</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://impactbiomedinc.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://impactbiomedinc.com/role/BalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://impactbiomedinc.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://impactbiomedinc.com/role/StatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Consolidated Statements of Stockholder's Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://impactbiomedinc.com/role/StatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholder's Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://impactbiomedinc.com/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - Nature of Operations and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://impactbiomedinc.com/role/NatureOfOperationsAndBasisOfPresentation</Role>
      <ShortName>Nature of Operations and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - Summary of Significant Accounting and Reporting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://impactbiomedinc.com/role/SummaryOfSignificantAccountingAndReportingPolicies</Role>
      <ShortName>Summary of Significant Accounting and Reporting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - Restatement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://impactbiomedinc.com/role/Restatement</Role>
      <ShortName>Restatement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - Prepaid Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://impactbiomedinc.com/role/PrepaidExpenses</Role>
      <ShortName>Prepaid Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - Notes Receivable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://impactbiomedinc.com/role/NotesReceivable</Role>
      <ShortName>Notes Receivable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://impactbiomedinc.com/role/Investments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - PROPERTY PLANT AND EQUIPMENT and INVESTMENT IN REAL ESTATE, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://impactbiomedinc.com/role/PropertyPlantAndEquipmentAndInvestmentInRealEstateNet</Role>
      <ShortName>PROPERTY PLANT AND EQUIPMENT and INVESTMENT IN REAL ESTATE, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://impactbiomedinc.com/role/Goodwill</Role>
      <ShortName>Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://impactbiomedinc.com/role/IntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://impactbiomedinc.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://impactbiomedinc.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://impactbiomedinc.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://impactbiomedinc.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://impactbiomedinc.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Supplemental Cash Flow Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://impactbiomedinc.com/role/SupplementalCashFlowInformation</Role>
      <ShortName>Supplemental Cash Flow Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://impactbiomedinc.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - Summary of Significant Accounting and Reporting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://impactbiomedinc.com/role/SummaryOfSignificantAccountingAndReportingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting and Reporting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://impactbiomedinc.com/role/SummaryOfSignificantAccountingAndReportingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - Nature of Operations and Basis of Presentation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://impactbiomedinc.com/role/NatureOfOperationsAndBasisOfPresentationTables</Role>
      <ShortName>Nature of Operations and Basis of Presentation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://impactbiomedinc.com/role/NatureOfOperationsAndBasisOfPresentation</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - PROPERTY PLANT AND EQUIPMENT and INVESTMENT IN REAL ESTATE, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://impactbiomedinc.com/role/PropertyPlantAndEquipmentAndInvestmentInRealEstateNetTables</Role>
      <ShortName>PROPERTY PLANT AND EQUIPMENT and INVESTMENT IN REAL ESTATE, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://impactbiomedinc.com/role/PropertyPlantAndEquipmentAndInvestmentInRealEstateNet</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://impactbiomedinc.com/role/GoodwillTables</Role>
      <ShortName>Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://impactbiomedinc.com/role/Goodwill</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://impactbiomedinc.com/role/IntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://impactbiomedinc.com/role/IntangibleAssets</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://impactbiomedinc.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://impactbiomedinc.com/role/IncomeTaxes</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - Supplemental Cash Flow Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://impactbiomedinc.com/role/SupplementalCashFlowInformationTables</Role>
      <ShortName>Supplemental Cash Flow Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://impactbiomedinc.com/role/SupplementalCashFlowInformation</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - Schedule of Condensed Financial Statements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://impactbiomedinc.com/role/ScheduleOfCondensedFinancialStatementsDetails</Role>
      <ShortName>Schedule of Condensed Financial Statements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - Nature of Operations and Basis of Presentation (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://impactbiomedinc.com/role/NatureOfOperationsAndBasisOfPresentationDetailsNarrative</Role>
      <ShortName>Nature of Operations and Basis of Presentation (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://impactbiomedinc.com/role/NatureOfOperationsAndBasisOfPresentationTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - Summary of Significant Accounting and Reporting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://impactbiomedinc.com/role/SummaryOfSignificantAccountingAndReportingPoliciesDetailsNarrative</Role>
      <ShortName>Summary of Significant Accounting and Reporting Policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://impactbiomedinc.com/role/SummaryOfSignificantAccountingAndReportingPoliciesPolicies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - Restatement (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://impactbiomedinc.com/role/RestatementDetailsNarrative</Role>
      <ShortName>Restatement (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://impactbiomedinc.com/role/Restatement</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - Prepaid Expenses (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://impactbiomedinc.com/role/PrepaidExpensesDetailsNarrative</Role>
      <ShortName>Prepaid Expenses (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://impactbiomedinc.com/role/PrepaidExpenses</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - Notes Receivable (Details Narrative)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://impactbiomedinc.com/role/NotesReceivableDetailsNarrative</Role>
      <ShortName>Notes Receivable (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://impactbiomedinc.com/role/NotesReceivable</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - Investments (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://impactbiomedinc.com/role/InvestmentsDetailsNarrative</Role>
      <ShortName>Investments (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://impactbiomedinc.com/role/Investments</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - Schedule of Property Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://impactbiomedinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails</Role>
      <ShortName>Schedule of Property Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - PROPERTY PLANT AND EQUIPMENT and INVESTMENT IN REAL ESTATE, NET (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://impactbiomedinc.com/role/PropertyPlantAndEquipmentAndInvestmentInRealEstateNetDetailsNarrative</Role>
      <ShortName>PROPERTY PLANT AND EQUIPMENT and INVESTMENT IN REAL ESTATE, NET (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://impactbiomedinc.com/role/PropertyPlantAndEquipmentAndInvestmentInRealEstateNetTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - Schedule of Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://impactbiomedinc.com/role/ScheduleOfGoodwillDetails</Role>
      <ShortName>Schedule of Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - Schedule of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://impactbiomedinc.com/role/ScheduleOfIntangibleAssetsDetails</Role>
      <ShortName>Schedule of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - Goodwill (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://impactbiomedinc.com/role/GoodwillDetailsNarrative</Role>
      <ShortName>Goodwill (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://impactbiomedinc.com/role/GoodwillTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - Schedule of Future Amortization of Developed Technologies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://impactbiomedinc.com/role/ScheduleOfFutureAmortizationOfDevelopedTechnologiesDetails</Role>
      <ShortName>Schedule of Future Amortization of Developed Technologies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - Intangible Assets (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://impactbiomedinc.com/role/IntangibleAssetsDetailsNarrative</Role>
      <ShortName>Intangible Assets (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://impactbiomedinc.com/role/IntangibleAssetsTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - Debt (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://impactbiomedinc.com/role/DebtDetailsNarrative</Role>
      <ShortName>Debt (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://impactbiomedinc.com/role/Debt</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - Stockholders??? Equity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://impactbiomedinc.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>Stockholders??? Equity (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://impactbiomedinc.com/role/StockholdersEquity</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - Related Party Transactions (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://impactbiomedinc.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>Related Party Transactions (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://impactbiomedinc.com/role/RelatedPartyTransactions</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://impactbiomedinc.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://impactbiomedinc.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - Schedule of Components of Income Tax Benefit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://impactbiomedinc.com/role/ScheduleOfComponentsOfIncomeTaxBenefitDetails</Role>
      <ShortName>Schedule of Components of Income Tax Benefit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://impactbiomedinc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Schedule of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - Summary of Effective Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://impactbiomedinc.com/role/SummaryOfEffectiveIncomeTaxRateDetails</Role>
      <ShortName>Summary of Effective Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>00000051 - Disclosure - Income Taxes (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://impactbiomedinc.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>Income Taxes (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://impactbiomedinc.com/role/IncomeTaxesTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="forms-1a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>00000052 - Disclosure - Schedule of Cash Flow Supplemental (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://impactbiomedinc.com/role/ScheduleOfCashFlowSupplementalDetails</Role>
      <ShortName>Schedule of Cash Flow Supplemental (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="S-1/A" original="forms-1a.htm">forms-1a.htm</File>
    <File>ex16-2.htm</File>
    <File>ex23-1.htm</File>
    <File>ex23-2.htm</File>
    <File>ex5-1.htm</File>
    <File>impb-20230331.xsd</File>
    <File>impb-20230331_cal.xml</File>
    <File>impb-20230331_def.xml</File>
    <File>impb-20230331_lab.xml</File>
    <File>impb-20230331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>aud_001.jpg</File>
    <File>forms-1a_001.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="2">http://fasb.org/srt/2023</BaseTaxonomy>
    <BaseTaxonomy items="741">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>75
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "forms-1a.htm": {
   "axisCustom": 0,
   "axisStandard": 16,
   "baseTaxonomies": {
    "http://fasb.org/srt/2023": 2,
    "http://fasb.org/us-gaap/2023": 741,
    "http://xbrl.sec.gov/dei/2023": 37
   },
   "contextCount": 178,
   "dts": {
    "calculationLink": {
     "local": [
      "impb-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "impb-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "forms-1a.htm"
     ]
    },
    "labelLink": {
     "local": [
      "impb-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "impb-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "impb-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    }
   },
   "elementCount": 375,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2023": 59,
    "http://impactbiomedinc.com/20230331": 7,
    "http://xbrl.sec.gov/dei/2023": 4,
    "total": 70
   },
   "keyCustom": 12,
   "keyStandard": 195,
   "memberCustom": 23,
   "memberStandard": 16,
   "nsprefix": "IMPB",
   "nsuri": "http://impactbiomedinc.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://impactbiomedinc.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "IMPB:PrepaidExpensesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000010 - Disclosure - Prepaid Expenses",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://impactbiomedinc.com/role/PrepaidExpenses",
     "shortName": "Prepaid Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "IMPB:PrepaidExpensesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000011 - Disclosure - Notes Receivable",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://impactbiomedinc.com/role/NotesReceivable",
     "shortName": "Notes Receivable",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000012 - Disclosure - Investments",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://impactbiomedinc.com/role/Investments",
     "shortName": "Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000013 - Disclosure - PROPERTY PLANT AND EQUIPMENT and INVESTMENT IN REAL ESTATE, NET",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://impactbiomedinc.com/role/PropertyPlantAndEquipmentAndInvestmentInRealEstateNet",
     "shortName": "PROPERTY PLANT AND EQUIPMENT and INVESTMENT IN REAL ESTATE, NET",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000014 - Disclosure - Goodwill",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://impactbiomedinc.com/role/Goodwill",
     "shortName": "Goodwill",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000015 - Disclosure - Intangible Assets",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://impactbiomedinc.com/role/IntangibleAssets",
     "shortName": "Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000016 - Disclosure - Debt",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://impactbiomedinc.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000017 - Disclosure - Stockholders\u2019 Equity",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://impactbiomedinc.com/role/StockholdersEquity",
     "shortName": "Stockholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000018 - Disclosure - Related Party Transactions",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://impactbiomedinc.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000019 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://impactbiomedinc.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000002 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://impactbiomedinc.com/role/BalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:NotesAndLoansReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2022-01-012022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000020 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://impactbiomedinc.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2022-01-012022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2022-01-012022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000021 - Disclosure - Supplemental Cash Flow Information",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://impactbiomedinc.com/role/SupplementalCashFlowInformation",
     "shortName": "Supplemental Cash Flow Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2022-01-012022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000022 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://impactbiomedinc.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000023 - Disclosure - Summary of Significant Accounting and Reporting Policies (Policies)",
     "menuCat": "Policies",
     "order": "23",
     "role": "http://impactbiomedinc.com/role/SummaryOfSignificantAccountingAndReportingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting and Reporting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfCondensedFinancialStatementsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000024 - Disclosure - Nature of Operations and Basis of Presentation (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://impactbiomedinc.com/role/NatureOfOperationsAndBasisOfPresentationTables",
     "shortName": "Nature of Operations and Basis of Presentation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfCondensedFinancialStatementsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000025 - Disclosure - PROPERTY PLANT AND EQUIPMENT and INVESTMENT IN REAL ESTATE, NET (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://impactbiomedinc.com/role/PropertyPlantAndEquipmentAndInvestmentInRealEstateNetTables",
     "shortName": "PROPERTY PLANT AND EQUIPMENT and INVESTMENT IN REAL ESTATE, NET (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:GoodwillDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000026 - Disclosure - Goodwill (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://impactbiomedinc.com/role/GoodwillTables",
     "shortName": "Goodwill (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:GoodwillDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000027 - Disclosure - Intangible Assets (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://impactbiomedinc.com/role/IntangibleAssetsTables",
     "shortName": "Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2022-01-012022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000028 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://impactbiomedinc.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2022-01-012022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2022-01-012022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000029 - Disclosure - Supplemental Cash Flow Information (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://impactbiomedinc.com/role/SupplementalCashFlowInformationTables",
     "shortName": "Supplemental Cash Flow Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2022-01-012022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://impactbiomedinc.com/role/BalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "srt:ScheduleOfCondensedFinancialStatementsTableTextBlock",
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2023-01-012023-03-31_custom_GlobalBioMedicalIncMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "IMPB:StateOrOtherJurisdictionOfIncorporationOrOrganization",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000030 - Disclosure - Schedule of Condensed Financial Statements (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://impactbiomedinc.com/role/ScheduleOfCondensedFinancialStatementsDetails",
     "shortName": "Schedule of Condensed Financial Statements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "srt:ScheduleOfCondensedFinancialStatementsTableTextBlock",
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2023-01-012023-03-31_custom_GlobalBioMedicalIncMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "IMPB:StateOrOtherJurisdictionOfIncorporationOrOrganization",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:MinorityInterest",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000031 - Disclosure - Nature of Operations and Basis of Presentation (Details Narrative)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://impactbiomedinc.com/role/NatureOfOperationsAndBasisOfPresentationDetailsNarrative",
     "shortName": "Nature of Operations and Basis of Presentation (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "AsOf2023-03-31_srt_SubsidiariesMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:MinorityInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000032 - Disclosure - Summary of Significant Accounting and Reporting Policies (Details Narrative)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://impactbiomedinc.com/role/SummaryOfSignificantAccountingAndReportingPoliciesDetailsNarrative",
     "shortName": "Summary of Significant Accounting and Reporting Policies (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InterestExpense",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000033 - Disclosure - Restatement (Details Narrative)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://impactbiomedinc.com/role/RestatementDetailsNarrative",
     "shortName": "Restatement (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2022-01-012022-12-31_srt_MinimumMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:InterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000034 - Disclosure - Prepaid Expenses (Details Narrative)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://impactbiomedinc.com/role/PrepaidExpensesDetailsNarrative",
     "shortName": "Prepaid Expenses (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "IMPB:PrepaidExpensesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "AsOf2023-03-31_custom_GRDGscienceLLCMember_us-gaap_RelatedPartyMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:OtherPrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "AsOf2021-02-21",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NotesReceivableNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000035 - Disclosure - Notes Receivable (Details Narrative)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://impactbiomedinc.com/role/NotesReceivableDetailsNarrative",
     "shortName": "Notes Receivable (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "AsOf2021-02-21",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NotesReceivableNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000036 - Disclosure - Investments (Details Narrative)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://impactbiomedinc.com/role/InvestmentsDetailsNarrative",
     "shortName": "Investments (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:InvestmentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "AsOf2021-01-01_custom_NanoNineLLCMember_custom_SecuritiesPurchaseAgreementMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000037 - Disclosure - Schedule of Property Plant and Equipment (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://impactbiomedinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails",
     "shortName": "Schedule of Property Plant and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000038 - Disclosure - PROPERTY PLANT AND EQUIPMENT and INVESTMENT IN REAL ESTATE, NET (Details Narrative)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://impactbiomedinc.com/role/PropertyPlantAndEquipmentAndInvestmentInRealEstateNetDetailsNarrative",
     "shortName": "PROPERTY PLANT AND EQUIPMENT and INVESTMENT IN REAL ESTATE, NET (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "us-gaap:GoodwillDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000039 - Disclosure - Schedule of Goodwill (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://impactbiomedinc.com/role/ScheduleOfGoodwillDetails",
     "shortName": "Schedule of Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SellingGeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000004 - Statement - Consolidated Statements of Operations",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://impactbiomedinc.com/role/StatementsOfOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SellingGeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000040 - Disclosure - Schedule of Intangible Assets (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://impactbiomedinc.com/role/ScheduleOfIntangibleAssetsDetails",
     "shortName": "Schedule of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:GoodwillDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "IMPB:NoncashOrPartNoncashAcquisitionValueOfAssetAcquiredDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000041 - Disclosure - Goodwill (Details Narrative)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://impactbiomedinc.com/role/GoodwillDetailsNarrative",
     "shortName": "Goodwill (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:GoodwillDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "IMPB:NoncashOrPartNoncashAcquisitionValueOfAssetAcquiredDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000042 - Disclosure - Schedule of Future Amortization of Developed Technologies (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://impactbiomedinc.com/role/ScheduleOfFutureAmortizationOfDevelopedTechnologiesDetails",
     "shortName": "Schedule of Future Amortization of Developed Technologies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000043 - Disclosure - Intangible Assets (Details Narrative)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://impactbiomedinc.com/role/IntangibleAssetsDetailsNarrative",
     "shortName": "Intangible Assets (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "AsOf2021-02-21",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "reportCount": 1,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000044 - Disclosure - Debt (Details Narrative)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://impactbiomedinc.com/role/DebtDetailsNarrative",
     "shortName": "Debt (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "AsOf2023-03-31_custom_RevolvingPromissoryNoteMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000045 - Disclosure - Stockholders\u2019 Equity (Details Narrative)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://impactbiomedinc.com/role/StockholdersEquityDetailsNarrative",
     "shortName": "Stockholders\u2019 Equity (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "AsOf2023-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000046 - Disclosure - Related Party Transactions (Details Narrative)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://impactbiomedinc.com/role/RelatedPartyTransactionsDetailsNarrative",
     "shortName": "Related Party Transactions (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2018-08-142018-08-15_custom_RoyaltyAgreementMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "IMPB:RoyaltyPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000047 - Disclosure - Commitments and Contingencies (Details Narrative)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://impactbiomedinc.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "shortName": "Commitments and Contingencies (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2018-08-142018-08-15_custom_RoyaltyAgreementMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "IMPB:RoyaltyPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2022-01-012022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredFederalIncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000048 - Disclosure - Schedule of Components of Income Tax Benefit (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://impactbiomedinc.com/role/ScheduleOfComponentsOfIncomeTaxBenefitDetails",
     "shortName": "Schedule of Components of Income Tax Benefit (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2022-01-012022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredFederalIncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000049 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://impactbiomedinc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails",
     "shortName": "Schedule of Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000005 - Statement - Consolidated Statements of Stockholder's Equity",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://impactbiomedinc.com/role/StatementsOfStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholder's Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2022-01-012022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000050 - Disclosure - Summary of Effective Income Tax Rate (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://impactbiomedinc.com/role/SummaryOfEffectiveIncomeTaxRateDetails",
     "shortName": "Summary of Effective Income Tax Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2022-01-012022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000051 - Disclosure - Income Taxes (Details Narrative)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://impactbiomedinc.com/role/IncomeTaxesDetailsNarrative",
     "shortName": "Income Taxes (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NotesPayable",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000052 - Disclosure - Schedule of Cash Flow Supplemental (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://impactbiomedinc.com/role/ScheduleOfCashFlowSupplementalDetails",
     "shortName": "Schedule of Cash Flow Supplemental (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "AsOf2022-12-31_us-gaap_RelatedPartyMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ConvertibleNotesPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000006 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://impactbiomedinc.com/role/StatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2021-01-012021-12-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DeferredIncomeTaxesAndTaxCredits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000007 - Disclosure - Nature of Operations and Basis of Presentation",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://impactbiomedinc.com/role/NatureOfOperationsAndBasisOfPresentation",
     "shortName": "Nature of Operations and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000008 - Disclosure - Summary of Significant Accounting and Reporting Policies",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://impactbiomedinc.com/role/SummaryOfSignificantAccountingAndReportingPolicies",
     "shortName": "Summary of Significant Accounting and Reporting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2023-01-01to2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2022-01-012022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000009 - Disclosure - Restatement",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://impactbiomedinc.com/role/Restatement",
     "shortName": "Restatement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "forms-1a.htm",
      "contextRef": "From2022-01-012022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 41,
   "tag": {
    "IMPB_AsiaPacificHoldingsLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asia Pacific Holdings Limited [Member]",
        "label": "Asia Pacific Holdings Limited [Member]"
       }
      }
     },
     "localname": "AsiaPacificHoldingsLimitedMember",
     "nsuri": "http://impactbiomedinc.com/20230331",
     "presentation": [
      "http://impactbiomedinc.com/role/InvestmentsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "IMPB_BioLifeSugarIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bio Life Sugar Inc [Member]",
        "label": "Bio Life Sugar Inc [Member]"
       }
      }
     },
     "localname": "BioLifeSugarIncMember",
     "nsuri": "http://impactbiomedinc.com/20230331",
     "presentation": [
      "http://impactbiomedinc.com/role/ScheduleOfCondensedFinancialStatementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "IMPB_ChemiaCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chemia Corporation [Member]",
        "label": "Chemia Corporation [Member]"
       }
      }
     },
     "localname": "ChemiaCorporationMember",
     "nsuri": "http://impactbiomedinc.com/20230331",
     "presentation": [
      "http://impactbiomedinc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "IMPB_ContinuingOperationsAndGoingConcernPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Continuing Operations And Going Concern [Policy Text Block].",
        "label": "Continuing Operations and Going Concern"
       }
      }
     },
     "localname": "ContinuingOperationsAndGoingConcernPolicyTextBlock",
     "nsuri": "http://impactbiomedinc.com/20230331",
     "presentation": [
      "http://impactbiomedinc.com/role/SummaryOfSignificantAccountingAndReportingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "IMPB_DevelopmentCostPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development cost percent.",
        "label": "Development cost, percent"
       }
      }
     },
     "localname": "DevelopmentCostPercent",
     "nsuri": "http://impactbiomedinc.com/20230331",
     "presentation": [
      "http://impactbiomedinc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "IMPB_DisclosurePrepaidExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expenses"
       }
      }
     },
     "localname": "DisclosurePrepaidExpensesAbstract",
     "nsuri": "http://impactbiomedinc.com/20230331",
     "xbrltype": "stringItemType"
    },
    "IMPB_GRDGscienceLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GRDG Science LLC [Member]",
        "label": "GRDG Science LLC [Member]"
       }
      }
     },
     "localname": "GRDGscienceLLCMember",
     "nsuri": "http://impactbiomedinc.com/20230331",
     "presentation": [
      "http://impactbiomedinc.com/role/PrepaidExpensesDetailsNarrative",
      "http://impactbiomedinc.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "IMPB_GlobalAndBioLifeSciencesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Global And Bio Life Sciences [Member]"
       }
      }
     },
     "localname": "GlobalAndBioLifeSciencesMember",
     "nsuri": "http://impactbiomedinc.com/20230331",
     "presentation": [
      "http://impactbiomedinc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "IMPB_GlobalBioLifeIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global Bio Life Inc [Member]",
        "label": "Global Bio Life Inc [Member]"
       }
      }
     },
     "localname": "GlobalBioLifeIncMember",
     "nsuri": "http://impactbiomedinc.com/20230331",
     "presentation": [
      "http://impactbiomedinc.com/role/ScheduleOfCondensedFinancialStatementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "IMPB_GlobalBioMedicalIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global Bio Medical Inc [Member]",
        "label": "Global Bio Medical Inc [Member]"
       }
      }
     },
     "localname": "GlobalBioMedicalIncMember",
     "nsuri": "http://impactbiomedinc.com/20230331",
     "presentation": [
      "http://impactbiomedinc.com/role/ScheduleOfCondensedFinancialStatementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "IMPB_GlobalBioMedicalPteLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global Bio Medical Pte Ltd [Member]",
        "label": "Global Bio Medical Pte Ltd [Member]"
       }
      }
     },
     "localname": "GlobalBioMedicalPteLtdMember",
     "nsuri": "http://impactbiomedinc.com/20230331",
     "presentation": [
      "http://impactbiomedinc.com/role/NatureOfOperationsAndBasisOfPresentationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "IMPB_GlobalSugarSolutionsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global Sugar Solutions Inc [Member]",
        "label": "Global Sugar Solutions Inc [Member]"
       }
      }
     },
     "localname": "GlobalSugarSolutionsIncMember",
     "nsuri": "http://impactbiomedinc.com/20230331",
     "presentation": [
      "http://impactbiomedinc.com/role/ScheduleOfCondensedFinancialStatementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "IMPB_HappySugarIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Happy Sugar Inc [Member]",
        "label": "Happy Sugar Inc [Member]"
       }
      }
     },
     "localname": "HappySugarIncMember",
     "nsuri": "http://impactbiomedinc.com/20230331",
     "presentation": [
      "http://impactbiomedinc.com/role/ScheduleOfCondensedFinancialStatementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "IMPB_ImpactOncologyPTELtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impact Oncology PTE Ltd [Member]",
        "label": "Impact Oncology PTE Ltd [Member]"
       }
      }
     },
     "localname": "ImpactOncologyPTELtdMember",
     "nsuri": "http://impactbiomedinc.com/20230331",
     "presentation": [
      "http://impactbiomedinc.com/role/InvestmentsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "IMPB_ImpairmentOfOtherInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://impactbiomedinc.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in impairment of other investments.",
        "label": "Impairment of other investments"
       }
      }
     },
     "localname": "ImpairmentOfOtherInvestments",
     "nsuri": "http://impactbiomedinc.com/20230331",
     "presentation": [
      "http://impactbiomedinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "IMPB_IncreaseDecreaseInImpairmentofOtherInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://impactbiomedinc.com/role/StatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in impairment of other investments.",
        "label": "IncreaseDecreaseInImpairmentofOtherInvestments",
        "negatedLabel": "Impairment of other investment"
       }
      }
     },
     "localname": "IncreaseDecreaseInImpairmentofOtherInvestments",
     "nsuri": "http://impactbiomedinc.com/20230331",
     "presentation": [
      "http://impactbiomedinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "IMPB_LicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement [Member]",
        "label": "License Agreement [Member]"
       }
      }
     },
     "localname": "LicenseAgreementMember",
     "nsuri": "http://impactbiomedinc.com/20230331",
     "presentation": [
      "http://impactbiomedinc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "IMPB_NanoNineLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nano9 LLC [Member]",
        "label": "Nano9 LLC [Member]"
       }
      }
     },
     "localname": "NanoNineLLCMember",
     "nsuri": "http://impactbiomedinc.com/20230331",
     "presentation": [
      "http://impactbiomedinc.com/role/InvestmentsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "IMPB_NoncashOrPartNoncashAcquisitionValueOfAssetAcquiredDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisition value of asset acquired, description"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionValueOfAssetAcquiredDescription",
     "nsuri": "http://impactbiomedinc.com/20230331",
     "presentation": [
      "http://impactbiomedinc.com/role/GoodwillDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "IMPB_OrdinarySharesPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ordinary shares percentage.",
        "label": "Ordinary shares percentage"
       }
      }
     },
     "localname": "OrdinarySharesPercentage",
     "nsuri": "http://impactbiomedinc.com/20230331",
     "presentation": [
      "http://impactbiomedinc.com/role/InvestmentsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "IMPB_PaymentsForProceedsFromNoteReceivableInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://impactbiomedinc.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments for proceeds from note receivable investments.",
        "label": "PaymentsForProceedsFromNoteReceivableInvestments",
        "negatedLabel": "Note receivable investment, net"
       }
      }
     },
     "localname": "PaymentsForProceedsFromNoteReceivableInvestments",
     "nsuri": "http://impactbiomedinc.com/20230331",
     "presentation": [
      "http://impactbiomedinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "IMPB_PrepaidExpensesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Expenses [Text Block].",
        "label": "Prepaid Expenses [Text Block].",
        "verboseLabel": "Prepaid Expenses"
       }
      }
     },
     "localname": "PrepaidExpensesTextBlock",
     "nsuri": "http://impactbiomedinc.com/20230331",
     "presentation": [
      "http://impactbiomedinc.com/role/PrepaidExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "IMPB_PromissoryNoteOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Promissory Note One [Member]",
        "label": "Promissory Note One [Member]"
       }
      }
     },
     "localname": "PromissoryNoteOneMember",
     "nsuri": "http://impactbiomedinc.com/20230331",
     "presentation": [
      "http://impactbiomedinc.com/role/NotesReceivableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "IMPB_PromissoryNoteTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Promissory Note Two [Member]",
        "label": "Promissory Note Two [Member]"
       }
      }
     },
     "localname": "PromissoryNoteTwoMember",
     "nsuri": "http://impactbiomedinc.com/20230331",
     "presentation": [
      "http://impactbiomedinc.com/role/NotesReceivableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "IMPB_RevolvingPromissoryNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revolving Promissory Note [Member]",
        "label": "Revolving Promissory Note [Member]"
       }
      }
     },
     "localname": "RevolvingPromissoryNoteMember",
     "nsuri": "http://impactbiomedinc.com/20230331",
     "presentation": [
      "http://impactbiomedinc.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "IMPB_RoyaltyAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Agreement [Member]",
        "label": "Royalty Agreement [Member]"
       }
      }
     },
     "localname": "RoyaltyAgreementMember",
     "nsuri": "http://impactbiomedinc.com/20230331",
     "presentation": [
      "http://impactbiomedinc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "IMPB_RoyaltyPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty percentage.",
        "label": "Royalty percentage"
       }
      }
     },
     "localname": "RoyaltyPercentage",
     "nsuri": "http://impactbiomedinc.com/20230331",
     "presentation": [
      "http://impactbiomedinc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "IMPB_SaleOfRoyaltyPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of royalty percentage.",
        "label": "Sale of royalty percentage"
       }
      }
     },
     "localname": "SaleOfRoyaltyPercentage",
     "nsuri": "http://impactbiomedinc.com/20230331",
     "presentation": [
      "http://impactbiomedinc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "IMPB_SecuritiesPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities Purchase Agreement [Member]",
        "label": "Securities Purchase Agreement [Member]"
       }
      }
     },
     "localname": "SecuritiesPurchaseAgreementMember",
     "nsuri": "http://impactbiomedinc.com/20230331",
     "presentation": [
      "http://impactbiomedinc.com/role/InvestmentsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "IMPB_StateOrOtherJurisdictionOfIncorporationOrOrganization": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "State or other jurisdiction of incorporation or organization.",
        "label": "State or other jurisdiction of incorporation or organization"
       }
      }
     },
     "localname": "StateOrOtherJurisdictionOfIncorporationOrOrganization",
     "nsuri": "http://impactbiomedinc.com/20230331",
     "presentation": [
      "http://impactbiomedinc.com/role/ScheduleOfCondensedFinancialStatementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "IMPB_StockIssuedDuringPeriodValueShareholder": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period Value Shareholder.",
        "label": "Proceeds from shareholder"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareholder",
     "nsuri": "http://impactbiomedinc.com/20230331",
     "presentation": [
      "http://impactbiomedinc.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "IMPB_StockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Purchase Agreement [Member]",
        "label": "Stock Purchase Agreement [Member]"
       }
      }
     },
     "localname": "StockPurchaseAgreementMember",
     "nsuri": "http://impactbiomedinc.com/20230331",
     "presentation": [
      "http://impactbiomedinc.com/role/InvestmentsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "IMPB_SweetSenseIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sweet Sense Inc [Member]",
        "label": "Sweet Sense Inc [Member]"
       }
      }
     },
     "localname": "SweetSenseIncMember",
     "nsuri": "http://impactbiomedinc.com/20230331",
     "presentation": [
      "http://impactbiomedinc.com/role/ScheduleOfCondensedFinancialStatementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "IMPB_SweetSenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sweet Sense [Member]",
        "label": "Sweet Sense [Member]"
       }
      }
     },
     "localname": "SweetSenseMember",
     "nsuri": "http://impactbiomedinc.com/20230331",
     "presentation": [
      "http://impactbiomedinc.com/role/NatureOfOperationsAndBasisOfPresentationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "IMPB_VivacitasAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vivacitas Agreement [Member]",
        "label": "Vivacitas Agreement [Member]"
       }
      }
     },
     "localname": "VivacitasAgreementMember",
     "nsuri": "http://impactbiomedinc.com/20230331",
     "presentation": [
      "http://impactbiomedinc.com/role/InvestmentsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "IMPB_VivacitasOncologyIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vivacitas Oncology Inc [Member]",
        "label": "Vivacitas Oncology Inc [Member]"
       }
      }
     },
     "localname": "VivacitasOncologyIncMember",
     "nsuri": "http://impactbiomedinc.com/20230331",
     "presentation": [
      "http://impactbiomedinc.com/role/InvestmentsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AddressTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "localname": "AddressTypeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_BusinessContactMember": {
     "auth_ref": [
      "r586",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business contact for the entity",
        "label": "Business Contact [Member]"
       }
      }
     },
     "localname": "BusinessContactMember",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of contact personnel",
        "label": "Contact Personnel Name"
       }
      }
     },
     "localname": "ContactPersonnelName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r584",
      "r586",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Addresses, Address Type [Axis]"
       }
      }
     },
     "localname": "EntityAddressesAddressTypeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Addresses [Line Items]"
       }
      }
     },
     "localname": "EntityAddressesLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressesTable": {
     "auth_ref": [
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container of address information for the entity",
        "label": "Entity Addresses [Table]"
       }
      }
     },
     "localname": "EntityAddressesTable",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://impactbiomedinc.com/role/PrepaidExpensesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when an entity was incorporated",
        "label": "Date of incorporation or formation"
       }
      }
     },
     "localname": "EntityIncorporationDateOfIncorporation",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/ScheduleOfCondensedFinancialStatementsDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://impactbiomedinc.com/role/PrepaidExpensesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "srt_BoardOfDirectorsChairmanMember": {
     "auth_ref": [
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leader of board of directors.",
        "label": "Board of Directors Chairman [Member]"
       }
      }
     },
     "localname": "BoardOfDirectorsChairmanMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r135",
      "r167",
      "r321",
      "r322",
      "r325",
      "r326",
      "r359",
      "r537",
      "r601",
      "r602",
      "r603",
      "r642",
      "r645",
      "r646"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by consolidated entity or group of entities.",
        "label": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/NatureOfOperationsAndBasisOfPresentationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r135",
      "r167",
      "r321",
      "r322",
      "r325",
      "r326",
      "r359",
      "r537",
      "r601",
      "r602",
      "r603",
      "r642",
      "r645",
      "r646"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity or group of entities consolidated into reporting entity."
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/NatureOfOperationsAndBasisOfPresentationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [
      "r207",
      "r208",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of investment including named security. Excludes entity that is consolidated."
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/InvestmentsDetailsNarrative",
      "http://impactbiomedinc.com/role/NatureOfOperationsAndBasisOfPresentationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r230",
      "r231",
      "r232",
      "r233",
      "r286",
      "r364",
      "r406",
      "r442",
      "r443",
      "r508",
      "r516",
      "r517",
      "r518",
      "r528",
      "r538",
      "r539",
      "r547",
      "r554",
      "r557",
      "r561",
      "r647",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/NotesReceivableDetailsNarrative",
      "http://impactbiomedinc.com/role/RestatementDetailsNarrative",
      "http://impactbiomedinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r230",
      "r231",
      "r232",
      "r233",
      "r286",
      "r364",
      "r406",
      "r442",
      "r443",
      "r508",
      "r516",
      "r517",
      "r518",
      "r528",
      "r538",
      "r539",
      "r547",
      "r554",
      "r557",
      "r561",
      "r647",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/RestatementDetailsNarrative",
      "http://impactbiomedinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.",
        "label": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/NatureOfOperationsAndBasisOfPresentationDetailsNarrative",
      "http://impactbiomedinc.com/role/ScheduleOfCondensedFinancialStatementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment."
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/NatureOfOperationsAndBasisOfPresentationDetailsNarrative",
      "http://impactbiomedinc.com/role/ScheduleOfCondensedFinancialStatementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r230",
      "r231",
      "r232",
      "r233",
      "r284",
      "r286",
      "r288",
      "r289",
      "r290",
      "r363",
      "r364",
      "r406",
      "r442",
      "r443",
      "r508",
      "r516",
      "r517",
      "r518",
      "r528",
      "r538",
      "r539",
      "r547",
      "r554",
      "r557",
      "r561",
      "r564",
      "r640",
      "r647",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/NotesReceivableDetailsNarrative",
      "http://impactbiomedinc.com/role/RestatementDetailsNarrative",
      "http://impactbiomedinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r230",
      "r231",
      "r232",
      "r233",
      "r284",
      "r286",
      "r288",
      "r289",
      "r290",
      "r363",
      "r364",
      "r406",
      "r442",
      "r443",
      "r508",
      "r516",
      "r517",
      "r518",
      "r528",
      "r538",
      "r539",
      "r547",
      "r554",
      "r557",
      "r561",
      "r564",
      "r640",
      "r647",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/NotesReceivableDetailsNarrative",
      "http://impactbiomedinc.com/role/RestatementDetailsNarrative",
      "http://impactbiomedinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [
      "r137",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r190",
      "r212",
      "r213",
      "r309",
      "r334",
      "r335",
      "r336",
      "r337",
      "r348",
      "r349",
      "r350",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.",
        "label": "Revision of Prior Period [Axis]"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/BalanceSheets",
      "http://impactbiomedinc.com/role/BalanceSheetsParenthetical",
      "http://impactbiomedinc.com/role/StatementsOfCashFlows",
      "http://impactbiomedinc.com/role/StatementsOfOperations",
      "http://impactbiomedinc.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [
      "r137",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r190",
      "r212",
      "r213",
      "r309",
      "r334",
      "r335",
      "r336",
      "r337",
      "r348",
      "r349",
      "r350",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision."
       }
      }
     },
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/BalanceSheets",
      "http://impactbiomedinc.com/role/BalanceSheetsParenthetical",
      "http://impactbiomedinc.com/role/StatementsOfCashFlows",
      "http://impactbiomedinc.com/role/StatementsOfOperations",
      "http://impactbiomedinc.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioPreviouslyReportedMember": {
     "auth_ref": [
      "r137",
      "r168",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r182",
      "r190",
      "r309",
      "r334",
      "r335",
      "r336",
      "r348",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r593",
      "r594",
      "r595",
      "r596",
      "r618",
      "r624",
      "r625",
      "r657",
      "r660",
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents amount as previously reported before adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.",
        "label": "Previously Reported [Member]"
       }
      }
     },
     "localname": "ScenarioPreviouslyReportedMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/BalanceSheets",
      "http://impactbiomedinc.com/role/BalanceSheetsParenthetical",
      "http://impactbiomedinc.com/role/StatementsOfCashFlows",
      "http://impactbiomedinc.com/role/StatementsOfOperations",
      "http://impactbiomedinc.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfCondensedFinancialStatementsTableTextBlock": {
     "auth_ref": [
      "r600",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of condensed financial statements, including, but not limited to, the balance sheet, income statement, and statement of cash flows.",
        "label": "Schedule of Condensed Financial Statements"
       }
      }
     },
     "localname": "ScheduleOfCondensedFinancialStatementsTableTextBlock",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/NatureOfOperationsAndBasisOfPresentationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r207",
      "r208",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of investment including named security. Excludes entity that is consolidated.",
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/InvestmentsDetailsNarrative",
      "http://impactbiomedinc.com/role/NatureOfOperationsAndBasisOfPresentationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SubsidiariesMember": {
     "auth_ref": [
      "r648",
      "r662",
      "r663",
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity in which controlling financial interest is held. Includes, but is not limited to, variable interest entity (VIE) consolidated by primary beneficiary. Excludes entity in which broker-dealer holds controlling financial interest but control is likely to be temporary.",
        "label": "Subsidiaries [Member]"
       }
      }
     },
     "localname": "SubsidiariesMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/NatureOfOperationsAndBasisOfPresentationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r621",
      "r664"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.",
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of individual, or nature of relationship to individual or group of individuals."
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Changes and Error Corrections [Abstract]"
       }
      }
     },
     "localname": "AccountingChangesAndErrorCorrectionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r16",
      "r560"
     ],
     "calculation": {
      "http://impactbiomedinc.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://impactbiomedinc.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r45",
      "r143",
      "r397"
     ],
     "calculation": {
      "http://impactbiomedinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Less accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r79",
      "r560",
      "r679"
     ],
     "calculation": {
      "http://impactbiomedinc.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r291",
      "r292",
      "r293",
      "r430",
      "r615",
      "r616",
      "r617",
      "r656",
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://impactbiomedinc.com/role/InvestmentsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r7",
      "r43"
     ],
     "calculation": {
      "http://impactbiomedinc.com/role/StatementsOfOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "negatedLabel": "Impairment of investment"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r115",
      "r146",
      "r163",
      "r192",
      "r197",
      "r199",
      "r210",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r321",
      "r325",
      "r338",
      "r389",
      "r468",
      "r560",
      "r572",
      "r643",
      "r644",
      "r666"
     ],
     "calculation": {
      "http://impactbiomedinc.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r139",
      "r149",
      "r163",
      "r210",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r321",
      "r325",
      "r338",
      "r560",
      "r643",
      "r644",
      "r666"
     ],
     "calculation": {
      "http://impactbiomedinc.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r318",
      "r555",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/InvestmentsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r56",
      "r57",
      "r318",
      "r555",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/InvestmentsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r2",
      "r3",
      "r11"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Consideration given for purchase",
        "verboseLabel": "Purchase price"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/InvestmentsDetailsNarrative",
      "http://impactbiomedinc.com/role/NatureOfOperationsAndBasisOfPresentationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r125",
      "r392",
      "r431",
      "r461",
      "r560",
      "r572",
      "r604"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/SummaryOfSignificantAccountingAndReportingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r29",
      "r141",
      "r540"
     ],
     "calculation": {
      "http://impactbiomedinc.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents",
        "verboseLabel": "Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/BalanceSheets",
      "http://impactbiomedinc.com/role/GoodwillDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/SummaryOfSignificantAccountingAndReportingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r29",
      "r93",
      "r159"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r4",
      "r93"
     ],
     "calculation": {
      "http://impactbiomedinc.com/role/StatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowSupplementalDisclosuresTextBlock": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Supplemental Cash Flow Information"
       }
      }
     },
     "localname": "CashFlowSupplementalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/SupplementalCashFlowInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r24",
      "r70",
      "r391",
      "r452"
     ],
     "calculation": {
      "http://impactbiomedinc.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and contingencies (Note 12)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r104",
      "r228",
      "r229",
      "r536",
      "r641"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r562",
      "r563",
      "r564",
      "r566",
      "r567",
      "r568",
      "r569",
      "r615",
      "r616",
      "r656",
      "r677",
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/InvestmentsDetailsNarrative",
      "http://impactbiomedinc.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par value",
        "verboseLabel": "Common stock par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/BalanceSheetsParenthetical",
      "http://impactbiomedinc.com/role/InvestmentsDetailsNarrative",
      "http://impactbiomedinc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r78",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/BalanceSheetsParenthetical",
      "http://impactbiomedinc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/BalanceSheetsParenthetical",
      "http://impactbiomedinc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r13",
      "r78",
      "r453",
      "r474",
      "r683",
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/BalanceSheetsParenthetical",
      "http://impactbiomedinc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r78",
      "r393",
      "r560"
     ],
     "calculation": {
      "http://impactbiomedinc.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock, $.001 par value; 3,000,000,000 shares authorized, 125,073,621 shares issued and outstanding (125,073,621 on March 31, 2023 and December 31, 2022)"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]"
       }
      }
     },
     "localname": "ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/NatureOfOperationsAndBasisOfPresentationDetailsNarrative",
      "http://impactbiomedinc.com/role/ScheduleOfCondensedFinancialStatementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable": {
     "auth_ref": [
      "r12",
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning the effects of any changes in a parent's ownership interest in a subsidiary on the equity attributable to the parent which may have occurred during the period. The changes represented by this element did not result in the deconsolidation of the subsidiary.",
        "label": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table]"
       }
      }
     },
     "localname": "ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/NatureOfOperationsAndBasisOfPresentationDetailsNarrative",
      "http://impactbiomedinc.com/role/ScheduleOfCondensedFinancialStatementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleNotesPayableCurrent": {
     "auth_ref": [
      "r20"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.",
        "label": "Transfer of promissory note 2 to related party"
       }
      }
     },
     "localname": "ConvertibleNotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/ScheduleOfCashFlowSupplementalDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://impactbiomedinc.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CostsIncurredDevelopmentCosts": {
     "auth_ref": [
      "r68"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development costs incurred, including capitalized costs and costs charged to expense, in oil and gas activities.",
        "label": "Development costs"
       }
      }
     },
     "localname": "CostsIncurredDevelopmentCosts",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r597",
      "r613",
      "r654"
     ],
     "calculation": {
      "http://impactbiomedinc.com/role/ScheduleOfComponentsOfIncomeTaxBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/ScheduleOfComponentsOfIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r112",
      "r307",
      "r313",
      "r613"
     ],
     "calculation": {
      "http://impactbiomedinc.com/role/ScheduleOfComponentsOfIncomeTaxBenefitDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current tax payable"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/ScheduleOfComponentsOfIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r597",
      "r613",
      "r654"
     ],
     "calculation": {
      "http://impactbiomedinc.com/role/ScheduleOfComponentsOfIncomeTaxBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/ScheduleOfComponentsOfIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDefaultLongtermDebtDescriptionOfNoticeOfDefault": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the facts pertaining to a notice received from a lender that an event of default has occurred with respect to the long-term debt instrument or borrowing, and a description of the expected financial consequences of receiving such notice, including the effects of a demand for immediate repayment of all amounts due, and the classification of the debt on the balance sheet.",
        "label": "Long term debt, description"
       }
      }
     },
     "localname": "DebtDefaultLongtermDebtDescriptionOfNoticeOfDefault",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r105",
      "r161",
      "r243",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r259",
      "r266",
      "r267",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r15",
      "r73",
      "r74",
      "r116",
      "r118",
      "r167",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r250",
      "r255",
      "r256",
      "r257",
      "r258",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r347",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/DebtDetailsNarrative",
      "http://impactbiomedinc.com/role/NotesReceivableDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r15",
      "r118",
      "r269"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Debt carrying amount"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/GoodwillDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r63",
      "r65",
      "r244",
      "r347",
      "r550",
      "r551"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt face amount",
        "verboseLabel": "Outstanding balance, including interest"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/DebtDetailsNarrative",
      "http://impactbiomedinc.com/role/NotesReceivableDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r22",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt stated percentage",
        "terseLabel": "Debt instrument interest, rate",
        "verboseLabel": "Debt interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/DebtDetailsNarrative",
      "http://impactbiomedinc.com/role/GoodwillDetailsNarrative",
      "http://impactbiomedinc.com/role/NotesReceivableDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r133",
      "r549",
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.",
        "label": "Maturity date",
        "verboseLabel": "Debt instrument, maturity date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/DebtDetailsNarrative",
      "http://impactbiomedinc.com/role/NotesReceivableDetailsNarrative"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r23",
      "r167",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r250",
      "r255",
      "r256",
      "r257",
      "r258",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r347",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/DebtDetailsNarrative",
      "http://impactbiomedinc.com/role/NotesReceivableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentPeriodicPayment": {
     "auth_ref": [
      "r23",
      "r71"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the required periodic payments including both interest and principal payments.",
        "label": "Debt principal and interest"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPayment",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/NotesReceivableDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r613",
      "r653",
      "r654"
     ],
     "calculation": {
      "http://impactbiomedinc.com/role/ScheduleOfComponentsOfIncomeTaxBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "negatedLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/ScheduleOfComponentsOfIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r7",
      "r112",
      "r131",
      "r312",
      "r313",
      "r613"
     ],
     "calculation": {
      "http://impactbiomedinc.com/role/ScheduleOfComponentsOfIncomeTaxBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "negatedTotalLabel": "Total deferred tax"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/ScheduleOfComponentsOfIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r75",
      "r76",
      "r117",
      "r304"
     ],
     "calculation": {
      "http://impactbiomedinc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedLabel": "Gross deferred tax liability"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r297",
      "r298",
      "r390"
     ],
     "calculation": {
      "http://impactbiomedinc.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred tax liability, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://impactbiomedinc.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.",
        "label": "Deferred tax benefit"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r613",
      "r653",
      "r654"
     ],
     "calculation": {
      "http://impactbiomedinc.com/role/ScheduleOfComponentsOfIncomeTaxBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "negatedLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/ScheduleOfComponentsOfIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://impactbiomedinc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Intangible assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r305"
     ],
     "calculation": {
      "http://impactbiomedinc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred tax asset",
        "totalLabel": "Gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/IncomeTaxesDetailsNarrative",
      "http://impactbiomedinc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r55",
      "r652"
     ],
     "calculation": {
      "http://impactbiomedinc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Research &amp; development cost"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://impactbiomedinc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from investments (excludes investments in subsidiaries and equity method investments).",
        "label": "Impairment of investment"
       }
      }
     },
     "localname": "DeferredTaxAssetsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r651"
     ],
     "calculation": {
      "http://impactbiomedinc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "negatedLabel": "Less valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r55",
      "r652"
     ],
     "calculation": {
      "http://impactbiomedinc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Net Operating loss"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r53",
      "r651"
     ],
     "calculation": {
      "http://impactbiomedinc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Net deferred tax liability"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/ScheduleOfCashFlowSupplementalDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r7",
      "r44"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/PropertyPlantAndEquipmentAndInvestmentInRealEstateNetDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r7",
      "r44"
     ],
     "calculation": {
      "http://impactbiomedinc.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://impactbiomedinc.com/role/StatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation and amortization",
        "verboseLabel": "Amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/IntangibleAssetsDetailsNarrative",
      "http://impactbiomedinc.com/role/StatementsOfCashFlows",
      "http://impactbiomedinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r156",
      "r173",
      "r174",
      "r176",
      "r177",
      "r179",
      "r184",
      "r185",
      "r187",
      "r188",
      "r189",
      "r190",
      "r336",
      "r337",
      "r385",
      "r403",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss per common share:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r156",
      "r173",
      "r174",
      "r176",
      "r177",
      "r179",
      "r185",
      "r187",
      "r188",
      "r189",
      "r190",
      "r336",
      "r337",
      "r385",
      "r403",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r35",
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings (Loss) per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/SummaryOfSignificantAccountingAndReportingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/SummaryOfEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r164",
      "r300",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Statutory United States federal rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/SummaryOfEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r650",
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/SummaryOfEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r650",
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "State income taxes net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/SummaryOfEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r13",
      "r136",
      "r152",
      "r153",
      "r154",
      "r168",
      "r169",
      "r170",
      "r172",
      "r180",
      "r182",
      "r191",
      "r211",
      "r214",
      "r283",
      "r291",
      "r292",
      "r293",
      "r308",
      "r309",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r335",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r350",
      "r407",
      "r408",
      "r409",
      "r430",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/InvestmentsDetailsNarrative",
      "http://impactbiomedinc.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityFairValueAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of addition (reduction) to the amount at which an instrument classified in shareholders' equity could be incurred (settled) in a current transaction between willing parties.",
        "label": "Equity fair value"
       }
      }
     },
     "localname": "EquityFairValueAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/GoodwillDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equitable ownership percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/InvestmentsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r9",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/SummaryOfSignificantAccountingAndReportingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancingReceivableModificationsLineItems": {
     "auth_ref": [
      "r203",
      "r204",
      "r205",
      "r206",
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Financing Receivable, Modified [Line Items]"
       }
      }
     },
     "localname": "FinancingReceivableModificationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/NotesReceivableDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r145",
      "r226"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/ScheduleOfFutureAmortizationOfDevelopedTechnologiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r100"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/ScheduleOfFutureAmortizationOfDevelopedTechnologiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/ScheduleOfFutureAmortizationOfDevelopedTechnologiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r100"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "verboseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/ScheduleOfFutureAmortizationOfDevelopedTechnologiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r100"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/ScheduleOfFutureAmortizationOfDevelopedTechnologiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r100"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/ScheduleOfFutureAmortizationOfDevelopedTechnologiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r100"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/ScheduleOfFutureAmortizationOfDevelopedTechnologiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r224",
      "r225",
      "r226",
      "r227",
      "r369",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r99",
      "r370"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Gross Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r41",
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r99",
      "r369"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Net Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r87",
      "r478"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and administrative expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r144",
      "r217",
      "r383",
      "r548",
      "r560",
      "r629",
      "r636"
     ],
     "calculation": {
      "http://impactbiomedinc.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Balance at March 31, 2023",
        "periodStartLabel": "Balance at December 31, 2022"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/BalanceSheets",
      "http://impactbiomedinc.com/role/ScheduleOfGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r216",
      "r222",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/SummaryOfSignificantAccountingAndReportingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillDisclosureTextBlock": {
     "auth_ref": [
      "r216",
      "r219",
      "r221",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill.",
        "label": "Goodwill Disclosure [Text Block]",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Goodwill"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r7",
      "r218",
      "r220",
      "r222",
      "r548"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Impairment of goodwill",
        "verboseLabel": "Goodwill adjustment"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/ScheduleOfGoodwillDetails",
      "http://impactbiomedinc.com/role/SummaryOfSignificantAccountingAndReportingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "auth_ref": [
      "r610",
      "r639"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.",
        "label": "Impairment of intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/SummaryOfSignificantAccountingAndReportingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r0",
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Recoverability of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/SummaryOfSignificantAccountingAndReportingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r1",
      "r84",
      "r121",
      "r192",
      "r196",
      "r198",
      "r200",
      "r386",
      "r399",
      "r545"
     ],
     "calculation": {
      "http://impactbiomedinc.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss from continuing operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r164",
      "r296",
      "r301",
      "r302",
      "r306",
      "r310",
      "r315",
      "r316",
      "r317",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r124",
      "r132",
      "r181",
      "r182",
      "r195",
      "r299",
      "r311",
      "r405"
     ],
     "calculation": {
      "http://impactbiomedinc.com/role/ScheduleOfComponentsOfIncomeTaxBenefitDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://impactbiomedinc.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income tax benefit",
        "negatedLabel": "Income tax (loss)/benefit",
        "totalLabel": "income tax benefit"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/ScheduleOfComponentsOfIncomeTaxBenefitDetails",
      "http://impactbiomedinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r6"
     ],
     "calculation": {
      "http://impactbiomedinc.com/role/StatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r6"
     ],
     "calculation": {
      "http://impactbiomedinc.com/role/StatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "verboseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredLiabilities": {
     "auth_ref": [
      "r6"
     ],
     "calculation": {
      "http://impactbiomedinc.com/role/StatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change during the period in carrying value for all deferred liabilities due within one year or operating cycle.",
        "label": "Deferred Tax benefit"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Decrease (increase) in assets:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) in liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r6"
     ],
     "calculation": {
      "http://impactbiomedinc.com/role/StatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/IntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r42",
      "r365",
      "r366",
      "r367",
      "r369",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "verboseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/SummaryOfSignificantAccountingAndReportingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r64",
      "r123",
      "r155",
      "r194",
      "r346",
      "r484",
      "r570",
      "r680"
     ],
     "calculation": {
      "http://impactbiomedinc.com/role/StatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/RestatementDetailsNarrative",
      "http://impactbiomedinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r89",
      "r193"
     ],
     "calculation": {
      "http://impactbiomedinc.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentOwnedAtCost": {
     "auth_ref": [
      "r418",
      "r439",
      "r440",
      "r511",
      "r515",
      "r521",
      "r530",
      "r564",
      "r572",
      "r678"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of the investment.",
        "label": "Investment cost"
       }
      }
     },
     "localname": "InvestmentOwnedAtCost",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/InvestmentsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentOwnedAtFairValue": {
     "auth_ref": [
      "r418",
      "r433",
      "r434",
      "r435",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r444",
      "r445",
      "r456",
      "r457",
      "r507",
      "r509",
      "r510",
      "r512",
      "r519",
      "r520",
      "r522",
      "r523",
      "r524",
      "r526",
      "r527",
      "r529",
      "r531",
      "r532",
      "r564",
      "r572",
      "r678"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in security owned.",
        "label": "Investment owned at fair value"
       }
      }
     },
     "localname": "InvestmentOwnedAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/InvestmentsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentOwnedPercentOfNetAssets": {
     "auth_ref": [
      "r436",
      "r439",
      "r440",
      "r509",
      "r519",
      "r522",
      "r525",
      "r531",
      "r564",
      "r678"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of investment owned to net assets.",
        "label": "Investment cost, percent"
       }
      }
     },
     "localname": "InvestmentOwnedPercentOfNetAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/InvestmentsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r404",
      "r418",
      "r419",
      "r420",
      "r421",
      "r513",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "verboseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/SummaryOfSignificantAccountingAndReportingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentTextBlock": {
     "auth_ref": [
      "r598",
      "r599",
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investment.",
        "label": "Investments"
       }
      }
     },
     "localname": "InvestmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Investments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsAllOtherInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, All Other Investments [Abstract]"
       }
      }
     },
     "localname": "InvestmentsAllOtherInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LaborAndRelatedExpense": {
     "auth_ref": [
      "r609"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.",
        "label": "Related costs for employees"
       }
      }
     },
     "localname": "LaborAndRelatedExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r19",
      "r163",
      "r210",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r322",
      "r325",
      "r326",
      "r338",
      "r451",
      "r544",
      "r572",
      "r643",
      "r666",
      "r667"
     ],
     "calculation": {
      "http://impactbiomedinc.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r83",
      "r120",
      "r396",
      "r560",
      "r612",
      "r623",
      "r659"
     ],
     "calculation": {
      "http://impactbiomedinc.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholder\u2019s equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDER\u2019S EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r21",
      "r140",
      "r163",
      "r210",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r322",
      "r325",
      "r326",
      "r338",
      "r560",
      "r643",
      "r666",
      "r667"
     ],
     "calculation": {
      "http://impactbiomedinc.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": {
     "auth_ref": [
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.",
        "label": "Notes Receivable"
       }
      }
     },
     "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/NotesReceivable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long term debt fair value"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/GoodwillDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment [Member]"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r26",
      "r119",
      "r163",
      "r210",
      "r234",
      "r236",
      "r237",
      "r238",
      "r241",
      "r242",
      "r338",
      "r395",
      "r455"
     ],
     "calculation": {
      "http://impactbiomedinc.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.",
        "label": "Non-controlling interest in subsidiary",
        "verboseLabel": "Noncontrolling interest"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/BalanceSheets",
      "http://impactbiomedinc.com/role/NatureOfOperationsAndBasisOfPresentationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.",
        "label": "Minority interest ownership percentage"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/NatureOfOperationsAndBasisOfPresentationDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Attributable interest percentage",
        "verboseLabel": "Ownership percentage"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/NatureOfOperationsAndBasisOfPresentationDetailsNarrative",
      "http://impactbiomedinc.com/role/ScheduleOfCondensedFinancialStatementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r126",
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations and Basis of Presentation"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/NatureOfOperationsAndBasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r158"
     ],
     "calculation": {
      "http://impactbiomedinc.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r158"
     ],
     "calculation": {
      "http://impactbiomedinc.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r93",
      "r94",
      "r95"
     ],
     "calculation": {
      "http://impactbiomedinc.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r85",
      "r95",
      "r122",
      "r138",
      "r150",
      "r151",
      "r154",
      "r163",
      "r171",
      "r173",
      "r174",
      "r176",
      "r177",
      "r181",
      "r182",
      "r186",
      "r192",
      "r196",
      "r198",
      "r200",
      "r210",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r337",
      "r338",
      "r402",
      "r476",
      "r497",
      "r498",
      "r545",
      "r570",
      "r643"
     ],
     "calculation": {
      "http://impactbiomedinc.com/role/StatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net loss attributable to common stockholders"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r61",
      "r114",
      "r150",
      "r151",
      "r181",
      "r182",
      "r401",
      "r608"
     ],
     "calculation": {
      "http://impactbiomedinc.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedLabel": "Loss from continuing operations attributed to noncontrolling interest"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "Recent Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/SummaryOfSignificantAccountingAndReportingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r58",
      "r283",
      "r615",
      "r616",
      "r617",
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesAndLoansReceivableGrossCurrent": {
     "auth_ref": [
      "r147",
      "r541",
      "r546",
      "r626"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost, before allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease.",
        "label": "Notes receivable current"
       }
      }
     },
     "localname": "NotesAndLoansReceivableGrossCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/NotesReceivableDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesAndLoansReceivableNetCurrent": {
     "auth_ref": [
      "r201",
      "r202",
      "r384"
     ],
     "calculation": {
      "http://impactbiomedinc.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease.",
        "label": "Current portion of notes receivable"
       }
      }
     },
     "localname": "NotesAndLoansReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesAndLoansReceivableNetNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://impactbiomedinc.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of financing receivable, classified as noncurrent.",
        "label": "Notes receivable",
        "verboseLabel": "Notes and loans receivable"
       }
      }
     },
     "localname": "NotesAndLoansReceivableNetNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/BalanceSheets",
      "http://impactbiomedinc.com/role/NotesReceivableDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayable": {
     "auth_ref": [
      "r15",
      "r118",
      "r676"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.",
        "label": "Outstanding balance",
        "negatedLabel": "Transfer of note payable, related party"
       }
      }
     },
     "localname": "NotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/DebtDetailsNarrative",
      "http://impactbiomedinc.com/role/ScheduleOfCashFlowSupplementalDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://impactbiomedinc.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Note payable, related party"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesReceivableNet": {
     "auth_ref": [
      "r201",
      "r215",
      "r462"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease.",
        "label": "Note receivable principal"
       }
      }
     },
     "localname": "NotesReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/NotesReceivableDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r192",
      "r196",
      "r198",
      "r200",
      "r545"
     ],
     "calculation": {
      "http://impactbiomedinc.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r54"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherGeneralExpense": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://impactbiomedinc.com/role/StatementsOfOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of general expenses not normally included in Other Operating Costs and Expenses.",
        "label": "Other general expense"
       }
      }
     },
     "localname": "OtherGeneralExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIntangibleAssetsNet": {
     "auth_ref": [],
     "calculation": {
      "http://impactbiomedinc.com/role/BalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other.",
        "label": "Other intangible assets, net"
       }
      }
     },
     "localname": "OtherIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLongTermInvestments": {
     "auth_ref": [
      "r388",
      "r605"
     ],
     "calculation": {
      "http://impactbiomedinc.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term investments classified as other.",
        "label": "Other investments"
       }
      }
     },
     "localname": "OtherLongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://impactbiomedinc.com/role/StatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other income (expense)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r606",
      "r627"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses includes prepaid inventory"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/PrepaidExpensesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromProductiveAssets": {
     "auth_ref": [],
     "calculation": {
      "http://impactbiomedinc.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash outflow or inflow from purchases, sales and disposals of property, plant and equipment and other productive assets, including intangibles.",
        "label": "Payments for (Proceeds from) Productive Assets",
        "negatedLabel": "Purchase of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsForProceedsFromProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r27"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.",
        "label": "Payment in funding of research and development"
       }
      }
     },
     "localname": "PaymentsToAcquireInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://impactbiomedinc.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Purchase of investment"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r77",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r77",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r77",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r77",
      "r453",
      "r474",
      "r683",
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r607"
     ],
     "calculation": {
      "http://impactbiomedinc.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses and other current assets",
        "verboseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/BalanceSheets",
      "http://impactbiomedinc.com/role/PrepaidExpensesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrentAndNoncurrent": {
     "auth_ref": [
      "r69",
      "r148",
      "r467",
      "r675"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.",
        "label": "Prepaid monthly fees"
       }
      }
     },
     "localname": "PrepaidExpenseCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r5"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/InvestmentsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "auth_ref": [
      "r5"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.",
        "label": "Proceeds from private placement"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/InvestmentsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRelatedPartyDebt": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://impactbiomedinc.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.",
        "label": "Borrowings from note payable, related party"
       }
      }
     },
     "localname": "ProceedsFromRelatedPartyDebt",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfessionalFees": {
     "auth_ref": [
      "r570",
      "r681",
      "r682"
     ],
     "calculation": {
      "http://impactbiomedinc.com/role/StatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.",
        "label": "Professional services"
       }
      }
     },
     "localname": "ProfessionalFees",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r138",
      "r150",
      "r151",
      "r157",
      "r163",
      "r171",
      "r181",
      "r182",
      "r192",
      "r196",
      "r198",
      "r200",
      "r210",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r320",
      "r323",
      "r324",
      "r337",
      "r338",
      "r386",
      "r400",
      "r429",
      "r476",
      "r497",
      "r498",
      "r545",
      "r558",
      "r559",
      "r571",
      "r608",
      "r643"
     ],
     "calculation": {
      "http://impactbiomedinc.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://impactbiomedinc.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/StatementsOfCashFlows",
      "http://impactbiomedinc.com/role/StatementsOfOperations",
      "http://impactbiomedinc.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock": {
     "auth_ref": [
      "r98",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for intangible assets and long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.",
        "label": "PROPERTY PLANT AND EQUIPMENT and INVESTMENT IN REAL ESTATE, NET"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/PropertyPlantAndEquipmentAndInvestmentInRealEstateNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r102",
      "r142",
      "r398"
     ],
     "calculation": {
      "http://impactbiomedinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, plant and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r8",
      "r387",
      "r398",
      "r560"
     ],
     "calculation": {
      "http://impactbiomedinc.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://impactbiomedinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, plant and equipment, net",
        "totalLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/BalanceSheets",
      "http://impactbiomedinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Schedule of Property Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/PropertyPlantAndEquipmentAndInvestmentInRealEstateNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Estimated Useful Life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReceivablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables [Abstract]"
       }
      }
     },
     "localname": "ReceivablesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r285",
      "r354",
      "r355",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r473",
      "r475",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/BalanceSheets",
      "http://impactbiomedinc.com/role/InvestmentsDetailsNarrative",
      "http://impactbiomedinc.com/role/PrepaidExpensesDetailsNarrative",
      "http://impactbiomedinc.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://impactbiomedinc.com/role/ScheduleOfCashFlowSupplementalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyMember": {
     "auth_ref": [
      "r165",
      "r166",
      "r354",
      "r355",
      "r356",
      "r357",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r473",
      "r475",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family.",
        "label": "Related Party [Member]"
       }
      }
     },
     "localname": "RelatedPartyMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/BalanceSheets",
      "http://impactbiomedinc.com/role/PrepaidExpensesDetailsNarrative",
      "http://impactbiomedinc.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://impactbiomedinc.com/role/ScheduleOfCashFlowSupplementalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "auth_ref": [
      "r67",
      "r354"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transactions with related party during the financial reporting period.",
        "label": "Related party owed transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [
      "r479",
      "r480",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r285",
      "r354",
      "r355",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r473",
      "r475",
      "r506",
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party, Type [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/BalanceSheets",
      "http://impactbiomedinc.com/role/InvestmentsDetailsNarrative",
      "http://impactbiomedinc.com/role/PrepaidExpensesDetailsNarrative",
      "http://impactbiomedinc.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://impactbiomedinc.com/role/ScheduleOfCashFlowSupplementalDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r351",
      "r352",
      "r353",
      "r355",
      "r358",
      "r425",
      "r426",
      "r427",
      "r481",
      "r482",
      "r483",
      "r503",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r72",
      "r295",
      "r674"
     ],
     "calculation": {
      "http://impactbiomedinc.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research &amp; development",
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development cost"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/PrepaidExpensesDetailsNarrative",
      "http://impactbiomedinc.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://impactbiomedinc.com/role/StatementsOfOperations",
      "http://impactbiomedinc.com/role/SummaryOfSignificantAccountingAndReportingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/SummaryOfSignificantAccountingAndReportingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r80",
      "r107",
      "r394",
      "r411",
      "r416",
      "r423",
      "r454",
      "r560"
     ],
     "calculation": {
      "http://impactbiomedinc.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated undistributed earnings (deficit).",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r136",
      "r168",
      "r169",
      "r170",
      "r172",
      "r180",
      "r182",
      "r211",
      "r214",
      "r291",
      "r292",
      "r293",
      "r308",
      "r309",
      "r327",
      "r329",
      "r330",
      "r332",
      "r335",
      "r407",
      "r409",
      "r430",
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated undistributed earnings (deficit).",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.",
        "label": "Schedule of Cash Flow Supplemental"
       }
      }
     },
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/SupplementalCashFlowInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Benefit"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable": {
     "auth_ref": [
      "r46",
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule, table or text reflecting arrangements that are not equity-based payments, or pension and other postretirement benefits, with individual employees. The arrangements (for example, profit sharing, deferred bonuses or certain split-dollar life insurance arrangements) are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain amounts at designated future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability.",
        "label": "Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]"
       }
      }
     },
     "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r10",
      "r47",
      "r48",
      "r49",
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/ScheduleOfCashFlowSupplementalDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Summary of Effective Income Tax Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock": {
     "auth_ref": [
      "r32",
      "r33",
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made.",
        "label": "Restatement"
       }
      }
     },
     "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/Restatement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFinancingReceivableTroubledDebtRestructuringsTable": {
     "auth_ref": [
      "r203",
      "r204",
      "r205",
      "r206",
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about financing receivable modified for debtor experiencing financial difficulty.",
        "label": "Financing Receivable, Modified [Table]"
       }
      }
     },
     "localname": "ScheduleOfFinancingReceivableTroubledDebtRestructuringsTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/NotesReceivableDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r41",
      "r42",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r548",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/GoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.",
        "label": "Schedule of Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/IntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r66",
      "r67",
      "r479",
      "r480",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of Short-Term Debt [Table]"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Future Amortization of Developed Technologies"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/IntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://impactbiomedinc.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, general and administrative compensation"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": {
     "auth_ref": [
      "r51",
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.",
        "label": "Option termination, description"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/InvestmentsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": {
     "auth_ref": [
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares purchased for issuance under share-based payment arrangement.",
        "label": "Options to purchase common stock"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/InvestmentsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share price"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/InvestmentsDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance, shares",
        "periodStartLabel": "Balance, shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermDebtLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Short-Term Debt [Line Items]"
       }
      }
     },
     "localname": "ShortTermDebtLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r96",
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Summary of Significant Accounting and Reporting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/SummaryOfSignificantAccountingAndReportingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r13",
      "r25",
      "r136",
      "r152",
      "r153",
      "r154",
      "r168",
      "r169",
      "r170",
      "r172",
      "r180",
      "r182",
      "r191",
      "r211",
      "r214",
      "r283",
      "r291",
      "r292",
      "r293",
      "r308",
      "r309",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r335",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r350",
      "r407",
      "r408",
      "r409",
      "r430",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/InvestmentsDetailsNarrative",
      "http://impactbiomedinc.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [
      "r168",
      "r169",
      "r170",
      "r191",
      "r368",
      "r418",
      "r432",
      "r444",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r453",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r463",
      "r464",
      "r465",
      "r466",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r475",
      "r477",
      "r478",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r499",
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/BalanceSheets",
      "http://impactbiomedinc.com/role/BalanceSheetsParenthetical",
      "http://impactbiomedinc.com/role/InvestmentsDetailsNarrative",
      "http://impactbiomedinc.com/role/PrepaidExpensesDetailsNarrative",
      "http://impactbiomedinc.com/role/RestatementDetailsNarrative",
      "http://impactbiomedinc.com/role/StatementsOfCashFlows",
      "http://impactbiomedinc.com/role/StatementsOfOperations",
      "http://impactbiomedinc.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r168",
      "r169",
      "r170",
      "r191",
      "r368",
      "r418",
      "r432",
      "r444",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r453",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r463",
      "r464",
      "r465",
      "r466",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r475",
      "r477",
      "r478",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r499",
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/BalanceSheets",
      "http://impactbiomedinc.com/role/BalanceSheetsParenthetical",
      "http://impactbiomedinc.com/role/InvestmentsDetailsNarrative",
      "http://impactbiomedinc.com/role/PrepaidExpensesDetailsNarrative",
      "http://impactbiomedinc.com/role/RestatementDetailsNarrative",
      "http://impactbiomedinc.com/role/StatementsOfCashFlows",
      "http://impactbiomedinc.com/role/StatementsOfOperations",
      "http://impactbiomedinc.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r77",
      "r78",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Number of common stock owned"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/InvestmentsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r13",
      "r77",
      "r78",
      "r107",
      "r422",
      "r499",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock issued during period shares",
        "verboseLabel": "Number of shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/InvestmentsDetailsNarrative",
      "http://impactbiomedinc.com/role/NatureOfOperationsAndBasisOfPresentationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.",
        "label": "Ordinary shares to purchase"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/InvestmentsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r13",
      "r77",
      "r78",
      "r107",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Stock option exercised, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/InvestmentsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r13",
      "r77",
      "r78",
      "r107",
      "r430",
      "r499",
      "r533",
      "r571"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Issuance of common stock, net",
        "verboseLabel": "Number of shares issued, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/InvestmentsDetailsNarrative",
      "http://impactbiomedinc.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.",
        "label": "Purchase price of shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValuePurchaseOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/InvestmentsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r13",
      "r25",
      "r107"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock option exercised, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/InvestmentsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r78",
      "r81",
      "r82",
      "r97",
      "r455",
      "r474",
      "r500",
      "r501",
      "r560",
      "r572",
      "r612",
      "r623",
      "r659",
      "r683"
     ],
     "calculation": {
      "http://impactbiomedinc.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.",
        "label": "Equity, Attributable to Parent",
        "totalLabel": "Total stockholder\u2019s equity of the company"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r58",
      "r59",
      "r60",
      "r136",
      "r137",
      "r153",
      "r168",
      "r169",
      "r170",
      "r172",
      "r180",
      "r211",
      "r214",
      "r283",
      "r291",
      "r292",
      "r293",
      "r308",
      "r309",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r335",
      "r339",
      "r340",
      "r344",
      "r350",
      "r408",
      "r409",
      "r428",
      "r455",
      "r474",
      "r500",
      "r501",
      "r534",
      "r571",
      "r612",
      "r623",
      "r659",
      "r683"
     ],
     "calculation": {
      "http://impactbiomedinc.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholder\u2019s equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/BalanceSheets",
      "http://impactbiomedinc.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholder\u2019s equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r106",
      "r162",
      "r270",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r333",
      "r502",
      "r504",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for equity.",
        "label": "Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubscriptionArrangementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Category of deferred revenue by arrangement wherein a subscribers pay in advance for media (TV, newspaper, magazine, internet), which will generally be recognized as revenue as the media is delivered.",
        "label": "Subscription Arrangement [Member]"
       }
      }
     },
     "localname": "SubscriptionArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/InvestmentsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r345",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r345",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r345",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r360",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]"
       }
      }
     },
     "localname": "SupplementalCashFlowElementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://impactbiomedinc.com/role/InvestmentsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r37",
      "r38",
      "r39",
      "r127",
      "r128",
      "r129",
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/SummaryOfSignificantAccountingAndReportingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r303"
     ],
     "calculation": {
      "http://impactbiomedinc.com/role/ScheduleOfComponentsOfIncomeTaxBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Less increase in valuation allowance",
        "verboseLabel": "Valuation allowance deferred tax"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/IncomeTaxesDetailsNarrative",
      "http://impactbiomedinc.com/role/ScheduleOfComponentsOfIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment",
        "verboseLabel": "Diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares used in computing loss per common share:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r184",
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "verboseLabel": "Basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://impactbiomedinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org//360/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org//440/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org//470/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org//505/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "https://asc.fasb.org//1943274/2147483043/710-10-30-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org//275/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Footnote": "4",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-33",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-34",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-42",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-42",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org//350-20/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org//350-30/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "730",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org//740/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "808",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(iii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(iv)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(i)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org//850/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481435/852-10-45-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org//855/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(b)",
   "Topic": "920",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(7))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(f))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(17))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(f)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(f)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(f)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)(2)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(c)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(c)(2)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(2)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(e)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(f)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(11))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(14))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(15))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(17))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(19))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "https://asc.fasb.org//1943274/2147483070/710-10-25-11",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(5)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(7)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(8))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(9))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(e)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(i)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(2)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(3)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 9))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column F))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r573": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r574": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r575": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r576": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r577": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r578": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r579": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r581": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r582": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r583": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r584": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r585": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r586": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r587": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r588": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r589": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r591": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r592": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "321",
   "URI": "https://asc.fasb.org//321/tableOfContent",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "325",
   "URI": "https://asc.fasb.org//325/tableOfContent",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "04",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r601": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(i)",
   "Subsection": "01",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r602": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iv)",
   "Subsection": "01",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r603": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iv)",
   "Subsection": "02",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-12",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4M",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4M",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//310-10/tableOfContent",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org//320/tableOfContent",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org//450/tableOfContent",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(3)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(18))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-18",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(i)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(k)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.6)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "230",
   "URI": "https://asc.fasb.org//230/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org//235/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org//350/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>76
<FILENAME>0001493152-23-025388-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-23-025388-xbrl.zip
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M6 Z$V<FEN9=8W9KOY*^F]^^J\U?:?P-02P,$%     @ Z8KX5DJHMAB^ 0
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M7%M([;'K0FJ[)Q0#VE%W8P!/"BT,.A>9^&Y"?,E(91LHI9;O12M/:F&<.IY
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MB)QH[>!#]R#^P;SPZF9SX\/[[L'B8,KLQK%G13@ST<N#SGKS?7OZS*<^4#$
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M?FT;QW \8W/43/Y@<;@M",N]<!QI7V(4)4')O\FI/[Z;B,V9 ](NVJ,^$_Z
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M^J**PP9HE48[J?1-B6M0D9:3XDSNMJXF-E47O'!'4B9Y1EUFY)04-SWC+K-
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MH]%/?7W/Q[^) OV- 5.I+[W(C_'6IW G]8\JF'DHO$_8U$5VFZ[++$C RKA
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MEW F'X7-1KIT9,I= 1.H'M;T9$_T0'AGK@MG[0>IW@N8GZ0_]X0?A$; 9($
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MOUXHF6X6I76.]3&=@YH0W%/:$<6^^+*G)>9LF1@%V@.!P$.JW8UU$KKQ#L:
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M3/JP- '63XQSY58,Y)169<L'DMI,%,+JM<!7Z90G\:P(I 00:<M<Q;7D=L4
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M_%G<..;F,2)',RC.E72X D^$!E:2"@N\*D[^D 6.?9(=AA-HU$+^Z+'T,6;
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M1W4>(+K3H#*'CMY$M"W#2K?MY."B.P%:VOG5K\1AX.T9:ND(24PJ+ 3=@=B
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MHZX]LYJ:K8FQ0 VXO0:E6Y.".7P=(A9JW((8,/)F@X)&BWJKO(IG2T-:R+
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M8MP+2%Y2IW0I]04XC% 09U795-:Z,PMWGY(< BZ33C:O[I$EC:P*20H/))=
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M#=,PF?\'*F=[ ^ >,/AV^8/-!37IDVT/DNL[ZLQY^S3E> L=ST=)A<M5JJ]
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M_+OM7X1[!8;OOMJ[A9#75\A!=O%S:CETQ*9W'JBZ<1)Q9THGB-_^\[N3-E#
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M2^31@/Y&-V3,37IW&?AA$7CX1!(6 J$#B#,D=8"GKPJ5W\@HW[06L#4%+LY
M!YR\L0@DXTM1,!D2X4]Q)>CT!7=EP%]$<H!WTC<<9*X RV9 G^EDA5"2!Y"D
M$*<5YZK4R%&,^&.6>S5$JRA!^&L% NTA =QERJM<?Z_I?Y%;K_(MS&IM?M.E
M7ZB7XS.2;%HE94S'-52,.*R!N3YQEQ*ZL"<](%6DL><DHXFE#P._1FNCT2"R
M3W3[\'3$:2M5X<*T&:F6#0&['"GP*L6?SXCM(NW%+ZO4<E2&04JZ4.$-5!(3
MF3/7GV81K8+>,]S.W!#I(4^7B"X3W<9T2.)$C=!8'3\1KPQOPCC1;1T-\CQ,
MBX.IF@[H!WI-Y5-E^C[>3N($72)C3H%"Q_0B'"F\668?4:3(C$'3S_5+AZ0V
M-B=5^%6=E>0[.V^VEAM/,H/@29<QRT;!Q&N0I6? \_BGGS,>D_M.RL9"\!E(
M/3UQ_?85G3B)'GT0D>DLCT0CEGN<ZE3X#]3A^-">X%PDT@&=7!).IV&9Y7/[
MB1J(__#0JQ=A\=>6/)!#133EM+Q\]?(,^&^-DZ_C3OC]M$(+^1GR"*2O-2</
M$(7183%1&:[HB\Z,KO32=-(C*O^@RGIG?T\YV,%I3D1J%W57^P#H2&0A9/0>
M\\0LD?J/<:06WPW8RG8.RF''/-^!,E../-IYZ6#/Z\..$;M-AP#5T@%ARG3S
M_#%2(5*=>O;.3&9$%,,'BM0+7GB(1O?ZL)Q-* S2M_& A?#31@;>+1#Q2&-C
M2@(@6.5,773_(0KHET/Z'$LCSDLHY"2<K3$9@SB'YK.LW\GPR(WI'IYHU+SE
MT38R*0I>6?+KRO!#+0/G*LQ%99&VJ]R<E!5,"$9< 20F(+42/.+0OR;]BPZ'
M)\(K1,Y=G1"19N[G??UY#]*SN6C_@>3((),!?.Z6Z/LA<B3K\R:>9M386V6:
MKDMW5)"L'#T&S,P$:-Z<Q#&7'^XVDT/_595C"DC6E-S#[K5A7+.?&4PVTBY5
MT9[SK;*IB*Q-T.SJW2PYKS%24^1H(JO'8[[JT#A#RDV."V=C)&&:HHXJ-F/(
M645T>.K#PA[(/>2C+$A'=09=<FJ:<NCR2/Y)!_W8]:8*L@(&AZ'0#NJ4?*CZ
MNS]K''T9)_;#]79R<T@[;$VQ^D[<ZK:]F"DNNMG+A:4WOWGHOZCRG"XXDF_K
MU?(V%BZI=*W2(0YO%9E*VBS><#[<I[GLAPJZG8[=(H=9$8K8RH5\BG-I"\)L
M@VB-ODQ6>-XP*,1C+.)T5N7#20CS(7"2/=@4.=#&!GYA#!89QAC9C(KHE)YU
MAA@N%WM;^'OP$AC>Z?3I+@WST J#VV_:'U<AJ4&ETAJBN;5..V\:TFL/R:F(
M8;GP*9-0@R1KT@"=C1F%-V0/:"8 UO&"DV;FO4V]#9YQ9_,L5&56*+N\O5KE
M7AZ-WG'/T8U1&T+EK"MQ78;0I+(AG39.0YO&+&XN1*P8 6,-I4"KB[%C3K!%
MQY:-*4U1VR:H>$$*C?+J09,L19YS"(L+7^,^\XYEPD);IAZ8']K?@]1/_4D\
MGASPKPO8@@70.RJ%IC57,&O((J7E@EMP=0QM!Y"&<.C_MN15R><=<FU[%'C
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M["KRQV&L_; )%Z,R5A(;BRK,4PG O*+/=4\]J\IZ]O[2V8LI6M^BHC%!W+_
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M\K:MN"T,ZVU+<?._!L7MKI;CY6AT\(NND7;%-=+.\ASQ>ET=:J-V8U=9NQ7
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M&19X^;AL+$WPKAJ>ZK.A8 &'":E(J?A6A76&\50J^*'.)EGU)'(&RM0X([G
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MA^G@U*>%/3 =FND8N:%9.>B2$]-4HU%$&VG',^NM@&XR=390IJ0\E^^5V@:
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M7WN'\]V4JZ=T9R*_=RL&X8@9)M*2_*JLHZ3<!4GI<KF^%9M .8/3SWGR2I
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M>0MO9N\8>P2M56O9E[G1@J'TXY$Q&#K:&AT7L59M41_L.'$'^MW"&Q?>"1\
M! B]ITBS%=*0A0.9MRG] $4Q/-=%Z>@<],&25[*T(_Z>E0[VS).CRKBR(-*(
M[I@#?.!9-74S,>>*;QGZ2CJ;&H\@/F0"0#8G^PY0>,(LNXBA=]=VQGKXO%E
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M)BX!$ZF\G8<7U"$L4/MH7 -(F]0=762 C]Q4NA][L&=.K(OY2>>H_X3_M=3
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MWUY_<+&%DNY" Z AH 4Q' ^HG#NY<)*U%(9Z"W>X;,QD7 _S""@EB-KQ! '
M2K/3LS4ODE:U  4*;-*^(-=WGCPY=(K,L4-&&EIH(%THZBS37B7B<#0)>*]<
M4!7-*!'T<?!5.&=EZ09IIRV.K0Q^BQ]4M[_Q;%6YH/"PYTN-+.^Q#<<9Z5U6
MR(O11>]8D_%>A?%8XO7$4;3?U339*5'W2[1<ADB6BORNIV^7Z<LM#F\!N5H
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M[7C,B&F1:8XD 7%YA:0$J7R*W&#Z89&IAD_UHQSQMW6C;OU$R1++,MM*YI2
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M :/!F3):*U4!#!P',TBS>C<Y.Y+4ZMU0@%N&'/H'R(<EU7 R]9&/.@HEG3)
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M&@RJ!Z=7EAGV@\5FR^:O<W<R UL^2]A9.HG9&*,!^&E_S!J3^S*9Z.++38S
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M!41#@AE4^/7OWC4D%0B(&C!H[G6?JQ5)I6K7GD>>SX)1:\L)N?,Z5F(2IYL
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M&4'^9(P_0:*E*.R;#/0_.K1?G36T/WMDOS0IM(\MCB<$]E.VL9R!_9$V7=.
M_O2X/NT53?M*46@^)9 ?13B49P7R9^:>>2#%+*5!'LZ3D@/P"ACF*^+]1<[
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M[/D2)W7V&C_\VYI-PE>0!R4IH.1YN4[+1"$/>!I'D"%7K'*M/O^$ZS<A/#/
M@7E$L2OSKS::-I]/]IDU?)\$V"7.\E#]WNGJ7H?E_TQBC7>]P;^'C=_.X>E\
M6>.\E<P)B7,Q++!]EA49)D6&WCPI,1T-\\642UKF=%O,=%U4@JC<W:_L$Z-L
MW9>[EFD2^ YPQ:IUW_+LBK:QMO*E'+7N>_DDS;6$^BI"HD@)V%?5<D)X3=SB
M;YLV=F7?N]#OB;]W'W@Z0-8"VA@<!*3G3QK]%*=AQ*R^IY\>#@\:7G/8JN_M
M[9D;/T]^OZ Z_(RH"0)-;0/4*$-A8%/="&XJZX@K_ L!@JY0CS[.$>'RF>>Q
M4=K<F+^3HM"\%X]:\\T7J:[-O]IKH?DBQ4RE_ 59"]AE[!K<'-.M@,]P5\ V
M<4C; KWHF-F_0A'Z\W?8.O>KZ]K^=;[]@C/70AY$.H_Z'O-2/_S38F<O+(ZY
M!CQ3\>UEU*)TL5:O%J.4"P1\KO*4CEM:J;:5G]'*A3+UYA2" G89*U-[(\W+
MK$"4]_0"KCSU]..#P^'AC=8<_J@<DJ_GOXPU35]"?]+$.7S')'A6;4\.!_P]
M0G1E..7O >]!C&!Y4I@VD+N_U/2_# ,$!<X] >?FH2-MKLV[*\E#Z%1XF]ZJ
MD"]@-\?L7M 38@=X(P@\JQ72"6$7[J3X7"(;(]*CS-.3[Y7>QL9]92W?[JAG
MM>MZ*'JG<P@2$V>O.@D(JA8'8>%-F*,WX=$(G<_X'PJA'#@E"B3-,9+.,Y*X
MOI8?IUBA];U!S:6 7<9:W]HDK4_.N(K4N;W;"UN_^?VSXG1>HULL4M3H,%Q0
MU0 8/1?3\ESCN@NO)=YK<IW]-V<>C 3^Y5,!VRA5UN<==7P3+K3EP[UYZE5:
MJ5;).D.K<*45BD&A5+V(4K4C*55[NN< &?JGQ#OOZA[9UGW+6%2_GRST*.[>
MZA,O4H?P'$5'GX+N\D9WVD-TQ_I2F&8NZ@(?/;)^6G$@5^CH*0LU<6YJ8BI6
M+=Y4.3C>GZ!+GM)M^2M?*JN%D?)VL>^IQDK^$2N5\>].8?R[EHV1MX6P_FS\
M5H_@]_QP!<T](R8S8^7MUL8\*F\GHGO6\;;B8B=>[.:+76SA<WFK]DL!NXQM
M/UD%^$5P&\1L (WH'7(<HFI]TF8:S$D8^('N(+$NDQLF#2CL0&KH$U.U''3/
M],-H?D/AL<G#)@O8S1Q^GI5J8T_.T',OOE5W&_N_*EO+[M)YIN]FF?!LNI'[
M*#1X(==+9!@+H[A6VMS8*%4WJX >6M%!="G0Y%D^DIQ@P(.E;JE@XEZ#<7W(
MO I9,SG&7BO:5__Z^%1SOW>70#]*XZG/](^\<G)Y& \*_EH@S/,1YC5QVG]H
M<N 71?G<?_PK>KK7L6!Y_&HE^4:@G@"().FUPI7+;;UGV8./#ZU-O^M;0R)X
MG]@]=VSUEV'/YX0HNH&&K.X,T))UW  6"%PUZ!)$+9J%KV,E3=MR=,>P=!M>
M#!\@\OFKRW7:E!M2/O^_<EG=MXAM?E1/@? ^P=,W(7$,>&I]\Y/Z4[=#7$ M
MESF#,:W;V<L7V/FB;]1Q&Y]9OJM!;)O+4)JKAK_#S@SQ>_(=(+IMO>_#5L1/
MG]0[RPRZ>+C*NY332E[.4=4@</MI]">1\?A%)%ZW\F6_+$-.P.R3>C'HPPX:
MGMZRC$_J,? X!M=C%R&X+C_TCW@*_Q)3O2#YS_\ I%-@[A']NLP:-'X$)02O
MC$,9CB5 '*&BA&#PL:YV/>1M_PE<HUFI5!-J5IG^_%&U CBXL?+E@EZ3VU:Q
M'1VB^^=_=(HV\L[D\^ Y*9X\GQ16V(NRI2@4&E9[$!/"'*@V>D=V9/NY19LP
M&X&R;;E'Q$1,5@\<@XYC/P];OF5:H EAB\[6EWERI/AL+7X\- +T/F#2VHIX
M\X[,-,\C5HEX=![GM?_??S:KVL8G7]F[":U@P'9.MRPAU%EHD[) *ID&'GL:
MKJ/K8>!&'U&M1'R6(.T4#D<IZQG563'*(>7P_\JDDSCJ?"\N G4F5#I7]6$V
M02$LT5IEHZEI:\TAN=G7[<WJUK=U[*82]F#/ _J5CS%"JF5U-DS]_WR5X>@3
M3-+99-?*DV-RIN7W;1V #1HIF60!YRW\!C# ._[?2O71$,UT0W,Y4.05V=YJ
M1DZ1"+<8(NV N@GW!:C6N+?\^&L[-'A"48^9L,UA>#BHU#K:YOG1X]LK+A.P
MM$<#JP'\  TPW3[5+?/ V='[J+<(P 7;NYXQN+O9OWI\Y=@R 6[GT8 [(X%N
M.<04>4L"8JVCSO[:W:_AL/+XEN:O&V+IQ= ";GJO53TZ;3>N3I_2<B+SL-@B
M0;G;')X9W_V3O5]GZ[NM%\::K#L79M5L5ICQT\[Z:)_S#%T-HBNKCYK2#W8;
M>%**@#@GDV),@YK[:1<+R5&%Y7DO2P=?+-=4%&QERRF ^'@@&D;8"VU]8BBF
M@-X4Z(&\*ZMRRR!I7//BP;DH2,Y?7LUT_.Q3-%^-(*LN5I"Q^,^KY1\+@6&C
MYX:31L45,)Q1H6*6;0'$YP!QE[0MPPJ>Y?&<$)Z37:K/6I^N]1X%+2HN'Z)5
MBYM_%AL7 9)! <?GP/'"128T!_I99L+)D[96>.N+ Q4'>F4'6DH/\<O[@4=2
ME&OUIH'IHQ6MHC6;^)-6K<G=.Z1XK\^" 0>.88?(_D]=#_UQLW6E/F\.N]^N
M]B__.OIU>[ZC/#*O$>$1Z34,2&_KMNX8I*3N$H/&.=2:5E(QH?*9,I6_I/IN
MALS5QRZJO9LADU7@Q-9FXOY',TSQ*ON6F8HVLP:0ID9VK[U_#W_<ACVMTEI1
M RO 8T=0]UGJZ?/ 47_WA#3<,4 D$VP;_DD[3JL5!VR.G6_A";=SP95E0?&Q
M4O=%(DPFG'.N6#8VN5ZK/J:M=(%:KQ^UIF:3/!7-0#!7UA\SL:; M+EAV@.=
MCA:(:NGY-QE,1UK?>,RPAFPN;4+WK3>+9KG!LFDY2T_F9Z6:5@C. L\>U8MZ
M!(6V2EO5Q;.IQ?= >N: J+=4%UJT4"E@5\"N@%T!NP)V+PN[U.XFV^F#O+N^
M%V Q150,SER^]-.'6E,TAW^N!N[7[]WK]C<[%T&"I\!N8H \^ZG?;W)X7SEC
M^"VBZ^N;O*@9&[]6M;ET]"WN-A=W.Y>FOL7=SO-NGS?@?KPKU70/;]:CX]+=
MP(L8&#<1*S.<Q5 @9(8(.;6 =2%H^8*#I NDS!=2+H@-@K7SPAB7FHBVFYY1
M]!QC,OLLMKWF\-]?>_5:O[79T:TE:L4Y-IV*YE.-);%5,TX,SW#6Q3.ZLT],
M=-N=GNBV-]]$-W)_<GRNG1WLGE8?3'2;+Y@R3( ;E;!+E "7R428)2>5I\^&
MF2/BS2]H^QC1NS39=@4>%W@\"QXO66I?@=8OA=8OER+X)+R>4Q[A9JG^POSZ
MN3F%!4XO*ZN>3]*BICW&(5HPZ@*ILT#J)^-KM52O;^4&85.=6(TE<6)M'AR>
MAM^UC:W[I\R3F:FY[DOYM%XE.YGHP:J]K ?K]*JUU3=:.W=KA0>K\&#E@E0*
MR5MXL H\?AMX7'BP"K0N/%B%!^M-XO1RH73AP2J0^K4@]6OR8,VYVC>[,INB
MF*LHA"M@5\ N!]LJ8%? [HW ;DK/4"V**&CSZQFZ6[LYN[JZM:V?1NZSK:<T
M!ZT\2[_+LC7/(V)+,[<!'<6$3&)+=]].#L*&=WM]E'47T#G%C2K+&S>:BV$[
M7ZQ];A>I/-F>66'.HL(S!;KD"EV6+ I28,_+1B1&T6=.P8;JQEQ<LUG'%)8.
M<7*#-_/QZ&_6*P73>:VX\U2T6--*&QO5Q>-%JO5;69SU>WU@[9[>]H_;UT^I
M-7[1-,UL\C%?R/+=?E'+]^3/\=GWUM'?[;MV8?H6IN];$ R%Z5N@2V'ZOA'L
M*4S?PO1=;K93F+X%[KP%T[=(#GMS ?\"=@7L"M@5L"M@5\#N25,A-D==X0>^
M'Q)S-_10F8)E7?.G;H<$WDG_\MR!$5?UZ^I6YS1TOZV]7(;8TV")YZ=M.-TV
M:([H^()5 6(EU2'!6T#/9PQR>,M4/6OK_?7U+%KO%Y"> =+U M(+@G0FHT(*
M2,\ Z4P&=Q20G@'26_.'=*JN5F\2(P25HS==5:.!6.8=>Z:R5MN\KU^'M^&Y
MJR_M=*^5+Z>>:Q!B^FK;<WLL(L^@\Q:0NM#9YLH+ZEK!=1<$Z6H!Z05!NE9
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M9JG;G3!MY3'KUM\]);#P0-EN-2K;K<ZG;!=PA4R+!6P@-\^X@'?J33RC3+S
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M[7J>>X=#RQF=]W6O\'3--_5Z&EKFRJ]5+:VO%34 !2+.M8!, ZLIZ\+![ H
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M%Q?#D_NAN^E\OR&_<N&+?;*PF.B,HD$6K$JAQC2)8:;J@=HB'<MQT)YVV^J
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M5-];'U2);1Q:#L& "?'X_C E_@KP32"G;O6HALYQ6M71N0?DY</)</ DZ#3
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MT'--("=XABDR@L<DM3MJ"*#NA)VG2Q-T&V6$Q?1='ZC63[Z=6U9" >P!%^B
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MG.OF,99)GH=SY(NZ9_I\VK"86+C?.-\6PPJ5U._ON";U9-"-B\<:YSOB*6G
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MIVMKB'4;V/.LXKU+) O:'B(76VT93[CMDZ)GK.&02*&+.,  /Y4V+-XV=2"
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M*.-L:G_$&)%2GC#*7,4;5Y<5_.L58NPP*:W4+W\^LOG[H4.,W1J-?TY @J<
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M*5<^GY27QFW1N\G8[A.&0\\S6:2TO[<NXSQN,@ZU>VA'1?I%./D9(6&8<;1
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MPJ-__XGL60K&GGC [DY9\7YP>_>[T\F_<!8G.N-A1Z@-5\Q5C5P7II(IWQ[
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M>LXV7N2G-W\X!Z;:8$?8)^$B:Q9#^I2ZE:@;9DK11B1U+G72[_,L29V@\TS
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MROU6:=5"6@A"V=SLI!S3X/H*2V/#[B\YE.:&C,,Y2+V6A'2IT$S?"W$'29A
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M8J]DD]ECKD]?!9YM#95,,I,/N2(]S%K$@S43#NHP 598CT8"J=R&@0.(C)!
MXR76$#Y(]JA"J?9VKMY?=D)LG0F6.;+/1B9E.$]'?<<Q'#K]=]1<Z"R*Y@1U
M+#+3'Q3B!]Z8.K3Q9+. U=:EG+/:^J"*KO<.FOR6H(F%TZ$))Z<EM%AA@LQ
M40>;JT6F<90U31%Z.AZ3UY&AF!^1DB*+(OI( R:*\>I\4OR<?GP^O[M5<G1Q
MQ_+,:[PZ;XQ7/SCD'-1A5B;_0%7($@:P<^Q3X;*F5%Y*2OUSDU+QU;ZVY[P8
M?!3T"726)/5?]YK74BKG?>H6H]PJ>#8CAR_0XI7VD%'011K=L<!U67LTX5":
MU<Z8V4A[0A:<)FAP$/=+QXQ"?> 10;_F7Y_9_/7&^+\ZR]\K_;->ZIH-\/KE
M8XY6'V"YY6_;KXUFW6W!MO#7U:B.8%G708YPFDK1'E;TPB^<>@R3F@7)G]0\
M(FO>B"2O+.O:4%:00N4\Z(>KIV;Z,*6\"'X(5/%#*,9ZRB(=E==_O4$_@T_Z
MEFZ5Y,L<M\;K@R)Q_@ A>(YNO*Y-5H%.M)ZSYGTBG#8V_W\C<EL ?'*![+++
M\-[ *XD]2.Y=;]PVB^^ZG.*7XYPL-5XDM])ZKS5(K=Q_GA7X:OJ:*P9\[7I(
M)2\^%!);<IHPR(N&!K!")IE/;R;+7* F YUT3=70#["<^ON_Y MS>)]W55T7
MOK6_[T%SO-0^NVE>W+ZS?FK2.)'C&('UY=(#&-1WSSU_U%Z'&:V_U@'60[KC
M"(="AZN.M&=B=-(DNHQ[%C.FRX49Q)&'&((".+K1FNDCGN<7"$!;SQ$* T"K
MQU C?P*>RX@M1N :4H49PY(*PYUYU@=:O=J_2&5VTOGJJENT#D;!D+,30:)8
M<K;]%N9YPRN:.5O)5"Y8V=)!<LDZH-HV@Q86J%9./KCG-4:0>*[&*!(B6;7,
MLOI(Q^5.5;XOL()9_:ODVGQ#ONG<M?J'-^[2<6H$5GSLHT_K?E].C:L1%PX/
MJ^A,__MVLEC(E@XX4R9PCO?O&&7AR!(?E!61L1=R6O[O@$FRQ3BT678X_<U=
M?4R>SF_Y$(/)Z]0:JKXQ91A4K0UYA)(1LG>C#C$O)YU% $8RO:68+*7"J*T[
M;"AM.[2AE,Q%IYQI!]O<")*LX*0-2<08JK@O/(^O:E+F_"Z:O2I;-@9()XX<
M$@QZP6='/U"JN7_LJ_<(S",N$F9-EN@(2\G_;-QL70%'T\'D:'@5<+G0\[ZF
MCI[4'DMZ>?8N/80XJV^C63"T<Q:,O^;^XA0<#G8C<?'I9#$=K$TQ%DH[0NFV
MHBR=S.=WT[(4%Q =1%E(?8V!-69]M70Y?GA/M>\KS1 G)FP_+LQ1B8T3$YNK
MC&,>8;4*B?&PL:/&U)&,(3-V@.]XQW>H>Y3-:[E7*$>V07GQTF'>I\WS"88U
M@EO@J9.E;)IL!+T<FXW[@L1(K(!M;F/YL;J;)=+1@L 7I>A&COWTL)[^)WK(
MN\Y++/IR(867U6.IP@D?P<W"N1OF\1F";:AVOV/%BFBOJ_K;5P@#7CSL8T28
MW.?:2%T_<<++A-1/JC,=HQ.4%235V)]4$\DZ LVF#!"D"\YO_6-^#?YDBPY3
M;OS[#P*U!] 5GGD[Z?%(]J%GCS&FG)1U-#!VP?-?AAHJ(*'_@U1 -Y7*N+:)
MG^"??U"0?1189.O@V\E]6$>N$=YD5D#0"7= "";H+R>9O\QR>W3#!I+3K)8X
M$^0;G@/2HI"'B(W:MAE5Q?V&7Q<"=F49\X9YPKQIQ:&K$FU+0P%'W(YYA<$S
M=[XR9+[K$J-SR(?B_M[=-:-5S29#.V\23(J;CFP&.;(TG>G.[NF/^TFGU\@-
MH7)!'Z'+3/%'D*8RB84ZH9Q41/E1T;?U@1E,G7P+% 19GJLQL>#M)WEXTVL$
MT="A 17_^Y:V(9PMU;NX7)1.T=VN73@JGA=?[ZJ7G^\Y?EZI+C&.5GC[YN7<
MY88!0U +S]XED"H FK0%I#0!4N6I^KOR.%9>ZUS$0$J' Z2@@;KU@G .D"WY
M^);?7CD6J2*KN'W76#VJNN8P9SF]IC$95G\0]C<5WQ 5^>Q?T""E&@V]YA#$
M'_,H#K:0W?<U]%^! X_V=[*!OA3P/4=Z@97UJ6T>1^S/>0FI%!&17)D;"9(
MY*8)'[Q!@!!6[<[.BYWIL'[5G'Q&N"/+.XMO'#-)#<A!,;4QKJ/BNAAT6*P8
M]UOV$0BF[MA979%'),I)H__3Y! BGD<\GG,+"*8)!,E/VU701S:VL^(J>%5Y
MT([HDE7^@Q=EO)+2Q7=J31UDV<(@=;')L)BP1N&9!Z7^CQF-?R+(68?=*ZDL
MA5_4/$8?\[R9]2$7'F_E(ZM7<_9WM12YSZLJKI&O\V0 "E)C7(E^OFN]7T\W
ML9^V4F/. U$JKWP([)YG,LV#*&J.21>/6"T% E:("BBR_<$5UY##L8(.@<TF
MT+0CJ.^8X7\2?GEH:B_%U+!TT=QDV/-F,Q><AR*VGN-8>Z6!)>"*>2=$N(7&
M1NG"3FJC\9H^PV!U66_I:O&F]'IQ18\R!S(KG6R\-#TIPV?_X@5M'N@Y$ <L
M+CS<!$_A:=E=K[M<%N?#Y6O=69Y+<7?50NY"W8_#EW;./E\([NU5C<Q#+&HF
M+@;L:3A(G1L(6*%Q4B$5\EJ@L)2E%W$?; GL01UF9?C8R$1"R3>,<[Z6523#
MD 0K"ESJ\;)4E*OY_2VJLPY'B>A<$8-W1:^M!Z#"%UU^C;8;R["HYZ2$!+0M
M1)@/R#:798LMR-N*L<,5#P=U&$]9E7<MR))D-T$9>M&577W,ZMS3FU9[*D:S
M52Z8Y,(>FH /27TW#*^_XRV;FY" <\!=0_K@53R FA" H[,0>>KCMZ?.T]G=
MPVM[)YZZTR4W#V+@?*]6HQ^0HC:UPTBW'0/(0C.X2Y'%APOS@2U?V4DX1\C6
M/M3*E9H7N#UF*+VEYEX)8SGPHN:H4+)LT4$NV$SX4K[DG F_-6U77?J \*F#
MF)M=3NC.:.UZ>'&>Z^OM3:9+A:,*Y@*S^S'!YR 4>4)]XW$O>W95@L IO)AE
M9E-=N6Q DG-@0UE5>0U*_ 4%M%IER"@#$IXD_#'A7Z^NF,M:KQ/M'/8 V0S[
ME% :+5B:^/@#Y0'E8R'K+Q__N.1"4)CE0H;9RLYU.X0!TH#LY='1:^Q:_C/<
M-&;M1>/5VB=R2Q$4!(E1I@V-'ZE^<U$ZW=GL6;ZF^RGVOA+B1K% SBK<B>JC
M2QG[?.!6E.QH=-FO7(X,[+N+WV6/-'ZW:^!'$ ?,;NICA1 'C,>)1)V^L C/
M,-O.>(GO"UIW]C'0M6;MFLN--W%HYP.XY#5X+6N/O.% 7*MB:E/7:O]'IT/U
M"IW&;Y/7;,D5;# 9L8KYEB[<C:[H3_T !R&N4-,48UP4]@?+L//-:VKB\1N(
M2Q76VIC?F0U ET*>;OQ5#/X=X#,"LV*S^3:1#S"+,X^AF1EI/X6"O;71K)*Z
MN2T^L5)O?SV</I.JT&EQP82E$7";.]()K&/7C3$&:A7%'O;PJQ7NBPMM.Y/T
M^5S(PZ]6SK'_XD@*7WQO.H!R%8IBT7T0HMOI"YB[$<S=D6>,*K"N@I&7S]=J
M:72?R4J;K-/>0)0;ICRRW"V)#">+JT,VP75M%:YQ@AL6P<W2K?I+Y^'^/?N8
MC33"ZB,UO'PZ?,(O+=X]<1*R+L8;Z3Q%O;7P-74::^3P4;:I9@Z&,*]%@J'I
M9^^&X_FK5P41 BJV#.%FV=_9#VFH7413*+.=.#&.>]S4&32 6%HC!?BU1P '
M!5@^9(#%YNY!F$#.&NDG+#IXKHPP 7-1=5B;>MM?V /KLH!K>OVQETO]_CW<
M9"Y02"73Y(B4KO(<K/:!84"ZU?L1&\NA4 J] :40(QHKOY>KSL?[YV.AOE'1
MT/H&M*^EO)=2T+4 %H6%Z[%?OE@HX+V)Z=QJ8^D@"Z^W!^I6-FBD(%T95O:\
MO&'#+4IL#F:]0F$<8<;,)Z/?OS'G=[?BKBW1)2;GX1#1:CC&/+I[\!X^MVZU
M5N) !QT?YTVV7"AQ^A5@X('-Y:LDZ'B51"BK)(KQ*@D+QO$JB7B51+Q*8HU5
M$MD@JR3:'KOC:L;NN*\+J7BUA.=JB4R7IK/=6:')%BY23+;X)FZX6L)!5?^?
M24\[6S+!">I89! (D1F./GG(.R<"&T8!-R00ER1@ > ^UT><Y;J.M<X&Z1 Z
MJ2!3&R$.45+Y4U#MCU5PX!53U@T/SE]W)C[?U&X?2H4IUPL?EN61K ?L_]LS
M+,MKP[*,WJCA ;0M1N :4H49@ZUDPK5Q^_;YW)<NK]["!ZOQJF. :V9MN-[S
M&B-(/&=F<$V =O2SEU%SJG*-8O@0K?)]@16.@E+7AZAW@;4)5R[SD>OIYU?2
M[PC@:IF-P3:O[QFTU>[L8W3-YF9/8B<;P?(=/,<Q'$"LOW-G;SHZ'X$ ) E$
MK,@.E[#6/)"/"K74# 5ZYD20OOJ%658?Z2(3H/SER&^*Y/()Y>SM<LR>"OOJ
MF]USXX<=DWSZ WV(/\W._^,,\#_./OX3#=<O99X&R8_O9"7D87\[<'%9B*?R
M*G_)G'59CPVOCG6&CMY$XIXV)%;4@99:L'!$EH+U\[>[L_/9M-]A7X<-<9-I
MH*L+9(PX:-;*M[GI^HP1&8GEDU259['/[+L^U5I-N8H_?$Y >WTQ0+&SB952
MT=DPM5#1 <"$BB,OQ 4-*BR-)39OKVMWI70M>X%\/DW0X&H6]%12ZC%WY?SJ
M*P?;4SA_67?12EF][>-2%3I]@FYK?*N[<(<=%K%LB?-=D]Q"B7O8" Q%7D2*
M=8^]8+E W:<QJO>%ZJ5!^HW'(Q>3J5RP@:Y_'.97=*3M$/7>>83M1\ E\Q%Q
M_4(OXA&A_6"POBS7L?DX=)H.-@SWCV/W?>-]8Y2FDT%'1VR#T[BO+CY,?)A#
M/\S*<12P;5C0\,BHV73RULX-6Q?"_6"?DP7MX5!;9'H"!Q"#(F2CP7$G 4..
MF_9\'SP @K5]TRDZ[%'9?P+,UFB5_^HP6^&;V5)N63^=W4T7M:>UZ?@U7S2N
M'/;RQV(P'*]I5P-38SSN;[+]NDC::^ZHUIVE"S>7=T^W-[U+9O>CPJS<$77#
M*.S0S!ME-D@)AS*X9KO<TMGRW%(MVMQ2^K?RWBR7VYT:OS*WM#TH0LPYS<O:
M?>:<?(8#;1&K.BC2W60,TX''N<*BGHUS5S')'#O)[#L'%E/0AA2TOUS:CCR\
M$E9<4=/0@KOPAY#/P5!/%#FY=+)$;S7Z.Q8_ATX_&ZLF.EE,IW9*&YY>;FEW
M7JY685*Y85F07FPO-U +=Y1.[T&SS:85E!%[N5>%ZLNU(I28MV'LY<9>[A\F
M\6,O-R:9V,O]PR@H]G)C+_<K"*#8RXWIYP_P<N/]V?%AXL,<PV$\@U(9'+M(
M6[&+='1MN_7WW^=B^2DSZ6RRCB]H%&I)?RZ]4J4MU5W;Q9$*03MQYW$12ARI
MHS:R6B'W?IM+KXPC[2Y(1!]0^VV8EM'V9+1@WQRX\1(6)C<.V,3H"Q-]^PZ>
M? EL[B^0,8_.B (9=#)7R(:'S]41BY@QHVEGS="QD-T9+C=&4RE92H?(;BM=
M@\KN7(.WZJ4\N+F[:\Y*V^>K-UK<'31'':&'4-NKAU 5I$R-X\M7=#_V$&+I
M%WL(,?IB#R'V$&(/X<@8,_80CAZ7!^LAQ+F^^##Q88[A,)XC; H^(VQD-L6^
MO;_>JD^;+)SV2<S-GR^>6_/EYXD$G<&2R\0S6-:&63:&63C3,A86E4<^MR;@
M8,%XWLG6&(QT;DTA'C\4+1JWQU VO[NA-?2.TB.U[NQ*?BD4^7$SGXYDQ.#:
MG7Q)]_R:A;T'!U4J[)MOR0?M[(LDWS*:#<\&;V>-F_SJBJR#ZNR;E[EQ9U]<
MY;[.G.:XLR\FF:U(9M^IIYB"CJZS;T>>'E):V4S<V??5!5 T*3:PSR,FG7]B
MJMDYU6R1S*,+NU5(GFYN:G=N;D&X8KF/=*4WSL53:W8TFS42W_:Y-=.8W/O]
MT]E;[-O&ONT?)O%CWS8FF=BW_<,H*/9M8]_V*PB@V+>-J>;+^K;H?^&JOQ*)
M?\=.4OE!T2D$_(XPXE6JR4^H>WG$2$GRBR35YA6A_Y,:,<I D$XT>?R#2L$A
MC%^81TO-YY!9'F X5^.#3]YG1H*(G-H5;\2?58493PYHW\@H QH?[TW:/)]@
M6!8YE8PT10A&_KV&'J#)E#;D@>1PU0'R0#FJ+TC(<Q08$;W8<$G5KP "#V0F
M_OU_)R=47>!%[@?58@9($K3Y=YU'CO,/JI"F3DX,*<4)'\$K-^:NEH>7_XLY
M =U*% T6PWP*_T;G8<U_N]_!(M' C%5T%O.GGY2Y#C65^LOCCDLJQA'HO9C6
MIX24@-_UNF^_ZB=.>)F0^DEUIF-T@K+"] 3V)]5$4I% LRD#!.F2\UO_F%^#
M/]FRPA05__Z#0.T!=(5GWDYZ/))_Z-ECC"DG21T-C%WP_)>AA@I(Z?\@U=%-
MI3+NCD_\\P\*'!*!_?:K@V\G]ZD** C,E,P*"#KA#@C!!+T1_WK11@">#I-_
M_^U9+-S[M1N!9/P.L(A^XX;"JZYJ0G\:\@T;2$"S6N),D&]X#DB+0D8$Q4@<
MU=9[JL )C"+PZE>& 'D8A%:9-\03N6_F32L.)96PHJ4JY@A&'5)U49Y\:<C4
M924!VKJ#A 9/W:!/#%6J)G%(9UOU85_Y_M]UB4'F-$+_W[N[YNX-S&!:S,P]
M9%)G79I.=V?<=>VQF>U-FM!4HH_07:;X$TA1F[Q"G5!.)J+\F.C;^K ,IDV_
M!=K&[MNQMH:[N:26%YT,P/V_;VD;BMG_G[TW;4X<61:&O^M7Z.U[YT9/!/8!
MO$^?IR/PVN[V@HWM7KX0 A4@6TA8"QA^_9N952650*P&C!E'G#.-0:HE*ROW
MY>"DG-)3H'=PN9T].*O='/;V1GM0$@+@&&U)HE%:*\(AH;*CDS47#)J#<HKC
MJN>W'_+FW<6);V\M!#0#4:ZS@28U,RNKN.NN6("87_3<M@6D]+![[S/SW+EN
M,<\(8+X"*,IM*P"N6ZCX >K-9>NPW-ORO=.CP^SV9;&QK"#A0<&2KFP-KZQ>
M\]RF[LI%ZT:TZG]6,%UNI1:3BB''Z;E[%MR!7O-/]>Y')]@.KW;GE[\GJ.3N
M]E]I!STL:4^\E?]KI&5-4N#4H0?,9?+I_I6\^]ZY(\$P8 E_=Z!]N_R.20";
M>LOVE5M6,%%J)&GDSKUEL,&J93- ?%" W";#;=^Y4U/J; YH=>GLEQ?\WB]E
MO5DJX8ZGU<-S;[ETS&4]98-H=_/D%G5'7&[\%C]7D:J'L#>]TOT@Z0LAZ<>L
M!?"W#++*.V:AB0;Z'OT). /2=-/\\7!SD"N>/RPE1YOC29[P1%T;:?Z&LKH%
M WLT 1H!M?D3^SYWZ/YDM?;?"$GG"[=74/(^J$WH]9GA-JD1;T"A/6;X[)CQ
M?U6:[/LL4.EQ'NBQFV\=7FP[%>]\ELLU+WHL5ZM_ML3Z_]8MN'&TX@\2.PM2
MY$8B1=%C+<,RCUF->1XS3UY:S/$97(CKH,$\CBF (5M79=,J]XX+SW[C]++6
MR\ZB8+V* HN%ZHROT"<J[.(B]6H(2W<"@24+/I<Q\N!L$%XTI=Z;3!@?(8&_
M>VC.C7YO398"/YW0?3+RDLK=7EA&Q;))W,0["??QO+;;:>1NPY=9M-[Y$6V^
M//W.>-$KS&&@$:T@=5R<H#%A_9*#$?5+9B#LV3*K@O+B-M-0!GU6EH>*C5NC
MJW'NM)G0=&)ZSK:][+$1UF[WZ\NCYQQIX@6BG9L3<BM:XP?ZI*#/WES19W<R
M85&A.7T2X_6OH/'0J^Z<M:MO2'SDTO7/)E,D1CM>]H?8.']=HE"MPF$&?M'H
MHF>,<Z.MAX?63L>\ZI7VERT=RO7 C[2@51-;^N"U-#/LULYD\<KO0/*;!(3S
M-[?NSFKB&"7M;8V[6UZ8(NR][)V>U@^V]O_L+5M#[_/N#;F N.A(/9O(4?B.
MZSI-<FQ+N^6YV9(2UK@JUX(.;WY*Y&S-CR>J:IA*<@HS>=?15W-7[GW?NMD]
M?CXU]@X?%\?8N4-UK)_E;=G2Y*!;WN7/9'.3%;Q>.2;_2FC.G]OO;+U27%+N
MWH(Y=*J\OT)*Q4HM9JP4-@03N=%D>,#1]_/O\/?5K[.3.4:=S!1E9,F5?KBD
M7XD6:OP#Z!ID,3MU/4"-*F.FC[0'/ILA@IE%#I(<-ZC]/L__Z!2M;#UX2YM(
M,?2J#;2)N#6]Y2$7#;H9O64;Z"1Q0$A_#JW6$LQLXV)G)H/NHITCD]456#[S
MG- NF,OMS-4N>)*"_W=NH0HXX[&D%5D@?=WM/3U>?'^PSG?F1P7'X?72;,43
M'\/,YMFWOG]II[M8]2<WF?HSG57E-/:'#*$L5V[ ;EF566VT(*7B<L5]"JY:
M[,&_L%;)R,+Q']>/,6IB \H=R&"0VIIJ[>>7Q<-AO&+HB2Y3_5J4(O^.3W((
MY9G?4<Z-%!TLQG:62J&.9M(XA!'FHA'6VV=G-V<'LU1 G]T(DZ99K*39( 5T
M2Z,"ZV6 F122\S? Y+*OE,8_## KN9BQFL803#SE=2^&&F#.;MGE<?/TP*KD
MWM@ 4Y,K_3# S#$P1140;IF-&;)%PPNZQZP2\,2OP_S.KXI_=K/;64&!_=#U
M/+>#%<@XDF"!%QFBD %)GC8$7\".WKW(-S9/:NA!+MK @QZ2.?<M6A,Q?<YG
M-C>A?'?&8I^S^T>W9^)%0C1_NCT[_UXYW+D,ER.:M\3*4#Q/XSN+MHC-(E.F
M0&]U[OU;17XN$I!+OXP3W[H/P7QU%C/6!88HB/_'ZHEMPT:#S"THAYY5!7:
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M,@N1,UQ8N^M%[\=9+/ Q\8N!:4F^)4?E&B5(%^B:Q5DKEMM@AAUP<V E$DI
MK00!%&:IN=40:T6Z]+QFF&WLORV+CIE>6-=--(* 4-VE,5H>:\.O,&$&)FE8
M%8M_QM\"4 @"^:[#0L^UW3H'+W8-C/[ 9ZUF,W18%.$'DZ"OS]_4[V 9 O8Z
MD%'#]EW=A#EMMT5NGQ9S-@S+@^]J6$<%%@$K,# 9$K;3:5C5!I:[K,!B#,=O
M6KXO8 /O ,YY#KZ!OD/+#?UHVHSNA_"B 3IX6&%>-;1=H.$:+=2IV: ;]8S-
MM;P*:TRWSVRW C<+KNJ%56/RBHMKRG_4Q8_RRB*B$DO'RZ-0@-S>%Q]0)!;?
M.;[#0TT#KEI<AD/8=.00:.IO1;=, TQ$D8#:'L%K-3?T^  &>KK_T3];?^L*
M";JP'(8. ^:)]6%<VR/@KD1TPVJ2U4C<#]U JR)<51]VAO4"0?(#NE/E][@%
M-PV-DU^TSQ;,8\ -[<">ZH9'.PNL( Q 43> ))G1"@P6N#[+B/F_P KYN\W0
M#JP-V)1>\XRZAT2C[]6M4[GHSZ>A4^7]JO53^;1V"DL);2*(?W\A<'ZVVG_K
M9):UO/]<L:8+_P*Q  5(^"P<Y,(P2,NUNZT&<UP;;C!#ISU,:^"9P/\"JVE5
M/;>"^@*G=CC%Q^5]9UM+C$1SF:SJ<M'K'T!ST)!MN!Z?OL:7)(+#&H)CC4_Z
MWK&M)T8]XH!GR\[VNM$"8F< D4.K. H60#%-( TF2$L1W]8[%L@V?HM5K9J@
M<S 3#A6C143X=)^Q)Z*7;JT&WP-E00NF(J5)@JFY+1*IX"U.Z5HV4T0496Q+
MH4 P<,?UGGA*()>,,.@8O;!5PQ0Y^37;:#:-P 5Q"EA!RZ5*W>*3A;9$FA-9
M2#2?=A[(67 ^8!>FY0$7(!N 9_B!=!RD@@\Y$1PHH\5,",(/:OG.MC8YM>0,
M_8-4OLNM_61:PVBSA%*$HH]NNYT-$+]<$$TS^(=>M[N@QL%]MO&I3"0Z-5T3
MKCF\PP4_2?N2TC I82AK8I69S!!94.LC?2W7!VKB)V<76JT4F)M G>J@[\5T
M$$4SFDU1^5K<;&9WB6 CV8+A;:M*ZIY8Q::>E.YU4)"-BFWY#8+'HPO*M8Z*
M:N@!1$H=Q@* *@S0IP8HO\0Z %'$&R"2%NCCYT[= S$2C<X9_>+BB @T4EL!
M?RHNH<'IA36CRJ?#K=8Y1('*!IY5":6&CB^FR=V;^K6C7X&:W03U4]_/Z/EL
M[B"CJB%Z2]1V,?LLDP=8UR,RTUY:#F!!T#U'RS0 Y;KC@#[0L%I%4&O1&%EG
MA]TK5,>!=[@V4(4Z?Z1LG9=;EEDV6^6P"-M %U3N()?+[I?+OA=L;$0C%5XL
MOUR6E40(@@3 2UI\N;<;/IQ?U>ZNC-HG'7:'6"]7138/7);NRM$P$DDL;%R0
MQ\Q[2XO8R!ULY'(;L#N^D7+_/B:,Y#B_.OVD W_'76[DE; .A.&GKSMI,1U$
MF?Y"=%#0C_!2HR3(D:CWOZ-._S#T@<S[/N!,Q7+H>J$KQ3*%T?(.C2*\%T$N
M.N ]]#'.=M27M:NB=_/M\+)1C\XZ,:%>!WV4"U(2?\>=\C1[2 L %P>[-[<C
M'JR(,2PXBPYV,W&J0,\<H(AP8OWGMCOMK2T:V,1E?O?TR3RZW-GYMG5[^!0=
MWO6BKB5?_-M=Q/W<YOZ(J]AQB"<* P_9;P8LO1]2\3O;VL12<6R@TB(#E:X8
MJ")Q(3)J_?TA0;_+K?5)C<"/^B1'"CBJ""3ADN#]9FESHT*2UU$#Q%H#1#*O
M)1^1J,%_BGT_L566=&O84@_#^21ZH1U"HWK](.\U7?\YM )7."@BU5PZ)?Y8
M3P9)E<?,J8<H839=](503QCIT@&-WQ;63NY&T;=.HY$5,ZV0ZY$S-0V3<9%#
M7:-KV3"U"^R:%@R_PHD9#DX"JVX8030J2/5MUS(W^_0''%H1W:MNLPF<@ \/
M Y"(3VN 9;IUAKO0"-(<AB" ,[2(ZT80L&8KZ-, MDXW]0+*PRX&7*&9MT4M
M9D4%B8!O7%C*X01M6Z\PV""(5/ A .[B]*\70<OGUD!*\4,L RIM*LQK^E)R
MSV<W]"X#P?W6[1HV2&@%$-"XM^PSE9[+Y?[^X!+O;&L3<PGAFOB@_.]R:^+T
M,FBW,!07$KGL,"&'DS;XM<)L"T@W6360<H15(-=^+;2IT::#-070E"+=R$[L
M]P:Z*Z;1^2P&DB@8*79$96@:#1E/Q7,-4QF0U6KP4+6K&W7#<D!'CDS/0;?%
M?&$_[G-=KP"Y>=^1_DM&0S6\H6.@-;\JA EFRJ@-"G/$X[YB;<,TR+6)2M &
M9W2QD]G1KZN!BQ:CW"Z9C/9Y]>J$1%.S4"OB?$LX4H]9E50K;2OG!_WV-S],
M,3&IU5]*@5M].J?GCD,/N#//VRXU@&?[  GZR2>]=#^7S>V2>4%\(@VU5(65
MA3:[KN%M";J7( )@WK>,<AG\EC$,8$\JM)R'Q^I9,6 7@2F56^-D[^+@H+GS
M:[<1*;>T<+E#DY8N\N!TGQ8_3M.=;.>I1HG]C5QV([<;?Y+J[JAM3*/Z1OIN
M26QE6$=3NE1BPTCB4'+R7: R]%7#M8'A*0*26)9>1",EK&Q3!A\@]G;@<;LK
MU.<*R$.VSP*=# '<<@.R]H75M!"Y/]->\/$20,X G&<Z.XZ-J+IX\.^,C"^0
M0^BM$-"Y*O$^ Z*@CR.ZXKI$P\D* 7#[JG ^9'>^0Z>84X^7(2V_9[]*=U)<
M)_/K)<5E;.7P)N6S2>/KD&MQ,M.UR&>S6UM9BNS/4F3_\JY%J_ C6P]V'LQ?
MUBI<"Q"H,4XY&WW*+?Q:Y+!8S^YV9C>?&W<Y>$0=J%I ^1%$HR^+EG99$*^^
MAX#S^6T5K0Y=PS.YCY8$#2+Z.$4)U92,KFHA_+8Q].72I,/"D_A2-5\]36H!
M'0; #QR\!'1GN29D.3"T W*MLMGAHW( <$X!\(8SH!>,$'#1(Z4Q 2B831NR
M@L1S@M]YK(6]Y2.T [K"//PZ\%Q43#&X#T!HF,B/42<5'A@^".UG!<2@#W%\
MFJT5?$U@G"F$'3(,<%0@"P!Y.ATWT.O,85P^0F\C1BG@S: X5" K7.MWH[#L
M3?TGAJ(Y]&9H>/ L8SA>9 E0Y7D-0_ JPN.0&.5:_<&BZ#\R*,"U\2S_"26W
M!O-X3"[M(Y*Z9 0LC["+QB IN07O,HR<%1G'Y#;%N _-9+;1I>@.7)(,$P1R
M(6M+H__4\)YX( ?H"@ G'V.!.^@9T4%E=5QTN9K C(/0<SZ".-[;UOYK?:74
M$:TO=82.O@A\M8K*H"^R#45^%*66K&F8_OHG(BC:H,)QQZ1_<\I803MF"^BE
MX7'-$1/*/9-,O&1,-7@[6"(R,?)P8HI2./S.6K'6J=T[)!^3\DE(5J!,,R.2
MF-$.KI\5"L58:KZ;)%U=4#L,6['EJOKE#9X3$/A:TWCDD0)<IZ J)L*=KWKH
M+)$J$+VOK()(+1?^86M<?+(HXL#7FZ@F!(T4=^S!HH(H1/;NE,[9.R-H=P_9
MWF'17.4H"IEH^*91%(A';3?H%R\U!7F2O+U@VQR&TI)"R2)\9!ZI!/(\]])P
M3TL"QQ-Y /%=9#9HF X^L:D#^.@^Y[XH4-2B8X-;R^F[SW,(Y+DRTO"2^3YC
M4Q&P;UG8-Q ?P?5\\49"<] <T-'CE 58"2C;?-O<HT0648>)6RH619DZPA5#
M44QI6XPP\U\C?%!>+GLA O=U9.6*[8_*%7.I7)'[J%RQ0I4KB#!+_%_:3?\H
M2O%1E&(!:?\?M2<67GL"I.!_8D,WP-I$8=&,X!R#F0C4'<QS:(,PEZQ,<;!?
M9GTV\\F'*O>..O>_CG]OWX2[;$WJ5J B^3I%+-*9C.BK?KLLN@_Q+ZYD(?&0
MEMCH24U:<&&4&G! MX,]?I9_5Q8@]27+@1R>EGO;O9W#W[]_%X_.]B(T,BV_
M91LP"]P7T%PD?FJ<T7(,'4)54L)*IA)!)@?H9,+*IXG:$0R6+IVNO*.D8RCG
M<8]+FJJU].X_<EG"%^\)U>@Q]"P?6&A4QR%RW],7\)A7-QQ1Z.&MUGPL+.H#
MB^.Z^.M6!JB"&/K_/N7[9=\I5UD(>&:,:-0J5&-.??Y;\?[S->&/W9I^R:NT
M/]I0VB9E* ;MD[[!8J(S;';2]B'Q?9V@Y\9\'DF#Z53]2!8V[F)[K@A:NHUZ
MWZ :-Q!BP87R_J,7@^3_&DDH)-G&Q_HMF]FX[3-1LVOO&FG9=X647=?.55H!
M3RAD++48X4AS9K_S'@:7=LWS;X?'IU=/P9^?-24 878:&UD[QPNG@];*H>O\
MI+;CG0EHV"H%@[>DX5(L+^;O\S[EG3(SF;6Q<8)R7#>Q,N0'?8LMF^9<C[7X
M8-6.+YW];X787#V>#2WJ\%2;,PH231BV81I=C(%CCCQ< -<_DT$+B'G+LVP]
MQQ,S]Q9RJ*E$(IV=Q7@P0B^.4>-H?IEFK[W]1T[%_M-F!XWX]J?+ 4M+/YL1
MK69U91QD-P^&.3.&'7,J9ORUJMAV.$=LR^?RK\ V]V'G6]!JNYW[W,I@F^BF
M\DZQ[37RTL1=')/).4FI*%4"[<? W-L)/+AB!0.WC+/.G[VB?WB[O4+23F*1
M2Q-U)CJZW25*,7UG95SO/'=^A$='MVSI(DS?B2Q,?MF>2'Y95#//OK,NO)%8
MTG?NMZ7=G1_F[YN7O>K*<(D9\&01B?'C.]S]M62<F3I*9T["11_.7&=?W$JI
MV]WYD5\9G!DF6:PJSBROWRV?5B;[EK#T#DD54W&FPZ4+%6+!M%X%]W+'9]O>
MK\O<DV^]O4R1NL;5$BF68!@9=E+//X\;VSL/E]G]94D40\YC40)%?HNG':Z&
M0#%/S?,5I[YK&=?[]U=FI[(RO&%Z+%F&QOGVXL3.<L6)(1@3%/,_OF]UJJV?
M]97!F#YI8M4Q9BF&B6]&J]7E\L/4XL/)TL4'6FT_JGGFK7=_72^YNP=O+SRD
MK'"U1(>CQ8L.J:>T4SJ]WC<KI8N2L2S!(?4L%B VA'683\_MK9+<,$^E<M8C
M;]_<7GG'>\]_PNV5X0'3HLB_PP2QOUR9(15;+EN%[=S-[IY1M%<&6_HDAM7&
MEF4;'_H+O4[%A@I+EQWB-"X%Z;*%\/N=Y1UL!<;;RPXI*UPMV6$)GHS44WHX
M<V_83J>Q<[HLT2'U*!9E<=C*KI+DL&071NJ!][[5KK)'?_:=TX.5X0738LC,
MNN/.YL[[D1R6'!F1BBT_?IB]FY/NN?''7!ELZ9,<5AM;EAD"P4T-)=<.>6;R
MU)+#P1M%0M#"HW4KZ->I]JH'-_>M_,[3V\L0(]>Z6M)$;EEQ$4-/KN"Y]X6+
MQS_U.VNYX1%#SV?^(D;4@(.;)PY60\A8LGEB#!X<!J<[IVTK>WVQ,OQC=K29
ME9/DAE=67#VQ8_LM8B:&XD_-;%5^6D;%;3^M# *EADZL/ ))241DZFO: +E2
M,F8+N7+/:5>O'VMWE:/?NVN2]KK&U<!X@;QD#EQ&- %04L80>WE-2:->]QAU
MUW(2Q7OB"X75'T4U%QAZH)'0J(8T2 SZ^8>:*'\BLH<Y*>"IV4IA 7GYV3E<
MP1\']S]?8NWC*GVUT][YD9P!%E0>7,^L_7_RF8/<R.JZ5'EH)OBJ]'4&^.:#
M[D[EU\[.ST9E*?"5A'.^\-W*Y'(C6RQE-.R8*0N#1MV0/:;[6 \- &93_\RJ
M[?IQG>!$88=#7N!)+S5 V?P7U4KL9Q'SJ^P050..BW06HA)T10!\%1!C2#T'
MS%&,"RE/-$"YM_?[^\VQD>W]#/)KPLY$&1(MO]E7;2!_5.X]7C0.2]EO^8>#
MK4]?]5+8;(I&50J\]!A@Q"INHPH.$GX1-JQ"#9/%@'!8-9_YH_J]C\6Z80]-
MK(B11.GM/06EDP^6>^9-[>#Q]]/];7=O75#7ZM,[]G?WRKU@]Z%C/31K%QY<
M>  "BC1,@B$ZG34M[KG&PBF6F^&U1PUIIIND^@P^A"(!2J!1:RTJ*:I[*)AB
M'7*8'M0U*GX8N/#7$XLQAFB:X?MAL\4-HM1+Q:C5J#!S5(<&ZX8VH^(V\#P3
MY0UMT#LMVXKZT0H1(?1DY1$DE3CSL'>BTCBF+)**?XABD9I/L@2]E;:0J&(U
M]>AX:3'J_2T*[J?60=\$>AY@LVY9HQ&(NXW+IO[ELMV5KT!H/069$96I%B_/
MG!B> V?B%YE'/02(DW:'"#+;>87JCWFSW.N^V-7OW>^7SU5K?=G :;GW]/UP
MN^3O'MCGUJ>O$BK:YPO7]_]&7-<)/!_\X-UN#>N65S4F3E;_;$<GRPO/6M1(
MHA4&O$V,:;4M4U(]K$:+#H0FD^\9JCE0E)M5"_ORMAL^CM1A:/-$.MMF'I:D
MY-TI4,X8TL1#;4:AT%Y.<3?UT] FW=&FM4ZV(]MZ0B8 ($AN1(L?9R]8;)NW
M&./-P[%:OV,$+K4*@]<\1ATFL<>(J-(61,TVB(V9IH5,S["C_8@6/CAFAQA#
M7(Q8V:5F<2X5]TM,OM\P3/Z.TK%#O#)T3NK/04 "#9P*<7N,?^FXT?>*%(#M
MS+R0Q #9& 0=><I1R$IR0<-C3"=7#M;Q-N')I T,7T3+PWIRNK=1V4\-RWLP
M[!"4E*@TW7E\9)QO]3$ZU2LUT?OE7KU:K[CN6>6DOB[VYW2MY^ [V]G?/^R=
M-[<_?478: 0<O,5QY3\%/NO.^-:_CP,=<IL.&:BYR8#R(27E5=E;<$V92J8K
M*.I7F25Z3/H,RW$Z7.E \M8R+/HA$)WN=2/20KJ\!Z5.%>GL1.%ZV=Q6XUUB
M8!0,2[%@BZB3<+;3!"8#V@YI5ZC"\!X*N'J=H^BE\L"=VP+Z(G2<&'$5$U,)
MJ;?AF;YH:"4[19P62H>R2826^OR1:Y+)BA8N7RN4CJ+^R7$/0VQ^2%QA W0P
MT'IPL1S4#?@;>4-7&( !T&BRAG/A@+<<X,^^'@)?U0!L?//$;*(Q. #B@>IP
M*/SE!@@6Y(7D@W;Q0$(GZD'U'+KX#YVMS]MO$,_CP/>)GUDF,ESJS4SZI ;?
MJ>KDYPOL?J?GU&-!\<?A'<%LMS.X +?B,Z\M'*6T/3'*5G(4VAAHA@BSJ/#K
MFY1B3;U\XDL+*Z+B0YL[EO,A:T^XM8/=O8,OFD">C$IN!K%#MA!/XFL2.Q7I
M;!"3_SURUMIL3<6/? (_!%+P0#MJ@S..CA';(@W&HI=,"UA7@#T_ 8.<^*\8
M\9(8IRD8YUNP(\,;C6\X\"AD'3[.P)*Q!1P?_ MZ9-?TM/\EB+R50.0T1A@U
M>P+V&M@44>JX BM0VC% "[?\P*=P"8^:?PBS,W>7\1+HQ&=-WI:6VGVZ'4>U
M.6<TB> H0!C<#@W"&$ES9)*-O@< 51N.]1RJG:A<AU9&C:C4?H;R:GJ);[F@
M8^+HP,81J=6=KPYM_N#GKRO=;WA>E[!0N LB_X%H "5<##JY&,BF9?@-WAT-
M/R 6 ZH@)<SPIG"6"9^B&O\MHTLWA?PGU:J'!IC( T%M:%_(?Z ITG6%50T0
MG:4"8#6Q=XB(U/8;L+J-@'E-@%80>B*DB#LC4LT^7-!6AH?''6RY(50AOKQX
M);X&@\'#$63X6T*E(J\2V9#0A8-[A+\\U2?#QS9=&+YFHWL(IX$+)<A!U76X
M:2O91BYJL!6WX/(U@^@$-M=#-:KJ\@+>P<!V^.Z3S;LD&_*885K8=*]M .O"
MJSL4'M%9*<"@UG@C01'W%L,C$IOVA^]Z+:_2<.?_Y&VZ=C[:=,VE35?^HTW7
M1YNNCS9='VVZ/MIT+:U-U^(]14<@;18<$_\YB67.T2$1:B#<1.^7>^SNS+_;
MO7KJG#VMKZ?HM-SSGMI71]YCOMO8_O05@:*EB?0?_J'WOD.ESS<%RED4OX!M
MV-#- 'J!;<%QFZK:(9IX]^E7BG,<G0G,CUP[ILC%-*HPDF]Q^X.+OB9$)TU!
MIX2_OC])H?^R8F*"Z2JY'[USZZGRY_>14?@=YW#@DZ/[3O2-Q?,<>D_.\7/M
MZD<IV*[WCS4R.8&>&9'PD<@\V/!9%;,/.L ;?4P,'9%Z,..T(@]BYFD=-R75
M85AZ&$\QZ2<2(CBQ+U@B-5]H/96_MPF=.(]N[&@F>*K<A:'OE'LWNW^>N]>]
MBO^RM;Z,;[?<"W-[S/AY=O3RF/_T-8;'!ZM[]SM4#A.=[B+?$&@A<C'T>@N^
M)BUB)D,S(LCOJ.?&]K",\-Y(XQXZ@4+'9#Q*3(S:9$'#-3-Z;*%C9*-3S&HX
MFQ8Z,)L-BS3UNF$Y(K#;]7T6N<;)TBK#_3;U4Y@N?>EN&$RR>AY_$)L"?4U=
M(!H1,X)]@TA@@61@>?A@1F_9(?%V&!0^\'@#+A!XS"9E![BZXOQ0(D#\*(K.
MIV::L:<LWD-&(_A/#9&UQ-4U]BH  FN)6Z+*EAF1#\D%4H_50T 2&S^U+=8A
M:W-"%"6/&$=TN%$-)MS'C,?!&BC9V/@3($S"@6"[':WBND\RUN:\EO86^6LM
MX97>0*_T!JCP6)7#ZZ9<)+T#F!PP1S?1,P=+4Z-Y2B ?HXE WZ6[4 L]'%1#
M+T'H^Y2JXJA;^_?@]>)%H3/7-3N6;8-^?^X$AE.W@#X5*/))_I0:2:J*1A./
M4>X=G+_8Q:W=EQ]V;GU%I<-RS]WV2Z6GUH^;$^O35PF$#SGIO>]0GJ1F<3\>
M9@CX(EW!)Q<OAH16*2O.E*$);EL(0$G'H?0:&S[&#G 10::PR1$&<]E\N/O$
MY V]$OI B7U?J[K-"J8E *7<U.42D>CZ8>61LNQ<15H!&/D\US@ 8<9 QZCC
MA 9F4.!T]&Z%T5-"A%/>%>&JXA5ZR!>I_%I@/*$GU#:J3$W2J+E(S_7GT/"
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M(/*/\9@X_!ES1;CQ5#/B\=1R!++0$&_,2_E69/Q4'F\E[J]L053IZI1V%Z<
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MEB8Q+1@?U;MO!%J_<V0 7@?]\ +UD!3&>"=GGNNGFPE[)X\_FV?;U6OGTDX
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MJ5E9N V>(Q,"4\2\AE$! *4 R,0YQ:@=4^\5+CB5&J ,^$4QPG6-NYB()X+
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M8)A&%P-RF)/&#=-A\>DK77A-7/CM =:\H&-&00WCCR05<0P*9*$&$W#X1$E
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M\QHWISOU!DL]NGCU4YS8L,6_Q<F! %.4IY?=S&9SPTYM4S\QJ@U^=@/7K=,
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MK0EUL#%[FU +D_Z=P67/>LI#:VA+'4R3-"+6Q5+..S_DO,?HW\=3GGZ_=K.
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MG3D RSLN?L:):BP^"?G_IS#+] >$XA>BRZLG,2M%PF+9&QO&V^*33T&,=2F
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MC%5*-W8#&2I1H>LSB(9WW\(0.W >)'[DD1&\J%TU:*9\LQD<" -I\&MZ%TS
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M,K?ZPV(Z1.EDVL)K#[Y\X=%.W&53O#;*+E]4+=.Y51^EM;8B\UU>6WW26ZH
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MSH8RB)![GD= %#P7(O!=I.S)@81ZUQ<DU".\H.0OO_H'VS@.S9(% /L2\@,
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MJX%XL<&WJUP#L5[\(IXR!Y+UY2[,>IX\6]/B1G6O$>X?;B1>CG]Z5JW\4EW
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M-[.-;<#-AQU2[H_^_&Y,GD.XY'Q#XAC7*$2I#AA#T&,L]^;Q@-E6Q?C=K K
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M2Y-CGPQ3.Q[3R9Z^,K'H[2&.74,R[RA/7$E@:&C5@AHJ"SI%%4:VZ)?K7.[
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M :F6_ N[XI$.>UTQ+#U\P$#@P[?3XSTAV,\/&N^7K3_/$-T/(A10D$.?/$V
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MX^^?CWJY 1R =IH<!RC46IT%=W BF:;46;ILB>?;1MBEN846&+XHL'14N>2
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MK(4'[&TSK8?OM<I-+3O7+N\QB\H]>KW0?GDM9YE'SKP=UB$+,HM"+];'FB]
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MUCG6GIBW$R:X[XY5.0GCG8[A'(<STBRN&EV\R.,$U#+,X4 X%1(KM431E$!
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M?>,V-1W@!*M9=2M+CV^<(!86:6"#*ZP.E1Z N,'N+1J#OE7T;8F)&X &I!
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MUF$Y4[QVCRUF2MXQ2M@J;Q=IS)8$;'UU#S?CR<R8V6-C+GZ<*LX"Y8H=.*=
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M[5/<:[##X'$-/IM!-#^@F8CMAL2W[B<SP>@N%[HI)9:XA>D\BU2AE/=67UW
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MSR%8@K1\UWX7,."SW;:@?7H0\HD)B6-(4HZ14PB(]K[#3P$>U"GR:!3CI)?
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M>KSN[%Y^2W_ M^2:+6=]6EM!DBOF9[#G\'7OJZL9J3)Z&X.IDK=G?J(Y8BB
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M%]91QDR(7BAN+5&+"4G;9$)F8/ZV=/;?-_VQ;> 8H:PTO3)Q,$?3PW;<@9_
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M(C$4A'MYD%?MN?G[R^U=-_RN\A??0II_&\#0W'HVAJWS9]([51FG(D"%XFI
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MF31/2W4"BU)W;FXF9)%Z4OO+$N/R&(X>5P6CV]YA;?]S (TP!YJ/PF8%<94
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MH=W/.$'3'I+7M@@C<IE<>^'0KVTQG4[BCJNQU[YPNK:@#*G?NN+F[L6U%>\
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M4^4& C>?-;5#6/C;QM)T^-^">&_U/R9(RNU=JUJ-\1,WS=])'8>62@Q@-CK
M<O2AV%^"O_C9(6-(&)FVP%F0R[J@Q[B1O/%#*-Z$+7:?L->HZX&CA^RS!>=.
MR3S<=SQ26'G"Y^.7"0OK@^W;4-F;S^XG?DJ8S@G\)+93T".(" T;G1V=F:U3
MDU\)<W89K1E>";@[O#G6!I.272\8Z^I+TU+S\!F;N!/W6*/R2D!N[+Z+!SQ@
MEF%9UEL7^8*63#VLVV<./;CS-O-CV^O3:GRG4R57OR'OB$T_RKG2JZ-E41D
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MW/5\C*B]PK..0(Z\MOT_+T3,_WZ7WXF(KS A77YO#'^$UE)&1+%@W-:KXY3
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MLIJ7;%'Z#5M+_%O7]56(V#-S29ATG]_K8NQ>H/I4@=*DVOA2T7=;XS;5E(R
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MW78,$X)O(&(8CA9,"-=[JCL3TC_"Z(=20E!@D=[MO9L4!ZM8Q^SQSV(H?I^
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M6/9ZKLK_MHK2)/)VDF=^_ P3DF1S939RY,J8^7;]9\Z\ +$W3\Z>K!3@I[L
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M9IHK)$H'?R32!/K.,.#*(1!9*"ZH E"]C!1CFW4!RG1A7XT%OJB@Q@R[#1G
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M@T'VW_3B?B+(;Z%3D:+#[Y^^2,.JOICE3DUW0V[4=,0%!9'\AD-)\YB ;UM
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M%A;S<H"-14<^3J/=W*()OM1Z6W<"UOLHL]SB9<J:5G^T2RE$54W\8FQFS,:
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MY5[&@2G$%H=CU(DR)1,-<!Z]?J+:>F4B\LF=_4T][CL N[?61SE&0:X(9J#
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M4+U@5""J!I.V[;EU#^DS@2:OJTV&&QA_B9U0;]U]V3$>+R9Y/H96\"MP<?#
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MPT3@G=G6YT;(_0%2<I;)QANBW[T,)CN0WNR'?[!,#[*7!&#2ATJ+/P"89(7
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MCN7,%EOX)S05U4A)-R;PL\Z-=K@06 CVZ^8L]PTZCH>>*521^*-!<B8I\?O
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M;N/ 54:LUN<W<$5H NH04=JM+Z)V6>HU51I^ MWN07S2&Q'DW.L>5(\Y 3H
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M\#%#2*M;+ILX)P5$-;<E7%"<>V9T"FI3T+.'-J?&+H4;H4VL  Z!COQKQ2R
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M.K>G16312YY,O@RCX2.8,S6K9G)!4KS,,]E2$TIJC%P5\M,YMYT_)N\<IA2
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MS-;ZT95%K5!5"IFC/M4LSWQEU"HW*79WF_#A];I!8/47ULE&8(2'&,+?B7S
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MK_D[#_^B5;ZGO N@=MO2E:&(!IMV8S .O$FCI%-T=H3E3N818AW6=ZI_WX*
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M0'^FU08##XFRIF\\PUIP04LH9M$Z!:PB(3R1>G-'5QFEB.GG'[_SPXNOEF#
MV^O//C9D2C^*&JN9^G&M[CN7?+>OOZ__H^F'L5[/PF/=<U747-/9^ D-HF@C
M7^5^9IC'2!GEXK2 J=40BFNQ/VY.%D]?V6',;("O2$QUA 9?)VQ%:;',]GK@
MY%A%*_&(?5L\%1 .LR"(X6#)W9Q)3S_,>=#LN9MS4HH*B!E<F<ILS54?T+3%
M)@G,VD/[;7D/8H*89[DZ@@7%ZT>WE*-A%@SQFX']O*M:"E5C%>]KO[34$[3>
M5$ZL6X^G3D_.8WS.%FSF(H/N[UM3*IF(21;1_FKQ:+YTQ/U?C2Q-K+%=/^_&
MUOV,OULFB1FOU&'D&3 K-8D\F<O'%A\D)DDTG.CA]BW%27QY7=>1XY=^NX3;
M(8C%_KLBK)WG1B+P2E[$QZHD9L=[*V6Z=J,B)J2)M8DR%6#*VX*D=JQ;[/Y$
M"'KCL>D)TEUB'/Z[IQOV(%X9Q-)5R>Q<TN[%F5.\^J6QQNCXF;KR62';FE$E
M^T4OCLTC>^-K\8G),T8_OYE%^I%L%X$<Q!VG%H)I DR_%%J$T8@KA:SS_NB?
M]O5!O?_$'9Z8/S5IJW=; Y[INN\M9!PQ)\7,[/J$80,1F\M%U/&EZ:ZI15P2
MABS6)7@1A1_?#"HE2K6W".(A,;5(IO9B*J!-.Y@ <6SY-+KG;7IS?*K=M&X8
M):!5X!ODFN]IT[EC7#UX*;+7<&PO0:\7C+-I-0VUXUCN,J6'"E!$'(@-6*YV
M>T3\$[@: 5Z)754R6K?_ ?EJ8XI?._B:I?+&]1*E'Y^)\3T'(MY^3V#(+"4F
MSCO='*S-$;UZ59U4!N3#=^U7\*EDGL')OQGSB.S%1O?[9:MGZCFDXS69I1^)
M9>NSZLAC[E7=;5'J]GN:8#L0[\JT*^E*Y.^L8.-A 1<D8L]=?)_I(I^,TVQB
MR_AI1=@3=X5F]]1SL=K>*R6 1IWW&!?$#!-N>V'+]NLA1NM#"7)NJM&5QHW/
MW7!^[6I?!6J27\[S"![BTNH9^[5'EM]M(/HOWLO]T#)( +<!0QEQ$%Z2,'[L
M#4%TO(O"1V1S(?@,=QRA8\N4(<R].&.I!60$7-$KE]67:27W0MVXR !*![N^
MZ7V/<*KE<ISMD*9I$'U.8M3S#_:K:!=CK@5@^)YOA*#P:!T8Z 05Z[2S^5J.
M6%1)>EY.>DH,*B?V8CAYN:+06)D:%+@F'1T12 5PKFJ=)CBFEU-RBHBAQY8:
MA:D%,W?7&U(@&LTKNVZTQ3T[V':G8Y%F/4>FB9F2\$MOL/*O/??DU3$>UE\?
MIN%'=AR,0UX_LN*QVK=<T>&(*=A8M."*;.NLX[;&)@'<ACN,Z/7J;1+*F:"'
MAA47*A0&TA\UL!HQ)K3JF;?J*6"P! XKC70Q^[6^P+4;Z9[;$1 7PA/"S(>7
MH[DW=>E.I=B^%K>ZXSB1?5FJR=DL6C?]P8D\]R6+)J^NR]U\F_<3/MV<Y6._
M9]56+0F]IWAEUQ>S=1;&3C0!?:7QPG#*96A2%Z]-.(4;BG8<WT4+KMI!PI7?
MHKD\M!@)6]$4T.3* >C<M-E 8"I^&=(R$)C$"X[90Y^W)U9C":+%>,JQOK^+
M?\/Q ^.%QA9-:+L!OBA"&7QV=M5\I;+2<0;Z8=IN:&\U"'P*JKC6MFXT4 Z3
MP#:B9&1*"A9&+>>@D<]#CC;W)+8V88T;>7N*+5JV%=ZI"Q)^E"!]NIR?;SI]
MP_L4E.2),+[>3U.?7:5E%;1_<50'M#^T^+[BC-\3>]%F.CWZ[F=DA&2Z6\1.
M-4K50N[K0^AW/8^T8UBE8L\VRL31B,VZ4#9#3C'!HR?=2OH<;TH&)[OD:+DD
M-'8W1[R.:2C;&YS1=1'T=RD^E!@F</7OW3%;CAKPGC016X(\,M+RWJ @LOZ/
M&F,:_1\WQJ3)\?\W.F/2A%57,Y(<TD$%O-,W*>RB";!]Q-XZ%^6E@ 9ZQH-$
M(]O\-%Y>#%I:@M-(:R3XZ/:-6/%B\3\UW8+]2]6G_X$*L.<Z7CSDI30&;1UR
MRU !ZPV425L;_/PP'WFQ?0M/T*>DMKOM^0YF^ERA IIHA,@09S$:""'N@?9&
M$6E!P[E%%#K:'&4">/^0LH:.I*'07TSL%G*<G7+F"%Y&F\^WJ@^QXH#_N\>_
M=PS[D+A.H1EMY<:+*[_^E(AF_F/,E\A%>2$I _KK7[";NDDI+]03+"C@WU3
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MF:^?X-S:V&_^=J4K>I/QGQ+>QOB&[YE.9.[S-8XC,9GSU9D;![(UP2XR.=/
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MDWU?\?.O21_7="/)[WXC4NW ^")@^4 GMEK-,-U%4K'X1C.#A'G)(F\U+)N
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M!?V@L\?75WZ$VCL-+P_740'GUKB^G"XO=-#1M'F2E9$>+),P(IMR\R4F]W:
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M0["<LB\JSP=4Q70ZL\Q'<GV@Z!UQXZX^Z3/@D#N_=QLA4?VT_&NE-AR.8G;
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MW@D*JG!A<"WY5!CCKVFLT;M#D*QO1T/"\6E6?8&W$[+'A ,(L3<X#8V&.40
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M,]B3+\"U(+@3W=).HXHD5M2&F=QRUO+;&R-]_DZ%??=>1'W-)_-"$E'$F;0
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MQ8G1N 2>1/U!\L+['@S.C\+(C5A8S)]#5?! :L/N,G&W&T>'-N_!L&B+A0@
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MP6*RW*E'00F<]&0UW)'$1^:B;7_B<?];W??_Y<H*"_%,28=-;\/@[?U7MA>
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MJP:I0,:8GHHF[93!$B/DE*;I<S6M3M;O]%+GZVVM:SC.Q:;8;>9'%6VC_&'
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M*>ZJK?Y@<#&Z4$1%":AZZ8.(*ISABS0B 4@O@,O%"E@WS**RV(_:B PX'XQ
MU\F[-N1Y_%,$S@<E?J8@)9<W'=:.9'?R#>74UNT.I1DLM1F7R7"Q'I-N?G9J
ME-CC:J"'J*F;P.YT(</)4%@-CFYA'Y6!17,#,6XP(G<H\D0V!7MY!57XBB&Z
M*H<]^/P(WQ>ZLF I# D0TW3] QU#QQO_V Y&*S,<U'RH:I9'3UO"NU$*=:KD
ML("#4@P&[N]LJ%']AO^4\\I20<0:R$7[S$>=+?SK8PRKB!$H6.C)+9HSG-4H
M;)U071."2Y$56?K3U#)$4U._M_#]^'<L7#2;1[9K5,K2)U.1N6+,/4TT6%:
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MM8D]-TSN?]'4NU-;;5#LAB>#JMQC IA;I>I,X?UG4.<UQ-XI%5%9_; E@P0
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MORN-/N!BLU+;+ JV02\QYGF@'C$ORSVC_J#ZFM9=+>,%E8?ID%16<6P$=VU
MOKI(W##KP/!O3VYX[(K;L74I-RQ_GE9]G5;1)"7'+Y4IH3R@Q'TP1OW>?R0>
M;+]=L(S^>*R<EV@DY'EJQ!TP/9\CE#QL.=##]WU--ZUJ;*LW;\K3<,15>C1+
MCD^'Y4APS_/N9J=K0"&>/YO,36V).#)-BB=3HHN%<= ?)$ +'YD=^:Q!,+'M
M!+*5A<"(0C#<?121?#=;NDD 9MTI&_ *DFA  FRW;FY P<2'B&.S900FW;^;
M #M%0XARZG^H>2(?VB;.<,1 . 3CBL$HEJC3*.(I$&_$/7*1!%"![I)-VI?!
MWH+,A'?M2(!>I R9XH]T@3>A\Y=) &P#&"6-A9T"CSH0>-=F82*C/[0.NO.9
M!.C\M>6\"3P#/B+W&?WI\+WN\1X)0$;KTXH@Q7DDV0;%B<8!\']RD.I5;5!D
M#I[LH[/AD^-$*#X-NEO9#_U=7[*SI;"O[8[O<$1J=@M^Y;7G5>_F+BQP)C?Q
M[T.\B5F2>$.-,@V;89&GHEQB2I!?R]%4+F B!A=ZCS1+CZ77FL-W9KT=N!3A
M6\TCP\9C2F5&,J-[;$_'JX];1[4D$^MIOUQ"T1\\,F6H6[@%.*"(XPYAN#L"
M>D53:1-W]FR8522@U2"1);LI[F7"&,(9A3NC#G/M?+:>Q[D01K_ &I?S$)CO
MVN[ 6/'M-TKA9O?\>DOW6[>_@KP7US2-/K"JLOH72T00?JA>08^,[^HU%.F3
M;\%NH;(.Q&_*LT4_5U/'*T7M)_+9CH+,]ZJ&^-$;4[-=C)Z!O3OZG0W/(V56
M>*5N\9S3>+Z0,-G3I?: K6B5 L!P)T8X>>9_VP+:__Q%M%UP=,XNXR )L'$B
M3F#TL*[_!\XN6#:!(_<R_]X '+.R=M*1/T.@VG.*7"%H$<@.I":J_9?KOA8V
M1P4>1F$_XN7^C7E6I*7)"#P2N!!%3$R0.)R*<< X38U^?OU.;43&Q5#U!P$S
MXCV=@3JO0?$\WC7W7)3EDLEQ,MX45[D(AX$OXVVQ[]#6B! TA-/_U+QE0L;*
MY%&Z\^LM5//;O*HA$6ZS.6%1*O679/:X'W^C:WQ@H'=8=)HO==TE9\TQT,_?
MN:MCR;XU5')1 !<L4T2/>*G2M =9/F-# G#+0@^VJ(BQYL17)V#4)T6\46R*
M?!^3#ALSJW&FK>!(H7Z"G;%37#Z;9LRG42.(W<T@ZP<-F?C/>GBFKG184I2#
M@+BM7,: X4]!#<U\H1].]/K:NSU:&>G4>J']8H8GJ:#J?>#1K^.>I .<5\$[
M*62O=MPWV2^;]SO*"3^5A_*",:PDP!ND: @581>!U^8(73-QF&(#X;A43"*7
M;\%I,5^2'?@U]"5K)221YX=$1)>[N522*.8QO% >/7VQ/$Z.([N\),NA9',G
MO63K!$F=?ND1<^GQ"#6)5[GR?&SWB]3T++_$I0['Y3K>+X^7GE"#[;@1+QI@
M*[O(8T<L9($O!-LM$LSW++%NKU:PA>TT<$8G*2V/$N<&M_:=RSV%_FYZH]O\
MV<O.S9I<M)T%<Q!=)4N(<I6?%TPVP)<8O^9W!_4&\/->YZ/+*GJ9  4>P.+T
M!@26@[D7.4D"4#9@/E" L;Y$61CTF/V]S\8\%C[>3[]P+-%E"!AV%:W#?A4(
M4Z1K]CKV)5Y$?Q<%"5SUT&9G?)2K&[UG+KVF)G0KBL]<IDR34?/*&J)<OBOY
M.FM[TOUGB<1^%'M26;O9.?.1+,WA'LG)@;P5087BY.+=/:]>SV1TQ=R!AJ9^
MCDJ99XO;G>IG3UV^FT9=NZH@/Q4%3)-Y5CS%^//SYH!F=L=SG3L[V1X)=?)K
MQG>H$/O@M_ S!;7:SBX&YELN^N,G%D%KSJLAES.YRN25YL:3K38WMQR5)E>W
M@I2YLO\_ZMX[J*DV;/>-K_JB%)%>)2H"TD5 JD1%0$! .H22%Y :$1"0"($H
MO:-4I44Z(6"D!!"!" F@H""]24M$NB2"L(0DG+R[S.SSG?/]<6;VWK//3%9F
M,D_6FN2YD^O^76NM^WZB_RT.E7T$&:KO8VG\QM@<+'?CE1\E]'/.5IC8CE2D
M$CEGMV-7GKZU@]\:=8+[;]7555L:7#@?MIW1&S]B[R]565>.G[4;F:QLVVWE
M,) VPOU[F+#=;=-;OINCC;[355XMYE^FWV!8#[8_,K_\U@[4:R+4:_S]^"V-
M7_01+': 4?]+!;[2FZQM/DEZQJREU+AY/DGC-0I&970^%DR^7*(V/FIV/=^W
M:G74EU[PWY8!NGJ=Y:KB_W3D85=;(I7 U 6-AM^1@MNE;O_E(_#?#\_8V5@S
M-E'Z9*+8/&)B&08/J9V;6<^967]>8#+IZ[KF4O&XR=<%V[3KZU)59KRJR#\W
MD/K=HQ)%G#P8;3P85YM8P]E,S/[,G8L(?1LL$Z&V^>8W5*8Q?+6HJ*#A\>.'
M@SW\KR0(*U4[E(T^*#1[U-Y,;<^W$FTFZG\]9+@C9.'FGU"G-]CQARVLY[9W
MK/E"H7> \.*38O&J+S88$#3857:KL[@M)*"N39K!%R$]TO;P4^5O.S.-4#A6
M>FY\?'=D?:^MC16;#29J*!RJHY<FC38L_G(]/U+47R\MVG?^BXZ.CMKFH8Z&
M=\WP]'K3N#-K6H3_8['ST#J:]KL2-3F"6DW"KFK^#VC6B1R'4#;N'H%PY4>@
M83[[KX&HZ@3F.Y8ZOU9$O$HX'&6-!*EWH5BB/;E..+"6*DV63]SX5U3%ZL,$
M9S0DJL31N.^RCS-N_K$:OL'SQQ(5A)+3K2:T$G*,#4!&RP:,'GKUKU(FF6DK
MQ7\,G".T+_2KK#_E,.6/3?:]$U$VL&^P_@PYY9_*RU:6_WWWP-NNR7]'8L;N
M'7NJS?F_I/[[__!VH0+?43R0[Y(EK#G?A1U<)'<\:L\@R]!C0R 'S)0CT&UG
M:R?<?UV?L@BV-#3Z.\GTORRF]2IBGQ7$-Y#A#8O_\'IMDLA-9<7<V$@D)K"$
MKD/AUR("^KV7 P,#Y\7'56.F:*SDX?77C-/EU?.)W*\-_B*,_07[ P+:@_IB
MVUWGCD"K+F.]>N]D9H5_$#[_-<J\7M<7Q/E$ GU^ S:,-F(("581-+C?AS9V
M_;AVR+#X@/19B*<71PA]9[9$9\( SJQ=U,4>?DO8<,)2B0'_/;8]%K^=8/FD
M;&>$-;-_I7>!89(6U;B*?J2P^VF(087_\F">RANB\U*Z.V/(*[W$8AV@FO+'
M?D,O:?_B ;KO^W4V8)**$D-]@O4,.!V!ZD0&7P#X=.<FYOZO/U/,WL4_O>**
MQ,&'DQ\;RG'O0];<OY&;PG%P\_V&=@IV8MZB.FI4VSSF$(8XOJ<_CI2L=5S_
MMWN4-TX8&4P-( FV-V7=I)TI60P0G0*L>R!<FR$94J$0X$[3=7GKD79X*,8@
M*-0K!+Y4-5!U,_3ZFS(P>@W<$D:,]&:R'R<3 )G?G2_4]#2H&1\.E5,FB]6S
M2#.2:QK:R\/#H4EZ(JAN=7%>O[U\QK_6\*P#TB#%NF/,G]Q*9317;I7KPP7S
ML'Y,R2/027 Z=[RK-"/F"/3 .Y^# S8=LX>CXN*C+L*%\IY#I]; ((A?>2-P
MCA9A]3X]XDDJ=2VLA<#]^WVY1$C]U)J0]72/1P0G=._%GS\GBS'E",A2 EW
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MM@?NE"3O&;O#!W/8L]WB0I?-N?=1%".2LCA=ZRM=IP;@6.Q+Z[RVWM9"@IQ
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M@>!;''L/WP-HFBK9^7D)($0-(\V$9N_<1HNIX^)%FZM*$5ED/4SE5.6KUX@
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M^:1XNY=Y@BI#PG$AP*31N2]A3Z0KI+%+L_$3$K]^NCQ8#]/(R_H68;1U[%"
MR1+EII])BUP<%&ZBF*(K),[1(AZZ$J^^+8C4HE41-[34/H8X%4EVS6L!83@$
MK"=<(J;:9V^BS;5J"5"W'U;GD'>ZWS:ZG#\Q$H'"5+])>/4C'0'%J7\Y=Y=?
MSJIK[$FZ_(R;KVT%NX#LU_S,;-G!.,VOV6)8(8,(F7#_#ROQECE6B#P+Q0^C
M!ULFMO5^F@BI1*QA,,:DXDZ_[84O[#DR=DIGRPX_19@&7QK*/P)Y#TUS[(4Q
M<L"]'GOA@&<97:$1>,;]]!^::]X2PY2T+VI72N"DJVC$T"5UPQ^WD+GL!OON
MI>BWO@1BK.NCYX] O="MGNT472>]1G*:D>7XS[<H7^XIU)X'HPZOS 9'2T2)
M0 $LB< -I>GR4<RX2:RO'4$Y G$Z^ED[#M7XAMNG1TD@L$2)BRDF8^5-'F&5
M%F%!E6C\O-JU0-.P4*F^"1L[RUX/MU3F<+J.>.,9GZ$-EA,CZ<(+?8PX1'3O
MKF@W9!)[U7!*$=TJ5JGO;)MRG?+&B+H"=\_P5O)5BH9<D..)FD&D^X5T3(WF
M-6.L_ *7,U<*K9>S+'YL)RPT@#?GJ.\7TSL.-0'Y);:8IHSH8L4&FA0Z3??$
MA#VTMX@2 )A2>/YM^.;G*M4QB30FI]2Y\\>/K.\[32J'"N_.PL]I#QY,S-[Y
M:OAB"<T%6<P#O]WO5A9%*),UGD5Q#KA1%A**E4?:/1<71. 07A;US))F3DXD
ME ,QMX?I&E7P*#W:2C)>..K<FIV>S,1#M87XM""9IUN_WQ.VII&08%2 UP3A
M=;9=TX["8!9N<^?N((> W&B/H5:\HA&?W.Z*82/)8"P;+M?D9U.B^46S/W;Y
M9M\4WEQ5 2M?^/97L=/3;&HR!Y=&7-E0PEYP'/1A]DAJR66[*G9:7H>4JUP'
M []NNK-!MJ?S#NT) ._)"R*(G3[T"=@]&IJD+ QD]<YKT^S2:/+DE6CZ38K8
M$4C0MUAT)'2;&U%E2[7(T-71:Z&N[XUV,25RHD2^/5N$GS.9M1P/J>.S(-"X
M$V7&WN-2P52+[6E52FX,-8_HJ@O8/5^#'=L]39>AAK!2-^2L'N\ZY Q=,BR@
M=,8584K,G^Q&"R*4[6&<+DY L'ZR/X=-Q[C:&I]9RX[BW)CFH5)RX.<=;>ON
ML:I77F<QSP)SV<N#6C-\8W*TY;G-'7S[;5U.ZW,+W.*-A2G*CR;?RW[=D^.9
MK)E82S@YD&*N^9(!S5,,U3DTL)02.W3UVM!L-6E$CDO)2JG_*LXXY&5^CI(
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MWF>D3K@^@^.G<'D*7QC)_^*=XGB4;>'M!^8R/^[:W!. A*!.E4WA1[Y*;CW
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M\&R&H@K@=T!W(S>37DUW&5J&#;!M2F?(Y(D#+(&$>DU3=7>K%L_265V41LV
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MAL%W4]R=?\#NX_VL=W*&( U^; G#803!G1EBQ+>5SP5=!@NSM8$WS&;8;H^
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MSFO+^^)F'5'-\V*<K5*Q3HH\1P+U#KVME1\\$D& @%#"R)M#^!OH*)1RK^]
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M9W'MFHPAZZQ4KXO9-XN*OJ9C[^N2U8VVV4014O(!C$?=-N[(?P%02P,$%
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M<PD?$8/0-9Y:)%B_4H5:2)PIRY20@B(Q-1*%2/3L-<P?<FOFHQ OT$+@/(U
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M')$2'OQH&U\]RN7=8[GF#V8RRU 6P[S6(=QPZ"J.WL%2_FP8@Q. BE]6126
M&V.1 I5K=WYU):P/GK\3A?>,NX&!VU4KK_9_;/M-R[^="9?_!5!+ P04
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M(A ?\HB(2;Z\?$OH!NO=-,:0WOBCV.AOPN/_.96FVS!$Y57%!%LK-JWZ^>,
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M-QZ[+L,8A7.?M8Q,*>G< DG8SH,4-[AJ-1Q%4/E;MAN]@!(TL;'(P)6/'OR
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MV,D$AL=, 3?H%EC#BCSW**1B,7'GX/C9!P]Z"T87\;O7J&YF-VR!4'[&N[R
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M;ZRJ-<0D=*L#)]+QTZ-EOA-9-2\S5I/6/).XD6%F%;_9X.S@AXGA]/)@2.8
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MJ8?4A;9_QD_O\)R<\0LD.IO#H\\DHWF3ZYQU/#7^RV(^.:0#V6?06 9,V-$
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M'!O.3A[%HK>4<,=QO4T<=YBYX'P]G@]RT&P-5)L\^5A)W.V(HMJ(\T')%XQ
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M PQ_9P*7^A.5&40RM-I5"X,LYN:U"3&3E'1&@O-:4VNK9<_B9M7[;5J]5UL
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MB?_WX"5DQ/&*DI]>$OK7-^*[Q6>?/WW#XL6[C^_??WCW?[]<W_N/9.F]I9'
MS2=OME*B%IG<AQ]__/%=]M=MT4;)EX<XW'[CT[NM.KN:^5^IIGQ)DX3^E&3J
M73/?2S/:C9\9*4N(G]YNB[T5OWK[X>/;3Q^^>4F"-UOP,P1C%I([,A^)_W+V
M=E^ERY7GIP^4+0EO=;[@[9TH\^Z<\7;)%<ZD'V,R_^L;7O:!?^3CI_>?\D_\
MH5(HW:QX^TRH:%YO1N\.^_R9%PK$[A\)21.3&M+"_:DS]6(2I8\DI;X76NDF
ME>Q44=&=R))_)+F=WZ[$$,#;F!% O51O"MZGS/_MD84!'X@FOZ]INK%15"W=
MF\+G7O)X&;)G*T ;0IVJ=\.'SYB4:1M'P9F74/[E:4P2KD/V:Y/&MO5TB_%Z
MN?3B#>>4+B(ZY[TC2L>^S]91RJ="KL@=6;%8_'O*0NI38B:@=8V=&G9'DFU+
M,&DL*=JI*IS$E4>#R<N*1(D90$7Q;MLN2TER1WQ"G[P'49^AB<J+=ZK25?3$
M><AZKDD=2=&."6.\+Z:;:2C:;A2(,6XE/L?_O?_V571'O'"2M9T;8FQE!U7:
MJ7F?&0N>:6B<0.OE.J:;+\P6E+>F<9( 5AJJ\ITJ=4$>C#R6RW0\W=G/R4>9
MA^](R%MCP)=0Z686>U'"BT'6-B:Y3I7DFZLES<<$WJ'.63;;\"T=8,8"B';<
M]/D_R<Q[,:LF*=KQ]+_BU0C3O7"[6A)[Q'@)6KH Q3M6^2$AOZ_Y-R=/D,E"
M51YY&=7?<JK7915TL3H3ZP2C<>UJPY_K8=9U4'4O\SY,>WGI7M< ,,7T4GV-
MU%#=% +''+5AJEI5TJWZ_B,)UB'O]WRN#<0F)[BDD<<G7"_<;]\O2.K1T&Q&
MF\I0AL1"AQLO%L6>S)NN ^M%GN!LS>WN"WWY$6PM HCVZ6>P51<HWJ<?PKJ+
MP,3[\E/8J@L0[6F@52Y%K$=9:$WXBS3[]M_A1WKB<;LHLZ9-(=B3FO4EFK6Z
MA@IZ61;;MA>37$_87J[%LF"\%'/AO[(%P.W\@CR1D+?>8$;\QXB%;+&?'N&@
MMZVYUSV!_1@+D^_<;VBKJ$ZF9[^B]=(,7,-1_([VZS"[>H[EE[2UHT55O>W;
MEBL6Y8>LNRWO&8G(G-JO*"PJZ\F<"S(G<<S'..\E'S0XO-?4>Z A3=L,I';U
M];-/F\SGQ!=-80?I'>\$4%.L:NG+Y6(_]!M%^^H/A?^D[%.Q[P?F2G3JKTHN
M@6O^BXH(>4E)%)!@6Y'0WS(2*:6ID"EBQ#Z,WHJ LK50D_\S+UGHL]4H9'Y%
MB5 $7K%::-,VB"T+KTJ(_\V"/;T+"'TG4!+_R.#*H.(__)I]:/R0I#%7>5M3
MZ#V0,*O_5UZF5N3=$;2:\*$XW8R#@'.0%*X_N7+RDG4=RUR.XZJ^7NQOJ^;_
MK!#9#%,K2KQ;9>%/;_U'&N[:P#QF2Q5HQ0>906\6\R7!7]]\>/\>!6?>S,E5
M2I8)".M2:7R\=2U&#7O)A +ZCTC0%_^8\?K'+Q1&0$-FJ#0T#-GU@^-P4?K^
M!5MZ-)+#+RGF'.**=E3"7F)% ?>1T#Y;)[S;)8E8<//!\0M9/NQGQ2KBBJ(F
MU'=]N0>\E6VE!+'6PE)C. ;:VT6%4%@.<K4$$-L^H#7-1B6$958=&=@Q_WX@
M=+@,O85BP*@6 4+[ 1E;J6%8X%Z0Q(_IJAS]HL"X4A)SA&@#M<1,I''BCBRH
M6+4*5>[K8;SR@4,A N3@DR-#B=9P)#+&4;3VPOR@5L]!M200^F\=@5YF)A+B
M?UM[<4KB< ,!O5$8B/MWCN"N,!9KA2)<R51 !<&^61H(_I\< 5]E+A+Z]X\D
M#(7KV(M ;5]6'LC ]XXPH#;9 0ZRX-H+/@W!:2B) )GXP4$F&H8CD3$E,64!
M7PG$ !H:A8$$_.@( 0IC4:&?1 $4^%U1\!;+*=QKEB*A?DD3WPMSC2[Y[Q1.
M2$UQ*/K8.URCQ:@,_(-X,1C_4F$H^MB;7H.U1\;^?!W'%66TPXZZ-!1][.VN
MR=XCPY]K+O)YW*S5?N!F*2C<V%M<E7TH,&]='%$J,I;HH*Z7A,*-O;/5V8D"
M^3DW+?;"JR@@+_]--CK,&T6AH&/O:+66HJ ^C:F(M[FGOGE4:9:%XHZ]C]7;
MB@+\S'NY"KB!V7T3@9<9?Z4(E ;L32S(<A0V1 !7O&(EG_:YN/X3;\Y9H!W^
M#8)09K!WMQ8HH/!3&%'\1UCR0<>*M#CXI,L)+C06.\+ 1SL&/L(9P-[U&BUV
MA(%/=@Q\@C. O?,U6HS)P#G_YVT\8\^*@W9E82CZV#M?@[68V&>STFT\C=D3
MS;,KF@AH2$!9<&-#K+<;M1OD:P-(']B6A$+OQN98;B<FY%.6I%[X_^C*M"R5
MEX?"[\8V66?SL5V?>1,0WA)5=%6M"!1J[)VQU+)CHRN4C8FG;M35$E!LL;>[
M,KN.#.TU$\<VCRS2.HV;I: 08^];5?8=>Y 6EYP2Y=A0^C,XU ]["*Y;=&1$
M_Q[3E&L@+IZNH\)/I#CF4Q2%(HV]V=1:>F34[[/\-N)R[Q>^W(SI/F%U%7)9
M.2C>V%M+M8U'!GL:$T$ZX<OY+,I-7).,;^=SU2BM*P\%'WMG:;89EX2K)%F3
MV)8*B124$.Q-)M3^8P]$Q%_S<7'SX>/#3-S^50Q#C5)0V+$WF"K[C@SS#9O%
MGGAYY'ZS?&"A^GZ.M" 4;.SMI,;*(^-=T4..=*T(%&/L?:34,J1!8_+B/WK1
M@JA#-^0EH5AC[RMU=J*-TPO0.+VP'*>Q]Y<J^Y!@WB6BO'T(Z:*2Z5J.N%0
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M:8S7]7<*C],@2Y]UHU'VWM&/T%!+H):?1C]>3,A.R?$+E34H7J96Y"LCOPE
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MV5I!NV55E<?>Z71)KAR+08<]P[NI15Z_WG8I79(I3?+7IJ].HL"-1>Q^RFR
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M\1?Q_QZ\A/#?_']02P$"% ,4    " #IBOA6-&8@93X*   _"P  "P
M        @ $     875D7S P,2YJ<&=02P$"% ,4    " #IBOA6[4US41D%
M   R(@  "@              @ %G"@  97@Q-BTR+FAT;5!+ 0(4 Q0    (
M .F*^%9GZD,KV 0  -D>   *              "  :@/  !E>#(S+3$N:'1M
M4$L! A0#%     @ Z8KX5DJHMAB^ 0  M0,   H              ( !J!0
M &5X,C,M,BYH=&U02P$"% ,4    " #IBOA6G/!3(: +  !;00  "0
M        @ &.%@  97@U+3$N:'1M4$L! A0#%     @ Z8KX5BY?^>O[H (
MU6H9  P              ( !52(  &9O<FUS+3%A+FAT;5!+ 0(4 Q0    (
M .F*^%9@I4DH#'L# )]'!  0              "  7K# @!F;W)M<RTQ85\P
M,#$N:G!G4$L! A0#%     @ Z8KX5G!1QS%+#   (H0  !$
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L &EM<&(M,C R,S S,S%?<')E+GAM;%!+!08     #  , -L"  !&"0<    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
